<SEC-DOCUMENT>0001493152-23-045293.txt : 20231218
<SEC-HEADER>0001493152-23-045293.hdr.sgml : 20231218
<ACCEPTANCE-DATETIME>20231218171735
ACCESSION NUMBER:		0001493152-23-045293
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		70
FILED AS OF DATE:		20231218
DATE AS OF CHANGE:		20231218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275993
		FILM NUMBER:		231494746

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>formposam.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:MGRX="http://mangorx.com/20230930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_MGRX_mangorx.com_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230101_20230930 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001938046 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_XDX_Z%2D%2D\2023 OPERATIONS\EDGAR\12 December\Mangoceuticals, Inc\12%2D18%2D2023\Form POS AM\Draft\Production\formposam.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_076_SO_Z%2D%2D\2023 OPERATIONS\EDGAR\12 December\Mangoceuticals, Inc\12%2D18%2D2023\Form POS AM\Draft\Production\forms%2D1.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityCentralIndexKey">0001938046</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0012" name="dei:DocumentType">POS AM</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0044" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-09-30_us-gaap_RelatedPartyMember" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-09-30_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl0095" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-09-30" id="xdx2ixbrl0116" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0161" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0164" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0166" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:CostOfRevenues" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:CostOfRevenues" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0170" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0176" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0178" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0183" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ImputedInterestRelatedParty" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0215" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl0225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0226" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0227" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0228" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:StockIssuedDuringWarrantsExercisedForCashValue" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0454" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0460" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0524" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0554" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0578" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0631" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0634" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0637" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0638" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0639" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0643" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0651" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0653" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0658" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-09-30" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-09-30" id="xdx2ixbrl0779" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-08-08" id="xdx2ixbrl0813" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="xdx2ixbrl1101" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" id="xdx2ixbrl1103" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1109" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1111" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1113" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1115" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl1133" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl1135" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl1137" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl1139" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1203" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl1205" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl1211" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl1213" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl1215" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl1217" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" id="xdx2ixbrl1239" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" id="xdx2ixbrl1241" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" id="xdx2ixbrl1243" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" id="xdx2ixbrl1245" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" contextRef="AsOf2023-09-30" id="xdx2ixbrl1322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:FixedAssets" contextRef="AsOf2021-12-31" id="xdx2ixbrl1365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2021-12-31" id="xdx2ixbrl1371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" id="xdx2ixbrl1374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2021-12-31" id="xdx2ixbrl1377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-12-31_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl1398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1410" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2021-12-31" id="xdx2ixbrl1413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Revenues" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1456" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:CostOfRevenues" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-10-06_us-gaap_CommonStockMember" id="xdx2ixbrl1518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-10-06_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-10-06_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-10-06" id="xdx2ixbrl1521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-10-06_us-gaap_CommonStockMember" id="xdx2ixbrl1523" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl1582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl1586" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:IssuanceOfCommonStockForServices" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1635" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1647" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1650" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1659" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1662" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1671" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-10-06" id="xdx2ixbrl1686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ContributionOfProperty" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1734" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1735" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1738" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1741" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1743" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1746" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1747" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1750" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1757" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1758" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1759" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1763" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-10-072021-12-31" id="xdx2ixbrl1801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_custom_ComputersMember" id="xdx2ixbrl1810" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-12-31_us-gaap_EquipmentMember" id="xdx2ixbrl1813" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-12-31" id="xdx2ixbrl1816" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl1819" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2022-08-08" id="xdx2ixbrl1925" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="xdx2ixbrl2035" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" id="xdx2ixbrl2037" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2043" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2045" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2047" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl2049" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl2097" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2021-12-31_us-gaap_WarrantMember" id="xdx2ixbrl2099" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl2105" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl2107" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl2109" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" id="xdx2ixbrl2111" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl2221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2021-12-31" id="xdx2ixbrl2222" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mgrx-20230930.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-072021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-07</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-06_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-06_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-10-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-10-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-072021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-07</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-07</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-10-07</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-282023-03-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-28</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-282023-03-31_custom_ResaleProspectusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:ResaleProspectusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-28</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ResaleProspectusMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:ResaleProspectusMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MGRX:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MGRX:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MasterServicesAgreementMember_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:MasterServicesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ComputersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MGRX:ComputersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ComputersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MGRX:ComputersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_ComputersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MGRX:ComputersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-102021-12-10_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-10</xbrli:startDate>
        <xbrli:endDate>2021-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-03-182022-03-18_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-03-18</xbrli:startDate>
        <xbrli:endDate>2022-03-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-15</xbrli:startDate>
        <xbrli:endDate>2022-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-16_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-152022-06-16_custom_StockPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-15</xbrli:startDate>
        <xbrli:endDate>2022-06-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-282022-06-29_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-28</xbrli:startDate>
        <xbrli:endDate>2022-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-172022-08-18_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-17</xbrli:startDate>
        <xbrli:endDate>2022-08-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-102021-12-10_custom_ZipDoctorIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-10</xbrli:startDate>
        <xbrli:endDate>2021-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ZipDoctorIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ZipDoctorIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_CohenEnterprisesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_ZipDoctorIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_JacobDCohenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JacobDCohenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-01-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-02-012023-02-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-01</xbrli:startDate>
        <xbrli:endDate>2023-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-232023-03-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-23</xbrli:startDate>
        <xbrli:endDate>2023-03-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-082022-08-08_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-08</xbrli:startDate>
        <xbrli:endDate>2022-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-082022-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-08</xbrli:startDate>
        <xbrli:endDate>2022-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-082022-08-08_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-08</xbrli:startDate>
        <xbrli:endDate>2022-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-162022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-16</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:PHXGlobalLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-06</xbrli:startDate>
        <xbrli:endDate>2022-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:PHXGlobalLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:EzekielElliottMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-06</xbrli:startDate>
        <xbrli:endDate>2022-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:EzekielElliottMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:DavidSandlerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-15</xbrli:startDate>
        <xbrli:endDate>2022-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:DavidSandlerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HsiaochingChouMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-15</xbrli:startDate>
        <xbrli:endDate>2022-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HsiaochingChouMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-01_us-gaap_RestrictedStockMember_srt_ChiefFinancialOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-13</xbrli:startDate>
        <xbrli:endDate>2022-10-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-14</xbrli:startDate>
        <xbrli:endDate>2022-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-142022-10-14_custom_JoanArangoMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JoanArangoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-14</xbrli:startDate>
        <xbrli:endDate>2022-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JoanArangoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JoanArangoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-14</xbrli:startDate>
        <xbrli:endDate>2022-10-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:WhiteUnicornLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:WhiteUnicornLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-09</xbrli:startDate>
        <xbrli:endDate>2022-12-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-212022-12-21_custom_CharteredServicesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:CharteredServicesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-21</xbrli:startDate>
        <xbrli:endDate>2022-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:CharteredServicesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-21</xbrli:startDate>
        <xbrli:endDate>2022-12-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:CharteredServicesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-03</xbrli:startDate>
        <xbrli:endDate>2023-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-03</xbrli:startDate>
        <xbrli:endDate>2023-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-06</xbrli:startDate>
        <xbrli:endDate>2023-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-06</xbrli:startDate>
        <xbrli:endDate>2023-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-06</xbrli:startDate>
        <xbrli:endDate>2023-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-242023-01-24_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-24</xbrli:startDate>
        <xbrli:endDate>2023-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-24_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-242023-01-24_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-24</xbrli:startDate>
        <xbrli:endDate>2023-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-222023-03-22_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-22</xbrli:startDate>
        <xbrli:endDate>2023-03-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-22_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-24_custom_PrivatePlacementWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-242023-04-24_custom_PrivatePlacementWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-24</xbrli:startDate>
        <xbrli:endDate>2023-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-25_custom_PrivatePlacementWarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-25</xbrli:startDate>
        <xbrli:endDate>2023-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-25_custom_PrivatePlacementWarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-25</xbrli:startDate>
        <xbrli:endDate>2023-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-25_custom_PrivatePlacementWarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-25</xbrli:startDate>
        <xbrli:endDate>2023-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-25_custom_PrivatePlacementWarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-25</xbrli:startDate>
        <xbrli:endDate>2023-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-26_custom_PrivatePlacementWarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-262023-04-26_custom_PrivatePlacementWarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-26</xbrli:startDate>
        <xbrli:endDate>2023-04-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-01_custom_PrivatePlacementWarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-01_custom_PrivatePlacementWarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-01_custom_HammerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HammerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-01_custom_HammerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HammerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MrAndrewMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-25</xbrli:startDate>
        <xbrli:endDate>2023-05-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MrAndrewMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MrAndrewMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-25</xbrli:startDate>
        <xbrli:endDate>2023-05-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MajorDodgeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MajorDodgeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MajorDodgeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:StreetGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:StreetGroupLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-06_custom_PrivatePlacementWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-062023-06-06_custom_PrivatePlacementWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-06</xbrli:startDate>
        <xbrli:endDate>2023-06-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-07_custom_PrivatePlacementWarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-072023-06-07_custom_PrivatePlacementWarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-07</xbrli:startDate>
        <xbrli:endDate>2023-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-08_custom_PrivatePlacementWarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-082023-06-08_custom_PrivatePlacementWarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-08</xbrli:startDate>
        <xbrli:endDate>2023-06-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-21_custom_PrivatePlacementWarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-212023-06-21_custom_PrivatePlacementWarrantFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-21</xbrli:startDate>
        <xbrli:endDate>2023-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-22_custom_PrivatePlacementWarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-222023-06-22_custom_PrivatePlacementWarrantFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-22</xbrli:startDate>
        <xbrli:endDate>2023-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-22_custom_PrivatePlacementWarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-222023-06-22_custom_PrivatePlacementWarrantSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-22</xbrli:startDate>
        <xbrli:endDate>2023-06-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-27_custom_PrivatePlacementWarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-272023-06-27_custom_PrivatePlacementWarrantSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-27</xbrli:startDate>
        <xbrli:endDate>2023-06-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefOperatingOfficerMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-01_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-01_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-01_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-20_us-gaap_CommonStockMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-202023-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-20</xbrli:startDate>
        <xbrli:endDate>2023-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember40800812">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-06</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-06</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-232022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LeovLawFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-23</xbrli:startDate>
        <xbrli:endDate>2022-06-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LeovLawFirmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember40801234">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember40801390">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember40801406">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-282022-09-28_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-28</xbrli:startDate>
        <xbrli:endDate>2022-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-282022-09-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-28</xbrli:startDate>
        <xbrli:endDate>2022-09-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LucaConsultingLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-10</xbrli:startDate>
        <xbrli:endDate>2023-10-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-10_us-gaap_SubsequentEventMember_custom_ConsultingAgreementMember_custom_LucaConsultingLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LucaConsultingLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-06</xbrli:startDate>
        <xbrli:endDate>2023-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-06</xbrli:startDate>
        <xbrli:endDate>2023-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-06</xbrli:startDate>
        <xbrli:endDate>2023-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-242023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-24</xbrli:startDate>
        <xbrli:endDate>2023-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-222017-12-22_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-22</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-222017-12-22_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-22</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001938046</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As
filed with the Securities and Exchange Commission on December 18, 2023.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration
No. 333-275993</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Post-Effective
Amendment No. 2<br/>
</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>to</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Form
<span id="xdx_90C_edei--DocumentType_dxL_c20230101__20230930_zDYlALtlwPke" title="::XDX::POS%20AM"><span style="-sec-ix-hidden: xdx2ixbrl0012">S-1</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>UNDER</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>THE
SECURITIES ACT OF 1933</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityRegistrantName_c20230101__20230930_zCDIQ78kdqKh"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityRegistrantName">Mangoceuticals,
Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
Name of Registrant as Specified in Its Charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20230101__20230930_zjMnpqEGlYwe"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Texas</ix:nonNumeric></span></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">8099</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20230101__20230930_z5QDb63Rd8B"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityTaxIdentificationNumber">87-3841292</ix:nonNumeric></span></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or Other Jurisdiction of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation
    or Organization)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Primary
    Standard Industrial</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification
    Code Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    Number)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20230101__20230930_zfaiDUU1eGF8"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine1">15110
N. Dallas Parkway</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20230101__20230930_zHPx1wWfRxP"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressAddressLine2">Suite 600</ix:nonNumeric></span><br/>
<span id="xdx_90D_edei--EntityAddressCityOrTown_c20230101__20230930_zXWFAX6eCRv3"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressCityOrTown">Dallas</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20230101__20230930_zHUwnnn9ddl6"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_903_edei--EntityAddressPostalZipCode_c20230101__20230930_zq4DxG2tC9Hd"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:EntityAddressPostalZipCode">75248</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span><span><span id="xdx_90D_edei--CityAreaCode_c20230101__20230930_zpyGg3yulbXb"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CityAreaCode">(214)</ix:nonNumeric></span></span>
<span><span id="xdx_907_edei--LocalPhoneNumber_c20230101__20230930_zrs3HPbvUQei"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:LocalPhoneNumber">242-9619</ix:nonNumeric></span></span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address,
Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--ContactPersonnelName_c20230101__20230930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zb0XzotEW0pg"><ix:nonNumeric contextRef="From2023-01-012023-09-30_dei_BusinessContactMember" name="dei:ContactPersonnelName">Jacob
D. Cohen</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
Executive Officer</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230101__20230930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zB7F4VBB9sBk"><ix:nonNumeric contextRef="From2023-01-012023-09-30_dei_BusinessContactMember" name="dei:EntityAddressAddressLine1">15110
N. Dallas Parkway</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20230101__20230930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zDtt72LxCpdh"><ix:nonNumeric contextRef="From2023-01-012023-09-30_dei_BusinessContactMember" name="dei:EntityAddressAddressLine2">Suite 600</ix:nonNumeric></span><br/>
<span id="xdx_900_edei--EntityAddressCityOrTown_c20230101__20230930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zSM85tjPzv9g"><ix:nonNumeric contextRef="From2023-01-012023-09-30_dei_BusinessContactMember" name="dei:EntityAddressCityOrTown">Dallas</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20230101__20230930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zVxPMEKkJKa2"><ix:nonNumeric contextRef="From2023-01-012023-09-30_dei_BusinessContactMember" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Texas</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressPostalZipCode_c20230101__20230930__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zBcdEiTYOVlg"><ix:nonNumeric contextRef="From2023-01-012023-09-30_dei_BusinessContactMember" name="dei:EntityAddressPostalZipCode">75248</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span><span id="xdx_901_edei--CityAreaCode_c20230101__20230930_z1O1zNuFHrtk"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:CityAreaCode">(214)</ix:nonNumeric></span>
<span id="xdx_902_edei--LocalPhoneNumber_c20230101__20230930_z6o6elRVzXRj"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:LocalPhoneNumber">242-9619</ix:nonNumeric></span></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Name,
Address, Including Zip Code, and Telephone Number, Including Area Code,<br/>
of Agent For Service)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Copies
to:</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    M. Loev, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Spencer
    G. Feldman, Esq.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    S. Gillies, Esq.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Olshan
    Frome Wolosky LLP</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Loev Law Firm, PC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1325
    Avenue of the Americas,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6300
    West Loop South, Suite 280</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15th
    Floor</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bellaire,
    Texas 77401</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, New York 10019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    (713) 524-4110</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    (212) 451-2300</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: <b>As soon as practicable after the effective date of this Registration Statement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;<b>large accelerated filer</b>,&#8221; &#8220;<b>accelerated filer</b>,&#8221;
&#8220;<b>smaller reporting company</b>&#8221; and &#8220;<b>emerging growth company</b>&#8221; in Rule 12b-2 of the Exchange Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20230101__20230930_zEgbITQF2Su7"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntitySmallBusiness_c20230101__20230930_z9Tp2iqhxdVd"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20230101__20230930_znJrwscb0QHa"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <span id="xdx_901_edei--EntityExTransitionPeriod_c20230101__20230930_zMOSojVj8Hw4"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_906_edei--AmendmentDescription_c20230101__20230930_zttws4NKbeEb"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" name="dei:AmendmentDescription">This Post-Effective Amendment No. 2 (this &#8220;Amendment&#8221;)
to the Registration Statement on Form S-1 of Mangoceuticals, Inc. (File No. 333- 275993), initially filed on December 11, 2023 and declared
effective by the Securities and Exchange Commission on December 14, 2023 (the &#8220;Registration Statement&#8221;), is being filed to
update the prospectus which forms part of the Registration Statement to (a) fill in blanks on the cover page of the prospectus and throughout
regarding pricing terms and the offering price of $0.30 per share; (b) reflect that a Plan of Compliance is being filed with Nasdaq on
December 18, 2023, and (c) make corresponding updates to the prospectus in connection therewith.</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>The
information in this preliminary prospectus is not complete and may be changed. We may not sell these securities nor may we accept offers
to buy these securities until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary
prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the
offer or sale is not permitted.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; color: Red; width: 40%; text-align: justify"><span style="color: Red"><b>PRELIMINARY
    </b></span><span style="color: Red"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS</span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>SUBJECT
    TO COMPLETION, DATED DECEMBER 18, 2023</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4,000,000
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="forms-1_001.jpg" alt="A black and white logo&#10;&#10;Description automatically generated" style="height: 74px; width: 333px"/></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 4,000,000 shares of our common stock, par value $0.0001 per share, on a firm commitment basis pursuant to this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on the Nasdaq Capital Market, or Nasdaq, under the symbol &#8220;MGRX&#8221;. The last reported sale price of
our common stock on Nasdaq on December 15, 2023 was $0.307 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>An
investment in our common stock involves a high degree of risk. You should carefully consider the risk factors set forth under &#8220;<a href="#nj_007">Risk Factors</a>,&#8221; beginning on page 18 of this prospectus, before you make your decision to invest in our common stock.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither
the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Per Share</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Public offering price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0.300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%; font-size: 11pt">&#160;</td>
    <td style="width: 1%; font-size: 11pt; text-align: left">$</td><td style="width: 16%; font-size: 10pt; text-align: right">1,200,000</td><td style="width: 1%; font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds to us, before expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.279</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,116,000</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
    refer to the section of this prospectus entitled &#8220;<a href="#mj_005">Underwriting</a>&#8221; for additional information regarding total underwriter
    compensation. We have agreed to pay the representative of the underwriters a non-accountable expense allowance equal to 1% of gross
    proceeds and reimburse the representative of the underwriters for its reasonable out-of-pocket expenses, including legal fees, up
    to $25,000. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the underwriters an option for a period of 45 days after the date of this prospectus to purchase up to 15% of the total
number of our shares of common stock to be offered by us pursuant to this offering, solely for the purpose of covering over-allotments,
at the public offering price less the underwriting discounts and commissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended, and, as such, may
elect to comply with certain reduced public company reporting requirements for future filings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the shares of common stock against payment as set forth under &#8220;<a href="#mj_005">Underwriting</a>,&#8221; on or about
__________, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
  <tr style="vertical-align: top">
    <td style="font: 18pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Boustead
    Securities, LLC </b></span></td>
    <td style="font: 18pt Times New Roman, Times, Serif; text-align: right; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Sutter
    Securities, Inc.</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
date of this prospectus is ____________________, 2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="abc_001"></span>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">About This Prospectus</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus Summary</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Glossary of Industry Terms</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate and Background Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Offering</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td></tr>
    <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary Financial Data</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">17</td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#nj_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">18</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary Statement Regarding Forward-Looking Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">52</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">53</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend Policy</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">54</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">56</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of&#160; Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">57</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">67</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#sj_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">90</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#mj_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive and Director Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#mj_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Party Transactions</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_003">Security Ownership of Certain Beneficial Owners and Management</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">120</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_004">Description of Capital Stock</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_005">Underwriting</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">126</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_006">Legal Matters</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_007">Experts</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_008">Changes in Accountants</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">133</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#mj_009">Where You Can Find More Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">134</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-top: 0in; padding-bottom: 0in; padding-left: 0in"><a href="#fintoc_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-top: 0in; padding-bottom: 0in">F-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="nj_001"></span>About
This Prospectus</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dealer, salesperson or other individual has been authorized to give any information or to make any representation other than those contained
in this prospectus in connection with the offer made by this prospectus and, if given or made, such information or representations must
not be relied upon as having been authorized by us. This prospectus does not constitute an offer to sell or a solicitation of an offer
to buy any securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such
offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation. Neither
the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create any implication that there has been
no change in our affairs or that information contained herein is correct as of any time subsequent to the date hereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>For
investors outside the United States</i>: We and the underwriters have not done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons
outside the United States who come into possession of this prospectus must inform themselves, and observe any restrictions relating to,
the offering of the shares of our common stock and the distribution of this prospectus outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and
service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus
may appear without the &#174;, &#8482; and <sup>SM</sup> symbols. References to our trademarks, tradenames and service marks are not intended
to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable
licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable
law, their rights thereto. We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship
with, or endorsement or sponsorship of us by, any other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market data and certain other statistical information used throughout this prospectus are based on independent industry publications,
reports by market research firms or other independent sources that we believe to be reliable sources; and we have not commissioned any
of the market or survey data that is presented in this prospectus. Industry publications and third-party research, surveys and studies
generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the
accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe
these industry publications and third-party research, surveys and studies are reliable. While we are not aware of any misstatements regarding
any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous
assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under
the section entitled &#8220;<a href="#nj_007">Risk Factors</a>&#8221; beginning on page 18 of this prospectus. These and other factors could cause our future
performance to differ materially from our assumptions and estimates. Some market and other data included herein, as well as the data
of competitors as they relate to Mangoceuticals, Inc., is also based on our good faith estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the context otherwise requires, references in this prospectus to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221;
and &#8220;Mangoceuticals&#8221; refer to Mangoceuticals, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
terms used in this prospectus are defined in the &#8220;<a href="#nj_003">Glossary of Industry Terms</a>&#8221; appearing on page 13 of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="nj_002"></span>Prospectus
Summary</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information that you
should consider before deciding to invest in our common stock. You should read this entire prospectus carefully, including the &#8220;<a href="#nj_007">Risk Factors</a>&#8221; section, our historical financial statements and the notes thereto, each included elsewhere in this prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
connect consumers to licensed healthcare professionals through our website at <span style="text-decoration: underline">www.MangoRX.com</span> for the provision of care via telehealth
on our customer portal and also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain
medications that may be prescribed as part of their telehealth consultations. We have developed what we believe is a go-to-market strategy
inclusive of product development, operations, marketing and advertising. To date, however, we have not sold a significant amount of products
and have not generated revenues sufficient to support our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have identified men&#8217;s wellness telemedicine services and products as a growing sector in recent years and especially related to
the areas of erectile dysfunction (&#8220;ED&#8221;), and hair growth and related products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mango
ED</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and are marketing and selling a new brand of ED product under the brand name &#8220;Mango.&#8221; This product is produced
at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded drug is necessary
for the individual patient. This product currently includes the following three ingredients: Either Sildenafil (the active ingredient
in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin, all of which are used in U.S. Food and Drug Administration (&#8220;FDA&#8221;)
approved drugs, as well as L-Arginine, an amino acid that is available as a dietary supplement. However, the fact that Tadalafil, Sildenafil
and Oxytocin are used in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients
will prove safe when combined into a single formulation to treat ED. We currently offer two dosage levels of our Mango ED product and
anticipate doctors prescribing a dosage based on the needs and medical history of the patient. Our Mango ED product currently includes
the following amounts of the three ingredients: (1) either Sildenafil (50 milligrams (mg)) or Tadalafil (10 (mg)), Oxytocin (100 International
units (IU)) and L-Arginine (50mg); and (2) either Sildenafil (100 milligrams (mg)) or Tadalafil (20mg), Oxytocin (100IU) and L-Arginine
(50mg). Our Mango ED product has not been, and will not be, approved by the FDA and instead we produce and sell our Mango ED product
and plan to produce and sell future pharmaceutical products, under an exemption provided by Section 503A of the Federal Food, Drug, and
Cosmetic Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any clinical studies involving the administration of Tadalafil or Sildenafil sublingually at the doses we provide patients,
or the compounding of Tadalafil or Sildenafil, Oxytocin and L-arginine to treat ED, as is contemplated by our ED product. We are, however,
aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of Tadalafil
and Sildenafil. Additionally, because our Mango ED product is being specially compounded for the customer by a pharmacist with a physician&#8217;s
prescription and because the ingredients for our Mango ED product are publicly disclosed, this product formula can be replicated by other
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mango
Hair Growth Product - &#8216;GROW&#8217; by MangoRx</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed, and since November 16, 2022 are marketing and selling, a new brand of hair growth product under the brand name &#8216;GROW&#8217;
by MangoRx (&#8220;Mango GROW&#8221;). This product is produced at our related party compounding pharmacy and is available to patients
on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mango GROW currently
includes the following four ingredients &#8211; (1) Minoxidil (the active ingredient in Rogaine&#174;) and (2) Finasteride (the active
ingredient in Propecia), each of which is used in FDA approved drugs, as well as (3) Vitamin D3 and (4) Biotin, which are available as
dietary supplements. However, the fact that Minoxidil and Finasteride are used in FDA approved drugs, and that Vitamin D3 and Biotin,
are available as a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to
attempt to treat hair growth. Mango GROW is encapsulated in convenient chewable, mint-flavored rapid dissolve tablets (&#8220;RDT&#8221;).</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently offer one dosage level of our Mango GROW product and anticipate doctors prescribing Mango GROW based on the needs and medical
history of the patient. Our Mango GROW product currently includes the following amounts of the four ingredients: (1) Minoxidil (2.5mg),
(2) Finasteride (1mg), (3) Vitamin D3 (2000IU) and (4) Biotin (1mg). Our Mango GROW product has not been, and will not be, approved by
the FDA and instead we produce and sell our Mango GROW product and plan to produce and sell future pharmaceutical products, under an
exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any clinical studies involving the administration of Minoxidil and Finasteride sublingually at the dose we provide patients,
or the compounding of Minoxidil, Finasteride, Vitamin D3 and Biotin to treat hair growth. We are, however, aware of other companies that
are currently selling oral tablets for hair growth, including those using a combination of Minoxidil and Finasteride. Additionally, because
our Mango GROW product is being specially compounded for the customer by a pharmacist with a physician&#8217;s prescription and because
the ingredients for our Mango GROW product are publicly disclosed, this product formula can be replicated by other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Additional
Information Regarding Mango ED and Mango GROW</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our Mango ED and Mango GROW products have not been, and will not be, approved by the FDA, our products have not had the benefit of the
FDA&#8217;s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur,
we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate using a substantial portion of the net proceeds of this offering to finance marketing and general operational expenses
associated with the sale of our Mango ED and Mango GROW products. We launched our website in mid-November 2022. To date, we have sold
only a small amount of products and generated only minimal revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mango
ED and Mango GROW have been formulated as RDT using a sublingual (applied under the tongue) delivery system to bypass the stomach and
liver. It is a generally established principle that sublingual drug absorption through the oral mucosa is generally faster than drug
absorption through the gastrointestinal tract. This is because sublingual drugs that are absorbed through the oral mucosa directly enter
the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver (see H. Zhang et al., <i>Oral mucosal
drug delivery: clinical pharmacokinetics and therapeutic applications</i>, 41 <span style="font-variant: small-caps">Clin Pharmacokinet
</span>661, 662 (2002). Though the active ingredients that comprise our Mango ED product are meant to treat ED &#8211; an issue that
according to a 2018 study published in <i>The Journal of Sexual Medicine</i> has been estimated to affect over one-third of today&#8217;s
men&#8217;s population (with prevalence increasing with age) &#8211; we are also aiming to brand ourselves as a lifestyle company marketed
to men seeking enhanced sexual vitality, performance, and overall mood and confidence, together with our Mango GROW hair growth product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Mango products are sold exclusively online via our website at <span style="text-decoration: underline">www.MangoRX.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Customer Portal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
customer platform connects consumers to licensed healthcare professionals through our website at <span style="text-decoration: underline">www.MangoRX.com </span>for the provision
of care via telehealth and also provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain
medications that may be prescribed as part of a telehealth consultation. Additional features to this backend technology solution allow
for the creation and management of customer accounts whereby customers have the ability to login, view and make changes to their respective
accounts, including reviewing order history, tracking order shipments, requesting and ordering product refills and making other profile
changes such as shipping address and payment changes. Our portal is not unique to the industry and is not anticipated to be difficult
or costly to replicate or replace.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
backend technology solution also houses and manages all customer data providing us with additional key functionality, including to provide
customer service and support and data analytics for various marketing initiatives and reporting functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate selling any third-party products via our portal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Growth Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
growth strategy includes the following key initiatives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Utilize
a variety of marketing channels using data analytics to attract customers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market and advertise our Mango products on a variety of advertising mediums including social media, online search websites, television,
radio, out-of-home, and other media channels, to the extent we are legally able to, and in compliance with applicable FDA rules and requirements;
however, due to such rules and requirements, we are extremely limited in the content of the claims and promotional statements that we
are able to make regarding our products under applicable FDA regulations. We believe advertising in a diversified set of media channels
is important to prevent overreliance on any single channel and to maximize the exposure of our brand to our desired customers. We also
seek to reach our customers through our own social media accounts, press coverage and public relations, internally developed educational
and lifestyle content, and through engagement of social media influencers, hired and paid celebrities and talent, and physical brand
advertising campaigns and in each case subject to applicable rules and regulations, which are expected to significantly limit the content
of such marketing materials. We believe that this overall strategy will drive customer traffic to our platform, including direct type-in
traffic and organic online search traffic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also utilize a marketing strategy focused on analytics and data. We have designed our internal systems to measure consumer behavior,
including which types of consumers generate more revenue in their first purchase, generate more revenue over time, generate more gross
profit from their purchases, and which types of consumers are most valuable over their lifetime. We also seek to measure the effectiveness
of our marketing budgets and the rate of return we generate from our marketing campaigns. We also use outside marketing and advertising
firms to assist management in identifying marketing and advertising campaigns, media purchases and mediums, and seeking to drive a sufficient
rate of return from our marketing and advertising budgets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Invest
in our telemedicine platform to enable sales throughout the United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize both a synchronous and asynchronous approach through our telemedicine platform, connecting customers through our platform and
contracted physicians and pharmacy. An asynchronous visit allows a physician to verify the patient&#8217;s identity, demographics and
collect the medical history online without needing to physically see or speak to the patient while a synchronous visit requires the doctor
to either speak directly to the patient and/or see the patient either via video conference or in person. As discussed above, we focus
our sales in the District of Columbia and the 47 states where our related party pharmacy is licensed, with the goal of eventually undertaking
sales across all 50 states, pending licensing approvals of our related party pharmacy.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provide
subscription plans for recurring revenue and introduction of new products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide our customers with an option to purchase our Mango products on a subscription basis. Subscription plans provide an easy and convenient
way for customers to get ongoing treatment while simultaneously providing us with predictability through a recurring revenue stream.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
subscription plans, customers are able to select a desired timeframe in which to receive products, which ranges from once every month
to once every six months, depending on several factors. The customer is then billed on a recurring basis based on the selected timeframe
and specified quantity of product, which is shipped after each billing from our contracted pharmacy (Epiq Scripts (defined and discussed
below)). Customers are able to cancel subscriptions in between billing periods to stop receiving additional products and reactivate subscriptions.
Our integrated technology platform allows us to efficiently serve customers from customer discovery, through the purchase of products
on our website, to connecting customers with medical providers for telehealth consultations (through our contracted physician network
(which is contracted through Epiq Scripts (defined and discussed below)), to the fulfillment and delivery of orders (through our contracted
pharmacy), and finally through ongoing management by medical providers (also through our contracted physician network). We believe that
our platform provides us cost advantages and efficiencies to offer customers affordable prices and generate increased revenues over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to launch new products over time and offer additional subscription-based offerings which we hope will result in growth in revenue
through recurring revenue streams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Market for ED Products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">According
to a January 2022 report published by Verified Market Research, the Global Erectile Dysfunction Drugs Market size was valued at</span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.63 billion in 2020, mainly due to the increase in patient
awareness and the early adoption of sedentary lifestyle. Verified Market Research also projects that the total Global Dysfunction Drugs
Market size will contract to $2.95 billion in 2028. The expected reason for this contraction is poor patient compliance with erectile
dysfunction drugs and the future availability of cost-effective imitation medicines, as well as side effects of ED drugs. We do not anticipate
our Mango ED drug suffering from these limitations, as we believe our product is easy to use and that we have priced our product competitively.
Separately, Grand View Research, in a July 2022 report, projects that the U.S. market (where we initially plan to market our ED product)
for erectile dysfunction drugs which is estimated at approximately $1.1 billion as of 2021, will increase at a 7.4% compound annual growth
rate though 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Further,
it is estimated that nearly 3-in-5 men questioned in the U.S. have suffered from erectile dysfunction, according to a survey reported
in February 2022 by LetsGetChecked, a leading at-home health screening and insights company (based on research carried out by Opinium
Research among 2,006 men in the U.S., 1,178 of whom had previously experienced erectile dysfunction, from February 7-10, 2020). According
to that study, age isn&#8217;t that big a factor either, with 56% of men 18 to 34 years old being affected, compared to 63% of those
over the age of 55. The study also determined that most men blame psychological factors for ED &#8211; with 41% blaming stress, 34% blaming
having &#8220;too much on their mind,&#8221; and 31% believing it is performance anxiety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Market for Mango GROW</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the website of the American Hair Loss Association, (a) two-thirds of American men will experience some degree of hair loss by the
age of 35, (b) by age 50, around 85 percent of men have significantly thinning hair; and (c) for around 25% of men, the start of male
pattern baldness can begin before the age of 21. Additionally, and <span style="background-color: white">contrary to societal belief,
we believe that most men who suffer from male pattern baldness are unhappy with their situation and would take steps to change that.
In our experience, hair loss affects every aspect of the hair loss sufferer&#8217;s life including interpersonal relationships as well
as the professional lives of those suffering. </span></span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a May 2022 market study entitled, &#8220;Hair Loss Prevention Products Market Forecast to 2028 &#8211; COVID-19 Impact and Global
Analysis &#8211; by Product Type (Shampoos and Conditioners, Oils, Serums, and Others), Category (Natural &amp; Organic, and Conventional),
End User (Men, Women, and Unisex), and Distribution Channel (Supermarkets and Hypermarkets, Convenience Stores, Online Retail, and Others)&#8221;,
by The Insight Partners, <span style="background-color: white">the hair loss prevention products market size was valued at $23.6 billion
in 2021 and is projected to reach $31.5 billion by 2028, growing at a projected </span>compound annual growth rate <span style="background-color: white">of
4.2% from 2021 to 2028.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mordor
Intelligence LLP believes that <span style="background-color: white">the major factors driving the hair loss prevention market are changing
lifestyle patterns, adoption of a hectic schedule that increases stress levels, which in turn results in frequent hair loss at an earlier
stage among the young population, growing disposable income, and increased emphasis on appearances. </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition
and Competitive Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
mainly compete with other companies offering men&#8217;s wellness products, including Hims &amp; Hers Health, Inc. and Roman. With our
Mango ED products, we compete against much larger pharmaceutical companies which offer ED branded drugs like Viagra (Pfizer) and Cialis
(marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation) and their generic forms. With our Mango
GROW product, we compete against the much larger pharmaceutical company Merck &amp; Co., which offers the branded hair loss product Propecia
and Johnson &amp; Johnson, the owner of Rogaine&#174; &#8211; a branded form of Minoxidil. These companies have much greater resources
than we do and well-known brand names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future men&#8217;s wellness products will also likely need to compete against other traditional healthcare providers, pharmacies, and
large retailers that sell non-prescription products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we compete with other companies, which have greater resources and a greater advertising budget, and which are also selling ED related
products with either or both Tadalafil and Sildenafil (or similar products) in an oral disintegrating tablet and who are selling compounded
Minoxidil and Finasteride in both topical form (e.g., gels, foams, liquid solutions) and in oral capsule, tablet or pill form. For example,
we are aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of
Tadalafil and Sildenafil (the active ingredient in Viagra). However, we are not aware of any companies that are selling a compound consisting
of Minoxidil and Finasteride in an oral disintegrating tablet form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to compete against these competitors based on our branding, advertising, unique compounding, and delivery system (i.e., our Mango
product has been designed to be taken sublingually, rather than in pill form).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
to other online direct to consumer telemedicine companies that are selling both generic ED medication and generic hair loss medications,
we believe we have priced both our Mango ED products and Mango GROW product at a premium, due to the cost of compounding the product
and the use of multiple ingredients. We are currently aware of a handful of other direct to consumer companies that are also selling
compounded hair loss and ED medications and who are selling their products at a higher price than Mango&#8217;s current price. When comparing
the current market for various pharmaceutical related hair loss and ED products, we have attempted to position our pricing to be slightly
above average as we anticipate marketing or Mango ED and Mango GROW products to a demographic that we expect will pay a premium for what
we believe to be a premium product relative to the competition for the treatment of hair loss and erectile dysfunction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
produce and sell our Mango ED and Mango GROW product and plan to produce and sell our future pharmaceutical products, under an exemption
provided by Section 503A of the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA Act&#8221;). Section 503A describes the conditions
under which compounded human drug products are exempt from the FFDCA Act sections on FDA approval, current good manufacturing practice
(&#8220;cGMP&#8221;) requirements, and labeling with adequate directions for use. One of these conditions is that the drugs must be compounded
based on the receipt of valid patient-specific prescriptions; another condition limits &#8220;copying&#8221; of FDA-approved products,
which restricts compounding drugs that have the same active ingredients and route of administration as FDA-approved products that are
commercially available. The FDA also prohibits any marketing or promotional statements that are &#8220;false or misleading in any particular,&#8221;
including making any unsupported superiority claims against other products or the failure to disclose a material fact.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Notwithstanding
the above, under relevant FDA guidance, the FDA generally does not consider a compounded drug to be &#8220;essentially a copy&#8221;
of a commercially available drug if the compounded drug has a different route of administration as compared with the approved alternative,
and our Mango ED and Mango GROW products are for a different route of administration (e.g., sublingual). In addition, the FDA does not
consider a compounded drug to be &#8220;essentially a copy&#8221; of a commercially available drug if the approved product cannot be
used for the prescribed route of administration, which is available in the compounded version (which we believe it cannot, as discussed
below). Finally, we do not expect that we will be deemed to have engaged in such &#8220;copying&#8221;, because our Mango ED and Mango
GROW products are based on a prescriber&#8217;s determination for each patient that the change associated with the compounded product
(our Mango ED or Mango GROW product) produces for the patient a significant difference as compared with the commercially available drug
product. Under relevant FDA guidance, the FDA does not consider a compounded drug &#8220;essentially a copy&#8221; if a prescriber determines
that there is a change, made for an identified individual patient, which produces for that patient a significant difference from the
commercially available product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 503A of the FFDCA Act, it is the prescribing practitioner who determines if a compounded drug is necessary for the identified
patient and whether the change associated with the compounded product produces for the patient a significant difference as compared with
the commercially available drug product. FDA&#8217;s guidance states that the FDA generally does not intend to question prescriber determinations
that are appropriately documented. Our Mango ED and Mango GROW compounded products have been formulated as a Rapid Dissolve Tablet using
a sublingual (applied under the tongue) delivery system to bypass the stomach and liver. We believe this offers a significant difference
based on the fact that the approved versions are not available in the same route of administration (i.e., sublingual). A sublingual formulation
may be able to meet the clinical needs of a particular patient who desires a more rapid onset of action compared to an FDA-approved oral
formulation. In addition, because the prevalence of ED generally increases with age, older patients who may have difficulty swallowing
an FDA-approved oral formulation may benefit from a sublingual formulation that dissolves under the tongue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compounded
drugs, like our Mango ED and Mango GROW products, are not FDA-approved. This means that the FDA does not verify the safety or effectiveness
of such drugs. Instead, consumers rely on the determination of a prescribing physician that the compounded drug is necessary for the
individual patient. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has the authority to impose significant restrictions on products through regulations on advertising, promotional and distribution
activities. In particular, the FDA will object to any promotional activity (including through testimonials and surrogates) that is &#8220;false
or misleading in any particular,&#8221; including the failure to disclose material facts. For example, the FDA will expect adequate substantiation
for an efficacy claim, which would require substantial evidence derived from adequate and well-controlled clinical trials. We believe
we can conduct truthful and non-misleading promotional activities, including activities involving the use of testimonials and surrogates,
with limited claims that do not require substantial evidence derived from adequate and well-controlled clinical trials and which do not
include efficacy claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aware of data in the scientific literature supporting how the proposed combination of the compounds which make up our Mango
ED product (i.e., Tadalafil or Sildenafil, Oxytocin, and L-arginine) might be expected to perform in ED patients. Previous clinical studies
(none of which we have paid for or undertaken ourselves) have suggested that either Sildenafil or Tadalafil and L-arginine in combination
for treatment of ED may be more effective than either compound alone&#8212;This is because L-arginine may increase nitric oxide, that
in turn may increase cyclic guanosine monophosphate, which has relaxation and vasodilation (dilatation of blood vessels) effects on smooth
muscle to assist in the treatment of ED. Furthermore, Oxytocin is a neurotransmitter linked to increased levels of social interaction,
well-being, and anti-stress effects and clinical studies suggest administration of Oxytocin may stimulate certain aspects of social interaction,
and may cause anti-anxiety and anti-stress effects.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we are aware of data in the scientific literature supporting the efficacy of Minoxidil as an oral treatment (as discussed below), as
opposed to topical treatments that have been more traditionally used and marketed for hair growth to date. <span style="background-color: white">Topical
Minoxidil and oral Finasteride are current the standard first-line treatments for androgenetic alopecia (AGA)(male pattern baldness).
Minoxidil in an oral formulation has been previously used for the treatment of severe and uncontrolled hypertension at a dose of 10&#8211;40
mg. Unintentionally, the early trials of oral minoxidil as an antihypertensive drug documented side effects such as hypertrichosis (excessive
hair growth anywhere on the body) and hirsutism (excess hair most often noticeable around the mouth and chin) with chronic use. A study
conducted by Ratchathorn Panchaprateep &amp; Suparuj Lueangarun, and published in the September 24, 2020 edition of Dermatology and Therapy,
found that oral minoxidil at a dose of 5 mg taken once daily, significantly increased hair growth in men with AGA after 12 and 24 weeks
of treatment (Panchaprateep, R., Lueangarun, S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients
with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb) 10, 1345&#8211;1357 (2020)). </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Separately,
Finasteride taken orally in the amount of 1 mg per day has shown to promote scalp hair growth and prevent further hair loss in a significant
proportion of men with male pattern hair loss (McClellan, K.J., Markham, A. Finasteride. Drugs 57, 111&#8211;126 (1999).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we, nor our representatives have had any conversations with the FDA staff regarding whether our Mango ED or Mango GROW product can be
sold pursuant to Section 503A of the FFDCA Act and future conversations with the FDA may result in the FDA staff raising issues with
such sales pursuant to Section 503A of the FFDCA, requiring certain pre-requisites or changes to our current business plan, which may
be costly or time consuming, and/or may result in us being prohibited from selling our Mango ED or Mango GROW product pursuant to Section
503A of the FFDCA Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Contracted Telehealth Provider</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
many states, including Texas where our principal business operations are located, the corporate practice of medicine doctrine prohibits
corporations from practicing medicine and from employing physicians to provide professional medical services. Many states that recognize
this doctrine also prohibit physicians from agreeing to share the fees they receive for professional services with unlicensed entities
or individuals, a practice that is commonly known as &#8220;fee splitting.&#8221; The requirements for compliance with any applicable
corporate practice of medicine and fee splitting restrictions vary among the states. In Texas, for example, there is no statute that
expressly prohibits fee splitting, but the corporate practice of medicine doctrine has been interpreted to prohibit physicians from ceding
control over their fee structures to corporate entities or giving a substantial portion of the fees received to corporate entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the corporate practice of medicine and fee splitting restrictions, we do not employ or directly contract with individual
physicians or physician groups, nor do we control their medical decision-making or charges. Rather, on August 1, 2022, we entered into
a Physician Services Agreement (the &#8220;Physicians Agreement&#8221;) with BrighterMD, LLC doing business as Doctegrity (&#8220;Doctegrity&#8221;),
as discussed in further detail below under, which has agreed to make available to us, healthcare professionals, to allow them to provide
clinical services directly to our future customers via telehealth. We have integrated these healthcare professionals to allow for telehealth
consultations and related services on our Mangoceuticals platform. This platform is the backbone of our business as it connects consumers
with both the medical provider and the pharmacy for fulfillment. It is also the system that we use to create marketing funnels for outgoing
marketing, customer management and support, and analytics for future sales.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Physician
Services Agreement with Doctegrity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Physicians Agreement, Doctegrity, which provides online telemedicine technology services and provides access to independently
contracted licensed physicians and providers, agreed to (a) arrange for the services of a physician or, where appropriate, a mid-level
practitioner with delegated authority from a physician, licensed in the appropriate state the practice of medicine will take place, who
will establish a physician/patient relationship with patients associated with our platform in accordance with the laws and regulations
of the appropriate state(s) and also provide physician review and assessment and quality control of our or related brands&#8217; advertising
of services, medical questionnaires and related prescription requests; and (b) provide an asynchronous telehealth platform (and in certain
cases, synchronous capabilities in certain U.S. states where and when available and applicable) which provides patient access to licensed
physicians in the state from which the patient, who is participating under our platform, resides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
chose to contract with Doctegrity after reviewing and comparing the fees and services offered by similar telehealth platform companies
that facilitate visits between health care professionals and patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a patient visits our website and submits a request for a consultation with a health care professional, Doctegrity will communicate the
patient&#8217;s information to one of its affiliated physicians. Doctegrity and the physicians are responsible for conducting the telehealth
consultation and any ongoing communication with the patient in accordance with applicable laws. The physicians make a determination,
in their sole discretion, as to whether or not to prescribe our products (currently our Mango ED and Mango GROW products) to potential
customers. If the physicians prescribe our Mango ED or Mango GROW product, then the customers will pay us for our products. In turn,
Epiq Scripts, LLC, pursuant to the Master Services Agreement discussed below, is provided information on the customer and compounding
of our product, compound the product, and ship the product to customers using packaging and shipping materials which we supply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
pay Doctegrity for each physician visit conducted in response to request made by a patient on our website, regardless of whether the
physician prescribes our product to the patient. The fee we pay Doctegrity is fixed, set in advance and was negotiated at arms&#8217;
length after comparing the prices offered by similar services. We are not a party to any contracts between Doctegrity and any health
professionals or physician groups and do not control how Doctegrity reimburses these providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our arrangement with Doctegrity, as summarized above, is structured to comply with applicable laws, including those restricting the corporate
practice of medicine and fee splitting, there may be a risk that a state agency, now or in the future as these laws (and interpretations
of them) evolve, would conclude that the arrangement and fee structure between Doctegrity and its contracted physicians and/or our agreement
with Doctegrity violates the corporate practice of medicine doctrine and fee splitting restrictions in Texas or in another state where
a patient who uses our Mangoceuticals platform is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Physicians Agreement has a term of one year subject to automatic one-year renewals unless and until terminated in accordance with the
Physicians Agreement, including by either party with 90 days&#8217; prior written notice with or without cause and for cause with ten
days&#8217; written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship
with Epiq Scripts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Master
Services Agreement with Epiq Scripts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2022, and effective on August 30, 2022, we entered into a Master Services Agreement (the &#8220;MSA&#8221;) with Epiq Scripts,
LLC (&#8220;Epiq Scripts&#8221;), which at the time was 51%-owned by American International Holdings Corp (&#8220;American International&#8221;).
Mr. Cohen, our Chairman and Chief Executive Officer, served as the Chief Executive Officer and a director of, and had voting control
over, American International at the time of the entry into the Master Services Agreement. As discussed under &#8220;Company Information
and Formation,&#8221; our company was wholly-owned by American International until April 16, 2022, when control of our company was sold
to Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), which is owned by Mr. Cohen. Epiq Scripts was formed in January 2022, and
only began compounding drugs for patients in November 2022. On February 15, 2023, the 51% of Epiq Scripts then owned by American International
was transferred to Mr. Cohen as part of an exchange transaction, whereby Mr. Cohen agreed to cancel his preferred stock of American International,
which provided him voting control over American International, in exchange for among other assets, American International&#8217;s ownership
of Epiq Scripts. As a result, Epiq Scripts is currently 51% owned by Mr. Cohen, our Chairman and Chief Executive Officer. Additionally,
Mr. Cohen has served as the co-Manager of Epiq Scripts since January 2022.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Master Services
Agreement and a related statement of work (&#8220;SOW&#8221;), Epiq Scripts agreed to provide pharmacy and related services to us, we
agreed to exclusively use Epiq Scripts as the provider of the Services (defined below) during the term of the agreement, so long as Epiq
Scripts complies with the terms of the Master Services Agreement. The agreement also includes a 30-day right of first refusal for Epiq
Scripts to provide pharmacy services for any new product that Mango may introduce during the term of the agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the SOW, Epiq Scripts agreed to provide for the online fulfillment, specialty compounding, packaging, shipping, dispensing and distribution
(collectively, the &#8220;Services&#8221;) of products sold exclusively via our website that may be prescribed as part of a telehealth
consultation on our platform. Epiq Scripts also agreed to provide mail service pharmacy services to us on an exclusive basis during the
term of the SOW.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to provide Epiq Scripts with all custom packaging materials, including but not limited to, individual sachet and/or blister packaging
materials, outer box packaging, and any custom inserts and/or marketing information to accompany the prescription shipment, if any and
to provide Epiq Scripts with quarterly sales forecasts to ensure Epiq Scripts has enough packaging materials on hand to cover a 90-day
period. We agreed to pay for all direct shipping, delivery and related courier costs and to provide Epiq Scripts with direct access to
any online accounts to access and generate shipping labels for the fulfillment and delivery of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SOW has a term through December 31, 2025, automatically renewable thereafter for successive one-year terms unless either party terminates
the agreement at least 90 days before renewal thereof and the SOW is subject to the same termination rights of the parties as set forth
in the Master Services Agreement (discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the SOW, we agreed to pay Epiq Scripts certain fixed rate fees for prescription fulfillment, processing and packaging (per prescription)
and drug compounding (per pill), provided the per pill rate is reduced upon us exceeding 3,500 product packages per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Master Services Agreement, we are solely responsible for billing and collecting funds from our customers and Epiq Scripts is paid
out of funds that we actually collect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid Epiq Scripts a total of $60,000 upon our entry into the Master Services Agreement, comprising $45,000 as a one-time non-refundable
technology systems setup and implementation fee and $15,000 as an upfront retainer to be credited towards the future provision of pharmacy
and related services as outlined and detailed in the Master Services Agreement and SOW, of which $11,745 remained outstanding as of December
31, 2022 and $84,382 remained outstanding as of September 30, 2023. All costs related to the pharmacy services provided by Epiq Scripts
are listed as related party costs of revenues on our statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Master Services Agreement has a term of five years, automatically renewable to additional one-year terms thereafter unless either party
provides the other notice of termination at least 90 days prior to the date of automatic renewal. The Master Services Agreement can be
terminated (i) upon breach of the agreement by the other party, subject to a 90-day cure right, (ii) if a party enters into bankruptcy
or fails to pay its debts as they become due, or (iii) if Epiq Scripts becomes unable to perform the services covered by the Master Services
Agreement and any statements of work associated therewith.&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Epiq Scripts is located in
Texas, and has filed with the Utilization Review Accreditation Commission (&#8220;URAC&#8221;) to obtain its pharmacy accreditation and
obtained its first state license in the State of Texas in February 2022. Epiq Scripts currently has State Board of Pharmacy (or its equivalent)
licenses to operate in the District of Columbia and 47 states: Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia,
Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi,
Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon,
Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming
and plans to eventually obtain licenses in all 50 states by the end of 2023, with some state licenses easier to obtain and quicker to
obtain than others. Although Epiq Scripts is physically located in Texas, it can ship products to customers in each state in which it
holds a license.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, Epiq Scripts can currently only provide the Services to us in the District of Columbia and the 47 states described
above, and we are unable to sell products to any customers in any states other than those named above, until Epiq Scripts is able to
obtain licenses in other states and will thereafter be limited to selling products to customers only in the states in which Epiq Scripts
holds licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreement With Epiq Scripts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2023, we entered into a Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with Epiq Scripts. Pursuant to the
Consulting Agreement, Epiq Scripts agreed to provide pharmacy consulting services in connection with the Company&#8217;s global expansion
efforts, and as reasonably requested by the Company, during the term of the agreement, which is for five years, unless otherwise earlier
terminated (a) due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof;
(b) the mutual agreement of the parties; or (c) the date that Epiq Scripts provides the Company written notice of termination, which
may be at any time and for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for agreeing to provide the services under the agreement, the Company agreed to pay Epiq Scripts (1) a one-time payment
of $65,000, payable within ten days of the entry into the agreement; and (2) a set fee, payable for each prescription drug pill sold
by the Company for cash, to the extent such pill must be prescribed by a medical doctor, or sold through retail pharmacies over the counter,
in jurisdictions where a doctor&#8217;s prescription is not required for the sale of such drugs, and sold in a Territory (defined below),
which consideration per pill decreases each year that the agreement is in effect, and is only payable for the first five years of the
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consulting Agreement further provides that no payments are due for the sale of any prescription pills until the First Sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Consulting Agreement, (a) &#8220;Territory&#8221; means worldwide, except for the United States, including its territories and possessions
and the District of Columbia; and (b) &#8220;First Sale&#8221; means the date that the first commercial sale of prescription pills occurs
in the Territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
payments are also required to be offset equitably for any prescription pill sold which is later refunded, charged back, returned, or
reimbursed to a purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement includes customary representations of the parties, confidentiality and non-solicitation provisions, rights of Epiq Scripts
to audit the sales of prescription pills, subject to certain limitations and requirements, and the requirement that the Company reimburse
certain expenses of Epiq Scripts, subject to certain limitations and pre-approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>First
Amendment to MSA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2023, we entered into a First Addendum to Master Services Agreement with Epiq Scripts (the &#8220;First Amendment&#8221;).&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>Pursuant
to the First Amendment, the parties agreed to amend the MSA to include certain Right of first negotiation rights and right of first refusal
rights (each as discussed below). Additionally, the First Amendment provides for certain rights to Epiq Scripts in the event that the
Company seeks to obtain pharmaceutical services in connection with certain Company products (collectively, &#8220;Pharmaceutical Services&#8221;)
in jurisdictions other than the United States, including, without limitation, Mexico and the United Kingdom, where Epiq Scripts does
not currently maintain licenses or permits (&#8220;Future Jurisdictions&#8221;, which shall also include, to the extent applicable, any
state in the United States in which Epiq Scripts does not then hold required permits or licenses for the provision of the Pharmaceutical
Services) and/or to terminate Epiq Scripts&#8217; rights to provide exclusive Pharmaceutical Services in any current state of the United
States or Future Jurisdiction where Epiq Scripts may then be providing Pharmaceutical Services to the Company (each a &#8220;Current
Jurisdiction&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the parties agreed in the First Amendment that should the Company decide to transfer any services provided by Epiq Scripts in a Current
Jurisdiction to another pharmaceutical service provider (&#8220;Transferred Services&#8221;), the Company will be required to pay Epiq
Scripts a fee of 1% of the total gross sales of all Prescription Products (defined below) by the Company resulting from the Transferred
Services in the Current Jurisdiction, for a period of the lesser of (a) five (5) years from the date the Company transferred the Transferred
Services; and (b) through the end of the term of the MSA (including where applicable, any renewal term)(the &#8220;Non-Use Fee&#8221;).
The Non-Use Fee is payable monthly in arrears, for calendar quarters, by the 15th day following the end of each calendar quarter. &#8220;Prescription
Products&#8221; means Products (as defined in the MSA) sold by the Company which must be prescribed by a medical doctor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, the Non-Use Fee shall not apply, and the Company shall not be obligated to pay any Non-Use Fee (a) in the event that the Transferred
Services are provided directly by the Company or a majority-owned subsidiary of the Company; (b) in the event the Company decides to
enter into an agreement with another pharmaceutical service provider to provide Pharmaceutical Services in a Future Jurisdiction; or
(c) in connection with any services provided by any parties in any Future Jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Amendment also provides that until the fifth anniversary of the First Amendment, the Company shall notify Epiq Scripts in writing
of any plans to (a) expand its need for pharmacy services outside of those contemplated by the MSA; (b) expand its need for pharmacy
services into a new jurisdiction which Epiq Scripts does not then operate in (including, but not limited to new countries); or (c) begin
providing pharmacy services internally (either through organic growth or acquisition). Thereafter Epiq Scripts has the right to provide
the Company written notice of its intention to provide such services (as described in (a) or (b) above, whereafter the Company is required
to discuss and negotiate such services in good faith with Epiq Scripts for a period of not less than 15 days). Otherwise, in the event
of the occurrence of an event discussed in (c) above, the Company is required to discuss the possibility of Epiq Scripts either co-operating
the pharmacy or providing management services to the Company in good faith for 15 days. In the event after such 15 day period, the Company
and Epiq Scripts cannot come to a mutually agreeable agreement, the Company is under no further obligation regarding the matter set forth
in the notice provided to Epiq Scripts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
the First Amendment includes a requirement whereby if Epiq Scripts receives notice of any proposed fundamental transaction involving
Epiq Scripts or its assets, including any agreement, arrangement, offer or proposal (including a letter of intent, term sheet, form of
definitive agreement or definitive agreement) for an asset sale or acquisition, merger, acquisition or sale of securities, or redemption
or repurchase of securities, Epiq Scripts must provide the Company notice of such offer within three days, after which receipt the Company
will have the right of first refusal for 30 days to become the purchaser in connection with the notified transaction, on the terms, and
subject to the conditions, set forth in such notified offer and pursuant to the conditions of the First Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b><i>Marketing
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2023, we entered into a Marketing Agreement with Marius Pharmaceuticals, LLC (&#8220;Marius&#8221;) allowing us the
use of the trademark &#8220;Kyzatrex&#174;&#8221; oral testosterone undecanoate softgel capsules (the &#8220;Marius Marks&#8221;), for
the purposes of branding, packaging, marketing, and selling Kyzatrex&#174; on our website, and to be sold via our telehealth platform
at <span style="text-decoration: underline">www.MangoRx.com </span>(the &#8220;Marius Agreement&#8221;). Pursuant to the Marketing Agreement, Marius granted us a non-exclusive,
non-transferable, royalty-free license to use the Marius Marks in the United States, for the purpose discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Marius Agreement contains customary confidentiality and indemnification provisions and has an initial term of two years, automatically
renewable thereafter for successive one year terms unless otherwise terminated (a) by Marius if we do not have at least 2,500 monthly
customers of &#8220;Kyzatrex&#174;&#8221; oral testosterone undecanoate softgel capsules (the &#8220;Minimum Subscribers&#8221;) at least
30 days prior to the end of the initial term, (b) by either party for cause in connection with a material breach that has not been cured
within 30 business days of written notice thereof provided by the non-breaching party to the breaching party, or (c) by Marius in its
sole discretion without cause by providing at least 60 days&#8217; prior written notice to us. Marius may also terminate the agreement
with written notice to us if we have not met at least 30% of the Minimum Subscribers within six months of the product launch date on
our website, which is anticipated to commence on or before January 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
30 days of the date the Marius Agreement is terminated (or on the date of termination, which cannot occur earlier than 60 days
after notice of termination is provided, if Marius terminates the Marius Agreement for convenience), we are required to
stop and cease all use of the Marius Marks and are required to remove all references to the Marius Marks from our advertising/promotional
materials, and signage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the term of the Marius Agreement and for a period of 12 months thereafter, we agreed to not create, publish or broadcast any advertisement
or otherwise promote or market any other product containing testosterone undecanoate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Marius Agreement, and in consideration of the license granted thereunder, we issued Marius 100,000 shares of our restricted common
stock (the &#8220;Marius Shares&#8221;) which are fully earned upon entry into the agreement. The Marius Shares were valued at $0.68
per share for a total of $68,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="font: 10pt Times New Roman, Times, Serif; width: 100%"><i><a href="#abc_001">Table of Contents</a></i></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding-right: 0.1in; padding-left: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Non-Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on Nasdaq under the symbol &#8220;MGRX&#8221;. Notwithstanding such listing, there is no guarantee that
we will be able to maintain our listing on NASDAQ for any period of time. Among the conditions required for continued listing on Nasdaq,
NASDAQ requires us to maintain at least $2.5 million in stockholders&#8217; equity, $35 million in market value of listed securities,
or $500,000 in net income over the prior two years or two of the prior three years, to have a majority of independent directors (subject
to certain &#8220;<span style="text-decoration: underline">controlled company</span>&#8221; exemptions, which we do not currently meet), to comply with certain audit committee
requirements, and to maintain a stock price over $1.00 per share. Our stockholders&#8217; equity is currently not above NASDAQ&#8217;s
$2.5 million minimum, as discussed below, we may not generate over $500,000 of yearly net income moving forward, we may not maintain
$35 million in market value of listed securities, we may not be able to maintain independent directors (to the extent required), and
as discussed below, we do not currently have a stock price over $1.00 per share. Nasdaq&#8217;s determination that we fail to meet the
continued listing standards of NASDAQ may result in our securities being delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 30, 2023, we received written notice from the Listing Qualifications Department of Nasdaq notifying us that we were not in compliance
with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Nasdaq Listing Rule
5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that
a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business
days. Based on the closing bid price of our common stock for the thirty (30) consecutive business days from September 15, 2023 to October
27, 2023, we no longer meet the minimum bid price requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
letter did not impact the listing of our common stock on Nasdaq. Instead, the letter stated that we have 180 calendar days or until April
29, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of our common stock must have
a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If we do not regain compliance by April
29, 2024, an additional 180 days may be granted to regain compliance, so long as we meet Nasdaq&#8217;s initial listing criteria (except
for the bid price requirement)(which we do not currently meet, as we do not have stockholders&#8217; equity of at least $5 million) and
notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split,
if necessary. If we do not qualify for the second compliance period or fail to regain compliance during the second 180-day period, our
common stock will be subject to delisting, at which point we would have an opportunity to appeal the delisting determination to a Hearings
Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain
compliance with the minimum bid price requirement under the Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
on November 3, 2023, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that our stockholders&#8217;
equity as reported in our Quarterly Report on Form 10-Q for the period ending September 30, 2023 (the &#8220;Form 10-Q&#8221;), did not
meet the minimum stockholders&#8217; equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies
listed on Nasdaq to maintain stockholders&#8217; equity of at least $2,500,000. In our Form 10-Q, we reported stockholders&#8217; equity
of $1,354,821, which is below the minimum stockholders&#8217; equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1).
Additionally, we do not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
notice of noncompliance had had no immediate impact on the continued listing or trading of our common stock on Nasdaq, which continues
to be listed and traded on Nasdaq, subject to our compliance with the other continued listing requirements. Nasdaq has given us until
December 18, 2023 to submit to Nasdaq a plan to regain compliance. We are submitting a plan of compliance on December 18, 2023,
and if our plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of Nasdaq&#8217;s letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are confident that we can regain compliance with Nasdaq&#8217;s minimum stockholders&#8217; equity standard within the compliance period. However, there can be no assurance
that our plan will be accepted or that if it is, we will be able to regain compliance. If our plan to regain compliance is not accepted,
or if it is and we do not regain compliance within 180 days from the date of Nasdaq&#8217;s letter, or if we fail to satisfy another
Nasdaq requirement for continued listing (including the requirement that we maintain a minimum bid price of at least $1.00 per share,
which as discussed above, the Company is not currently in compliance with), Nasdaq could provide notice that our common stock will become
subject to delisting. In such event, Nasdaq rules would permit us to appeal the decision to reject our proposed compliance plan or any
delisting determination to a Nasdaq Hearings Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we demonstrate compliance with the requirements of Nasdaq as discussed above, we will have to continue to meet other objective and
subjective listing requirements to continue to be listed on Nasdaq. Delisting from Nasdaq could make trading our common stock more difficult
for investors, potentially leading to declines in our share price and liquidity. Without a Nasdaq listing, stockholders may have a difficult
time getting a quote for the sale or purchase of our stock, the sale or purchase of our stock would likely be made more difficult, and
the trading volume and liquidity of our stock could decline. Delisting from Nasdaq could also result in negative publicity and could
also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of
our common stock as currency or the value accorded by other parties. Further, if we are delisted, we would also incur additional costs
under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity
of our common stock and the ability of our stockholders to sell our common stock in the secondary market. If our common stock is delisted
by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB Market or the OTC Pink
market, where an investor may find it more difficult to sell our stock or obtain accurate quotations as to the market value of our common
stock. In the event our common stock is delisted from Nasdaq, we may not be able to list our common stock on another national securities
exchange or obtain quotation on an over-the counter quotation system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
delisting of our common stock from the Nasdaq could adversely affect our business, financial condition and results of operations and
our ability to attract new investors, reduce the price at which our common stock trades, decrease, investors&#8217; ability to make transactions
in our common stock, decrease the liquidity of our outstanding shares, increase the transaction costs inherent in trading such shares,
and reduce our flexibility to raise additional capital without overall negative effects for our stockholders.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="nj_003"></span>Glossary
of Industry Terms</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are abbreviations, acronyms and definitions of certain terms used in this document, which are commonly used in our industry:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;cGMP&#8221;
means current good manufacturing practice regulations promulgated by the FDA under the authority of the FFDCA. These regulations, which
have the force of law, require that manufacturers, processors, and packagers of drugs, medical devices, some food, and blood take proactive
steps to ensure that their products are safe, pure, and effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;FFDCA&#8221;
means the Federal Food, Drug and Cosmetic Act, which is a set of U.S. laws passed by Congress in 1938 giving authority to the FDA to
oversee the safety of food, drugs, medical devices, and cosmetics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;HIPAA&#8221;
means the Health Insurance Portability and Accountability Act of 1996, which has the goal of making it easier for people to keep health
insurance, protect the confidentiality and security of healthcare information and help the healthcare industry control administrative
costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;HITECH&#8221;
means the Health Information Technology for Economic and Clinical Health Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;IU&#8221;
means International Unit, which is a unit of measurement for the effect, not mass of a substance; the variance is based on the biological
activity or effect, for the purpose of easier comparison across similar forms of substances. IUs are used to measure the activity of
many vitamins, hormones, enzymes, and drugs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Individually
identifiable health information&#8221; is defined by HIPPA to mean information that is a subset of health information, including demographic
information collected from an individual, and: (1) is created or received by a health care provider, health plan, employer, or health
care clearinghouse; and (2) relates to the past, present, or future physical or mental health or condition of an individual; the provision
of health care to an individual; or the past, present, or future payment for the provision of health care to an individual; and (a) that
identifies the individual; or (b) with respect to which there is reasonable basis to believe the information can be used to identify
the individual.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Mg&#8221;
means <span style="background-color: white">milligrams.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NCPDP&#8221;
means the National Council for Prescription Drug Programs, which is an American National Standards Institute accredited, standards development
organization providing healthcare solutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NPI&#8221;
means National Provider Identifier, which is a Health Insurance Portability and Accountability Act (HIPAA) Administrative Simplification
Standard. The NPI is a unique identification number for covered health care providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;PII&#8221;
means personal identifiable information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;TSBP&#8221;
means The Texas State Board of Pharmacy, which is the state agency responsible for the licensing/registration of Texas pharmacists, pharmacy
technicians, and pharmacies; for establishing regulations for pharmacy practice; and for disciplining licensees and registrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;URAC&#8221;
means the Utilization Review Accreditation Commission, which is a review accreditation commission which offers health organizations an
opportunity to have trained reviewers examine their operations and publicly ensure they are delivering care in a manner consistent with
national standards.</span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b>Selected Risks Associated
with Our Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks and uncertainties, including those in the section entitled &#8220;<a href="#nj_007">Risk Factors</a>&#8221; and elsewhere
in this prospectus. These risks include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    need for additional funding, the availability and terms of such funding, and dilution caused thereby;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have a limited operating history, have produced only a limited amount of products and have generated only limited revenues to date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to execute our growth strategy and scale our operations and risks associated with such growth, and our ability to attract
    members and customers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effect of pandemics and governmental responses thereto on our operations, those of our vendors, our customers and the economy in
    general;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with our ED product which has not been, and will not be, approved by the FDA and has not had the benefit of the FDA&#8217;s
    clinical trial protocol which seeks to prevent the possibility of serious patient injury and death;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    that the FDA may determine that the compounding of our planned products does not fall within the exemption from the FFDCA Act provided
    by Section 503A;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    significant reliance on related party transactions and risks associated with such related party relationships and agreements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    effect of data security breaches, malicious code and/or hackers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competition
    and our ability to create a well-known brand name;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in consumer tastes and preferences;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    changes and/or terminations of our relationships with key parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause
    health issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to innovate, expand our offerings and compete against competitors which may have greater resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Chairman and Chief Executive Officer, Jacob D. Cohen our President and Director, Jonathan Arango, have majority voting control over
    the company which may deter some investors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to prevent credit card and payment fraud;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
    associated with inflation, and increases in interest rates and economic downturns, including potential recessions, as well as macroeconomic,
    geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and Israel/Hamas
    conflict) and other large-scale crises;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk of unauthorized access to confidential information;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    ability to protect our intellectual property and trade secrets, claims from third-parties that we have violated their intellectual
    property or trade secrets and potential lawsuits in connection therewith;</span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

</div>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 19; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    and our providers&#8217; ability to comply with government regulations, changing regulations and laws, penalties associated with
    any non-compliance (inadvertent or otherwise), the effect of new laws or regulations, and our ability to comply with such new laws
    or regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    reliance on our current management and the terms of their employment agreements with us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    outcome of future lawsuits, litigation, regulatory matters or claims;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    fact that certain recent initial public offerings of companies with public floats comparable to the public float of the Company have
    experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company; and the fact
    that we may experience similar volatility, which may make it difficult for investors to assess the value of our common stock;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
    terms and provisions of our governing documents which may prevent a change of control, and which provide for indemnification of officers
    and directors, limit the liability of officers or directors, and provide for the board of director&#8217;s ability to issue blank
    check preferred stock; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    volatile nature of the trading price of our common stock; dilution experienced by investors in the offering; and dilution which may
    be caused by future sales of securities.</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span id="nj_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
and Background Information</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Texas corporation formed on October 7, 2021. Our address is 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248. Our telephone
number is (214) 242-9619. Our website is <span style="text-decoration: underline">www.MangoRX.com</span>. Information contained on or accessible through our website is not a
part of this prospectus and is not incorporated by reference herein, and the inclusion of our website address in this prospectus is an
inactive textual reference only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, we consummated our initial public offering (the &#8220;IPO&#8221;) of 1,250,000 shares of common stock at a price to
the public of $4.00 per share, pursuant to that certain Underwriting Agreement, dated March 20, 2023 (the &#8220;Underwriting Agreement&#8221;),
between the Company and Boustead Securities, LLC, as representative (&#8220;Boustead&#8221;) of several underwriters named in the Underwriting
Agreement. The Company received gross proceeds of approximately $5 million, before deducting underwriting discounts and commissions and
estimated offering expenses payable by the Company upon the sale of the shares. In connection with the IPO, the Company also granted
Boustead a 45-day option to purchase up to an additional 187,500 shares of its common stock, which expired unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the same time, and as part of the same registration statement, but pursuant to a separate prospectus (the &#8220;Resale Prospectus&#8221;)
the Company registered the sale of 4,765,000 shares of common stock, including 2,000,000 shares of common stock issuable upon the exercise
of outstanding warrants to purchase shares of common stock with an exercise price of $1.00 per share, of which warrants to purchase 975,500
shares of common stock remain outstanding, and unexercised, as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration in connection with the IPO, we granted Boustead, the representative of the underwriters named in the Underwriting
Agreement for the IPO, warrants to purchase 87,500 shares of common stock with an exercise price of $5.00 per share, which are exercisable
beginning six months after the effective date of the registration statement filed in connection with the IPO (March 20, 2023) and expire
five years after such effectiveness date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span id="nj_006"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
    stock we are offering</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 78%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,000,000
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Over-allotment
    option</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have granted a 45-day option to the underwriter to purchase up to 600,000 additional
                                            shares of common stock (up to 15% of the number of shares of common stock sold in the offering)
                                            solely to cover overallotments, if any.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
    stock outstanding immediately before this offering</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,419,500
    shares</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
    stock outstanding immediately after this offering</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21,419,500
                                            </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
                                            (22,019,500 shares if the underwriters&#8217; option to purchase additional shares
                                            is exercised in full).<sup>(1)</sup></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use
    of proceeds</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            estimate that the net proceeds from this offering will be approximately $1.0 million,
                                            or approximately $1.2 million if the underwriters exercise their over-allotment
                                            option in full, at a public offering price of $0.30 per share, after deducting
                                            the underwriting discounts and commissions and estimated offering expenses payable by us.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the proceeds from this offering primarily for general corporate purposes, including to finance the marketing and operational
    expenses associated with the planned marketing of our Mango ED and Mango GROW products ($722,880, or approximately 72% of
    the net proceeds), hiring additional personnel to build organizational talent ($80,320, or approximately 8% of the net proceeds),
    capital expenditures for software development and maintenance $50,200, or approximately 5% of the net proceeds) and working
    capital ($150,600, or approximately 15% of the net proceeds). See &#8220;<a href="#sj_002">Use of Proceeds</a>.&#8221;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risk
    Factors</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &#8220;<a href="#nj_007">Risk Factors</a>&#8221; and other information appearing elsewhere in this prospectus for a discussion of factors you should carefully
    consider before deciding whether to invest in our common stock.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lock-up</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    previously agreed, subject to certain exceptions and without the approval of the representative of the underwriters, not to offer,
    issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities until March
    20, 2024.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, in connection with our IPO, our directors, executive officers, and shareholders holding 5% or more of our outstanding common
    stock previously agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose
    of any of our securities until March 20, 2024, subject to certain exceptions, and any director or officers who did not enter into
    a lock up agreement with the Representative in connection with our IPO has entered into a lock up agreement with us agreeing to not
    to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities
    for a period of 90 days after the date the registration statement of which this prospectus forms a part is declared effective by
    the Commission.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
    to the extent the registration statement of which this prospectus is a part, is not declared effective by the Commission on or before
    December 31, 2023, we agreed to cause each of our officers, directors and owners of 5% or more of our outstanding common stock (or
    securities convertible or exercisable into common stock), to deliver an executed lock-up agreement to the Representative and agree
    to be locked up for a period of 90 days after the date the registration statement of which this prospectus forms a part is declared
    effective by the Commission.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    &#8220;<a href="#mj_005">Underwriting</a>&#8221; for more information.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
    trading symbol</i></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;MGRX.&#8221;
</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding after this offering is based on 17,419,500 shares outstanding as of December 18,
2023, and excludes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    of outstanding options to purchase 1,250,000 shares of common stock at an exercise price of $1.10 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    of outstanding warrants to purchase 1,063,000 shares of common stock at a weighted&#160;&#160;average exercise price of $1.00 per
    share; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    awards under our 2022 Equity Incentive Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated, all information in this prospectus reflects and assumes no exercise by the underwriters of their over-allotment
option to purchase additional shares of common stock from us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<div style="border: Black 1.5pt solid; padding: 0.1in">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span id="nj_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
Financial Data</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents our summary historical financial data for the periods indicated. The summary historical financial data as of
September 30, 2023, and for the nine months ended September 30, 2023 and 2022, are derived from the unaudited financial statements included
herein and the summary financial data as of December 31, 2022, for the year ended December 31, 2022 and for the period from October 7,
2021 (Inception) through December 31, 2021, are derived from the audited financial statements included herein. See &#8220;<a href="#fintoc_001">Index to Financial Statements</a>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
results are included for illustrative and informational purposes only and are not necessarily indicative of results we expect in future
periods, and results of interim periods are not necessarily indicative of results for the entire year. You should read the following
summary financial data in conjunction with &#8220;<a href="#sj_006">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a>&#8221;
and our financial statements and related notes appearing elsewhere in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Statements of Operations Data:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine Months Ended September 30, 2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">487,119</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198,201</td><td style="text-align: left">)</td>
    <td style="text-align: right">(1)</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">288,918</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,939,761</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,727</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,473</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,673</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,644,370</td><td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,324,400</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.45</td><td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.13</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Statements of Operations Data:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>From</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>October 7, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Inception) to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, 2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,939</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,089</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,996,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,520</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Imputed interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,473</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,998,055</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,701</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.19</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">September 30, 2023</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">(unaudited)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Balance Sheet Data:</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Actual</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As Adjusted <sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,236,747</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,240,747</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,595,505</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,599,505</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,183,534</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3,424,281</p></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,660,126</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,660,126</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,354,821</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,717,579</p></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)
</sup>Includes $96,663 of related party cost of revenues for the nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)
</sup>The As Adjusted column gives effect to the sale of 4,000,000 shares of common stock in this offering based on a public offering
price of $0.30 per share, less the underwriting discounts and commissions and estimated offering expenses payable by us. See also
&#8220;Capitalization&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span id="nj_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
Factors</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
in our common stock involves a high degree of risk. You should carefully consider each of the following risks, together with all other
information set forth in this prospectus, including the financial statements and the related notes, before making a decision to buy our
common stock. If any of the following risks actually occurs, our business could be harmed. In that case, the trading price of our common
stock could decline, and you may lose all or part of your investment.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to our Operating History and Need for Funding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
were recently formed, have a limited operating history and have generated only limited revenues to date and there is no assurance that
we can generate revenues or sell any commercial amount of our products in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were only recently formed and have a limited operating history. We launched our website in mid-November 2022. To date we have sold only
a small number of products and generated only limited revenues and have not sold sufficient quantities of our Mango ED or Mango GROW
products to support our operations. There is no assurance that we can generate revenues sufficient to support our operations, and even
if additional revenues are generated, there is no assurance that we can generate sufficient net income to support our operations. As
reflected in the accompanying financials, the Company had a net loss of $6,644,370 for the nine months ended September 30, 2023 and an
accumulated deficit of $8,660,126 as of September 30, 2023. Additionally, the Company had a net loss of $1,998,055 for the year ended
December 31, 2022 and an accumulated deficit of $2,015,756 as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced recurring net losses since inception. We believe that we will continue to incur substantial operating expenses in the
foreseeable future as we continue to invest to bring our Mango ED and Mango GROW products to market and to attract customers, expand
the product offerings and enhance technology and infrastructure. These efforts may prove more expensive than we anticipate, and we may
not succeed in generating commercial revenues or net income to offset these expenses. Accordingly, we may not be able to achieve profitability,
and we may incur significant losses for the foreseeable future. Our independent registered public accounting firm included an explanatory
paragraph in its report on our financial statements as of December 31, 2022, included herein. As of the date of this prospectus, our
current capital resources, combined with the net proceeds from the offering, are expected to be sufficient for us to fund operations
for the next 12 months. We may need funding in addition to the funding raised in our IPO and which are sought to be raised through this
offering, to support our operations in the future. We may also seek to acquire additional businesses or assets in the future, which may
require us to raise funding. We currently anticipate such funding, if required, being raised through the offering of debt or equity.
Such additional financing, if required, may not be available on favorable terms, if at all. If debt financing is available and obtained,
our interest expense may increase and we may be subject to the risk of default, depending on the terms of such financing. If equity financing
is available and obtained it may result in our shareholders experiencing significant dilution. If such financing is unavailable, we may
be forced to curtail our business plan, which may cause the value of our securities to decline in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Since
we have a limited operating history, it is difficult for potential investors to evaluate our business and our business is in a relatively
new consumer product segment, which is difficult to forecast.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
limited operating history in the health and wellness industry may hinder our ability to successfully meet our objectives and makes it
difficult for potential investors to evaluate our business or prospective operations. As an early-stage company, we are subject to all
the risks inherent in the financing, expenditures, operations, regulatory compliance, complications and delays inherent in a new business.
Accordingly, our business and success face risks from uncertainties faced by developing companies in a competitive environment. The likelihood
of our success must be considered in light of the problems, expenses, difficulties, regulatory challenges, complications and delays frequently
encountered in connection with the formation of a new business, the development of a new strategy and the competitive environment in
which we operate. There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our industry segment is relatively new, and is constantly evolving. As a result, there is a lack of available information with which
to forecast industry trends or patterns. There is no assurance that sustainable industry trends or preferences will develop that will
lead to predictable growth or earnings forecasts for individual companies or the industry segment as a whole. We are also unable to determine
what impact future governmental regulation may have on trends and preferences or patterns within our industry segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
need additional capital which may not be available on commercially acceptable terms, if at all, and this raises questions about our ability
to continue as a going concern.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
need capital to support our operations and continue to market and commercialize our current Mango ED and Mango GROW products. We may
also require additional funding in the future to support our operations, expand our product line, pay expenses, or expand or complete
acquisitions. The most likely source of future funds presently available to us will be through the sale of equity capital or debt. Any
sale of share capital will result in dilution to existing shareholders. Furthermore, we may incur debt in the future, and may not have
sufficient funds to repay our future indebtedness or may default on our future debts, jeopardizing our business viability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to borrow or raise additional capital in the future to meet our needs or to otherwise provide the capital necessary to
expand our operations and business, which might result in the value of our securities decreasing in value or becoming worthless. Additional
financing may not be available to us on terms that are acceptable. Consequently, we may not be able to proceed with our intended business
plans. Obtaining additional financing contains risks, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    equity financing may not be available to us on satisfactory terms and any equity we are able to issue could lead to dilution for
    current shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loans
    or other debt instruments may have terms and/or conditions, such as interest rate, restrictive covenants and control or revocation
    provisions, which are not acceptable to management or our directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    current environment in capital markets combined with our capital constraints may prevent us from being able to obtain adequate debt
    financing; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to obtain required additional financing to commercialize our products and grow our business, we would need to delay or scale
    back our business plan, reduce our operating costs, or delay product launches, each of which would have a material adverse effect
    on our business, future prospects, and financial condition.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we may have difficulty obtaining additional funding, and we may have to accept terms that would adversely affect our shareholders. For
example, the terms of any future financings may impose restrictions on our right to declare dividends (provided that none are currently
planned) or on the manner in which we conduct our business. Additionally, lending institutions or private investors may impose restrictions
on a future decision by us to make capital expenditures, acquisitions or significant asset sales. If we are unable to raise additional
funds, we may be forced to curtail or even abandon our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Business Activities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to successfully commercialize our Mango ED or Mango GROW products or any other potential future men&#8217;s wellness
products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to effectively commercialize our Mango ED or Mango GROW products or any other potential future men&#8217;s wellness products.
If we are unable to successfully commercialize our Mango ED and Mango GROW products or successfully develop, produce, launch and commercialize
any other potential future men&#8217;s wellness products, our ability to generate product sales will be severely limited, which will
have a material adverse impact on our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 24; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect to face intense competition, often from companies with greater resources and experience than we have.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health, wellness, and telemedicine industries are highly competitive and subject to rapid change. The industries continue to expand and
evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential competitors
have substantially greater financial, technological, managerial and research and development resources and experience than we have. We
mainly compete with other companies offering men&#8217;s wellness products, including Hims &amp; Hers Health, Inc. and Roman, and with
our Mango ED products, we are also competing against much larger pharmaceutical companies who offer ED branded drugs like Viagra (Pfizer)
and Cialis (marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation) and their generic forms.
With our Mango GROW product, we compete against the much larger pharmaceutical company Merck &amp; Co., which offers the branded hair
loss product Propecia, and Johnson &amp; Johnson, the owner of Rogaine&#174; &#8211; a branded form of Minoxidil. The majority of these
competitors and potential competitors have more experience than we have in the development of health and wellness services and products.
In addition, our planned services and products will compete with service and product offerings from large and well-established companies
that have greater marketing and sales experience and capabilities than we or the parties with which we contract have. If we are unable
to compete successfully, we may be unable to grow and sustain our revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ability to compete depends upon many factors both within and beyond our control, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    marketing efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    flexibility and variety of our product offerings relative to our competitors, and our ability to timely launch new product initiatives;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    quality and price of products offered by us and our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation and brand strength relative to our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
    satisfaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size and composition of our customer base;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience of the experience that we provide;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to comply with, and manage the costs of complying with, laws and regulations applicable to our business; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to cost-effectively source and distribute the products we offer and to manage our operation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
competitors also have longer operating histories, and will have larger fulfillment infrastructures, greater technical capabilities, faster
shipping times, lower-cost shipping, lower operating costs, greater financial, marketing, institutional and other resources and larger
consumer bases than we do. These factors may also allow our competitors to derive greater revenue and profits from their existing consumer
bases, acquire consumers at lower costs or respond more quickly than we are able to, to new or emerging technologies and changes in product
trends and consumer shopping behavior. These competitors may engage in more extensive research and development efforts, enter or expand
their presence in any or all of the ecommerce or retail channels where we compete, undertake more far-reaching marketing campaigns, and
adopt more aggressive pricing policies, which may allow them to build larger consumer bases or generate revenue from their existing consumer
bases more effectively than we are able to. As a result, these competitors may be able to offer comparable or substitute products to
consumers at similar or lower costs. This could put pressure on us to lower our prices, resulting in lower revenue and margins or cause
us to lose market share even if we lower prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
companies with greater resources or more well-known brand names may attempt to compete with us, and as a result, we may lose current
or potential customers and may be unable to generate sufficient revenues to support our operations, any one of which could have a material
adverse effect on our ability to grow and our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not successfully compete with larger competitors that have greater financial, sales, technical and other resources. Companies with
greater resources may acquire our competitors or launch new products, and they may be able to use their resources and scale to respond
to competitive pressures and changes in consumer preferences by reducing prices or increasing promotional activities, among other things.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to successfully provide a good customer experience, including by developing new product offerings, our ability to attract members
and customers may be materially adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain customers and retain future customers, attract customers and increase customer engagement with us will depend in part
on our ability to successfully implement and improve our customer experience, including by continuing to create and introduce new product
offerings, improving upon and enhancing our existing product offerings and strengthening our customers interactions with our brand and
products. If new or enhanced product offerings are unsuccessful, we may be unable to attract or retain customers and our operating results
could be materially adversely affected. Furthermore, new or shifting customer demands, tastes or interests, superior competitive offerings
or a deterioration in our product offering quality or our ability to bring new or enhanced product offerings to market quickly and efficiently
could negatively affect the attractiveness of our products and the economics of our business and require us to make substantial changes
to and additional investments in our product offerings or business model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may expend our limited resources to pursue particular products or services and may fail to capitalize on products or services that may
be more profitable or for which there is a greater likelihood of success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we have limited financial and managerial resources, we must focus our efforts on particular service programs and products. As a result,
we may forego or delay pursuit of opportunities with other services or products that later prove to have greater commercial potential.
Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Any such failure could result in missed opportunities and/or our focus on products or services with low market potential, which would
harm our business and financial condition. Our current use of proceeds is specifically focused on among other things, the marketing and
selling of our current Mango ED and Mango GROW products and includes capital allocated for future products or services anticipated to
be sold in the future under the &#8216;Mango&#8217; label and brand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, which entity is currently
licensed to provide pharmacy services in only 47 states and the District of Columbia.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in greater detail under &#8220;Business&#8212;<span style="text-decoration: underline">Material Agreements&#8212;Master Services Agreement with Epiq Scripts</span>&#8221;
and &#8220;<span style="text-decoration: underline">&#8212;First Amendment to MSA</span>,&#8221; we have entered into a Master Services Agreement and SOW for Epiq Scripts, a
related party, 51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, to provide us pharmacy and compounding
services. Epiq Scripts has filed with the Utilization Review Accreditation Commission (&#8220;URAC&#8221;) to obtain its pharmacy accreditation
and has State Board of Pharmacy (or its equivalent) licenses in the District of Columbia and 47 states: Alaska, Arizona, Arkansas, Colorado,
Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts,
Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina,
North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington,
West Virginia, Wisconsin, and Wyoming. It is also in the process of applying for additional state licenses and plans to eventually obtain
licenses in all 50 states by the end of 2023, with some state licenses easier to obtain and quicker to obtain than others. As a result
of the above, Epiq Scripts can currently only provide the Services to us in the 47 states described above and the District of Columbia,
and we are unable to sell products to any customers in any states other than those 47 states and the District of Columbia, until Epiq
Scripts is able to obtain licenses in other states and is limited to selling products to customers only in the states in which Epiq Scripts
holds licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Master Services Agreement does not address product liability claims which may result in us bringing legal claims or actions against Epiq
Scripts to attempt to seek indemnification or contribution for product liability claims.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to the Master Services Agreement agreed to indemnify, defend, and hold harmless the other and the other party&#8217;s officers,
directors, shareholders, employees, and agents from and against any and all nonparty claims, or actions for damages, liabilities (including
strict liability), penalties, costs and expenses (including reasonable legal fees, expenses and costs) to the proportionate extent caused
by (1) the negligence or willful misconduct of the indemnitor or any of its employees or agents in connection with the performance of
the agreement, or (2) any breach of any representation, warranty or covenant under the agreement by the indemnitor or any of its employees
or agents. Additionally, the parties agreed that neither party will be liable to the other for special, incidental, or exemplary damages,
subject to certain limited exceptions. The Master Services Agreement does not address product liability claims or assign any rights of
indemnification or contribution in connection therewith. As a result, in the event of product liability claims, we may be forced to bring
legal claims or actions against Epiq Scripts to attempt to seek indemnification or contribution for product liability claims, to the
extent that we are sued in connection with such claims and Epiq Scripts isn&#8217;t sued or that we are found primarily liable for such
claims. Such claims may be costly, time consuming, and may not ultimately result in a favorable outcome to us, all of which may have
an adverse effect on the value of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently owe certain rights to Epic Scrips under the Management Services Agreement which may limit our future operations and/or have
a material adverse effect on our operations and cash flow. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described in greater detail under &#8220;Business&#8212;Material Agreements&#8212;Master Services Agreement with Epiq Scripts&#8221;
and &#8220;&#8212;First Amendment to MSA,&#8221; we have entered into a Master Services Agreement and SOW for Epiq Scripts, a related
party, 51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, to provide us pharmacy and compounding services.
Pursuant to the Master Services Agreement and a related SOW, Epiq Scripts agreed to provide pharmacy and related services to us, we agreed
to exclusively use Epiq Scripts as the provider of online fulfillment, specialty compounding, packaging, shipping, dispensing and distribution
services relating to products sold exclusively via our website, that may be prescribed as part of a telehealth consultation on our platform,
during the term of the Master Services Agreement, so long as Epiq Scripts complies with the terms of the Master Services Agreement. The
agreement also includes a 30-day right of first refusal for Epiq Scripts to provide pharmacy services for any new product that Mango
may introduce during the term of the Master Services Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Master Services Agreement, as amended, Epiq Scripts has certain rights in the event that the Company seeks to obtain pharmaceutical
services in connection with certain Company products (collectively, &#8220;Pharmaceutical Services&#8221;) in jurisdictions other than
the United States, including, without limitation, Mexico and the United Kingdom, where Epiq Scripts does not currently maintain licenses
or permits (&#8220;Future Jurisdictions&#8221;, which shall also include, to the extent applicable, any state in the United States in
which Epiq Scripts does not then hold required permits or licenses for the provision of the Pharmaceutical Services) and/or to terminate
Epiq Scripts&#8217; rights to provide exclusive Pharmaceutical Services in any current state of the United States or Future Jurisdiction
where Epiq Scripts may then be providing Pharmaceutical Services to the Company (each a &#8220;Current Jurisdiction&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
should the Company decide to transfer any services provided by Epiq Scripts in a Current Jurisdiction to another pharmaceutical service
provider (&#8220;Transferred Services&#8221;), the Company will be required to pay Epiq Scripts a fee of 1% of the total gross sales
of all Prescription Products (defined below) by the Company resulting from the Transferred Services in the Current Jurisdiction, for
a period of the lesser of (a) five (5) years from the date the Company transferred the Transferred Services; and (b) through the end
of the term of the Master Services Agreement (including where applicable, any renewal term)(the &#8220;Non-Use Fee&#8221;). The Non-Use
Fee is payable monthly in arrears, for calendar quarters, by the 15th day following the end of each calendar quarter. &#8220;Prescription
Products&#8221; means Products (as defined in the Master Services Agreement) sold by the Company which must be prescribed by a medical
doctor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 27; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, the Non-Use Fee shall not apply, and the Company shall not be obligated to pay any Non-Use Fee (a) in the event that the Transferred
Services are provided directly by the Company or a majority-owned subsidiary of the Company; (b) in the event the Company decides to
enter into an agreement with another pharmaceutical service provider to provide Pharmaceutical Services in a Future Jurisdiction; or
(c) in connection with any services provided by any parties in any Future Jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Master Services Agreement, as amended, until September 15, 2028, the Company is required to notify Epiq Scripts in writing of
any plans to (a) expand its need for pharmacy services outside of those contemplated by the Master Services Agreement; (b) expand its
need for pharmacy services into a new jurisdiction which Epiq Scripts does not then operate in (including, but not limited to new countries);
or (c) begin providing pharmacy services internally (either through organic growth or acquisition). Thereafter Epiq Scripts has the right
to provide the Company written notice of its intention to provide such services (as described in (a) or (b) above, whereafter the Company
is required to discuss and negotiate such services in good faith with Epiq Scripts for a period of not less than 15 days). Otherwise,
in the event of the occurrence of an event discussed in (c) above, the Company is required to discuss the possibility of Epiq Scripts
either co-operating the pharmacy or providing management services to the Company in good faith for 15 days. In the event after such 15
day period, the Company and Epiq Scripts cannot come to a mutually agreeable agreement, the Company is under no further obligation regarding
the matter set forth in the notice provided to Epiq Scripts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and obligations set forth above could have a material adverse effect on the Company, its plans for future products and expansions,
or make such future products or expansion more costly or time consuming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently exclusively rely, and continue to exclusively rely, on Epiq Scripts, a related party entity with a limited operating history,
for our pharmacy compounding services.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed herein, we have entered into a Master Services Agreement with Epiq Scripts, a related party, 51% owned and controlled by Jacob
D. Cohen, our Chairman and Chief Executive Officer, to operate as our sole and exclusive licensed pharmacy to compound our Mango ED and
Mango GROW products to customers, assuming such Mango ED and Mango GROW products are prescribed by physicians pursuant to our agreement
with Doctegrity. Epiq Scripts was only formed in January 2022, and has only been compounding drugs for patients for a short period of
time. We currently exclusively rely, and continue to exclusively rely, on Epiq Scripts. We face risks relying on a newly formed pharmacy
with limited operations. Those risks include risks that Epiq Scripts will not be able to follow applicable regulatory guidelines relating
to, will not be able to timely or cost effectively complete, or may not correctly, fulfill, specialty compound, package, ship, dispense
and/or distribute our Mango ED and Mango GROW products. If Epiq Scripts is not able to scale its operations to meet the demand of our
operations, or is unable to undertake any of the actions described above, our business may be materially and adversely affected, we may
need to find a new partner pharmacy, which may charge us more money for its services or may not have as favorable contract terms, we
may be delayed or prevented from selling our Mango ED and Mango GROW products, and may face fines, penalties or litigation. In the event
of the occurrence of any of the above, the value of our securities may decline in value or become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
use of social media and influencers may materially and adversely affect our reputation or subject us to fines or other penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use third-party social media platforms as part of our marketing strategy. We also maintain relationships with social media influencers.
As existing e-commerce and social media platforms continue to rapidly evolve and new platforms develop, we expect to maintain a presence
on these existing platforms and expect them to be an important part of our marketing strategy. If we are unable to cost-effectively use
social media platforms as marketing tools, if the social media platforms we use change their policies or algorithms, or if evolving laws
and regulations limit how we can market through these channels, if at all, we may not be able to fully optimize our use of such platforms
and our ability to retain current customers and acquire new customers may suffer. Any such failure could adversely affect our reputation,
revenue, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, an increase in the use of social media for product promotion and marketing may increase the burden on us to monitor compliance
related thereto, and increase the risk that such materials could contain problematic product or marketing claims in violation of applicable
regulations. For example, in some cases, the Federal Trade Commission has sought enforcement action where an endorsement has failed to
clearly and conspicuously disclose a financial relationship or material connection between an influencer and an advertiser. We do not
control the content of what our influencers post on social media, and if we were held responsible for any false, misleading, or otherwise
unlawful content of their posts or their actions, we could be fined or subjected to other monetary liabilities or required to alter our
practices, which could have an adverse impact on our business, reputation, cash flows and ability to operate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Negative
commentary regarding our business, or influencers who endorse our products and other third parties who are affiliated with or endorse
us, may also be posted on social media platforms. Influencers with whom we maintain endorsement arrangements could engage in behavior
or use their platforms to communicate with our customers in a manner that reflects poorly on our brand and may be attributed to us or
otherwise adversely affect our reputation. Any such negative commentary could impact our reputation or brand and affect our ability to
attract and retain customers, which could have a material adverse effect on our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business depends on our brand, and any failure to maintain, protect or enhance our brand, including as a result of events outside our
control, could materially adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our future success depends on our ability to maintain and grow the value of the &#8220;Mango&#8221; brand. Maintaining, promoting
and positioning our brand and reputation will depend on, among other factors, the success of our marketing and merchandising efforts
and our ability to provide a consistent, high-quality customer experience. Any negative publicity, regardless of its accuracy, could
materially adversely affect our business. Brand value is based in large part on perceptions of subjective qualities, and any incident
that erodes the loyalty of our customers, including adverse publicity or a governmental investigation or litigation, could significantly
reduce the value of our brand and significantly damage our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of our brand also depends on effective customer support to provide a high-quality customer experience, which requires significant
personnel expense. If not managed properly, this expense could impact our profitability. Failure to manage or train our own or outsourced
customer support representatives properly, or our inability to hire sufficient customer support representatives could result in lower-quality
customer support and/or increased customer response times, compromising our ability to handle customer complaints effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to gain and increase market acceptance and generate commercial revenues is subject to a variety of risks, many of which are out
of our control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Mango ED and Mango GROW products and any other potential future men&#8217;s wellness products may not gain or increase market acceptance
among physicians, patients, healthcare payors or the medical community. We believe that the degree of market acceptance and our ability
to generate commercial revenues from such products will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand the use of our products through targeted patient and physician education;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    and timing of market introduction of competitive products;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 29; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">quality,
    safety and efficacy in the approved setting;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of any side effects, including those of the components of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emergence
    of previously unknown side effects, including those of the generic components of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    or perceived advantages or disadvantages over alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience and ease of purchasing the product, as perceived by potential patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strength
    of sales, marketing and distribution support;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">price,
    both in absolute terms and relative to alternative treatments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of any future collaborators&#8217; sales and marketing strategies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of current and future healthcare laws;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of coverage and reimbursement from government and other third-party payors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommendations
    for prescribing physicians to complete certain educational programs for prescribing drugs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of government or third-party coverage; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    labeling, product insert, or new studies or trial requirements of the FDA or other regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Mango ED and Mango GROW and/or future products may fail to achieve market acceptance or generate significant revenue to achieve sustainable
profitability. In addition, our efforts to educate the medical community and third-party payors on the safety and benefits of our drugs
may require significant resources and may not be successful.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to scale our operations fast enough to bring down our cost of sales and generate revenues sufficient to support our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that in general, the faster we are able to scale up our operations, the lower our cost of sales, as a percentage of revenue,
will be, as we believe that certain economies of scale exist with our operations. If we are unable to grow our business fast enough to
take advantage of these economies of scale, our operations may suffer, and we may not be profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Economic
downturns or a change in consumer preferences, perception and spending habits could limit consumer demand for our products and negatively
affect our future business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
products that we sell and plan to sell in the future (including our Mango ED and Mango GROW products) may be adversely affected from
time to time by economic downturns that impact consumer spending, including discretionary spending. Future economic conditions such as
employment levels, business conditions, housing starts, market volatility, interest rates, inflation rates, energy and fuel costs and
tax rates, or our actions in response to these conditions, such as price increases, could reduce consumer spending or change consumer
purchasing habits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
performance depends significantly on factors that may affect the level and pattern of consumer spending in the markets in which we operate.
Such factors include consumer preference, consumer confidence, consumer income, consumer perception of the safety and quality of our
future products and shifts in the perceived value for our products relative to alternatives. A general decline in the consumption of
our future products could occur at any time as a result of change in consumer preference, perception, confidence and spending habits,
including an unwillingness to pay a premium or an inability to purchase our products due to financial hardship or increased price sensitivity,
which may be exacerbated by inflationary pressures, interest rates, and economic uncertainty. If consumer preferences shift away from
our products, our business, financial condition and results of operations could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our products depends on a number of factors including our ability to accurately anticipate changes in market demand and consumer
preferences, our ability to differentiate the quality of our future products from those of our competitors, and the effectiveness of
our marketing and advertising campaigns for our products. We may not be successful in identifying trends in consumer preferences and
developing products that respond to such trends in a timely manner. We also may not be able to effectively promote our products by our
marketing and advertising campaigns and gain market acceptance. If our products fail to gain market acceptance, are restricted by regulatory
requirements or have quality problems, we may not be able to fully recover costs and expenses incurred in our operation, and our business,
financial condition, results of operations and prospects could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely upon independent third-party transportation providers for all of our product shipments and are subject to increased shipping costs
as well as the potential inability of our third-party transportation providers to deliver on a timely basis.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely upon independent third-party transportation providers for all of our product shipments, including shipments from our related party
pharmacy to our customers. Our utilization of these third-party delivery services for shipments is subject to risks which may impact
a shipping company&#8217;s ability to provide delivery services that adequately meet our shipping needs, including risks related to employee
strikes, labor and capacity constraints, port security considerations, trade policy changes or restrictions, military conflicts, acts
of terrorism, accidents, natural disasters and inclement weather. Any interruption in service provided by our shipping companies could
cause temporary disruptions in our business, a loss of sales and profits, and other material adverse effects. In addition, we are subject
to increased shipping costs when fuel prices increase, as we use expedited means of transportation such as air freight. If we change
the shipping company we use, we could face logistical difficulties that could adversely affect deliveries, and we would incur costs and
expend resources in connection with such change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
failure of our physician services provider, Doctegrity, to attract and retain physicians in a competitive labor market could limit our
ability to execute our growth strategy, resulting in a slower rate of growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
success of our wellness business will depend on the ability of Doctegrity and any future contracted telemedicine services provider(s)
to continue to recruit and retain a sufficient number of qualified licensed doctors. Although we believe such provider(s) will have an
effective recruitment process, there is no assurance that such provider(s) will be able to secure arrangements with sufficient numbers
of licensed doctors or retain the services of such practitioners. If Doctegrity or any provider(s) we engage in the future, experience
delays or shortages in obtaining access to qualified physicians, we would be unable to operate and may be forced to seek alternative
arrangements which could be more costly or may be forced to suspend our business operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to maintain or enter into future agreements with suppliers or our suppliers fail to supply us with our Mango ED and Mango
GROW products ingredients or any other potential future men&#8217;s wellness products, we may experience delays in selling our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be successful in maintaining or entering into new supply agreements on reasonable terms or at all or that we or our suppliers
will be able to obtain or maintain the necessary regulatory approvals or state and federal controlled substances registrations for current
or potential future suppliers in a timely manner or at all. If we are unable to obtain a sufficient quantity of active pharmaceutical
ingredients manufactured at a facility that is registered and listed with the FDA and required to produce products, there could be a
delay in producing products, which could adversely affect our product sales and operating results materially, which could significantly
harm our business. This has not occurred to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not have any manufacturing facilities and intend to rely on third parties for the supply of our products (such as Epiq Scripts,
which is a related party), as well as for the supply of materials. However, we cannot be certain that we or our suppliers will be able
to obtain or maintain the necessary regulatory approvals or registrations for these suppliers in a timely manner or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business is exposed to risks associated with credit card and other online payment chargebacks and fraud.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
majority of our revenue is, and is expected to be, processed through credit cards and other online payments. If we experience refunds
or chargebacks, our processors could require us to create reserves, increase fees or terminate contracts with us, which would have an
adverse effect on our financial condition. Our failure to limit fraudulent transactions conducted on our website, such as through the
use of stolen credit card numbers, could also subject us to liability and adversely impact our reputation. Under credit card association
rules, penalties may be imposed at the discretion of the association for inadequate fraud protection. Any such potential penalties would
be imposed on our credit card processor by the association. However, we face the risk that we may fail to maintain an adequate level
of fraud protection and that one or more credit card associations or other processors may, at any time, assess penalties against us or
terminate our ability to accept credit card payments or other form of online payments from customers, which would have a material adverse
effect on our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could also incur significant fines or lose our ability to give customers the option of using credit cards to pay for our products if
we fail to follow payment card industry data security standards, even if there is no compromise of customer information. Although we
believe that we operate in compliance with payment card industry data security standards, it is possible that at times we may not be
in full compliance with these standards. Accordingly, we could be fined, which could impact our financial condition, or our ability to
accept credit and debit cards as payment could be suspended, which would cause us to be unable to process payments using credit cards.
If we are unable to accept credit card payments, our business, financial condition and operating results may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we could be liable if there is a breach of the payment information. Online commerce and communications depend on the secure
transmission of confidential information over public networks. We rely on encryption and authentication technology to authenticate and
secure the transmission of confidential information, including cardholder information. However, this technology may not prevent breaches
of the systems we use to protect cardholder information. In addition, some of our contracting parties may also collect or possess information
about our customers, and we may be subject to litigation or our reputation may be harmed if our contracting parties fail to protect our
customers&#8217; information or if they use it in a manner inconsistent with our policies and practices. Data breaches can also occur
as a result of non-technical issues. Under contracts with processors, if there is unauthorized access to, or disclosure of, credit card
information we store, we could be liable to the credit card issuing banks for their cost of issuing new cards and related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Security
breaches, loss of data and other disruptions could compromise sensitive information related to our business or customers, or prevent
us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of our business, we collect, store, use and disclose sensitive data, including health information and other types
of personally identifiable information, or PII. We also process and store, and use additional third parties to process and store, confidential
and proprietary information such as intellectual property and other proprietary business information, including that of our customers,
providers and contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches,
and employee or contractor error, negligence or malfeasance, can create system disruptions, shutdowns or unauthorized disclosure or modifications
of information, causing sensitive, confidential or proprietary information to be accessed or acquired without authorization or to become
publicly available. Because of the nature of the sensitive, confidential and proprietary information that we expect to collect, store,
transmit, and otherwise process, the security of our technology platform and other aspects of our services, including those provided
or facilitated by our third-party service providers, will be important to our operations and business strategy. Measures taken to protect
our systems, those of our third-party service providers, or sensitive, confidential and proprietary information that we or our third-party
service providers process or maintain, may not adequately protect us from the risks associated with the collection, storage and transmission
of such information. A security breach or privacy violation that leads to disclosure or unauthorized use or modification of, or that
prevents access to or otherwise impacts the confidentiality, security, or integrity of, sensitive, confidential, or proprietary information
we or our third-party service providers maintain or otherwise process, could harm our reputation, compel us to comply with breach notification
laws, and cause us to incur significant costs for remediation, fines, penalties, notification to individuals and governmental authorities,
implementation of measures intended to repair or replace systems or technology and to prevent future occurrences, potential increases
in insurance premiums, and forensic security audits or investigations. As a result, a security breach or privacy violation could result
in increased costs or loss of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
actual or suspected security breach or other compromise of our security measures or those of our third-party vendors, whether as a result
of hacking efforts, denial-of-service attacks, viruses, malicious software, break-ins, phishing attacks, social engineering or otherwise,
could harm our reputation and business, damage our brand and make it harder to retain existing customers or acquire new ones, require
us to expend significant capital and other resources to address the breach, and result in a violation of applicable laws, regulations
or other legal obligations. Our insurance policies may not cover, or may not be adequate to reimburse us for, losses caused by any such
security breach.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on email and other messaging services to connect with our existing and potential customers. Our customers may be targeted by parties
using fraudulent spoofing and phishing emails to misappropriate passwords, payment information or other personal information or to introduce
viruses through Trojan horse programs or otherwise through our customers&#8217; computers, smartphones, tablets or other devices. Despite
our efforts to mitigate the effectiveness of such malicious email campaigns through product improvements, spoofing and phishing may damage
our brand and increase our costs. Any of these events or circumstances could materially adversely affect our business, financial condition
and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this filing, there have been no such data breaches or other security related issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience fluctuations in our tax obligations and effective tax rate, which could adversely affect our business, results of operations,
and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to taxes in every jurisdiction in which we operate. We record tax expense based on current tax liabilities and our estimates
of future tax liabilities, which may include reserves for estimates of probable settlements of tax audits. At any one-time, multiple
tax years are subject to audit by various taxing jurisdictions. The results of these audits and negotiations with taxing authorities
may affect the ultimate settlement of these issues. Further, our effective tax rate in a given financial statement period may be materially
impacted by changes in tax laws, changes in the mix and level of earnings by taxing jurisdictions, or changes to existing accounting
rules or regulations. Fluctuations in our tax obligations and effective tax rate could adversely affect our business, results of operations,
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we become subject to product liability claims, we may be required to pay damages that exceed our insurance coverage, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products are subject to risks for product liability claims due to inherent potential side effects. We may be unable to obtain or maintain
product liability coverage. A product liability claim in excess of, or excluded from, our insurance coverage which currently covers exposure
to product liability claims, both technology products and physical products, would have to be paid out of cash reserves and could have
a material adverse effect upon our business, financial condition and results of operations. Product liability insurance is expensive
even with large self-insured retentions or deductibles, difficult to maintain, and current or increased coverage may not continue to
be available on acceptable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully defend ourselves against a product liability claim, we may incur substantial liabilities. Regardless of merit
or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of defending the claim and/or related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost
    of any potential adverse verdict;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients or other claimants; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Damages
awarded in a product liability action could be substantial and could have a negative impact on our financial condition. Whether or not
we were ultimately successful in product liability litigation, such litigation would consume substantial amounts of our financial and
managerial resources, and might result in adverse publicity, all of which would impair our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, a 2014 study published in The Journal of the American Medical Association determined that Sildenafil (the active ingredient
in Viagra and one of the ingredients we alternatively use, together with Sildenafil in our Mango ED product) may be associated with a
higher risk of developing melanoma. The study evaluated data from more than 25,000 men who used Sildenafil and found that Sildenafil
use was significantly associated with an increased risk of subsequent melanoma, after considering other risk factors. It is possible
that the ingredients we use in our Mango ED and Mango GROW products or any other products we sell (including our Mango ED product, which
is made with Sildenafil as an alternative to Tadalafil), could be found to result in increases in the likelihood of developing cancer
or other diseases, which could subject us to litigation, penalties or recalls, all of which could have a material adverse effect on our
operations and cause the value of our securities to decline in value or become worthless. Furthermore, our use of Sildenafil in our products
could subject us to litigation, penalties or recalls, all of which could have a material adverse effect on our operations and cause the
value of our securities to decline in value or become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Disruptions
in our data and information systems could harm our reputation and our ability to run our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely extensively on data and information systems for our supply chain, financial reporting, human resources and various other operations,
processes and transactions. Furthermore, a significant portion of the communications between us, our suppliers and customers depend on
information technology. Our data and information systems are subject to damage or interruption from power outages, computer and telecommunications
failures, computer viruses, security breaches (including breaches of our transaction processing or other systems that could result in
the compromise of confidential customer data), catastrophic events, data breaches and usage errors by our employees or third-party service
providers. Our data and information technology systems may also fail to perform as we anticipate, and we may encounter difficulties in
adapting these systems to changing technologies or expanding them to meet the future needs of our business. If our systems are breached,
damaged or cease to function properly, we may have to make significant investments to fix or replace them, suffer interruptions in our
operations, incur liability to our customers and others or face costly litigation, and our reputation with our customers may be harmed.
We also rely on third parties for a majority of our data and information systems, including for third-party hosting and payment processing.
If these facilities fail, or if they suffer a security breach or interruption or degradation of service, a significant amount of our
data could be lost or compromised and our ability to operate our business and deliver our product offerings could be materially impaired.
In addition, various third parties, such as our suppliers and payment processors, also rely heavily on information technology systems,
and any failure of these systems could also cause loss of sales, transactional or other data and significant interruptions to our business.
Any material interruption in the data and information technology systems we rely on, including the data or information technology systems
of third parties, could materially adversely affect our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Legal, Regulatory and Government</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur significant costs to ensure compliance with U.S. and Nasdaq reporting and corporate governance requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur significant costs associated with our public company reporting requirements and with applicable U.S. and Nasdaq corporate governance
requirements, including requirements under the Sarbanes-Oxley Act of 2002 and other rules implemented by the SEC and Nasdaq. We expect
all of these applicable rules and regulations to significantly increase our legal and financial compliance costs and to make some activities
more time-consuming and costly. We also expect that these applicable rules and regulations may make it more difficult and more expensive
for us to retain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur
substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain
qualified individuals to serve on our Board of Directors or as executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with government laws and regulations it could have a materially adverse effect on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is subject to extensive federal, state and local laws and regulations relating to licensure, conduct of operations,
ownership of facilities, addition of facilities and services, payment for services and prices for services that are extremely complex
and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We exercise
care in structuring our arrangements with physicians and other referral sources to attempt to comply in all material respects with applicable
laws. We also take such laws into account when planning future marketing and other activities, and expect that our operations are in
compliance with applicable laws. The laws, rules and regulations described above are complex and subject to interpretation. In the event
of a determination that we are in violation of such laws, rules or regulations, or if further changes in the regulatory framework occur,
any such determination or changes could have a material adverse effect on our business. There can be no assurance however that we will
not be found in noncompliance in any particular situation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
Federal law limits compounded drugs that are &#8220;essentially copies&#8221; of commercially available FDA approved drugs, including
those with the same route of administration. If our Mango ED and Mango GROW products, or any future products we may choose to market
in the future are deemed to be &#8220;essentially copies&#8221; of commercially available FDA approved drugs we would be prohibited from
compounding such drugs and would be unable to sell our Mango ED and Mango GROW drug or future products. If that were to occur, we would
need to change our business plan which would require substantial additional expenses and would have a material adverse effect on our
cash flows and the value of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Marketing
activities for our Mango ED and Mango GROW products are subject to strict governmental regulation which may limit our ability to market
or promote such product.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model depends on qualifying for certain statutory exemptions for drugs that are compounded by pharmacies in accordance with
applicable requirements. Pharmacy compounding is also subject to state oversight and regulation. Federal requirements include obtaining
individual prescriptions establishing that the compounded drug is necessary for each drug prescribed for each of our customers. Federal
law also limits compounded drugs that are &#8220;essentially copies&#8221; of commercially available FDA approved drugs, including those
with the same route of administration. These restrictions will limit our ability to market compounded drugs that have the same active
ingredients and route of administration as FDA-approved drugs, unless the compounded version offers a significant difference that the
prescriber determines is necessary for each individual patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA also has the authority to impose significant restrictions on approved products through regulations on advertising, promotional and
distribution activities. In particular, the FDA will object to any promotional activity (including through testimonials and surrogates)
that is &#8220;false or misleading in any particular,&#8221; including the failure to disclose material facts. For example, the FDA will
expect adequate substantiation for an efficacy claim, which would require substantial evidence derived from adequate and well-controlled
clinical trials. We believe we can conduct truthful and non-misleading promotional activities, including activities involving the use
of testimonials and surrogates, with limited claims that do not require substantial evidence derived from adequate and well-controlled
clinical trials and which do not include efficacy claims. If our products (including our Mango ED and Mango GROW products) are marketed
in contradiction with FDA laws and regulations, the FDA may issue warning letters that require specific remedial measures to be taken,
as well as an immediate cessation of the impermissible conduct, resulting in adverse publicity. The FDA may also require that all future
promotional materials receive prior agency review and approval before use. Certain states have also adopted regulations and reporting
requirements surrounding the promotion of pharmaceuticals. Failure by us or any of our collaborators to comply with state requirements
may affect our ability to promote or sell future products in certain states. This, in turn, could have a material adverse impact on our
financial results and financial condition and could subject us to significant liability, including civil and administrative remedies
as well as criminal sanctions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
restrictions may be more burdensome for compounded products as compared with FDA approved products because the latter have substantial
evidence of safety and effectiveness, which will limit our ability to compete against the sale of comparable FDA-approved products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Evolving
government regulations and enforcement activities may require increased costs or adversely affect our results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations may be subject to direct and indirect adoption, expansion or reinterpretation of various laws and regulations. Compliance
with these evolving laws, regulations and interpretations may require us to change our practices at an undeterminable and possibly significant
initial monetary and annual expense. These additional monetary expenditures may increase future overhead, which could have a material
adverse effect on our results of operations. There could also be laws and regulations applicable to our business that we have not identified
or that, if changed, may be costly to us, and we cannot predict all the ways in which implementation of such laws and regulations may
affect us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the introduction of new products may require us to comply with additional, yet undetermined, laws and regulations. Compliance may require
obtaining appropriate federal, state, or local licenses or certificates, increasing our security measures and expending additional resources
to monitor developments in applicable rules and ensure compliance. The failure to adequately comply with these future laws and regulations
may delay or possibly prevent our products from being offered to customers, which could have a material adverse effect on our business,
financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with federal, state and foreign laws and regulations relating to privacy, data protection and consumer protection, or the expansion
of current or the enactment of new laws or regulations relating to privacy, data protection and consumer protection, could adversely
affect our business and our financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
variety of federal, state and foreign laws and regulations govern the collection, use, retention, sharing and security of consumer data.
Laws and regulations relating to privacy, data protection and consumer protection are evolving and subject to potentially differing interpretations.
These requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another or may conflict with
other rules or our practices. As a result, our practices may not comply with all such laws, regulations, requirements and obligations.
Any failure, or perceived failure, by us to comply with any federal, state or foreign privacy or consumer protection-related laws, regulations,
industry self-regulatory principles, industry standards or codes of conduct, regulatory guidance, orders to which we may be subject or
other legal obligations relating to privacy or consumer protection could adversely affect our reputation, brand and business, and may
result in claims, investigations, proceedings or actions against us by governmental entities or others or other liabilities or require
us to change our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
collect, store, process, and use personal information and other customer data, and will rely on third parties that are not directly under
our control to manage certain of these operations and to collect, store, process and use payment information. Our customers&#8217; personal
information may include names, addresses, phone numbers, email addresses, payment card data, and payment account information, as well
as other information. Due to the volume and sensitivity of the personal information and data we and these third parties manage, the security
features of our information systems are critical. If our security measures, some of which are managed by third parties, are breached
or fail, unauthorized persons may be able to access sensitive customer data, including payment card data. If we or our independent service
providers or business partners experience a breach of systems that collect, store or process our members&#8217; and customers&#8217;
sensitive data, our brand could be harmed, sales of our products could decrease, and we could be exposed to claims, losses, administrative
fines, litigation or regulatory and governmental investigations and proceedings. Any such claim, investigation, proceeding or action
could hurt our reputation, brand and business, force us to incur significant expenses in defense of such proceedings, distract our management,
increase our costs of doing business, result in a loss of customers and suppliers and may result in the imposition of monetary penalties
and administrative fines. Depending on the nature of the information compromised, we may also have obligations to notify users, law enforcement,
or payment companies about the incident and may need to provide some form of remedy, such as refunds, for the individuals affected by
the incident.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy
laws, rules, and regulations are constantly evolving in the United States and abroad and may be inconsistent from one jurisdiction to
another. We expect that new industry standards, laws and regulations will continue to be proposed regarding privacy, data protection
and information security in many jurisdictions, including privacy acts previously adopted by the states of California, Virginia, Colorado,
Utah, Connecticut, Iowa, Indiana, Tennessee, Montana, Texas and Oregon, certain of which are already effective, and certain of which
become effective during 2023, and from 2024 to 2026. We cannot yet determine the impact such future laws, regulations and standards may
have on our business. Complying with these evolving obligations is costly. For instance, expanding definitions and interpretations of
what constitutes &#8220;<span style="text-decoration: underline">personal data</span>&#8221; (or the equivalent) within the United States and elsewhere may increase our compliance
costs. Any failure to comply could give rise to unwanted media attention and other negative publicity, damage our customer and consumer
relationships and reputation, and result in lost sales, claims, administrative fines, lawsuits or regulatory and governmental investigations
and proceedings and may harm our business and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Mango ED and Mango GROW products have not been, and will not be, approved by the FDA. The use of such products may cause serious side
effects which could subject us to material litigation, damages and penalties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Mango ED and Mango GROW products have not been, and will not be, approved by the FDA. It is compounded using bulk drug substances and
as such, we believe it is exempt from specific FDA approval, provided that it is compounded in accordance with statutory requirements.
Because compounded drugs are not FDA-approved, the FDA does not verify their safety, effectiveness, or quality before they are marketed.
In addition, poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too
much or too little active ingredient, among other possible quality deficiencies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any clinical studies involving the administration of Sildenafil or Tadalafil sublingually at the doses we intend to
provide patients, or the compounding of Sildenafil or Tadalafil, Oxytocin, and L-arginine to treat ED, as is contemplated by our Mango
ED products. We are also not aware of any clinical studies involving the administration of Minoxidil and Finasteride sublingually at
the dose we provide patients, or the compounding of Minoxidil, Finasteride, Vitamin D3 and Biotin, to attempt to treat hair loss, as
is contemplated by our Mango GROW product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our Mango ED and Mango GROW products have not been, and will not be, approved by the FDA, our products have not had the benefit of the
FDA&#8217;s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur,
we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties.
For example, in October 2012, a pharmacy in Massachusetts shipped compounded drugs that were contaminated with a fungus throughout the
country, and these drugs were injected into patients&#8217; spines and joints. More than 750 people in 20 states developed fungal infections,
and more than 60 people died. This type of action could have a significant negative impact on our brand name, results of operations and
cash flows, and result in us having to cease selling products, curtailing our business plan, or seeking bankruptcy protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
main ingredients of our Mango ED and Mango GROW products are publicly disclosed and separately our Mango ED products are being specially
compounded for the customer by a pharmacist with a physician&#8217;s prescription, and as a result, our Mango ED and Mango GROW products
formula can be replicated by other companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Mango ED products are made up of the following three ingredients: (1) Either Sildenafil (50 milligrams (mg) or Tadalafil (10 (mg)), Oxytocin
(100 International units (IU)) and L-Arginine (50mg); and (2) either Sildenafil (100mg) or Tadalafil (20mg), Oxytocin (100IU) and L-Arginine
(50mg), an amino acid that is available as a dietary supplement. However, the fact that Sildenafil, Tadalafil and Oxytocin are used in
FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients will prove safe when combined
into a single formulation to treat ED. Further, our Mango GROW product currently includes the following amounts of the four ingredients
discussed below: (1) Minoxidil (2.5mg), (2) Finasteride (1mg), (3) Vitamin D3 (2000IU), and (4) Biotin (1mg). However, the fact that
Minoxidil and Finasteride are used in FDA approved drugs, and Vitamin D3 and Biotin are available as a dietary supplement, does not mean
that these ingredients will prove safe when combined into a single formulation to treat hair growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently offer two dosage levels of our Mango ED products and one dosage level of our Mango GROW product and anticipate a prescribing
doctor prescribing a dosage based on the needs and medical history of the patient. Additionally, because our Mango ED and Mango GROW
products are being specially compounded for the customer by a pharmacist with a physician&#8217;s prescription and because the ingredients
for our Mango ED and Mango GROW products are publicly disclosed, these product formulas can be replicated by other companies. As a result,
competitors, including those with greater resources, marketing, and brand recognition, may compete against us in the future using our
exact product ingredients or variations thereof. We may be unable to distinguish our Mango ED and Mango GROW products from copycat products
and may not be able to differentiate our product from competitors in the marketplace. As a result, we may fail to obtain a significant
market share, or may lose any market share we may obtain in the future, may be unable to compete with competitors, and may be forced
to abandon or curtail our business plan, which could cause the value of our shares to decline in value or become worthless.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Mango ED and Mango GROW products need to be compounded by licensed pharmacists who are subject to risks regarding applicable exemptions
from the Federal Food, Drug, and Cosmetic Act.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
503A of the FFDCA describes the conditions under which compounded human drug products are exempt from the FFDCA sections on FDA approval
prior to marketing, current good manufacturing practice (&#8220;cGMP&#8221;) requirements, and labeling with adequate directions for
use. One of these conditions is that the drugs must be compounded based on the receipt of valid patient-specific prescriptions. Our ED
product needs to be compounded by licensed pharmacists, after being prescribed by a licensed physician. Licensed pharmacists who compound
drug products in accordance with Section 503A of the FFDCA are not required to comply with CGMP requirements and the drugs that they
compound are not required to be approved by the FDA, provided that the compounding complies with applicable requirements. Therefore,
the FDA is often not aware of potential problems with compounded drug products or compounding practices unless it receives a complaint,
such as a report of a serious adverse event or visible contamination. As such, the compounding of our products is subject to limited
FDA oversight, which could lead to such products not being compounded safely and could lead to product recalls and litigation which could
have a significant negative impact on our brand name, results of operations and cash flows, and result in us having to cease selling
products, curtailing our business plan, or seeking bankruptcy protection. Neither we, nor our representatives have had any conversations
with the FDA staff regarding whether our Mango ED or Mango GROW products can be sold pursuant to Section 503A of the FFDCA Act and future
conversations with the FDA may result in the FDA staff raising issues with such sales pursuant to Section 503A of the FFDCA, requiring
certain pre-requisites or changes to our current business plan, which may be costly or time consuming, and/or may result in us being
prohibited from selling our Mango ED and Mango GROW products pursuant to Section 503A of the FFDCA Act. We also face risks that the compounding
of our products does not fall within the exemption from the FFDCA provided by Section 503A thereof. For example, if the FDA determined
that any of our products are essentially a copy of an FDA approved product, we would be severely limited in our ability to compound such
a product. If any of the above were to apply, we may need to change our business plan or compounding activities, which could force us
to curtail our business plan or expend significant additional resources to obtain FFDCA or FDA approval for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, under relevant FDA guidance, the FDA generally does not consider a compounded drug to be &#8220;essentially a copy&#8221;
of a commercially available drug if the compounded drug has a different route of administration as compared with the approved alternative,
and our Mango ED and Mango GROW products are for a different route of administration (e.g., sublingual). In addition, we do not expect
that we will be deemed to have engaged in such &#8220;copying&#8221;, because our Mango ED and Mango GROW products are based on a prescriber&#8217;s
determination for each patient that the change associated with the compounded product (our Mango ED and Mango GROW products) produces
for the patient a significant difference as compared with the commercially available drug product. Under relevant FDA guidance, the FDA
does not consider a compounded drug &#8220;essentially a copy&#8221; if a prescriber determines that there is a change, made for an identified
individual patient, which produces for that patient a significant difference from the commercially available product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
care services, including arrangements with health care professionals, are heavily regulated at the state level, and the laws and regulations
may be changed or subject to new interpretations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
state separately licenses health care professionals and determines when and under what conditions they may interact with and provide
services to patients. Telehealth consultations initiated through our platform must be offered in accordance with the laws and regulations
of the state where a patient is located, which may include laws that restrict the corporate practice of medicine and fee splitting. Each
state&#8217;s laws are subject to legislative and regulatory changes, as well as judicial interpretations, and future changes or interpretations
of state laws restricting the corporate practice of medicine and fee splitting could adversely affect the permissibility of (a) our relationship
with Doctegrity; and/or (b) Doctegrity&#8217;s relationship with its contracted physicians. If our relationship with Doctegrity and/or
Doctegrity&#8217;s relationship with its contracted physicians needed to be restructured in light of any such adverse changes or interpretations,
that restructuring could negatively affect our ability to connect consumers with medical providers in certain states, and thus those
customers&#8217; ability to ultimately receive our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not have a pharmacy and depend on a related party to compound our Mango product and other potential future men&#8217;s wellness products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a related party pharmacy for the manufacture of our Mango product and will rely on this pharmacy or others for any potential
future men&#8217;s wellness products we market and we cannot assure you that they will be successful. This subjects us to a number of
risks, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to control the commercialization of our products, including the amount, timing and quality of resources that our
    contracting parties may devote to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    contracting parties may experience financial, regulatory or operational difficulties, which may impair their ability to fulfill their
    contractual obligations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    combinations or significant changes in a contracting parties&#8217; business strategy may adversely affect a contracting party&#8217;s
    willingness or ability to perform their obligations under any arrangement;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 39; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
    disputes or disagreements may occur with one or more of our contracting parties or between our contracting parties and our suppliers
    or former contracting parties; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    contracting party could independently move forward with a competing product developed either independently or in collaboration with
    others, including with one of our competitors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our contracting parties fail to fulfill their future contractual obligations, our business may be negatively affected and we may
receive limited or no revenues under our agreements with them. See also the risk factor, &#8220;<i>The related party pharmacy we have
entered into an agreement with may not receive licenses in all of the 50 United States to provide national coverage for us to sell our
Mango ED and Mango GROW products and future products</i>&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and
security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in
significant liability or reputational harm and, in turn, a material adverse effect on our client base and revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and
integrity of personally identifiable information, or PII, including protected health information, or PHI. These laws and regulations
include the Health Information Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information
Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations (referred to collectively as &#8220;HIPAA&#8221;).
HIPAA establishes a set of basic national privacy and security standards for the protection of PHI. HIPAA requires us to develop and
maintain policies and procedures with respect to PHI that is used or disclosed, including the adoption of administrative, physical and
technical safeguards to protect such information. HIPAA imposes mandatory penalties for certain violations. Penalties for violations
of HIPAA and its implementing regulations start at $100 per violation and are not to exceed $50,000 per violation, subject to a cap of
$1.5 million for violations of the same standard in a single calendar year. However, a single breach incident can result in violations
of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts are able to award
damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of
action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care
in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI. In addition, HIPAA mandates that the
Secretary of Health and Human Services, or HHS, conduct periodic compliance audits of HIPAA covered entities or business associates for
compliance with the HIPAA Privacy and Security Standards. It also tasks HHS with establishing a methodology whereby harmed individuals
who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. HIPAA
further requires that patients be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises
the privacy or security of such information, with certain exceptions related to unintentional or inadvertent use or disclosure by employees
or authorized individuals. HIPAA specifies that such notifications must be made &#8220;without unreasonable delay and in no case later
than 60 calendar days after discovery of the breach.&#8221; If a breach affects 500 patients or more, it must be reported to HHS without
unreasonable delay, and HHS will post the name of the breaching entity on its public web site. Breaches affecting 500 patients or more
in the same state or jurisdiction must also be reported to the local media. If a breach involves fewer than 500 people, the covered entity
must record it in a log and notify HHS at least annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PII, including PHI. These
laws in many cases are more restrictive than, and may not be pre-empted by, the HIPAA rules and may be subject to varying interpretations
by courts and government agencies, creating complex compliance issues for us and our clients and potentially exposing us to additional
expense, adverse publicity and liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the extreme sensitivity of the PII we store and transmit, the security features of our technology platform are very important. If
our security measures are breached or fail, unauthorized persons may be able to obtain access to sensitive client data, including HIPAA-regulated
PHI. As a result, our reputation could be severely damaged, adversely affecting client confidence. In addition, we could face litigation,
damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant
costs for remediation, notification to individuals and for measures to prevent future occurrences. Any potential security breach could
also result in increased costs associated with liability for stolen assets or information, repairing system damage that may have been
caused by such breaches, incentives offered to clients in an effort to maintain our business relationships after a breach and implementing
measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies,
training employees and engaging third-party experts and consultants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 40; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Related Party Relationships and Transactions and Our Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend heavily on our senior management, including our Chief Executive Officer, who may have a conflict of interest with regard to various
matters. The ability of certain key employees to devote adequate time to us is critical to the success of our business, and failure to
do so may adversely affect our revenues and as a result could materially adversely affect our business, financial condition and results
of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must retain the services of our key employees and strategically recruit and hire new talented employees. Our future business and results
of operations depend in significant part upon the continued contributions of our senior management personnel, particularly our Chairman
and Chief Executive Officer, Jacob D. Cohen. Mr. Cohen currently serves as a member of the Board of Directors of American International
Holdings Corp., as a co-Manager and 51% owner of Epiq Scripts, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private
investment company, and in various positions with other entities and groups. Mr. Cohen currently spends approximately 75% of his time
on Company matters. As a result, Mr. Cohen dedicates only a portion of his professional efforts to our business and operations, and there
is no contractual obligation for him to spend a specific amount of his time with us. Mr. Cohen may not be able to dedicate adequate time
to our business and operations and we could experience an adverse effect on our operations due to the demands placed on him from his
other professional obligations. Such involvement in other businesses may therefore present a conflict of interest regarding decisions
he makes for us or with respect to the amount of time available for us. If we lose his services or if he fails to perform in his current
position, or if we are not able to attract and retain skilled personnel as needed, our business could suffer. Significant turnover in
our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend
on the skills and abilities of these key personnel in managing our operations, product development, marketing and sales aspects of our
business, any part of which could be harmed by turnover in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, should the services of Mr. Cohen be lost for any reason, we will incur costs associated with recruiting replacements and any
potential delays in operations which this may cause. If we are unable to replace such individual with a suitably trained alternative
individual(s), we may be forced to scale back or curtail our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
if our executive officers do not devote sufficient time towards our business, we may never be able to effectuate our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have engaged and in the future may engage in transactions with related parties and such transactions present possible conflicts of interest
that could have an adverse effect on us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered, and may continue to enter, into transactions with related parties for financing, corporate, business development and operational
services. Included in such transactions is a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party,
51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, as discussed in greater detail below under &#8220;Business&#8212;Material
Agreements&#8212;Master Services Agreement with Epiq Scripts&#8221; and &#8220;&#8212;First Amendment to MSA,&#8221; for pharmacy and
compounding services. Such transactions may not have been/may not be, entered into on an arm&#8217;s-length basis, and we may have achieved
more or less favorable terms because such transactions were entered into with our related parties. This could have a material effect
on our business, results of operations and financial condition. Such conflicts could cause an individual in our management to seek to
advance his or her economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts
of interest created by related party transactions could impair the confidence of our investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are significantly reliant on related party relationships.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled
by Jacob D. Cohen, our Chairman and Chief Executive Officer, who also serves as a co-Manager of Epiq Scripts, as discussed in greater
detail below under &#8220;Business&#8212;Material Agreements&#8212;Master Services Agreement with Epiq Scripts&#8221; and &#8220;&#8212;First
Amendment to MSA,&#8221; for pharmacy and compounding services. In the event that relationship is terminated, our costs may increase,
and we may be unable to effectively obtain the services currently provided by Epiq Scripts, LLC. Additionally, certain of our consultants
are employed by Epiq Scripts, LLC. We also anticipate entering into other related party relationships in the future. While we believe
that all related party agreements have been and will be on arms-length terms, such significant related party relationships may be perceived
negatively by potential shareholders or investors and/or may result in conflicts of interest. Each of our officers and directors (including
those discussed above) presently has, and any of them in the future may have, additional fiduciary or contractual obligations to other
entities pursuant to which such officer or director may be required to present a business opportunity to such entity, subject to his
or her fiduciary duties under applicable law. Additionally, such persons may have conflicts of interest in allocating their time among
various business activities. These conflicts may not be resolved in our favor. Our significant related party relationships and transactions,
the terms of such relationships and transactions, and/or the termination of any such relationships or transactions, may have a material
adverse effect on our results of operations moving forward and/or create conflicts of interest or perceived conflicts of interest which
may have a material adverse effect on the value of our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
related party pharmacy we have entered into an agreement with may not receive licenses in all of the 50 United States to provide national
coverage for us to sell our Mango ED and Mango GROW products and future products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled
by Jacob D. Cohen, our Chairman and Chief Executive Officer, as discussed in greater detail below under &#8220;<span style="text-decoration: underline">Business&#8212;Material
Agreements&#8212;Master Services Agreement with Epiq Scripts</span>,&#8221; for pharmacy and compounding services. Epiq Script&#8217;s ability
to provide pharmacy services in each state is subject to, among other things, receipt of regulatory approvals and licenses in the states
in which it operates. Currently Epiq Scripts holds State Board of Pharmacy (or its equivalent) licenses to operate in the District of
Columbia and 47 states: Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana,
Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada,
New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South
Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming. Its failure to receive regulatory
approval or licenses in the other states in which we hope to operate, or loss of such licenses in the future, may prohibit us from selling
our Mango products to customers that reside in those states limiting our ability to grow and compete with other companies that have those
capabilities. Any of the above may have an adverse effect on our revenues, operations and cash flow and cause the value of our securities
to decline in value or become worthless. We also face related party conflicts associated with our engagement of Epiq Scripts, LLC as
discussed in greater detail above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 42; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jacob
D. Cohen, our Chairman and Chief Executive Officer, and Jonathan Arango, our President and Director, beneficially own greater than 50%
of our outstanding common stock and will continue to exercise significant voting control over us following the offering, which will limit
shareholders&#8217; abilities to influence corporate matters and could delay or prevent a change in corporate control.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
D. Cohen, our Chairman and Chief Executive Officer, and Jonathan Arango, our President and Director, beneficially own approximately 54.9%
of the outstanding shares of our common stock (when including shares issuable upon exercise of outstanding and vested options) and will
continue to hold a significant portion of our issued and outstanding shares of common stock after this offering. As a result, they will
have significant influence on the shareholder vote. Consequently, they have the ability to influence matters affecting our shareholders
and therefore exercise significant control in determining the outcome of all corporate transactions or other matters, including (i) making
amendments to our certificate of formation; (ii) whether to issue additional shares of common stock and preferred stock, including to
himself; (iii) employment decisions, including compensation arrangements; (iv) whether to enter into material transactions with related
parties; (v) election of directors; and (vi) any merger or significant corporate transactions, including with himself or other related
parties. Additionally, it will be difficult if not impossible for investors to remove our current directors (including, but not limited
to Mr. Cohen and Mr. Arango), which will mean they will remain in control of who serves as officers of the Company as well as whether
any changes are made in the Board of Directors. As a potential investor in the Company, you should keep in mind that even if you own
shares of our common stock and wish to vote them at annual or special shareholder meetings, your shares will have little effect on the
outcome of corporate decisions. Because Mr. Cohen and Mr. Arango will significantly influence the vote on all shareholder matters, investors
may find it difficult to replace our management if they disagree with the way our business is being operated. The interests of Mr. Cohen
and Mr. Arango may not coincide with our interests or the interests of other shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Cohen and Mr. Arango acquired their shares of common stock for substantially less than the price of the shares of common stock acquired
in our IPO, sold pursuant to this offering, and/or the current trading price of our common stock, and may have interests, with respect
to their common stock, that are different from other investors and the concentration of voting power held by Mr. Cohen and Mr. Arango
may have an adverse effect on the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, this concentration of ownership might adversely affect the market price of our common stock by: (1) delaying, deferring or
preventing a change of control of our Company; (2) impeding a merger, consolidation, takeover or other business combination involving
our Company; or (3) discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
competition from our existing executive officers, after they leave their employment with us, and subject to the non-compete terms of
their employment agreements, could negatively impact our profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Chief Executive Officer, Jacob D. Cohen, our President, Jonathan Arango, and our Chief Operating Officer, Amanda Hammer, are prohibited
from competing with us while they are employed with us and for 12 months thereafter (subject to the terms of, and exceptions set forth
in, their employment agreements with the Company), none of such individuals will be prohibited from competing with us after such 12-month
period ends. Accordingly, any of these individuals could be in a position to use industry experience gained while working with us to
compete with us. Such competition could distract or confuse customers, reduce the value of our intellectual property and trade secrets,
or reduce our future revenues, earnings or growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 43; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate in an industry with the risk of intellectual property litigation. Claims of infringement against us may hurt our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
must protect the proprietary nature of the intellectual property used in our business. There can be no assurance that trade secrets and
other intellectual property will not be challenged, invalidated, misappropriated or circumvented by third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our success depends, in part, upon non-infringement of intellectual property rights owned by others and being able to resolve claims
of intellectual property infringement without major financial expenditures or adverse consequences. Participants that own, or claim to
own, intellectual property may aggressively assert their rights. From time to time, we may be subject to legal proceedings and claims
relating to the intellectual property rights of others. Future litigation may be necessary to defend us by determining the scope, enforceability,
and validity of third-party proprietary rights or to establish its proprietary rights. Our competitors have substantially greater resources
and are able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time. In
addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us.
Regardless of whether claims that we are infringing patents or other intellectual property rights have any merit, these claims are time-consuming
and costly to evaluate and defend and could:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cause
    delays or stoppages in providing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">divert
    management&#8217;s attention and resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    technology changes to our products that would cause our Company to incur substantial cost;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    us to significant liabilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    us to cease some or all of our activities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to liability for monetary damages, which may be tripled and may include attorneys&#8217; fees, or, in some circumstances, damages
against clients, we may be prohibited from developing, commercializing, or continuing to provide some or all of our products unless we
obtain licenses from, and pay royalties to, the holders of the patents or other intellectual property rights, which may not be available
on commercially favorable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Telehealth Operations of Our Contracting Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
telehealth business of our telehealth provider could be adversely affected by ongoing legal challenges or by new state actions restricting
the ability to provide telehealth services in certain states.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use telehealth providers to provide telehealth consultations and related services on our Mangoceuticals platform, which connects users/customers
with third-party health care providers and Epiq Scripts, LLC, a related party pharmacy. We have entered into an agreement with Doctegrity,
pursuant to which Doctegrity provides clinical services directly to our customers via telehealth. Through these arrangements, the professionals
or professional entities are responsible for the practice of medicine and control of the clinical decision-making.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to conduct business operations in each state is dependent upon the state&#8217;s treatment of medicine under such state&#8217;s
laws, and rules and policies governing the practice of physician supervised services, which are subject to changing political, regulatory
and other influences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on our contracted parties to maintain appropriate telehealth licenses to be able to provide telehealth services to our potential
customers and prescribe them our products, which are required to be prescribed by licensed physicians. In the event we are not able to
maintain relationships with telehealth providers, state licensing laws make it harder, more costly or impossible to provide telehealth
services, or our customers are otherwise unable to obtain prescriptions for our products, we may be unable to sell products, which could
result in us having to curtail our business plan or cease operating.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
contracting parties&#8217; telehealth business could be adversely affected by ongoing legal challenges to their business model or by
new state actions restricting their ability to provide the full range of services in certain states.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of our contracted parties&#8217; telehealth operations in each state is dependent upon the state&#8217;s treatment of medicine
under such state&#8217;s laws, rules and policies governing the practice of physician supervised services, which are subject to changing
political, regulatory and other influences. In the event our contracted parties are unable to provide telehealth services for any reason,
it would have a material adverse effect on our ability to sell products and in turn our revenues and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Governing Documents and Texas Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Certificate of Formation, Bylaws and Texas law provide for indemnification of officers and directors at our expense and limit the liability
of our directors, which may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be
expended for the benefit of officers or directors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Formation, Bylaws and Texas law provide for us to indemnify and hold harmless, to the fullest extent permitted by applicable
law, each person who is or was made a party or is threatened to be made a party to or is otherwise involved in any threatened, pending
or completed action, suit or proceeding by reason of the fact that he or she is or was a director or officer of the Company or, while
a director or officer of the Company, is or was serving at the request of the Company as a director, officer, employee or agent of another
corporation or of a partnership, joint venture, trust, other enterprise or nonprofit entity, including service with respect to an employee
benefit plan. Our Certificate of Formation also provides that the personal liability of our directors is eliminated to the fullest extent
permitted by the Texas Business Organizations Code, as such may be amended or supplemented. These indemnification obligations and limitations
of liability may result in a major cost to us and hurt the interests of our shareholders because corporate resources may be expended
for the benefit of officers or directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public
policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification for liabilities
arising under federal securities laws, other than the payment by us of expenses incurred or paid by a director, officer or controlling
person in the successful defense of any action, suit or proceeding, is asserted by a director, officer or controlling person in connection
with our activities, we will (unless in the opinion of our counsel, the matter has been settled by controlling precedent) submit to a
court of appropriate jurisdiction, the question whether indemnification by us is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue. The legal process relating to this matter if it were to occur is likely
to be very costly and may result in us receiving negative publicity, either of which factors is likely to materially reduce the market
and price for our shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have established preferred stock which can be designated by our Board of Directors without shareholder approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have 10,000,000 shares of preferred stock authorized. The shares of our preferred stock may be issued from time to time in one or more
series, each of which shall have a distinctive designation or title as shall be determined by our Board of Directors prior to the issuance
of any shares thereof. The preferred stock shall have such voting powers, full or limited, or no voting powers, and such preferences
and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as adopted
by the Board of Directors. Because the Board of Directors is able to designate the powers and preferences of the preferred stock without
the vote of a majority of our shareholders, our shareholders will have no control over what designations and preferences our preferred
stock will have. The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our
existing shareholders. Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact
that such preferred stock may have voting rights and/or other rights or preferences which could provide the preferred shareholders with
substantial voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in
control might benefit our shareholders. As a result, the issuance of shares of preferred stock may cause the value of our securities
to decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions in our Certificate of Formation and our Bylaws, as well as provisions of Texas law, might discourage, delay or prevent a change
in control of our company or changes in our management and, therefore, depress the trading price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Formation, Bylaws and Texas law contain provisions that may discourage, delay or prevent a merger, acquisition or other
change in control that shareholders may consider favorable, including transactions in which you might otherwise receive a premium for
your shares of our common stock. These provisions may also prevent or delay attempts by our shareholders to replace or remove our management.
Our corporate governance documents include provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring
    advance notice of shareholder proposals for business to be conducted at meetings of our shareholders and for nominations of candidates
    for election to our Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorizing
    blank check preferred stock, which could be issued with voting, liquidation, dividend and other rights superior to our common stock;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing
    indemnification to, our directors and officers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the
future for shares of our common stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that
you could receive a premium for your common stock in an acquisition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to this Offering and Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b><i>We are currently not
in compliance with Nasdaq&#8217;s continued listing requirements and there is no guarantee that our common stock will continue to trade
on Nasdaq.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a condition to consummating
our IPO, we were required to list our common stock on Nasdaq and in March 2023, our common stock was approved for listing on Nasdaq under
the symbol &#8220;MGRX&#8221;. Notwithstanding such listing, there is no guarantee that we will be able to maintain our listing on NASDAQ
for any period of time. Among the conditions required for continued listing on Nasdaq, NASDAQ requires us to maintain at least $2.5 million
in stockholders&#8217; equity, $35 million in market value of listed securities, or $500,000 in net income over the prior two years or
two of the prior three years, to have a majority of independent directors (subject to certain &#8220;<span style="text-decoration: underline">controlled company</span>&#8221;
exemptions, which we do not currently meet), to comply with certain audit committee requirements, and to maintain a stock price over
$1.00 per share. Our stockholders&#8217; equity is currently not above NASDAQ&#8217;s $2.5 million minimum, as discussed below, we may
not generate over $500,000 of yearly net income moving forward, we may not maintain $35 million in market value of listed securities,
we may not be able to maintain independent directors (to the extent required), and as discussed below, we do not currently have a stock
price over $1.00 per share. Nasdaq&#8217;s determination that we fail to meet the continued listing standards of NASDAQ may result in
our securities being delisted from Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 30, 2023, we received
written notice from the Listing Qualifications Department of Nasdaq notifying us that we were not in compliance with the minimum bid
price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires
listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet
the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days. Based on
the closing bid price of our common stock for the thirty (30) consecutive business days from September 15, 2023 to October 27, 2023,
we no longer meet the minimum bid price requirement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The letter did not impact
the listing of our common stock on Nasdaq. Instead, the letter stated that we have 180 calendar days or until April 29, 2024, to regain
compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of our common stock must have a closing bid price
of at least $1.00 per share for a minimum of 10 consecutive business days. If we do not regain compliance by April 29, 2024, an additional
180 days may be granted to regain compliance, so long as we meet Nasdaq&#8217;s initial listing criteria (except for the bid price requirement)(which
we do not currently meet, as we do not have stockholders&#8217; equity of at least $5 million) and notify Nasdaq in writing of our intention
to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If we do not qualify for
the second compliance period or fail to regain compliance during the second 180-day period, our common stock will be subject to delisting,
at which point we would have an opportunity to appeal the delisting determination to a Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We intend to monitor the closing
bid price of our common stock and may, if appropriate, consider implementing available options to regain compliance with the minimum
bid price requirement under the Nasdaq Listing Rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Separately, on November 3,
2023, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that our stockholders&#8217; equity as reported
in our Quarterly Report on Form 10-Q for the period ending September 30, 2023 (the &#8220;Form 10-Q&#8221;), did not meet the minimum
stockholders&#8217; equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies listed on Nasdaq
to maintain stockholders&#8217; equity of at least $2,500,000. In our Form 10-Q, we reported stockholders&#8217; equity of $1,354,821,
which is below the minimum stockholders&#8217; equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1). Additionally,
we do not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This notice of noncompliance
had had no immediate impact on the continued listing or trading of our common stock on Nasdaq, which continues to be listed and traded
on Nasdaq, subject to our compliance with the other continued listing requirements. Nasdaq has given us until December 18, 2023 to submit
to Nasdaq a plan to regain compliance. We are submitting a plan of compliance on December 18, 2023 and if our plan is accepted,
Nasdaq may grant an extension of up to 180 calendar days from the date of Nasdaq&#8217;s letter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are confident that we can
regain compliance with Nasdaq&#8217;s minimum stockholders&#8217; equity standard within the compliance period. However, there can be no assurance that our plan will
be accepted or that if it is, we will be able to regain compliance. If our plan to regain compliance is not accepted, or if it is and
we do not regain compliance within 180 days from the date of Nasdaq&#8217;s letter, or if we fail to satisfy another Nasdaq requirement
for continued listing (including the requirement that we maintain a minimum bid price of at least $1.00 per share, which as discussed
above, the Company is not currently in compliance with), Nasdaq could provide notice that our common stock will become subject to delisting.
In such event, Nasdaq rules would permit us to appeal the decision to reject our proposed compliance plan or any delisting determination
to a Nasdaq Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 46; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Even if we demonstrate compliance
with the requirements of Nasdaq as discussed above, we will have to continue to meet other objective and subjective listing requirements
to continue to be listed on Nasdaq. Delisting from Nasdaq could make trading our common stock more difficult for investors, potentially
leading to declines in our share price and liquidity. Without a Nasdaq listing, stockholders may have a difficult time getting a quote
for the sale or purchase of our stock, the sale or purchase of our stock would likely be made more difficult, and the trading volume
and liquidity of our stock could decline. Delisting from Nasdaq could also result in negative publicity and could also make it more difficult
for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as currency
or the value accorded by other parties. Further, if we are delisted, we would also incur additional costs under state blue sky laws in
connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the
ability of our stockholders to sell our common stock in the secondary market. If our common stock is delisted by Nasdaq, our common stock
may be eligible to trade on an over-the-counter quotation system, such as the OTCQB Market or the OTC Pink market, where an investor
may find it more difficult to sell our stock or obtain accurate quotations as to the market value of our common stock. In the event our
common stock is delisted from Nasdaq, we may not be able to list our common stock on another national securities exchange or obtain quotation
on an over-the counter quotation system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A delisting of our common
stock from the Nasdaq could adversely affect our business, financial condition and results of operations and our ability to attract new
investors, reduce the price at which our common stock trades, decrease, investors&#8217; ability to make transactions in our common stock,
decrease the liquidity of our outstanding shares, increase the transaction costs inherent in trading such shares, and reduce our flexibility
to raise additional capital without overall negative effects for our stockholders.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stockholders
may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of additional shares
of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
possible, our Board of Directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that
the non-cash consideration will consist of restricted shares of our common stock or where shares are to be issued to our officers, directors
and applicable consultants. Our Board of Directors has authority, without action or vote of the stockholders, but subject to Nasdaq rules
and regulations (which generally require stockholder approval for any transactions which would result in the issuance of more than 20%
of our then outstanding shares of common stock or voting rights representing over 20% of our then outstanding shares of stock), to issue
all or part of the authorized but unissued shares of common stock. In addition, we may attempt to raise capital by selling shares of
our common stock, possibly at a discount to market. These actions will result in dilution of the ownership interests of existing stockholders,
which may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing
management&#8217;s ability to maintain control of the Company because the shares may be issued to parties or entities committed to supporting
existing management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Certain
recent initial public offerings of companies with public floats comparable to the anticipated public float of the Company have experienced
extreme volatility that was seemingly unrelated to the underlying performance of the respective company. We have in the past, and may
in the future experience similar volatility, which may make it difficult for prospective investors to assess the value of our common
stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the risks addressed below under the heading &#8220;&#8212; <i>Our common stock prices have been, and may continue to be,
volatile and could decline substantially</i>,&#8221; our common stock may be subject to extreme volatility that is seemingly unrelated
to the underlying performance of our business. For example, since our common stock began trading on the Nasdaq Capital Market in connection
with our IPO on March 20, 2023, the trading price of our common stock has traded as high as $4.37 and as low as $0.42 per share. The
trading price of our common stock is expected to continue to be volatile, and our common stock may be subject to rapid and substantial
price volatility. Such volatility, including any stock-run up, may be unrelated to our actual or expected operating performance, financial
condition or prospects, making it difficult for prospective investors to assess the rapidly changing value of our common stock. There
have been recent instances of extreme stock price run-ups followed by rapid price declines following public offerings, particularly among
companies with relatively smaller public floats, and we expect that such instances may continue and/or increase in the future. Contributing
to this risk of volatility are a number of factors. First, our common stock is likely to be more sporadically and thinly traded than
that of larger, more established companies. As a consequence of this lack of liquidity, the trading of relatively small quantities of
shares by our shareholders may disproportionately influence the price of those shares in either direction, which may cause our stock
price to deviate, potentially significantly, from a price that better reflects the underlying performance of our business. The price
of our shares could, for example, decline precipitously in the event that a large number of our shares are sold in the market without
commensurate demand (including as our IPO lockups expire &#8211; 12 months after the IPO (unless earlier waived in the discretion of
the underwriter of the IPO)) as compared to a seasoned issuer that could better absorb those sales without an adverse impact on its stock
price. Second, we are a speculative investment due to our limited operating history, not being profitable, and not expecting to be profitable
in the near term. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their
investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at
greater discounts than would be the case with the stock of a larger, more established company that has a relatively large public float.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of these factors are beyond our control and may decrease the market price of our securities. Such volatility, including any stock run-ups,
may be unrelated or disproportionate to our actual or expected operating performance and financial condition or prospects, making it
difficult for prospective investors to assess the rapidly changing value of our shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the stock market in general, and the market for men&#8217;s wellness product companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market
and industry factors, as well as general economic, political and market conditions such as recessions, or changes in inflation or interest
rates, may seriously affect the market price of our securities, regardless of our actual operating performance. These fluctuations may
be even more pronounced in the trading market for our securities shortly following this offering. As a result of this volatility, investors
may experience losses on their investment in our common stock. A decline in the market price of our common stock also could adversely
affect our ability to issue additional shares of common stock or other securities and our ability to obtain additional financing in the
future. No assurance can be given that an active market in our common shares will develop or be sustained. If an active market does not
develop, holders of our common stock may be unable to readily sell the shares they hold or may not be able to sell their shares at all.
If the market price of our shares after this offering does not exceed the per share offering price, you may not realize any return on
your investment in us and may lose some or all of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
common stock prices have been, and may continue to be, volatile and could decline substantially following this offering.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may be highly volatile and subject to wide fluctuations. Our financial performance, government regulatory
action, tax laws, interest rates, and market conditions in general could have a significant impact on the future market price of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the factors that could negatively affect or result in fluctuations in the market price of our common stock include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our quarterly operating results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in market valuations of similar companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    market reaction to the level of our indebtedness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    by shareholders;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market, economic, and political conditions, including an economic slowdown or dislocation in the global credit markets;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic and market conditions;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments related to our intellectual property or other proprietary rights, including litigation;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating performance and the performance of other similar companies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting principles; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">passage
    of legislation or other regulatory developments that adversely affect us or our industry.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our stock price fluctuates after the offering, you could lose a significant part of your investment.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock could be subject to wide fluctuations in response to, among other things, the risk factors described
in this Report, and other factors beyond our control, such as fluctuations in the valuation of companies perceived by investors to be
comparable to us For example, since our common stock began trading on the Nasdaq Capital Market in connection with our IPO on March 20,
2023, the trading price of our common stock has traded as high as $4.37 and as low as $0.42 per share. Furthermore, the stock markets
have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many
companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad
market and industry fluctuations, as well as general economic, political, and market conditions, such as recessions, interest rate changes
or international currency fluctuations, may negatively affect the market price of our common stock. In the past, many companies that
have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s
attention from other business concerns, which could seriously harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about us, or if they adversely change their recommendations regarding
our common stock, then our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us,
our industry and our market. If no analyst elects to cover us and publish research or reports about us, the market for our common stock
could be severely limited and our stock price could be adversely affected. As a small-cap company, we are more likely than our larger
competitors to lack coverage from securities analysts. In addition, even if we receive analyst coverage, if one or more analysts ceases
coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause
our stock price or trading volume to decline. If one or more analysts who elect to cover us issue negative reports or adversely change
their recommendations regarding our common stock, our stock price could decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have broad discretion in how we use the net proceeds of this offering and may not use these proceeds effectively, which could affect
our results of operations and cause our common stock to decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will have considerable discretion in the application of the net proceeds of this offering. We intend to use the net proceeds from this
offering for new product development, marketing and advertising and for working capital. As a result, investors will be relying upon
management&#8217;s judgment with only limited information about our specific intentions for the use of the net proceeds of this offering.
We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition,
pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Purchasers
in this offering will experience immediate and substantial dilution in net tangible book value.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
the price per share of our common stock being offered is higher than the book value per share of our common stock, you will suffer substantial
dilution in the net tangible book value of the common stock you purchase in this offering. Based on a public offering price of
$0.30 per share, and the net tangible book value of the common stock of $0.07 per share as of September 30, 2023, if you purchase
shares of common stock in this offering, you will suffer dilution of $0.19 per share in the net tangible book value of the common
stock, which will be $0.11 per share following the offering (on an adjusted basis). See &#8220;<a href="#sj_005">Dilution</a>&#8221;
below for a more detailed discussion of the dilution you will incur if you purchase our common stock in the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales of our common stock, other securities convertible into our common stock, or preferred stock could cause the market value of our
common stock to decline and could result in dilution of your shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors is authorized, without your approval, to cause us to issue additional shares of our common stock or to raise capital
through the creation and issuance of preferred stock, other debt securities convertible into common stock, options, warrants and other
rights, on terms and for consideration as our Board of Directors in its sole discretion may determine. Additionally, pursuant to the
Resale Prospectus, we registered the resale of an aggregate of 4,765,000 shares of common stock, which shares of common stock are available
for immediate resale in the public market (which number includes 2,000,000 shares of common stock issuable upon the exercise of warrants,
of which 975,500 shares of common stock remain issuable thereunder as of the date of this prospectus). An additional 87,500 shares of
common stock are issuable upon exercise of outstanding warrants to purchase shares at $5.00 per share, which were issued in connection
with the IPO, which were first exercisable on September 20, 2023. Sales of substantial amounts of our common stock or of preferred stock
could cause the market price of our common stock to decrease significantly. We cannot predict the effect, if any, of future sales of
our common stock, or the availability of our common stock for future sales, on the value of our common stock. Sales of substantial amounts
of our common stock by large shareholders, or the perception that such sales could occur, may adversely affect the market price of our
common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with our IPO, we, our directors, executive officers, and shareholders holding 5% or more of our outstanding common stock have
agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities
for a period of 12 months following the closing of the IPO (until March 20, 2024), subject to certain exceptions, and any director or
officers who did not enter into a lock up agreement with the Representative in connection with our IPO has entered into a lock up agreement
with us agreeing to not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any
of our securities for a period of 90 days after the date the registration statement of which this prospectus forms a part is declared
effective by the Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
to the extent the registration statement of which this prospectus is a part, is not declared effective by the Commission on or before
December 31, 2023, we agreed to cause each of our officers, directors and owners of 5% or more of our outstanding common stock (or securities
convertible or exercisable into common stock), to deliver an executed lock-up agreement to the Representative and agree to be locked
up for a period of 90 days after the date the registration statement of which this prospectus forms a part is declared effective by the
Commission.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representative of the IPO&#8217;s and/or this offering&#8217;s underwriters may, at any time, release, or authorize us to release, as
the case may be, all or a portion of our common stock subject to the foregoing lock-up provisions without required notice. If the restrictions
under the lock-up provisions of the lock-up agreements entered into in connection with the IPO and/or this offering are waived, shares
of our common stock may become available for sale into the market, subject to applicable law, which could reduce the market price for
our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 50; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have no intention of declaring dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decision to pay cash dividends on our common stock rests with our Board of Directors and will depend on our earnings, unencumbered cash,
capital requirements and financial condition. We do not anticipate declaring any dividends in the foreseeable future, as we intend to
use any excess cash to fund our operations. Investors in our common stock should not expect to receive dividend income on their investment,
and investors will be dependent on the appreciation of our common stock to earn a return on their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
issuance and sale of common stock upon exercise of outstanding warrants may cause substantial dilution to existing shareholders and may
also depress the market price of our common stock. Outstanding warrants to purchase shares of our common stock have cashless exercise
rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, we had a total of 1,063,000 warrants outstanding with a weighted average exercise price of $1.00 per
share and term ranging from August 16, 2027 through March 20, 2028. If the holders of the warrants choose to exercise the warrants, it
may cause significant dilution to the then holders of our common stock. If exercises of the warrants and sales of such shares issuable
upon exercise thereof take place, the price of our common stock may decline. In addition, the common stock issuable upon exercise of
the warrants may represent overhang that may also adversely affect the market price of our common stock. Overhang occurs when there is
a greater supply of a company&#8217;s stock in the market than there is demand for that stock. When this happens the price of our stock
will decrease, and any additional shares which shareholders attempt to sell in the market will only further decrease the share price.
If the share volume of our common stock cannot absorb shares sold by the warrant holders, then the value of our common stock will likely
decrease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
total of 87,500 of the warrants discussed above (which have an exercise price of $5.00 per share) currently allow for cashless exercise
rights. In a &#8216;cashless exercise&#8217;, the holder reduces the number of shares of common stock issuable upon exercise of the warrants
in amount equal to the aggregate value of the exercise price of the exercised warrants. For example, if our common stock was trading
at $2.00 per share and a holder desires to exercise warrants to purchase 100 shares of common stock with an exercise price of $1.00 per
share on a cashless basis, the number of shares of common stock issuable to the holder upon such exercise would be reduced by 50 shares,
equal in value to $100 ($2.00 per share x 50 shares), and the holder would receive 50 shares of common stock upon such exercise. We do
not receive any cash upon a cashless exercise and as such, while a cashless exercise reduces the dilution which would otherwise exist
upon a warrant exercise, it is also not as beneficial to us, as it does not bring in any new investment proceeds. Additionally, holders
of warrants with cashless exercise provisions may be more likely to exercise their warrants as they do not have to come out of pocket
with any cash exercise payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
industry and the broader U.S. economy experienced higher than expected inflationary pressures during 2022 related to continued supply
chain disruptions, labor shortages and geopolitical instability, and if these conditions persist, our business, results of operations
and cash flows could be materially and adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022
saw significant increases in the costs of labor and certain materials and equipment, and longer lead times for such materials and equipment,
as a result of availability constraints, supply chain disruption, increased demand, labor shortages associated with a fully employed
U.S. labor force, high inflation and other factors. Supply and demand fundamentals have been further aggravated by disruptions in global
energy supply caused by multiple geopolitical events, including the ongoing conflict between Russia and Ukraine. Recent supply chain
constraints and inflationary pressures may in the future adversely impact our operating costs, and as a result, our business, financial
condition, results of operations and cash flows could be materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
and the health and wellness industry in general may be adversely affected during periods of high inflation, primarily because of higher
shipping and product manufacturing costs. While we plan to attempt to pass on increases in our costs through increased sales prices,
market forces may limit our ability to do so. If we are unable to raise sales prices enough to compensate for higher costs, our future
revenues, gross profit margin and revenues could be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 51; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Economic
uncertainty may affect our access to capital and/or increase the costs of such capital.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Global
economic conditions continue to be volatile and uncertain due to, among other things, consumer confidence in future economic conditions,
fears of recession and trade wars, the price of energy, fluctuating interest rates, the availability and cost of consumer credit, the
availability and timing of government stimulus programs, levels of unemployment, increased inflation, tax rates, and the war between
Ukraine and Russia which began in February 2022, and has continued through the date of this prospectus, as well as the current ongoing
war between Hamas and Israel, which began in October 2023. These conditions remain unpredictable and create uncertainties about our ability
to raise capital in the future. In the event required capital becomes unavailable in the future, or more costly, it could have a material
adverse effect on our business, future results of operations, and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business may be materially and adversely disrupted by epidemics or pandemics in the future, including COVID-19.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
epidemic, pandemic or similar serious public health issue, and the measures undertaken by governmental authorities to address it, could
significantly disrupt or prevent us from operating our business in the ordinary course for an extended period, and thereby, and/or along
with any associated economic and/or social instability or distress, have a material adverse impact on our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 11, 2020, the World Health Organization characterized the outbreak of COVID-19 as a global pandemic and recommended containment
and mitigation measures. On March 13, 2020, the United States declared a national emergency concerning the outbreak, and several states
and municipalities have declared public health emergencies. The U.S. Congress formally ended the COVID-19 national emergency on April
10, 2023. Although COVID-19 has to date not had a material impact on our operations, should the COVID-19 public health effort re-intensify
to such an extent that we cannot operate, if there are new government restrictions on our business and our customers, and/or an extended
economic recession or significant inflation, we could be unable to produce significant revenues and cash flows sufficient to conduct
our business. Such a circumstance could, among other things, exhaust our available liquidity (and ability to access liquidity sources)
and/or trigger an acceleration to pay a significant portion or all of our then-outstanding debt obligations, which we may be unable to
do.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could be disrupted by catastrophic events and man-made problems, such as power disruptions, data security breaches, and terrorism.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
systems are vulnerable to damage or interruption from the occurrence of any catastrophic event, including earthquake, fire, flood, or
other weather event, power loss, telecommunications failure, software or hardware malfunction, cyber-attack, war, terrorist attack, or
incident of mass violence, which could result in lengthy interruptions in access to our systems. In addition, acts of terrorism, including
malicious internet-based activity, could cause disruptions to the internet or the economy as a whole. If our systems were to fail or
be negatively impacted as a result of a natural disaster or other event, our ability to provide products to customers would be impaired
or we could lose critical data. We do not carry business interruption insurance sufficient to compensate us for the potentially significant
losses, including the potential harm to our business, financial condition and results of operations that may result from interruptions
in access to our platform as a result of system failures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Economic
uncertainty may affect consumer purchases of discretionary items, which may affect demand for our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products may be considered discretionary items for consumers. Factors affecting the level of consumer spending for such discretionary
items include general economic conditions and other factors such as consumer confidence in future economic conditions, fears of recession
and trade wars, the price of energy, fluctuating interest rates, the availability and cost of consumer credit, the availability and timing
of government stimulus programs, levels of unemployment, inflation, and tax rates. As U.S. economic conditions continue to be volatile
or economic uncertainty remains, and with increasing inflation and interest rates, trends in consumer discretionary spending also remain
unpredictable and subject to reductions as a result of significant increases in employment, financial market instability, and uncertainties
about the future. Unfavorable economic conditions have led, and in the future may lead, consumers to reduce their spending on men&#8217;s
wellness products, which in turn has in the past led to a decrease in the demand for such products. Consumer demand for the Company&#8217;s
products may decline as a result of an economic downturn, or economic uncertainty. The sensitivity to economic cycles and any related
fluctuation in consumer demand may have a material adverse effect on the Company&#8217;s business, results of operations, and financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, an armed conflict escalated between Russia and Ukraine. The sanctions announced by the United States and other countries
against Russia and Belarus following Russia&#8217;s invasion of Ukraine to date include restrictions on selling or importing goods, services,
or technology in or from affected regions and travel bans and asset freezes impacting connected individuals and political, military,
business, and financial organizations in Russia and Belarus. The United States and other countries could impose wider sanctions and take
other actions should the conflict further escalate. Separately, in October 2023, Israel and certain Iranian-backed Palestinian forces
began an armed conflict in Israel, the Gaza Strip, and surrounding areas. This conflict currently threatens to spread to other Middle
Eastern countries, and may ultimately result in the United States and other countries becoming involved in the conflict. Although the
Company does not, and does not plan to, do business in Russia, Belarus, Ukraine, Israel, or the Middle East, it is not possible to predict
the broader consequences of these ongoing conflicts, which could include further sanctions, embargoes, regional instability, and geopolitical
shifts. It is also not possible to predict with certainty these ongoing conflicts and additional adverse effects on existing U.S. macroeconomic
conditions, consumer spending habits, currency exchange rates, and financial markets, all of which could impact the business, financial
condition, and results of operations of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Global
economic conditions could materially adversely affect our business, results of operations, financial condition and growth.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adverse
macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs, changes to fiscal and monetary policy,
tighter credit, higher interest rates, high unemployment and currency fluctuations could materially adversely affect our operations,
expenses, access to capital and the market for our products. In addition, consumer confidence and spending could be adversely affected
in response to financial market volatility, negative financial news, conditions in the real estate and mortgage markets, declines in
income or asset values, changes to fuel and other energy costs, labor and healthcare costs and other economic factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, uncertainty about, or a decline in, global or regional economic conditions could have a significant impact on our expected
funding sources, suppliers and partners. Potential effects include financial instability; inability to obtain credit to finance operations
and purchases of our products; and insolvency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
downturn in the economic environment could also lead to limitations on our ability to issue new debt; reduced liquidity; and declines
in the fair value of our financial instruments. These and other economic factors could materially adversely affect our business, results
of operations, financial condition and growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become party to litigation, mediation and/or arbitration from time to time given our product focus.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become party to regulatory proceedings, litigation, mediation and/or arbitration from time to time in the ordinary course of business
which could adversely affect our business. Monitoring and defending against legal actions, whether or not meritorious, can be time-consuming,
divert management&#8217;s attention and resources and cause us to incur significant expenses. In addition, legal fees and costs incurred
in connection with such activities may be significant and we could, in the future, be subject to judgments or enter into settlements
of claims for significant monetary damages. While we expect to have insurance in the future that may cover the costs and awards of certain
types of litigation, the amount of our future insurance may not be sufficient to cover any costs or awards. Substantial litigation costs
or an adverse result in any litigation may adversely impact our business, operating results or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 53; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Higher
labor costs due to statutory and regulatory changes could materially adversely affect our business, financial condition and operating
results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various
federal and state labor laws, including new laws and regulations enacted in response to COVID-19, govern our relationships with our employees
and affect operating costs. These laws include employee classifications as exempt or non-exempt, minimum wage requirements, unemployment
tax rates, workers&#8217; compensation rates, overtime, family leave, workplace health and safety standards, payroll taxes, citizenship
requirements and other wage and benefit requirements for employees classified as non-exempt. As certain of our employees are paid at
rates set at, or above but related to, the applicable minimum wage, further increases in the minimum wage could increase our labor costs.
Significant additional government regulations could materially adversely affect our business, financial condition and operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to adequately manage our planned aggressive growth strategy may harm our business or increase our risk of failure.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the foreseeable future, we intend to pursue an aggressive growth strategy for the expansion of our operations through increased marketing.
Our ability to rapidly expand our operations will depend upon many factors, including our ability to work in a regulated environment,
establish and maintain strategic relationships with suppliers, and obtain adequate capital resources on acceptable terms. Any restrictions
on our ability to expand may have a materially adverse effect on our business, results of operations, and financial condition. Accordingly,
we may be unable to achieve our targets for sales growth, and our operations may not be successful or achieve anticipated operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our growth may place a significant strain on our managerial, administrative, operational, and financial resources and our infrastructure.
Our future success will depend, in part, upon the ability of our senior management to manage growth effectively. This will require us
to, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement
    additional management information systems;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    develop our operating, administrative, legal, financial, and accounting systems and controls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
    additional levels of management within our company;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">locate
    additional office space; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain
    close coordination among our operations, legal, finance, sales and marketing, and client service and support personnel.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result, we may lack the resources to deploy our services on a timely and cost-effective basis. Failure to accomplish any of these requirements
could impair our ability to deliver services in a timely fashion or attract and retain new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 54; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we make any acquisitions, they may disrupt or have a negative impact on our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we make acquisitions in the future, we could have difficulty integrating the acquired company&#8217;s assets, personnel and operations
with our own. We do not anticipate that any acquisitions or mergers we may enter into in the future would result in a change of control
of the Company. In addition, the key personnel of the acquired business may not be willing to work for us. We cannot predict the effect
expansion may have on our core business. Regardless of whether we are successful in making an acquisition, the negotiations could disrupt
our ongoing business, distract our management and employees and increase our expenses. In addition to the risks described above, acquisitions
are accompanied by a number of inherent risks, including, without limitation, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    difficulty of integrating acquired products, services or operations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential disruption of the ongoing businesses and distraction of our management and the management of acquired companies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in maintaining uniform standards, controls, procedures and policies;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential impairment of relationships with employees and customers as a result of any integration of new management personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential inability or failure to achieve additional sales and enhance our customer base through cross-marketing of the products
    to new and existing customers;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of any government regulations which relate to the business acquired;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    unknown liabilities associated with acquired businesses or product lines, or the need to spend significant amounts to retool, reposition
    or modify the marketing and sales of acquired products or operations, or the defense of any litigation, whether or not successful,
    resulting from actions of the acquired company prior to our acquisition; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    expenses under the labor, environmental and other laws of various jurisdictions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be severely impaired if and to the extent that we are unable to succeed in addressing any of these risks or other problems
encountered in connection with an acquisition, many of which cannot be presently identified. These risks and problems could disrupt our
ongoing business, distract our management and employees, increase our expenses and adversely affect our results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Claims,
litigation, government investigations, and other proceedings may adversely affect our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to actual and threatened claims, litigation, reviews, investigations, and other proceedings, including proceedings relating
to products offered by us and by third parties, and other matters. Any of these types of proceedings, may have an adverse effect on us
because of legal costs, disruption of our operations, diversion of management resources, negative publicity, and other factors. The outcomes
of these matters are inherently unpredictable and subject to significant uncertainties. Determining legal reserves and possible losses
from such matters involves judgment and may not reflect the full range of uncertainties and unpredictable outcomes. Until the final resolution
of such matters, we may be exposed to losses in excess of the amount recorded, and such amounts could be material. Should any of our
estimates and assumptions change or prove to have been incorrect, it could have a material effect on our business, consolidated financial
position, results of operations, or cash flows. In addition, it is possible that a resolution of one or more such proceedings, including
as a result of a settlement, could require us to make substantial future payments, prevent us from offering certain products or services,
require us to change our business practices in a manner materially adverse to our business, requiring development of non-infringing or
otherwise altered products or technologies, damaging our reputation, or otherwise having a material effect on our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may incur indebtedness in the future which could reduce our financial flexibility, increase interest expense and adversely impact our
operations and our costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may incur significant amounts of indebtedness in the future. Our level of indebtedness could affect our operations in several ways, including
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    significant portion of our cash flows is required to be used to service our indebtedness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    high level of debt increases our vulnerability to general adverse economic and industry conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">covenants
    contained in the agreements governing our outstanding indebtedness limit our ability to borrow additional funds and provide additional
    security interests, dispose of assets, pay dividends and make certain investments;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    high level of debt may place us at a competitive disadvantage compared to our competitors that are less leveraged and, therefore,
    may be able to take advantage of opportunities that our indebtedness may prevent us from pursuing; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">debt
    covenants may affect our flexibility in planning for, and reacting to, changes in the economy and in our industry.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
high level of indebtedness increases the risk that we may default on our debt obligations. We may not be able to generate sufficient
cash flows to pay the principal or interest on our debt, and future working capital, borrowings or equity financing may not be available
to pay or refinance such debt. If we do not have sufficient funds and are otherwise unable to arrange financing, we may have to sell
significant assets or have a portion of our assets foreclosed upon which could have a material adverse effect on our business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span id="sj_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cautionary
Statement Regarding Forward-Looking Information</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities
Act, Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking
statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221;
&#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221;
&#8220;project,&#8221; &#8220;should,&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking
statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily
be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based
on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that
may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied
by the forward-looking statements in this Report. These factors include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements include, but are not limited to, statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain additional funding, the terms of such funding, and dilution caused thereby;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effect of pandemics on our operations, sales, and the market for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to build and maintain our brand;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cybersecurity,
    information systems and fraud risks and problems with our websites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand and grow our operations, and successfully market our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in, and our compliance with, rules and regulations affecting our operations, sales, and/or our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shipping,
    production or manufacturing delays;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to increase sales;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulations
    we are required to comply with in connection with our operations, manufacturing, labeling and shipping;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competition
    from existing competitors or new competitors or products that may emerge;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    dependency on third-parties to prescribe and compound our erectile dysfunction (ED) product;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to establish or maintain relations and/or relationships with third-parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    safety risks associated with our Mango ED and Mango GROW products, including the use of ingredients, combination of such ingredients
    and the dosages thereof;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effects of high inflation, increasing interest rates and economic downturns, including potential recessions, as well as macroeconomic,
    geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and ongoing conflict
    in and around Israel) and other large-scale crises;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to protect intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support future growth;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain key personnel to manage our business effectively; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    risk factors included under &#8220;<a href="#nj_007">Risk Factors</a>&#8221; below.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the matters described in &#8220;<a href="#nj_007">Risk Factors</a>&#8221; and the other cautionary statements made in this prospectus, as being
applicable to all related forward-looking statements wherever they appear in this prospectus. We cannot assure you that the forward-looking
statements in this prospectus will prove to be accurate and therefore prospective investors are encouraged not to place undue reliance
on forward-looking statements. These cautionary statements qualify all forward-looking statements attributable to us or persons acting
on our behalf. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though
our situation may change in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span id="sj_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
of Proceeds</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate that the net proceeds to us from the sale of our shares of common stock in this offering will be approximately $1.0
million, based on a public offering price of $0.30 per share, after deducting underwriting discounts and
commissions and estimated offering expenses. Our net proceeds will increase by approximately $0.5 million if the underwriters&#8217;
over-allotment option to purchase additional shares of common stock is exercised in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to use the proceeds from this offering primarily to finance the marketing and operational expenses associated with the
planned marketing of our Mango ED and Mango GROW products ($722,880, or approximately 72% of the net proceeds), hiring additional personnel
to build organizational talent ($80,320, or approximately 8% of the net proceeds), capital expenditures for software development and
maintenance $50,200, or approximately 5% of the net proceeds) and for general corporate purposes, including working capital ($150,600,
or approximately 15% of the net proceeds). In addition, we may use a portion of the net proceeds of this offering to finance future acquisitions
or invest in complementary businesses, services, technologies or intellectual property rights. However, we do not have any agreements
or commitments with respect to any such acquisitions or investments at this time. We will need additional funds to complete these
uses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the net proceeds of this offering, together with our cash and cash equivalents, will be sufficient to meet our cash, operational
and liquidity requirements for at least 12 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
our use of the net proceeds as described above, we intend to invest the net proceeds in short-term bank deposits or interest-bearing,
investment-grade securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing represents our current intentions with respect to the use and allocation of the net proceeds of this offering based upon our
present plans and business conditions, but our management will have significant flexibility and discretion in applying the net proceeds.
The occurrence of unforeseen events or changed business conditions could result in the application of the net proceeds of this offering
in a manner other than as described above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span id="sj_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
Policy</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any cash dividends on our capital stock. We currently intend to retain earnings, if any, to finance the growth
and development of our business. We do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of
future dividends, if any, will be at the discretion of our Board of Directors and will depend on our financial condition, results of
operations, capital requirements, restrictions contained in any financing instruments, provisions of applicable law and other factors
the board deems relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_004"></span>Capitalization</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and capitalization as of September 30, 2023 on:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    actual basis; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    as adjusted basis after giving effect to the sale of 4,000,000 shares of our common stock in this offering at a public
    offering price of $0.30 per share, and our receipt of the estimated $1.0 million in net proceeds from this offering,
    after deducting underwriting commissions and estimated offering expenses payable by us.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this capitalization table together with &#8220;<a href="#sj_002">Use of Proceeds</a>,&#8221; &#8220;<a href="#sj_006">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a>&#8221; and our financial statements and the related notes appearing elsewhere in this
prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>As of September 30, 2023 </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(In thousands)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Actual</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As Adjusted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; padding-bottom: 2.5pt">Cash</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">1,237</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; text-align: right">2,600</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock, $0.0001 par value; 200,000,000 shares authorized; 16,789,500 and 20,789,500
    shares issued and outstanding at September 30, 2023, on an actual and as adjusted basis, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,013</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,376</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,660</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.718</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total capitalization</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,355</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,718</p></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding after this offering in the table above is based on 16,789,500 shares outstanding as
of September 30, 2023, and does not give effect to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    of outstanding options to purchase 1,250,000 shares of common stock at an exercise price of $1.10 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    of outstanding warrants to purchase 1,063,000 shares of common stock at weighted average exercise price of $1.00 per share; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    awards under our 2022 Equity Incentive Plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_005"></span>Dilution</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchasers
of our common stock in this offering will experience an immediate dilution of net tangible book value per share from the public offering
price. Dilution in net tangible book value per share represents the difference between the amount per share paid by the purchasers of
shares of common stock and the net tangible book value per share immediately after this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, our net tangible book value was $1.2 million, or $0.07 per share of common stock. Net tangible book value per
share represents our total tangible assets, less our total liabilities, divided by the number of outstanding shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
in net tangible book value per share of common stock represents the difference between the public offering price per share of our common
stock in this offering and the as adjusted net tangible book value per share of our common stock after giving effect to this offering.
After giving effect to the sale of shares of common stock in this offering at a public offering price of $0.30 per share,
and after deducting underwriting commissions and estimated offering expenses payable by us, our as adjusted, net tangible book value
would have been $2.2 million, or $0.11 per share. This represents an immediate increase in pro forma net tangible book
value of $0.04 per share to our existing shareholders and immediate dilution of $0.19 per share to new investors purchasing
shares at the assumed public offering price. The following table illustrates the dilution in net tangible book value per share to new
investors as of September 30, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Public offering price per share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.30</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%">Net tangible book value per share of common stock as of September 30, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.07</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Increase in net tangible book value per share of common stock attributable to this offering</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">As adjusted net tangible book per share of common stock as of September 30, 2023, after this offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Dilution per share common stock to investors participating in this offering</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(0.19</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the underwriters exercise their option to purchase additional shares of common stock in full, the net tangible book value per share,
as adjusted to give effect to this offering, would be $2.4 million or $0.11 per share, and the dilution in net tangible book value
per share to investors in this offering would be $(0.19) per share.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that outstanding options or warrants are exercised, you will experience further dilution. In addition, we may choose to raise
additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or
future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the
issuance of these securities may result in further dilution to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilution information set forth in the table above is illustrative only and will be adjusted based on the actual public offering price
and other terms of this offering determined at pricing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock to be outstanding after this offering in the table above is based on 16,789,500 shares outstanding as
of September 30, 2023, and does not give effect to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    of outstanding options to purchase 1,250,000 shares of common stock at an exercise price of $1.10 per share;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exercise
    of outstanding warrants to purchase 1,063,000 shares of common stock at weighted average exercise price of $1.00 per share; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    awards under our 2022 Equity Incentive Plan.</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"></p>

<!-- Field: Page; Sequence: 61; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="sj_006"></span>Management&#8217;s
Discussion and Analysis of</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Condition and Results of Operations</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion should be read in conjunction with our financial statements and accompanying notes included elsewhere in this prospectus.
The following discussion contains forward-looking statements regarding future events and the future results of the Company that are based
on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions
of the management of the Company. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;targets,&#8221; &#8220;goals,&#8221;
&#8220;projects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221;
variations of such words, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements
are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results
may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to
such differences include, but are not limited to, those discussed elsewhere in this prospectus, particularly under &#8220;<a href="#nj_007">Risk Factors</a>,&#8221;
and in other reports we file with the SEC. See also &#8220;<a href="#sj_001">Cautionary Statement Regarding Forward-Looking Statements.</a>&#8221; The Company
undertakes no obligation to revise or update publicly any forward-looking statements for any reason except as required by law. Factors
that could cause or contribute to these differences include those discussed below and elsewhere in this prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion is based upon our financial statements included elsewhere in this prospectus, which have been prepared in accordance
with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments
that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingencies.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Introduction</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is provided in addition
to the accompanying financial statements and notes to assist readers in understanding our results of operations, financial condition,
and cash flows. MD&amp;A is organized as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
    Performance Indicators. </b>Indicators describing our performance for the periods presented.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan
    of Operations.</b> A description of our plan of operations for the next 12 months including required funding.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
    of Operations.</b> An analysis of our financial results comparing the three and nine months ended September 30, 2023 and 2022 and
    the year ended December 31, 2022 and the period from October 7, 2021 (inception) through December 31, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
    and Capital Resources.</b> An analysis of changes in our balance sheets and cash flows and discussion of our financial condition.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
    Accounting Policies and Estimates.</b> Accounting estimates that we believe are important to understanding the assumptions and judgments
    incorporated in our reported financial results and forecasts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
information should be read in conjunction with the financial statements and related notes included in the audited financial statements
beginning under &#8220;<a href="#fintoc_001">Index to Financial Statements</a>&#8221; in this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
also &#8220;<a href="#nj_003">Glossary of Industry Terms</a>&#8221; above for information on certain of the terms used below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 62; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Plan
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had working capital of $1.2 million as of September 30, 2023. With our current cash on hand, expected revenues, and based on our current
average monthly expenses, we currently anticipate the need for additional funding in order to continue our operations at their current
levels and to pay the costs associated with being a public company for the next 12 months. We may also require additional funding in
the future to expand or complete acquisitions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
plan for the next 12 months is to continue using the same marketing and management strategies and continue providing a quality product
with excellent customer service while also seeking to expand our operations organically or through acquisitions as funding and opportunities
arise. As our business continues to grow, customer feedback will be integral in making small adjustments to improve products and our
overall customer experience.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are headquartered in Dallas, Texas and intend to grow our business both organically and through identifying acquisition targets over
the next 12 months in the technology, health and wellness space, funding permitting. Specifically, we plan to continue to make additional
and ongoing technology enhancements to our platform, further develop, market and advertise additional men&#8217;s health and wellness
related products on our telemedicine platform, and identify strategic acquisitions that complement our vision. As these opportunities
arise, we will determine the best method for financing such acquisitions and growth which may include the issuance of debt instruments,
common stock, preferred stock, or a combination thereof, all of which may result in significant dilution to existing shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the proceeds from this offering plus our current cash will be sufficient to fund our operations and execute our growth strategy
(as discussed above) for at least 12 months after the date of this prospectus. After this offering, we may seek additional funding through
equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions.
We may not be able to obtain financing on acceptable terms or at all. The terms of any financing may adversely affect the holdings or
rights of our shareholders. Although we continue to pursue these plans, there is no assurance that we will be successful in obtaining
sufficient funding on terms acceptable to us to fund continued operations, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Performance Indicators</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key
performance indicators that we use to evaluate our business, measure our performance, identify trends affecting our business, formulate
financial projections and make strategic decisions include average order value (&#8220;AOV&#8221;); the percentage breakdown between
subscribing and non-subscribing customers; and the percentage breakdown between new orders and refills/auto-refills.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average
Order Value (AOV)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Subscribing Customers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">130.27</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">130.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Non-Subscribing Customers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">105.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">104.65</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
Breakdown Between Subscribing and Non-Subscribing Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; text-align: justify">Subscribing Customers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">11</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">9</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Non-Subscribing Customers</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">89</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">91</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 63; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to continuously working to acquire new customers for our Mango ED and Mango GROW products, our goal is to gradually increase
the percentage and number of subscribing customers, compared to one-time non-subscribing customers, which if successful, we expect will
drive greater predictability and growth in revenues and cash flow, allowing us to invest even more aggressively in new customer acquisition.
Further, our goal is to increase our AOVs, which we also anticipate will grow over time as the Company launches, markets and sells additional
men&#8217;s health and wellness products through its online telemedicine platform.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Three and Nine months Ended September 30, 2023 and 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
began generating revenues in November 2022 and had revenues of $245,160 and $487,119 for the three and nine months ended September 30,
2023, respectively, and we did not generate any revenues for the three and nine months ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cost of revenues of $52,193 and $101,538 for the three and nine months ended September 30, 2023, respectively, and related party
cost of revenues of $48,378 and $96,663 for the three and nine months ended September 30, 2023, respectively, relating to amounts paid
to Epiq Scripts, a related party, 51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, which entity
provides us pharmacy and compounding services, resulting in gross profit of $144,589 and $288,918 for the three and nine months ended
September 30, 2023, respectively. The related party cost of revenues was associated with the Master Services Agreement entered into with
Epiq Scripts and a related statement of work and the remaining cost of revenues was attributed to the amounts paid to our unrelated party
doctors network and shipping expenses. We did not have any cost of revenues for the three and nine months ended September 30, 2022, as
we did not begin generating revenues until November 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company analyzed the following factors when determining the amounts to be paid to Epiq Scripts under the Master Services Agreement and
related statement of work: a) the fairness of the terms for the Company (including fairness from a financial point of view); b) the materiality
of the transaction; c) bids / terms for a similar transaction from unrelated parties; d) the structure of the transaction; and e) the
interests of each related party in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Expenses and Net Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had total general and administrative expenses of $1,944,049 and $6,939,761 and imputed interest gain of $0 and $6,473 (which represented
imputed interest canceled and reversed on the related party loans repaid as discussed below under &#8220;<i>Liquidity and Capital Resources</i>&#8221;)
for the three and nine months ended September 30, 2023, resulting in a net loss of $1,799,460 and $6,644,370, respectively, compared
to general and administrative expenses of $991,825 and $1,319,727 and $3,090 and $4,673 of imputed interest expense (which represented
imputed interest on the related party loans discussed below under &#8220;<i>Liquidity and Capital Resources</i>&#8221;) for the three
and nine months ended September 30, 2022. This resulted in a net loss of $994,915 and $1,324,400, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 64; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in general administration expenses for the three and nine months ended September 30, 2023, compared to the prior period, was
due primarily to (a) stock-based compensation totaling $151,592 and $1,367,134 (including a total of $84,750 and $1,171,750 attributed
to stock issued for services and $66,842 and $195,384 attributed to stock-based compensation from issuances of options and warrants)
and 0 and $490,000 for the three and nine months ended September 30, 2023 and 2022, respectively, which increase was due to us having
issued less stock for compensation during the 2022 period; (b) advertising and marketing expenses in the amount of $720,531 and $1,633,528
and $98,797 and $164,085, for the three and nine months ended September 30, 2023 and 2022, respectively, related to us increasing our
advertising and marketing costs in the 2023 period as we ramped up our marketing efforts in connection with the expansion of our operations;
(c) legal fees of $58,725 and $257,111 and $0 and $156,987, for the three and nine months ended September 30, 2023 and 2022, respectively,
mainly related to legal fees in connection with our initial public offering and related matters; (d) placement agent fees of $0 and $400,000,
for the three and nine months ended September 30, 2023 and $0 and $120,040 for 2022, respectively, relating to fees paid to our placement
agent in connection with our private placement and initial public offering; (e) salaries and benefits of $262,092 and $642,007 and $51,000
and $51,000 for the three and nine months ended September 30, 2023 and 2022, respectively, which increased due to the engagement of new
employees as we ramped up our operations in the current period; (f) accounting and auditing fees of $9,200 and $86,800 and $7,644 and
$17,644, for the three and nine months ended September 30, 2023 and 2022, respectively, which was in connection with fees paid to our
accountants and auditors in connection with the preparation of the financial statements for our initial public offering and quarterly
reviews; (g) general consulting related expenses of $156,929 and $376,070 and $75,180 and $75,180, for the three and nine months ended
September 30, 2023 and 2022, respectively, related to other various consulting fees paid in connection with our operations in the current
period; and (h) software development fees of $70,599 and $361,740 and $31,420 and $41,020 for the three and nine months ended September
30, 2023 and 2022, respectively, related to the front and backend development of our website in the current period. Software development
expenses are integral to customers accessing our ordering system and successfully placing an order for our products. We had not yet implemented
our online ordering in the first nine months of 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Year Ended December 31, 2022 and the period from October 7, 2021 (inception) through December 31, 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
launched our website in mid-November 2022. Through December 31, 2022, we sold only a small amount of products and generated only $8,939
in revenues for the year ended December 31, 2022. We did not generate any revenue for the period from October 7, 2021 (inception) through
December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cost
of Revenues</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cost of revenues of $4,089 for the year ended December 31, 2022 and gross profit of $4,850 for the year ended December 31, 2022.
A total of $3,255 of our cost of revenues for the year ended December 31, 2022, was attributed to related party pharmacy services provided
by Epiq Scripts in accordance with the costs as outlined and detailed in the Master Services Agreement and a related statement of work
and the remaining $834 was attributed to an unrelated party carrier and shipping expenses. We did not have any cost of revenues for the
period from October 7, 2021 (inception) through December 31, 2021. The Company analyzed the following factors when determining the amounts
to be paid to Epiq Scripts under the Master Services Agreement and related statement of work: a) the fairness of the terms for the Company
(including fairness from a financial point of view); b) the materiality of the transaction; c) bids / terms for a similar transaction
from unrelated parties; d) the structure of the transaction; and e) the interests of each related party in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Expenses and Net Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had total general and administrative expenses of $1,996,432 and imputed interest expense of $6,473 (which represented imputed interest
on the related party loans discussed below under &#8220;Liquidity and Capital Resources&#8221;) for the year ended December 31, 2022,
resulting in a net loss of $1,998,055, compared to general and administrative expenses of $17,520 and $181 of imputed interest expense
(which represented imputed interest on the related party loans discussed below under &#8220;Liquidity and Capital Resources&#8221;) for
the period of October 7, 2021 (inception) to December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 65; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
increase in general administration expenses for the year ended December 31, 2022, compared to the prior period, was due primarily to
(a) stock-based compensation from issuances of options and warrants, totaling $622,333 (including a total of <span style="background-color: white">$540,065
</span>attributed to stock issued for services and $82,268 attributed to stock-based compensation from issuances of options and warrants)
and $0 for the years ended December 31, 2022 and 2021, respectively, which increase was due to us having issued no stock compensation
during the 2021 period; (b) advertising and marketing expenses in the amount of $352,860 and $17,500, for the years ended December 31,
2022 and 2021, respectively, related to us increasing our advertising and marketing costs in the 2022 period as we ramped up our marketing
efforts in connection with the expansion of our operations; (c) legal fees of $231,798 and $0, for the years ended December 31, 2022
and 2021, respectively, mainly related to legal fees in the current period in connection with our initial public offering and related
matters; (d) placement agent fees of $160,000 and $0, for the year ended December 31, 2022 and 2021, respectively, relating to fees paid
to our placement agent in connection with our 2022 private placement offering (discussed below); (e) salaries and benefits of $163,246
and $0, for the year ended December 31, 2022 and 2021, respectively, which increased due to the engagement of new employees as we ramped
up our operations in the current period; (f) accounting and auditing fees of $44,500 and $0 for the year ended December 31, 2022 and
2021, respectively, which increase was in connection with fees paid to our accountants and auditors in connection with the preparation
of the financial statements for our initial public offering; (g) general consulting related expenses of $209,657 and $0 for the year
ended December 31, 2022 and 2021, respectively, related to due diligence fees paid to our placement agent in connection with our initial
public offering and other various consulting fees paid in connection with our operations in the current period; and (h) software development
fees of $72,440 and $0 for the year ended December 31, 2022 and 2021, respectively, related to the front and backend development of our
website in the current period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, we had $1,236,747 of cash on-hand, compared to $682,860 of cash on-hand of December 31, 2022. We also had $84,382
of prepaid expenses, related party, relating to amounts funded to Epiq Scripts, which is 51% owned and controlled by Jacob D. Cohen,
our Chairman and Chief Executive Officer, $21,581 of inventory; $102,420 of property and equipment, net, consisting of computers, office
and custom product packaging equipment, $16,942 of security deposit, representing the security deposit on our leased office space and
$133,433 of right of use asset in connection with our office space lease. Cash increased mainly due to funds raised in the IPO, offset
by cash used for general operating expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the Company had total current liabilities of $159,176, consisting of $89,059 of accounts payable and accrued liabilities,
$8,200 of payroll tax liabilities, and $61,917 of right-of-use liability, operating lease, current portion. We also had $81,507 of right-of-use
liability, long-term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, we had $1,595,505 in total assets, $240,684 in total liabilities, working capital of $1.2 million and a total
accumulated deficit of $8,660,126.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have mainly relied on related party loans, as well as funds raised through the sale of securities, mainly through the private placement
offering and our IPO discussed below, and revenues generated from sales of our Mango ED and Mango GROW products, to support our operations
since inception. We have primarily used our available cash to pay operating expenses. We do not have any material commitments for capital
expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 66; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have experienced recurring net losses since inception. We believe that we will continue to incur substantial operating expenses in the
foreseeable future as we continue to invest to bring our Mango ED and Mango GROW products to market and to attract customers, expand
the product offerings and enhance technology and infrastructure. These efforts may prove more expensive than we anticipate, and we may
not succeed in generating commercial revenues or net income to offset these expenses. Accordingly, we may not be able to achieve profitability,
and we may incur significant losses for the foreseeable future. Our independent registered public accounting firm included an explanatory
paragraph in its report on our financial statements as of December 31, 2022. As of September 30, 2023, our current capital resources,
combined with the net proceeds from the offering, are expected to be sufficient for us to fund operations for the next 12 months. We
need to raise funding in addition to the funding raised in our IPO, to support our operations in the future. We may also seek to acquire
additional businesses or assets in the future, which may require us to raise funding. We currently anticipate such funding being raised
through the offering of debt or equity. Such additional financing, if required, may not be available on favorable terms, if at all. If
debt financing is available and obtained, our interest expense may increase and we may be subject to the risk of default, depending on
the terms of such financing. If equity financing is available and obtained it may result in our shareholders experiencing significant
dilution. If such financing is unavailable, we may be forced to curtail our business plan, which may cause the value of our securities
to decline in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
support our existing operations or any future expansion of business, including the ability to execute our growth strategy, we must have
sufficient capital to continue to make investments and fund operations. We have plans to pursue an aggressive growth strategy for the
expansion of operations through marketing to attract new customers for our Mango ED and Mango GROW products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nine months</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(5,299,634</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(696,958</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,519</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,531</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,857,040</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,550,430</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">553,887</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">850,941</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $5,299,634 for the nine months ended September 30, 2023, which was mainly due to $6,644,370 of
net loss, offset by $1,171,750 of common stock issued for services, $195,384 for options vested for stock-based compensation, offset
by an increase in prepaid expense of $72,637.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $696,958 for the nine months ended September 30, 2022, which was mainly due to $1,324,400 of net
loss offset by $490,000 of common stock issued for services and $169,817 for options vested for stock-based compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $3,519 for the nine months ended September 30, 2023, compared to $2,531 for the nine months ended
September 30, 2022, which were due to the purchase of equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $5,857,340 for the nine months ended September 30, 2023, which was mainly due to $5,000,000
of funds raised in the IPO and $1,024,500 in proceeds from the exercise of warrants, offset by repayments of notes payable of $78,260
and repayments of related party notes payable of $89,200.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 67; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $1,550,430 for the nine months ended September 30, 2022, which was mainly due to $1,500,500
of proceeds from the sale of common stock in our private offering, discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31, <br/>
2022</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>From</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>October 7, 2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Inception) to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/>
 2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left">Cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,346,518</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(17,520</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,102</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,049,930</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,070</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">660,310</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,550</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $1,346,518 for the year ended December 31, 2022, which was mainly due to $1,998,055 of net loss,
offset by $540,065 of common stock issued for services and $234,088 of stock-based compensation from issuances of options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was $17,520 for the period from October 7, 2021 (Inception) through December 31, 2021, which was due
to $17,701 of net loss offset by $181 of imputed interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was $43,102 for the year ended December 31, 2022, which was due to the purchase of equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $2,049,930 for the year ended December 31, 2022, which was mainly due to $2,000,000 of sales
of common stock and warrants to purchase common stock, representing amounts raised in the 2022 private offering, discussed below and
$75,000 of notes payable from related parties, offset by $25,070 of repayment of related party notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $40,070 for the period from October 7, 2021 (Inception) through December 31, 2021, which was
due to $39,270 of notes payable from related parties and $800 of proceeds from the sale of stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Loans and Advances</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company received an advance of $70 from ZipDoctor, Inc., a wholly-owned subsidiary of its then sole shareholder,
American International, which was used to open and establish the Company&#8217;s bank account. The advance bears no interest and is due
on demand upon the Company&#8217;s ability to repay the advance from either future revenues or investment proceeds. The amount owed to
ZipDoctor was $70 as of December 31, 2021. Imputed interest equal to 8% per annum, or $0, was recorded against the related party advance
as of December 31, 2021. The amount was paid in full on May 24, 2022 and the amount owed to ZipDoctor was $0 as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021 and March 18, 2022, the Company received advances of $39,200 and $50,000, respectively, for a total of $89,200 from
its previous majority shareholder, American International, in order to cover various general and administrative expenses. The amount
owed to American International was $39,200 as of December 31, 2021. Imputed interest equal to 8% per annum, or $181, was recorded against
the related party advance as of December 31, 2021. Other than the imputed interest discussed above, the advances bear no interest and
are due on demand upon the Company&#8217;s ability to repay the advances from either future revenues or investment proceeds. Pursuant
to the terms of the June 16, 2022, SPA discussed below, on June 16, 2022, Cohen Enterprises also acquired the right to be repaid the
$89,200 advanced from American International to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2022, American International entered into and closed the transactions contemplated by a Stock Purchase Agreement (the &#8220;SPA&#8221;),
with Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), which entity is owned by Jacob D. Cohen, the Chairman and Chief Executive
Officer of the Company, who is also the majority shareholder of the Company. Pursuant to the SPA, American International sold 8,000,000
shares of the outstanding common stock of the Company which represented 80% of the then outstanding shares of common stock of the Company,
to Cohen Enterprises in consideration for $90,000, which was approximately the same amount that had been advanced to the Company from
American International through the date of the SPA ($89,200). Cohen Enterprises also acquired the right to be repaid the $89,200 advanced
from American International to the Company, from the Company, pursuant to the terms of the SPA. As a result of the closing of the SPA,
Cohen Enterprises increased its ownership of the Company to 90% (with the remaining 10% of the Company then being owned by Mr. Arango,
as discussed above), and American International completely divested its interest in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 68; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2022, the Company received an advance of $25,000 from Cohen Enterprises, which is owned by Mr. Cohen, the Chairman and Chief
Executive Officer of the Company, who is also the majority shareholder of the Company, in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $25,000 on August 18, 2022 and the remaining $89,200 on April 4, 2023, bringing the total
amount owed to Cohen Enterprises to $0 as of September 30, 2023. The Company further recorded a credit of $6,473 towards imputed interest
(previously calculated at a rate of 8% per annum) against the related party advances for the nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2022, the Company entered into a Secured Installment Promissory Note with a vendor for the purchase of equipment in the
amount of $78,260 (the &#8220;Note Payable&#8221;). The note bears no interest unless an event of default occurs, and then it bears interest
at the rate of 10% per annum until paid in full. The Note Payable was payable in installments, requiring payments of $5,000 on each of
January 1, 2023, February 1, 2023, and March 1, 2023, with a $31,630 payment due on April 1, 2023 and a final payment due on May 1, 2023.
The January 1 and March 1, 2023 payments were timely made and on March 23, 2023, the Company elected to pay off the remaining balance
of $63,260. The outstanding balance on December 31, 2022 was $78,260 and as of September 30, 2023, was $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
Private Placement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the Company initiated a private placement of up to $2 million of units to accredited investors, with each unit consisting
of one share of common stock and a warrant to purchase one share of common stock, at a price of $1.00 per unit. The warrants have a five-year
term (from each closing date that units were sold) and an exercise price of $1.00 per share. If at any time after the six-month anniversary
of the issuance date, there is no effective registration statement registering, or no current prospectus available for the resale of
the shares of common stock issuable upon exercise the warrants, the holder of the warrants may elect a cashless exercise of the warrants.
Boustead Securities, LLC, the representative of the underwriters in our IPO, served as the placement agent in connection with the private
placement. In total, we sold an aggregate of 2,000,000 units for $2,000,000 to 23 accredited investors between August 16, 2022 and December
22, 2022, the end date of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Initial
Public Offering</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, we consummated our IPO of 1,250,000 shares of common stock at a price to the public of $4.00 per share, pursuant to that
certain Underwriting Agreement, dated March 20, 2023, between the Company and Boustead Securities, LLC, as representative of several
underwriters named in the Underwriting Agreement. The Company received gross proceeds of approximately $5 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable by the Company upon the sale of the shares. In connection with the
IPO, the Company also granted Boustead a 45-day option to purchase up to an additional 187,500 shares of its common stock, which expired
unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the same time, and as part of the same registration statement, but pursuant to a separate prospectus the Company registered the sale
of 4,765,000 shares of common stock, including 2,000,000 shares of common stock issuable upon the exercise of outstanding warrants to
purchase shares of common stock with an exercise price of $1.00 per share, of which warrants to purchase 975,500 shares of common stock
remain outstanding, and unexercised, as of the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration in connection with the IPO, we granted Boustead, the representative of the underwriters named in the Underwriting
Agreement for the IPO, warrants to purchase 87,500 shares of common stock with an exercise price of $5.00 per share, which are exercisable
beginning six months after the effective date of the registration statement filed in connection with the IPO (March 20, 2023) and expire
five years after such effectiveness date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 69; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the same time, and as part of the same registration statement, but pursuant to a separate prospectus (the &#8220;<span style="text-decoration: underline">Resale Prospectus</span>&#8221;)
the Company registered the sale of 4,765,000 shares of common stock, including 2,000,000 shares of common stock issuable upon the exercise
of outstanding warrants to purchase shares of common stock with an exercise price of $1.00 per share, of which warrants to purchase 975,500
shares of common stock remain outstanding and unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead, the representative of the underwriters
named in the Underwriting Agreement for the IPO, warrants to purchase 87,500 shares of common stock with an exercise price of $5.00 per
share, which are exercisable beginning six months after the effective date of the registration statement filed in connection with the
IPO (March 20, 2023) and expire five years after such effectiveness date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Need
for Future Funding</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, our current capital resources, combined with the net proceeds from the offering, are expected to be sufficient for us
to fund operations for the next 12 months. We may need funding in addition to the funding raised in our IPO, to support our operations
in the future. We may also seek to acquire additional businesses or assets in the future, which may require us to raise funding. We currently
anticipate such funding, if required, being raised through the offering of debt or equity. Such additional financing, if required, may
not be available on favorable terms, if at all. If debt financing is available and obtained, our interest expense may increase and we
may be subject to the risk of default, depending on the terms of such financing. If equity financing is available and obtained it may
result in our shareholders experiencing significant dilution. If such financing is unavailable, we may be forced to curtail our business
plan, which may cause the value of our securities to decline in value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of the Company&#8217;s financial statements in accordance with accounting principles generally accepted in the United States
of America (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities
and expenses. <a href="#abc_002">Note 2 &#8211; Summary of Significant Accounting Policies</a>&#8221; to the audited financial statements included under &#8220;Index
to Financial Statements,&#8221; below describes the significant accounting policies used in the preparation of the financial statements.
Certain of these significant accounting policies and estimates have a higher degree of inherent uncertainty and require significant judgments.
Accordingly, actual results could differ from those estimates. To the extent that there are differences between our estimates and actual
results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management
to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations.
Specifically, critical accounting estimates have the following attributes: (1) we are required to make assumptions about matters that
are highly uncertain at the time of the estimate; and (2) different estimates we could reasonably have used, or changes in the estimate
that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimates
and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience
and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new
events occur, as additional information is obtained and as our operating environment changes. These changes have historically been minor
and have been included in the financial statements as soon as they became known. Based on a critical assessment of our accounting policies
and the underlying judgments and uncertainties affecting the application of those policies, management believes that our financial statements
are fairly stated in accordance with GAAP and present a meaningful presentation of our financial condition and results of operations.
We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation
of our consolidated financial statements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 70; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-Based
Compensation</i></b> &#8211; Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of
Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 718, which requires recognition
in the consolidated financial statements of the cost of employee and director services received in exchange for an award of equity instruments
over the shorter of period the employee or director is required to perform the services in exchange for the award or the vesting period.
ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date
fair value of the award. Pursuant to ASC 505-50, for share-based payments to non-employees, compensation expense is determined at the
&#8220;measurement date.&#8221; The expense is recognized over the service period of the award. Until the measurement date is reached,
the total amount of compensation expense remains uncertain. The Company initially records compensation expense based on the fair value
of the award at the reporting date. Additionally, we used this same methodology when determining the fair value of our restricted common
stock issuances to managers and other related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Estimating
the Fair Value of Common Stock &#8211;</i></b> We are required to estimate the fair value of the common stock underlying our stock-based
awards and warrants when performing the fair value calculations using the Black-Scholes option pricing model</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
determination of the fair value of stock options with time-based vesting on the date of grant utilizes the Black-Scholes option pricing
model, and is impacted by our common stock price as well as other variables including, but not limited to, expected term that options
will remain outstanding, expected common stock price volatility over the term of the option awards, risk-free interest rates and expected
dividends. Estimating the fair value of equity-settled awards as of the grant date using valuation models, such as the Black-Scholes
option pricing model, is affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect
the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require
significant analysis and judgment to develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants
&#8211;</i></b> In accordance with ASC 480, the Company classifies as equity any contracts that (i) require physical settlement or net-share
settlement or (ii) gives the Company a choice of net-cash settlement in its own shares. The Company classifies as liabilities any contracts
that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is
outside the control of the Company) or (ii) give the counterparty a choice of net-cash settlement or settlement in shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its currently issued warrants in conjunction with the Company&#8217;s ordinary shares in permanent equity. These
warrants are indexed to the Company&#8217;s stock and meet the requirements of equity classification as prescribed under ASC 815-40.
Warrants classified as equity are initially measured at fair value, and subsequent changes in fair value are not recognized so long as
the warrants continue to be classified as equity. The value of the warrant is based on accepted valuation procedures and practices that
rely substantially on the third-party professional&#8217;s use of numerous assumptions and its consideration of various factors that
are relevant to the operation of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>JOBS
Act and Recent Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section
7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221;
can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected
to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised
accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no
longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in Section
7(a)(2)(B) of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 71; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented all new accounting pronouncements that are in effect and may impact our financial statements and we do not believe that
there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">From
time to time, new accounting pronouncements are issued by the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Accounting Standards Board (&#8220;<span style="background-color: white">FASB&#8221;) that are adopted by the Company as of the specified
effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will
not have a material impact on the Company&#8217;s financial statements upon adoption.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued ASU 2020-06, <i>&#8220;Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211; 40)&#8221; </i>(&#8220;ASU 2020-06&#8221;). ASU 2020-06
simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments
and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative, which aims to reduce unnecessary
complexity in U.S. GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December 15, 2023, and interim periods
within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span id="sj_007"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
connect consumers to licensed healthcare professionals through our website at <span style="text-decoration: underline">www.MangoRX.com</span>, for the provision of care via telehealth
on our customer portal. We also provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain
medications that may be prescribed as part of telehealth consultations, including our Mango ED and Mango GROW products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have identified men&#8217;s wellness telemedicine services and products as a growing sector in recent years and especially related to
the areas of erectile dysfunction (&#8220;ED&#8221;) and hair growth products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Mango
ED</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed, and are commercially marketing and selling, a new brand of ED product under the brand name &#8220;Mango.&#8221; This
product is produced at a compounding pharmacy and is available to patients on the determination of a prescribing physician that the compounded
drug is necessary for the individual patient. This product currently includes the following three ingredients: either Tadalafil (the
active ingredient in Cialis) or Sildenafil (the active ingredient in Viagra) and Oxytocin, all of which are used in FDA approved drugs,
as well as L-Arginine, an amino acid that is available as a dietary supplement. However, the fact that Tadalafil and Oxytocin are used
in FDA approved drugs, and L-arginine is available as a dietary supplement, does not mean that these ingredients will prove safe when
combined into a single formulation to treat ED. We currently offer two dosage levels of our Mango ED product and anticipate doctors prescribing
a dosage based on the needs and medical history of the patient. Our Mango ED product currently includes the following amounts of the
three ingredients: (1) either Sildenafil (50 milligrams (mg)) or Tadalafil (10 (mg)), Oxytocin (100 International units (IU)) and L-Arginine
(50mg); and (2) either Sildenafil (100 milligrams (mg)) or Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). Our Mango ED product
has not been, and will not be, approved by the FDA and instead we produce and sell our products, including our Mango ED product, under
an exemption provided by Section 503A of the FFDCA Act, as discussed below. Additionally, because our Mango ED product is being specially
compounded for the customer by a pharmacist with a physician&#8217;s prescription and because the ingredients for our Mango ED product
are publicly disclosed, this product formula can be replicated by other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 72; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any clinical studies involving (i) administration of Tadalafil or Sildenafil sublingually at the doses we provide patients,
or (ii) compounding of Tadalafil or Sildenafil, Oxytocin, and L-arginine to treat ED, similar to our Mango ED products. We are, however,
aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of Tadalafil
(the active ingredient in Cialis) and Sildenafil (the active ingredient in Viagra). We believe that the potential safety risks associated
with our Mango ED products are comparable to the safety risks associated with oral formulations of Tadalafil and Sildenafil approved
by the FDA for the treatment of ED. We do not expect significant safety risks associated with L-arginine, as the FDA has recognized in
its regulations that L-arginine may be safely added as a nutrient to foods. Clinical studies of intranasal Oxytocin have also found that
Oxytocin is generally safe and well-tolerated. Notwithstanding the above, because our ED product has not been, and will not be, approved
by the FDA, our product has not had the benefit of the FDA&#8217;s clinical trial protocol which seeks to prevent the possibility of
serious patient injury and death. If this were to occur, we could be subject to litigation and governmental action, which could result
in costly litigation, significant fines, judgments or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Launch
of Mango Hair Growth Product - &#8216;GROW&#8217; by MangoRx</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed, since November 16, 2022 are marketing, and selling, a new brand of hair growth product under the brand name &#8216;GROW&#8217;
by MangoRx (&#8220;Mango GROW&#8221;). This product is produced at our related party compounding pharmacy and is available to patients
on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mango GROW currently
includes the following four ingredients &#8211; (1) Minoxidil (the active ingredient in Rogaine&#174;) and (2) Finasteride (the active
ingredient in Propecia), each of which is used in FDA approved drugs, as well as (3) Vitamin D3 and (4) Biotin, which are available as
dietary supplements. However, the fact that Minoxidil and Finasteride are used in FDA approved drugs, and that Vitamin D3 and Biotin,
are available as a dietary supplement, does not mean that these ingredients will prove safe when combined into a single formulation to
attempt to treat hair growth. Mango GROW is encapsulated in convenient chewable, mint-flavored RDT&#8217;s.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently offer one dosage level of our Mango GROW product and anticipate doctors prescribing Mango GROW based on the needs and medical
history of the patient. Our Mango GROW product currently includes the following amounts of the four ingredients discussed above: (1)
Minoxidil (2.5mg), (2) Finasteride (1mg), (3) Vitamin D3 (2000IU), and (4) Biotin (1mg). Our Mango GROW product has not been, and will
not be, approved by the FDA and instead we produce and sell our Mango GROW product and plan to produce and sell future pharmaceutical
products, under an exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any clinical studies involving the administration of Minoxidil and Finasteride sublingually at the dose we provide patients,
or the compounding of Minoxidil, Finasteride, Vitamin D3, and Biotin, to treat hair growth, as is contemplated by our Mango GROW product.
We are, however, aware of other companies that are currently selling oral tablets for hair growth, including those using a combination
of Minoxidil and Finasteride. Additionally, because our Mango GROW product is being specially compounded for the customer by a pharmacist
with a physician&#8217;s prescription and because the ingredients for our Mango GROW product are publicly disclosed, this product formula
can be replicated by other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Additional
Information Regarding Mango ED and Mango GROW</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our Mango ED and Mango GROW products have not been, and will not be, approved by the FDA, our products have not had the benefit of the
FDA&#8217;s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death. If this were to occur,
we could be subject to litigation and governmental action, which could result in costly litigation, significant fines, judgments or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently anticipate using a substantial portion of the net proceeds of this offering to finance marketing and general operational expenses
associated with the sale of our Mango ED and Mango GROW products. We launched our website in mid-November 2022. To date, we have sold
only a small amount of products and generated only minimal revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 73; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mango
ED and Mango GROW have been formulated as RDT using a sublingual (applied under the tongue) delivery system to bypass the stomach and
liver. It is a generally established principle that sublingual drug absorption through the oral mucosa is generally faster than drug
absorption through the gastrointestinal tract. This is because sublingual drugs that are absorbed through the oral mucosa directly enter
the systemic circulation, bypassing the gastrointestinal tract and first-pass metabolism in the liver (see H. Zhang et al., <i>Oral mucosal
drug delivery: clinical pharmacokinetics and therapeutic applications</i>, 41 <span style="font-variant: small-caps">Clin Pharmacokinet
</span>661, 662 (2002). Though the active ingredients that comprise our Mango ED product are meant to treat ED &#8211; an issue that
according to a 2018 study published in <i>The Journal of Sexual Medicine</i> has been estimated to affect over one-third of today&#8217;s
men&#8217;s population (with prevalence increasing with age) &#8211; we are also aiming to brand ourselves as a lifestyle company marketed
to men seeking enhanced sexual vitality, performance, and overall mood and confidence, together with our Mango GROW product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Mango products are sold exclusively online via our website at <span style="text-decoration: underline">www.MangoRX.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="forms-1_002.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Contracted Telehealth Provider</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
many states, including Texas where our principal business office is located, the corporate practice of medicine doctrine prohibits corporations
from practicing medicine and from employing physicians to provide professional medical services. Many states that recognize this doctrine
also prohibit physicians from agreeing to share the fees they receive for professional services with unlicensed entities or individuals,
a practice that is commonly known as &#8220;fee splitting.&#8221; The requirements for compliance with any applicable corporate practice
of medicine and fee splitting restrictions vary among the states. In Texas, for example, there is no statute that expressly prohibits
fee splitting, but the corporate practice of medicine doctrine has been interpreted to prohibit physicians from ceding control over their
fee structures to corporate entities or giving a substantial portion of the fees received to corporate entities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with corporate practice of medicine and fee splitting restrictions, we do not employ or directly contract with individual
physicians or physician groups, nor do we control their medical decision-making or charges. Rather, on August 1, 2022, we entered into
a Physician Services Agreement (the &#8220;Physicians Agreement&#8221;) with BrighterMD, LLC doing business as Doctegrity (&#8220;Doctegrity&#8221;),
as discussed in further detail below under, which has agreed to make available to us, healthcare professionals, to allow them to provide
clinical services directly to our future customers via telehealth. We have integrated these healthcare professionals to allow for telehealth
consultations and related services on our Mangoceuticals platform which has been developed and is complete. This platform is the backbone
of our business as it connects consumers with both the medical provider and the pharmacy for fulfillment. It is also the system that
we will use to create marketing funnels for outgoing marketing, customer management and support, and analytics for future sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 74; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our Physician Services Agreement with Doctegrity (as defined below), the healthcare professionals are responsible for the practice of
medicine and control of the clinical decision-making.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Related Party Pharmacy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in greater detail below under &#8220;&#8212;Material Agreements&#8212;Master Services Agreement with Epiq Scripts&#8221; and
&#8220;&#8212;First Amendment to MSA,&#8221; we have entered into an exclusive Master Services Agreement and statement of work with Epiq
Scripts, LLC (&#8220;Epiq Scripts&#8221;), for its specialty compounding and packaging capabilities, fulfillment, and distribution of
certain prescription products available through our platform. These prescription products include our Mango ED and Mango GROW products.
Epiq Scripts is a related party because it was 51%-owned by American International at the time of our entry into the Master Services
Agreement and is currently 51% owned by Mr. Cohen, our Chairman and Chief Executive Officer. Mr. Cohen, our Chairman and Chief Executive
Officer, also served as the Chief Executive Officer and a director of, and had voting control over, American International at the time
of the entry into the Master Services Agreement. As discussed under &#8220;Company Information and Formation,&#8221; our company was
wholly-owned by American International until April 16, 2022, when control of our company was sold to Cohen Enterprises, which is owned
by Mr. Cohen. Epiq Scripts is a relatively newly formed entity, having been formed in January 2022, and only began compounding drugs
for patients in November 2022. On February 15, 2023, the 51% of Epiq Scripts then owned by American International was transferred to
Mr. Cohen as part of an exchange transaction, whereby Mr. Cohen agreed to cancel his preferred stock of American International, which
provided him voting control over American International, in exchange for among other assets, American International&#8217;s ownership
of Epiq Scripts. As a result, Epiq Scripts is currently 51% owned by Mr. Cohen, our Chairman and Chief Executive Officer. Additionally,
Mr. Cohen has served as the co-Manager of Epiq Scripts since January 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epiq
Scripts is currently fully licensed with the Texas State Board of Pharmacy (&#8220;TSBP&#8221;) and further has State Board of Pharmacy
(or its equivalent) licenses from the District of Columbia and 46 other states: Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware,
Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota,
Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio,
Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin,
and Wyoming, with the intent of obtaining the remaining 3 state licenses by the end of 2023. Epiq Scripts has <span style="background-color: white">obtained
its National Provider Identifier (&#8220;NPI&#8221;) number and is now a member of the National Council for Prescription Drug Programs
(&#8220;NCPDP&#8221;), a standards development organization. </span>Additionally, Epiq Scripts has applied for the highest level of accreditation
with the Utilization Review Accreditation Commission (&#8220;URAC&#8221;), <span style="background-color: white">a Washington DC-based
healthcare accrediting organization that establishes quality standards for the entire healthcare industry</span>. Until Epiq Scripts
receives licenses in the other three states, we are limited to selling our Mango ED and Mango GROW products in only the states in which
Epiq Scripts holds licenses. Although Epiq Scripts is physically located in Texas, it can ship products to customers in each state in
which it holds licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, Epiq Scripts can currently only provide services to the Company in the District of Columbia and those 47 states
described above and the Company will be unable to sell its products to any customers in any states other than those listed above, until
Epiq Scripts is able to obtain licenses in other states and will thereafter be limited to selling products to customers only in the states
in which Epiq Scripts holds licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 75; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Customer Portal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
customer platform connects consumers to licensed healthcare professionals through our website at <span style="text-decoration: underline">www.MangoRX.com</span>, for the provision
of care via telehealth and also provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain
medications that may be prescribed as part of telehealth consultations. Additional features to this backend technology solution allow
for the creation and management of customer accounts whereby customers have the ability to login, view and make changes to their respective
accounts. These changes include, but are not limited to, reviewing order history, tracking order shipments, requesting and ordering product
refills and making other profile changes such as shipping address and payment changes. Our portal is not unique to the industry and is
not anticipated to be difficult or costly to replicate or replace.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
backend technology solution also houses and manages all customer data allowing the Company with additional key functionality, including
but not limited to, providing customer service and support and data analytics for various marketing initiatives and reporting functions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate selling any third-party products via our portal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Growth Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Utilize
a variety of marketing channels using data analytics to attract customers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently market and advertise our Mango ED and Mango GROW products on a variety of advertising mediums including, but not limited to,
social media, online search websites, podcasts, television, radio, out-of-home, and other media channels, in compliance with applicable
FDA rules and requirements. However, due to such rules and requirements, we are extremely limited in the content of the claims and promotional
statements that we are able to make regarding our products under applicable FDA regulations. We believe advertising in a diversified
set of media channels is important to prevent overreliance on any single channel and to maximize the exposure of our brand to our desired
customers. We also intend to reach customers through our own social media accounts, press coverage and public relations, internally developed
educational and lifestyle content, and through engagement of social media influencers, hired and paid celebrities and talent, and physical
brand advertising campaigns, in each case funding permitting, and in each case subject to applicable rules and regulations, which are
expected to significantly limit the content of such marketing materials. We believe that this overall strategy will drive significant
customer traffic to our platform, including direct type-in traffic and organic online search traffic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also intend to utilize a marketing strategy focused on analytics and data. We are designing our internal systems to measure consumer
behavior, including which types of consumers generate more revenue in their first purchase, generate more revenue over time, generate
more gross profit from their purchases, and which types of consumers are most valuable over their lifetime. We also plan on measuring
the effectiveness of our marketing budgets and the rate of return we generate from our marketing campaigns. We have retained and plan
on using an outside marketing and advertising firm to assist management in identifying marketing and advertising campaigns, media purchases
and mediums, and seeking to drive a sufficient rate of return from our marketing and advertising budgets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Invest
in our telemedicine platform to enable sales throughout the United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize both a synchronous and asynchronous approach through our telemedicine platform, connecting customers through our platform and
contracted physicians and pharmacy. An asynchronous visit allows a physician to verify the patient&#8217;s identity, demographics and
collect the medical history online without needing to physically see or speak to the patient. A synchronous visit requires the doctor
to either speak directly to the patient and/or see the patient either via video conference or in person. As discussed above, we initially
are focusing our sales in the District of Columbia and 47 states where our related party pharmacy is licensed, with the goal of eventually
undertaking sales across all 50 states, pending licensing approvals of our related party pharmacy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provide
subscription plans for recurring revenue and introduction of new products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provide our customers with an option to purchase our Mango ED and Mango GROW products on a subscription basis. Subscription plans provide
an easy and convenient way for customers to get ongoing treatment while simultaneously providing the Company with predictability through
a recurring revenue stream.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 76; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
subscription plans, customers are able to select a desired timeframe in which to receive products, which range from once every month
to once every six months. The customer will then be billed on a recurring basis based on the selected timeframe and specified quantity
of product, which is shipped after each billing from our contracted pharmacy (Epiq Scripts). Customers are able to cancel subscriptions
in between billing periods to stop receiving additional products and reactivate subscriptions. Our integrated technology platform serves
customers from customer discovery, through the purchase of products on our website, to connecting customers with medical providers for
telehealth consultations (through our contracted physician network), to the fulfillment and delivery of orders (through our contracted
pharmacy), and finally through ongoing management by medical providers (also through our contracted physician network). We believe our
platform provides us cost advantages and efficiencies to offer customers affordable prices and generate increased revenues over time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our Mango ED and Mango GROW products, we intend to launch new products over time and offer additional subscription-based
offerings which we hope will result in growth in revenue through recurring revenue streams.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Marketing
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2023, the Company entered into a Marketing Agreement with Marius Pharmaceuticals, LLC allowing the Company the use
of the trademark &#8220;Kyzatrex&#174;&#8221; oral testosterone undecanoate softgel capsules, for the purposes of branding, packaging,
marketing, and selling Kyzatrex&#174; on the Company&#8217;s website, and to be sold via its telehealth platform at <span style="text-decoration: underline">www.MangoRx.com</span>.
Pursuant to the Marketing Agreement, Marius granted the Company a non-exclusive, non-transferable, royalty-free license to use the Marius
Marks in the United States, for the purpose discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Marius Agreement contains customary confidentiality and indemnification provisions and has an initial term of two years, automatically
renewable thereafter for successive one year terms unless otherwise terminated (a) by Marius if the Company does not have at least 2,500
monthly customers of &#8220;Kyzatrex&#174;&#8221; oral testosterone undecanoate softgel capsules at least 30 days prior to the end of
the initial term, (b) by either party for cause in connection with a material breach that has not been cured within 30 business days
of written notice thereof provided by the non-breaching party to the breaching party, or (c) by Marius in its sole discretion without
cause by providing at least 60 days&#8217; prior written notice to the Company. Marius may also terminate the agreement with written
notice to the Company if the Company has not met at least 30% of the Minimum Subscribers within six months of the product launch date
on the Company&#8217;s website, which is anticipated to commence on or before January 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
30 days of the date the Marius Agreement is terminated (or on the date of termination, which cannot occur earlier than 60 days
after notice of termination is provided, if Marius terminates the Marius Agreement for convenience),
we are required to stop and cease all use of the Marius Marks and are required to remove all references to the Marius Marks from our
advertising/promotional materials, and signage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the term of the Marius Agreement and for a period of 12 months thereafter, we agreed to not create, publish or broadcast any advertisement
or otherwise promote or market any other product containing testosterone undecanoate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Marius Agreement, and in consideration of the license granted thereunder, the Company issued Marius 100,000 shares of the Company&#8217;s
restricted common stock (the &#8220;Marius Shares&#8221;) which are fully earned upon entry into the agreement. The Marius Shares
were valued at $0.68 per share for a total of $68,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 77; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq
Non-Compliance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to consummating our IPO, we were required to list our common stock on Nasdaq and in March 2023, our common stock was approved
for listing on Nasdaq under the symbol &#8220;MGRX&#8221;. Notwithstanding such listing, there is no guarantee that we will be able to
maintain our listing on NASDAQ for any period of time. Among the conditions required for continued listing on Nasdaq, NASDAQ requires
us to maintain at least $2.5 million in stockholders&#8217; equity, $35 million in market value of listed securities, or $500,000 in
net income over the prior two years or two of the prior three years, to have a majority of independent directors (subject to certain
&#8220;<span style="text-decoration: underline">controlled company</span>&#8221; exemptions, which we do not currently meet), to comply with certain audit committee requirements,
and to maintain a stock price over $1.00 per share. Our stockholders&#8217; equity is currently not above NASDAQ&#8217;s $2.5 million
minimum, as discussed below, we may not generate over $500,000 of yearly net income moving forward, we may not maintain $35 million in
market value of listed securities, we may not be able to maintain independent directors (to the extent required), and as discussed below,
we do not currently have a stock price over $1.00 per share. Nasdaq&#8217;s determination that we fail to meet the continued listing
standards of NASDAQ may result in our securities being delisted from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 30, 2023, we received written notice from the Listing Qualifications Department of Nasdaq notifying us that we were not in compliance
with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Nasdaq Listing Rule
5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that
a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business
days. Based on the closing bid price of our common stock for the thirty (30) consecutive business days from September 15, 2023 to October
27, 2023, we no longer meet the minimum bid price requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
letter did not impact the listing of our common stock on Nasdaq. Instead, the letter stated that we have 180 calendar days or until April
29, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of our common stock must have
a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If we do not regain compliance by April
29, 2024, an additional 180 days may be granted to regain compliance, so long as we meet Nasdaq&#8217;s initial listing criteria (except
for the bid price requirement)(which we do not currently meet, as we do not have stockholders&#8217; equity of at least $5 million) and
notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split,
if necessary. If we do not qualify for the second compliance period or fail to regain compliance during the second 180-day period, our
common stock will be subject to delisting, at which point we would have an opportunity to appeal the delisting determination to a Hearings
Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options to regain
compliance with the minimum bid price requirement under the Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
on November 3, 2023, we received a letter from the Listing Qualifications Department of Nasdaq notifying us that our stockholders&#8217;
equity as reported in our Quarterly Report on Form 10-Q for the period ending September 30, 2023 (the &#8220;Form 10-Q&#8221;), did not
meet the minimum stockholders&#8217; equity requirement for continued listing on Nasdaq. Nasdaq Listing Rule 5550(b)(1) requires companies
listed on Nasdaq to maintain stockholders&#8217; equity of at least $2,500,000. In our Form 10-Q, we reported stockholders&#8217; equity
of $1,354,821, which is below the minimum stockholders&#8217; equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1).
Additionally, we do not meet the alternative Nasdaq continued listing standards under Nasdaq Listing Rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
notice of noncompliance had had no immediate impact on the continued listing or trading of our common stock on Nasdaq, which continues
to be listed and traded on Nasdaq, subject to our compliance with the other continued listing requirements. Nasdaq has given us until
December 18, 2023 to submit to Nasdaq a plan to regain compliance. We are submitting a plan of compliance on December 18, 2023
and if our plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of Nasdaq&#8217;s letter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are confident that we can regain compliance with Nasdaq&#8217;s minimum stockholders&#8217; equity standard within the compliance period. However, there can be no assurance
that our plan will be accepted or that if it is, we will be able to regain compliance. If our plan to regain compliance is not accepted,
or if it is and we do not regain compliance within 180 days from the date of Nasdaq&#8217;s letter, or if we fail to satisfy another
Nasdaq requirement for continued listing (including the requirement that we maintain a minimum bid price of at least $1.00 per share,
which as discussed above, the Company is not currently in compliance with), Nasdaq could provide notice that our common stock will become
subject to delisting. In such event, Nasdaq rules would permit us to appeal the decision to reject our proposed compliance plan or any
delisting determination to a Nasdaq Hearings Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we demonstrate compliance with the requirements of Nasdaq as discussed above, we will have to continue to meet other objective and
subjective listing requirements to continue to be listed on Nasdaq. Delisting from Nasdaq could make trading our common stock more difficult
for investors, potentially leading to declines in our share price and liquidity. Without a Nasdaq listing, stockholders may have a difficult
time getting a quote for the sale or purchase of our stock, the sale or purchase of our stock would likely be made more difficult, and
the trading volume and liquidity of our stock could decline. Delisting from Nasdaq could also result in negative publicity and could
also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of
our common stock as currency or the value accorded by other parties. Further, if we are delisted, we would also incur additional costs
under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity
of our common stock and the ability of our stockholders to sell our common stock in the secondary market. If our common stock is delisted
by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB Market or the OTC Pink
market, where an investor may find it more difficult to sell our stock or obtain accurate quotations as to the market value of our common
stock. In the event our common stock is delisted from Nasdaq, we may not be able to list our common stock on another national securities
exchange or obtain quotation on an over-the counter quotation system.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
delisting of our common stock from the Nasdaq could adversely affect our business, financial condition and results of operations and
our ability to attract new investors, reduce the price at which our common stock trades, decrease, investors&#8217; ability to make transactions
in our common stock, decrease the liquidity of our outstanding shares, increase the transaction costs inherent in trading such shares,
and reduce our flexibility to raise additional capital without overall negative effects for our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 78; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Market for ED Products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a January 2022 report published by Verified Market Research, the Global Erectile Dysfunction Drugs Market size was valued at $3.63
billion in 2020, mainly due to the increase in patient awareness and the early adoption of sedentary lifestyle. Verified Market Research
also projects that the total Global Dysfunction Drugs Market size will contract to $2.95 billion in 2028. The expected reason for this
contraction is poor patient compliance with erectile dysfunction drugs and the future availability of cost-effective imitation medicines,
as well as side effects of ED drugs. We do not anticipate our Mango ED drug suffering from these limitations, as we believe our product
is easy to use and that we have priced our product competitively. Separately, Grand View Research, in a July 2022 report, projects that
the U.S. market (where we are initially marketing our ED product) for erectile dysfunction drugs estimated at approximately $1.1 billion
as of 2021, will increase at a 7.4% compound annual growth rate though 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is also estimated that nearly 3-in-5 men in the US have suffered from erectile dysfunction, according to a survey reported in February
2022, by LetsGetChecked, a leading at-home health screening and insights company (based on research carried out by Opinium Research among
2,006 men in the USA, 1,178 of whom had previously experienced erectile dysfunction, from February 7-10, 2020). According to that study,
age isn&#8217;t that big a factor either, with 56% of men 18 to 34 years old being affected, compared to 63% of those over the age of
55. The study also determined that most men blame psychological factors for ED &#8211; with 41% blaming stress, 34% blaming having &#8220;too
much on their mind,&#8221; and 31% believing it is performance anxiety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
Market for Mango GROW</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the website of the American Hair Loss Association, (a) two-thirds of American men will experience some degree of hair loss by the
age of 35, (b) by age 50, around 85 percent of men have significantly thinning hair; and (c) for around 25% of men, the start of male
pattern baldness can begin before the age of 21. Additionally, and contrary to societal belief, we believe that most men who suffer from
male pattern baldness are unhappy with their situation and would take steps to change that. In our experience, hair loss affects every
aspect of the hair loss sufferer&#8217;s life including interpersonal relationships as well as the professional lives of those suffering.
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a May 2022 market study entitled, &#8220;Hair Loss Prevention Products Market Forecast to 2028 &#8211; COVID-19 Impact and Global
Analysis &#8211; by Product Type (Shampoos and Conditioners, Oils, Serums, and Others), Category (Natural &amp; Organic, and Conventional),
End User (Men, Women, and Unisex), and Distribution Channel (Supermarkets and Hypermarkets, Convenience Stores, Online Retail, and Others)&#8221;,
by The Insight Partners, the hair loss prevention products market size was valued at $23.6 billion in 2021 and is projected to reach
$31.5 billion by 2028, growing at a projected compound annual growth rate of 4.2% from 2021 to 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mordor
Intelligence LLP believes that the major factors driving the hair loss prevention market are changing lifestyle patterns, adoption of
a hectic schedule that increases stress levels, which in turn results in frequent hair loss at an earlier stage among the young population,
growing disposable income, and increased emphasis on appearances. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition
and Competitive Advantages</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
mainly compete with other companies offering men&#8217;s wellness products, including Hims &amp; Hers Health, Inc. and Roman, and with
our Mango ED products, we compete against much larger pharmaceutical companies who offer ED branded drugs like Viagra (Pfizer) and Cialis
(marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation) and their generic forms. With our Mango
GROW product, we compete against the much larger pharmaceutical company Merck &amp; Co., which offers the branded hair loss product Propecia,
and Johnson &amp; Johnson, the owner of Rogaine&#174; &#8211; a branded form of Minoxidil. These companies have much greater resources
than we do and well-known brand names.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 79; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future men&#8217;s wellness products will also likely need to compete against other traditional healthcare providers, pharmacies, and
large retailers that sell non-prescription products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we compete with other companies, which have greater resources and a greater advertising budget, and which are also selling ED related
products with either or both Tadalafil and Sildenafil (or similar products), in an oral disintegrating tablet and who are selling compounded
Minoxidil and Finasteride in both topical form (e.g., gels, foams, liquid solutions) and in oral capsule, tablet or pill form. For example,
we are aware of other companies that are currently selling oral disintegrating tablets for ED, including those using a combination of
Tadalafil and Sildenafil (the active ingredient in Viagra). However, we are not aware of any companies that are selling a compound consisting
of Minoxidil and Finasteride in an oral disintegrating tablet form.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compete against these competitors based on our branding, advertising, unique compounding, and product delivery system (i.e., our Mango
ED and Mango GROW products have been designed to be taken sublingually, rather than in pill form).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
to other online direct to consumer telemedicine companies that are selling both generic ED medication and generic hair loss medications,
we believe we have priced both our Mango ED products and Mango GROW product at a premium, due to the cost of compounding the product
and the use of multiple ingredients. We are currently aware of a handful of other direct to consumer companies that are also selling
compounded hair loss and ED medications and who are selling their products at a higher price than Mango&#8217;s current price. When comparing
the current market for various pharmaceutical related hair loss and ED products, we have attempted to position our pricing to be slightly
above average as we anticipate marketing our Mango ED and Mango GROW products to a demographic that we expect will pay a premium for
what we believe to be a premium product relative to the competition for the treatment of hair loss and erectile dysfunction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory
Environment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently produce and sell our Mango ED and Mango GROW products, and plan to produce and sell future pharmaceutical products, under an
exemption provided by Section 503A of the Federal Food, Drug, and Cosmetic Act (&#8220;FFDCA Act&#8221;). Section 503A describes the
conditions under which compounded human drug products are exempt from the FFDCA Act sections on FDA approval, prior to marketing, current
good manufacturing practice (&#8220;cGMP&#8221;) requirements and labeling with adequate directions for use. One of these conditions
is that the drugs must be compounded based on the receipt of valid patient-specific prescriptions; another condition limits &#8220;copying&#8221;
of FDA-approved products, which restricts compounding drugs that have the same active ingredients and route of administration as ingredients
that are used in other FDA approved drugs which are commercially available. The FDA also prohibits any marketing or promotional statements
that are &#8220;false or misleading in any particular,&#8221; including making any unsupported superiority claims against other products
or the failure to disclose a material fact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, under relevant FDA guidance, the FDA generally does not consider a compounded drug to be &#8220;essentially a copy&#8221;
of a commercially available drug if the compounded drug has a different route of administration as compared with the approved alternative,
and our Mango ED and Mango GROW products are for a different route of administration (e.g., sublingual). In addition, the FDA does not
consider a compounded drug to be &#8220;essentially a copy&#8221; of a commercially available drug if the approved product cannot be
used for the prescribed route of administration, which is available in the compounded version (which we believe it cannot, as discussed
below). Finally, we do not expect that we will be deemed to have engaged in such &#8220;copying&#8221;, because our Mango ED and Mango
GROW products are based on a prescriber&#8217;s determination for each patient that the change associated with the compounded product
(our Mango ED and Mango GROW products) produces for the patient a significant difference as compared with the commercially available
drug product. Under relevant FDA guidance, the FDA does not consider a compounded drug &#8220;essentially a copy&#8221; if a prescriber
determines that there is a change, made for an identified individual patient, which produces for that patient a significant difference
from the commercially available product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 80; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 503A of the FFDCA Act, it is the prescribing practitioner who determines if a compounded drug is necessary for the identified
patient and whether the change associated with the compounded product produces for the patient a significant difference as compared with
the commercially available drug product. FDA&#8217;s guidance states that FDA generally does not intend to question prescriber determinations
that are appropriately documented. Our Mango ED and Mango GROW compounded products have been formulated as a Rapid Dissolve Tablet using
a sublingual (applied under the tongue) delivery system to bypass the stomach and liver. We believe this offers a significant difference
based on the fact that the approved versions are not available in the same route of administration (i.e., sublingual). A sublingual formulation
may be able to meet the clinical needs of a particular patient who desires a more rapid onset of action compared to an FDA-approved oral
formulation. In addition, because the prevalence of ED generally increases with age, older patients who may have difficulty swallowing
an FDA-approved oral formulation may benefit from a sublingual formulation that dissolves under the tongue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compounded
drugs, like our Mango ED and Mango GROW products, are not FDA-approved. This means that the FDA does not verify the safety or effectiveness
of such drugs. Instead, consumers rely on the determination of a prescribing physician that the compounded drug is necessary for the
individual patient. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has the authority to impose significant restrictions on products through regulations on advertising, promotional and distribution
activities. In particular, the FDA will object to any promotional activity (including through testimonials and surrogates) that is &#8220;false
or misleading in any particular,&#8221; including the failure to disclose material facts. For example, the FDA will expect adequate substantiation
for an efficacy claim, which would require substantial evidence derived from adequate and well-controlled clinical trials. We believe
we can conduct truthful and non-misleading promotional activities, including activities involving the use of testimonials and surrogates,
with limited claims that do not require substantial evidence derived from adequate and well-controlled clinical trials and which do not
include efficacy claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also aware of data in the scientific literature supporting how the proposed combination of the compounds which make up our Mango
ED products (i.e., Tadalafil or Sildenafil, Oxytocin, and L-arginine) might be expected to perform in ED patients. Previous clinical
studies (none of which we have paid for or undertaken ourselves) have suggested that either Sildenafil Tadalafil and L-arginine in combination
for treatment of ED may be more effective than either compound alone (see L. Gallo et al., <i>The Daily Therapy With L-Arginine 2,500
mg and Tadalafil 5 mg in Combination and in Monotherapy for the Treatment of Erectile Dysfunction: A Prospective, Randomized Multicentre
Study</i>, 8 <span style="font-variant: small-caps">Sex Med</span> 178, 184 (June 2020) &#8211; finding that in general, combination
therapy with Tadalafil and L-Arginine was superior to monotherapies for the treatment of ED; and M. Abu El-Hamd &amp; E. Mohammed Hegazy,
<i>Comparison of the clinical efficacy of daily use of L-arginine, tadalafil and combined L-arginine with tadalafil in the treatment
of elderly patients with erectile dysfunction</i>, 52 <span style="font-variant: small-caps">Andrologia</span> e13640, 3 (Aug. 2020)
(&#8220;Hamd and Hegazy&#8221;) &#8211; finding that the combined daily use of L-arginine with Tadalafil therapy for elderly male patients
with ED could significantly increase Sexual Health Inventory for Men (SHIM) scores and levels of total testosterone in comparison to
L-arginine, or Tadalafil alone)&#8212;This is because L-arginine may increase nitric oxide, that in turn may increase cyclic guanosine
monophosphate, which has relaxation and vasodilation (dilatation of blood vessels) effects on smooth muscle to assist in the treatment
of ED (see Hamd and Hegazy paper). Furthermore, Oxytocin is a neurotransmitter linked to increased levels of social interaction, well-being,
and anti-stress effects and clinical studies suggest administration of Oxytocin may stimulate certain aspects of social interaction,
and may cause anti-anxiety and anti-stress effects (see Hamd and Hegazy paper).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 81; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
we are aware of data in the scientific literature supporting the efficacy of Minoxidil as an oral treatment (as discussed below), as
opposed to topical treatments that have been more traditionally used and marketed for hair growth to date. Topical Minoxidil and oral
Finasteride are current the standard first-line treatments for androgenetic alopecia (AGA)(male pattern baldness). Minoxidil in an oral
formulation has been previously used for the treatment of severe and uncontrolled hypertension at a dose of 10&#8211;40 mg. Unintentionally,
the early trials of oral minoxidil as an antihypertensive drug documented side effects such as hypertrichosis (excessive hair growth
anywhere on the body) and hirsutism (excess hair most often noticeable around the mouth and chin) with chronic use. A study conducted
by Ratchathorn Panchaprateep &amp; Suparuj Lueangarun, and published in the September 24, 2020 edition of Dermatology and Therapy, found
that oral minoxidil at a dose of 5 mg taken once daily, significantly increased hair growth in men with AGA after 12 and 24 weeks of
treatment (Panchaprateep, R., Lueangarun, S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients
with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb) 10, 1345&#8211;1357 (2020)). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separately,
Finasteride taken orally in the amount of 1 mg per day has shown to promote scalp hair growth and prevent further hair loss in a significant
proportion of men with male pattern hair loss (McClellan, K.J., Markham, A. Finasteride. Drugs 57, 111&#8211;126 (1999).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
we, nor our representatives have had any conversations with the FDA staff regarding whether our Mango ED and Mango GROW products can
be sold pursuant to Section 503A of the FFDCA Act and future conversations with the FDA may result in the FDA staff raising issues with
such sales pursuant to Section 503A of the FFDCA, requiring certain pre-requisites or changes to our current business plan, which may
be costly or time consuming, and/or may result in us being prohibited from selling our Mango ED and Mango GROW products pursuant to Section
503A of the FFDCA Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
as are many other companies, are also subject to environmental laws, rules and regulations which could affect our operations, including
those disclosed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians
who provide professional clinical services via telehealth must, in most instances, hold a valid license to provide the applicable professional
services in the state in which the patient is located. As such, the physicians provided to us through our relationship with BrighterMD,
LLC dba Doctegrity, discussed below under &#8220;Business&#8212;Material Agreements&#8212;Master Services Agreement with Epiq Scripts&#8221;
and &#8220;&#8212;First Amendment to MSA,&#8221; are required to be licensed under applicable state law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
qualify for the exemptions under section 503A of the FFDCA Act, among other requirements, a drug must be compounded by a licensed pharmacist
or a licensed physician that does not compound regularly or in inordinate amounts any drug products that are essentially copies of a
commercially available drug product. As discussed below under &#8220;Business&#8212;Material Agreements&#8212;Master Services Agreement
with Epiq Scripts&#8221; and &#8220;&#8212;First Amendment to MSA,&#8221; we have entered into an agreement with Epiq Scripts, a related
party, 51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, to provide us compounding and other pharmacy
services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to extensive government regulation, from the entry into agreements with physicians or groups of physicians to
provide telehealth services to our potential customers, to the marketing and promotion of our products, the creation of our products,
and the sale of our products through licensed pharmacists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the rules and regulations we expect to be subject to include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Federal
Anti-Kickback Statute</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b) is broadly worded and prohibits the knowing and willful offer, payment, solicitation
or receipt of any form of remuneration in return for, or to induce, (i) the referral of a person covered by Medicare, Medicaid or other
governmental programs, (ii) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid
or other governmental programs or (iii) the purchasing, leasing or ordering or arranging or recommending purchasing, leasing or ordering
of any item or service reimbursable under Medicare, Medicaid or other governmental programs. In addition, a person or entity does not
need to have actual knowledge of this statute or specific intent to violate it to have committed a violation. Moreover, the government
may assert that a claim including items or services resulting from a violation of the Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the False Claims Act, we do not expect to apply to our operations as we do not plan to seek payment for our services
from the federal government. Violations of the Anti-Kickback Statute can result in exclusion from Medicare, Medicaid or other governmental
programs as well as civil and criminal penalties and fines. Imposition of any of these remedies could have a material adverse effect
on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 82; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate our current operations being subject to the Anti-Kickback Statute as we do not seek reimbursement under a federal health
care program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>U.S.
Food and Drug Administration (&#8220;FDA&#8221;) Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates product promotion and noncompliance and this could result in the FDA requesting that we modify our product promotion or
subject us to regulatory and/or legal enforcement actions, including the issuance of a warning letter, injunction, seizure, civil fine,
and criminal penalties. Other federal, state or foreign enforcement authorities also monitor product promotion and have the authority
to levy significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement, if
violations of applicable law or regulations occur. We also believe that the FDA will likely consider our compounded combination product
to be different from previously FDA-approved products, and that the FDA will not likely allow us to rely on any FDA-approved labeling
or prescribing information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risk
of Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
federal and state statutes provide for private causes of action to plaintiffs alleging misleading marketing claims, or otherwise making
allegations which are found to be in violation of such laws. As such, misleading promotional statements and practices can lead to litigation
under state consumer protection and unfair trade practices laws. To date, there has been a substantial amount of litigation under these
laws challenging the marketing and sale of compound drugs and we may face legal actions, and be subject to significant penalties, judgments
and damages, if we are found to have violated these laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Health
Information Privacy and Security Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
U.S. state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability,
integrity, and other processing of health information. We believe that, because of our operating processes, we are not a covered entity
or a business associate under the Health Insurance Portability and Accountability Act and the implementing regulations (&#8220;HIPAA&#8221;),
which establishes a set of national privacy and security standards for the protection of protected health information by health plans,
healthcare clearinghouses, and certain healthcare providers, referred to as covered entities, and the business associates with whom such
covered entities contract for services. Because we need to use and disclose customers&#8217; health and personal information in order
to provide our services, we develop and maintain policies and procedures to protect that information in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the confidentiality, privacy, availability,
integrity and security of health information and other types of personal information. These laws and regulations are often uncertain,
contradictory, and subject to changing or differing interpretations. Additionally, these laws may be similar to or even more protective
than, and may not be preempted by, HIPAA and other federal privacy laws. The privacy and data protection laws in many states in which
we operate are more restrictive than HIPAA and/or may apply more broadly than HIPAA. In certain cases, it may be necessary to modify
our operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and
penalties upon violators, but also some, unlike HIPAA, may afford private rights of action to individuals who believe their personal
information has been misused. We expect new laws, rules and regulations regarding privacy, data protection, and information security
to be proposed and enacted in the future; as state laws are changing rapidly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, as of the date of this prospectus, eleven states&#8212;California, Colorado, Connecticut, Iowa, Indiana, Tennessee, Montana,
Texas, Utah, Virginia and Oregon&#8212;have enacted consumer data privacy laws. The data privacy laws have a number of things in common
with each other, including allowing residents of those states the right to access and delete their personal information and to opt-out
of the sale of their personal information, among others. Other provisions require commercial websites or online services to post a privacy
policy that describes the types of personal information collected, what information is shared with third parties, and how consumers can
request changes to certain information. Our compliance with these and future rules may increase our operating and expenses and our failure
to comply with these rules could subject us to fines, penalties and litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 83; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above, proposed or new legislation and regulations could also significantly affect our business. There currently are
a number of proposals pending before federal, state, and foreign legislative and regulatory bodies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Product
Liability</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a distributor of men&#8217;s health and wellness products, the Company faces an inherent risk of exposure to product liability claims,
regulatory action and litigation if its future products are alleged to have caused significant loss or injury. In addition, the sale
of our products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously
unknown adverse reactions resulting from human consumption of our products alone or in combination with other medications or substances
could occur. We may be subject to various product liability claims, including, among others, that our future products caused injury or
illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with
other substances. A product liability claim or regulatory action against the Company could result in increased costs, could adversely
affect our reputation with our clients and consumers generally, and could have a material adverse effect on our results of operations
and financial condition of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, a 2014 study published in The Journal of the American Medical Association determined that Sildenafil (the active ingredient
in Viagra) may be associated with a higher risk of developing melanoma. The study evaluated data from more than 25,000 men who used Sildenafil
and found that Sildenafil use was significantly associated with an increased risk of subsequent melanoma, after considering other risk
factors. It is possible that the ingredients we use in our Mango ED and Mango GROW products or any other products we sell in the future
could be found in the future to result in increases in the likelihood of developing cancer or other diseases, which could subject us
to litigation, penalties or recalls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have an insurance policy in effect that includes customary coverage and protection for professional liability, general liability, employee
benefits and protection against claims including technology products, services and against cyber security. Our insurance policy also
covers exposure to product liability claims, including both technology product claims related to customer data breaches, copyright infringement
and/or misrepresentation and fraud and any claims made in connection with any physical products and services sold through the Company&#8217;s
website.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Physician
Services Agreement with Doctegrity</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Physicians Agreement, Doctegrity, which provides online telemedicine technology services and provides access to independently
contracted licensed physicians and providers, agreed to (a) arrange for the services of a physician or, where appropriate, a mid-level
practitioner with delegated authority from a physician, licensed in the appropriate state the practice of medicine will take place, who
will establish a physician/patient relationship with patients associated with the Company&#8217;s platform in accordance with the laws
and regulations of the appropriate state(s) and also provide physician review and assessment and quality control of the Company&#8217;s
or related brands&#8217; advertising of services, medical questionnaires and related prescription requests; and (b) provide an asynchronous
telehealth platform (and in certain cases, synchronous capabilities in certain U.S. states where and when available and applicable) which
provides patient access to licensed physicians in the state from which the patient, who is participating under our platform, resides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 84; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
chose to contract with Doctegrity after reviewing and comparing the fees and services offered by similar telehealth platform companies
that facilitate visits between health care professionals and patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a patient visits our website and submits a request for a consultation with a health care professional, Doctegrity will communicate the
patient&#8217;s information to one of its affiliated physicians. Doctegrity and the physicians are responsible for conducting the telehealth
consultation and any ongoing communication with the patient in accordance with applicable laws. The physicians make a determination,
in their sole discretion, as to whether or not to prescribe our products (currently our Mango ED and Mango GROW products) to potential
customers. If the physicians prescribe our Mango ED or Mango GROW products, then the customers pay us for our products. In turn, Epiq
Scripts, LLC, pursuant to the Master Services Agreement discussed below, is provided information on the customer and compounding of our
product, compound the product, and ship the product to customers using packaging and shipping materials which we supply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
pay Doctegrity for each physician visit conducted in response to request made by a patient on our website, regardless of whether the
physician prescribes our product to the patient. The fee we pay Doctegrity is fixed, set in advance and was negotiated at arms&#8217;
length after comparing the prices offered by similar services. We are not a party to any contracts between Doctegrity and any health
professionals or physician groups and do not control how Doctegrity reimburses these providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our arrangement with Doctegrity, as summarized above, is structured to comply with applicable laws, including those restricting the corporate
practice of medicine and fee splitting, there may be a risk that a state agency, now or in the future as these laws (and interpretations
of them) evolve, would conclude that the arrangement and fee structure between Doctegrity and its contracted physicians and/or our agreement
with Doctegrity violates the corporate practice of medicine doctrine and fee splitting restrictions in Texas or in another state where
a patient who uses our Mangoceuticals platform is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Physicians Agreement has a term of one year subject to automatic one-year renewals unless and until terminated in accordance with the
Physicians Agreement, including by either party with 90 days&#8217; prior written notice with or without cause and for cause with ten
days&#8217; written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Physicians Agreement requires us and Doctegrity to maintain certain minimum levels of insurance, and contains customary representations
and warranties, force majeure provisions and confidentiality obligations. Pursuant to the Physicians Agreement, each party is required
to indemnify and hold harmless the other party, its affiliates and representatives, from and against any third party claims, liabilities,
damages, judgments or other losses (including reasonable attorneys&#8217; fees) imposed upon or incurred by them arising out of or as
a result of: (i) any acts or omissions by or the willful misconduct of the other party, its affiliates or representatives in connection
with the performance of any of their respective obligations under the agreement; and (ii) any material breach of the agreement by the
other party, or its affiliates or representatives; except to the extent that such losses arising pursuant to (i) and/or (ii), arise from
the bad faith, willful misconduct or gross negligence of the party seeking indemnification. The Physicians Agreement also includes customary
limitation of liability language, whereby each party waived any liability from the other for any indirect, incidental, exemplary, punitive
or consequential damages.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Doctegrity&#8217;s
physicians are tasked with determining whether patients seeking Mango ED or Mango GROW products are eligible to be prescribed our Mango
ED and Mango GROW products, respectively, with the sole purpose of the telemedicine engagement being for the determination, in the physician&#8217;s
sole judgment, of whether the patient is qualified to obtain a prescription for the Mango ED or Mango GROW products. Doctegrity&#8217;s
physicians are required to electronically send prescriptions to Epiq Scripts (the Company&#8217;s designated and accredited pharmacy
partner), which financial relationship is required to be disclosed in writing to the patient via the Terms and Conditions listed on the
Company&#8217;s website, including informed consent, and also informing the patient that the prescription is sent to the Company&#8217;s
designated pharmacy partner. Doctegrity&#8217;s physicians are only able to prescribe Mango ED or Mango GROW products to patients seeking
ED medical and/or treatment hair loss , respectively, through our customer portal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 85; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement also includes certain covenants restricting our operations, restricting us and our owners, directors, officers, and managers,
during the term of the agreement and for 12 months thereafter from providing to or for any customer any services or products, solutions,
of the type provided by Doctegrity, using confidential information received during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Master
Services Agreement with Epiq Scripts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2022, and effective on August 30, 2022, we entered into a Master Services Agreement with Epiq Scripts, which at the time
was 51%-owned by American International. Mr. Cohen, our Chairman and Chief Executive Officer, served as the Chief Executive Officer and
a director of, and had voting control over, American International at the time of the entry into the Master Services Agreement, and currently
serves on the Board of Directors of American International. As discussed above under &#8220;&#8212;Formation and Transfer of Control,&#8221;
the Company was wholly-owned by American International until June 16, 2022, when control of the Company was sold to Cohen Enterprises,
which is owned by Mr. Cohen. Epiq Scripts was formed in January 2022, and only began compounding drugs for patients in November 2022.
On February 15, 2023, the 51% of Epiq Scripts then owned by American International was transferred to Mr. Cohen as part of an exchange
transaction, whereby Mr. Cohen agreed to cancel his preferred stock of American International, which provided him voting control over
American International, in exchange for among other assets, American International&#8217;s ownership of Epiq Scripts. As a result, Epiq
Scripts is currently 51% owned by Mr. Cohen, our Chairman and Chief Executive Officer. Additionally, Mr. Cohen has served as the co-Manager
of Eqiq Scripts since January 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Master Services Agreement and a related statement of work (&#8220;SOW&#8221;), Epiq Scripts agreed to provide pharmacy and related
services to the Company, the Company agreed to exclusively use Epiq Scripts as the provider of the Services (defined below) during the
term of the agreement, so long as Epiq Scripts complies with the terms of the Master Services Agreement. The agreement also includes
a 30 day right of first refusal for Epiq Scripts to provide pharmacy services for any new product that Mango may introduce during the
term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the SOW, Epiq Scripts agreed to provide for the online fulfillment, specialty compounding, packaging, shipping, dispensing and distribution
(collectively, the &#8220;Services&#8221;) of products sold exclusively via our website that may be prescribed as part of a telehealth
consultation on our platform. Epiq Scripts also agreed to provide mail service pharmacy services to us on an exclusive basis during the
term of the SOW.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to provide Epiq Scripts with all custom packaging materials, including but not limited to, individual sachet and/or blister packaging
materials, outer box packaging, and any custom inserts and/or marketing information to accompany the prescription shipment, if any and
to provide Epiq Scripts with quarterly sales forecasts to ensure Epiq Scripts has enough packaging materials on hand to cover a 90 day
period. We agreed to pay for all direct shipping, delivery and related courier costs and to provide Epiq Scripts with direct access to
any online accounts to access and generate shipping labels for the fulfillment and delivery of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SOW has a term through December 31, 2025, automatically renewable thereafter for successive one-year terms unless either party terminates
the agreement at least 90 days before renewal thereof and the SOW is subject to the same termination rights of the parties as set forth
in the Master Services Agreement (discussed below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the SOW, we agreed to pay Epiq Scripts certain fixed rate fees for prescription fulfillment, processing and packaging (per prescription)
and drug compounding (per pill), provided the per pill rate is reduced upon us exceeding 3,500 product packages per month.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 86; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Master Services Agreement, we are solely responsible for billing and collecting funds from our customers and Epiq Scripts is paid
out of funds that we actually collect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid Epiq Scripts a total of $60,000 upon our entry into the Master Services Agreement, comprising $45,000 as a one-time non-refundable
technology systems setup and implementation fee and $15,000 as an upfront retainer to be credited towards the future provision of pharmacy
and related services as outlined and detailed in the Master Services Agreement and SOW. All costs related to the pharmacy services provided
by Epiq Scripts are listed as related party costs of revenues on our statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Master Services Agreement has a term of five years, automatically renewable to additional one-year terms thereafter unless either party
provides the other notice of termination at least 90 days prior to the date of automatic renewal. The Master Services Agreement can be
terminated (i) upon breach of the agreement by the other party, subject to a 90-day cure right, (ii) if a party enters into bankruptcy
or fails to pay its debts as they become due, or (iii) if Epiq Scripts becomes unable to perform the services covered by the Master Services
Agreement and any statements of work associated therewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
under the Master Services Agreement are due within 15 days after the end of each month during which collections are received. The Master
Services Agreement contains customary confidentiality obligations, record retention provisions, audit rights, and representations and
warranties of the parties. Each party to the Master Services Agreement agreed to indemnify, defend, and hold harmless the other and the
other party&#8217;s officers, directors, shareholders, employees, and agents from and against any and all nonparty claims, or actions
for damages, liabilities (including strict liability), penalties, costs and expenses (including reasonable legal fees, expenses and costs)
to the proportionate extent caused by (1) the negligence or willful misconduct of the indemnitor or any of its employees or agents in
connection with the performance of the agreement, or (2) any breach of any representation, warranty or covenant under the agreement by
the indemnitor or any of its employees or agents. Additionally, the parties agreed that neither party will be liable to the other for
special, incidental, or exemplary damages, subject to certain limited exceptions. The Master Services Agreement does not address product
liability claims or assign any rights of indemnification or contribution in connection therewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid Epiq Scripts a total of $60,000 upon our entry into the Master Services Agreement, comprising $45,000 as a one-time non-refundable
technology systems setup and implementation fee and $15,000 as an upfront retainer to be credited towards the future provision of pharmacy
and related services as outlined and detailed in the Master Services Agreement and SOW, of which $11,745 remained outstanding as of December
31, 2022 and $84,382 remained outstanding as of September 30, 2023. All costs related to the pharmacy services provided by Epiq Scripts
are listed as related party costs of revenues on our statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epiq
Scripts has filed with the Utilization Review Accreditation Commission (&#8220;URAC&#8221;) to obtain its pharmacy accreditation and
obtained its first state license in the State of Texas in February 2022. Epiq Scripts has State Board of Pharmacy (or its equivalent)
licenses to operate in 47 states: Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois,
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska,
Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island,
South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming and plans to eventually obtain
licenses in all 50 states by the end of 2023, with some state licenses easier to obtain and quicker to obtain than others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the above, Epiq Scripts can currently only provide the Services to the Company in the District of Columbia and 47 states
described above, and the Company will be unable to sell its products to any customers in any states other than those named above, until
Epiq Scripts is able to obtain licenses in other states and will thereafter be limited to selling products to customers only in the states
in which Epiq Scripts holds a license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 87; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreement With Epiq Scripts</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2023, we entered into a Consulting Agreement (the &#8220;Consulting Agreement&#8221;) with Epiq Scripts. Pursuant to the
Consulting Agreement, Epiq Scripts agreed to provide pharmacy consulting services in connection with the Company&#8217;s global expansion
efforts, and as reasonably requested by the Company, during the term of the agreement, which is for five years, unless otherwise earlier
terminated (a) due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof;
(b) the mutual agreement of the parties; or (c) the date that Epiq Scripts provides the Company written notice of termination, which
may be at any time and for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for agreeing to provide the services under the agreement, the Company agreed to pay Epiq Scripts (1) a one-time payment
of $65,000, payable within ten days of the entry into the agreement; and (2) a set fee, payable for each prescription drug pill sold
by the Company for cash, to the extent such pill must be prescribed by a medical doctor, or sold through retail pharmacies over the counter,
in jurisdictions where a doctor&#8217;s prescription is not required for the sale of such drugs, and sold in a Territory (defined below),
which consideration per pill decreases each year that the agreement is in effect, and is only payable for the first five years of the
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consulting Agreement further provides that no payments are due for the sale of any prescription pills until the First Sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Consulting Agreement, (a) &#8220;Territory&#8221; means worldwide, except for the United States, including its territories and possessions
and the District of Columbia; and (b) &#8220;First Sale&#8221; means the date that the first commercial sale of prescription pills occurs
in the Territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
payments are also required to be offset equitably for any prescription pill sold which is later refunded, charged back, returned, or
reimbursed to a purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement includes customary representations of the parties, confidentiality and non-solicitation provisions, rights of Epiq Scripts
to audit the sales of prescription pills, subject to certain limitations and requirements, and the requirement that the Company reimburse
certain expenses of Epiq Scripts, subject to certain limitations and pre-approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>First
Amendment to MSA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2023, we entered into a First Addendum to Master Services Agreement (&#8220;MSA&#8221;) with Epiq Scripts (the &#8220;First
Amendment&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the First Amendment, the parties agreed to amend the MSA to include certain Right of first negotiation rights and right of first refusal
rights (each as discussed below). Additionally, the First Amendment provides for certain rights to Epiq Scripts in the event that the
Company seeks to obtain pharmaceutical services in connection with certain Company products (collectively, &#8220;Pharmaceutical Services&#8221;)
in jurisdictions other than the United States, including, without limitation, Mexico and the United Kingdom, where Epiq Scripts does
not currently maintain licenses or permits (&#8220;Future Jurisdictions&#8221;, which shall also include, to the extent applicable, any
state in the United States in which Epiq Scripts does not then hold required permits or licenses for the provision of the Pharmaceutical
Services) and/or to terminate Epiq Scripts&#8217; rights to provide exclusive Pharmaceutical Services in any current state of the United
States or Future Jurisdiction where Epiq Scripts may then be providing Pharmaceutical Services to the Company (each a &#8220;Current
Jurisdiction&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
the parties agreed in the First Amendment that should the Company decide to transfer any services provided by Epiq Scripts in a Current
Jurisdiction to another pharmaceutical service provider (&#8220;Transferred Services&#8221;), the Company will be required to pay Epiq
Scripts a fee of 1% of the total gross sales of all Prescription Products (defined below) by the Company resulting from the Transferred
Services in the Current Jurisdiction, for a period of the lesser of (a) five (5) years from the date the Company transferred the Transferred
Services; and (b) through the end of the term of the MSA (including where applicable, any renewal term)(the &#8220;Non-Use Fee&#8221;).
The Non-Use Fee is payable monthly in arrears, for calendar quarters, by the 15th day following the end of each calendar quarter. &#8220;Prescription
Products&#8221; means Products (as defined in the MSA) sold by the Company which must be prescribed by a medical doctor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 88; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the above, the Non-Use Fee shall not apply, and the Company shall not be obligated to pay any Non-Use Fee (a) in the event that the Transferred
Services are provided directly by the Company or a majority-owned subsidiary of the Company; (b) in the event the Company decides to
enter into an agreement with another pharmaceutical service provider to provide Pharmaceutical Services in a Future Jurisdiction; or
(c) in connection with any services provided by any parties in any Future Jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
First Amendment also provides that until the fifth anniversary of the First Amendment, the Company shall notify Epiq Scripts in writing
of any plans to (a) expand its need for pharmacy services outside of those contemplated by the MSA; (b) expand its need for pharmacy
services into a new jurisdiction which Epiq Scripts does not then operate in (including, but not limited to new countries); or (c) begin
providing pharmacy services internally (either through organic growth or acquisition). Thereafter Epiq Scripts has the right to provide
the Company written notice of its intention to provide such services (as described in (a) or (b) above, whereafter the Company is required
to discuss and negotiate such services in good faith with Epiq Scripts for a period of not less than 15 days). Otherwise, in the event
of the occurrence of an event discussed in (c) above, the Company is required to discuss the possibility of Epiq Scripts either co-operating
the pharmacy or providing management services to the Company in good faith for 15 days. In the event after such 15 day period, the Company
and Epiq Scripts cannot come to a mutually agreeable agreement, the Company is under no further obligation regarding the matter set forth
in the notice provided to Epiq Scripts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finally,
the First Amendment includes a requirement whereby if Epiq Scripts receives notice of any proposed fundamental transaction involving
Epiq Scripts or its assets, including any agreement, arrangement, offer or proposal (including a letter of intent, term sheet, form of
definitive agreement or definitive agreement) for an asset sale or acquisition, merger, acquisition or sale of securities, or redemption
or repurchase of securities, Epiq Scripts must provide the Company notice of such offer within three days, after which receipt the Company
will have the right of first refusal for 30 days to become the purchaser in connection with the notified transaction, on the terms, and
subject to the conditions, set forth in such notified offer and pursuant to the conditions of the First Amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (&#8220;PHX&#8221;), which is owned by Peter &#8220;Casey&#8221;
Jensen, who was a member of the Board of Directors of American International. Pursuant to the Consulting Agreement, PHX agreed to provide
consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was
for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach
30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX
50,000 shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. We also agreed
to include the shares issued to PHX in the Resale Prospectus, which shares of common stock were included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#8220;Elliott&#8221;), currently a professional football
player in the National Football League (NFL), to provide consulting and general business advisory services as reasonably requested by
the Company during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Elliott 100,000 shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. We also agreed to include the shares issued to Elliott in the Resale Prospectus, which
shares of common stock were included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#8220;Sandler&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler 10,000
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. We also agreed to
include the shares issued to Sandler in the Resale Prospectus, which shares of common stock were included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 89; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#8220;Chou&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou 5,000 shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. We also agreed to include
the shares issued to Chou in the Resale Prospectus, which shares of common stock were included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with United
States Generally Accepted Accounting Principles (&#8220;US GAAP&#8221;); (c) assistance to the Company with compliance filings for the
quarters ended September 30, 2022, March 31, 2023, June 30, 2023 and the year ended December 31, 2022, including the consolidation structure
and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting
systems relating to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP
or disclosures required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third
party service providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015,
Eugene M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022), has served as Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree 100,000 shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $50,000 in cash, payable as follows: (a) $12,500 on or before September 30, 2022, which has been paid;
(b) $12,500 on or before December 31, 2022, which has been paid; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June
30, 2023. We also agreed to include the 100,000 shares of common stock issued to Greentree in the Resale Prospectus, which shares of
common stock are included therein, and to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s
activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Service Agreement continued in effect through August 14, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Service Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with
regard to certain matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#8220;White Unicorn&#8221;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn 100,000 shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 90; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#8220;Chartered Services&#8221;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which was for six months unless otherwise earlier terminated due to
breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for
agreeing to provide the services under the agreement, the Company agreed to pay Chartered Services $150,000 in cash (with $75,000 payable
upon entry into the agreement and $75,000 payable on January 31, 2023, which amount has been paid to date) and issued Chartered Services
250,000 shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#8220;DojoLabs&#8221;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $100,000 in cash and issued DojoLabs 50,000 shares of restricted common
stock with registration rights (the registration of the resale of which shares were included in the Resale Prospectus) and fully vest
upon the completion of all work performed under the scope of work. The agreement contains customary confidentiality and non-solicitation
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#8220;Bethor&#8221;), to provide strategic advisory services
to the Company during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor 250,000 shares of restricted common stock with registration rights (the registration
of the resale of which shares were included in the Resale Prospectus). The agreement contains customary confidentiality and non-solicitation
provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the
&#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#8217;s development of new business ventures
and strategic planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#8220;Dr. Rudman&#8221;)
and Mr. Jarrett Boon (&#8220;Mr. Boon&#8221;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman serves as Chairman of the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. Rudman&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Dr. Rudman
Consulting Agreement&#8221;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman 25,000
shares of the Company&#8217;s restricted common stock, pay Dr. Rudman $2,000 per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests
of the performance of his duties to the Company in service on the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Boon&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Mr. Boon
Consulting Agreement&#8221;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon 25,000 shares
of the Company&#8217;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties to the Company in service
on the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 91; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of the agreement, which each had a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock to the consultants as
follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3)
Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued
to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful
launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product
category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at
the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category,
and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the
18-month anniversary of the applicable agreement. Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (&#8220;Redlime&#8221;) to provide software
development services during the term of the agreement, which is for 12 months. In consideration for agreeing to provide the services
under the agreement, the Company agreed to pay Redlime $300,000 in cash and issue Redlime 180,000 shares of restricted common stock.
The shares were valued at $1.00 per share for a total of $180,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew, an independent, non-Board member and non-Company employee, to the Advisory
Board. In connection with Mr. Andrew&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Andrew
Consulting Agreement&#8221;), dated effective May 25, 2023, with Mr. Andrew, whereby the Company agreed to issue Mr. Andrew 50,000 shares
of the Company&#8217;s restricted common stock under the 2022 Plan and to reimburse Mr. Andrew for reasonable out-of-pocket expenses,
including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of
his duties to the Company in service on the Advisory Board. The shares were valued at $1.10 per share for a total of $55,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Consulting Agreement with Major Dodge (&#8220;Major&#8221;), to provide acting and production related
services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of
the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued Major 20,000 shares of restricted common stock under the 2022 Plan. The
agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $1.10 per share for a total of
$22,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (&#8220;New To The Street&#8221;),
to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which was for
3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company
issued New To The Street 50,000 shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $5,000.
The shares were valued at $1.10 per share for a total of $55,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, we entered into a service agreement with Greentree. Pursuant to the Service Agreement, Greentree agreed to perform
the following services: (a) bookkeeping services for the Company for the period from October 1, 2023 through September 30, 2024; (b)
advice and assistance to the Company in connection with the conversion of its financial reporting systems, including its projected financial
statements, to a format that is consistent with US GAAP; (c) assistance to the Company with compliance filings for the quarters ended
September 30, 2023, March 31, 2024, June 30, 2024 and the year ended December 31, 2023, including the structure and entries as well as
assistance with US GAAP footnotes; (d) reviewing, and providing advice to the Company on, all documents and accounting systems relating
to its finances and transactions, with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures
required by the SEC; and (e) providing necessary consulting services and support as a liaison for the Company to third party service
providers, including coordination amongst the Company and its attorneys, CPAs and transfer agent. Since February 2015, Eugene (Gene)
M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as an Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 92; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree 75,000 shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $40,000 in cash, payable as follows: (a) $20,000 on or before September 30, 2023; (b) $20,000 on or before
March 31, 2024. We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s
activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service
Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard
to certain matters. The shares were valued at $1.13 per share for a total of $84,750.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2023, the Board of Directors appointed Dr. Douglas Christianson (&#8220;Dr. Christianson&#8221;) an independent, non-Board
member and non-Company employee, to the Advisory Board. In connection with Dr. Christianson&#8217;s appointment to the Advisory Board,
the Company entered into an Advisor Agreement (the &#8220;Christianson Consulting Agreement&#8221;), dated effective November 1, 2023,
with Dr. Christianson, whereby the Company agreed to issue Dr. Christianson 50,000 shares of the Company&#8217;s common stock under the
2022 Plan, which vest six months from the issuance date, and to reimburse Dr. Christianson for reasonable out-of-pocket expenses, including,
without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties
to the Company in his service on the Advisory Board. The agreement has a one year term, but can be terminated with written notice from
either party with 30 days&#8217; notice. The agreement includes customary confidentiality obligations relating to Dr. Christianson and
indemnification obligations of the parties, requiring each party to indemnify and hold harmless the other against breaches of the agreement
and intentionally misconduct or gross negligence (Dr. Christianson) and the operations of the Company (the Company). The shares were
valued at $0.65 per share for a total of $32,500.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2023, we entered into an Influencer Contract with Jason Szkup (&#8220;Scoop&#8221;), to provide influencer and marketing
related services to the Company during the term of the agreement, including posting social media videos. The agreement has a term of
three months, unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company
agreed to pay Scoop $10,000 and to issue Scoop 30,000 shares of common stock under the 2022 Plan. The agreement contains customary confidentiality
and non-disclosure provisions. The shares were valued at $0.65 per share for a total of $19,500.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2023, we entered into a subsequent Consulting Agreement with PHX to provide consulting and general business advisory services
as reasonably requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated
due to breach of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company paid PHX $25,000 in cash and issued PHX 200,000 shares of common
stock under the 2022 Plan. The agreement contains customary confidentiality and non-solicitation provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Master
Services Agreement with Global Career Networks</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2022, the Company entered into a Master Services Agreement with Global Career Networks, Inc. (&#8220;GCN&#8221;). Pursuant
to the agreement, we issued GCN 100,000 shares of restricted common stock with registration rights (which shares were included in the
Resale Prospectus) and GCN agreed to assist us with a planned twitter marketing campaign. The agreement has a one year term (provided
the individual project described therein had a six month term, beginning December 1, 2022), and may be renewed thereafter for additional
one year terms with the mutual approval of the parties. Either party may terminate the agreement at any time for any reason, with at
least 60 days&#8217; notice, or upon the occurrence of any breach or default under the agreement, which remains uncured within 30 days
of written notice thereof, or if the non-terminating party is subject to bankruptcy. The agreement contains customary confidentiality,
indemnification obligations, and limitations of liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 93; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our ability to obtain and maintain intellectual property protection for our technology platform, preserve the confidentiality
of our trade secrets, and operate without violating the intellectual property rights of others will be important to our success. We rely
on a combination of trademark, copyright, trade secret, including federal, state and common law rights in the United States and other
countries, nondisclosure agreements, and other measures to protect our intellectual property, and may seek patent protection of our intellectual
property in the future. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects
of our products or to obtain and use information that we regard as proprietary. Our business is affected by our ability to protect against
misappropriation and infringement of our intellectual property and other proprietary rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property includes the content of our websites, our registered domain names, our unregistered trademarks, and certain trade
secrets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied with the United States Patent and Trademark Office for a federal trademark for the word mark:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_003.jpg" alt="A black text on a white background&#10;&#10;Description automatically generated" style="height: 51px; width: 158px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is currently operated and managed by the Founder, Chairman and Chief Executive Officer, Jacob D. Cohen, the President and Founder,
Jonathan Arango, and Amanda Hammer, the Chief Operating Officer of the Company. The Company utilizes the assistance of various independent
contractors for administrative and technology development related services. We anticipate establishing a compensation program designed
to align the compensation of our employees with performance and to provide the proper incentives to attract, retain and motivate employees
to achieve superior results in the future. The structure of our anticipated compensation program will balance incentives earnings for
both short-term and long-term performance such as incentive bonuses and flexible schedules. The Company also intends to develop a culture
of inclusion and diversity and places a high value on diversity and inclusion. Our future success will depend partially on our ability
to attract, retain and motivate qualified personnel. We are not a party to any collective bargaining agreements and have not experienced
any strikes or work stoppages. We consider our relations with our employees to be satisfactory. Mr. Cohen, Mr. Arango and Mrs. Hammer,
are currently party to employment agreements with the Company as discussed below under &#8220;<a href="#mj_001">Executive and Director Compensation</a>&#8212;Employment
Agreements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#8220;Landlord&#8221;) to lease and occupy approximately 2,201 square feet of office space located at 15110 N. Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#8217;s main headquarters (the &#8220;Lease Agreement&#8221;). The Lease Agreement
has a term of 38 months (through December 31, 2025) and has a monthly base rent of $0 for the second month; $5,778, or $31.50 per square
foot, for months 1 and 3-18 and increases at the rate of $1 per square foot per annum thereafter until the end of the lease term (the
&#8220;Base Rent&#8221;). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all
real estate taxes and assessments, hazard and liability insurance and common area maintenance costs for the building at the rate of 2.45%
(the &#8220;Proportionate Rent&#8221;). Upon the execution of the Lease Agreement, the Company agreed to prepay the first full month&#8217;s
Base Rent along with a security deposit equal to $16,942. The lease includes an option to extend the lease for an additional period of
36 calendar months at market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our facilities are sufficient to meet our current needs and that suitable space will be available as and when needed. We do not
own any real property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no pending or threatened legal proceedings involving our company. However, from time to time, we may become involved in various legal
proceedings that arise in the ordinary course of business. Those claims, even if lacking merit, could result in the expenditure by us
of significant financial and managerial resources. We may become involved in material legal proceedings in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center"><span id="sj_008"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is certain information regarding our directors and executive officers as of December 18, 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Since</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
    Arango</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Secretary and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
    M. Johnston</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amanda
    Hammer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine
    D&#8217;Alessio</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex
    P. Hamilton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Kenny Myers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
    2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Experience</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a brief description of the education and business experience of our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jacob
D. Cohen &#8211; <i>Chairman and Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and
capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising,
healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique
investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of
debt and/or equity and in both private and public markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer,
wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE
JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller
of Metiscan, Inc., a publicly-traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline
Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the
company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded
the company&#8217;s financial audit process and managed its various filings with the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the
end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital
signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research
analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance
Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts
in International Economics and Finance from Brandeis University in Waltham, Massachusetts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman
from September 2022 to present. Mr. Cohen also currently serves as a director of American International Holdings Corp (&#8220;American
International&#8221;), a publicly-traded company which was the majority owner and parent to Epiq Scripts, LLC prior to February 15, 2023,
and which is the former sole owner of the Company, having fully divested its ownership in June 2022. Mr. Cohen served as Chief Executive
Officer and President of American International from April 2019 to March 2023. Cohen also serves as Chief Executive Officer of Ronin
Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive
Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013. Since February 15,
2023, Mr. Cohen has owned 51% of and controlled, Epiq Scripts. Mr. Cohen has served as the co-Manager of Epiq Scripts since January 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 95; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Cohen&#8217;s extensive background in investment banking, public company management and corporate finance makes him
well qualified to serve on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jonathan
Arango &#8211; <i>President, Secretary and Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business
development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies
in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical
&amp; health, restaurants, and cryptocurrency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Arango has served as the President, and director of the Company since October 2021 and as Secretary of the Company since February 2023.
From October 2021 to May 2023, Mr. Arango served as the Chief Operating Officer of the Company. Prior to his appointment to the Company,
Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously
owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting,
a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019.
He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&amp;J Marketing). A&amp;J
Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple
sectors. Industries included were Home Improvement, Oil &amp; Gas, Health &amp; Wellness, Professional Development, and E-commerce.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that Mr. Arango&#8217;s extensive experience in the healthcare industry and e-commerce makes him well qualified to serve as a
member of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eugene
M. Johnston &#8211; <i>Chief Financial Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit
Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served
as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr.
Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served
as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January
1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products
company. Mr. Johnston received a Bachelor&#8217;s in Science in Business Administration from the University of North Carolina Charlotte.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amanda
Hammer &#8211; <i>Chief Operating Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mrs.
Hammer has served as the Company&#8217;s Chief Operating Officer since May 2023 and as director of e-Commerce from October 2022 to May
2023. Prior to that, she served in various roles with D Magazine Partners, a media/publishing company, including Chief Operating Officer
(December 2021 to September 2022); Audience Development and Digital Operations Director (July 2019 to November 2021); and Audience Development
Director (August 2018 to June 2019). From February 2018 to July 2018, Mrs. Hammer served as a Sales Consultant with Liberty Mutual insurance.
From October 2014 to October 2017, Mrs. Hammer served as Director of Membership and Product Development at McKissock LLC, a professional
development / e-learning company. Prior to that, from August 2008 to September 2014, she served as Training and Membership Director at
The Institute for Luxury Home Marketing, a real estate / professional association. Mrs. Hammer obtained dual Bachelor of Arts degrees
(i) with a concentration in Graphic Design, and (ii) in Communication Studies, from the University of Iowa. She has also obtained a Negotiation
and Leadership Certificate from Harvard Law School. She is a member of the Texas Women&#8217;s Foundation and the MetroTex Young Professionals
Network.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 96; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Independent
Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lorraine
D&#8217;Alessio&#160;<i>&#8211; Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine
D&#8217;Alessio was elected as a director of the Company effective October 14, 2022. From January 2022 to March 2023, Ms. D&#8217;Alessio
has served as a member of the Board of Directors and member of the Audit Committee of the Board of Directors of American International.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
2010, Ms. D&#8217;Alessio has served as CEO and Managing Partner at D&#8217;Alessio Law Group, PLC, a law firm in Beverly Hills, California
which provides immigration and entertainment law services. In that capacity, she has provided counsel to entertainment agencies, unions,
private companies, academic institutions, tech startups, entrepreneurs and enterprises including: Next Models, Food Network, SubPac,
Pepperdine University, ACTRA, New York Film Academy, Plug and Play, Expert Dojo, and 500 Startups.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
D&#8217;Alessio was named the 2017 Leader in Law by the Los Angeles Business Journal and is the recipient of the 2018 Enterprising Woman
Award. Since 2016, Ms. D&#8217;Alessio has also served on the board of directors of Artists for Change, a non-profit organization which
focuses on creating high impact film, television, and multimedia projects to inspire individuals, organizations, and communities to bring
about positive social change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
2005 to 2007, Ms. D&#8217;Alessio served as a policy analyst and advisor for the government of Ontario, Canada.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
D&#8217;Alessio received her Bachelor&#8217;s degree in International Relations from the University of Toronto in 2005, a Master&#8217;s
of Public Policy in Public Policy Administration from Queen&#8217;s University, in Kingston, Ontario in 2006, and a Juris Doctorate degree
from Southwestern Law School in Los Angeles, California in 2010.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that Ms. D&#8217;Alessio is well qualified to serve on the Board of Directors because of her legal expertise
and extensive knowledge of corporate governance and controls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Alex
P. Hamilton&#160;<i>&#8211; Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex
P. Hamilton was elected as a director of the Company effective October 14, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2016, Mr. Hamilton founded Hamilton Laundry, a boutique laundromat that serves high-end luxury commercial companies, and has served
as its chief executive officer since then. He has also served as Chief Executive Officer of Hamilton Strategy Group, Inc., a consulting
firm, since November 2014. Mr. Hamilton is also the Co-Founder of Donald Capital LLC, a FINRA registered investment banking firm, and
has served as its president since May 2019. Since May 2021, Mr. Hamilton has served as a member of the Board of Directors, the Chairman
of the Audit Committee and member of the Corporate Governance and Nominating Committee of Addentax Group Corp. (ATXG:Nasdaq), an integrated
service provider focusing on garment manufacturing, logistics service, property management and subleasing, and epidemic prevention supplies.
From February 2017 to July 2019, Mr. Hamilton served as Chief Financial Officer of Hemp Logic, Inc. From December 2018 to February 2019,
Mr. Hamilton served as the Interim Chief Financial Officer of ChineseInvestors.com, Inc. From December 2020 to July 2021, Mr. Hamilton
served as a non-executive Board Member, Chairman of the Audit Committee and Member of the Nominating and Compensation Committee of Meiwu
Technology Co., LTD (WNW:Nasdaq). Mr. Hamilton, served as the Chief Financial Officer and Director of CBD Biotech, Inc. from November
2018 to February 2021. From January 2015 to May 2019, Mr. Hamilton served as Senior Managing Director of Consilium Global Research. From
November 2013 to November 2014, Mr. Hamilton was the president of Kei Advisors. From November 2012 to November 2013, Mr. Hamilton served
as Senior Director of FTI Consulting, a management consulting company. Prior to that, Mr. Hamilton served as managing director of Early
Bird Capital (August 2010 to September 2012) and Jesup &amp; Lamont (July 2007 to February 2010), and as a Vice President of The Benchmark
Company (February 2006 to July 2007). Mr. Hamilton holds his Series 7, 24 and 63 licenses. Mr. Hamilton received a Batchelor&#8217;s
Degree in Economics from Brandeis University in Waltham, Massachusetts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 97; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that Mr. Hamilton is well qualified to serve on the Board of Directors because of his extensive business
knowledge, public company experience and experience serving in various positions with investment management firms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Kenny Myers&#160;<i>&#8211; Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Kenny Myers was elected as a director of the Company effective October 14, 2022. From January 2022 to March 2023, Dr. Myers has served
as a member of the Board of Directors and Audit Committee of American International.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
March 2020, Dr. Myers has served as VP of Business Development for Living Fit Nation, Inc., a corporate wellness provider which designs
and implements customized employee health and wellness programs for corporations around the United States. From March 2012 to February
2020, Dr. Myers worked as VP of Business Development at One Health Medical Systems, LLC, an integrated health services provider, where
he was responsible for overseeing the planning, development and execution of the organization&#8217;s marketing and advertising initiatives.
From May 1998 to March 2012, Dr. Myers was CEO of Texas Physicians Network, a healthcare management company where he was responsible
for the marketing and management of several urgent care centers, medical clinics and other related healthcare facilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Myers received his Bachelor of Science degree in Microbiology from Oklahoma University in 1989, and a Doctor of Chiropractic Degree from
Parker University in Dallas, Texas in 1996.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors believes that Dr. Myers is well qualified to serve on the Board of Directors because of his background in the health
services industry and his experience in business marketing and development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of Office of Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until December 31, 2024, one
fiscal year following our listing on Nasdaq. The term of office of our directors will expire at our first annual meeting of shareholders,
subject to re-nomination and reappointment to the board by our shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers are appointed by the Board of Directors and serve at the discretion of the Board of Directors, rather than for specific terms
of office. Our Board of Directors is authorized to appoint persons to the offices set forth in our Bylaws as it deems appropriate. Our
Bylaws provide that our officers may consist of a Chairman of the Board, Chief Executive Officer, Chief Financial Officer, President,
Vice Presidents, Secretary, Treasurer, Assistant Secretaries and such other offices as may be determined by the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Family
Relationships among Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among our directors and executive officers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Arrangements
between Directors and Officers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, there is no arrangement or understanding between any of our officers or directors and any other person, including directors,
pursuant to which the officer was selected to serve as an officer or director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 98; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Involvement
in Certain Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our executive officers or directors has been involved in any of the following events during the past ten years: (1) any bankruptcy
petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy
or within two years prior to that time; (2) any conviction in a criminal proceeding or being a named subject to a pending criminal proceeding
(excluding traffic violations and minor offenses); (3) being subject to any order, judgment, or decree, not subsequently reversed, suspended
or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his
involvement in any type of business, securities or banking activities; (4) being found by a court of competent jurisdiction (in a civil
action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law; (5)
being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently
reversed, suspended or vacated, relating to an alleged violation of (i) any Federal or State securities or commodities law or regulation;
(ii) any law or regulation respecting financial institutions or insurance companies, including, but not limited to, a temporary or permanent
injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or
prohibition order, or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
(6) being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory
organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section (1a)(40) of the Commodity
Exchange Act), or any equivalent exchange, association, entity, or organization that has disciplinary authority over its members or persons
associated with a member.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Leadership Structure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has the responsibility for selecting the appropriate leadership structure for the Company. In making leadership structure
determinations, the Board of Directors considers many factors, including the specific needs of the business and what is in the best interests
of the Company&#8217;s shareholders. Our current leadership structure is comprised of a combined Chairman of the Board and Chief Executive
Officer (&#8220;CEO&#8221;), Mr. Jacob D. Cohen. The Board of Directors believes that this leadership structure is the most effective
and efficient for the Company at this time. Mr. Cohen possesses detailed and in-depth knowledge of the issues, opportunities, and challenges
facing the Company, and is thus best positioned to develop agendas that ensure that the Board of Directors&#8217; time and attention
are focused on the most critical matters. Combining the Chairman of the Board and CEO roles promotes decisive leadership, fosters clear
accountability and enhances the Company&#8217;s ability to communicate its message and strategy clearly and consistently to our shareholders,
particularly during periods of turbulent economic and industry conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risk
Oversight</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
risk oversight is an important priority of the Board of Directors. Because risks are considered in virtually every business decision,
the Board of Directors discusses risk throughout the year generally or in connection with specific proposed actions. The Board of Directors&#8217;
approach to risk oversight includes understanding the critical risks in the Company&#8217;s business and strategy, evaluating the Company&#8217;s
risk management processes, allocating responsibilities for risk oversight, and fostering an appropriate culture of integrity and compliance
with legal responsibilities. The directors exercise direct oversight of strategic risks to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee reviews and assesses the Company&#8217;s processes to manage business and financial risk and financial reporting risk.
It also reviews the Company&#8217;s policies for risk assessment and assesses steps management has taken to control significant risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 99; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Directorships</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director of the Company is also a director of an issuer with a class of securities registered under Section 12 of the Exchange Act (or
which otherwise are required to file periodic reports under the Exchange Act), except for our Chairman, Jacob D. Cohen, who also serves
as a member of the Board of Directors of American International Holdings Corp. (OTC PINK:AMIH) and Mr. Alex Hamilton who serves as a
member of the Board of Directors, the Chairman of the Audit Committee and member of the Corporate Governance and Nominating Committee,
of Addentax Group Corp. (NASDAQ:ATXG).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has three standing committees: an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance
Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Board
Committee Membership</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committee
membership of the Board of Directors is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Independent</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation<br/>
    Committee</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nominating</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>and</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Governance</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committee</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 67%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob D. Cohen<sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan Arango</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine D&#8217;Alessio</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex P. Hamilton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Kenny Myers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(1)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chairman
    of Board of Directors.</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>C &#8211;</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Chairman of Committee.</i></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>M &#8211;</i></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><i>Member.</i></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established&#160;an Audit Committee of the Board of Directors. Ms. D&#8217;Alessio, Mr. Hamilton and Dr. Meyers serve as members
of our Audit Committee, and Mr. Hamilton chairs the Audit Committee. Under the Nasdaq listing standards and applicable SEC rules, we
are required to have at least three members of the Audit Committee, all of whom must be independent. The Board of Directors has determined
that each of Ms. D&#8217;Alessio, Mr. Hamilton and Dr. Meyers meet the independent director standard under Nasdaq listing standards and
under Rule 10-A-3(b)(1) of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has determined that Mr. Hamilton, is an &#8220;audit committee financial expert&#8221; (as defined in the SEC rules) because he
has the following attributes: (i) an understanding of generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;)
and financial statements; (ii) the ability to assess the general application of such principles in connection with accounting for estimates,
accruals and reserves; (iii) experience analyzing and evaluating financial statements that present a breadth and level of complexity
of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised
by our financial statements; (iv) an understanding of internal control over financial reporting; and (v) an understanding of Audit Committee
functions. Mr. Hamilton has acquired these attributes as a result of his significant experience serving on the Board of Directors of
various private and public companies and the Co-Founder and president of Donald Capital LLC, a FINRA registered investment banking firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 100; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted an Audit Committee Charter, which details the principal functions of the Audit Committee, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the appointment,
    compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm engaged by us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving all audit
    and permitted non-audit services to be provided by the independent registered public accounting firm engaged by us, and establishing
    pre-approval policies and procedures;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting clear hiring policies
    for employees or former employees of the independent registered public accounting firm, including but not limited to, as required
    by applicable laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting clear policies
    for audit partner rotation in compliance with applicable laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining and reviewing
    a report, at least annually, from the independent registered public accounting firm describing (i) the independent registered public
    accounting firm&#8217;s internal quality-control procedures, (ii) any material issues raised by the most recent internal quality-control
    review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities within
    the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such
    issues and (iii) all relationships between the independent registered public accounting firm and us to assess the independent registered
    public accounting firm&#8217;s independence;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior to us
    entering into such transaction; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with management,
    the independent registered public accounting firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters,
    including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material
    issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated
    by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee also has the sole authority, at its discretion and at our expense, to retain, compensate, evaluate and terminate our
independent auditors and to review, as it deems appropriate, the scope of our annual audits, our accounting policies and reporting practices,
our system of internal controls, our compliance with policies regarding business conduct and other matters. In addition, the Audit Committee
has the authority, at its discretion and at our expense, to retain special legal, accounting or other advisors to advise the Audit Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee and Nominating and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established&#160;a Compensation Committee of the Board of Directors. Ms. D&#8217;Alessio and Dr. Meyers serve as members of our
Compensation Committee. Under the Nasdaq listing standards and applicable SEC rules, we are required to have at least two members of
the Compensation Committee, all of whom must be independent. Each of Ms. D&#8217;Alessio and Dr. Meyers are independent, and Dr. Meyer&#8217;s
chairs the Compensation Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Compensation Committee Charter, which details the principal functions of the Compensation Committee, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and
    approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation, if
    any is paid by us, evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining
    and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving
    on an annual basis the compensation, if any is paid by us, of all of our other officers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing on an annual
    basis our executive compensation policies and plans;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 101; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
    and administering our incentive compensation equity-based remuneration plans;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting management in
    complying with our proxy statement and annual report disclosure requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving all special perquisites,
    special cash payments and other special compensation and benefit arrangements for our officers and employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if required, producing
    a report on executive compensation to be included in our annual proxy statement; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, evaluating and
    recommending changes, if appropriate, to the remuneration for directors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
charter also provides that the Compensation Committee may, in its sole discretion, retain or obtain the advice of a compensation consultant,
legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such
adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the
Compensation Committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominations
for Directors</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have established&#160;a Nominating and Corporate Governance Committee. The members of our nominating and corporate governance are Ms.
D&#8217;Alessio and Dr. Meyers and Ms. D&#8217;Alessio serves as chair of the Nominating and Corporate Governance Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary purposes of our Nominating and Corporate Governance Committee are to assist the board in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    screening and reviewing individuals qualified to serve as directors and recommending to the Board of Directors candidates for nomination
    for election at the annual meeting of shareholders or to fill vacancies on the Board of Directors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing, recommending
    to the Board of Directors and overseeing implementation of our corporate governance guidelines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating and overseeing
    the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the governance of the
    company; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing on a regular
    basis our overall corporate governance and recommending improvements as and when necessary.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee is governed by a charter that complies with the rules of the Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Nominating and Corporate Governance Committee will recommend to the Board of Directors candidates for nomination for election at the
annual meeting of the shareholders. The Board of Directors will also consider director candidates recommended for nomination by our shareholders
during such times as they are seeking proposed nominees to stand for election at the next annual meeting of shareholders (or, if applicable,
a special meeting of shareholders).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not formally established any specific, minimum qualifications that must be met or skills that are necessary for directors to possess.
In general, in identifying and evaluating nominees for director, the Board of Directors considers educational background, diversity of
professional experience, knowledge of our business, integrity, professional reputation, independence, wisdom, and the ability to represent
the best interests of our shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 102; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
listing standards require that a majority of our Board of Directors be independent. An &#8220;independent director&#8221; is defined
generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship
which in the opinion of the company&#8217;s Board of Directors, would interfere with the director&#8217;s exercise of independent judgment
in carrying out the responsibilities of a director. Our Board of Directors has determined that all of our directors, other than Mr. Cohen
and Mr. Arango, are &#8220;independent directors&#8221; as defined in the Nasdaq listing standards and applicable SEC rules. Our independent
directors have regularly scheduled meetings at which only independent directors are present.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
assessing director independence, the Board considers, among other matters, the nature and extent of any business relationships, including
transactions conducted, between the Company and each director and between the Company and any organization for which one of our directors
is a director or executive officer or with which one of our directors is otherwise affiliated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shareholder
Communications with the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our Secretary,
15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248, who, upon receipt of any communication other than one that is clearly marked
&#8220;Confidential,&#8221; will note the date the communication was received, open the communication, make a copy of it for our files
and promptly forward the communication to the director(s) to whom it is addressed. Upon receipt of any communication that is clearly
marked &#8220;Confidential,&#8221; our Secretary will not open the communication, but will note the date the communication was received
and promptly forward the communication to the director(s) to whom it is addressed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
on Equity Ownership</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not have a policy on equity ownership at this time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Policy
against Hedging</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes that hedging against losses in Company shares may disturb the alignment between shareholders and executives that equity
awards are intended to build; however, while &#8216;short sales&#8217; are discouraged by the Company, the Company does not currently
have a policy prohibiting such transactions. We plan to implement a policy prohibiting such transactions in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
Recovery</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 26, 2023, the Board of Directors of the Company approved the adoption of a Policy for the Recovery of Erroneously Awarded Incentive
Based Compensation (the &#8220;<span style="text-decoration: underline">Clawback Policy</span>&#8221;), with an effective date of October 2, 2023, in order to comply with the
final clawback rules adopted by the Securities and Exchange Commission under Section 10D and Rule 10D-1 of the Securities Exchange Act
of 1934, as amended (&#8220;<span style="text-decoration: underline">Rule 10D-1</span>&#8221;), and the listing standards, as set forth in the Nasdaq Listing Rule 5608 (the &#8220;<span style="text-decoration: underline">Final
Clawback Rules</span>&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Clawback Policy provides for the mandatory recovery of erroneously awarded incentive-based compensation from current and former executive
officers as defined in Rule 10D-1 (&#8220;<span style="text-decoration: underline">Covered Officers</span>&#8221;) of the Company in the event that the Company is required to
prepare an accounting restatement, in accordance with the Final Clawback Rules. The recovery of such compensation applies regardless
of whether a Covered Officer engaged in misconduct or otherwise caused or contributed to the requirement of an accounting restatement.
Under the Clawback Policy, the Board of Directors may recoup from the Covered Officers erroneously awarded incentive compensation received
within a lookback period of the three completed fiscal years preceding the date on which the Company is required to prepare an accounting
restatement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 103; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a Code of Ethical Business Conduct (&#8220;Code of Ethics&#8221;) that applies to all of our directors, officers and employees.
We intend to disclose any amendments to our Code of Ethics and any waivers with respect to our Code of Ethics granted to our principal
executive officer, our principal financial officer, or any of our other employees performing similar functions in a Current Report on
Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no waivers granted with respect to our Code of Ethics to any such officers or employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Whistleblower
Protection Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted a Whistleblower Protection Policy (&#8220;Whistleblower Policy&#8221;) that applies to all of its directors, officers,
employees, consultants, contractors and agents of the Company. The Whistleblower Policy has been reviewed and approved by the Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Diversity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we do not have a formal policy on diversity, our Board of Directors considers diversity to include the skill set, background, reputation,
type and length of business experience of our board members as well as a particular nominee&#8217;s contributions to that mix. Our Board
of Directors believes that diversity promotes a variety of ideas, judgments and considerations to the benefit of our Company and shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2021, the Securities and Exchange Commission approved a proposed rule from Nasdaq on diversity of boards of directors of companies
listed on Nasdaq. Pursuant to the rule as approved (the &#8220;Diversity Rule&#8221;), any company newly listing on The Nasdaq Capital
Market that was not previously subject to a substantially similar requirement of another national securities exchange, is required to
have, explain why it does not have, at least two Diverse (as defined below) directors by the later of: (a) two years from the date of
listing; or (b) the date the company files its proxy statement or its information statement (or, if the company does not file a proxy,
in its Form 10-K) for the company&#8217;s second annual meeting of shareholders subsequent to the company&#8217;s listing; provided that
if the company has a board of five or fewer members it need only have, or explain why it does not have, one Diverse director. Unless
exempt from the rules as discussed below, at least one Diverse director must self-identify as female and at least one Diverse director
must self-identify as an underrepresented minority or as LGBTQ+ (unless we remain as a smaller reporting company, in which case both
Diverse directors may self-identify as female). &#8220;Diverse&#8221; means an individual who self-identifies as one or more of the following:
female, LGBTQ+, or an underrepresented individual based on national, racial, ethnic, indigenous, cultural, religious or linguistic. We
currently have one director who self-identifies as female.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 104; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_001"></span>Executive
and Director Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Compensation Table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of (i) all individuals serving as our principal executive officer
or acting in a similar capacity for the period from October 7, 2021 (Inception) to December 31, 2022 (&#8220;PEO&#8221;), regardless
of compensation level; (ii) our two most highly compensated executive officers other than the PEO who were serving as executive officers
for the periods ended December 31, 2021 and 2022, if any (subject to the limitations below); and (iii) up to two additional individuals
for whom disclosure would have been provided pursuant to (ii) but for the fact that the individual was not serving as an executive officer
at December 31, 2021 or 2022 (collectively, the &#8220;Named Executive Officers&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fiscal Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option Awards ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Other Compensation ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%; text-align: left">Jacob D. Cohen</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">2022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">70,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">100,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">462,750</td><td style="width: 1%; text-align: left"><sup>(5)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">632,750</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO and Chairman<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jonathan Arango</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">308,500</td><td style="text-align: left"><sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">458,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Secretary and Director<sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eugene M. Johnston</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,763</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,763</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO<sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with SEC rules, the amounts included in this column are the grant date fair value for awards granted in the fiscal years shown, computed
    in accordance with the stock-based compensation accounting rules that are a part of generally accepted accounting principles in effect
    in the United States (as set forth in Financial Accounting Standards Board&#8217;s Accounting Standards Codification Topic 718),
    but excluding the effect of any estimated forfeitures of such awards. The values in this column reflect the full grant date fair
    value of all equity awards granted during the year, although the awards are subject to vesting periods based on continued employment.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include perquisites
    and other personal benefits or property, unless the aggregate amount of such compensation is more than $10,000. No executive officer
    earned any non-equity incentive plan compensation or nonqualified deferred compensation during the periods reported above. No executive
    officer serving as a director received any compensation for services on the Board of Directors separate from the compensation paid
    as an executive for the periods above.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Cohen and Mr. Arango
    became officers of the Company effective on October 7, 2021, the date of formation.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Johnston was appointed
    as Chief Financial Officer of the Company effective on October 1, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2022, in
    consideration for agreeing to an employment agreement with the Company, Mr. Cohen received a sign-on bonus of options to purchase
    750,000 shares of common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 250,000 shares
    vesting every 12 months that the agreement is in effect, beginning September 1, 2023. The options have a term of five years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;On August 31, 2022,
    in consideration for agreeing to an employment agreement with the Company, Mr. Arango received a sign-on bonus of options to purchase
    500,000 shares of common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 166,666 shares
    vesting every 12 months that the agreement is in effect, beginning September 1, 2023. The options have a term of five years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective on October 1,
    2022, the Company granted Mr. Johnston 150,000 shares of the Company&#8217;s restricted stock which vest over a 6-month period at
    the rate of 25,000 shares per month with the first 25,000 shares vesting on November 1, 2022, which have vested to date. The shares
    were valued at $0.28 per share for a total of $41,763.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 105; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information as of December 31, 2022 concerning outstanding equity awards for the executive officers named
in the Summary Compensation Table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Awards<sup>(3)</sup>&#160;&#160;</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options (#) exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of securities underlying unexercised options (#) unexercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Exercise price ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option expiration date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of shares or units of stock that have not vested (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Market value of shares or units of stock that have not vested ($)(4)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Jacob D. Cohen</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">750,000</td><td style="width: 1%; text-align: left">(1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2027</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jonathan Arango</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">500,000</td><td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/1/2027</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Eugene M. Johnston</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100,000</td><td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31,
    2022, in consideration for agreeing to an employment agreement with the Company, Mr. Cohen received a sign-on bonus of options to
    purchase 750,000 shares of common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 250,000
    shares vesting every 12 months that the agreement is in effect, beginning September 1, 2023. The options have a term of five years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2022, in
    consideration for agreeing to an employment agreement with the Company, Mr. Arango received a sign-on bonus of options to purchase
    500,000 shares of common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 166,666 shares
    vesting every 12 months that the agreement is in effect, beginning September 1, 2023. The options have a term of five years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective on October 1,
    2022, the Company granted Mr. Johnston 150,000 shares of the Company&#8217;s restricted stock which vest over a 6-month period at
    the rate of 25,000 shares per month with the first 25,000 shares vesting on November 1, 2022.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated by multiplying
    the number of shares shown in the table by $0.28, the fair market value of our common stock as of December 31, 2022, as determined
    by management.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Compensation Awards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2023, the Company executed a Summary of Terms and Conditions with Gene Johnston continuing his appointment as the Company&#8217;s
Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the agreement, the Company issued Johnston 50,000 shares
of the Company&#8217;s common stock and agreed to pay him $2,000 per month. The shares were issued under, and subject to the terms of,
the Company&#8217;s 2022 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, the Company granted 150,000 options to purchase shares of common stock of the Company, under the 2022 Plan to Amanda Hammer,
the Company&#8217;s COO, related to her employment agreement. The options have an exercise price of $1.10 per share, an original life
of five years and vest at the annual renewal of their employment over three years. The options were issued under, and subject to the
terms of, the Company&#8217;s 2022 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 106; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jacob
D. Cohen, Chief Executive Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2022, we entered into an Executive Employment Agreement with Jacob D. Cohen. The agreement, which provides for Mr. Cohen to
serve as our Chief Executive Officer, was effective September 1, 2022, and has a term extending through September 1, 2025, provided that
the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least 60
days prior notice of their intention not to renew the terms of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the agreement, Mr. Cohen&#8217;s annual compensation package currently includes (a) a base salary of $300,000 per year
($180,000 per year through May 1, 2023), subject to automatic annual increases of $60,000 each year the agreement is in place, and subject
to further increases as determined in the sole discretion of the Compensation Committee or the Board of Directors, and (b) a bonus payment
to be determined in the sole discretion of the Compensation Committee or the Board of Directors in an annual targeted amount of 200%
of his base salary (the &#8220;Targeted Bonus&#8221;), subject to the compliance by Mr. Cohen with performance goals that may be established
by the Compensation Committee or the Board of Directors from time to time, provided no goals have been established to date, and that
in the absence of performance goals, the amount of such bonus would be wholly determined in the discretion of the Compensation Committee
or the Board of Directors. Mr. Cohen is also paid an automobile allowance of $1,500 per month during the term of the agreement and is
eligible to participate in our stock option plan and other benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for agreeing to the terms of the agreement, Mr. Cohen received a sign-on bonus of options to purchase 750,000 shares of
common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 250,000 shares vesting every 12 months
that the agreement is in effect. The options have a term of five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Cohen&#8217;s compensation under his employment agreement may be increased from time to time, by the Compensation Committee, or the Board
of Directors (with the recommendation of the Compensation Committee), which increases do not require the entry into an amended employment
agreement. Mr. Cohen may also receive bonuses from time to time, in the discretion of the Board and/or Compensation Committee in cash,
stock, or options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement prohibits Mr. Cohen from competing against us during the term of the agreement and for a period of 12 months after the termination
of the agreement in any state and any other geographic area in which we or our subsidiaries provide Restricted Services or Restricted
Products, directly or indirectly, during the 12 months preceding the date of the termination of the agreement. &#8220;Restricted Services&#8221;
means the or men&#8217;s wellness services and any other services and any other services that we or our subsidiaries have provided or
are researching, developing, performing and/or providing at any time during the two years immediately preceding the date of termination,
or which Mr. Cohen has obtained any trade secret or other confidential information about at any time during the two years immediately
preceding the date of termination of the agreement. &#8220;Restricted Products&#8221; branded men&#8217;s wellness products sold to consumers
via a telemedicine platform and any other product and any other product, that we or our subsidiaries have provided or are researching,
developing, manufacturing, distributing, selling and/or providing at any time during the two years immediately preceding the date the
agreement is terminated, or which Mr. Cohen obtained any trade secret or other confidential information in connection with at any time
during the two years immediately preceding the date of termination of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 107; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mr. Cohen&#8217;s employment (a) for &#8220;cause&#8221; which means (i) Mr. Cohen materially breaches any obligation,
duty, covenant or agreement under the agreement, which breach is not cured or corrected within 30 days of written notice thereof from
the Company (except for breaches of the assignment of inventions or confidentiality/non-solicitation and non-compete provisions of the
agreement, which cannot be cured and for which the Company need not give any opportunity to cure); or (ii) Mr. Cohen commits any act
of misappropriation of funds or embezzlement; or (iii) Mr. Cohen commits any act of fraud; or (iv) Mr. Cohen is convicted of, or pleads
guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude, or a felony under federal or applicable state
law; and, in the case of any of the above offenses, such offense casts reasonable doubt on Mr. Cohen&#8217;s ability to perform his duties
going forward; (b) in the event Mr. Cohen suffers a physical or mental disability which renders him unable to perform his duties and
obligations for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason without &#8220;cause&#8221;; (d) upon
expiration of the initial term of the agreement (or any renewal) upon notice as provided above, or (e) at any time without cause. The
agreement also automatically terminates upon the death of Mr. Cohen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Cohen may terminate his employment (a) for &#8220;good reason&#8221; if there is (i) a material diminution in his authority, duties,
or responsibilities; (ii) a material diminution in the authority, duties, or responsibilities of the supervisor to whom Mr. Cohen is
required to report, including, if applicable, a requirement that Mr. Cohen report to an officer or employee of the Company rather than
reporting to the Board; (iii) a material breach by the Company of the agreement, or (iv) a material diminution in Mr. Cohen&#8217;s base
salary; provided, however, prior to any such termination by Mr. Cohen for &#8220;good reason,&#8221; Mr. Cohen must first advise us in
writing (within 90 days of the occurrence of such event) and provide us 30 days to cure, after which in the event we do not cure the
issue leading to such &#8220;good reason&#8221; notice, Mr. Cohen has 30 days to resign for &#8220;good reason&#8221;); (b) for any reason
without &#8220;good reason&#8221;; and (c) upon expiration of the initial term of the agreement (or any renewal) upon notice as provided
above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Cohen&#8217;s employment is terminated due to his death or disability, Mr. Cohen or his estate is entitled to a lump sum cash severance
payment equal to the sum of (i) Mr. Cohen&#8217;s base salary accrued through the termination date; (ii) any unpaid cash bonus for the
prior year that would have been paid had Mr. Cohen not been terminated prior to such payment; and (iii) Mr. Cohen&#8217;s Targeted Bonus
for the year of termination multiplied by the number of days in such year preceding the termination date divided by 365. Additionally,
and notwithstanding anything to the contrary in any equity agreement, any unvested stock options or equity compensation held by Mr. Cohen
shall vest and shall be exercisable until the earlier of (x) ninety days from the date of termination and (y) the latest date upon which
such stock options or equity would have expired by their original terms under any circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Cohen&#8217;s employment is terminated pursuant to Mr. Cohen without &#8220;good reason&#8221; or his non-renewal of the agreement,
or by the Company with cause, Mr. Cohen is entitled to his base salary accrued through the termination date and no other benefits other
than continuation of health insurance benefits on the terms and to the extent required by COBRA, or such other similar law or regulation
as may be applicable to the Mr. Cohen or the Company with respect to the Mr. Cohen. Additionally, any unvested stock options or equity
compensation held by Mr. Cohen shall immediately terminate and be forfeited (unless otherwise provided in the applicable award) and any
previously vested stock options (or if applicable equity compensation) shall be subject to terms and conditions set forth in the applicable
equity agreement, as such may describe the rights and obligations upon termination of employment of Mr. Cohen.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mr. Cohen&#8217;s employment is terminated by Mr. Cohen for &#8220;good reason&#8221; or by the Company without &#8220;cause&#8221; or
due to the Company&#8217;s non-renewal, (a) Mr. Cohen is entitled to his base salary accrued through the termination date and any unpaid
cash bonus for the prior completed calendar year that would have been paid had Mr. Cohen not been terminated prior to such payment, plus
a lump sum cash severance payment equal to the sum of (i) an amount equal to Mr. Cohen&#8217;s current annual base salary plus (ii) an
amount equal to Mr. Cohen&#8217;s Targeted Bonus for the year containing the termination date (the &#8220;Severance Payment&#8221;);
and (b) provided Mr. Cohen elects to receive continued health insurance coverage through COBRA, the Company will pay Mr. Cohen&#8217;s
monthly COBRA contributions for health insurance coverage, as may be amended from time to time (less an amount equal to the premium contribution
paid by active Company employees, if any) for 12 months following the termination date (the &#8220;Health Payment&#8221;); provided,
however, that if at any time Mr. Cohen is covered by a substantially similar level of health insurance through subsequent employment
or otherwise, the Company&#8217;s health benefit obligations shall immediately cease, and the Company shall have no further obligation
to make the Health Payment. Additionally, and notwithstanding anything to the contrary in any equity agreement, any unvested stock options
or equity compensation previously granted to the Mr. Cohen will vest immediately upon such termination and shall be exercisable by the
Mr. Cohen until the earlier of (A) ninety days from the date of termination and (B) the latest date upon which such stock options or
equity would have expired by their original terms under any circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 108; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to Mr. Cohen&#8217;s right to receive any Severance Payment, (a) Mr. Cohen must execute and deliver to the Company a written
release in form and substance satisfactory to the Company, of any and all claims against the Company and all directors and officers of
the Company with respect to all matters arising out of Mr. Cohen&#8217;s employment, or the termination thereof (other than claims for
entitlements under the terms of the agreement or plans or programs of the Company in which Mr. Cohen has accrued a benefit); and (b)
Mr. Cohen must not have breached any of his covenants and agreements under the Agreement relating to assignment of inventions and confidentiality,
including the non-solicitation and non-compete provisions thereof, which shall continue following the Termination Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Change of Control (as defined below) occurs during the term of the agreement, or within six months after Mr. Cohen&#8217;s termination
of employment by him for good reason or by the Company without cause or upon non-renewal, the Company is required to pay Mr. Cohen, within
60 days following the date of such Change of Control, a cash payment in a lump sum in an amount equal to (x) minus (y) where (x) equals
3.0 times the sum of (a) the current annual base salary of the Mr. Cohen; and (b) the amount of the most recent cash bonus paid to the
Mr. Cohen (collectively (a) and (b), the &#8220;Change of Control Payment&#8221;) and (y) equals the amount of any severance payment
actually paid to Mr. Cohen in connection with a non-Change of Control termination, as discussed above). In the event the Compensation
Committee has not previously made a determination regarding cash bonus or the most recent cash bonus was zero, the &#8220;amount of the
most recent cash bonus paid to the Mr. Cohen&#8221; is instead equal to &#8220;the targeted bonus for the year in which the Change in
Control occurs.&#8221; Additionally, following a change of control termination, all outstanding stock options and other equity compensation
held by Mr. Cohen are exercisable by the Mr. Cohen pursuant to the terms thereof until the earlier of (a) ninety (90) days from his termination
date and (b) the latest date upon which such stock options and other equity compensation would have expired by their original terms under
any circumstances; provided any equity awards outstanding prior to the entry into the Executive Employment Agreement continue to be governed
by the terms set forth in such award agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Change
of Control&#8221; for the purposes of the agreement means: (a) any person obtaining beneficial ownership representing more than 50% of
the total voting power represented by our then outstanding voting securities without the approval of not fewer than two-thirds of our
Board of Directors; (b) a merger or consolidation of us whether or not approved by our Board of Directors, other than a merger or consolidation
that would result in our voting securities immediately prior thereto continuing to represent at least 50% of the total voting power outstanding
immediately after such merger or consolidation, (c) our shareholders approving a plan of complete liquidation or an agreement for the
sale or disposition by us of all or substantially all of our assets, or (d) as a result of the election of members to our Board of Directors,
a majority of the Board of Directors consists of persons who are not members of the Board of Directors on September 1, 2022, except in
the event that such slate of directors is proposed by a committee of the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement contains standard assignment of inventions, indemnification and confidentiality provisions. Further, Mr. Cohen is subject to
non-solicitation covenants during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Mr. Cohen will be prohibited from competing with us while he is employed with us, he will only be prohibited from competing for 12 months
after his employment with us ends pursuant to the agreement. Accordingly, Mr. Cohen could be in a position to use industry experience
gained while working with us to compete with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Jonathan
Arango, President and Secretary</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2022, we entered into an Executive Employment Agreement with Jonathan Arango. The agreement, which provides for Mr. Arango
to serve as our President, Chief Operating Officer (which role he ceased serving as in May 2023) and Secretary, was effective September
1, 2022, and has a term extending through September 1, 2025, provided that the agreement automatically extends for additional one-year
terms thereafter in the event neither party provides the other at least 60 days prior notice of their intention not to renew the terms
of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 109; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the agreement, Mr. Arango&#8217;s annual compensation package currently includes (1) a base salary of $120,000 per year,
subject to annual increases of $30,000, each year the agreement is in place, and subject to further increases as determined in the sole
discretion of the Compensation Committee or the Board of Directors, and (2) a bonus payment to be determined in the sole discretion of
the Compensation Committee or the Board of Directors in an annual targeted amount of 200% of his base salary, subject to the compliance
by Mr. Arango with performance goals that may be established by the Compensation Committee or the Board of Directors from time to time,
provided no goals have been established to date, and that in the absence of performance goals, the amount of such bonus would be wholly
determined in the discretion of the Compensation Committee or the Board of Directors. Mr. Arango is also paid an automobile allowance
of $1,000 per month during the term of the agreement and is eligible to participate in our stock option plan and other benefit plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time the Compensation Committee or the Board of Directors may also pay or grant discretionary cash bonuses or equity bonuses
to Mr. Arango in their discretion, or increase the targeted bonus or the base salary, which increases in target and/or base salary are
not required to be set forth in an amendment to the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for agreeing to the terms of the agreement, Mr. Arango received a sign-on bonus of options to purchase 500,000 shares of
common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 166,666 shares vesting every 12 months
that the agreement is in effect. The options have a term of five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than as discussed above, Mr. Arango&#8217;s employment, including, but not limited to required severance and change of control payments,
is identical terms as Mr. Cohen&#8217;s agreement discussed above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Mr. Arango will be prohibited from competing with us while he is employed with us, he will only be prohibited from competing for 12 months
after his employment with us ends pursuant to the agreement. Accordingly, Mr. Arango could be in a position to use industry experience
gained while working with us to compete with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eugene
M. Johnston, Chief Financial Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company entered into an offer letter with Eugene M. Johnston (the &#8220;Offer Letter&#8221;). The Offer Letter
provided for Mr. Johnston to serve as the full-time Chief Financial Officer of the Company, reporting to the Company&#8217;s Board of
Directors and Chief Executive Officer, for a term of 12 months from October 1, 2022 to September 30, 2023. Pursuant to the Offer Letter,
the Company agreed to grant Mr. Johnston 150,000 shares of the Company&#8217;s restricted stock which vested over a 6-month period at
the rate of 25,000 shares per month with the first 25,000 shares vesting on November 1, 2022. Pursuant to the Offer Letter, Mr. Johnston
is eligible to participate in any of the Company&#8217;s future sponsored benefit plans, including but not limited to, health insurance
benefits, 401k, stock option or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of
the month following 105 days of Johnston&#8217;s start date. Mr. Johnston is also eligible to receive equity incentive grants or cash
bonus awards as determined by the Company&#8217;s Board (or a committee of the Board) in their sole discretion from time to time. The
shares were valued at $0.28 per share for a total of $41,763.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2023, the Company executed a Summary of Terms and Conditions with Mr. Johnston continuing his appointment as the Company&#8217;s
Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the agreement, the Company issued Mr. Johnston 50,000
shares of the Company&#8217;s common stock and agreed to pay him $2,000 per month. The shares were issued under, and subject to the terms
of, the Company&#8217;s 2022 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 110; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amanda
Hammer, Chief Operating Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
and effective on May 1, 2023, we entered into an Employment Agreement with Mrs. Amanda Hammer. The Employment Agreement provides for
Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending through May 1, 2026, provided
that the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least
60 days prior notice of their intention not to renew the terms of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
agreement provides for Mrs. Hammer to receive an annual salary of $150,000 per year (the &#8220;Base Salary&#8221;). The Employment Agreement
also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000 shares of common stock of the Company, vested in full upon
issuance, and (b) options to purchase an additional 150,000 shares of common stock of the Company, with an exercise price of the greater
of (i) $1.10 per share; and (ii) the closing sales price of the Company&#8217;s common stock on the Nasdaq Capital Market on the date
the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $1.10 per
share, with options to purchase 50,000 shares vesting every 12 months that the Employment Agreement is in effect, subject to the terms
of the Company&#8217;s 2022 Equity Incentive Plan. The options are exercisable for a period of ten years and are documented by a separate
option agreement entered into by the Company and Mrs. Hammer (the &#8220;Option Agreement&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Employment Agreement, Mrs. Hammer&#8217;s annual compensation package includes (1) a Base Salary (described above),
subject to increases from time to time in the determination of the Compensation Committee of the Board (or the Board with the recommendation
of the Compensation Committee), and (2) a discretionary bonus payment to be determined in the sole discretion of the Compensation Committee
or the Board of Directors in the targeted amount of 100% of her Base Salary (the &#8220;Cash Bonus&#8221;). Mrs. Hammer is also eligible
for discretionary equity bonuses and/or cash awards, from time to time in the discretion of the Compensation Committee and/or Board of
Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mrs.
Hammer&#8217;s compensation under her employment agreement may be increased from time to time, by the Compensation Committee, or the
Board of Directors (with the recommendation of the Compensation Committee), which increases do not require the entry into an amended
employment agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employment Agreement prohibits Mrs. Hammer from competing against us during the term of the agreement and for a period of 12 months after
the termination of the agreement in any state and any other geographic area in which we or our subsidiaries provide Restricted Services
or Restricted Products, directly or indirectly, during the 12 months preceding the date of the termination of the agreement. &#8220;Restricted
Products&#8221; means any product that the Company or any of its subsidiaries has provided or is developing, manufacturing, distributing,
selling and/or providing at any time during the term of the Agreement, or which she obtained any trade secret or other confidential information
about at any time during the term, or which she became aware of as a result of services rendered under the Employment Agreement. &#8220;Restricted
Services&#8221; means any services that the Company or any of its subsidiaries has provided or is developing, performing and/or providing
at any time during the term of the agreement, or which she obtained any trade secret or other confidential information about at any time
during the term, or which she became aware of as a result of services rendered under the Employment Agreement. The non-compete requirements
described in the paragraph above, as well as the restriction on Mrs. Hammer to refrain, for a period of 12 months from the termination
date, from soliciting customers of the Company with whom Mrs. Hammer worked during the last year of Mrs. Hammer&#8217;s employment with
the Company and from soliciting employees of the Company to leave the employment of the Company, are defined as the &#8220;Non-Compete
Provisions&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may terminate Mrs. Hammer&#8217;s Employment Agreement (a) for &#8220;cause&#8221; which means (i) that Mrs. Hammer has materially breached
any obligation, duty, covenant or agreement under the agreement, which breach is not cured or corrected within 30 days of written notice
thereof from the Company (except for breaches of the assignment of inventions or confidentiality/non-solicitation and non-compete provisions
of the agreement, which cannot be cured and for which the Company need not give any opportunity to cure); (ii) Mrs. Hammer commits any
act of misappropriation of funds or embezzlement; (iii) Mrs. Hammer commits any act of fraud; or (iv) Mrs. Hammer is convicted of, or
pleads guilty or nolo contendere with respect to, theft, fraud, a crime involving moral turpitude, or a felony under federal or applicable
state law; (b) in the event Mrs. Hammer suffers a physical or mental disability which renders him unable to perform her duties and obligations
for either 90 consecutive days or 180 days in any 12-month period; (c) for any reason without &#8220;cause&#8221;; or (d) upon expiration
of the initial term of the agreement (or any renewal) upon notice as provided above. The agreement also automatically terminates upon
the death of Mrs. Hammer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 111; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mrs.
Hammer may terminate her employment (a) for &#8220;good reason&#8221; if there is (i) a material diminution in her authority, duties,
or responsibilities; (ii) a material diminution in the authority, duties, or responsibilities or a requirement that Mrs. Hammer report
to an officer or employee of the Company rather than reporting to the Board; (iii) a material breach by the Company of the agreement,
or (iv) a material diminution in Mrs. Hammer&#8217;s Base Salary, in each case without her prior written consent; provided, however,
prior to any such termination by Mrs. Hammer for &#8220;good reason,&#8221; Mrs. Hammer must first advise us in writing (within 30 days
of the occurrence of such event) and provide us 30 days to cure (5 days in the event the event results to a reduction in her salary),
after which in the event we do not cure the issue leading to such &#8220;good reason&#8221; notice, Mrs. Hammer has 30 days to resign
for &#8220;good reason&#8221;); (b) for any reason without &#8220;good reason&#8221;; and (c) upon expiration of the initial term of
the agreement (or any renewal) upon notice as provided above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mrs. Hammer&#8217;s employment is terminated due to her death or disability, Mrs. Hammer or her estate is entitled to a lump sum cash
severance payment equal to the sum of (i) Mrs. Hammer&#8217;s Base Salary accrued through the termination date; (ii) any unpaid Cash
Bonus for the prior year that would have been paid had Mrs. Hammer not been terminated prior to such payment; and (iii) the pro rata
amount of the current year&#8217;s targeted bonus, multiplied by the number of days in such year preceding the termination date divided
by 365. Additionally, and notwithstanding anything to the contrary in any equity agreement, any unvested stock options or equity compensation
held by Mrs. Hammer upon such termination shall vest and shall be exercisable until the earlier of (A) ninety days from the date of termination
and (B) the latest date upon which such stock options or equity would have expired by their original terms under any circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mrs. Hammer&#8217;s employment is terminated by Mrs. Hammer without &#8220;good reason&#8221; or her non-renewal of the agreement, or
by non-renewal by the Company, by the Company with cause or the Company&#8217;s non-renewal of the agreement, Mrs. Hammer is entitled
to her Base Salary accrued through the termination date and no other benefits other than continuation of health insurance benefits on
the terms and to the extent required by COBRA, or such other similar law or regulation as may be applicable to Mrs. Hammer or the Company
with respect to Mrs. Hammer. Additionally, any unvested stock options or equity compensation held by Mrs. Hammer shall immediately terminate
and be forfeited (unless otherwise provided in the applicable award) and any previously vested stock options (or if applicable equity
compensation) shall be subject to terms and conditions set forth in the applicable equity agreement, as such may describe the rights
and obligations upon termination of employment of Mrs. Hammer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Mrs. Hammer&#8217;s employment is terminated by Mrs. Hammer for &#8220;good reason&#8221;, or by the Company without &#8220;cause&#8221;,
(a) Mrs. Hammer is entitled to her Base Salary accrued through the termination date and any unpaid Cash Bonus for the prior completed
calendar year that would have been paid had Mrs. Hammer not been terminated prior to such payment, plus a lump sum cash severance payment
equal to (x) the sum of (i) an amount equal to her current annual Base Salary; plus (ii) an amount equal to her targeted bonus for the
year containing the termination date, multiplied by (y) a fraction, (A) the numerator of which shall equal the Severance Months (defined
below), and (B) the denominator of which is 12 (the &#8220;Severance Payment&#8221;); and (b) provided Mrs. Hammer elects to receive
continued health insurance coverage through COBRA, the Company will pay Mrs. Hammer&#8217;s monthly COBRA contributions for health insurance
coverage, as may be amended from time to time (less an amount equal to the premium contribution paid by active Company employees, if
any) for the Severance Months following the termination date (the &#8220;Health Payment&#8221;); provided, however, that if at any time
Mrs. Hammer is covered by a substantially similar level of health insurance through subsequent employment or otherwise, the Company&#8217;s
health benefit obligations shall immediately cease, and the Company shall have no further obligation to make the Health Payment. Additionally,
and notwithstanding anything to the contrary in any equity agreement, any unvested stock options or equity compensation previously granted
to Mrs. Hammer will vest immediately upon such termination and shall be exercisable by Mrs. Hammer until the earlier of (A) ninety (90)
days from the date of termination and (B) the latest date upon which such stock options or equity would have expired by their original
terms under any circumstances, provided that such provisions shall not affect any equity awards outstanding prior to the date of the
Employment Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 112; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition to Mrs. Hammer&#8217;s right to receive any Severance Payment, (A) Mrs. Hammer must execute and deliver to the Company a
written release in form and substance satisfactory to the Company, of any and all claims against the Company and all directors and officers
of the Company with respect to all matters arising out of Mrs. Hammer&#8217;s employment, or the termination thereof (other than claims
for entitlements under the terms of the agreement or plans or programs of the Company in which Mrs. Hammer has accrued a benefit), which
must be effective by the 60th day following her termination date; and (B) Mrs. Hammer must not have breached any of her covenants and
agreements under the Agreement relating to assignment of inventions and confidentiality, including the non-solicitation and non-compete
provisions thereof, which shall continue following the termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Severance
Months&#8221; means (a)&#160;<i>three</i>, in the event the period of time between the effective date and the termination date is less
than one year; (b)&#160;<i>six</i>, in the event the period of time between the effective date and the termination date is one year or
more, but less than two years; (c)&#160;<i>nine</i>, in the event the period of time between the effective date and the termination date
is two years or more, but less than three years; and (d)&#160;<i>twelve</i>, in the event the period of time between the effective date
and the termination date is more than three years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employment Agreement also contains standard assignment of inventions, indemnification and confidentiality provisions. Further, Mrs. Hammer
is subject to non-solicitation covenants during the term of the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Mrs. Hammer will be prohibited from competing with us while she is employed with us, she will only be prohibited from competing for twelve
months after her employment with us ends pursuant to her employment agreement. Accordingly, Mrs. Hammer could be in a position to use
industry experience gained while working with us to compete with us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth compensation information with respect to our non-executive directors during our fiscal year ended December
31, 2022. The compensation of our executive directors is included above under &#8220;Executive Compensation Table.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees Earned or Paid in Cash ($)*</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards ($) (1) (2)(3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Lorraine D&#8217;Alessio</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">20,881</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">20,881</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Alex P. Hamilton</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,881</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Kenny Myers</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,881</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">20,881</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
The table above does not include the amount of any expense reimbursements paid to the above directors. No directors received any Non-Equity
Incentive Plan Compensation or Nonqualified Deferred Compensation. Does not include perquisites and other personal benefits, or property,
unless the aggregate amount of such compensation is more than $10,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance
    with SEC rules, the amounts included in this column are the grant date fair value for awards granted in the fiscal years shown, computed
    in accordance with the stock-based compensation accounting rules that are a part of generally accepted accounting principles in effect
    in the United States (as set forth in Financial Accounting Standards Board&#8217;s Accounting Standards Codification Topic 718),
    but excluding the effect of any estimated forfeitures of such awards. The values in this column reflect the full grant date fair
    value of all equity awards granted during the year, although the awards are subject to vesting periods based on continued employment.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 113; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific board compensation
    policy has been adopted to date; however, on October 14, 2022, we entered into offer letters with each of our three independent non-executive
    directors, Ms. D&#8217;Alessio, Mr. Hamilton and Dr. Meyers. Pursuant to the Offer Letters, each non-executive director agreed to
    serve as a member of our Board of Directors, and we agreed to grant each non-executive director 75,000 shares of restricted common
    stock (the &#8220;Director Shares&#8221;). The Director Shares were issued under the Company&#8217;s 2022 Equity Incentive Plan (the
    &#8220;Plan&#8221;), with the following vesting schedule: 1/3 of the Director Shares vested on October 14, 2022, and the remaining
    Director Shares vest annually in two increments on each of October 14, 2023 and 2024, subject to such directors continuing to provide
    services to the Company on such dates, and subject to the Restricted Stock Award agreements entered into in order to evidence such
    grants. The shares were valued at $.28 per share for a total of $72,039.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate number of
    unvested shares of restricted common stock held by each non-employee director listed above as of December 31, 2022 was as follows:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unvested Restricted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Shares (#)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Lorraine D&#8217;Alessio</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">50,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Alex P. Hamilton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Kenny Myers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
specific board compensation policy has been adopted to date, however, we expect that our non-executive directors will be granted equity
compensation and paid cash, from time to time, for their services on the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Key
Man Insurance</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
obtained key man life insurance in the aggregate amount of $2,000,000 on the life of Jacob D. Cohen, the Chief Executive Officer of the
Company, prior to the effectiveness of this offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022
Equity Incentive Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2022, the Board of Directors and our majority shareholders adopted the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;2022
Plan&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Plan provides an opportunity for any employee, officer, director or consultant of the Company, subject to limitations provided by
federal or state securities laws, to receive (i) incentive stock options (to eligible employees only); (ii) nonqualified stock options;
(iii) stock appreciation rights; (iv) restricted stock awards; (v) restricted stock units; (vi) shares in performance of services; (vii)
other awards of equity or equity based compensation; or (viii) any combination of the foregoing. In making such determinations, the Board
may take into account the nature of the services rendered by such person, his or her present and potential contribution to the Company&#8217;s
success, and such other factors as the Board in its discretion shall deem relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Shares
Available Under the 2022 Plan; Evergreen Provision</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to adjustment in connection with the payment of a stock dividend, a stock split or subdivision or combination of the shares of common
stock, or a reorganization or reclassification of the Company&#8217;s common stock, the aggregate number of shares of common stock which
may be issued pursuant to awards under the 2022 Plan is the sum of (i) 3,500,000 shares, and (ii) an automatic increase on April 1<sup>st&#160;</sup>of
each year for a period of nine years commencing on April 1, 2023 and ending on (and including) April 1, 2032, in an amount equal to the
lesser of (x) five percent (5%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding
fiscal year (the &#8220;Evergreen Measurement Date&#8221;); and (y) 1,000,000 shares of common stock; provided, however, that the Board
may act prior to April 1<sup>st</sup>&#160;of a given year to provide that the increase for such year will be a lesser number of shares
of common stock. This is also known as an &#8220;evergreen&#8221; provision. Notwithstanding the foregoing, no more than a total of 10,000,000
shares of common stock (or awards) may be issued or granted under the 2022 Plan in aggregate, and no more than 10,000,000 shares of common
stock may be issued pursuant to the exercise of Incentive Stock Options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 114; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an award granted under the 2022 Plan entitles a holder to receive or purchase shares of our common stock, then on the date of grant of
the award, the number of shares covered by the award (or to which the award relates) will be counted against the total number of shares
available for granting awards under the 2022 Plan. As a result, the shares available for granting future awards under the 2022 Plan will
be reduced as of the date of grant. However, certain shares that have been counted against the total number of shares authorized under
the 2022 Plan in connection with awards previously granted under such 2022 Plan will again be available for awards under the 2022 Plan
as follows: shares of our common stock covered by an award or to which an award relates which were not issued because the award terminated
or was paid in cash or any portion thereof that was forfeited or cancelled without the delivery of shares will again be available for
awards, including, but not limited to shares forfeited to pay any exercise price or tax obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, shares of common stock related to awards that expire, are forfeited or cancelled or terminate for any reason without the issuance
of shares shall not be treated as issued pursuant to the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares available for awards under the 2022 Plan will be authorized but unissued shares of our common stock or shares acquired in the
open market or otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Administration</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is the issuer (manager) of the 2022 Plan. The 2022 Plan is administered by either (a) the entire Board of Directors of the Company,
or (b) the Compensation Committee; or (b) as determined from time to time by the Board of Directors (the &#8220;Administrator&#8221;).
Subject to the terms of the 2022 Plan, the Administrator may determine the recipients, the types of awards to be granted, the number
of shares of our common stock subject to or the cash value of awards, and the terms and conditions of awards granted under the 2022 Plan,
including the period of their exercisability and vesting. The Administrator also has the authority to provide for accelerated exercisability
and vesting of awards. Subject to the limitations set forth below, the Administrator also determines the fair market value applicable
to an award and the exercise or strike price of stock options and stock appreciation rights granted under the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may also delegate to one or more executive officers the authority to designate employees who are not executive officers
to be recipients of certain awards and the number of shares of our common stock subject to such awards. Under any such delegation, the
Administrator will specify the total number of shares of our common stock that may be subject to the awards granted by such executive
officer. The executive officer may not grant an award to himself or herself.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
or after the date of grant of an award under the 2022 Plan, the Administrator may (i) accelerate the date on which any such award becomes
vested, exercisable or transferable, as the case may be, (ii) extend the term of any such award, including, without limitation, extending
the period following a termination of a participant&#8217;s employment during which any such award may remain outstanding, or (iii) waive
any conditions to the vesting, exercisability or transferability, as the case may be, of any such award; provided, that the Administrator
shall not have any such authority to the extent that the grant of such authority would cause any tax to become due under Section 409A
of the Internal Revenue Code (the &#8220;Code&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Eligibility</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our employees (including our affiliates), non-employee directors and consultants are eligible to participate in the 2022 Plan and
may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the 2022 Plan only to
our employees (including our affiliates).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 115; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
awards are issuable by the Company under the 2022 Plan (a) in connection with services associated with the offer or sale of securities
in a capital-raising transaction; or (b) where the services directly or indirectly promote or maintain a market for the Company&#8217;s
securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Limit
on Non-Employee Director Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of shares subject to awards granted during a single calendar year to any non-employee director, taken together with any
cash fees paid during the compensation year to the non-employee director, in respect of the director&#8217;s service as a member of the
Board during such year (including service as a member or chair of any committees of the Board), will not exceed $500,000, or $1,000,000
in the first year such non-employee director is appointed to the Board, or in the case of any non-employee chairperson of the Board,
in total value (calculating the value of any such awards based on the grant date fair value of such awards for financial reporting purposes).
Compensation will count towards this limit for the fiscal year in which it was granted or earned, and not later when distributed, in
the event it is deferred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option
Terms</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options may be granted by the Administrator and may be either non-qualified (non-statutory) stock options or incentive stock options.
The Administrator, in its sole discretion, determines the exercise price of any options granted under the Plan which exercise price is
set forth in the agreement evidencing the option, provided however that at no time can the exercise price be less than the $0.0001 par
value per share of the Company&#8217;s common stock. Stock options are subject to the terms and conditions, including vesting conditions,
set by the Administrator (and incentive stock options are subject to further statutory restrictions that will be set forth in the grant
agreement for those options). The exercise price for all stock options granted under the 2022 Plan will be determined by the Administrator,
except that no stock options can be granted with an exercise price that is less than 100% of the fair market value of the Company&#8217;s
common stock on the date of grant. Further, shareholders who own greater than 10% of the Company&#8217;s voting stock will not be granted
incentive stock options that have an exercise price less than 110% of the fair market value of the Company&#8217;s common stock on the
date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of all stock options granted under the 2022 Plan will be determined by the Administrator, but the term of an incentive stock option
may not exceed 10 years (five years for incentive stock options granted to shareholders who own greater than 10% of the Company&#8217;s
voting stock). Each stock option gives the grantee the right to receive a number of shares of the Company&#8217;s common stock upon exercise
of the stock option and payment of the exercise price. The exercise price may be paid in cash or if approved by the Administrator, shares
of the Company&#8217;s common stock. The Administrator may also permit other ways for a grantee to pay the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
granted under the 2022 Plan may be exercisable in cumulative increments, or &#8220;vest,&#8221; as determined by the Administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incentive
stock options granted under the 2022 Plan are intended to qualify as &#8220;incentive stock options&#8221; within the meaning of Section
422 of the Internal Revenue Code of 1986, as amended, which we refer to as the Code. Nonqualified (non-statutory stock options) granted
under the 2022 Plan are not intended to qualify as incentive stock options under the Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator may impose limitations on the transferability of stock options granted under the 2022 Plan in its discretion. Generally,
a participant may not transfer a stock option granted under the 2022 Plan other than by will or the laws of descent and distribution
or, subject to approval by the Administrator, pursuant to a domestic relations order. However, the Administrator may permit transfer
of a stock option in a manner that is not prohibited by applicable tax and securities laws. Options may not be transferred to a third
party financial institution for value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 116; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the optionholder, provide otherwise,
if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death,
or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service.
This period may be extended in the event that exercise of the option is prohibited by applicable securities laws or the immediate sale
of shares acquired upon exercise of the option is prohibited by our insider trading policy. If an optionholder&#8217;s service relationship
with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service,
the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If
an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally
exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options
generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term. Acceptable consideration
for the purchase of common stock issued upon the exercise of a stock option will be determined by the administrator and may include (i)
cash, check, bank draft or money order; (ii) a broker-assisted cashless exercise; (iii) the tender of shares of our common stock previously
owned by the optionholder; (iv) a net exercise of the option (to the extent allowed); or (v) other legal consideration approved by the
administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as explicitly provided otherwise in a participant&#8217;s stock option agreement or other written agreement with us or one of our affiliates,
the term &#8220;cause&#8221; is defined in the 2022 Plan to mean any event which would qualify as cause for termination under the participant&#8217;s
employment agreement with the Company, or, if there is no such employment agreement, any of the following (i) the recipient&#8217;s dishonest
statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers, vendors
or other third parties with which such entity does business; (ii) the recipient&#8217;s commission of (A) a felony or (B) any misdemeanor
involving moral turpitude, deceit, dishonesty or fraud; (iii) the recipient&#8217;s failure to perform the recipient&#8217;s assigned
duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the
Company, after written notice given to the recipient by the Company; (iv) the recipient&#8217;s gross negligence, willful misconduct
or insubordination with respect to the Company or any affiliate of the Company; or (v) the recipient&#8217;s material violation of any
provision of any agreement(s) between the recipient and the Company relating to noncompetition, non-solicitation, nondisclosure and/or
assignment of inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Unit Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock unit (RSU) awards are granted under restricted stock unit award agreements adopted by the administrator. Restricted stock unit
awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board of Directors and permissible
under applicable law. A restricted stock unit award may be settled by cash, delivery of stock, a combination of cash and stock as deemed
appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally,
dividend equivalents may be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the
applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested
will be forfeited once the participant&#8217;s continuous service ends for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
stock awards are granted under restricted stock award agreements adopted by the administrator. A restricted stock award may be awarded
in consideration for cash, check, bank draft or money order, past or future services to us, or any other form of legal consideration
that may be acceptable to our Board of Directors and permissible under applicable law. The administrator determines the terms and conditions
of restricted stock awards, including vesting and forfeiture terms. If a participant&#8217;s service relationship with us ends for any
reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant
terminates service with us through a forfeiture condition or a repurchase right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 117; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock
Appreciation Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
appreciation rights are granted under stock appreciation right agreements adopted by the administrator. The administrator determines
the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value
of our common stock on the date of grant. A stock appreciation right granted under our 2022 Plan will vest at the rate specified in the
stock appreciation right agreement as determined by the administrator. Stock appreciation rights may be settled in cash or shares of
our common stock or in any other form of payment as determined by our Board of Directors and specified in the stock appreciation right
agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
administrator determines the term of stock appreciation rights granted under our 2022 Plan, up to a maximum of 10 years. If a participant&#8217;s
service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may
generally exercise any vested stock appreciation right for a period of three months following the cessation of service. This period may
be further extended in the event that exercise of the stock appreciation right following such a termination of service is prohibited
by applicable securities laws. If a participant&#8217;s service relationship with us, or any of our affiliates, ceases due to disability
or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally
exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death.
In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. In no event may a stock
appreciation right be exercised beyond the expiration of its term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2022 Plan permits the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured
so that the stock or cash will be issued or paid only following the achievement of certain pre-established performance goals during a
designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or
in part by reference to, or otherwise based on, our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance goals may be based on any measure of performance selected by our Board of Directors. The performance goals may be based on
company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either
absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless
specified otherwise by our Board of Directors at the time the performance award is granted, our Board of Directors will appropriately
make adjustments in the method of calculating the attainment of performance goals as follows: (i) to exclude restructuring and/or other
nonrecurring charges; (ii) to exclude exchange rate effects; (iii) to exclude the effects of changes to generally accepted accounting
principles; (iv) to exclude the effects of any statutory adjustments to corporate tax rates; (v) to exclude the effects of items that
are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles;
(vi) to exclude the dilutive effects of acquisitions or joint ventures; (vii) to assume that any business divested by us achieved performance
objectives at targeted levels during the balance of a performance period following such divestiture; (viii) to exclude the effect of
any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization,
recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions
to common shareholders other than regular cash dividends; (ix) to exclude the effects of stock based compensation and the award of bonuses
under our bonus plans; (x) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be
expensed under generally accepted accounting principles; and (xi) to exclude the goodwill and intangible asset impairment charges that
are required to be recorded under generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
administrator may grant other awards based in whole or in part by reference to our common stock. The administrator will set the number
of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 118; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Tax
Withholding Adjustments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent provided by the terms of an option or other award, or otherwise agreed to by the Administrator, a participant may satisfy
any federal, state or local tax withholding obligation relating to the exercise of such option, or award by a cash payment upon exercise,
or in the discretion of the Administrator, by authorizing our company to withhold a portion of the stock otherwise issuable to the participant,
by delivering already-owned shares of our common stock or by a combination of these means.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
to Capital Structure</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization,
appropriate adjustments will be made to (i) the class and maximum number of shares reserved for issuance under our 2022 Plan, (ii) the
class and maximum number of shares by which the share reserve may increase automatically each year, (iii) the class and maximum number
of shares that may be issued on the exercise of ISOs, and (iv) the class and number of shares and exercise price, strike price, or purchase
price, if applicable, of all outstanding stock awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Corporate
Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a corporate transaction (as defined in the 2022 Plan), unless otherwise provided in a participant&#8217;s stock award agreement
or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of
grant, any stock awards outstanding under our 2022 Plan may be assumed, continued or substituted for by any surviving or acquiring corporation
(or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the
successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute
for such stock awards, then (i) with respect to any such stock awards that are held by participants whose continuous service has not
terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable)
of such stock awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the
level of performance, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction
(contingent upon the effectiveness of the corporate transaction), and such stock awards will terminate if not exercised (if applicable)
at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to
such stock awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii) any such stock awards that are
held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of the corporate
transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may
continue to be exercised notwithstanding the corporate transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the administrator may
provide, in its sole discretion, that the holder of such stock award may not exercise such stock award but instead will receive a payment
equal in value to the excess (if any) of (i) the value of the property the participant would have received upon the exercise of the stock
award, over (ii) any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar
provisions in the definitive agreement for the corporate transaction may apply to such payment to the same extent and in the same manner
as such provisions apply to the holders of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span></p>

<!-- Field: Page; Sequence: 119; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Change
in Control</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
awards granted under our 2022 Plan may be subject to acceleration of vesting and exercisability upon or after a change in control (as
defined in the 2022 Plan) as may be provided in the applicable stock award agreement or in any other written agreement between us or
any affiliate and the participant, but in the absence of such provision, no such acceleration will automatically occur.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Repricing;
Cancellation and Re-Grant of Stock Options or Stock Appreciation Rights</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Administrator has the right to effect, at any time and from time to time, subject to the consent of any participant whose award is materially
impaired by such action, (1) the reduction of the exercise price (or strike price) of any outstanding option or SAR; (2) the cancellation
of any outstanding option or SAR and the grant in substitution therefor of (A) a new option, SAR, restricted stock award, RSU award or
other award, under the 2022 Plan or another equity plan of the Company, covering the same or a different number of shares of common stock,
(B) cash and/or (C) other valuable consideration (as determined by the Board); or (3) any other action that is treated as a repricing
under generally accepted accounting principles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Duration;
Termination of the 2022 Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has the authority to amend, suspend, or terminate our 2022 Plan at any time, provided that such action does not materially
impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments also require
the approval of our shareholders. No incentive stock options may be granted after the tenth anniversary of the date our Board of Directors
adopted our 2022 Plan. No stock awards may be granted under our 2022 Plan while it is suspended or after it is terminated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Current
Available Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, an aggregate of 2,268,250 shares are available for awards under the 2022 Plan, which allows for an aggregate
of 4,168,250 total awards thereunder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 120; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_002"></span>Certain
Relationships and Related Party Transactions</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as discussed below or otherwise disclosed above under &#8220;<a href="#mj_001">Executive and Director Compensation</a>,&#8221; which information is incorporated
by reference where applicable in this &#8220;<a href="#mj_002">Certain Relationships and Related Transactions</a>&#8221; section, the following sets forth
a summary of all transactions since October 7, 2021 (Inception), or any currently proposed transaction, in which the Company was to be
a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of the Company&#8217;s
total assets at the fiscal year-end for December 31, 2021 and 2022, and in which any officer, director, or any shareholder owning greater
than five percent (5%) of our outstanding voting shares, nor any member of the above referenced individual&#8217;s immediate family,
had or will have a direct or indirect material interest (other than compensation described above under &#8220;<a href="#mj_001">Executive and Director Compensation</a>&#8221;). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the
transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm&#8217;s-length
transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuances
and Sales of Securities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company issued 1,000,000 shares of restricted common stock each to Mr. Cohen (the Company&#8217;s Chairman, Chief
Executive Officer, Director and majority shareholder) and Mr. Jonathan Arango (the Company&#8217;s President, then Chief Operating Officer,
Secretary, Director and greater than 5% shareholder), in consideration for services rendered as the Chief Executive Officer and President
and then Chief Operating Officer, respectively, of the Company. The shares were valued at $0.10 per share or a total of $100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2022, the Company issued 250,000 shares of restricted common stock to The Loev Law Firm, PC, in consideration for legal services
to be rendered, which vested upon issuance. David M. Loev, the Managing Partner, President and sole owner of The Loev Law Firm, PC, is
the brother-in-law of Jacob D. Cohen, our Chairman and Chief Executive Officer. These shares were valued at $0.10 per share or a total
of $25,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 16, 2022, American International entered into and closed the transactions contemplated by a Stock Purchase Agreement (the &#8220;SPA&#8221;),
with Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), which entity is owned by Jacob D. Cohen, the Chairman and Chief Executive
Officer of the Company, who is also the majority shareholder of the Company. Pursuant to the SPA, American International sold 8,000,000
shares of the outstanding common stock of the Company which represented 80% of the then outstanding shares of common stock of the Company,
to Cohen Enterprises in consideration for $90,000, which was approximately the same amount that had been advanced to the Company from
American International through the date of the SPA ($89,200). Cohen Enterprises also acquired the right to be repaid the $89,200 advanced
from American International to the Company, from the Company, pursuant to the terms of the SPA. As a result of the closing of the SPA,
Cohen Enterprises increased its ownership of the Company to 90% (with the remaining 10% of the Company then being owned by Mr. Arango,
as discussed above), and American International completely divested its interest in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2022, Cohen Enterprises sold an aggregate of 600,000 shares of our restricted common stock to third parties for $0.10 per share
or $60,000 in aggregate and 40,000 shares of our restricted common stock to a third party for $0.25 per share or $10,000 in aggregate.
The shares were sold in private transactions to accredited investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 30, 2022, Cohen Enterprises gifted 360,000 restricted shares of common stock to Isaak Cohen, the father of Jacob D. Cohen. These
shares were valued at $0.10 per share or $36,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2022, in consideration for agreeing to an employment agreement with the Company, Mr. Cohen received a sign-on bonus of options
to purchase 750,000 shares of common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 250,000
shares vesting every 12 months that the agreement is in effect, beginning September 1, 2023. The options have a term of five years. The
fair value of the 750,000 options on the grant date was $462,750 and as of December 31, 2022, the Company recognized $51,417 as stock-based
compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 121; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2022, in consideration for agreeing to an employment agreement with the Company, Mr. Arango received a sign-on bonus of options
to purchase 500,000 shares of common stock of the Company, with an exercise price of $1.10 per share, with options to purchase 166,666
shares vesting every 12 months that the agreement is in effect, beginning September 1, 2023. The options have a term of five years. The
fair value of the 500,000 options on the grant date was $308,500 and as of December 31, 2022, the Company recognized $30,850 as stock-based
compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company agreed to grant Eugene M. Johnston, its Chief Financial Officer, 150,000 shares of the Company&#8217;s restricted
stock which vest over a 6-month period at the rate of 25,000 shares per month with the first 25,000 shares vesting on November 1, 2022.
The shares were valued at $0.28 per share for a total of $41,763.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued 75,000 restricted shares of common stock to each of its three independent directors, which shares
vested 1/3 on October 14, 2022, with the remaining shares vesting in one-third increments on each of October 14, 2023 and 2024, subject
to such directors continuing to provide services to the Company on such dates, and subject to the Restricted Stock Award agreements entered
into in order to evidence such grants. These shares were valued at $0.28 per share or a total of $20,881.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued its Project Manager, Joan Arango, 25,000 shares of restricted common stock under the Plan. The shares
were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#8217;s President and then
Chief Operating Officer, Secretary and Director, Jonathan Arango. The shares were valued at $0.28 per share for a total of $7,204.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
May 1, 2023, the Board of Directors of the Company, with Mr. Cohen abstaining, with the recommendation of the Compensation Committee
of the Board of Directors of the Company, approved an increase in the annual salary of Mr. Jacob Cohen, the Chief Executive Officer and
Chairman of the Company, from $180,000 to $300,000 per year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer. The Employment Agreement provides
for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending through May 1, 2026, provided
that the agreement automatically renews for additional one-year terms thereafter in the event neither party provides the other at least
60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for Mrs. Hammer to receive an
annual salary of $150,000 per year. The Employment Agreement also required the Company to grant Mrs. Hammer a sign-on bonus of (a) 75,000
restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase an additional 150,000 shares
of common stock of the Company, under the Company&#8217;s 2022 Equity Incentive Plan, with an exercise price of the greater of (i) $1.10
per share; and (ii) the closing sales price of the Company&#8217;s common stock on the Nasdaq Capital Market on the date the Employment
Agreement and the grant is approved by the Board (which date was May 1, 2023), and which exercise price was $1.00 per share, with options
to purchase 50,000 shares vesting every twelve months that the Employment Agreement is in effect, subject to the terms of the 2022 Plan.
The options are exercisable for a period of ten years and are documented by a separate option agreement entered into by the Company and
Mrs. Hammer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2023, the Company executed a Summary of Terms and Conditions with Gene Johnston continuing his appointment as the Company&#8217;s
Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the agreement, the Company issued Mr. Johnston 50,000
shares of the Company&#8217;s common stock and agreed to pay him $2,000 per month. The shares were issued under, and subject to the terms
of, the Company&#8217;s 2022 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 122; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Party Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2022, and effective on August 30, 2022, we entered into a Master Services Agreement with Epiq Scripts, LLC (&#8220;Epiq
Scripts&#8221;), 51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer. Pursuant to the Master Services
Agreement and a related statement of work (&#8220;SOW&#8221;), Epiq Scripts agreed to provide for the online fulfillment, specialty compounding,
packaging, shipping, dispensing and distribution (collectively, the &#8220;Services&#8221;) of products sold exclusively via our website
that may be prescribed as part of a telehealth consultation on our platform. Epiq Scripts also agreed to provide mail service pharmacy
services to us on an exclusive basis during the term of the SOW. The Master Services Agreement and SOW are described in greater detail
above under &#8220;Business&#8212;Material Agreements&#8212;Master Services Agreement with Epiq Scripts&#8221; and &#8220;&#8212;First
Amendment to MSA&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid Epiq Scripts a total of $60,000 upon our entry into the Master Services Agreement, comprising $45,000 as a one-time non-refundable
technology systems setup and implementation fee and $15,000 as an upfront retainer to be credited towards the future provision of pharmacy
and related services as outlined and detailed in the Master Services Agreement and SOW, of which $11,745 remained outstanding as of December
31, 2022 and $84,382 remained outstanding as of September 30, 2023.&#160;All costs related to the pharmacy services provided by Epiq
Scripts are listed as related party costs of revenues on our statement of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 31, 2022, Mr. Peter &#8220;Casey&#8221; Jensen, who was then a member of the Board of Directors of American International, purchased
25,000 units in our private placement, including 25,000 shares of common stock and warrants to purchase 25,000 shares of common stock
with an exercise price of $1.00 per share, for $25,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC, which is owned by Mr. Jensen. The Consulting Agreement
is described in greater detail above under &#8220;Business&#8212;Material Agreements&#8212;Consulting Agreements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)&#160;Justin
Baker; and (4)&#160;Maja Matthews, each of whom is also an employee of Epiq Scripts. The Consulting Agreements are described in greater
detail above under &#8220;Business&#8212;Material Agreements&#8212;Consulting Agreements.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2023, the 51% of Epiq Scripts then owned by American International was transferred to Mr. Cohen as part of an exchange transaction,
whereby Mr. Cohen agreed to cancel his preferred stock of American International, which provided him voting control over American International,
in exchange for among other assets, American International&#8217;s ownership of Epiq Scripts. As a result, Epiq Scripts is currently
51% owned by Mr. Cohen, our Chairman and Chief Executive Officer. Mr. Cohen has served as the co-Manager of Epiq Scripts since January
2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Related
Party Loans and Advances</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021 and March 18, 2022, the Company received advances of $39,200 and $50,000, respectively, for a total of $89,200 from
its previous majority shareholder, American International, in order to cover various general and administrative expenses. The amount
owed to American International was $39,200 as of December 31, 2021. Imputed interest equal to 8% per annum, or $181, was recorded against
the related party advance as of December 31, 2021. Other than the imputed interest discussed above, the advances bear no interest and
are due on demand upon the Company&#8217;s ability to repay the advances from either future revenues or investment proceeds. Pursuant
to the terms of the June 16, 2022, Securities Purchase Agreement discussed above, on June 16, 2022, Cohen Enterprises also acquired the
right to be repaid the $89,200 advanced from American International to the Company. As of December 31, 2022, the total unpaid amount
of the advance totaled $89,200.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2022, the Company received an advance of $25,000 from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $25,000 on August 18, 2022, bringing the total amount owed to Cohen Enterprises to $89,200
as of December 31, 2022. &#160;The Company paid Cohen Enterprises $89,200 on April 4, 2023, bringing the total amount owed to Cohen Enterprises
to $0 as of September 30, 2023. The Company further recorded a credit of $6,473 towards imputed interest (previously calculated at a
rate of 8% per annum) against the related party advances for the nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 123; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company received an advance of $70 from ZipDoctor, Inc., a wholly owned subsidiary of its then sole shareholder,
American International, which was used to open and establish the Company&#8217;s bank account. The advance bears no interest and is due
on demand upon the Company&#8217;s ability to repay the advance from either future revenues or investment proceeds. The amount owed to
ZipDoctor was $70 as of December 31, 2021. Imputed interest equal to 8% per annum, or $0, was recorded against the related party advance
as of December 31, 2021. The amount was paid in full on May 24, 2022 and the amount owed to ZipDoctor was $0 as of December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chairman and Chief Executive Officer, Jacob D. Cohen, has made his personal credit card available for purchases on behalf
of the Company to cover various general and administrative expenses. Mr. Cohen has been repaid a total of $746,581 as of the date of
this prospectus for Company purchases made on his personal credit card.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2022, the Company entered into a Secured Installment Promissory Note with a vendor for the purchase of equipment in the
amount of $78,260. The note bears no interest unless an event of default occurs, and then it bears interest at the rate of 10% per annum
until paid in full. The Note Payable was payable in installments, requiring payments of $5,000 on each of January 1, 2023, February 1,
2023, and March 1, 2023, with a $31,630 payment due on April 1, 2023 and a final payment due on May 1, 2023. The January 1 and March
1, 2023 payments were timely made and on March 23, 2023, the Company elected to pay off the remaining balance of $63,260. The outstanding
balance on December 31, 2022 was $78,260 and as of September 30, 2023, was $0. The outstanding balance on December 31, 2022 was $78,260
and on September 30, 2023, was $0.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Review,
Approval and Ratification of Related Party Transactions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval or ratification
of transactions, such as those described above, with our executive officers, directors and significant shareholders. However, all of
the transactions described above were approved and ratified by our directors. In connection with the approval of the transactions described
above, our directors took into account various factors, including his fiduciary duty to the Company; the relationships of the related
parties described above to the Company; the material facts underlying each transaction; the anticipated benefits to the Company and related
costs associated with such benefits; whether comparable products or services were available; and the terms the Company could receive
from an unrelated third party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Audit Committee is tasked with reviewing related party transactions to determine whether such transactions are fair to the Company and
its shareholders. The Audit Committee of the Board of Directors of the Company will also review and approve any issues relating to conflicts
of interests and all related party transactions of the Company (&#8220;Related Party Transactions&#8221;). The Audit Committee, in undertaking
such review and will analyze the following factors, in addition to any other factors the Audit Committee deems appropriate, in determining
whether to approve a Related Party Transaction: (1) the fairness of the terms for the Company (including fairness from a financial point
of view); (2) the materiality of the transaction; (3) bids / terms for such transaction from unrelated parties; (4) the structure of
the transaction; (5) the policies, rules and regulations of the U.S. federal and state securities laws; (6) the policies of the Committee;
and (7) interests of each related party in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee will only approve a Related Party Transaction if the Audit Committee determines that the terms of the Related Party Transaction
are beneficial and fair (including fair from a financial point of view) to the Company and are lawful under the laws of the United States.
In the event multiple members of the Audit Committee are deemed a related party, the Related Party Transaction will be considered by
the disinterested members of the Board of Directors in place of the Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our Code of Business Conduct and Ethics (described above under &#8220;<span style="text-decoration: underline">Management&#8212;Code of Ethics</span>&#8221;), which
is applicable to all of our employees, officers and directors, requires that all employees, officers and directors avoid any conflict,
or the appearance of a conflict, between an individual&#8217;s personal interests and our interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 124; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_003"></span>Security
Ownership of Certain Beneficial Owners and Management</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information regarding the beneficial ownership of our common stock as of December 18, 2023
(the &#8220;Date of Determination&#8221;) by (i) each Named Executive Officer, as such term is defined above under &#8220;<a href="#mj_001">Executive
and Director Compensation</a>,&#8221; (ii) each member of our Board of Directors, (iii) each person deemed to be the beneficial owner
of more than five percent (5%) of our common stock, and (iv) all of our executive officers and directors as a group. Unless otherwise
indicated, each person named in the following table is assumed to have sole voting power and investment power with respect to all shares
of our common stock listed as owned by such person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
column titled &#8220;Beneficial Ownership&#8212;Percent Prior to Offering&#8221; is based on a total of 17,419,500 shares of our common
stock outstanding as of the Date of Determination. The column titled &#8220;Beneficial Ownership&#8212;Percent After Offering&#8221;
is based on 21,419,500 shares of our common stock to be outstanding after this offering, which gives further effect to the issuance
of 4,000,000 shares of common stock in this offering and assumes no exercise of the underwriters&#8217; option to purchase additional
shares to cover over-allotments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting and/or investing power with respect to securities.
These rules generally provide that shares of common stock subject to options, warrants or other convertible securities that are currently
exercisable or convertible, or exercisable or convertible within 60 days of the Date of Determination, are deemed to be outstanding and
to be beneficially owned by the person or group holding such options, warrants or other convertible securities for the purpose of computing
the percentage ownership of such person or group, but are not treated as outstanding for the purpose of computing the percentage ownership
of any other person or group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, as of the Date
of Determination, (a) the persons named in the table have sole voting and investment power with respect to all shares of common stock
shown as beneficially owned by them, subject to applicable community property laws; and (b) no person owns more than 5% of our common
stock. Unless otherwise indicated, the address for each of the officers or directors listed in the table below is 15110 N. Dallas Parkway,
Suite 600, Dallas, Texas 75248.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of<br/> Common Stock Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Beneficial Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Beneficially Owned</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent Before Offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent After Offering</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Directors, Named Executive Officers and Executive Officers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; text-align: left">Jacob D. Cohen</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">8,525,000</td><td style="width: 1%; text-align: center"><sup>(1)</sup></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">48.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">39.3</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jonathan Arango</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,166,667</td><td style="text-align: center"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Eugene M. Johnston</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200,000</td><td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amanda Hammer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: center"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lorraine D&#8217;Alessio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: center"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Alex P. Hamilton</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: center"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Kenny Myers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">75,000</td><td style="text-align: center"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">All executive officers and directors as a group (7 persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">10,191,667</td><td style="font-weight: bold; text-align: center"><sup>(1)(2)</sup></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">57.1</td><td style="font-weight: bold; text-align: left">%</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">46.7</td><td style="font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Less than 1%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The outstanding
    shares of common stock beneficially owned by Mr. Cohen are held in the name of The Tiger Cub Trust, which is beneficially owned by
    Jacob D. Cohen, its Trustee, and which shares Mr. Cohen is deemed to beneficially own. Includes 250,000 shares of common stock issuable
    upon exercise of options to purchase shares of common stock of the Company held by Mr. Cohen, with an exercise price of $1.10 per
    share, and does not include options to purchase 500,000 shares of common stock which an exercise price of $1.10 per share, which
    vest at the rate of 1/2 of such options on each of September 1, 2024 and 2025, with a term of five years.</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 125; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes 166,667 shares
    of common stock issuable upon exercise of options to purchase shares of common stock of the Company held by Mr. Cohen, with an exercise
    price of $1.10 per share, and does not include options to purchase 333,333 shares of common stock which an exercise price of $1.10
    per share, which vest at the rate of 1/2 of such options on each of September 1, 2024 and 2025, with a term of five years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does not include options
    to purchase 150,000 shares of common stock with an exercise price of $1.10 per share, which vest at the rate of 1/3 of such options
    on each of May 1, 2024, 2025 and 2026, which have not vested as of the Date of Determination. The options have a 10 year term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 75,000 shares of restricted
    common stock vest at the rate of 25,000 of such shares on October 14, 2022, with the remaining shares vesting in one-third increments
    on each of October 14, 2023 and 2024, subject to the holder&#8217;s continued service with the Company.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Change
of Control</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity
Compensation Plan Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information as of December 31, 2022 regarding the Company&#8217;s 2022 Equity Incentive Plan, under which equity
securities are authorized for issuance:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Plan Category</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> securities<br/> to be issued upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants and<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> average<br/> exercise price<br/> of<br/> outstanding<br/> options,<br/> warrants and<br/> rights</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> securities<br/> available for future<br/> issuance under<br/> equity<br/> compensation plans<br/> (excluding those in<br/> first column)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: justify">Equity compensation plans approved by the security holders (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,275,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,850,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Equity compensation plans not approved by the security holders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,275,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1.00</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,850,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    options issuable upon grants previously made under the Company&#8217;s 2022 Equity Incentive Plan, which is discussed under &#8220;<span style="text-decoration: underline">Executive
    and Director Compensation&#8212;2022 Equity Incentive Plan</span>.&#8221;</span></td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_004"></span>Description
of Capital Stock</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following summary is a description of the material terms of our capital stock and is not complete. You should also refer to the Mangoceuticals,
Inc. Certificate of Formation, as amended and Bylaws, which are included as exhibits to the registration statement of which this prospectus
forms a part, and the applicable provisions of the Texas Business Organizations Code.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Capitalization</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total number of authorized shares of our common stock is 200,000,000 shares, $0.0001 par value per share. The total number of &#8220;blank
check&#8221; authorized shares of our preferred stock is 10,000,000 shares, $0.0001 par value per share. There are no shares of preferred
stock currently outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Voting
Rights</i></b>. Each share of our common stock is entitled to one vote on all shareholder matters. Shares of our common stock do not
possess any cumulative voting rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the election of directors, if a quorum is present, an action on a matter is approved if it receives the affirmative vote of the holders
of the majority of the shares entitled to vote on, and who voted for, against, or expressly abstained with respect to, the matter at
a shareholders&#8217; meeting of a corporation at which a quorum is present is the act of the shareholders, unless otherwise required
by applicable law. The election of directors is determined by a plurality of the votes cast in respect of the shares present in person
or represented by proxy at the meeting and entitled to vote, meaning that the nominees with the greatest number of votes cast, even if
less than a majority, will be elected. The rights, preferences and privileges of holders of common stock are subject to, and may be impacted
by, the rights of the holders of shares of any series of preferred stock that we have designated, or may designate and issue in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividend
Rights</i></b>. Each share of our common stock is entitled to equal dividends and distributions per share with respect to the common
stock when, as and if declared by our Board of Directors, subject to any preferential or other rights of any outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidation
and Dissolution Rights</i></b>. Upon liquidation, dissolution or winding up, our common stock will be entitled to receive pro rata on
a share-for-share basis, the assets available for distribution to the shareholders after payment of liabilities and payment of preferential
and other amounts, if any, payable on any outstanding preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>No
Preemptive, Conversion, or Redemption Rights</i></b>. Holders of our outstanding common stock have no preemptive, conversion, or redemption
rights. Shares of our common stock are not assessable. To the extent that additional shares of our common stock may be issued in the
future, the relative interests of the then existing shareholders may be diluted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fully
Paid Status.&#160;</i></b>All outstanding shares of the Company&#8217;s common stock are validly issued, fully paid and non-assessable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has the authority to issue undesignated shares of &#8220;blank check&#8221; preferred stock in one or more series
and to fix the designation, relative powers, preferences and rights and qualifications, limitations or restrictions of all shares of
each such series, including, without limitation, dividend rates, conversion rights, voting rights, redemption and sinking fund provisions,
liquidation preferences and the number of shares constituting each such series, without any further vote or action by the stockholders.
The issuance of additional preferred stock could decrease the amount of earnings and assets available for distribution to holders of
our common stock or adversely affect the rights and powers, including voting rights, of the holders of our common stock and could, among
other things, have the effect of delaying, deferring or preventing a change in control of our company without further action by the stockholders.
We have no present plans to issue any shares of preferred stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 127; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business
Combinations under Texas Law</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of provisions of Texas law, our Certificate of Formation, as amended, and Bylaws could make it more difficult for the acquisition
of our company by means of a tender offer, a proxy contest or otherwise and the removal of incumbent officers and directors. These provisions
are intended to discourage coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control
of our company to negotiate first with our Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
2, Chapter 21, Subchapter M of the Texas Business Organizations Code (the &#8220;Texas Business Combination Law&#8221;) provides that
a Texas corporation may not engage in specified types of business combinations, including mergers, consolidations and asset sales, with
a person, or an affiliate or associate of that person, who is an &#8220;affiliated shareholder,&#8221; for a period of three years from
the date that person became an affiliated shareholder, subject to certain exceptions (described below). An &#8220;affiliated shareholder&#8221;
is generally defined as the holder of 20% or more of the corporation&#8217;s voting shares. The law&#8217;s prohibitions do not apply
if the business combination or the acquisition of shares by the affiliated shareholder was approved by the Board of Directors of the
corporation before the affiliated shareholder became an affiliated shareholder; or the business combination was approved by the affirmative
vote of the holders of at least two-thirds of the outstanding voting shares of the corporation not beneficially owned by the affiliated
shareholder, at a meeting of shareholders called for that purpose, not less than six months after the affiliated shareholder became an
affiliated shareholder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
law applies to Texas corporations which have more than 100 of record shareholders and which have not affirmatively elected to not be
governed by such law, we do not have more than 100 record shareholders and are not considered an &#8220;issuing public corporation&#8221;
for purposes of this law. Separately, we have elected in our Certificate of Formation, as amended, to not be governed by the Texas Business
Corporation Law. Notwithstanding the above, the Texas Business Combination Law does not apply to the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the business
    combination of an issuing public corporation: where the corporation&#8217;s original charter or bylaws contain a provision expressly
    electing not to be governed by the Texas Business Combination Law; or that adopts an amendment to its charter or bylaws, by the affirmative
    vote of the holders, other than affiliated shareholders, of at least two-thirds of the outstanding voting shares of the corporation,
    expressly electing not to be governed by the Texas Business Combination Law and so long as the amendment does not take effect for
    18 months following the date of the vote and does not apply to a business combination with an affiliated shareholder who became affiliated
    on or before the effective date of the amendment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business combination
    of an issuing public corporation with an affiliated shareholder that became an affiliated shareholder inadvertently, if the affiliated
    shareholder divests itself, as soon as possible, of enough shares to no longer be an affiliated shareholder and would not at any
    time within the three-year period preceding the announcement of the business combination have been an affiliated shareholder but
    for the inadvertent acquisition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business combination
    with an affiliated shareholder who became an affiliated shareholder through a transfer of shares by will or intestacy and continuously
    was an affiliated shareholder until the announcement date of the business combination; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a business combination
    of a corporation with its wholly owned Texas subsidiary if the subsidiary is not an affiliate or associate of the affiliated shareholder
    other than by reason of the affiliated shareholder&#8217;s beneficial ownership of voting shares of the corporation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed above, our Certificate of Formation, as amended, contains a provision expressly providing that we are not subject to the Texas
Business Combination Law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 128; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover
Provisions of Our Charter Documents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Certificate of Formation, as amended, and Bylaws contain various provisions intended to promote the stability of our shareholder base
and render more difficult certain unsolicited or hostile attempts to take us over, that could disrupt us, divert the attention of our
directors, officers and employees and adversely affect the independence and integrity of our business. These provisions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Special
    Meetings of Shareholders &#8212;&#160;</i>Our Bylaws provide that special meetings of the shareholders may only be called by our
    Chairman, our President, or upon written notice to our Board of Directors by our shareholders holding not less than 30% of our outstanding
    voting capital stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bylaws &#8212;&#160;</i>Our
    Bylaws may be amended by our Board of Directors alone.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Advance Notice Procedures
    &#8212;&#160;</i>Our Bylaws establish an advance notice procedure for shareholder proposals to be brought before an annual meeting
    of our shareholders. At an annual meeting, our shareholders elect a Board of Directors and transact such other business as may properly
    be brought before the meeting. By contrast, at a special meeting, our shareholders may transact only the business for the purposes
    specified in the notice of the meeting.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No cumulative voting&#160;</i>&#8212;
    Our Certificate of Formation, as amended, and Bylaws do not include a provision for cumulative voting in the election of directors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Vacancies&#160;</i>&#8212;
    Our Bylaws provide that vacancies on our Board may be filled by a majority of directors in office, although less than a quorum, and
    not by the shareholders.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i>&#160;&#8212;
    Our Certificate of Formation, as amended, allows us to issue up to 10,000,000 shares of preferred stock. The undesignated preferred
    stock may have rights senior to those of the common stock and that otherwise could adversely affect the rights and powers, including
    voting rights, of the holders of common stock. In some circumstances, this issuance could have the effect of decreasing the market
    price of the common stock as well as having an anti-takeover effect.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized but Unissued
    Shares &#8212; </i>Our Board of Directors may cause us to issue our authorized but unissued shares of common stock in the future
    without shareholders&#8217; approval. These additional shares may be utilized for a variety of corporate purposes, including future
    public offerings to raise additional capital, corporate acquisitions and employee benefit plans. The existence of authorized but
    unissued shares of common stock could render more difficult or discourage an attempt to obtain control of a majority of our common
    stock by means of a proxy contest, tender offer, merger or otherwise.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Action by Written Consent
    &#8212; </i>Any action required or permitted to be taken by our common shareholders may be effected by written consent of the
    shareholders having not less than the minimum percentage of the vote required by the Texas Business Organizations Code for the proposed
    corporate action.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Majority Vote</i>&#160;&#8212;
    Under the Texas Business Organizations Code, the affirmative vote of the holders of at least two-thirds of the outstanding voting
    shares is typically required to approve certain fundamental transactions, including amending a company&#8217;s Certificate of Formation,
    approving mergers and conversions, and winding up the corporation; however, in compliance with the Texas Business Organizations Code,
    our Certificate of Formation, as amended, provides that all such fundamental transactions may be approved by majority vote of shareholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants
and Options</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this offering, we have options to purchase 1,250,000 shares of common stock outstanding, which have an exercise price
of $1.10 per share and a term through September 1, 2027; warrants to purchase 975,500 shares of common stock outstanding, which have
an exercise price of $1.00 per share and terms ending between August 16, 2027 and December 22, 2027; and warrants to purchase 87,500
shares of common stock with an exercise price of $5.00 per share, which are exercisable until September 20, 2028.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 129; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Limitations
on Liability and Indemnification of Officers and Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
authorized by Chapter 8 of the Texas Business Organizations Code, we may indemnify our officers and directors (and our former officers
and directors) against expenses incurred by such persons in connection with any (A) threatened, pending, or completed action or other
proceeding, whether civil, criminal, administrative, arbitrative, or investigative; (B) an appeal of an action or proceeding described
by (A); and (C) an inquiry or investigation that could lead to an action or proceeding described by (A), involving such persons in their
capacities as officers and directors, if it is determined in accordance with the Texas Business Organizations Code that: (1) the person:
(A) acted in good faith; (B) reasonably believed: (i) in the case of conduct in the person&#8217;s official capacity, that the person&#8217;s
conduct was in the enterprise&#8217;s best interests; and (ii) in any other case, that the person&#8217;s conduct was not opposed to
the enterprise&#8217;s best interests; and (C) in the case of a criminal proceeding, did not have a reasonable cause to believe the person&#8217;s
conduct was unlawful; (2) with respect to expenses, the amount of expenses other than a judgment is reasonable; and (3) indemnification
should be paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Texas law, corporations may also purchase and maintain insurance or make other financial arrangements on behalf of any person who is
or was a director or officer (or is serving at our request as a director or officer of another corporation) for any liability asserted
against such person and any expenses incurred by him in his capacity as a director or officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our Bylaws (&#8220;Bylaws&#8221;), state that we shall indemnify every (i) present or former director, advisory director or officer of
us, (ii) any person who while serving in any of the capacities referred to in clause (i) served at our request as a director, officer,
partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or domestic corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise, and (iii) any person nominated or designated by (or pursuant to authority
granted by) the Board of Directors or any committee thereof to serve in any of the capacities referred to in clauses (i) or (ii) (each
an &#8220;Indemnitee&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that we shall indemnify an Indemnitee against all judgments, penalties (including excise and similar taxes), fines, amounts
paid in settlement and reasonable expenses actually incurred by the Indemnitee in connection with any proceeding in which he was, is
or is threatened to be named as a defendant or respondent, or in which he was or is a witness without being named a defendant or respondent,
by reason, in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined
that the Indemnitee (a) conducted himself in good faith, (b) reasonably believed, in the case of conduct in his official capacity, that
his conduct was in our best interests and, in all other cases, that his conduct was at least not opposed to our best interests, and (c)
in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful; provided, however, that in
the event that an Indemnitee is found liable to us or is found liable on the basis that personal benefit was improperly received by the
Indemnitee, the indemnification (i) is limited to reasonable expenses actually incurred by the Indemnitee in connection with the proceeding
and (ii) shall not be made in respect of any proceeding in which the Indemnitee shall have been found liable for willful or intentional
misconduct in the performance of his duty to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided above, the Bylaws provide that no indemnification shall be made in respect to any proceeding in which such Indemnitee has
been (a) found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an
action taken in the Indemnitee&#8217;s official capacity, or (b) found liable to us. The termination of any proceeding by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself determinative that the Indemnitee did not
meet the requirements set forth in clauses (a) or (b) above. An Indemnitee shall be deemed to have been found liable in respect of any
claim, issue or matter only after the Indemnitee shall have been so adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom. Reasonable expenses shall include, without limitation, all court costs and all fees and disbursements of attorneys&#8217;
fees for the Indemnitee. The indemnification provided shall be applicable whether or not negligence or gross negligence of the Indemnitee
is alleged or proven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
our Bylaws nor our Certificate of Formation include any specific indemnification provisions for our officers or directors against liability
under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been
advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock trades on The Nasdaq Capital Market under the symbol &#8220;MGRX&#8221;. Trading of our common stock on The Nasdaq Capital
Market began on March 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
Agent</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent for our common stock is Worldwide Stock Transfer, LLC located at One University Plaza, Suite 505, Hackensack, NJ 07601.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 130; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_005"></span>Underwriting</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we entered into an underwriting agreement with Boustead Securities, LLC (which we refer to herein
as the &#8220;Representative&#8221;), as representative of the underwriters named in this prospectus, with respect to the common stock
being sold in this offering. Under the terms and subject to the conditions contained in the underwriting agreement, the Representative
agreed to purchase from us on a firm commitment basis the respective number of shares of common stock at the public offering price
less the underwriting discounts and commissions set forth on the cover page of this prospectus, and each of the underwriters severally
agreed to purchase, and we agreed to sell to the underwriters, at the public offering price per share less the underwriting
discounts and commissions set forth on the cover page of this prospectus, the number of shares of common stock set forth opposite its
name in the following table.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriters</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
    of Shares</b></span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">Boustead Securities, LLC</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">4,000,000</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sutter
    Securities, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,000,000</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares of common stock sold by the underwriters to the public will initially be offered at the public offering price set forth on the
cover page of this prospectus. Any shares of common stock sold by the underwriters to securities dealers may be sold at a discount from
the public offering price not to exceed $0.20 per share. If all of the shares are not sold at the initial offering price, the
Representative may change the offering price and the other selling terms. The Representative has advised us that the underwriters do
not intend to make sales to discretionary accounts. The underwriting agreement provides that the obligations of the underwriters to pay
for and accept delivery of the shares of common stock are subject to the passing upon certain legal matters by counsel and certain conditions
such as confirmation of the accuracy of representations and warranties by us about our financial condition and operations and other matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Over-Allotment
Option</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option, exercisable one or more times in whole or in part, not later than 45 days after the
date of this prospectus, to purchase up to 600,000 additional shares of common stock at the public offering price less the underwriting
discounts and commissions set forth on the cover page of this prospectus, constituting 15% of the total number of shares of common stock
to be offered in this offering (excluding shares subject to this option). The underwriters may exercise this option solely for the purpose
of covering over-allotments in connection with this offering, if any. This offering is being conducted on a firm commitment basis. Any
shares of common stock issued or sold under the option will be issued and sold on the same terms and conditions as the other shares of
common stock that are the subject of this offering. If the over-allotment option is exercised in full, the total proceeds to us will
be $1.38 million before deduction of underwriting discounts and estimated offering expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Discounts
and Commissions; Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price and the underwriting discounts and commissions payable to the underwriters by us
in connection with this offering (assuming both the exercise in full and non-exercise of the over-allotment option that we have granted
to the Representative):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Per Share</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total without Exercise of Over-allotment option</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Total with Exercise of Over-allotment option</b></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%">Public offering price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">0.30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,200,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,380,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Underwriting discounts and commissions (7.0%)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.02</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">84,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">96,600&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds, before expenses, to us</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.28</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,116,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,283,400</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 131; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total expenses of the offering, not including the underwriting discount
and commissions, are estimated at approximately $100,100 (of which approximately $98,000 remains unpaid as of the date of this prospectus
and will be payable upon the closing of the offering) and are payable by us. We have also agreed to pay the underwriters the following:
(i) a non-accountable expense allowance equal to 1.0% of the gross proceeds for expenses in connection with this offering; (ii) a cash
discount of 7.0% of the gross proceeds from the sale of securities in this offering; and (iii) an accountable expense reimbursement of
up to $25,000 for out-of-pocket expenses incurred in connection with this offering, including the fees of the underwriters&#8217; legal
counsel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been advised by the Representative that the underwriters propose to offer the common stock to the public at the public offering
price set forth on the cover of this prospectus and to dealers at a price that represents a concession not in excess of $[ ] per share
under the public offering price. After the offering, the Representative may change the public offering price and other selling terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Representative&#8217;s
Warrants</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also agreed to issue to the Representative (or its permitted assignees) a warrant to purchase a number of shares of our common stock
equal to 7% of the aggregate number of shares of common stock sold in this offering (the &#8220;Representative&#8217;s Warrant&#8221;).
The Representative&#8217;s Warrant will be exercisable on a cashless basis at an exercise price equal to 125% of the public offering
price of the shares sold in this offering. The Representative&#8217;s Warrant is exercisable commencing six months after the effective
date of the registration statement of which this prospectus forms a part, in whole or in part, and will be exercisable for a period of
five years from the effective date of the registration statement of which this prospectus forms a part. We have agreed to a one-time
demand registration of the shares of common stock underlying the Representative&#8217;s Warrant for a period of five years from the effective
date of the registration statement. The Representative&#8217;s Warrant also provides for customary anti-dilution provisions and immediate
&#8220;piggyback&#8221; registration rights with respect to the underlying shares of common stock during the five year period commencing
from the effective date of the registration statement related to this offering. The Representative&#8217;s Warrant is not redeemable
by us. The Representative&#8217;s Warrant and the shares of common stock issuable upon exercise of such warrant have been included on
the registration statement of which this prospectus forms a part. Pursuant to applicable FINRA rules, and in particular Rule 5110, the
Representative&#8217;s Warrant (and underlying shares) issued to the Representative may not be sold, transferred, assigned, pledged,
or hypothecated, or the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective disposition
of the securities by any person for a period of 180 days after the effective date of the registration statement related to this offering;
provided, however, the Representative&#8217;s Warrant (and underlying shares) may be transferred to an underwriter&#8217;s officers,
partners, registered persons or affiliates as long as the Representative&#8217;s Warrant (and underlying shares) remains subject to the
lock-up.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration statement, of which this prospectus is a part, also registers for sale the 322,000 shares of common stock underlying
the Representative&#8217;s Warrants that we intend to issue to the Representative in connection with this offering (which represents
the maximum number of shares underlying such warrants issuable to the representative of the underwriters in the event the underwriters&#8217;
over-allotment option is exercised).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the offering, the underwriters may purchase and sell shares in the open market. Purchases and sales in the open market
may include short sales, purchases to cover short positions, which may include purchases pursuant to the over-allotment option, and stabilizing
purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
    sales involve secondary market sales by an underwriter of a greater number of shares than they are required to purchase in the offering.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 132; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Covered&#8221;
    short sales are sales of shares in an amount up to the number of shares represented by the over-allotment option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Naked&#8221;
    short sales are sales of shares in an amount in excess of the number of shares represented by the over-allotment option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covering
    transactions involve purchases of shares either pursuant to the over-allotment option or in the open market after the distribution
    has been completed in order to cover short positions.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    close a naked short position, an underwriter must purchase shares in the open market after the distribution has been completed. A
    naked short position is more likely to be created if an underwriter is concerned that there may be downward pressure on the price
    of the shares in the open market after pricing that could adversely affect investors who purchase in the offering.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    close a covered short position, an underwriter must purchase shares in the open market after the distribution has been completed
    or must exercise the over-allotment option. In determining the source of shares to close the covered short position, the underwriters
    will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which
    they may purchase shares through the over-allotment option.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions involve bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
to cover short positions and stabilizing purchases, as well as other purchases by an underwriter for its own account, may have the effect
of preventing or retarding a decline in the market price of the common stock. They may also cause the price of the common stock to be
higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters may conduct
these transactions in the over-the-counter market or otherwise. If the underwriters commence any of these transactions, they may discontinue
them at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the Representative and the other underwriters against certain liabilities, including liabilities under the Securities
Act. If we are unable to provide this indemnification, we will contribute to payments that the Representative and the other underwriters
may be required to make for these liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Right
of First Refusal</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with our IPO, the Representative was granted a right of first
refusal, which expires on March 20, 2024, to act as financial advisor on at least equal economic terms on any public or private financing
(debt or equity), merger, business combination, recapitalization or sale of some or all of our equity or our assets, whether in conjunction
with another broker-dealer or on our own volition (collectively, &#8220;Future Services&#8221;). In the event that we engage the Representative
to provide such Future Services, the Representative will be compensated consistent with the engagement agreement with the Representative,
unless we mutually agree otherwise. To the extent we are approached by a third party to lead any public or private financing (debt or
equity), merger, business combination, recapitalization or sale of some or all of our equity or assets, the Representative will be notified
of the transaction and be granted the right to exercise its right of first refusal to provide Future Services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 133; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lock-Up
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with our IPO, certain of our officers, directors and greater
than 1% shareholders previously agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any shares of
our common stock prior to March 20, 2024, except that the shareholders are permitted to transfer shares so long as (a) the transferee
executes a lock-up agreement for the balance of the lock-up period, (b) the transfer is not a disposition for value, (c) the transfer
is not required to be reported in any public report or filing with the SEC, and (d) the shareholder does not voluntarily effect any public
filing or report regarding such transfer: (i) as a gift, (ii) to any immediate family member, (iii) if the shareholder is a business entity
that transfers the shares to another entity that is an affiliate of the shareholder or if the shareholder is a business entity that transfers
the shares to its limited partners, members or shareholders, (iv) if the shareholder is a trust that transfers the shares to a trust beneficiary,
or (v) by will or other testamentary document or intestate succession, or by operation of law pursuant to a domestic order or in connection
with a divorce settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers, directors and greater than 5% shareholders who did not enter into any lock-up agreement in connection with our IPO have each
agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any shares of our common stock for a period
of 90 days following the effectiveness of this offering, except that the shareholders are permitted to transfer shares so long as (a)
the transferee executes a lock-up agreement for the balance of the lock-up period, (b) the transfer is not a disposition for value, (c)
the transfer is not required to be reported in any public report or filing with the SEC, and (d) the shareholder does not voluntarily
effect any public filing or report regarding such transfer: (i) as a gift, (ii) to any immediate family member, (iii) if the shareholder
is a business entity that transfers the shares to another entity that is an affiliate of the shareholder or if the shareholder is a business
entity that transfers the shares to its limited partners, members or shareholders, (iv) if the shareholder is a trust that transfers
the shares to a trust beneficiary, or (v) by will or other testamentary document or intestate succession, or by operation of law pursuant
to a domestic order or in connection with a divorce settlement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the underwriters of this offering may engage in stabilization activities
as described above. The Representative may in its sole discretion and at any time without notice release some or all of the shares subject
to lock-up agreements prior to the expiration of the applicable lock-up period. When determining whether or not to release shares from
the lock-up agreements, the Representative will consider, among other factors, the security holder&#8217;s reasons for requesting the
release, the number of shares for which the release is being requested and market conditions at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Electronic
Offer, Sale and Distribution of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the Representative. In addition, shares of common
stock may be sold by the Representative to securities dealers who resell our common stock to online brokerage account holders. Other
than the prospectus in electronic format, the information on the Representative&#8217;s website and any information contained in any
other website maintained by the Representative is not part of the prospectus or the registration statement of which this prospectus forms
a part, has not been approved and/or endorsed by us or the Representative in its capacity as Representative and should not be relied
upon by investors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Selling
Restrictions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
action has been taken in any jurisdiction (except in the United States) that would permit a public offering of our common stock, or the
possession, circulation or distribution of this prospectus or any other material relating to us or our common stock, where action for
that purpose is required. Accordingly, our common stock may not be offered or sold, directly or indirectly, and neither this prospectus
nor any other offering material or advertisements in connection with our common stock may be distributed or published, in or from any
country or jurisdiction except in compliance with any applicable rules and regulations of any such country or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offer
Restrictions Outside the United States</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful. In particular, our common stock has not been qualified for distribution
by prospectus in Canada and may not be offered or sold in Canada during the course of their distribution hereunder except pursuant to
a Canadian prospectus or prospectus exemption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 134; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the underwriters and/or their affiliates have provided, and may in the future provide, various investment banking and other
financial services for us for which services it has received and, may in the future receive, customary fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the services provided in connection with this offering and as described below, the underwriters have not provided any investment
banking or other financial services during the 180-day period preceding the date of this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, we initiated a private placement of up to $2 million in units to accredited investors, with each unit consisting
of one share of common stock and a warrant to purchase one share of common stock, at a price of $1.00 per unit (the &#8220;2022 Private
Placement&#8221;). The warrants have a five-year term (from each closing date that units were sold) and an exercise price of $1.00 per
share. If at any time after the six-month anniversary of the issuance date, there is no effective registration statement registering,
or no current prospectus available for the resale of the shares of common stock issuable upon exercise the warrants, the holder of the
warrants may elect a cashless exercise of the warrants. The Representative, served as the placement agent in connection with the 2022
Private Placement (the &#8220;Placement Agent&#8221;). In total, we sold an aggregate of 2,000,000 units for $2,000,000 to 23 accredited
investors between August 16, 2022 and December 22, 2022, the end date of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the 2022 Private Placement, we paid the Placement Agent
a success fee of 7% of the gross purchase price of the units sold in the 2022 Private Placement, which amounted to $140,000, and a 1%
non-accountable expense allowance, which amounted to $20,000. Additionally, we granted the Placement Agent warrants to purchase 7% of
the number of shares and warrants sold in the offering, totaling warrants to purchase 280,000 shares of common stock, with an exercise
price of $1.00 per share. The warrants granted to the Placement Agent have cashless exercise rights (regardless of whether the shares
underlying such warrants are registered) and a term of five years from their original grant date (a total of 56,000 warrants were granted
to the Placement Agent on August 16, 2022; a total of 51,870 warrants were granted to the Placement Agent on September 9, 2022; a total
of 102,200 warrants were granted to the Placement Agent on September 21, 2022; a total of 45,500 warrants were granted to the Placement
Agent on November 11, 2022; and a total of 24,430 warrants were granted to the Placement Agent on December 22, 2022). The private placement
warrants are not exercisable or convertible for more than five years from the commencement of our IPO. Pursuant to applicable FINRA rules
and, in particular, Rule 5110(e)(1), the private placement warrants may not be sold, transferred, assigned, pledged or hypothecated, or
be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of the securities for a period of 180 days beginning on the date of commencement of sales of our IPO; provided, however, the private placement
warrants may be transferred to the Placement Agent&#8217;s officers, partners, registered persons or affiliates as long as the warrants
remain subject to the lock-up restriction above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2022, we entered into a Waiver of Warrant agreement with the Placement Agent, whereby it agreed to surrender all 280,000
private placement warrants issued to it in connection with the 2022 Private Offering (the &#8220;Placement Agent Warrants&#8221;) for
no consideration and it irrevocably waived any right or interest in the Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We agreed to indemnify the Placement Agent for certain liabilities, including certain liabilities under the Securities Act, or to
contribute to payments that the Placement Agent may be required to make in respect thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 23, 2023, we consummated our IPO of 1,250,000 shares of common stock
at a price to the public of $4.00 per share, pursuant to that certain underwriting agreement, dated March 20, 2023, between us and Boustead
Securities, LLC, as representative of several underwriters named therein. In connection with the IPO, we also granted the underwriters
a 45-day option to purchase up to an additional 187,500 shares of our common stock, which expired unexercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the closing date of our IPO, we received gross proceeds of approximately $5 million, before deducting underwriting discounts and
commissions and estimated offering expenses payable by us. We sold the shares in the IPO to Boustead at a price of $3.72 per share,
a 7% discount to the initial public offering price of $4.00 per share. We also paid Boustead a non-accountable expense allowance
equal to $50,000 (1% of gross proceeds of the offering).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration in connection with the IPO, upon the closing of
the IPO, we granted Boustead warrants to purchase 87,500 shares of our common stock with an exercise price of $5.00 per share, which are
exercisable beginning six months after the effective date of the registration statement filed in connection with the IPO (March 20, 2023)
and expire five years after such effective date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We agreed to indemnify Boustead for certain liabilities, including certain liabilities under the Securities Act, or to contribute
to payments that Boustead may be required to make in respect thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Listing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is traded on The Nasdaq Capital Market under the symbol &#8220;MGRX&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 135; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_006"></span>Legal
Matters</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the securities offered by this prospectus will be passed upon for us by The Loev Law Firm, PC, Bellaire, Texas. David M.
Loev, the Managing Partner, President and sole owner of The Loev Law Firm, PC, beneficially owns less than 2% of the outstanding shares
of our common stock and is the brother-in-law of Jacob D. Cohen, our Chairman and Chief Executive Officer. Certain legal matters in connection
with this offering will be passed upon for the underwriters by Olshan Frome Wolosky LLP, New York, New York.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 136; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_007"></span>Experts</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Mangoceuticals, Inc. as of December 31, 2022 and for the year ended December 31, 2022, included in this prospectus
and the registration statement have been audited by Turner, Stone &amp; Company, L.L.P., Dallas, Texas, independent registered public
accounting firm, as stated in their report dated February 21, 2023, which includes an explanatory paragraph regarding Mangoceuticals,
Inc.&#8217;s ability to continue as a going concern, has been so included in reliance upon the report of such firm given upon their authority
as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Mangoceuticals, Inc. as of December 31, 2021 and for the period from October 7, 2021 (Inception) through December
31, 2021, included in this prospectus and the registration statement, have been audited by M&amp;K CPAS, PLLC, Houston, Texas, independent
registered public accounting firm, as stated in their report dated July 1, 2022, which includes an explanatory paragraph regarding Mangoceuticals,
Inc.&#8217;s ability to continue as a going concern, has been so included in reliance upon the report of such firm given upon their authority
as experts in accounting and auditing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 137; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_008"></span>Changes
in Accountants</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we dismissed M&amp;K CPAS, PLLC, as our independent accountants with the approval of the Audit Committee of the Board
of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
report of M&amp;K CPAS, PLLC on our consolidated financial statements for the period from October 7, 2021 (Inception) through December
31, 2021, did not contain any adverse opinion or disclaimer of opinion, nor was such report qualified or modified as to uncertainty,
audit scope, or accounting principles, except that such report contained an explanatory paragraph regarding Mangoceuticals, Inc.&#8217;s
ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period from October 7, 2021 (Inception) to December 31, 2021, and the subsequent interim period through January 24, 2023 (a)&#160;there
were no &#8220;disagreements&#8221; (within the meaning of Item&#160;304(a)(1)(iv) of&#160;Regulation&#160;S-K)&#160;between us and M&amp;K
CPAS, PLLC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which
disagreements, if not resolved to the satisfaction of M&amp;K CPAS, PLLC, would have caused M&amp;K CPAS, PLLC to make reference to the
subject matter of the disagreement in their report on the financial statements for such periods; and (b)&#160;there were no &#8220;reportable
events&#8221; (as that term is defined in Item&#160;304(a)(1)(v) of&#160;Regulation&#160;S-K).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
provided a copy of this disclosure to M&amp;K CPAS, PLLC and requested that they furnish us a letter addressed to the SEC stating whether
they agree with the above statements. Their letter to the SEC is attached as Exhibit 16.1 to the registration statement of which this
prospectus forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we engaged Turner, Stone &amp; Company, L.L.P. as our independent registered public accounting firm with the approval
of the Audit Committee of the Board of Directors. During the period from October 7, 2021 (Inception) to December 31, 2021, and the subsequent
interim period through January 24, 2023, neither we nor anyone acting on our behalf has consulted with Turner, Stone &amp; Company, L.L.P.
with respect to (a)&#160;the application of accounting principles to a specified transaction, either completed or proposed, or the type
of audit opinion that might be rendered on our financial statements, and neither a written report nor oral advice was provided to us
that Turner, Stone &amp; Company, L.L.P. concluded was an important factor considered by us in reaching a decision as to any accounting,
auditing, or financial reporting issue, or (b)&#160;any matter that was either the subject of a &#8220;disagreement&#8221; or &#8220;reportable
event&#8221; within the meaning of Item&#160;304(a)(1) of&#160;Regulation&#160;S-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 138; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="mj_009"></span>Where
You Can Find More Information</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 (File No. 333-275993) under the Securities Act, with respect to the
securities offered by this prospectus. This prospectus, which is part of the registration statement, omits certain information, exhibits,
schedules and undertakings set forth in the registration statement. For further information pertaining to us and our common stock, reference
is made to the registration statement and the exhibits and schedules to the registration statement. Statements contained in this prospectus
as to the contents or provisions of any documents referred to in this prospectus are not necessarily complete, and in each instance where
a copy of the document has been filed as an exhibit to the registration statement, reference is made to the exhibit for a more complete
description of the matters involved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
may read registration statements and certain other filings made with the SEC electronically are publicly available through the SEC&#8217;s
website at https://www.sec.gov. The registration statement, including all exhibits and amendments to the registration statement, has
been filed electronically with the SEC. If you do not have internet access, requests for copies of such documents should be directed
to Jacob D. Cohen, the Company&#8217;s Chairman and Chief Executive Officer, at Mangoceuticals, Inc., 15110 N. Dallas Parkway, Suite
600, Dallas, Texas 75248.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. Our Annual Report
on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including any amendments to those reports, and other information
that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge on
the &#8220;Investors&#8221; section of our website under the heading &#8220;SEC Filings&#8221;. These filings will be available as soon
as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Our website address is www.mangoceuticals.com.
Information contained on or accessible through our website is not a part of this prospectus and is not incorporated by reference herein,
and the inclusion of our website address in this prospectus is an inactive textual reference only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 139; Value: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: left; width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="fintoc_001"></span>Index
to Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unaudited
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin01_001">Balance Sheets as of September 30, 2023 and December 31, 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin01_002">Statement of Operations for the three and nine months ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin01_003">Statements of Changes in Stockholders&#8217; deficit for the nine months September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin01_004">Statements of Cash Flows for the nine months ended September 30, 2023 and 2022</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin01_005">Notes to Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audited
Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_001">Report of Independent Registered Public Accounting Firm (PCAOB ID NO: 76)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-21</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_002">Report of Independent Registered Public Accounting Firm (PCAOB ID NO: 2738)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-22</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_003">Balance Sheets as of December 31, 2022 and 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-23</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_004">Statement of Operations for the year ended December 31, 2022 and for the period from October 7, 2021 (inception) to December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_005">Statements of Changes in Stockholders&#8217; deficit for the year ended December 31, 2022 and for the period from October 7, 2021 (inception) to December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_006">Statements of Cash Flows for the year ended December 31, 2022 and for the period from October 7, 2021 (inception) to December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-26</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#fin02_007">Notes to Audited Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-27</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 140; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin01_001"></span>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zDYjU6GrMWCi" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20230930_zVyWMYeKP6C1" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20221231_zYeb5CIvceu5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z1a7PtWeKqza" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maACz5hs_zaQwiEjutEYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,747</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryNet_i01I_maACz5hs_zY8qUu1S4Nm2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,581</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0044">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--PrepaidExpenseCurrent_i01I_maACz5hs_zABJqf4nk1Bi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses - related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,382</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,745</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AssetsCurrent_i01TI_maAzvsO_mtACz5hs_zrGLGPw3NpNk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    CURRENT ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,342,710</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,605</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNetAbstract_iB_zZjsbkzgkkqi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FIXED
    ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maTFAzQbh_z0aRK5aAKKmh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net of accumulated depreciation of $<span id="xdx_904_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20230930_zGN68p5CSF08" title="Accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,461</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20221231_zkkfjuK3abJb" title="Accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--FixedAssets_i01TI_mtTFAzQbh_maAzvsO_z9NYwVQcgP8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    FIXED ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:FixedAssets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,420</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:FixedAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsAbstract_i01B_zXInc84rzHg3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OTHER
    ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DepositsAssets_i01I_maOAzOJb_zxCSdkWBarK6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deposits</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maOAzOJb_zOyWa3ESHFoi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use - asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,433</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,241</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherAssets_i01TI_mtOAzOJb_maAzvsO_zvWAFmbE6w11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    OTHER ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,375</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,183</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--Assets_iTI_mtAzvsO_zpAgOHVGk39h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,595,505</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,003,287</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zhAtjoyN6Vq1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIABILITIES
    AND STOCKHOLDERS&#8217; EQUITY</b></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrentAbstract_i01B_zKxemWp3hmMk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_maLCzqFM_zt4NS7mPA5Yg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,675</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedPayrollTaxesCurrent_i02I_maLCzqFM_zjQNXkZzwOM7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payroll
    tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,717</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzqFM_zaqcmVhy0oC2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable to related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0092">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzqFM_zZPEMWIRbubh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0095">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzqFM_zp66yzr2ROd2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    liability - operating lease</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,917</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,725</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzqFM_maLzSb7_zxZpeMqGSHDj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    CURRENT LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,176</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,577</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_z4VAoSgPAo43" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LONG-TERM
    LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLNzaiy_zkN9I6IyPBW6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right-of-use
    liability - operating lease</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,508</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,680</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesNoncurrent_i02TI_mtLNzaiy_maLzSb7_zlOxX7Vcmnr4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LONG-TERM LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,508</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,680</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--Liabilities_i01TI_mtLzSb7_maLASEzyiY_zzWmuOykPhO6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,684</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,257</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzyiY_zu2TO1qBMa6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITMENTS
    AND CONTINGENCIES (SEE NOTE 9)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0116">-</span>&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zw02wubjr2U2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDERS&#8217;
    EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--CommonStockValue_i02I_maSEz6CI_z3hdaSt3F34g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock (par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930_zUhDfwJYJOLg" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zAxRTKMViZL5" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20230930_zbGiGoYJZEt6" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zrI8XhZ9pwj7" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, of which <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_ztWPTpslQhik" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_z67JjirgF5wl" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,789,500</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zeHgVY8RJSs7" title="Common stock, shares issued"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_z5utFBninFqb" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of September
    30, 2023 and December 31, 2022, respectively)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,679</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdditionalPaidInCapital_i02I_maSEz6CI_zRe53sGNVq21" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,013,268</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,628,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEz6CI_zDQMyeNtzlg2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,660,126</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,015,756</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_i02TI_mtSEz6CI_maLASEzyiY_zSCvi3OBfwkb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    STOCKHOLDERS&#8217; EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,354,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,030</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzyiY_zV3Qucvy0VJf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,595,505</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,003,287</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin01_002"></span>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_113_zk7oj94z9jJ4" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_494_20230701__20230930_zvjV0aouhW52" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_49B_20220701__20220930_z3EFXnTomEp8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_492_20230101__20230930_zS25BMUiYny" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_492_20220101__20220930_z1ETVbN5jxR1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            The Three Months</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ended</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            The Three Months</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ended</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            The Nine Months</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ended</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            The Nine Months</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ended</span></p></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--RevenuesAbstract_iB_zkx5rIjS4Clf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--Revenues_i01_maGPzxO2_zPNPb7UPfGN" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">245,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0159">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">487,119</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0161">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CostOfRevenue_i01_msGPzxO2_zb94p7d66ebi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenues</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,193</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0164">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,538</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0166">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--CostOfRevenues_i01N_di_msGPzxO2_zs45UTuHKym4" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Cost of revenues ($<span id="xdx_90E_eus-gaap--CostOfRevenue_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4qkJI6yzVab" title="Cost of revenues - related party"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,255</ix:nonFraction></span> of related party cost of revenues for the year
    ended December 31, 2022)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0168">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0170">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CostsAndExpensesRelatedParty_i01_msGPzxO2_zL0kulF2yj4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenues - related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,378</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0176">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,663</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0178">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--GrossProfit_i01T_mtGPzxO2_maOILz45o_zcNFsTvhrgV8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    profit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">144,589</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">288,918</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0183">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zet1O3eNlUcg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzqBb_zWeRGxG8DJxj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,944,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">991,825</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,939,761</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,727</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpenses_i01T_mtOEzqBb_msOILz45o_zeeteMmLR7cf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,944,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">991,825</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,939,761</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,727</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtOILz45o_maILFCOz6D9_z2v7EeEzZwtc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,799,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">991,825</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,650,843</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,319,727</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zwckGOoGANk9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    (income) expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_ecustom--ImputedInterestRelatedParty_i01N_di_maNIEzQ60_zeeNOOynn03j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest - related party</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0210">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:ImputedInterestRelatedParty" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,090</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="MGRX:ImputedInterestRelatedParty" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,473</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:ImputedInterestRelatedParty" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,673</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NonoperatingIncomeExpense_iNT_di_maILFCOz6D9_mtNIEzQ60_zXfi7ywZyQwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other (income) expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0215">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,090</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,473</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,673</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_maNILzpYd_mtILFCOz6D9_zlUnHzopb2J3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,799,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">994,915</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,644,370</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,324,400</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iN_di_msNILzpYd_zB01S0QFNV5f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0225">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0226">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0227">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0228">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_iT_mtNILzpYd_zc0YM7aGFOe8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,799,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">994,915</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,644,370</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,324,400</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAbstract_iB_zIFDqRR0yrk7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted loss per share</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted loss per share</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20230701__20230930_zm3ZzjrPED3" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20230701__20230930_zUOx39Duw2Ea" title="Earnings per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.11</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20220701__20220930_zzy4WWRhswag" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220701__20220930_zmXF9rl3OBK6" title="Earnings per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.10</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_c20230101__20230930_z0DTRsqif2J5" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20230101__20230930_zWkX1f9IdZkc" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.45</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--EarningsPerShareBasic_c20220101__20220930_zMBK87CH9iM9" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_c20220101__20220930_zqpW1nj3acab" title="Earnings per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasicOtherDisclosuresAbstract_iB_zW0XEnWyaYA7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average number of shares outstanding</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230701__20230930_zGYEYce1Pm7a" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230701__20230930_z8wDHWrrNOe5" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,923,588</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220701__20220930_zTJ8oFnveAwk" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220701__20220930_zgTQcVmLcnlj" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,049,100</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20230930_zQR66IiytLRf" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20230930_z4g8Kv6r3AH9" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,923,461</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20220930_z9IoWyAyrXcg" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20220930_z1FYyjDoUiza" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,913,388</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin01_003"></span>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement
of Changes in Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Nine Months Ended September 30, 2023 and 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zJITlnhHr6a2" summary="xdx: Statement - Statement of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zEm3sVvo5xN9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zU3bYJVvX45e" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zg0pv0EWYMN" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_4BD_z84ijkcMeiU7" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Additional</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid-in</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></p>
                                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&#8217;</span></p>
                                                                      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Deficit)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_435_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zHpP3eBjTuNh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 35%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjrztwo39576" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,720</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zW1lzVrBb9Sf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">889</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0286">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">889</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zMQlDsu579e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,599</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,599</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zv4R5p4P316a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSv2WUW6JOm" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,070</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,300</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,430</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zCiXxTUPA8L4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,583</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,583</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zOHZYpYLsS29" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zteoQO7p6Opg" title="Issuance of common stock for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,250,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">224,775</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_zssb6aGfpNci" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">310,185</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">310,185</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20220701__20220930_eus-gaap--StockholdersEquity_iS_zIRoPnFf6Eij" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf8lkVCk4lCl" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,250,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,428</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">347,485</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">119,032</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zWs7SItIgMc6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0325">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,202</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,202</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zXxdKZEXzLYi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfvJ3QqbKGFc" title="Issuance of common stock for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">265,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">264,973</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0332">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zY8OeO8rTnof" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Options and warrants vested for services
</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0337">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,817</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,817</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zOgMhTSoPXWl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Issuance of common stock for cash
</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUGdBPqh1ct5" title="Issuance of common stock for cash, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,350</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0344">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_z1b77SgyPaf2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0350">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">994,915</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">994,915</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_438_c20220701__20220930_eus-gaap--StockholdersEquity_iE_zKyg4JoSOJ4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx5943UewGac" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,015,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,202</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,164,770</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,342,400</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">823,572</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43F_c20230101__20230331_eus-gaap--StockholdersEquity_iS_zyZfVL3aYLIb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    December 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrP4v2oQH4y5" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,628,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,015,756</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,030</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zfEt8G87YnJe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6iF34fsnxYd" title="Issuance of common stock for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">700,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,930</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">700,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z21wjY72MQr8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z09ujDk0HL18" title="Issuance of common stock for cash, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,999,875</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_z8eBB408kwa5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,760</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0384">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,760</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zV6ABYL0qEi1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    and warrants vested for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,271</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,271</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_z6MKPaRaAYr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0392">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,560,885</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,560,885</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_437_c20230401__20230630_eus-gaap--StockholdersEquity_iS_zKueoLe3gqti" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    March 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKzvaFWOWeyf" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,315,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,532</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,394,285</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,576,641</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,819,176</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_z3iP0E5Sx1ea" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLHnLOlk30Ag" title="Issuance of common stock for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">386,963</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">387,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_z4dnHOKeAGNl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0411">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,233</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,233</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zj457PcEFe38" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    and warrants vested for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,271</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,271</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--StockIssuedDuringWarrantsExercisedForCashValue_ziKkqrVqAGni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    exercised for cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--StockIssuedDuringWarrantsExercisedForCashShares_pid_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwMnAcQ4AAVg" title="Warrants exercised for cash, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:StockIssuedDuringWarrantsExercisedForCashShares" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,024,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:StockIssuedDuringWarrantsExercisedForCashValue" contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:StockIssuedDuringWarrantsExercisedForCashValue" contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,024,398</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:StockIssuedDuringWarrantsExercisedForCashValue" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,024,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zicm6SbY1Z5l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,284,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012023-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,284,025</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43D_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zOJLBADrlYO4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    June 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zazHZz1QgG7" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,714,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,671</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,861,684</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,860,666</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,002,689</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_436_c20230701__20230930_eus-gaap--StockholdersEquity_iS_zCAHZFYpod1f" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIT1RffBdiU8" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,714,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,671</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,861,684</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,860,666</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,002,689</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zrmcLVgTnzdl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0CFL4w8uR0f" title="Issuance of common stock for services, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,742</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,750</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zRzD363JeZJc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    and warrants vested for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0454">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,842</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0456">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,842</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_z6wpjXDMeOP" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0459">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0460">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,799,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,799,460</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_438_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zqUSCPHFwYt" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbKzG7ECbO4i" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,789,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,679</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,013,268</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,660,126</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,354,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43E_c20230701__20230930_eus-gaap--StockholdersEquity_iE_zjzloeuGTFX" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBQKgSr9EVO7" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,789,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,679</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,013,268</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,660,126</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,354,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin01_004"></span>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_112_zW70w30cdJw8" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_497_20230101__20230930_z9bi10neQp6i" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_494_20220101__20220930_z3dCLgOZIjF2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the Nine Months</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ended</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            the Nine Months</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ended</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z9zGvM07YQKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM OPERATING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--NetIncomeLoss_i01_maNCPBUzpYe_z24UDKcLwPFf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,644,370</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,324,400</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zQsvNVOYKNVa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Depreciation_i02_maNCPBUzpYe_zLJbgfZH8dc5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,598</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0488">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--IssuanceOfCommonStockForServices_i02_maNCPBUzpYe_zlW2WRLu2p48" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of common stock for services</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:IssuanceOfCommonStockForServices" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,171,750</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:IssuanceOfCommonStockForServices" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">490,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_i02_maNCPBUzpYe_zmm7TrCZ7Kp1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Imputed
    interest expense</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,473</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,673</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--ShareBasedCompensation_i02_maNCPBUzpYe_znQmz5i2GXRi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested for stock-based compensation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,384</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,817</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--WarrantsForServiceCancelled_i02_maNCPBUzpYe_zQ5eZ54nQw5b" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Warrants for service cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i01B_zIxmoOfcFk0j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Increase)
    decrease in operating assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInDepositOtherAssets_i02N_di_msNCPBUzpYe_zhjxcAU9vQPf" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Rent deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"/><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUzpYe_zvgTVEO1qHdf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,581</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0509">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msNCPBUzpYe_zQrAaePZBl43" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,637</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,719</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInOperatingLeaseRightOfUseAsset_i02N_di_msNCPBUzpYe_zWdUbSoFxP6k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,808</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0515">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i01B_zVzUsJZiRv3i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Decrease)
    increase in operating liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i02_maNCPBUzpYe_zPitR5EUbMv2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable and accrued liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,384</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0521">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maNCPBUzpYe_ztkobuMH1yU" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right of use liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">41,980</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0524">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i02_maNCPBUzpYe_zPRs37q3wGt3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payroll
    tax liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,483</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_maCCERCzN1I_mtNCPBUzpYe_zOLgPT678qb7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH USED IN OPERATING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,299,634</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">696,958</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zkJKguiSF3Q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM INVESTING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzU08_zGgFQHHPg2p9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchases
    of property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,519</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,531</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzU08_maCCERCzN1I_z8e348V0ENFi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH USED IN INVESTING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,519</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,531</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zA84wm0qjUe7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzEEt_zKh77JKEX599" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from borrowings on notes payable to related parties</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0544">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msNCPBUzEEt_zWqhLYIn4gc2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    on notes payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0548">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_msNCPBUzEEt_zjKv1AwHhBG8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    on notes payable - related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,070</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzEEt_zy4yBaiGlcw5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from exercise of warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,024,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzEEt_z5abojC3uxt2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from sales of common stock for cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,500</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzN1I_mtNCPBUzEEt_zFu22O9wQqH" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    CASH PROVIDED BY FINANCING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,857,040</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,550,430</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzN1I_zFSPBaqIossa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NET
    INCREASE IN CASH AND CASH EQUIVALENTS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">553,887</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">850,941</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAbstract_iB_zYFTlZGnSSJ6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    AND CASH EQUIVALENTS:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zqHgcL3AZ6Xe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beginning
    of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zS7rANveHWX1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">End
    of period</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,747</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">873,491</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zzsDTRM5X6cb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    disclosure of cash flow information:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxesPaid_i01_zo5XIlOfW0Ea" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0578">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaid_i01_zCPQORDnUj18" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0581">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin01_005"></span>MANGOCEUTICALS,
INC.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
and Nine Month Periods Ended September 30, 2023 and September 30, 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zusKlb0PZE3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_82C_z7mOY4GaihEh">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Inc. (&#8220;Mangoceuticals&#8221; or the &#8220;Company&#8221;), was incorporated in the State of a Texas on <span id="xdx_90D_edei--EntityIncorporationDateOfIncorporation_c20230101__20230930_zEyjqjOgeTk5" title="Date of incorporation"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">October 7, 2021</ix:nonNumeric></span>, with the
intent of focusing on developing, marketing, and selling a variety of men&#8217;s wellness products and services via a telemedicine platform.
To date, the Company has identified men&#8217;s wellness telemedicine services and products as a growing sector in the most recent years
and especially related to the areas of erectile dysfunction (&#8220;ED&#8221;). In this regard, Mangoceuticals has developed and is commercially
marketing and selling a new brand of ED product under the brand name &#8220;Mango.&#8221; This product is produced at a compounding pharmacy
using a proprietary combination of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved ingredients and is available to patients
on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently
marketing and selling this new brand of ED product exclusively online via its website at <span style="text-decoration: underline">www.MangoRx.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial
Public Offering. </i>In March 2023, the Company completed an initial public offering (the &#8220;IPO&#8221;), in which the Company issued
and sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQVOBmR5n01b" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-282023-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares of authorized common stock for $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQA3db6z22je" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zePQZfNAYq1h" title="Net proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-02-282023-03-31_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">4.35</ix:nonFraction></span> million, after deducting underwriting
discounts and commissions, and offering costs. At the same time, and as part of the same registration statement, but pursuant to a separate
prospectus (the &#8220;Resale Prospectus&#8221;) the Company registered the sale of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zHxlzn0wd4Ad" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-02-282023-03-31_custom_ResaleProspectusMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,765,000</ix:nonFraction></span> shares of common stock, including <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zGJPlcYPm1Lb" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-02-282023-03-31_custom_ResaleProspectusMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span>
shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with an exercise price of
$<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zEenTGcvHOu4" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-31_custom_ResaleProspectusMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8uc8ZVVcA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_82F_zvOF5ANRGewa">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoM89gSRtiC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z4InLRg3CQJ3">Basis
of Preparation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) under the accrual basis of accounting. These financial statements are presented in
U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The
accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto
for the years ended December 31, 2022 and 2021 included in the Company&#8217;s Registration Statement on Form S-1 (Amendment No. 4),
filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2023 (the &#8220;Form S-1&#8221;). In the opinion
of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position
and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim
periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the Form S-1 have been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zt74Z5NYOB02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z5f5eUmEVx45">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority
of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insures a total cash balance
of up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zCJdFQyH08v8" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits and the excess would be
at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_z8gGFZgDUiMg" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8YyU761TWmg" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents at September 30, 2023 and December 31, 2022
and the Company has not experienced any losses related to uninsured deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zeL0KlYdTD41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zJCvRNouYZcd">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
740, <i>Income Taxes</i>. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the
temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income
in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount
that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 145; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPyf1Znyl1L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zUdGq2W2Elxi">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted
earnings per share (&#8220;EPS&#8221;) on the face of the statement of operations. Basic EPS is computed by dividing net loss available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. For diluted net loss per share purposes, the Company
excludes stock options and other stock-based awards, including shares issued as a result of option and warrant exercises, whose effect
would be anti-dilutive, from the calculation. There were <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zj4qWpLuazEl" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zswAe54AWVKl" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> options, <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5mOXkQDoyXd" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,063,000</ix:nonFraction></span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPsAaRYHEyLe" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> warrants and no derivative
securities outstanding as of September 30, 2023 and December 31, 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zVFAYw6EG7ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGVKYnO6DQV2">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will,
differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvGsztSKuih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zEocmiercZQj">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, <i>Fair Value Measurement</i>, which provides guidance with respect to valuation techniques to be utilized in the determination
of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach
(present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement
cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three
broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&#160;&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGc2F4ugj03e">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zQlxyzjNg5Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSQun2tac6T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zL77S0uwFqaj">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zv5AdiU3SWYi" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-09-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>) to five (<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zOzywZjQtBke" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-09-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>) years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 146; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zc4QLMcybnDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zXyxnK0PyS9b">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had
no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmn4mCXQx4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zXaQfJUDULfh">Black
Scholes Option Pricing Model</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVvKL7gtheDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zQSvLXfN6N13">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211;
40)</span>&#8221;</i>. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="MGRX:RelatedPartiesPolicyTextBlock"><p id="xdx_84B_ecustom--RelatedPartiesPolicyTextBlock_ztEzXVMCZP7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zNTKqI17OSA1">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of FASB ASC 850, <i>Related Party Disclosures</i> for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825&#8211;10&#8211;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 147; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zGcnex4hEIPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLP4fB0Ithn9">Stock-Based
Compensation</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB ASC 718 <i>Compensation - Stock Compensation</i> (&#8220;ASC 718&#8221;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zq6kwL7zRzYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zVuB9u7zNZ3g">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our
websites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated
through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The
transaction price in the Company&#8217;s contracts with customers is the total amount of consideration to which the Company expects to
be entitled in exchange for transferring products or services to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#8217;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#8217;s completion of its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (&#8220;Doctegrity&#8221;) to provide online
telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii)
the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs
for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its
sole discretion, sets all listed prices charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (&#8220;Contracted Pharmacy&#8221;),
which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts
that include sale of prescription products and to fill prescriptions that are ordered by the Company&#8217;s customers for fulfillment
through the Company&#8217;s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer&#8217;s
prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using
the Company&#8217;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites
for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 148; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_z2OaZ4CAzi51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zHrWce5thqYb">Inventories</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or market with cost being determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. The Company writes down its
inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated
market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those
projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zN9k9dblTWd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z6n4niJJiHS4">Marketing
and advertising</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations
$<span id="xdx_904_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230930_zH0FTQGqUCal" title="Marketing and advertising expense"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,633,528</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220930_zlmyhEi4oUcc" title="Marketing and advertising expense"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> for the nine months ended September 30, 2023 and 2022. We did not begin advertising until November 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zkZnNZ0OtbVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuSVPpc9WSU7">Subsequent
events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events.
The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 10).</span></p>

</ix:nonNumeric><p id="xdx_858_zX8ptlnZnK7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="MGRX:PrepaidExpensesAndDepositsTextBlock"><p id="xdx_802_ecustom--PrepaidExpensesAndDepositsTextBlock_zM0A1yqHFbj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_z0AGLu4ZJqz9">PREPAID EXPENSES AND DEPOSITS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2023 and the year ended December 31, 2022, and in association with the Master Services
Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy
as a retainer to be credited towards future product sales. As of September 30, 2023 and December 31, 2022, the balance was $<span id="xdx_90A_ecustom--PrepaidExpensesRelatedParty_iI_c20230930_zRNRpL1WIlVl" title="Prepaid expenses related party"><ix:nonFraction name="MGRX:PrepaidExpensesRelatedParty" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,382</ix:nonFraction></span> and
$<span id="xdx_901_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_zVa22T2R9x0a" title="Prepaid expenses related party"><ix:nonFraction name="MGRX:PrepaidExpensesRelatedParty" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,745</ix:nonFraction></span>, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $<span id="xdx_90F_eus-gaap--SecurityDeposit_iI_c20221001_z5nki9dG1w5j" title="Security deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2022-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_ztEqO1cYDDqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82D_zDL0HzKljptd">INVENTORY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company purchased inventories related to
promotional merchandise intended to be sold online. As of September 30, 2023 and December 31, 2022, the inventory balance was $<span id="xdx_901_eus-gaap--InventoryNet_iI_c20230930_zmkp1nJiz2z1" title="Inventory"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,581</ix:nonFraction></span>
and $<span id="xdx_908_eus-gaap--InventoryNet_iI_dxL_c20221231_zF1dXx8jlO8f" title="Inventory::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0701">0</span></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlBxZ5Yj2RL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82C_zh0O9PLWN7td">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2023, the Company acquired custom product packaging equipment totaling $<span id="xdx_900_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20230101__20230930_zCyS9eNzto62" title="Property acquired value"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,519</ix:nonFraction></span>. Depreciation expense
for the nine months ended September 30, 2023 and 2022, was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20230930_zr78gp1RqXUj" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,598</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--Depreciation_dxL_c20220101__20220930_zU4Ll2Fvvdpl" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0709">0</span></span>, respectively. Total net property and equipment was $<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230930_zXg57NZXRzWk" title="Property plant and equipment net"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,420</ix:nonFraction></span>
and $<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zLkhUOZwiQ" title="Property plant and equipment net"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></span>, as of September 30, 2023 and December 31, 2022, respectively.</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zonsr7B2iWOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zusoPAkZbQZ" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230930_zO69tluKu5nh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/>
2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zobx2ETRm9G" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zVsot07MGY0d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-09-30_custom_ComputersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zkhBR20if40i" style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-09-30_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">119,819</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zs0GDdoo2Nsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less accumulated depreciation:</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,461</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zbu3rt5Ghehe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zVBL8PSLs7Vi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 149; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWsqC9YWJni7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_826_zNqFaFcaFp2f">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021 and March 18, 2022, the Company received advances of $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zPfcDRhHOYu8" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-12-102021-12-10_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,200</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220318__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zGu30BeKGR7h" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-03-182022-03-18_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>, respectively, for a total of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zxWQITIbCeNd" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2023-01-012023-09-30_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span> from
its previous majority shareholder, American International Holdings Corp (&#8220;AMIH&#8221;), in order to cover various general and administrative
expenses. The advances bear no interest and are due on demand upon the Company&#8217;s ability to repay the advances from either future
revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), an entity owned and controlled
by Jacob D. Cohen, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors, entered into and closed a Stock
Purchase Agreement (the &#8220;SPA&#8221;) for the purchase of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zAjgC1umwcje" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span> shares of the outstanding common stock of the Company which
were then held by AMIH, which represented <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_z2qgLsAV0V3c" title="Equity ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-06-16_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>% of the Company&#8217;s then outstanding shares of common stock, in consideration for $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zL0xCLZZtY9i" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span>.
Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zxJcYaEaPQSl" title="Repayments of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-06-152022-06-16_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span> advanced from AMIH to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2022, the Company received an advance of $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zmV2yXiMmhL4" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-06-282022-06-29_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z2aac0KzVyPi" title="Repayments of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-08-172022-08-18_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z4u8ccAnseSa" title="Repayment of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span>
as of December 31, 2022. This amount was paid in full on April 4, 2023 and the amount owed to Cohen Enterprises was $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z4LBINMC4F13" title="Proceeds from related party"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zeCK7UyAaz9b" title="Proceeds from related party"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span> as
of September 30, 2023 and December 31, 2022, respectively. Previously recorded imputed interest equal to eight percent (<span id="xdx_905_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zrixixkFFYk2" title="Imputed interest percentage"><ix:nonFraction name="MGRX:InterestExpenseRelatedPartyPercentage" contextRef="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%) per annum,
or a total of $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_znUmZuSatg48" title="Related party transaction purchases"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,232</ix:nonFraction></span> against the related party advances, was canceled and reversed for the nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company received an advance of $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zJBH0cNK6C76" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-12-102021-12-10_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70</ix:nonFraction></span> from ZipDoctor, Inc., a then wholly-owned subsidiary of its then majority shareholder,
AMIH, which was used to open and establish the Company&#8217;s bank account. The advance bears no interest and is due on demand upon
the Company&#8217;s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May
24, 2022 and the amount owed to ZipDoctor was $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zwlgEno65Sd3"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2023-01-012023-09-30_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zfHN6nTio4X1"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> as of September 30, 2023 and December 31, 2022, respectively. Imputed interest
at eight percent (<span id="xdx_906_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zijD1xghzHQ3" title="Imputed interest percentage"><ix:nonFraction name="MGRX:InterestExpenseRelatedPartyPercentage" contextRef="From2023-01-012023-09-30_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%) per annum on this advance was insignificant and therefore was not calculated, recorded or paid during the time
the advance was outstanding from December 10, 2021 to May 24, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information on related party prepaid expenses see Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zBbTSUkJpFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82B_zy2feB68R9Aj">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_z2AXWunyFFj5" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></span>. The
note bears no interest and was due in three payments of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230101_zvLZ4AL6Q227" title="Debt instrument periodic payment"><span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230201__20230201_z1iYVRWVlIhc" title="Debt instrument periodic payment"><span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20230301__20230301_zdfv0d1DhGQ9" title="Debt instrument periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-01-012023-01-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-02-012023-02-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-03-012023-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> each January 1, 2023 through March 1, 2023, a $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_zhko9I7tSOo7" title="Debt instrument periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-04-012023-04-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,630</ix:nonFraction></span> payment on April
1, 2023 and a final payment on May 1, 2023 for the outstanding balance. The January 1 and March 1, 2023 payments were timely made and
on March 23, 2023, the Company elected to pay off the remaining balance of $<span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20230323__20230323_zsWpalWZFWU5" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-03-232023-03-23" format="ixt:numdotdecimal" decimals="0" unitRef="USD">63,260</ix:nonFraction></span>. The outstanding balance as of September 30, 2023
and December 31, 2022 was $<span id="xdx_90E_eus-gaap--NotesPayable_iI_dxL_c20230930_zgYHm7K6WXO1" title="Notes payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0779">0</span></span> and $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20221231_zq7Jk5Wi8av3" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></span>, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxJFk2oXgPz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_822_zCtGAgReVxac">CAPITAL STOCK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to<span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930_zLpoTlhGhTbh" title="Preferred stock, shares authorized"> <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zvbUkDwjBDR" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of &#8220;blank check&#8221; preferred stock, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20230930_zSQGV2nPOM26" title="Preferred stock par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zUJm7dbb3Kw7" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value. All preferred
stock was undesignated as of September 30, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 150; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20230930_zS2JRQIOeAue" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zTZFOqS9Fmm3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20230930_zNdX2GBL0o3l" title="Common stock par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_z5vuSDeyThtg" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share, of which <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20230930_zuRDuZRSy1X7" title="Common stock shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230930_zd0lPBuR3MNk" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,789,500</ix:nonFraction></ix:nonFraction></span></span> shares were issued
and outstanding at September 30, 2023 and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20221231_zQoPItDPGfFl" title="Common stock shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zcWGcKmXxaRc" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></ix:nonFraction></span></span> were issued and outstanding at December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2022, the Company began a private placement of up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220808__20220808__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrlPXNlALsL1" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-08-082022-08-08_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> of units (the &#8220;Units&#8221;), each consisting of one
share of common stock (the &#8220;Shares&#8221;) and a warrant to purchase one share of common stock (the &#8220;Warrants&#8221;), at
a price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zNVESgylncBi" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per Unit. The Warrants have a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_uUSDPShares_c20220808_zGVDFiodftO7" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0813">five-year</span></span> term and an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220808_zldAAiy3KWRl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share, for which cash would need to
be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise the Warrants are
exercisable on either a cash basis or a cashless basis. The offering of the Units is referred to as the &#8220;Offering.&#8221; The Units
were offered by the Company only to investors that qualify as &#8220;accredited investors,&#8221; as that term is defined in Rule 501(a)
of Regulation D promulgated by the SEC under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The price of
the Units was determined by the Company and such price did not necessarily bear any relation to the book value or other recognized criteria
of value of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering commenced on August 8, 2022 and the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220808__20220808_zjwMzldA73Kl" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-08-082022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Units at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zW4DcNpuw8ca" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per Unit to 23 investors in exchange for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220808__20220808__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIVsdZIyTU3" title="Proceeds from investors"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2022-08-082022-08-08_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>
in gross proceeds from the investors, and subsequently issued the investors <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220816__20221231_zFbyWJ5VNGnj" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-08-162022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Shares and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z24kmFQbpDp8" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Warrants between August 16,
2022 and December 31, 2022. As of December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zHrhxkBa1f76" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,299</ix:nonFraction></span>. Because the
Warrants vested immediately the fair value was assessed on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (&#8220;PHX&#8221;), which is owned by Peter &#8220;Casey&#8221;
Jensen, who is a member of the Board of Directors of AMIH and a related party. Pursuant to the Consulting Agreement, PHX agreed to provide
consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was
for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach
30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX
<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVw3BrO6iXg8" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares
were valued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPLB7zBNysC6" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0pzosJVQp79" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,921</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#8220;Elliott&#8221;), currently a professional football
player in the National Football League, to provide consulting and general business advisory services as reasonably requested by the Company
during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement by either
party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services
under the agreement, the Company issued Elliott <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcZUOwmODG1j" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction> </span>shares of restricted common stock. The agreement contains customary confidentiality
and non-solicitation provisions. The shares were valued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrSeUjugV734" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQKy6ySlzhg9" title="Shares issued value">$<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,842</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#8220;Sandler&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrwMYTDmxp4d" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span>
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJoEzdGBPqMj" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction> </span>per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwFsi4ymeFgg" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,784</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#8220;Chou&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zO3SuRX8OqKa" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued
at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVGopmaDZ5El" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPLTXeXrg1T" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 151; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP;
(c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023 and the
year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing
advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing
such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services
and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys,
CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1,
2022) has served as an Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zvc0FVqV6z01" title="Shares issued in consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zmuWIHwFBSik" title="Paid in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in cash, payable as follows: <span id="xdx_903_eus-gaap--CommonStockConversionFeatures_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zbIng9aiQGwj" title="Settlement description"><ix:nonNumeric contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember" name="us-gaap:CommonStockConversionFeatures">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023</ix:nonNumeric></span>. We also agreed to include the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAPrBDthzOIl" title="Shares new issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein, and to reimburse
Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s activities under the agreement, including
the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification
obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zTMevqJaXP06" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-30_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zWRLgqMXQxm3" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,842</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company executed a Summary of Terms and Conditions (&#8220;Offer Letter&#8221;) with Gene Johnston (&#8220;Johnston&#8221;)
appointing Johnston to serve as the Company&#8217;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to
the Offer Letter, the Company issued Johnston <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr1zHL1GVOah" title="Restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of the Company&#8217;s restricted stock and vest over a 6-month period at
the rate of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxiMd9F1QsNc" title="Shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares per month with the first <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zotYiUMtgZc8" title="Shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-11-012022-11-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares vesting on November 1, 2022. Johnston is eligible to participate in
any of the Company&#8217;s future sponsored benefit plans, including but not limited to, health insurance benefits, 401k, stock option
or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of the month following 105 days
of Johnston&#8217;s start date. Johnston is also eligible to receive equity incentive grants or cash bonus awards as determined by the
Company&#8217;s Board (or a committee of the Board) in their sole discretion. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z3HgTvHx8Fb7" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-01_us-gaap_RestrictedStockMember_srt_ChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of
$<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221001__20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_znkdrhTiZosc" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,763</ix:nonFraction></span>. Mr. Johnston is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company entered into Director Offer Letter agreements with each of Alex Hamilton (&#8220;Hamilton&#8221;), Dr.
Kenny Myers (&#8220;Myers&#8221;) and Lorraine D&#8217;Alessio (&#8220;Alessio), compensating each of them with <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrt8jMP62pUl" title="Restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of restricted
common stock (for a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTliGhmLeLod" title="Restricted stock issued net"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000</ix:nonFraction></span> shares) (the &#8220;Director Shares&#8221;). The Director Shares were issued under the Company&#8217;s
2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;), with the following vesting schedule: 1/3 of the Director Shares vested on October
14, 2022, and the remaining Director Shares will vest annually in one-third increments commencing on the first anniversary date thereof.
The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zIgs3klM3J6a" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zwnFkWkVJHIj" title="Shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,881</ix:nonFraction></span>. These individuals are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued its Project Manager, Joan Arango, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221014__20221014__srt--TitleOfIndividualAxis__custom--JoanArangoMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zobh0oSN3ckd" title="Restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-10-142022-10-14_custom_JoanArangoMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction> </span>shares of restricted common stock under the 2022 Plan.
The shares were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#8217;s President
and Chief Operating Officer, Jonathan Arango. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_znf3MuiGjJEb" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_z2FaGvk0Lzk6" title="Shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,204</ix:nonFraction></span>. Ms. Arango is a related
party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 152; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#8220;White Unicorn&#8221;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztBTF3tqU1o" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAYAz4ZWmICj" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember_zL2NT57lZuO5" title="Shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,816</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (&#8220;Global&#8221;) to provide marketing
services as reasonably requested by the Company during the term of the agreement, which was for six months unless otherwise earlier terminated
due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company issued Global <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zngwb1LKBlcl" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of restricted common stock. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcuKaVFvj909" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zU3J3htYDVOa" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,816</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#8220;Chartered Services&#8221;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which was for six months unless otherwise earlier terminated due to
breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for
agreeing to provide the services under the agreement, the Company agreed to pay Chartered Services $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zx7CH4gNLmXi" title="Paid in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-12-212022-12-21_custom_CharteredServicesLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> in cash (<span id="xdx_902_eus-gaap--CommonStockConversionFeatures_c20221221__20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zT4rTgtD7Kt6" title="Settlement description"><ix:nonNumeric contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember" name="us-gaap:CommonStockConversionFeatures">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000</ix:nonNumeric></span> shares of restricted common
stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zF6RvCTc1ZR" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for
a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcBn2lQVoBc5" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,039</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#8220;DojoLabs&#8221;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $<span id="xdx_90F_eus-gaap--Cash_iI_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3K5xhtyoLT3" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash and issued DojoLabs <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzQxVV2oefRg" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of restricted common
stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains
customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHJFCjUwYnVh" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction> </span>per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeGvMAZ7BfFl" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#8220;Bethor&#8221;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuSqpcK1p1Fb" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of restricted common stock with registration rights. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z3bDENf1MwXd" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaXZhJWAS4J8" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the
&#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#8217;s development of new business ventures
and strategic planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#8220;Dr. Rudman&#8221;)
and Mr. Jarrett Boon (&#8220;Mr. Boon&#8221;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 153; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. Rudman&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Dr. Rudman
Consulting Agreement&#8221;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zhPwIMHLM0ge" title="Shares issued"> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span>
shares of the Company&#8217;s restricted common stock, pay Dr. Rudman $<span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zQtXtbJBL9da" title="Compensation expense"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests
of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zws41mpvw9Bf" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a total
of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zkHNOVi3zuTa" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Boon&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Mr. Boon
Consulting Agreement&#8221;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zTIbRW5h7mDb" title="Shares issued"> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction> </span>shares
of the Company&#8217;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties to the Company in service
on the Advisory Board. The shares were valued at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zYngiV2qwhpb" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zyi1tD0EkqB8" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of each agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, <span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXwL6xjhuHD7" title="Settlement description"><ix:nonNumeric contextRef="From2023-01-242023-01-24_us-gaap_RestrictedStockMember" name="us-gaap:CommonStockConversionFeatures">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</ix:nonNumeric></span> Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zKOMGHOyZ0Zf" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-24_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per
share for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zJL5xzwYHG6j" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-242023-01-24_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2023, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6NmiXb1rp39" title="Number of shares sold"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-03-222023-03-22_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares of its common stock at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCSVEUzUmg46" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-03-22_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share to investors in connection with its
IPO for gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW9mIS5mZDSb" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-03-222023-03-22_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zlkoPRj84cA2" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-24_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_ztgw9NX9Epu6" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-24_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230424__20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zBJjGiLGI8rk" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-04-242023-04-24_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zX1a5nQTrfzf" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zycNosj9zZve" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zLMSbslYysAe" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zlSUiou18w68" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_z7tjBUlDUvkj" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction> </span>per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zJh7uyEfi7V8" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zE0ce4Edjok5" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zYV9Jg85otHa" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction> </span>per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zmyOLcs22zxj" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFourMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 154; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_ztVdf344iDa6" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zkHZTlmoZVg5" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_z31qIAQm4iJc" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFiveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zRrNgeFtvh46" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-26_custom_PrivatePlacementWarrantSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zyPwh7czQSu9" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-04-26_custom_PrivatePlacementWarrantSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230426__20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXvXH59NxE5k" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-04-262023-04-26_custom_PrivatePlacementWarrantSixMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z5IRNo1G3Fhk" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-05-01_custom_PrivatePlacementWarrantSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of common stock with an exercise price of
$<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zue27ivEjLd" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-05-01_custom_PrivatePlacementWarrantSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zG0ZfLpziaqk" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantSevenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the &#8220;Employment Agreement&#8221;).
The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending
through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party
provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for
Mrs. Hammer to receive an annual salary of $<span id="xdx_906_eus-gaap--PaymentsToEmployees_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zTbCJliE0LS6" title="Annual salary"><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="From2023-05-012023-05-01_custom_HammerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> per year. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zHCBBu0WVZ1i" title="Share based compensation arrangement by share-based payment award, description"><ix:nonNumeric contextRef="From2023-05-012023-05-01_custom_HammerMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The Employment Agreement also required the Company to grant Mrs. Hammer
a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase
an additional 150,000 shares of common stock of the Company, under the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;Plan&#8221;),
with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company&#8217;s common stock on
the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and
which exercise price was $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_uUSDPShares_c20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zp0vnnuI3XMl" title="Exercise price"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-05-01_custom_HammerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share, with options to purchase <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zbgtJsgZOqOd" title="Shares vesting"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-05-012023-05-01_custom_HammerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares vesting every twelve months that the Employment Agreement
is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate
option agreement entered into by the Company and Mrs. Hammer.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (&#8220;Redlime&#8221;) to provide software
development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services
under the agreement, the Company agreed to pay Redlime $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvOO9uhDx6sa" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span> in cash and issue Redlime <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zw9f3qurBVT" title="Shares new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180,000</ix:nonFraction></span> shares of restricted common stock.
The shares were valued at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zo6V6zDRToRl" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9ttdPeUMUCi" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">180,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (&#8220;Mr. Andrew&#8221;), an independent, non-Board member and non-Company
employee, to the Advisory Board. In connection with Mr. Andrew&#8217;s appointment to the Advisory Board, the Company entered into an
Advisor Agreement (the &#8220;Mr. Andrew Consulting Agreement&#8221;), dated effective May 25, 2023, with Mr. Andrew, whereby the Company
agreed to issue Mr. Andrew <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zKjdwYhcKJ1i" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of the Company&#8217;s restricted common stock under the 2022 Plan and to reimburse Mr. Andrew
for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s
requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrLZJo9pUXea" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction> </span>per share
for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpR0ypG570oa" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Consulting Agreement with Major Dodge (&#8220;Major&#8221;), to provide acting and production related
services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of
the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued Major <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zhQrjX8GIiof" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction> </span>shares of restricted common stock under the 2022 Plan. The
agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXzGz0vF7R0j" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></span> per share for a total of
$<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTTl3GIc5uM6" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (&#8220;New To The Street&#8221;),
to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which was for
3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company
issued New To The Street <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zarrpgFH0yF5" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHZHYZL1B5dj" title="Debt instrument periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span>.
The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEy71t101Wx4" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></span> per share for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJpVghc0jHmk" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 155; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zy2APh38F328" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-06_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zDuAaoCG03pg" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-06_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230606__20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z0R8K0WoNDul" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-062023-06-06_custom_PrivatePlacementWarrantOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z0AtNk7ZzSrc" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-07_custom_PrivatePlacementWarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zCihRc46gTQd" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-07_custom_PrivatePlacementWarrantTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230607__20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z5io9mgrj2ui" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-072023-06-07_custom_PrivatePlacementWarrantTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zFprQXIQ7Y12" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-08_custom_PrivatePlacementWarrantThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">24,500</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zkG6qLVdDHMf" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-08_custom_PrivatePlacementWarrantThreeMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230608__20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zmRIaLsAl1Ne" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-082023-06-08_custom_PrivatePlacementWarrantThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,500</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zCWGS2hIzEOa" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-21_custom_PrivatePlacementWarrantFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zTrmJTqCX2c8" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-21_custom_PrivatePlacementWarrantFourMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230621__20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zNxZ28dMcs1k" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-212023-06-21_custom_PrivatePlacementWarrantFourMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zzQYHxEv7zw" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zbQ8lqWkCpx1" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantFiveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zjczq1iWDCz1" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-222023-06-22_custom_PrivatePlacementWarrantFiveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXmuH1Y2wbyj" title="Warrants to purchase"> <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction> </span>shares of common stock with an exercise price
of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zNYJ9eGW8Nv2" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantSixMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_z7bviaGGTqR4" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-222023-06-22_custom_PrivatePlacementWarrantSixMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z9Yuz2pdC8Ci" title="Warrants to purchase"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-27_custom_PrivatePlacementWarrantSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of common stock with an exercise price
of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z53VlWraBBp6" title="Sale of stock price"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-06-27_custom_PrivatePlacementWarrantSevenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230627__20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z9coXxNmfZvk" title="Consideration paid"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2023-06-272023-06-27_custom_PrivatePlacementWarrantSevenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with
the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with
US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024
and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing,
and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose
of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting
services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its
attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed
October 1, 2022) has served as an Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zwHQfx4NYXCg" title="Shares issued in consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_ziaLGLPbnMjk" title="Paid in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> in cash, payable as follows: <span id="xdx_90A_eus-gaap--CommonStockConversionFeatures_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zbw8brAuw34k" title="Settlement description"><ix:nonNumeric contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember" name="us-gaap:CommonStockConversionFeatures">(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before
March 31, 2024.</ix:nonNumeric></span> We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s
activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service
Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard
to certain matters. The shares were valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zVpfOyf3jOz1" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.13</ix:nonFraction></span> per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zss08gDbTOq7" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,750</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 156; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company granted a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zQlIcltAJaB" title="Number of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> options to purchase shares of common stock of the Company,
under the 2022 Plan, of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zjugoApWhFJ6" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> were granted to Jacob Cohen, the Company&#8217;s CEO, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_znuKT5JEptf2" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefOperatingOfficerMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> were granted to Jonathan Arango,
the Company&#8217;s President and then COO, related to their respective employment agreement. The options have an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVVB4FuGJwFl" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></span>
per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2K5atqtrGX8" title="Vesting term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">three years</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z3qQ4bz98Jmd" title="Number of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-05-01_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> options to purchase shares of common stock of the Company, under the 2022 Plan to Amanda Hammer,
the Company&#8217;s COO, related to her employment agreement. The options have an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziGnC6iqtl41" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-05-01_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></span> per share, an original life
of five years and vest at the annual renewal of their employment over <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230501__20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHe2zDhxQIJ2" title="Vesting term"><ix:nonNumeric contextRef="From2023-05-012023-05-01_us-gaap_CommonStockMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">three years</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_zSwvuuykv341" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,954</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zyAHgS3J7z0g" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,267</ix:nonFraction></span> has been recorded as stock-based compensation. Mr. Cohen, Mr. Arango
and Ms. Hammer are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyi1rsR2Htf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock options activity: The following table summarizes common stock options activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zlnCXFgqu0eg" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average<br/> Exercise Price</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znhH9QhV8Jz9" title="Options, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zeKHtmvQD3p8" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zHSc0soTBJ65" title="Options, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zSj0pmVHzf72" title="Weighted Average Exercise Price, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z4M1W5clqAig" title="Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zWw9zwFbNmu4" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zLbeTZscYov8" title="Options, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zikBFPG16421" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhddE771qBg8" title="Options, Outstanding Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zzpqysnH1Wqk" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z1MP2jF4AFQ7" title="Options, Exercisable Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zHFZEa6PWQll" title="Weighted Average Exercise Price, Exercisable Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zf1atKcT80X9" title="Options, Outstanding Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20230930_zyW2d14wPidh" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_z3Ptx0XNd0V5" title="Options, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zZFpnFBVW2fg" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zWOR2HFj1J1a" title="Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_z14JGxLafKJ7" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230930_zrXwuRePGnI" title="Options, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zLEIlWnHh8m1" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_z6pDRX1w20Mh" title="Options, Outstanding Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_z6aTTMyvay9b" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zfOYJOY5k1o2" title="Options, Exercisable Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,167</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zNfU28RYePX6" title="Weighted Average Exercise Price, Exercisable Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Outstanding Options</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Exercisable Options</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Exercise<br/> Price Per <br/> Share</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Life <br/> (Years)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average <br/> Exercise Price</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average <br/> Exercise Price</b></span></p></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20230101__20230930_zpfuwp5dq2B8" title="Option Exercise Price Per Share" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zhhNJGX7130k" title="Outstanding Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z05q5jUmYmX" title="Options Term"><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">4.53</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zjS2Z9bdup3h" title="Weighted Average Exercisable Price Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zymTshplVVMd" title="Exercisable Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">454,167</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zv4uyDEuL4I3" title="Weighted Average Exercisable Price Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z3ZpUXQeFDjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the fair value of options outstanding was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230930_z4xStvq1s4ge" title="Fair value of options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">640,194</ix:nonFraction></span>. The aggregate initial fair value of the options measured on
the grant date of August 31, 2022 and May 1, 2023 was calculated using the Black-Scholes option pricing model based on the following
assumption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEuwjyXnOBz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zIZVbbHJx3N5" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 68%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930_zvk6SeZs4NWb" title="Fair value of common stock on measurement date" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z5rM1yKNJIo1" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.64</ix:nonFraction></span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_z0slP4fXaPnb" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.30</ix:nonFraction></span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zZ0HuAO9GC46" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">224.70</ix:nonFraction></span>% <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdfCWyRnImbd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.54</ix:nonFraction></span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zCUiNUvFDl07" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zktdNJwouND1" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-09-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zxy0hr7KDDEd" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-09-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, in accordance with staff accounting bulletin (&#8220;SAB&#8221;)14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AF_zTENkGUvqxZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 157; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued a total of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z9gv0kRhW6kj" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Warrants to investors and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zBHrSr03DRp7" title="Warrants issued for services"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,070</ix:nonFraction></span> Warrants as compensation
for services rendered in connection with the Offering. The Warrants have an original life of five years and vested immediately. The Warrants
for services were expensed as stock-based compensation at the aggregate fair value in the amount of $<span id="xdx_903_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220101__20221231_zWy5hWNJnyT7" title="Fair value of warrant"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,821</ix:nonFraction></span>. Because the Warrants vested
immediately, the fair value was assessed on the grant date. The aggregate fair value of the Warrants were measured using the Black-Scholes
option pricing model. The Company and the holder of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zOQcb9AmtzMh" title="Warrants issued for services"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,070</ix:nonFraction></span> Warrants for services agreed to cancel the Warrants and reversed the entries
for stock-based compensation to zero at year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative
of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zPj1ryfeFcX1" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-20_us-gaap_CommonStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction> </span>shares of common stock with an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwMJcNrlIgR5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-20_us-gaap_CommonStockMember_us-gaap_IPOMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span> per share, which are exercisable six months after the effective date of the registration statement filed in connection
with the IPO (March 20, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was
$<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230320__20230320_zhYd2LjGR678" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-03-202023-03-20" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,995</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zlQoxU6gX5L1" title="Fair value of Warrants outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-09-30_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">581,264</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zO5c5OEQ0BH2" title="Fair value of Warrants outstanding"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zk6NPSL72gMc" title="Fair value of Warrants outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,299</ix:nonFraction></ix:nonFraction></span></span>, respectively.
Because the Warrants vested immediately, the fair value was assessed on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zBNhKo7fwRy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock warrant activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zEBdMiAKxqZg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average<br/> Exercise Price</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoh8dvznIjJh" title="Warrants Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmdzcqHQyni8" title="Weighted Average Exercise Price Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQGTuc1YVqmj" title="Warrants Granted" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,210,070</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTncY7ZGcOz8" title="Weighted Average Exercise Price Granted" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDh1G5xiXu03" title="Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFtBIZm2jSx5" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1213">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoJUZp1hIQyg" title="Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDGC8QqIw544" title="Weighted Average Exercise Price Expired" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJL28tJgdRc" title="Warrants Cancelled" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">210,070</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCJmbrIdijk" title="Weighted Average Exercise Price Cancelled" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8iRJOGpHFzl" title="Warrants Outstanding, Ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSV2VZbyu11" title="Weighted Average Exercise Price Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDzgqgo7B9Y6" title="Warrants Exercisable Ending balance" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRg934nPAxXd" title="Weighted Average Exercise Price Exercisable price" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCDjEPEqNrI3" title="Warrants Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">87,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL93hfP3zhW1" title="Weighted Average Exercise Price Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp61h1Zmertg" title="Warrants Exercised" style="text-align: right">(<ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,024,500</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM16wPuNZt8e" title="Weighted Average Exercise Price Exercised" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN6LGRvfip1b" title="Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsW6qE1SHTq2" title="Weighted Average Exercise Price Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWwmwXM0Kpu1" title="Warrants Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgfUfOllZdyc" title="Weighted Average Exercise Price Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQwkEgQUqG2b" title="Warrants Outstanding, Ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,063,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZs1OBoLSK21" title="Weighted Average Exercise Price Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.30</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQtwYXbBSpd" title="Warrants Exercisable Ending balance" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">975,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2OvWN19gtlc" title="Weighted Average Exercise Price Exercisable price" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Warrant Exercise Price Per Share</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY3FElUSndtl" title="Weighted Average Exercise Price Exercised" style="width: 30%; text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zviqeeycKM92" title="Outstanding and Vested Warrants Ending balance" style="width: 30%; text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,063,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTDFcVl5jPIb" title="Outstanding and Vested Warrants Expected Term" style="width: 30%; text-align: right"><ix:nonNumeric contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt-sec:duryear" name="MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">3.83</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zIUvQSjzqFjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, warrants to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDCRYvrtk2S2" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,063,000</ix:nonFraction></span> shares of common stock are outstanding and vested, and the vested stock warrants
have a weighted average remaining life of <span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4XXavrzjzc4" title="Outstanding and vested warrants expected term"><ix:nonNumeric contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt-sec:duryear" name="MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">3.83</ix:nonNumeric></span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><ix:nonNumeric contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40801390" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXniw0lhn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BB_zmc19E8WnEi5" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHbH2bsAL481" title="Fair value of common stock on measurement date"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-09-30_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.37</ix:nonFraction></span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zqA4XUr2W09l" title="Fair value of common stock on measurement date"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-09-30_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFJjnXUMlQ4" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.95</ix:nonFraction></span>% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zhOsdSKWfmak" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.00</ix:nonFraction></span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaz6PgL5z1Ff" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.92</ix:nonFraction></span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAIYLYlD3Awd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.87</ix:nonFraction></span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcbCSHkmB32" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrGkHub8P62" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zrdq3VifZuSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 158; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4wQJNloSbsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_829_zfoVTCEQbUvb">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company is not currently subject to any such litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a lease for an office in Dallas, Texas, classified as an operating lease under ASC 842, <i>Leases.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#8220;Landlord&#8221;) to lease and occupy approximately <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20220928_zKgJj1o9MGa7"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-09-28" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">2,201</ix:nonFraction></span> square feet of office space located at 15110 Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#8217;s main headquarters (the &#8220;<span style="text-decoration: underline">Lease Agreement</span>&#8221;). <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZYS0DoDTiAd" title="Operating lease, description"><ix:nonNumeric contextRef="From2022-09-282022-09-28_custom_LeaseAgreementMember" name="us-gaap:LesseeOperatingLeaseDescription">The Lease
Agreement has a term of thirty-eight (<span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zy8nQ2Bjoxvl" title="Lease term"><ix:nonNumeric contextRef="AsOf2022-09-28" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">38</ix:nonNumeric></span>) months and has a monthly base rent of $<span id="xdx_908_eus-gaap--PaymentsForRent_c20220928__20220928_zhsjLx3nwRbh" title="Base rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-09-282022-09-28" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,778</ix:nonFraction></span>, or $31.50 per square foot, for the from months
3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term</ix:nonNumeric></span> (the &#8220;<span style="text-decoration: underline">Base Rent</span>&#8221;).
In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments,
hazard and liability insurance and common area maintenance costs for the building at the rate of <span id="xdx_90F_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zgPXQ0GcHlI3" title="Percentage of proportionate rent"><ix:nonFraction name="MGRX:PercentageOfProportionateRent" contextRef="From2022-09-282022-09-28" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.45</ix:nonFraction></span>% (the &#8220;<span style="text-decoration: underline">Proportionate Rent</span>&#8221;).
Upon the execution of the Lease Agreement, the Company agreed to prepay the first full month&#8217;s Base Rent along with a security
deposit equal to $<span id="xdx_909_eus-gaap--PaymentsForRent_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z9xGeoroPGq5" title="Base rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-09-282022-09-28_custom_LeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily
determinable. The Company used an estimated incremental borrowing rate of <span id="xdx_90A_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zMlOWvijXZJg" title="Percentage of incremental borrowing rate"><ix:nonFraction name="MGRX:PercentageOfIncrementalBorrowingRate" contextRef="From2022-09-282022-09-28" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% to estimate the present value of the right-of-use liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has right-of-use assets of $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230930_zZcUpSuvKlBb" title="Right of use of asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,433</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zJieVvJPtFt2" title="Right of use of asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,241</ix:nonFraction></span> and operating lease liabilities of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_c20230930_zLJ5zrwP4I13" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,424</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20221231_zkGPL5F4H6He" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,405</ix:nonFraction></span> as of September 30,
2023 and December 31, 2022, respectively. Operating lease expense for the nine months ended September 30, 2023 and 2022 was $<span id="xdx_906_eus-gaap--OperatingLeaseCost_c20230101__20230930_zlP6umDqxl5j" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,826</ix:nonFraction></span> and
$<span id="xdx_908_eus-gaap--OperatingLeaseCost_c20220101__20220930_zPa41U6jFuH1" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, respectively. The Company has recorded $<span id="xdx_903_eus-gaap--AssetImpairmentCharges_c20230101__20230930_ze3QG1AuZSf2" title="Asset impairment charges"><span id="xdx_90F_eus-gaap--AssetImpairmentCharges_c20220101__20220930_z9aVKEklHrD4" title="Asset impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-01-01to2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> in impairment charges related to right-of-use assets during the nine months ended September
30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zfxAqQM2PIij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zswRigTIq3uh" style="display: none">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Maturity of Lease Liabilities at September 30, 2023</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zDWWLFhDsfTk" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 82%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_ma1_c20230930_zTpIGPR0wXn6" title="Remainder of Fiscal Year" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,516</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_ma1_c20230930_zmD2YYkVOW4h" title="Year One" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">2025</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_ma1_c20230930_zC43oirSPia" title="Year Two" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="Year Three" id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pp0p0_ma1_c20230930_z0JCCsLn33E7" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mt1_c20230930_ztEXhojbu4k3" title="Total lease payments" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,821</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zGqopNm9d9W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Less: Imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,397</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zJjgVhWwhBbg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Present value of lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">143,424</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A7_zhAQOiM0QUN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zbDY2sXtahjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_82C_ziWvXwKUMICl">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based on the
evaluation, the Company identified the following subsequent events:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2023, the Company executed a Summary of Terms and Conditions (&#8220;Consulting Agreement&#8221;) with Gene Johnston (&#8220;Johnston&#8221;)
continuing his appointment as the Company&#8217;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the
Consulting Agreement, the Company issued Johnston <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8RPkUwiI0A1" title="Stock issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of the Company&#8217;s common stock and $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmnIvU1NqbD2" title="Stock issued during period, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> per month. The Consulting
Shares were issued under, and subject to the terms of, the Company&#8217;s 2022 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (&#8220;Luca Consulting&#8221;), to provide management
consulting and business advisory services to the Company during the term of the agreement, which is for three months. In consideration
for agreeing to provide the services under the agreement, the Company agreed to pay Luca Consulting $<span id="xdx_902_eus-gaap--StockIssued1_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zktTsPvJJ1Oe" title="Stock value paid in cash"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></span> in cash and issued Luca Consulting
<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231010__20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zDwg78mazDLd" title="Stock issued during period, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares of restricted common stock. The agreement contains customary confidentiality and non-circumvention provisions. The shares
were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zpnWL06zEUE4" title="Stock issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-10-10_us-gaap_SubsequentEventMember_custom_ConsultingAgreementMember_custom_LucaConsultingLlcMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.60</ix:nonFraction></span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231010__20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zjAe5Judgemg" title="Stock issued during period, value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,000</ix:nonFraction></span>.</span></p>

</ix:nonNumeric><p id="xdx_81B_z15cUiRe0OU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="fin02_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_004.jpg" alt=""/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Report
of Independent Registered Public Accounting Firm</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors and Stockholders of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Opinion
on the Financial Statements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheet of Mangoceuticals, Inc. as of December 31, 2022, and the related statements of operations,
changes in stockholders&#8217; equity (deficit) and cash flows for the year ended December 31, 2022, and the related notes (collectively
referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects,
the financial position of Mangoceuticals, Inc. as of December 31, 2022, and the results of its operations and its cash flows for the
year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going
Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note
8 to the financial statements, the entity has suffered recurring losses from operations that raise substantial doubt about its ability
to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 8. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis
for Opinion</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the entity&#8217;s management. Our responsibility is to express an opinion on these financial
statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to Mangoceuticals, Inc. in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Mangoceuticals,
Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our
audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an
opinion on the effectiveness of the entity&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">/s/
Turner, Stone &amp; Company, L.L.P.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as Mangoceuticals, Inc.&#8217;s auditor since 2023.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">February
21, 2023</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner,
    Stone &amp; Company, L.L.P.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accountants
    and Consultants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12700
    Park Central Drive, Suite 1400</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
                                            Texas 75251</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:
    972-239-1660 &#8260; Facsimile: 972-239-1665</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toll
    Free: 877-853-4195</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Web
    site: turnerstone.com</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="forms-1_005.jpg" alt=""/></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.6pt"></p>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="fin02_002"></span><img src="forms-1_006.jpg" alt="" style="height: 88px; width: 408px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and Shareholders of Mangoceuticals, Inc.,</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheet of Mangoceuticals, Inc. (the Company) as of December 31, 2021, and the related statements
of operations, changes in stockholders&#8217; deficit, and cash flows for the period from October 7, 2021 (inception) to the period then
ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of December 31, 2021, and the results of its operations
and its cash flows for the period from October 7, 2021 (inception) to the period then ended in conformity with accounting principles
generally accepted in the United States of America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going
Concern</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
8 to the financial statements, the Company has suffered a net loss from start-up operations, which raises substantial doubt about
its ability to continue as a going concern. Management&#8217;s plans regarding those matters are discussed in Note 8. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and the significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe our audits provide
a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Audit Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
critical audit matter communicated below is a matter arising from the current period audit of the financial statements that were communicated
or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial
statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters
does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit
matter below, providing separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the net loss for the year, The Company evaluated the need for a going concern. Auditing management&#8217;s evaluation of a going concern
can be a significant judgement given the fact that the Company uses the management estimates on future revenues and expenses which are
not able to be substantiated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 8, the Company has a going concern due to the net loss during the year ended December 31, 2021. To evaluate
the appropriateness of the going concern, we examined and evaluated the financial information along with management&#8217;s plans to
mitigate the going concern and management&#8217;s disclosure on going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
M&amp;K CPAS, PLLC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">M&amp;K
CPAS, PLLC</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&#8217;s auditor since 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
TX</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
1, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p id="xdx_049_c20220101__20221231_z4FBiWLm6cMl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="fin02_003"></span><b>MANGOCEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zfXiWKAqTyNk" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20221231_zuneHem6cU0k" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20211231_zNRALHl83Rqe" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_znQSewvato6c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_zjsZnB5mHLRe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_i01I_zODycVaBL1d8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1351">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrent_i01TI_zlDGa8NZ0QI2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL CURRENT ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNetAbstract_iB_zbtTp2ukZXkh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">FIXED ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i01I_zwHS75qDlmXc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and equipment, net of accumulated depreciation of
    $<span id="xdx_90F_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20221231_zcT6RW7sZRO5" title="Accumulated depreciation"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1360">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--FixedAssets_i01TI_zPks7aLmDZAa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL FIXED ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="MGRX:FixedAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1365">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsAbstract_i01B_zQXbDb1T0gk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DepositsAssets_i01I_zGaGHzrC2Mo8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_zjvN4GuVo95c" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Right of use - asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,241</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1374">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssets_i01TI_zTEkTcEEi7de" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL OTHER ASSETS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">191,183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_iTI_z9OQbeQAdT9h" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,003,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zVSesJSbfZB6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center"><b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrentAbstract_i01B_zYzQ5skTr5pg" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CURRENT LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i02I_zV6tk62FZc7e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedPayrollTaxesCurrent_i02I_ztnqDobrCTWa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payroll tax liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1392">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVBdfqQogXhg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zBK0qPeOka1i" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1398">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zJqrbeBRJt0b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Right-of-use liability - operating lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,725</ix:nonFraction></p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1401">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesCurrent_i02TI_zGFZZcCyu3E6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL CURRENT LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,577</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zJ2i7KubPCW" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LONG-TERM LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_zLpTTcKTVWTd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Right-of-use liability - operating lease</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesNoncurrent_i02TI_zwWQYkCk4E84" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">TOTAL LONG-TERM LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1413">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--Liabilities_i01TI_z4cAe4Pbh7j1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL LIABILITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">389,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,270</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zM95KSjogqi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i02I_zTrKPoIml8gb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock (par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zq7C4NBo9sj7" title="Common stock, par value"><span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zNplZd93Q0B" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction></ix:nonFraction></span></span>, <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zBFzSfUUbo9e" title="Common stock, shares authorized"><span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zQ0NOlVnvBda" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, of which <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zoBu6gaHJ74c" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zDs6iUge6lYi" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></ix:nonFraction></span>
    </span>and <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zvfMZcs2K0Lh" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_z3DnsVDziov9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of December 31, 2022 and 2021, respectively)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i02I_zRQyqAONlrtj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,628,449</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zwMoeSkCAiof" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,015,756</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_zIFrAnXmlenl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zSKWA12pnCI3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&#8217;
    EQUITY (DEFICIT)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,003,287</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="fin02_004"></span><b>MANGOCEUTICALS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_113_z9Rdp8uJ23k" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231_z9ABvyvEYI8e" style="text-align: center">For The Year</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49A_20211007__20211231_zbyTPeDZBYfh" style="text-align: center">For the period from October 7, 2021(Inception)</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Ended</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">through</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenuesAbstract_iB_zKTRJ3FPsVi2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Revenues_i01_zwtTVQdqwaGd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,939</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1456">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CostOfRevenues_i01N_pp0p0_di_zsdHTfisUWm6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Cost of revenues ($<span id="xdx_90E_eus-gaap--CostOfRevenue_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zycDItS9LDVd" title="Cost of revenues - related party"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,255</ix:nonFraction></span> of related party cost of revenues for the year
    ended December 31, 2022)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b>(<ix:nonFraction name="MGRX:CostOfRevenues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,089</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left"><b>)</b></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1459">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GrossProfit_i01T_zL7CHK5CN2g7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Gross profit (loss)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zAaWfXRIgKXe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--GeneralAndAdministrativeExpense_i01_zf7gsqS67TNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,996,432</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_i01T_z2F8fgPi1xRk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,996,432</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingIncomeLoss_iT_zRxkGljAZzv2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,991,582</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zZwHTcCdTWb7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ImputedInterestRelatedParty_i01N_di_zk5mQYBr9ob8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Imputed interest &#8211; related party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="MGRX:ImputedInterestRelatedParty" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="MGRX:ImputedInterestRelatedParty" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iNT_di_z15ZmZslqksj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,473</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_z1FdacB0WrQ2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss before income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,998,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iN_di_zRhrMjMD5OZf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1490">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1491">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_iT_z6iHJ92e9Y8j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net income (loss)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,998,055</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAbstract_iB_zedH2vqoCCZ6" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Basic and diluted loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareBasicOtherDisclosuresAbstract_iB_zryb1Fyyo3Wf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted loss per share</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_c20220101__20221231_ztXsrhu7s1y8" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zPdbBDcKv1Oh" title="Earnings per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.19</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20211007__20211231_zNIVXjSvzHw4" title="Earnings per share, basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_c20211007__20211231_z114m6tpJcO" title="Earnings per share, diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_zvs30NqPFjcg" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_90A_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zi2UcE93hO3i" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,798,083</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20211007__20211231_z0Pzz4e32Yr9" title="Weighted average number of shares outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20211007__20211231_zW0zr4PB4VJd" title="Weighted average number of shares outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin02_005"></span>MANGOCEUTICAL,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statement
of Changes in Stockholders&#8217; Equity (Deficit)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_zH5zPAGeNAUd" summary="xdx: Statement - Statement of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zfXYOUDYtEig" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zZBFRmQbb9D9" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zvtd4xoektV5" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_4B7_zqAunKEq7Op8" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Common Stock</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Additional</p>
                                                                      <p style="margin-top: 0; margin-bottom: 0">Paid-in</p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Accumulated</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">Total Stockholders&#8217;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Capital</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Deficit</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">(Deficit)</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_43C_c20211007__20211231_eus-gaap--StockholdersEquity_iS_zQOcB3W8yn8h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">October 7, 2021 (inception)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20211007__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ2I4UYZOg91" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1523">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1518">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1519">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1520">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1521">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zYWkaPeNbqOc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%">Issuance of Common Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20211007__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxWpTbmrCnR2" title="Issuance of common stock for services, shares" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1526">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1527">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zpnK7BMddd8k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Imputed Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1532">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1534">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zHPFM5B6may6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1537">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1538">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_438_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zujeLp6AJ284" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOHJNpEVNith" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,720</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zXt19sU0Bxa8" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLGUELjMaT2l" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,720</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zW6lSDjC5PB9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Common Stock for Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyeu39Gh0Kl7" title="Issuance of common stock for services, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,365,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">337</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,728</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1558">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,065</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zjbWvHFYQpXh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of Units for Cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcY0Lzw64T73" title="Issuance of common stock for cash, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,999,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1565">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z3kHQ2prjSh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options and Warrants Vested for Services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1570">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl1572">-</span></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_iN_di_zgJU1rGwYbs8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants for Services Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1575">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,821</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,821</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_zexsO6HCiWnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Imputed Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1580">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1582">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,473</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zXB32oGJIzJd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Net Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1585">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1586">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,998,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,998,055</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zNPdt1pLwqcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, December 31, 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvzOj06nUcCd" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,628,449</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,015,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,030</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_437_c20220101__20221231_eus-gaap--StockholdersEquity_iE_zzTBKp1Ebqb3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWKNkUrnNvE9" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,337</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,628,449</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,015,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">614,030</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="fin02_006"></span><b>MANGOCEUTICALS,
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_z2l6C2XGl782" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20220101__20221231_z2PKttYi2Woj" style="padding-bottom: 1.5pt; text-align: center">For the Year Ended</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20211007__20211231_zihUvszqJ7X9" style="padding-bottom: 1.5pt; text-align: center">For the Period from October 7, 2021 (inception) through</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zJxgTJD5N4H4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_zNVNpigCtkn4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,998,055</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,701</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zgcj5awjbZTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Adjustments to reconcile net loss to net cash (used in) operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Depreciation_i02_zW4FiKF0LUgk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1614">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfCommonStockForServices_i02_zGt5zDM66O12" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Issuance of common stock for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="MGRX:IssuanceOfCommonStockForServices" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,065</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1617">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InterestExpense_i02_zJoqfxUPeBS7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Imputed interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,473</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_zLlo9WzdIKNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Options vested for stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,088</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantsForServiceCancelled_i02_zvep5SZqZgte" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Warrants for service cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="MGRX:WarrantsForServiceCancelled" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">151,821</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingAssetsAbstract_i01B_zZRAZLkKwx4b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Increase) decrease in operating assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInDepositOtherAssets_i01N_di_zPy6eV15vW87" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Rent deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDepositOtherAssets" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_zBnEfea4ZG5l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,745</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1635">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--IncreaseDecreaseInOperatingLeaseRightOfUseAsset_i02N_di_zcalstIXZvuc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Operating lease right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,241</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOperatingLiabilitiesAbstract_i01B_ze5nopC1iDnj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">(Decrease) increase in operating liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i02_zj9zXdC7pA5k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zdfH9CvktXO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Operating lease right of use liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,405</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1647">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccruedIncomeTaxesPayable_i02_zskGQQX3fEX2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Payroll tax liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,717</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_zuJlfyZuicT1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET CASH USED IN OPERATING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,346,518</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,520</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zpmu1OFpgoC1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_z7gzSvxKrp89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Purchases of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1659">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_zJKDDfqxonPf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET CASH USED IN INVESTING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,102</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1662">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zGczUQtMHUEe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromRelatedPartyDebt_i01_zaowa7GP3bo" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from borrowings on notes payable to related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RepaymentsOfRelatedPartyDebt_i01N_di_zsLRGLxaaWK7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Repayment of borrowings - related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,070</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1671">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_zzqLmRN1Mr3e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Proceeds from sales of units for cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_zQYh6BgBf4rb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,049,930</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zLgR7sCwlxbc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">NET INCREASE IN CASH AND CASH EQUIVALENTS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660,310</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-10-072021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAbstract_iB_zB7RQJV7ZcZj" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH AND CASH EQUIVALENTS:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zqBOhzXqHSJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt">Beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1686">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_zLaykDwgfFt9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">End of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z45xgLI2F0S4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxesPaid_i01_zJPfDtFeN3M9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1694">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1695">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaid_i01_zvzKxFNfmIQ1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1697">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1698">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ContributionOfProperty_i01_zT0Dgm8DfIk2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Accounts payable for purchase of property and equipment</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="margin: 0"><ix:nonFraction name="us-gaap:ContributionOfProperty" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1701">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these audited financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="fin02_007"></span>MANGOCEUTICALS,
INC.</b></span></p>

<p id="xdx_045_c20220101__20221231_zJcqDj78jAPk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
Ended December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Audited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zprwrOCul4H8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_825_zhilY9hCUpJ4">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc. (&#8220;Mangoceuticals&#8221; or the &#8220;Company&#8221;),
was incorporated in the State of a Texas on <span id="xdx_904_edei--EntityIncorporationDateOfIncorporation_c20220101__20221231_zGBUehANNMM2" title="Date of incorporation"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt:datemonthdayyearen" name="dei:EntityIncorporationDateOfIncorporation">October 7, 2021</ix:nonNumeric></span>, with the intent of focusing on developing, marketing, and selling a variety
of men&#8217;s wellness products and services via a telemedicine platform. To date, the Company has identified men&#8217;s wellness telemedicine
services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (ED). In
this regard, Mangoceuticals has developed and is currently in the process of preparing to commercially market a new brand of ED product
under the brand name &#8220;Mango.&#8221; This product is produced at a compounding pharmacy using a proprietary combination of U.S. Food
and Drug Administration (&#8220;FDA&#8221;) approved ingredients and is available to patients on the determination of a prescribing physician
that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling this new brand of
ED product exclusively online via its website at <span style="text-decoration: underline">www.MangoRx.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor&#8217;s
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
of COVID-19 Pandemic on Consolidated Financial Statements.</i> The outbreak of the 2019 novel coronavirus disease (&#8220;COVID-19&#8221;),
which was declared a global pandemic by the World Health Organization on March 11, 2020, and the related responses by public health and
governmental authorities to contain and combat its outbreak and spread has severely impacted the U.S. and world economies during the
end of the first quarter of 2020, and continuing through the end of 2022. COVID-19 and the U.S. response to the pandemic are significantly
affecting the economy. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as
a result, the ultimate effect of the pandemic is highly uncertain and subject to change. The Company does not yet know the full extent
of the effects on the economy, the markets we serve, our business, or our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, economic recessions, increased inflation and/or interest rates, including those brought on by the continued COVID-19 outbreak
may have a negative effect on the demand for our services and our operating results. Any prolonged disruption to our operations or workforce
availability is likely to have a significant adverse effect on our results of operations, cash flows and ability to meet continuing debt
service requirements. All of the above may be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto
continue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zccpqDWH7U7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="abc_002"></span>NOTE
2 &#8211; <span id="xdx_82B_zKT3SZ5fToSh">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zl0LWu022Ftb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Basis
of Presentation</span> &#8211; </b>The financial statements present the financial position, results of operations and cash flows of the Company
in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_865_zMLgBDKVUJv9" style="display: none">Basis
of Preparation</span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqGvzgcRejG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zDDDltW6eFD7">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the
majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insures
the total cash balance up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zSUbtzyJPKW2" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, and
the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8qdOIxSTQ1b" title="Cash equivalents"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zXGLVpdMLuI5" title="Cash equivalents"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> cash equivalents at December 31, 2022
 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zmEN3HlOgpE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z2IJvFQC74Vg">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (&#8220;ASC&#8221;)
740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are measured using enacted tax rates
expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in
tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce
deferred tax assets to the amount that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 166; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zigppskZO7Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zrGxXkGjTFR5">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net loss per share in accordance with ASC 260, <i>Earnings</i><i> per Share</i> (&#8220;ASC 260&#8221;). ASC 260
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the statement of operations.
Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares
outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the
period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average
stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or
warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zgaEi1peE4Oa" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> options, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5Nko9cSctB2" title="Anti-dilutive securities"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span>
warrants and no derivative securities outstanding as of December 31, 2022. These were excluded because their effect would be anti-dilutive.
There were no options, warrants nor derivative securities outstanding as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84C_eus-gaap--UseOfEstimates_zy6JJ1GbZep8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zMrRStIaDkw9">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases
will, differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zsPUu87JF5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zbSpYL66boT6">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, <i>Fair Value Measurement</i>, which provides guidance with respect to valuation techniques to be utilized
in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices),
(ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity
of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value into three broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zv48K9wbXr23">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1734">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1735">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1739">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">682,860</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 167; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1750">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1758">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,550</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zMubUzvLqyDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3zdvDvfpKUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zMy6APj0VJa4">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember_zuZALQuxDMSb" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>) to five (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember_zfeWc2DTshNi" title="Property plant and equipment estimated useful lives"><ix:nonNumeric contextRef="AsOf2022-12-31_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>) years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zExz47PoCRSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zNH1coZdeGv2">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing
operations which were derived from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQJ9Su7Xbslf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Binomial
Calculation Model</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_86E_zp5CMlYlnvY2" style="display: none">Black
Scholes Option Pricing Model</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBASBHZEgpnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zjdxtEXNx2nl">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211;
40)</span></i>. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 168; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="MGRX:RelatedPartiesPolicyTextBlock"><p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zp2aZa5mM4Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zTwHksa6PKd4">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section
825&#8211;10&#8211;15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such
as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company;
e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the
management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing
its own separate interests; and g. other parties that can significantly influence the management or operating policies of the
transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to
an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zI8Z0VOgvfCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zv0yc8j1B8m1">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (&#8220;ASC 718&#8221;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zxwhSaUY1Uak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z4IJ12cfj9Kh">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue
is generated by selling directly to consumers through our websites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through
websites. The transaction price in the Company&#8217;s contracts with customers is the total amount of consideration to which the Company
expects to be entitled in exchange for transferring products or services to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 169; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#8217;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#8217;s completion of its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a Physician Services Agreement with BrighterMD, LLC &#160;&#160;dba Doctegrity (&#8220;Doctegrity&#8221;) to
provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer;
(ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs
costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company,
at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq &#160;&#160;Scripts, LLC (&#8220;Contracted
Pharmacy&#8221;), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers
for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company&#8217;s customers
for fulfillment through the Company&#8217;s websites. The Company accounts for prescription product revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills
a customer&#8217;s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company,
including using the Company&#8217;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer
for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices
charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zG5ilX5YTyog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNwo7LFpL7P1">Subsequent
events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent
events. The Company will evaluate subsequent events through the date when the financial statements were issued.</span></p>

</ix:nonNumeric><p id="xdx_85C_zuYJB86uzqY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="MGRX:PrepaidExpensesAndDepositsTextBlock"><p id="xdx_80B_ecustom--PrepaidExpensesAndDepositsTextBlock_zJSm2YB5uuNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span>PREPAID EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82A_zrsAd8MODQt2">PREPAID
EXPENSES AND DEPOSITS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, and in association with the Master Services Agreement and Statement of Work with our related party
Contracted Pharmacy, the Company prepaid the related party Contracted Pharmacy $<span id="xdx_90A_eus-gaap--OperatingCostsAndExpenses_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zj5pmXl5rOZd" title="Prepaid the related party expense"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="From2022-01-012022-12-31_custom_MasterServicesAgreementMember_us-gaap_RelatedPartyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,000</ix:nonFraction></span> as a retainer to be credited towards future product
sales. As of December 31, 2022 and December 31, 2021, the balance was $<span id="xdx_903_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_z8FQpn7RYYnf" title="Prepaid expenses related party"><ix:nonFraction name="MGRX:PrepaidExpensesRelatedParty" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,745</ix:nonFraction></span> and $<span id="xdx_902_ecustom--PrepaidExpensesRelatedParty_iI_c20211231_zooxdSoewhPh" title="Prepaid expenses related party"><ix:nonFraction name="MGRX:PrepaidExpensesRelatedParty" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>. respectively. Additionally, the Company has signed
a lease agreement for office space, effective October 1, 2022. The initial security deposit was $<span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20221001_zVKmOQksLPz6" title="Securtiy deposit"><ix:nonFraction name="us-gaap:SecurityDeposit" contextRef="AsOf2022-10-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxFxaK6Kzs3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_825_zhczP5OaGscj">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company acquired computers, office and custom product packaging equipment totaling $<span id="xdx_90F_eus-gaap--PaymentsToAcquireMachineryAndEquipment_c20220101__20221231_zbn6f20ZEsTj" title="Property acquired value"><ix:nonFraction name="us-gaap:PaymentsToAcquireMachineryAndEquipment" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,362</ix:nonFraction></span>. Depreciation
for the years ended December 31, 2022 and 2021 was $<span id="xdx_907_eus-gaap--Depreciation_c20220101__20221231_z7PtdvaxZH81" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--Depreciation_dxL_c20211007__20211231_z4TndwNWhex6" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1801">0</span></span>, respectively. Total net property and equipment was $<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zNnW0nU4Kmmd" title="Property plant and equipment net"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20211231_zH2EAcdPLBrc" title="Property plant and equipment net::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1805">0</span></span>, as of December 31, 2022 and December 31, 2021, respectively.</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxyIOXSUtr3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zcYYUSYfHjej" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zesVQFOY5otk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zUSb9ScIwbq5" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_z6V6muUREk9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_custom_ComputersMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,062</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zdDH7zmJQxJi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,300</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1813">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNR0W1yiGpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,863</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1816">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z81M7spwxWZh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">117,499</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zYzqX7hNRBG2" style="margin-top: 0; margin-bottom: 0">&#160;</p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 170; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4tvWK5IrHA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_829_zixfBrIEA3x6">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021 and March 18, 2022, the Company received advances of $<span id="xdx_907_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zrrvNHsoLfg1" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-12-102021-12-10_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,200</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220318__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zDC1i6YtvbAh" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-03-182022-03-18_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span>, respectively, for a total of $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zba4MXZDMN4h" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2023-01-012023-09-30_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span> from
its previous majority shareholder, American International Holdings Corp (&#8220;AMIH&#8221;), in order to cover various general and administrative
expenses. The advances bear no interest and are due on demand upon the Company&#8217;s ability to repay the advances from either future
revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), an entity owned
and controlled by Jacob D. Cohen, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors, entered into and
closed a Stock Purchase Agreement (the &#8220;SPA&#8221;) for the purchase of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zSIMoXnJdAs" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></span> shares of the outstanding common stock of the
Company which were then held by AMIH, which represented <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zQHQIi6IBnzf" title="Equity ownership interest"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2022-06-16_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction>%</span> of the Company&#8217;s then outstanding shares of common stock, in consideration
for $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zaXuJJwEc6bc" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,000</ix:nonFraction></span>. Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zDWmlutQmvk2" title="Repayments of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-06-152022-06-16_custom_StockPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span> advanced from AMIH
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2022, the Company received an advance of $<span id="xdx_903_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z11cQwltOsSl" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2022-06-282022-06-29_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_ziDGZauM3F3" title="Repayments of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-08-172022-08-18_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span> on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $<span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zQ7QgyfEDX06" title="Repayment of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">89,200</ix:nonFraction></span>
as of December 31, 2022. As of December 31, 2021, the balance was $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zjiNbnVGufb9" title="Repayment of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-01-012021-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,200</ix:nonFraction></span>. The Company recorded imputed interest equal to eight percent
(<span id="xdx_905_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zLF3lWetvm4e" title="Imputed interest percentage"><ix:nonFraction name="MGRX:InterestExpenseRelatedPartyPercentage" contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction>%</span>) per annum, or $<span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zDPICgRm9hF9" title="Related party transaction purchases"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,674</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--PaymentsForAdvanceToAffiliate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zLFF26pGTOB7" title="Related party transaction purchases"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2021-01-012021-12-31_custom_CohenEnterprisesIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></span>, against the related party advances for the years ended December 31, 2022 and December 31, 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company received an advance of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zNfdbIeaqb26" title="Related party advances received"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2021-12-102021-12-10_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70</ix:nonFraction></span> from ZipDoctor, Inc., a wholly-owned subsidiary of its then majority shareholder,
AMIH, which was used to open and establish the Company&#8217;s bank account. The advance bears no interest and is due on demand upon
the Company&#8217;s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May
24, 2022 and the amount owed to ZipDoctor was $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_z8oigcTNmNx7"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zLAqDiNlhVe6"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2021-01-012021-12-31_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70</ix:nonFraction></span> as of December 31, 2022 and December 31, 2021, respectively. Imputed interest
equal to eight percent (<span id="xdx_90F_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zeA3XM0Bkfg4" title="Imputed interest percentage"><ix:nonFraction name="MGRX:InterestExpenseRelatedPartyPercentage" contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction>%</span>) per annum, or $<span id="xdx_900_eus-gaap--PaymentsForAdvanceToAffiliate_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zKAFCbSkMNG8" title="Related party transaction purchases"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction> </span>and $<span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_z8JXeMrrzjRl" title="Related party transaction purchases"><ix:nonFraction name="us-gaap:PaymentsForAdvanceToAffiliate" contextRef="From2021-01-012021-12-31_custom_ZipDoctorIncMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>, was recorded against the related party advance as of December 31, 2022 and 2021,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer, Jacob D. Cohen, has made his personal credit card available for purchases on behalf of the Company
to cover various general and administrative expenses. Mr. Cohen has been repaid a total of $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__srt--TitleOfIndividualAxis__custom--JacobDCohenMember_zQIoZT8zqsuh" title="Repayments of related party debt"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="From2022-01-012022-12-31_custom_JacobDCohenMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,151</ix:nonFraction></span> as of December 31, 2022 for Company
purchases made on his personal credit card. &#160;&#160;There was no balance due as of December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information on related party prepaid expense see Note 3 and for related party stock-based transactions see Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zrDLVtWx8oxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82B_zedDvcTXJl8e">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On November 18, 2022, the Company
entered into a note payable with a vendor for the purchase of equipment in the amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_zBs9iRYygtT9" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-11-18" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></span>. The note bears no interest and is due
in three payments of $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230101_zQVCkq8z9e27" title="Debt instrument periodic payment"><span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20230201__20230201_zyoODReq12uf" title="Debt instrument periodic payment"><span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20230301__20230301_zkoKD3h44iql" title="Debt instrument periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-01-012023-01-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-02-012023-02-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-03-012023-03-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> each on January 1, 2023, February 1, 2023, and March 1, 2023, a $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_z48zBHVYJiA7" title="Debt instrument periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-04-012023-04-01" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,630</ix:nonFraction></span> payment is due on April 1, 2023 and
a final payment is due on May 1, 2023 for the outstanding balance. The outstanding balance on December 31, 2022 was $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20221231_zg7uLcKyjUA5" title="Notes payable"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,260</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z19KKraDpTyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>NOTE 7</b><b> &#8211; <span id="xdx_82B_ziBPst2JUnq9">CAPITAL
STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zgTTndP4Kv4h" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zKFfpPRQNbb4" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of &#8220;blank check&#8221; preferred stock, $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zuwynNIVMxpl" title="Preferred stock par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20211231_zC0AAo3JxgRe" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value. All preferred
stock were undesignated as of December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfAtL9czMWf" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zvHmqg1xxAAh" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zh5Ee8uyRmL" title="Common stock par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20211231_zjRAuAZlXFEe" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share, of which <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221231_zs23tA0cKzYe" title="Common stock shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zTiLnhMBhDVf" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,365,000</ix:nonFraction></ix:nonFraction></span></span> shares were issued
and outstanding at December 31, 2022 and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20211231_z1dZCQ4H6rgd" title="Common stock shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z8TozicLBGVe" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,000,000</ix:nonFraction></ix:nonFraction></span></span> were issued and outstanding at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjZLJeo0w9ke" title="Shares issued in consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of restricted common stock to the Company&#8217;s co-founder and CEO, Jacob D. Cohen,
in consideration for services rendered. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zgg8XQkfODMf" title="Shares issued in consideration,share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share, based on recent third-party sales of shares, for a
total of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z7zVIQdSgB82" title="Shares issued in consideration value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. Mr. Cohen is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 171; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z2YU8G9rZY4j" title="Shares issued in consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares of restricted common stock to the Company&#8217;s co-founder, President and COO, Jonathan
Arango, in consideration for services rendered to the Company. The shares were valued at $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zkZl4LQCM1X9" title="Shares issued in consideration,share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share, based on recent third-party
sales of shares, for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zs5v12wmxAlh" title="Shares issued in consideration value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span>. Mr. Arango is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2022, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220623__20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_ztBmiK6oWup6" title="Shares issued in consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-06-232022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of restricted common stock to The Loev Law Firm, PC in consideration for legal services
rendered to the Company. The managing partner of The Loev Law Firm, PC is David M. Loev, who is the brother-in-law of the Company&#8217;s
CEO, Jacob D. Cohen. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_z9s6zafao86k" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.10</ix:nonFraction></span> per share, based on recent third-party sales of shares, for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220623__20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_z0LckWaVlEGg" title="Shares issued in consideration value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-06-232022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,000</ix:nonFraction></span>.
Mr. Loev is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2022, the Company began a private placement of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220808__20220808__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAkLjVCwqbOc" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-08-082022-08-08_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span> of units (the &#8220;Units&#8221;), each consisting of one
share of common stock (the &#8220;Shares&#8221;) and a warrant to purchase one share of common stock (the &#8220;Warrants&#8221;), at
a price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zFfLmoJ5GYD9" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per Unit. The Warrants have a <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_uUSDPShares_c20220808_zzbQLlVEKDKc" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1925">five-year</span></span> term and an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220808_zNbDuqumIJ2l" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share, for which cash would need to
be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise the Warrants are
exercisable on either a cash basis or a cashless basis. The offering of the Units is referred to as the &#8220;Offering.&#8221; The Units
were offered by the Company only to investors that qualify as &#8220;accredited investors,&#8221; as that term is defined in Rule 501(a)
of Regulation D promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;) under the Securities Act of 1933, as
amended (the &#8220;Securities Act&#8221;). The price of the Units were determined by the Company and such price did not necessarily
bear any relation to the book value or other recognized criteria of value of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering commenced on August 8, 2022 and the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220808__20220808_zUHwwSVSt8Oc" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-08-082022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Units at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zrDWSi3vOZw" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-08-08" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per Unit to 23 investors in exchange for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220808__20220808__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJTOokKTOqbj" title="Proceeds from investors"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2022-08-082022-08-08_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></span>
in gross proceeds from each investor, and subsequently issued the investors <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220816__20221231_zdBnKGmTZl4f" title="Sale of stock, shares"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-08-162022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Shares and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z6eGwT7T4OTb" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Warrants between August 16,
2022 and December 31, 2022. As of December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zqhKMmf1GB48" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,299</ix:nonFraction></span>. Because the
Warrants vested immediately, the fair value was assessed on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC &#160;&#160;(&#8220;PHX&#8221;), which is owned by Peter
&#8220;Casey&#8221; Jensen, who is a member of the Board of Directors of AMIH. Pursuant to the Consulting Agreement, PHX agreed
to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement,
which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure
such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company
issued PHX <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcyBwzL9iCJi" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions.
The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQvN4OSsyY6i" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQc319LyiT3" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,921</ix:nonFraction></span>. PHX is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#8220;Elliott&#8221;), currently a professional football
player and the running back for the Dallas Cowboys, to provide consulting and general business advisory services as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Elliott <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkdHKczVU5Ng" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zahdjkEw1887" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction> </span>per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJZft5JsYe5e" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,842</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#8220;Sandler&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zld2LwNFlUQ3" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span>
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKeYisrPFYB1" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRFkqWryOUQl" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,784</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#8220;Chou&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaO5jJWoOXk1" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued
at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvbnHFSMdBs" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8b52etEvnO9" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,392</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 172; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US
GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023
and the year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes;
(d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions,
with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing
necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst
the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer
(who was appointed October 1, 2022) has served as Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z2UErOVVDDE" title="Shares issued in consideration"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z9OWJbKvLao6" title="Paid in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></span> in cash, payable as follows: <span id="xdx_906_eus-gaap--CommonStockConversionFeatures_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zyJnm43mMYVa" title="Settlement description"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember" name="us-gaap:CommonStockConversionFeatures">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023</ix:nonNumeric></span>. We also agreed to include the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZq7tgRMzOg5" title="Shares new issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein, and to reimburse
Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s activities under the agreement, including
the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification
obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zwZk8aGIgOc4" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-31_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_ztakrZ6pyCid" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-01-012022-12-31_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,842</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company executed a Summary of Terms and Conditions (&#8220;Offer Letter&#8221;) with Gene Johnston (&#8220;Johnston&#8221;)
appointing Johnston to serve as the Company&#8217;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to
the Offer Letter, the Company issued Johnston <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgb7WDH2nSIe" title="Restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span> shares of the Company&#8217;s restricted stock and vest over a 6-month period at
the rate of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoPsUBIlqeaf" title="Shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares per month with the first <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjtS2cR6FTi9" title="Shares vested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-11-012022-11-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares vesting on November 1<sup>st</sup>, 2022. Johnston is eligible to participate
in any of the Company&#8217;s future sponsored benefit plans, including but not limited to, health insurance benefits, 401k, stock option
or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of the month following 105 days
of Johnston&#8217;s start date. Johnston is also eligible to receive equity incentive grants or cash bonus awards as determined by the
Company&#8217;s Board (or a committee of the Board) in their sole discretion. The shares were valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zy3rM3OqxRR" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-01_us-gaap_RestrictedStockMember_srt_ChiefFinancialOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction> </span>per share for a total of
$<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221001__20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_znHlssWNeWI" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,763</ix:nonFraction></span>. Mr. Johnston is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company approved the appointments of each of Alex Hamilton (&#8220;Hamilton&#8221;), Dr. Kenny Myers (&#8220;Myers&#8221;)
and Lorraine D&#8217;Alessio (&#8220;Alessio) to serve as independent members of the Board of Directors and</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
entered into Director Offer Letter agreements with Hamilton, Myers and D&#8217;Alessio compensating each of them with <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr77GlLClka1" title="Restricted stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of
restricted common stock (for a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwwlzsQE5DWb" title="Restricted stock issued net"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000</ix:nonFraction></span> shares) (the &#8220;Director Shares&#8221;). The Director Shares were issued under the
Company&#8217;s 2022 Equity Incentive Plan (the &#8220;Plan&#8221;), with the following vesting schedule: 1/3 of the Director Shares
vested on October 14, 2022, and the remaining Director Shares will vest annually in one-third increments commencing on the first anniversary
date thereof. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_ztri0cDqr373" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zaR0gnNGNcia" title="Shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,881</ix:nonFraction></span>. These individuals are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued its Project Manager, Joan Arango, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221014__20221014__srt--TitleOfIndividualAxis__custom--JoanArangoMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zpuiQkRWCmu9" title="Restricted common stock issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-10-142022-10-14_custom_JoanArangoMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares of restricted common stock under the Plan. The shares
were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#8217;s President and Chief
Operating Officer, Jonathan Arango. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_zhHMZQ1vuusk" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_zVqYUfvgXeqj" title="Shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,204</ix:nonFraction></span>. Ms. Arango is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#8220;White Unicorn&#8221;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHmzQQ7ITdP9" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeBLn7flpVG8" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember_z78BNfxG0a42" title="Shares value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,816</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 173; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (&#8220;Global&#8221;) to provide marketing
services as reasonably requested by the Company during the term of the agreement, which is for six months unless otherwise earlier terminated
due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company issued Global <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEKcedeDg98f" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of restricted common stock. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z71FZUg4qjh6" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLLaR31a5p16" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,816</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#8220;Chartered Services&#8221;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company agreed to pay Chartered Services $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zlZlaSxmoxd1" title="Paid in cash"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2022-12-212022-12-21_custom_CharteredServicesLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span> in cash (<span id="xdx_900_eus-gaap--CommonStockConversionFeatures_c20221221__20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zse18P8rkRha" title="Settlement description"><ix:nonNumeric contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember" name="us-gaap:CommonStockConversionFeatures">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000</ix:nonNumeric></span> shares of restricted common stock.
The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_z69c1bCZUoVg" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total
of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQoZNuLCZkh" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,039</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company granted options to purchase a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zIvBl2kuCoZa" title="Number of options"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares of common stock,
of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zBdm04VV3Pf4" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> were granted to Jacob Cohen, the Company&#8217;s CEO, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zWPHaiZbhmZb" title="Number of options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefOperatingOfficerMember_custom_TwentyTwentyTwoPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> were granted to Jonathan Arango, the Company&#8217;s
President and COO, as Bonus Equity Shares related to their respective employment agreement. The options have an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zElCtDJhEgae" title="Exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></span>
per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2fp8oOGua78" title="Vesting term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">three years</ix:nonNumeric></span>. As of December 31, 2022,
$<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zip64gV5bRi" title="Share based compensation"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,267</ix:nonFraction></span> has been recorded as stock-based compensation. Both Mr. Cohen and Arango are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFQ9mTYd1mUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock options activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmxzQdBkkpvk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfv0MGxuIbe1" title="Options, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2035">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zN8BW6OCny14" title="Weighted Average Exercise Price, Outstanding Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2037">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zSrPSGHbvuW6" title="Options, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zuBdwVacSAI" title="Weighted Average Exercise Price, Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zbQF8cnMfUL5" title="Options, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2043">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zOakZRnLunH3" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zBJnFiZ6IWM6" title="Options, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2047">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_z6HBjICtft8i" title="Weighted Average Exercise Price, Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2049">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zAtz53k6Gd2b" title="Options, Outstanding Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zwebE1QXQ4dl" title="Weighted Average Exercise Price, Outstanding Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zJB1Cha6VH4i" title="Options, Exercisable Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,333</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zMZVhPWnSnfd" title="Weighted Average Exercise Price, Exercisable Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20220101__20221231_zQn5skYMKtj4" title="Option Exercise Price Per Share" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zUvzjHEQCMk1" title="Outstanding Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zu3Ihh8EzdLb" title="Options Term"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">4.67</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zdfZrNcJrmyk" title="Weighted Average Outstanding Price Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zyn2TAT3PEOa" title="Exercisable Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">133,333</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zIvM10tSOKHc" title="Weighted Average Exercisable Price Ending Balance" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zHD1ZkAoGTa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 174; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the fair value of options outstanding was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_zJ1N5gUJA3bf" title="Fair value of options outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">688,984</ix:nonFraction></span>. The aggregate initial fair value of the options measured on
the grant date of August 31, 2022 was calculated using the Black-Scholes option &#160;&#160;pricing model based on the following assumption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQ6JxRHlI772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_znVgFVy2pF38" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231_zzL2TOKhG9N6" title="Fair value of common stock on measurement date" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zvOrrmtjR2d2" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.30</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zQ460uEm9Xr8" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.54</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zVlmAjG216zl" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zqyrWwP8FWi8" title="Expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.5</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zdH82mflRGFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zhpvu2YSvzp5" title="Warrants issued"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Warrants to investors and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zgEJg43hZIZk" title="Warrants issued for services"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,070</ix:nonFraction></span> Warrants as compensation
for services rendered in connection with the Offering. The Warrants have an original life of five years and vest immediately. The Warrants
for services were expensed as stock-based compensation at the aggregate fair value in the amount of $<span id="xdx_902_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220101__20221231_zt0buDyfL3Be" title="Fair value of warrant"><ix:nonFraction name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">151,821</ix:nonFraction></span>. Because the Warrants vest
immediately the fair value was assessed on the grant date. The aggregate fair value of the Warrants were measured using the Black-Scholes
option pricing model. The Company and the holder of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_ziZf21L6gey4" title="Warrants issued for services"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">210,070</ix:nonFraction></span> Warrants for services agreed to cancel the Warrants and reversed the entries
for stock based compensation to zero at year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zZsoOlnoC6hc" title="Fair value of warrants outstanding"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,299</ix:nonFraction></span>. Because the Warrants vested immediately
their fair value was assessed on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpi7F1Mp7Dh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock warrants activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zJk73NNH3RBb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WARRANT ACTIVITY</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRbHK54XpMg3" title="Warrants Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNejRM6N0fXb" title="Weighted Average Exercise Price Beginning Balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2099">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRNn5P0enlGa" title="Warrants Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,210,070</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3T9LPDWwQ7" title="Weighted Average Exercise Price Granted" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeTliNAnLnFe" title="Warrants Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z67sIyNRrFuh" title="Weighted Average Exercise Price Exercised" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2107">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjJpCUAI8I" title="Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9T2GOhGthRe" title="Weighted Average Exercise Price Expired" style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2111">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdbvENdkeMie" title="Warrants Cancelled" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">210,070</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znNCowjp1Ai9" title="Weighted Average Exercise Price Cancelled" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6iIASFSpjb" title="Warrants Outstanding, Ending balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMtyggziK6hd" title="Weighted Average Exercise Price Ending Balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3NLjhjGSxYi" title="Warrants Exercisable Ending balance" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoH9R2qqvG4b" title="Weighted Average Exercise Price Exercisable price" style="text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 175; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercise</b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Exercisable Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                                                                 (Years)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeQNSF8rmD2" title="Warrants Exercise Price Per Share" style="width: 30%; text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8g7Mdt9ysue" title="Outstanding and Vested Warrants Ending balance" style="width: 30%; text-align: right"><ix:nonFraction name="MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthrO8mkf6n2" title="Outstanding and Vested Warrants Expected Term" style="width: 30%; text-align: right"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt-sec:duryear" name="MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">4.74</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zJgo7LfpoZgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z62apZB4xIM7" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,000,000</ix:nonFraction></span> Warrants are outstanding and vested, and the vested stock Warrants have a weighted average remining life
of <span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7jpXEWPVYm7" title="Outstanding and vested warrants expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt-sec:duryear" name="MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">4.74</ix:nonNumeric></span> years.</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801406" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPEGDsUf92i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_z9wemA891r8" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWISYOmTNbL4" title="Fair value of common stock on measurement date"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.62</ix:nonFraction></span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztJTTO9yhpG2" title="Fair value of common stock on measurement date"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS1lvbebtna7" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.95</ix:nonFraction>%</span> to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjd88JF9Jki5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.00</ix:nonFraction></span></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS2mSedIdXn4" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.92</ix:nonFraction>%</span> to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSqQ4I40eb71" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">92.87</ix:nonFraction>%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDOCefVqkoc" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA55nUZLTbL6" title="Expected term"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A3_zd3sFhMDuzC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zXZE06xa5Ecd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_822_z3uxcKQ3TfUl">GOING CONCERN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization
of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying
financials, the Company had a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zcoxvJv3YXU9" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,998,055</ix:nonFraction></span> for the year ended December 31, 2022 and an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zndTQMDnMS11" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,015,756</ix:nonFraction></span>
as of December 31, 2022. The Company will need to raise additional capital to successfully execute its business plan of which there can
be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable
terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital
moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to
abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless
management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during
the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcayYwRMijae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82F_zOYkjV8m9q0d">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company is not currently subject to any such litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has a lease for an office in Dallas, TX classified as operating leases </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">under
ASC 842, <i>Leases</i>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#8220;Landlord&#8221;) to lease and occupy approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20220928_zE3gPM3ElVsb" title="Area of land"><ix:nonFraction name="us-gaap:AreaOfLand" contextRef="AsOf2022-09-28" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">2,201</ix:nonFraction></span> square feet of office space located at 15110 Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#8217;s main headquarters (the &#8220;<span style="text-decoration: underline">Lease Agreement</span>&#8221;). <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928_zxXiqTuwEBn1" title="Operating lease, description"><ix:nonNumeric contextRef="From2022-09-282022-09-28" name="us-gaap:LesseeOperatingLeaseDescription">The Lease
Agreement has a term of thirty-eight (<span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zBCZJtiLvAdl" title="Lease term"><ix:nonNumeric contextRef="AsOf2022-09-28" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">38</ix:nonNumeric></span>) months and has a monthly base rent of $<span id="xdx_90A_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928_zG08NoHFOMwd" title="Base rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-09-282022-09-28" format="ixt:numdotdecimal" decimals="2" unitRef="USD">5,777.63</ix:nonFraction></span>, or $31.50 per square foot, from months 3-18,
which increases at the rate of $1 per square foot per annum thereafter until the end of the lease term</ix:nonNumeric></span> (the &#8220;<span style="text-decoration: underline">Base
Rent</span>&#8221;). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real
estate taxes and assessments, hazard and liability insurance and common area maintenance costs for the building at the rate of <span id="xdx_905_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zGRfPgOA6Ttl" title="Percentage of proportionate rent"><ix:nonFraction name="MGRX:PercentageOfProportionateRent" contextRef="From2022-09-282022-09-28" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.45</ix:nonFraction>%</span>
(the &#8220;<span style="text-decoration: underline">Proportionate Rent</span>&#8221;). Upon the execution of the Lease Agreement, the Company agreed to prepay the first full
month&#8217;s Base Rent along with a security deposit equal to $<span id="xdx_907_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGt4WGPE423k" title="Base rent"><ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="From2022-09-282022-09-28_custom_LeaseAgreementMember" format="ixt:numdotdecimal" decimals="2" unitRef="USD">16,941.79</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 176; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company utilizes the incremental borrowing rate </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<span style="background-color: white">in
determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental
borrowing rate of <span id="xdx_900_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zWB9sM41lobh" title="Percentage of incremental borrowing rate"><ix:nonFraction name="MGRX:PercentageOfIncrementalBorrowingRate" contextRef="From2022-09-282022-09-28" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction>%</span> to estimate the present value of the right of use liability.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has right-of-use assets of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zcXPKYDcblRf" title="Right of use of asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,241</ix:nonFraction></span> and operating lease liabilities of $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_c20221231_zpyOi0i6Eqcl" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,405</ix:nonFraction></span> as of December 31, 2022. Operating lease expense
for the year ended December 31, 2022 was $<span id="xdx_90E_eus-gaap--OperatingLeaseCost_c20220101__20221231_zumUp55RaZoi" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,942</ix:nonFraction></span>. The Company has recorded $<span id="xdx_90E_eus-gaap--AssetImpairmentCharges_c20220101__20221231_zWBDXPzoF5ob" title="Asset impairment charges"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> in impairment charges related to right-of-use assets during
the year ended December 31, 2022.</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv51npV57e2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zSOjxkum5cj" style="display: none">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity of Lease Liabilities at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z8jP4j647OH3" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20221231_pp0p0" title="Year One" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,515</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20221231_pp0p0" title="Year Two" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71,716</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_c20221231_pp0p0" title="Year Three" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,589</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zqfX6Beqgvbe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,820</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNPS6ta9cobh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,415</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zwnEehXgygM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">185,405</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_ziFmjzeXaIE8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z5WgiUatoOM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10- <span id="xdx_82F_zwo6ZtOoQlA2">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the &#8220;Act&#8221;), which significantly changed U.S. tax law. The
Act lowered the Company&#8217;s U.S. statutory federal income tax rate from <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MaximumMember_zDLuHO10x811" title="Statutory federal income tax rate, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2017-12-222017-12-22_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">35</ix:nonFraction>%</span> to <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MinimumMember_zdxVJWDYZ5ae" title="Statutory federal income tax rate, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2017-12-222017-12-22_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction>%</span> effective January 1, 2018, while also imposing
a deemed repatriation tax on previously deferred foreign income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Act also created a new minimum tax on certain future foreign earnings. The impact of the Act increases the Company&#8217;s deferred
tax asset related to the Company&#8217;s net operating loss by approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_iI_c20221231_z1pBgVX4Hb4h" title="Deferred tax asset"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,015,756</ix:nonFraction></span> and increase the Company&#8217;s valuation allowance
by approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20221231_zxrFYRyzYCGb" title="Deferred tax assets, valuation allowance"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,015,756</ix:nonFraction></span> resulting in no impact to the Company&#8217;s financials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgement changes as a result of
the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution
may result in a payment that is materially different from our current estimate of the recognized tax benefit liabilities. These differences
will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December
31, 2022, and 2021 we have not recorded any uncertain tax positions in our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The effective US federal income corporate
tax rates for 2022 and 2021 are <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_z2qxRl9fPgQ2" title="US federal income corporate tax rates, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction>%</span> and <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zc85FSnSL1ze" title="US federal income corporate tax rates, percentage"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2021-01-012021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction>%</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has net operating loss carry forwards of approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zh2hw1HavwYe" title="Net operating loss carry forwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,015,756</ix:nonFraction></span> at December 31, 2022 that do not expire. However, utilization
of these losses may be limited pursuant to Section 382 of the Internal Revenue Code due to a recapitalization in 2007 and subsequent
stock issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSa12UH9nVQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a deferred tax asset as shown in the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z3T4mU5qsMo6" style="display: none">SCHEDULE
OF DEFERRED TAX ASSET</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zFmT8XeCbYih" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zEZCNnucIaIl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_zdU2QVNyj0Wl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Deferred Tax Asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,015,756</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,701</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_zHsUZFtj0wx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,015,756</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,701</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_z0L3lNNFcJSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2222">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zhlhlBzKEiJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 177; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#fintoc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-012022-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zjfDU99Gm5ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_827_zKugN4RrnDm3">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#8220;DojoLabs&#8221;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $<span id="xdx_906_eus-gaap--Cash_iI_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfkarDNSR3e" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,000</ix:nonFraction></span> in cash and issued DojoLabs <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zehfNDlvchA7" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of restricted common
stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains
customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zc7P9lX814W2" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction> </span>per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi0TAUs4eep9" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,000</ix:nonFraction></span>.&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#8220;Bethor&#8221;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFCl17ukFpog" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> shares of restricted common stock with registration rights. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zppYM6bmdGej" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVahsqXlL6td" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the
&#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#8217;s development of new business ventures
and strategic planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#8220;Dr. Rudman&#8221;)
and Mr. Jarrett Boon (&#8220;Mr. Boon&#8221;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. Rudman&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Dr. Rudman
Consulting Agreement&#8221;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuSIeLR0uNRg" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span>
shares of the Company&#8217;s restricted common stock, pay Dr. Rudman $<span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4eaOkxvWtbh" title="Compensation expense"><ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,000</ix:nonFraction></span> per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests
of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztmjmkuCsAY5" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction> </span>per share for a total
of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE8gqTjmI6cd" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Boon&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Mr. Boon
Consulting Agreement&#8221;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqb8t2R1Qfz" title="Shares issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> shares
of the Company&#8217;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties to the Company in service
on the Advisory Board. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztgMovpx7VGg" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBZpqGn9qTo8" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, <span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zG9lE3BeRUqb" title="Settlement description"><ix:nonNumeric contextRef="From2023-01-242023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember" name="us-gaap:CommonStockConversionFeatures">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</ix:nonNumeric></span> Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_z8k6d1Z6Atrc" title="Share price"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.28</ix:nonFraction></span> per
share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zJ1UXs6jWio8" title="Shares issued value"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-242023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,000</ix:nonFraction></span>.</span></p>

</ix:nonNumeric><p id="xdx_81A_zkY9GStSQGF3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>







<!-- Field: Page; Sequence: 178 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>4,000,000
</b></span><span style="font-family: Times New Roman, Times, Serif"><b>Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="forms-1_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 24pt"><b>Mangoceuticals,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRELIMINARY
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 18pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <tr style="font: 18pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 18pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Boustead
    Securities, LLC </b></span></td>
    <td style="font: 18pt Times New Roman, Times, Serif; width: 50%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>Sutter
    Securities, Inc.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>__________,
</b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 179 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
13. Other Expenses of Issuance and Distribution.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the estimated costs and expenses to be incurred in connection with the issuance and distribution of the securities
of Mangoceuticals, Inc. (the &#8220;Registrant&#8221;) which are registered under this Registration Statement on Form S-1 (this &#8220;Registration
Statement&#8221;), except any expenses incurred by the selling shareholders and other than underwriting discounts and commissions. All
amounts are estimates except the Securities and Exchange Commission registration fee, the Nasdaq Capital Market listing fee, and the
Financial Industry Regulatory Authority, Inc. filing fee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount to</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>be Paid</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">SEC Registration fee</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">665</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financial Industry Regulatory Authority, Inc. filing fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,189</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Printing and engraving expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">65,000</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Transfer Agent&#8217;s fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,000</td><td style="text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Miscellaneous fees and expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,146</td><td style="padding-bottom: 1.5pt; text-align: left">*</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Total</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">100,000</td><td style="text-align: left">*</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
14. Indemnification of Directors and Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
authorized by Chapter 8 of the Texas Business Organizations Code, we may indemnify our officers and directors (and our former officers
and directors) against expenses incurred by such persons in connection with any (A) threatened, pending, or completed action or other
proceeding, whether civil, criminal, administrative, arbitrative, or investigative; (B) an appeal of an action or proceeding described
by (A); and (C) an inquiry or investigation that could lead to an action or proceeding described by (A), involving such persons in their
capacities as officers and directors, if it is determined in accordance with the Texas Business Organizations Code that: (1) the person:
(A) acted in good faith; (B) reasonably believed: (i) in the case of conduct in the person&#8217;s official capacity, that the person&#8217;s
conduct was in the enterprise&#8217;s best interests; and (ii) in any other case, that the person&#8217;s conduct was not opposed to
the enterprise&#8217;s best interests; and (C) in the case of a criminal proceeding, did not have a reasonable cause to believe the person&#8217;s
conduct was unlawful; (2) with respect to expenses, the amount of expenses other than a judgment is reasonable; and (3) indemnification
should be paid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Texas law, corporations may also purchase and maintain insurance or make other financial arrangements on behalf of any person who is
or was a director or officer (or is serving at our request as a director or officer of another corporation) for any liability asserted
against such person and any expenses incurred by him in his capacity as a director or officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our Bylaws (&#8220;Bylaws&#8221;), state that we shall indemnify every (i) present or former director, advisory director or officer of
us, (ii) any person who while serving in any of the capacities referred to in clause (i) served at our request as a director, officer,
partner, venturer, proprietor, trustee, employee, agent or similar functionary of another foreign or domestic corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise, and (iii) any person nominated or designated by (or pursuant to authority
granted by) the Board of Directors or any committee thereof to serve in any of the capacities referred to in clauses (i) or (ii) (each
an &#8220;Indemnitee&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 180; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Bylaws provide that we shall indemnify an Indemnitee against all judgments, penalties (including excise and similar taxes), fines, amounts
paid in settlement and reasonable expenses actually incurred by the Indemnitee in connection with any proceeding in which he was, is
or is threatened to be named as a defendant or respondent, or in which he was or is a witness without being named a defendant or respondent,
by reason, in whole or in part, of his serving or having served, or having been nominated or designated to serve, if it is determined
that the Indemnitee (a) conducted himself in good faith, (b) reasonably believed, in the case of conduct in his official capacity, that
his conduct was in our best interests and, in all other cases, that his conduct was at least not opposed to our best interests, and (c)
in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful; provided, however, that in
the event that an Indemnitee is found liable to us or is found liable on the basis that personal benefit was improperly received by the
Indemnitee, the indemnification (i) is limited to reasonable expenses actually incurred by the Indemnitee in connection with the proceeding
and (ii) shall not be made in respect of any proceeding in which the Indemnitee shall have been found liable for willful or intentional
misconduct in the performance of his duty to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided above, the Bylaws provide that no indemnification shall be made in respect to any proceeding in which such Indemnitee has
been (a) found liable on the basis that personal benefit was improperly received by him, whether or not the benefit resulted from an
action taken in the Indemnitee&#8217;s official capacity, or (b) found liable to us. The termination of any proceeding by judgment, order,
settlement or conviction, or on a plea of nolo contendere or its equivalent, is not of itself determinative that the Indemnitee did not
meet the requirements set forth in clauses (a) or (b) above. An Indemnitee shall be deemed to have been found liable in respect of any
claim, issue or matter only after the Indemnitee shall have been so adjudged by a court of competent jurisdiction after exhaustion of
all appeals therefrom. Reasonable expenses shall include, without limitation, all court costs and all fees and disbursements of attorneys&#8217;
fees for the Indemnitee. The indemnification provided shall be applicable whether or not negligence or gross negligence of the Indemnitee
is alleged or proven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
our Bylaws nor our Certificate of Formation, as amended, include any specific indemnification provisions for our officers or directors
against liability under the Securities Act. Additionally, insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the
Company has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
15. Recent Sales of Unregistered Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of transactions by us within the past three years involving sales or our securities that were not registered under
the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company issued 1,000,000 shares of restricted common stock each (2,000,000 shares in aggregate) to Mr. Cohen and Jonathan
Arango, in consideration for services rendered as the Chief Executive Officer and President and then Chief Operating Officer, respectively,
of the Company. The shares were valued at $0.10 per share or a total of $100,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, and effective on October 7, 2021, we issued 8,000,000 shares of restricted common stock of the Company to American International
Holdings Corp., of which Jacob D. Cohen, our Chairman and Chief Executive Officer, is the President, Chief Executive Officer and a director,
in consideration for $800 or $0.0001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2022, we issued 250,000 shares of restricted common stock to The Loev Law Firm, PC, in consideration for services rendered to
the Company. The Managing Partner of The Loev Law Firm, PC, is David M. Loev, the brother-in-law of Jacob D. Cohen, our Chairman and
Chief Executive Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2022, the Company began a private placement of up to $2,000,000&#160;of units (the &#8220;Units&#8221;), each consisting of
one share of common stock (the &#8220;Shares&#8221;) and a warrant to purchase one share of common stock (the &#8220;Warrants&#8221;),
at a price of $1.00&#160;per Unit. The Warrants have a&#160;five-year&#160;term and an exercise price of $1.00&#160;per share, for which
cash would need to be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise
the Warrants are exercisable on either a cash basis or a cashless basis. The price of the Units was determined by the Company and such
price did not necessarily bear any relation to the book value or other recognized criteria of value of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering commenced on August 8, 2022 and the Company sold&#160;2,000,000&#160;Units at $1.00&#160;per Unit to 23 investors in exchange
for $2,000,000&#160;in gross proceeds from the investors, and subsequently issued the investors&#160;2,000,000&#160;Shares and&#160;2,000,000&#160;Warrants
between August 16, 2022 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (&#8220;PHX&#8221;), which is owned by Peter &#8220;Casey&#8221;
Jensen, who was a member of the Board of Directors of American International. Pursuant to the Consulting Agreement, PHX agreed to provide
consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was
for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach
30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX
50,000 restricted shares of common stock. The agreement contains customary confidentiality and non-solicitation provisions. We also agreed
to include the shares issued to PHX in the Resale Prospectus, which shares of common stock are included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott, currently a professional football player, and a running
back in the National Football League (&#8220;Elliott&#8221;) to provide consulting and general business advisory services as reasonably
requested by the Company during the term of the agreement, which was for 12 months, unless otherwise earlier terminated due to breach
of the agreement by either party, and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued Elliott 100,000 restricted shares of common stock. The agreement contains
customary confidentiality and non-solicitation provisions. We also agreed to register the shares issued to Elliott in the Resale Prospectus,
which shares of common stock are included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with David Sandler (&#8220;Sandler&#8221;), to provide consulting and general
business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months, unless
otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written
notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler 10,000 restricted
shares of common stock. The agreement contains customary confidentiality and non-solicitation provisions. We also agreed to include the
shares issued to Sandler in the Resale Prospectus, which shares of common stock are included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou (&#8220;Chou&#8221;), to provide consulting and general
business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months, unless
otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after written
notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou 5,000 restricted shares
of common stock. The agreement contains customary confidentiality and non-solicitation provisions. We also agreed to include the shares
issued to Chou in the Resale Prospectus, which shares of common stock are included therein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. Pursuant to the Service Agreement, Greentree
agreed to perform various following services. The Company agreed to issue Greentree 100,000 shares of the Company&#8217;s restricted
common stock upon the parties&#8217; entry into the agreement, and to pay Greentree $50,000 in cash. We also agreed to include the 100,000
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein. Since February
2015, Mr. Eugene M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022) has served as Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, we initiated a private offering, pursuant to which we have sold an aggregate of 2,000,000 units, each consisting of one
share of our common stock and one warrant to purchase one share of common stock with an exercise price of $1.00 per share, for $1.00
per unit, or 2,000,000 in aggregate in a private placement, made solely to accredited investors. The offering closed on December 22,
2022. Boustead Securities, LLC served as placement agent for the offering. As additional consideration for serving as Placement Agent,
we granted Boustead warrants to purchase 280,000 shares of common stock, representing 7% of the number of shares and warrants sold in
the private placement with an exercise price equal to $1.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company agreed to grant Eugene M. Johnston, its Chief Financial Officer, 150,000 shares of the Company&#8217;s restricted
stock which vest over a 6-month period at the rate of 25,000 shares per month with the first 25,000 shares vesting on November 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued 75,000 restricted shares of common stock to each of its three independent directors, which shares
vest 1/3 on October 14, 2022, with the remaining shares vesting in one-third increments on each of October 14, 2023 and 2024, subject
to such directors continuing to provide services to the Company on such dates, and subject to the Restricted Stock Award agreements entered
into to evidence such grants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued its Project Manager, Joan Arango, 25,000 shares of restricted common stock under the Plan. The shares
were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#8217;s President and Chief
Operating Officer, Secretary and Director, Jonathan Arango. The shares were valued at $0.28 per share for a total of $7,204.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#8220;White Unicorn&#8221;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn 100,000 shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $0.28 per share for a total of $28,816.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 1, 2022, the Company entered into a Master Services Agreement with Global Career Networks, Inc. (&#8220;GCN&#8221;). Pursuant
to the agreement, we agreed to issue GCN 100,000 shares of restricted common stock with registration rights (which are included in the
Resale Prospectus) and GCN agreed to assist us with a planned twitter marketing campaign. The agreement has a one year term (provided
the individual project described therein has a six month term, beginning December 1, 2022), and may be renewed thereafter for additional
one year terms with the mutual approval of the parties. Either party may terminate the agreement at any time for any reason, with at
least 60 days&#8217; notice, or upon the occurrence of any breach or default under the agreement, which remains uncured within 30 days
of written notice thereof, or if the non-terminating party is subject to bankruptcy. The agreement contains customary confidentiality,
indemnification obligations, and limitations of liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#8220;Chartered Services&#8221;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company agreed to pay Chartered Services $150,000 in cash (with $75,000 payable upon
entry into the agreement and $75,000 payable on January 31, 2023, which amount has been paid to date) and issued Chartered Services 250,000
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $0.28 per share for a total of $72,039.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2022, we entered into a Waiver of Warrant agreement with the placement agent in our 2022 Private Offering, Boustead Securities,
LLC (&#8220;Boustead&#8221;), whereby Boustead agreed to surrender all 280,000 warrants issued to them in connection with the 2022 Private
Offering (the &#8220;Placement Agent Warrants&#8221;) for no consideration and Boustead irrevocably waived any right or interest in the
Placement Agent Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#8220;DojoLabs&#8221;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $100,000 in cash and issued DojoLabs 50,000 shares of restricted common
stock with registration rights (the registration of the resale of which shares are included in the Resale Prospectus) and fully vest
upon the completion of all work performed under the scope of work. The agreement contains customary confidentiality and non-solicitation
provisions. The shares were valued at $0.28 per share for a total of $28,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#8220;Bethor&#8221;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor 250,000 shares of restricted common stock with registration rights (the registration
of the resale of which shares are included in the Resale Prospectus). The agreement contains customary confidentiality and non-solicitation
provisions. The shares were valued at $0.28 per share for a total of $70,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the
&#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board will be
comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any time.
In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the Advisory
Board is to assist the Board of Directors in its general oversight of the Company&#8217;s development of new business ventures and strategic
planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#8220;Dr. Rudman&#8221;)
and Mr. Jarrett Boon (&#8220;Mr. Boon&#8221;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. Rudman&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Dr. Rudman
Consulting Agreement&#8221;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman 25,000
shares of the Company&#8217;s restricted common stock, pay Dr. Rudman $2,000 per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests
of the performance of his duties to the Company in service on the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Boon&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Mr. Boon
Consulting Agreement&#8221;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon 25,000 shares
of the Company&#8217;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties to the Company in service
on the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1)&#160;Sultan Haroon; (2)&#160;John Helfrich;
(3) Justin Baker; and (4)&#160;Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements,
the Consultants agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical
and other over-the-counter related products during the term of the agreement, which each had a term of 18 months unless otherwise earlier
terminated due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In
consideration for agreeing to provide the services under the agreement, the Company issued an aggregate of 350,000 shares of common stock
to the consultants as follows: (1)&#160;Sultan Haroon 150,000 shares of restricted common stock; (2)&#160;John Helfrich 25,000 shares
of restricted common stock; (3)&#160;Justin Baker 25,000 shares of restricted common stock; and (4)&#160;Maja Matthews 150,000 shares
of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement,
50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful
launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The
shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s
successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new
product category, in each case prior to the 18-month anniversary of the applicable agreement. Any shares not vested by the eighteen-month
anniversary of the applicable agreement are forfeited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 100,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 100,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $25,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 25,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $25,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 25,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase 75,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $75,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 75,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 100,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 shares of common stock with an exercise price of
$1.00 per share in consideration for $25,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act. The Company issued 25,000 shares of common stock in connection with such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (&#8220;Redlime&#8221;) to provide software
development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services
under the agreement, the Company agreed to pay Redlime $300,000 in cash and issue Redlime 180,000 shares of restricted common stock.
The shares were valued at $1.00 per share for a total of $180,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (&#8220;Mr. Andrew&#8221;), an independent, non-Board member and non-Company
employee, to the Advisory Board. In connection with Mr. Andrew&#8217;s appointment to the Advisory Board, the Company entered into an
Advisor Agreement (the &#8220;Mr. Andrew Consulting Agreement&#8221;), dated effective May 25, 2023, with Mr. Andrew, whereby the Company
agreed to issue Mr. Andrew&#160;50,000&#160;shares of the Company&#8217;s restricted common stock under the 2022 Plan and to reimburse
Mr. Andrew for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the
Company&#8217;s requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at
$1.10&#160;per share for a total of $55,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
June 6, 2023 to June 23, 2023, six holders of warrants to purchase outstanding common stock exercised warrants to purchase 474,500 shares
of common stock for cash, and paid the Company an aggregate of $474,500 in connection with such exercises (based on the $1.00 per share
exercise price of the warrants). Upon such exercises, the Company issued the holders an aggregate of 474,500 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Consulting Agreement with Major Dodge (&#8220;Major&#8221;), to provide acting and production related
services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of
the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued Major&#160;20,000&#160;shares of restricted common stock under the 2022
Plan. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $1.10&#160;per share
for a total of $22,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (&#8220;New To The Street&#8221;),
to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which is for
3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company
issued New To The Street 50,000 shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $5,000.
The shares were valued at $1.10 per share for a total of $55,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2023, a warrant holder exercised private placement Warrants to purchase 150,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $150,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2023, a warrant holder exercised private placement Warrants to purchase 75,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $75,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2023, a warrant holder exercised private placement Warrants to purchase 24,500 shares of common stock with an exercise price
of $1.00 per share in consideration for $24,500 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase 25,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $25,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2023, a warrant holder exercised private placement Warrants to purchase 100,000 shares of common stock with an exercise price
of $1.00 per share in consideration for $100,000 in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, the Company entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the
&#8220;Service Agreement&#8221;). The Company and Greentree were previously party to a service agreement which expired pursuant to its
terms on August 14, 2023. Since February 2015, Mr. Eugene M. Johnston, our Chief Financial Officer (who was appointed October 1, 2022)
has served as Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for the Company for the period
from October 1, 2023 through September 30, 2024; (b) assistance to the Company with compliance filings for the quarters ended September
30, 2023, March 31, 2024, June 30, 2024 and the year ended December 31, 2023, including the consolidation structure and entries as well
as assistance with United States Generally Accepted Accounting Principles (&#8220;<span style="text-decoration: underline">US GAAP</span>&#8221;) footnotes; (c) reviewing, and
providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose
of bringing such documents and systems into compliance with US GAAP or disclosures required by the Securities and Exchange Commission
(the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;); (d) providing necessary consulting services and support as a liaison for the Company to third party service
providers, including coordination amongst the Company and its attorneys, certified public accountants and transfer agent; and (e) preparing
and filing the Company&#8217;s tax returns with the Internal Revenue Service for the 2022 and 2023 tax years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree 75,000 shares of the Company&#8217;s restricted common stock (the &#8220;Greentree Shares&#8221;) upon
the parties&#8217; entry into the agreement, and to pay Greentree $40,000 in cash, payable as follows: (a) $20,000 on or before September
30, 2023; and (b) $20,000 on or before March 31, 2024. We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses
incurred in connection with Greentree&#8217;s activities under the agreement, including the reasonable fees and travel expenses for the
meetings on behalf of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Service Agreement continues in effect through September 30, 2024, but may be terminated earlier with 45 days&#8217; notice from the Company
to Greentree, provided that in the event the Company terminates the agreement prior to the end of the Term, the entire cash fee due during
the term of the Service Agreement is immediately due and payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Service Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with
regard to certain matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2023, we entered into a Consulting Agreement with Luca Consulting to provide management consulting and business advisory
services to the Company during the term of the agreement, which is for three months. In consideration for agreeing to provide the services
under the agreement, the Company agreed to pay Luca Consulting $15,000 in cash and issued Luca Consulting 200,000 shares of restricted
common stock. The agreement contains customary confidentiality and non-circumvention provisions. The shares were valued at $0.60 per
share for a total of $120,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2023, the Company entered into a Marketing Agreement with Marius allowing the Company the use of the trademark &#8220;Kyzatrex&#174;&#8221;
oral testosterone undecanoate softgel capsules for purposes of branding, packaging, marketing, and selling Kyzatrex&#174; on the Company&#8217;s
website and to be sold via its telehealth platform at <span style="text-decoration: underline">www.MangoRx.com</span>. Pursuant to the Marketing Agreement, the Company agreed
to issue Marius 100,000 shares of the Company&#8217;s restricted common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
* * * *</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of proceeds associated with the above listed sales of unregistered securities was for general working capital purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuances and grants described above were exempt from registration pursuant to Section 4(a)(2), and/or Rule 506 of Regulation D of the
Securities Act, since the foregoing issuances and grants did not involve a public offering, the recipients took the securities for investment
and not resale, we took take appropriate measures to restrict transfer, and the recipients were (a) &#8220;accredited investors&#8221;;
(b) had access to similar documentation and information as would be required in a Registration Statement under the Securities Act; and/or
(c) were officers or directors of the Company. The securities are subject to transfer restrictions, and the certificates evidencing the
securities contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be
offered or sold absent registration or pursuant to an exemption therefrom. The securities were not registered under the Securities Act
and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities
Act and any applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
16. Exhibits and Financial Statement Schedules.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 234.9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Exhibits</i></b>:
    Exhibits Pursuant to Item 601 of Regulation S-K:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed/</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Furnished</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description
    of Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Herewith</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/ex1-1.htm" style="-sec-extract: exhibit">Form of Underwriting Agreement</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-275993</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Formation of Mangoceuticals, Inc., filed with the Secretary of State of Texas on October 7, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Formation of Mangoceuticals, Inc., filed with the Secretary of State of Texas on April 15, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex3-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws of Mangoceuticals, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223016003/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Purchase Warrant granted to Boustead Securities, LLC evidencing the right to acquire 87,500 shares of common stock (dated March 23, 2023)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/10/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant (Investors &#8211; 2022 Private Placement)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/ex4-3.htm" style="-sec-extract: exhibit">Form of Representative&#8217;s Warrant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-275993</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion and consent of The Loev Law Firm, PC re: the legality of the securities being registered</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Purchase Agreement between American International Holdings Corp. and Cohen Enterprises, Inc., dated June 16, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Subscription Agreement (2022 Private Placement)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physician Services Agreement dated August 1, 2022, between Mangoceuticals, Inc. and BrighterMD, LLC dba Doctegrity</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#163;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Services Agreement and Statement of Work dated September 1, 2022, and effective August 31, 2022, between Epiq Scripts, LLC and Mangoceuticals, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#163;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 188; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement dated August 31, 2022, between Mangoceuticals, Inc. and Jacob D. Cohen</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-6.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Employment Agreement dated August 31, 2022, between Mangoceuticals, Inc. and Jonathan Arango</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-7.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc. 2022 Equity Incentive Plan</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-8.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Option Agreement dated August 31, 2022 between Mangoceuticals, Inc. and Jacob D. Cohen (750,000 option shares)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-9.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Option Agreement dated August 31, 2022 between Mangoceuticals, Inc. and Jonathan Arango (500,000 option shares)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-10.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated September 6, 2022, between Mangoceuticals, Inc. and PHX Global, LLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-11.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated September 6, 2022, between Mangoceuticals, Inc. and Ezekiel Elliott</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-12.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated September 15, 2022, between Mangoceuticals, Inc. and David Sandler</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-13.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated September 15, 2022, between Mangoceuticals, Inc. and Hsiaoching Chou</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service Agreement dated September 22, 2022, by and between Mangoceuticals, Inc. and Greentree Financial Group, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer Letter dated October 1, 2022 entered into between Mangoceuticals, Inc. and Eugene M. Johnston</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Restricted Stock Grant and Restricted Stock Grant Agreement dated October 1, 2022 between Mangoceuticals, Inc. and Eugene M. Johnston</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Restricted Stock Grant and Restricted Stock Grant Agreement dated October 14, 2022 between Mangoceuticals, Inc. and Dr. Kenny Myers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-18.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 14, 2022 Offer Letter entered into between Mangoceuticals, Inc. and Dr. Kenny Myers</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-19.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Restricted Stock Grant and Restricted Stock Grant Agreement dated October 14, 2022 between Mangoceuticals, Inc. and Alex P. Hamilton</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 14, 2022 Offer Letter entered into between Mangoceuticals, Inc. and Alex P. Hamilton</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Restricted Stock Grant and Restricted Stock Grant Agreement dated October 14, 2022 between Mangoceuticals, Inc. and Lorraine D&#8217;Alessio</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 189; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-22.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">October 14, 2022 Offer Letter entered into between Mangoceuticals, Inc. and Dr. Lorraine D&#8217;Alessio</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-23.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated November 1, 2022, between Mangoceuticals, Inc. and White Unicorn, LLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-24.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Services Agreement dated December 1, 2022, between Mangoceuticals, Inc. and Global Career Networks, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-25.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated December 21, 2022, between Mangoceuticals, Inc. and Chartered Services, LLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-26.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver Agreement dated December 30, 2022, between Mangoceuticals, Inc. and Boustead Securities, LLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-27.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated January 3, 2023, between Mangoceuticals, Inc. and DojoLabs Group, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-28.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisor Agreement dated January 6, 2023, between Mangoceuticals, Inc. and Dr. Brian Rudman</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-29.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisor Agreement dated January 6, 2023, between Mangoceuticals, Inc. and Jarrett Boon</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-30.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated January 6, 2023, between Mangoceuticals, Inc. and Bethor, Ltd</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223002627/ex10-31.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated January 24, 2023, between Mangoceuticals, Inc. and Sultan Haroon</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/26/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223002627/ex10-32.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated January 24, 2023, between Mangoceuticals, Inc. and John Helfrich</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/26/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223002627/ex10-33.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated January 24, 2023, between Mangoceuticals, Inc. and Justin Baker</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/26/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223002627/ex10-34.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated January 24, 2023, between Mangoceuticals, Inc. and Maja Matthews</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/26/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223005634/ex10-35.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secured Installment Promissory Note dated November 18, 2022, between Mangoceuticals, Inc. and BPI Equipment, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/21/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223015389/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement dated and effective May 1, 2023, by and between Mangoceuticals, Inc. and Amanda Hammer</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/4/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223015389/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock Option Agreement dated May 1, 2023 between Mangoceuticals, Inc. and Amanda Hammer (150,000 option shares)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/4/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 190; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223032100/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service Agreement dated September 1, 2023, by and between Mangoceuticals, Inc. and Greentree Financial Group, Inc.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/8/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39&#163;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex10-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Services Agreement and Statement of Work dated September 1, 2022, and effective August 31, 2022, between Epiq Scripts, LLC and Mangoceuticals, Inc. (filed as Exhibit 10.4 to the Registration Statement on Form S-1 filed by the Company with the Securities and Exchange Commission on January 13, 2023, and incorporated herein by reference)(File Number: 333-269240)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/21/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223033356/ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Addendum to Master Services Agreement dated September 15, 2023, by and between Mangoceuticals, Inc. and Epiq Scripts, LLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/21/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223035673/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement dated and effective October 3, 2023, by and between Mangoceuticals, Inc. and Eugene M. Johnston</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/4/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223038526/ex10-42.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc., Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;10/27/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;001-41615</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/ex10-43.htm" style="-sec-extract: exhibit">Advisor Agreement dated November 1, 2023, between Mangoceuticals, Inc. and Dr. Douglas Christianson</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-275993</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/ex10-44.htm" style="-sec-extract: exhibit">Notice of Restricted Stock Grant and Restricted Stock Grant Agreement dated November 1, 2023 between Mangoceuticals, Inc. and Dr. Douglas Christianson</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-275993</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/ex10-1.htm" style="-sec-extract: exhibit">Marketing Agreement dated December 10, 2023, by and between Mangoceuticals, Inc. and Marius Pharmaceuticals</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-41615</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex14-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct and Ethics</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223002627/ex16-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter from M&amp;K CPAS, PLLC to the U.S. Securities and Exchange Commission dated January 26, 2023, from M&amp;K CPAS, PLLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/26/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/ex21-1.htm" style="-sec-extract: exhibit">Subsidiaries</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">S-1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">21.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">12/11/2023</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">333-275993</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex23-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of M&amp;K CPAS, PLLC</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex23-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Turner, Stone &amp; Company, L.L.P.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of The Loev Law Firm, PC (included in Exhibit 5.1)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/forms-1.htm#poa_001" style="-sec-extract: exhibit">Power of Attorney (included on the signature page of the original Form S-1 Registration Statement)</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-275993</span></td>
    </tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee Charter</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td>
    </tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 191; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex99-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Committee Charter</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex99-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance Committee Charter</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex99-4.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whistleblower Protection Policy</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223001478/ex99-5.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc. Advisory Board Charter, adopted January 6, 2023</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/13/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-269240</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Schema Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Calculation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Definition Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Label Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Presentation Linkbase Document</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as&#160;Inline XBRL&#160;and contained in Exhibit 101)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCECFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1938046/000149315223044447/ex107.htm" style="-sec-extract: exhibit">Filing Fee Table</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/11/2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-275993</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Indicates management contract or compensatory plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#163;
Certain portions of these Exhibits have been omitted in accordance with Regulation S-K Item 601 because they are both (i) not material
to investors and (ii) the type of information that the Registrant customarily and actually treats as private or confidential, and have
been marked with &#8220;[***]&#8221; to indicate where omissions have been made. The Registrant agrees to furnish supplementally an unredacted
copy of the Exhibit to the SEC upon its request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)
Financial Statement Schedule.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules are omitted because the information called for is not required or is shown either in the financial statements
or the notes thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
17. Undertakings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Include any prospectus required by Section 10(a)(3) of the Securities Act;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration
Fee&#8221; table in the effective registration statement; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 192; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule
424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other
than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is
part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first
use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement
or made in any such document immediately prior to such date of first use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of
the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
That, for the purpose of determining liability of the Registrant under the Securities Act to any purchaser in the initial distribution
of the securities, the undersigned Registrant undertakes that in a primary offering of securities of the undersigned Registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned Registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned Registrant relating to the offering required to be filed pursuant to Rule
424;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned Registrant or used or referred to by
the undersigned registrant;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned Registrant
or its securities provided by or on behalf of the undersigned Registrant; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned Registrant to the purchaser.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 33.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)
The undersigned registrant hereby undertakes that:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time
it was declared effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 193; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><a href="#abc_001" style="font-style: italic">Table of Contents</a></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, Texas on the 18th day of December 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANGOCEUTICALS,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jacob D. Cohen</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="poa_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons
in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NAME</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POSITION</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DATE</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jacob D. Cohen</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    D. Cohen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Executive Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Jonathan Arango</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
    Arango</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary
    and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eugene M. Johnston</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
    M. Johnston</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(Principal
    Financial and Accounting Officer)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lorraine
    D&#8217;Alessio</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alex
    P. Hamilton</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Kenny Myers</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">* Mr. Jacob D. Cohen hereby
signs this Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 on behalf of the indicated persons for whom
he is attorney-in-fact, pursuant to powers of attorney previously filed as Exhibit 24.1 to the Registration Statement on Form S-1 of
Mangoceuticals, Inc. filed with the Securities and Exchange Commission on December 18, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="padding-bottom: 1.5pt; width: 3%">By:</td>
  <td style="border-bottom: Black 1.5pt solid; width: 47%"><i>/s/ Jacob D. Cohen</i></td>
  <td style="padding-bottom: 1.5pt; width: 50%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Jacob D. Cohen</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>Attorney-in-fact</td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 194; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT="" STYLE="height: 143px; width: 670px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
18, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15110
N. Dallas Parkway, Suite 600</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas 75248&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mangoceuticals,
    Inc.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    Statement on Form S-1</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as U.S. securities counsel to Mangoceuticals, Inc., a Texas corporation (the &ldquo;<U>Company</U>&rdquo;), in connection
with the preparation and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)&nbsp;pursuant to the
Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of a Registration Statement on Form S-1 (as amended through
the date hereof, the &ldquo;<U>Registration Statement</U>&rdquo;), relating to the registration by the Company of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
up to 4,600,000 shares (the &ldquo;<U>Shares</U>&rdquo;)&nbsp;of the Company&rsquo;s common stock, par value $0.0001 per share
(the &ldquo;<U>Common Stock</U>&rdquo;), including up to 600,000 shares of Common Stock issuable upon exercise of the Underwriters&rsquo;
(as defined below) over-allotment option,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
warrants (the &ldquo;<U>Representative&rsquo;s Warrants</U>&rdquo;)&nbsp;to purchase up to 322,000 shares of Common Stock of the
Company to be issued to the Representative (as defined below)&nbsp;of the several Underwriters (as defined below)&nbsp;as additional
compensation pursuant to the Underwriting Agreement (as defined below), and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
up to 322,000 shares of Common Stock issuable upon exercise of the Representative&rsquo;s Warrants (the &ldquo;<U>Representative&rsquo;s
Warrant Shares</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares, the Representative&rsquo;s Warrants and the Representative&rsquo;s Warrant Shares, are collectively referred to as the &ldquo;<U>Securities</U>.&rdquo;
The Securities are to be sold by the Company pursuant to an underwriting agreement (the &ldquo;<U>Underwriting Agreement</U>&rdquo;)&nbsp;to
be entered into by and between the Company and Boustead Securities, LLC, as representative (the &ldquo;<U>Representative</U>&rdquo;)&nbsp;of
the several underwriters named therein (the &ldquo;<U>Underwriters</U>&rdquo;), the form of which has been or will be filed as&nbsp;<U>Exhibit
1.1</U>&nbsp;to the Registration Statement. This opinion is being furnished in accordance with Item 601(b)(5)(i)&nbsp;of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
reaching the opinions set forth herein, we have examined and are familiar with originals or copies, certified or otherwise identified
to our satisfaction, of such documents and records of the Company and such statutes, regulations and other instruments as we have deemed
necessary or advisable for purposes of this opinion, including (i)&nbsp;the Company&rsquo;s Certificate of Formation, as amended to date,
(ii)&nbsp;the Company&rsquo;s Bylaws, as amended to date, (iii)&nbsp;the Registration Statement and the exhibits thereto, (iv)&nbsp;the
minutes, consents, resolutions, and applicable agreements relating to the sale, issuance and grant, of the Securities, (v)&nbsp;the form
of Underwriting Agreement, (vi)&nbsp;the form of common stock purchase warrant evidencing the Representative&rsquo;s Warrants, and (vii)&nbsp;such
other agreements, certificates, instruments, and documents as we have considered necessary for purposes of this opinion letter. We have
also reviewed such matters of law as we considered necessary or appropriate as a basis for the opinion expressed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
to various questions of fact material to the opinions expressed below, we have, without independent third party verification of their
accuracy, relied in part, and to the extent we have deemed reasonably necessary or appropriate, upon the representations and warranties
of the Company contained in such documents, records, certificates, instruments or representations furnished or made available to us by
the Company, including the Registration Statement and, to the extent that we deemed such reliance proper, upon certificates of public
officials and officers or other representatives of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
your permission, we have made and relied upon the following assumptions, without any independent investigation or inquiry by us, and
our opinion expressed below is subject to, and limited and qualified by the effect of, such assumptions: (1)&nbsp;all corporate records
furnished to us by the Company are accurate and complete; (2)&nbsp;the Registration Statement to be filed by the Company with the Commission
will be identical to the form of the document that we have reviewed; (3)&nbsp;all statements as to factual matters that are contained
in the Registration Statement (including the exhibits to the Registration Statement)&nbsp;are accurate and complete; and (4) all the
Securities will be issued and sold in the manner specified in the Registration Statement and the related prospectuses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also assumed (i)&nbsp;the legal capacity of all natural persons, (ii)&nbsp;the genuineness of all signatures, (iii)&nbsp;the authority
of all persons signing all documents submitted to us on behalf of the parties to such documents, (iv)&nbsp;the authenticity of all documents
submitted to us as originals, (v)&nbsp;the conformity to authentic original documents of all documents submitted to us as copies, and
(vi)&nbsp;that all information contained in all documents reviewed by us is true, correct and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
regard to our opinions concerning the Representative&rsquo;s Warrants constituting valid and binding obligations of the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    opinions are subject to, and may be limited by, (a)&nbsp;applicable bankruptcy, reorganization, insolvency, conservatorship, moratorium,
    fraudulent conveyance, debtor and creditor, and similar laws which relate to or affect creditors&rsquo;&nbsp;rights generally, and
    (b)&nbsp;general principles of equity (including, without limitation, concepts of materiality, reasonableness, impossibility of performance,
    good faith and fair dealing)&nbsp;regardless of whether considered in a proceeding in equity or at law.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    opinions are subject to the qualification that the availability of specific performance, an injunction or other equitable remedies
    is subject to the discretion of the court before which the request is brought.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    express no opinion as to any provision of the Representative&rsquo;s Warrants that: (a)&nbsp;provide for liquidated damages, buy-in
    damages, monetary penalties, prepayment or make-whole payments or other economic remedies to the extent such provisions may constitute
    unlawful penalties, (b)&nbsp;relate to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing,
    evidentiary requirements, statutes of limitations, trial by jury, or procedural rights, (c)&nbsp;restrict non-written modifications
    and waivers, (d)&nbsp;provide for the payment of legal and other professional fees where such payment is contrary to law or public
    policy, (e)&nbsp;relate to exclusivity, election or accumulation of rights or remedies, (f)&nbsp;authorize or validate conclusive
    or discretionary determinations, or (g)&nbsp;provide that provisions of the Representative&rsquo;s Warrants are severable to the
    extent an essential part of the agreed exchange is determined to be invalid and unenforceable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    express no opinion as to whether a state court outside of the State of New York or a federal court of the United States would give
    effect to the choice of New York law or jurisdiction provided for in the Representative&rsquo;s Warrant.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    opinions stated herein as to the enforceability of the Representative&rsquo;s Warrants are subject to the qualification that such
    enforceability may be subject to, in each case, (i) the exceptions and limitations in New York General Obligations Law sections 5-1401
    and 5-1402, and (ii) principles of comity or constitutionality.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the foregoing, it is our opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Shares have been duly authorized for issuance and, when issued, delivered and paid for in accordance with the terms of the Underwriting
    Agreement, the Shares will be validly issued, fully paid and non-assessable.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Representative&rsquo;s Warrants, when executed and delivered by the Company in accordance with and in the manner described in the
    Registration Statement, the Underwriting Agreement and the Representative&rsquo;s Warrants, will constitute legal, valid and binding
    agreements of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s
    Warrant Shares have been duly authorized for issuance and, when issued and sold by the Company and delivered by the Company and upon
    valid exercise thereof and against receipt of the exercise price therefor, in accordance with and in the manner described in the
    Registration Statement, the Underwriting Agreement and the Representative&rsquo;s Warrants, will be validly issued, fully paid and
    non-assessable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are opining solely on all applicable statutory provisions of Texas corporate law, including the rules and regulations underlying those
provisions, all applicable provisions of the Texas Constitution and all applicable judicial and regulatory determinations. This opinion
is limited to the laws of the State of Texas as in effect on the date hereof and as to the Representative&rsquo;s Warrants constituting
valid and legally binding obligations of the Company, the laws of the State of New York as in effect on the date hereof and we express
no opinion with respect to the laws of any other jurisdiction. We express no opinion as to any county, municipal, city, town or village
ordinance, rule, regulation or administrative decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is expressly limited in scope to the Securities enumerated herein which are to be expressly covered by the referenced Registration
Statement. Without limiting the generality of the foregoing, we neither express nor imply any opinion regarding the accuracy or completeness
of the information included in the Registration Statement or the compliance and conformity thereof with the rules and regulations of
the SEC or the requirements of Form S-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion (i)&nbsp;is rendered in connection with the filing of the Registration Statement, (ii)&nbsp;is based upon the law in effect (and
published or otherwise generally available)&nbsp;on the date hereof, (iii)&nbsp;is rendered as of the date hereof, and we undertake no,
and hereby disclaim any kind of, obligation to advise you of any change or any new developments that might affect any matters or opinions
set forth herein, and (iv)&nbsp;is limited to the matters stated herein and no opinions may be inferred or implied beyond the matters
expressly stated herein. Where our opinions expressed herein refer to events to occur at a future date, we have assumed that there will
have been no changes in the relevant law or facts between the date hereof and such future date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the filing of this opinion with the Securities and Exchange Commission as an exhibit to the Registration Statement
and further consent to statements made therein regarding our firm and use of our name under the heading &ldquo;<U>Legal Matters</U>&rdquo;
in the prospectus constituting a part of such Registration Statement. In providing this consent, we do not thereby admit that we are
within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission
promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    The Loev Law Firm, PC</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Loev Law Firm, PC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the incorporation in this Post-Effective Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-275993)
of our report dated July 1, 2022, of Mangoceuticals, Inc. relating to the audit of the consolidated financial statements as of December
31, 2021, and for the period then ended, and the reference to our firm under the caption &ldquo;Experts&rdquo; in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    M&amp;K CPAS, PLLC</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Houston,
    TX</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    18, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: left; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Your
Vision Our Focus</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex23-2_001.jpg" ALT="" STYLE="height: 81pt; width: 81pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Consent
of Independent Registered Public Accounting Firm</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use in the Prospectus constituting a part of this Registration Statement of our report dated February 21, 2023,
relating to the financial statements of Mangoceuticals, Inc., which are contained in that Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to us under the caption &ldquo;Experts&rdquo; in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Turner, Stone &amp; Company, L.L.P.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
Texas</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
18, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner,
    Stone &amp; Company, L.L.P.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accountants
                                            and Consultants</FONT></P>
                                                                             <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12700
                                            Park Central Drive, Suite 1400</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dallas,
                                            Texas 75251</FONT></P>
                                                                             <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:972-239-1660
                                            &frasl; Facsimile: 972-239-1665</FONT></P>
                                                                             <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toll
                                            Free: 877-853-4195</FONT></P>
                                                                             <P STYLE="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Web
                                            site: turnerstone.com</FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex23-2_002.jpg" ALT="" STYLE="height: 57px; width: 250px"></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #K!$P# 2(  A$! Q$!_\0
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MX7G\%_\ HKWPL_\ #A^$O_EK0!ZK17E7_"\_@O\ ]%>^%G_AP_"7_P M:/\
MA>?P7_Z*]\+/_#A^$O\ Y:T >JT5Y5_PO/X+_P#17OA9_P"'#\)?_+6C_A>?
MP7_Z*]\+/_#A^$O_ ):T >JT5Y5_PO/X+_\ 17OA9_X</PE_\M:/^%Y_!?\
MZ*]\+/\ PX?A+_Y:T >JT5Y5_P +S^"__17OA9_X</PE_P#+6C_A>?P7_P"B
MO?"S_P .'X2_^6M 'JM%>5?\+S^"_P#T5[X6?^'#\)?_ "UH_P"%Y_!?_HKW
MPL_\.'X2_P#EK0!ZK17E7_"\_@O_ -%>^%G_ (</PE_\M:/^%Y_!?_HKWPL_
M\.'X2_\ EK0!ZK17E7_"\_@O_P!%>^%G_AP_"7_RUH_X7G\%_P#HKWPL_P##
MA^$O_EK0!ZK17E7_  O/X+_]%>^%G_AP_"7_ ,M:/^%Y_!?_ **]\+/_  X?
MA+_Y:T >JT5Y5_PO/X+_ /17OA9_X</PE_\ +6C_ (7G\%_^BO?"S_PX?A+_
M .6M 'JM%>5?\+S^"_\ T5[X6?\ AP_"7_RUH_X7G\%_^BO?"S_PX?A+_P"6
MM 'JM%>5?\+S^"__ $5[X6?^'#\)?_+6C_A>?P7_ .BO?"S_ ,.'X2_^6M '
MJM%>5?\ "\_@O_T5[X6?^'#\)?\ RUH_X7G\%_\ HKWPL_\ #A^$O_EK0!ZK
M17E7_"\_@O\ ]%>^%G_AP_"7_P M:/\ A>?P7_Z*]\+/_#A^$O\ Y:T >JT5
MY5_PO/X+_P#17OA9_P"'#\)?_+6C_A>?P7_Z*]\+/_#A^$O_ ):T >JT5Y5_
MPO/X+_\ 17OA9_X</PE_\M:/^%Y_!?\ Z*]\+/\ PX?A+_Y:T >JT5Y5_P +
MS^"__17OA9_X</PE_P#+6C_A>?P7_P"BO?"S_P .'X2_^6M 'JM%>5?\+S^"
M_P#T5[X6?^'#\)?_ "UH_P"%Y_!?_HKWPL_\.'X2_P#EK0!ZK17E7_"\_@O_
M -%>^%G_ (</PE_\M:/^%Y_!?_HKWPL_\.'X2_\ EK0!ZK17E7_"\_@O_P!%
M>^%G_AP_"7_RUH_X7G\%_P#HKWPL_P##A^$O_EK0!ZK17E7_  O/X+_]%>^%
MG_AP_"7_ ,M:/^%Y_!?_ **]\+/_  X?A+_Y:T >JT5Y5_PO/X+_ /17OA9_
MX</PE_\ +6C_ (7G\%_^BO?"S_PX?A+_ .6M 'JM%>5?\+S^"_\ T5[X6?\
MAP_"7_RUH_X7G\%_^BO?"S_PX?A+_P"6M 'JM%>5?\+S^"__ $5[X6?^'#\)
M?_+6C_A>?P7_ .BO?"S_ ,.'X2_^6M 'JM%>5?\ "\_@O_T5[X6?^'#\)?\
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M0!ZK17E7_"\_@O\ ]%>^%G_AP_"7_P M:/\ A>?P7_Z*]\+/_#A^$O\ Y:T
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M.\66WA#QK8W%]I$7B32(+ZVTS6$M[>ZLV%[:0:E?1Q.961([J:,1D/D?1%%
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MS_\ "7OO_EI1_P .&_\ @CW_ -(]OV<__"7OO_EI7ZX44 ?D?_PX;_X(]_\
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M]_\ 2/;]G/\ \)>^_P#EI1_PX;_X(]_](]OV<_\ PE[[_P"6E?KA10!^1_\
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M  1[_P"D>W[.?_A+WW_RTH_X<-_\$>_^D>W[.?\ X2]]_P#+2OUPHH _(_\
MX<-_\$>_^D>W[.?_ (2]]_\ +2C_ (<-_P#!'O\ Z1[?LY_^$O??_+2OUPHH
M _(__APW_P $>_\ I'M^SG_X2]]_\M*/^'#?_!'O_I'M^SG_ .$O??\ RTK]
M<** /R/_ .'#?_!'O_I'M^SG_P"$O??_ "TH_P"'#?\ P1[_ .D>W[.?_A+W
MW_RTK]<** /R/_X<-_\ !'O_ *1[?LY_^$O??_+2C_APW_P1[_Z1[?LY_P#A
M+WW_ ,M*_7"B@#\C_P#APW_P1[_Z1[?LY_\ A+WW_P M*/\ APW_ ,$>_P#I
M'M^SG_X2]]_\M*_7"B@#\C_^'#?_  1[_P"D>W[.?_A+WW_RTH_X<-_\$>_^
MD>W[.?\ X2]]_P#+2OUPHH _(_\ X<-_\$>_^D>W[.?_ (2]]_\ +2C_ (<-
M_P#!'O\ Z1[?LY_^$O??_+2OUPHH _(__APW_P $>_\ I'M^SG_X2]]_\M*/
M^'#?_!'O_I'M^SG_ .$O??\ RTK]<** /R/_ .'#?_!'O_I'M^SG_P"$O??_
M "TH_P"'#?\ P1[_ .D>W[.?_A+WW_RTK]<** /R/_X<-_\ !'O_ *1[?LY_
M^$O??_+2C_APW_P1[_Z1[?LY_P#A+WW_ ,M*_7"B@#\C_P#APW_P1[_Z1[?L
MY_\ A+WW_P M*/\ APW_ ,$>_P#I'M^SG_X2]]_\M*_7"B@#\C_^'#?_  1[
M_P"D>W[.?_A+WW_RTH_X<-_\$>_^D>W[.?\ X2]]_P#+2OUPHH _(_\ X<-_
M\$>_^D>W[.?_ (2]]_\ +2C_ (<-_P#!'O\ Z1[?LY_^$O??_+2OUPHH _(_
M_APW_P $>_\ I'M^SG_X2]]_\M*/^'#?_!'O_I'M^SG_ .$O??\ RTK]<**
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M?_+2C_APW_P1[_Z1[?LY_P#A+WW_ ,M*_7"B@#\C_P#APW_P1[_Z1[?LY_\
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M]]_\M*_7"B@#\C_^'#?_  1[_P"D>W[.?_A+WW_RTH_X<-_\$>_^D>W[.?\
MX2]]_P#+2OUPHH _(_\ X<-_\$>_^D>W[.?_ (2]]_\ +2C_ (<-_P#!'O\
MZ1[?LY_^$O??_+2OUPHH _(__APW_P $>_\ I'M^SG_X2]]_\M*/^'#?_!'O
M_I'M^SG_ .$O??\ RTK]<** /R/_ .'#?_!'O_I'M^SG_P"$O??_ "TH_P"'
M#?\ P1[_ .D>W[.?_A+WW_RTK]<** /R/_X<-_\ !'O_ *1[?LY_^$O??_+2
MC_APW_P1[_Z1[?LY_P#A+WW_ ,M*_7"B@#\C_P#APW_P1[_Z1[?LY_\ A+WW
M_P M*/\ APW_ ,$>_P#I'M^SG_X2]]_\M*_7"B@#\C_^'#G_  1['/\ P[V_
M9T./3PO?9_#_ (FG7T/8UZ-\'_\ @D!_P3.^ 'Q+\'_&3X+_ +%OP5^''Q2\
M :C-JW@SQOX<T*_M=;\.ZG-8WFF27FG3OJLJ1RR6&H7MHY>*0&&YE7:<X/Z5
M44 01*5/(8D*!O8Y9NF=W.,D\\ 5/110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !6+K6N:;X>T[4M:US5--T31-'LYM1U75]6O+;3=+TVPM8FGN;S4=3OI(+
M*QM8HHW:6XNI8K:"-6EEG  06]0NK:RMKF\O;R'3[.TMI[J[O;F>.VM;2VMH
MI)Y[JYN9RL%M!;0QO/-/*PBCCC8SYCX/\;7Q!M?B?_P<&^*/'OQ.^)7QA^)O
MP7_X(X_#OXJ^(?A1^SO\%?@KJ%OH/Q6_X*">/_ FIOH_B/XD>*=:EL]1DTWX
M5SZQ#+IWAZTU#3=3338&BM--T&Q\80:IK0 /U[^.W_!Q3_P1[_9XU6^T#QE^
MV7X,\5Z[ITK07NF_"+0O%GQ::TN!M_T>74/ NA:QI,DHSDM'>B- ?WI0C->#
M^'O^#JW_ ((J>(;Z'3_^&E?&.A238Q=>(?@1\7]-T]!R"7O#X1N(8@#@YDD/
M^R&PVWG/A1_P;K_L$^']*LXM-_8H_9Z\&:=']GGMK3XBVWB_XX^+;G'W[G6M
M6^)_B7QA(]\T4@6[M+>/3= ^T2!H- T_9##!_'__ ,'&_P"R?\!/A)_P4/\
MV6OV'?V7?A5\*_A]K5]\./!MUXXF^$WPN\->!%U;QM\:OB'J6D:+:ZI'H,$5
MUK(T'PQH>DZE8+?2R?9(]<G\G;]HD*@']]_PW_X+G_\ !)'XKF-/"'[>_P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$1%2/(2-4C4>R $=AUS@\<XXXH F) Z\<@?B3@?F3BOP2_X.4?VP[O\ 8_\
M^"37Q^U3PYJS:5X]^.RZ;^SIX(G@G>WO$F^)BWEMXONK.52 LMC\/]/\5SY?
MY<[5P2P(_>J7 1L@D8&0.3C(SCW Y'O7^?-_P>J?'O4?%GQ/_83_ &(_#,ZW
M>JQ:-XH^.FO:-;SRM/>:KX^\0)\*OAD)K5%:,/O\+?$".T)9IS]NF/EJKHT@
M!]!?\&JO[(D7A_\ 93\(^.];TPIJ?[1OQ/\ $'Q-U@7<+)*_PQ^&=[)X2\+6
M<T4JJ\=KKVJZ1K]Y#'@#4-*U^RU" O R2'^Y:/[NXCDY/4-@9)P"N<@DDC'/
M..V*_)#_ ()._ #3_@-\"?AY\/;2)/L_P;^#OPQ^$<$X1 )M5T3P_:GQ)=EU
M9F:6\U2WFGN';<\KW/GLTBRJ6_6_>J !C@L21T_B+$#KC)&>G'!YQS0 NQ6Y
M*]>3GKSZCU_PJIJ%]::?8W>H7EU:6=C86\U[>WM]<QV=E9V=K$US<W=W=S%8
M;6TMX8VEN+F5A'!$CR.0$-6?.C/1L\*>.<;R0N<=R00!UZ>HS_(I_P '&O[9
M7CKXG_%W]E__ ((D?LX^/3X)^(?[:7B#P_<?M,>/--DDFOOA]\ =4U2YMWT6
M[MK26*XN!K>AZ/XK\7>)-+@N8+W4_"OA2WTG8+?Q8KN >O?'C_@K!^WW^VWJ
M_CSP;_P1/^$7PRF^ _PY\0ZAX'\<_P#!2C]IK6+/PQ\ =6\8Z1*T>J:)\ =#
MO3<ZS\4;.UN()[(>+O#?AOQG;3WS6L]GHBZ9?Z%K.L_RC?MM?MW?\' G@7]H
M_1?V!?CG^WPVO^)OVC+7PKH4^B_L^Q^"-/T]/"7Q/UI_#^G1Z?XATWX5?#_Q
MSX7N=0M8;J]1(-0TO6_[)=#=30179CE_T*/V0OV>OAMHGPZ\ >#_  =X2LO"
MW[.GP*T>V^&WP#^&0CC.G6VC>'(UL;CQ9XD\HQQ:]XJUJ9'U?6M6O?M<U_X@
MGU#499I)WD+?PJ?"7Q18_P#!1#_@YG_:)^/$%I!J/PW_ &<M4^(NL^%$C59=
M(MM ^"=MIWP8\ -#']GMEAM[[Q;?VVL0""W,275R\H>1$:Y< _JK_:B_X*37
MW_!.[]ES]E;X._!3X=^$O$7Q9^,?Q.^%/[$G[(VD?%SQG?Z!X$M-3T+P_P"'
M?"6N?$WXS^,7EDOFT'PW?3Z='>PV)&M:KJFIK:)>W,MO=7+_  U_P4?_ &FO
MVGOV _V>M8^/?[5?_!7KXUZQX]DUF3P5X!^#_P"Q;^S-\ OA5X$\:?%9(KBZ
MN/ FA>,/C'X0^+FJ3^'/"\2-J7BOQ5,+^33M!LA;_P"E>(=2T_P_<_NM\:/^
M":O[+_[9'P'^!7P^_:4^'<?C2^^#_B?3OC#X"U6/6]?T'5/"GQ-GB.H/J9N?
M#^HV$^HZ=-=7%K;ZSX?U%I](UB"QMS?6[^3 ]?P!_P#!S5X@^*7Q(_X*9_L[
M?L,>(];M#X=^$?@KX7>#O#-KHLM_-H*^)OC]XFBU37=<%M/!8W%SJ+17FD:?
M<WKVT4]TFEJD,,$+!* /Z$_^" 'C;_@H1\9-+T[]N7]L;]H_]ICX^>/?CUX?
MUSPA\#OV>?$'Q'\.Z!\!],^$":MI5W!\6_$WPQ\-Z9IOAFU^(%_?:'JT>@:_
M!X;\/WJ>$)6U*[DO;/6K"$?C[_P=Q_\ !2?XTZ[^W!X$_8<^#?Q)\9^"?!_[
M-?A3X?>-_'FC>!/$>NZ'>ZU^T+X_M++Q[X;FU.XT@:=+J<W@CP+JG@*^\(?9
M[J]ATW6?$.KWD+0ZF@ALO[A_V!/@KX8^%_@"WAT33K?3M'\%Z%H?PG\&6"(B
MII/ASP;I.GZ;+Y VAA)<S6]E'),ZQ32)#+)-EIW-?YW'[2_P\\/?M*_\'5'Q
M=\%?$Z=KOP_-^V%=/>6HD29-5M?A!X$TZ^\,Z#([.R?9KA?!>D:=J,#$M'IX
MN;41B4", '^DQ^Q;\4_''Q0^!/@6;XEQ@_$/P_X+^'NG>-]25II)-3\1W7@C
M0[G7+J[2=Y735WU<WC:A&N8C>NK0;D,@K^5?_@IWJ?[37[+_ /P<W_\ !/3X
MX>#_ (J^,-6^&_[1O@*+PCIOPY;Q/KS>$]*\)>%-%UCPS\8O!-_X7AU"33SX
M7U!CH7Q,NC#IP@;Q*4UY8;G6]#@NX_ZV_P!F3PE+X8^%>E7UZH&I^-)KCQ5=
M(P(9;750/[)B;!#KY]EY-_+\BB"YOKB'8@5:_G,M]1MO^"B7_!5_X^?ML:=:
M1Z[^S/\ \$\/AQK/["_[*VN[!<:9\4/VM_BCJ*+\</'?@N[BE>VOM-^'?A*^
MU_P5?W A:.\U&XT*[L[W=ID\% ']2?P_\1CQ?X.\/>*!";?^W=*L]1> NLGD
MS31#SXO,!)D"2JP1S@>5Y:JJJH%=8^?,0 \DY/'1%!+=OF).% Z@,V,9YY/X
M?>'CX3\%>%_#9QNT70=,T^0C/^O@MQYX&2?D65F5<G=D,&Y%=9+Y@&8T#LH+
M*I<(&8$$JSX8J&' PI!/W\+0!_&#_P $2_B/9?M2?M4?\%;?'/B&\>?XP?'+
M_@H:_@'QW<"?S]3TO]GOX1VOB"'X=^%[*]D^2+1Y7MM:LS9VV$EC\.PQ.&M@
MSC]I_P#@O-^T+;?LG?\ !(O]L#QEHEVF@:KK7PM_X4MX(>VEBLY(M7^*EU!X
M"M[6SWJ&D:WTS4]2G-LJDRVT$C*23(!^5W[-G_!'[]H?_@F'_P %8_V@/VT/
M!'Q2\)>*?V._VC=7\9:[;_"[3(/$TWQ%3QKXQ\4?\)A9:%XHTYM%7PUI%EX1
MU+4O$D/A[Q9IWB/59-4TK5)-'N/#VG?;9Y;?Y._X/6OVIHM#^ '['G[)6BZE
M*FJ?%GQSXJ^/'C72TN;9+BR\)_#C2+'PSX-@UK3V_P!)6'Q!XE\;ZU<Z5.BK
M";OP)JT3,S1A: /R/_X-SOVVO^">?[$?PX\<7_[5'QSD^'/CWXC_ !KT#5=7
MTJ#X-?'OXB^3\-?AWI$%QH,@U+X9_"SQAI#2:OXBU#Q%#-9V>IS7"6Z6LM_;
MQIP/ZZ?AQ_P7_P#V<_VO/V^/V9/V3_V"O$L'QC^'6M>%OCI\4_VNOBIXJ^%7
MQA^'\?PQ^'/PW^'%UK7A.V\'Z7\0_#G@3Q#J?B#7_&;Z9INK7C^%]2T>QTN]
MLHK*:YO[UH[;G/\ @B?^Q1H?@G]C']G'X8>)]/&BZSX!^!GA'7O%.H:38:(F
MM'Q_\3IKWQWK^GWNHW>CW<DPTNY\07>E --*KP::D2Y@XKZ;\<?\$E_!?AK]
MKSQ3^W?X#\6^+=1^(FM?L\Z+^S6GPWCT#PY#IEQI-]\2- \5>(_&FI>(-'@T
MW4]2U"YM-)L[&6TGL%BM-.LI8TN)()F10#U#_@H;^U=\?_AUX1^#WPY_8;_9
M@UW]IS]J7]H&;6+OX->(/$WAC4-)_9Y^!&BZ):Z=%K_QL^-WQ.UZRT_2/"=M
MX9L/$-O/X?\ !J7T'C'QE=2W.F:7I\@5;:\_SZ?BQJ/_  4+UC_@OO\ !/\
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MB#XDTJ#X6^#O$?B*:T$)UG5+GQ3XAT]K>=XVW:M=:EJ[!IS$Q_G/_P"#5?\
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M)_#O@+3;?4=6N?$NJW'AS6BSQW]SJUOI]\WVB/3Q;R36UL]T0I /[F_VYO\
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M;XL\*7#3:/X@TI=3M;[3YQ';W%YI=]:7MI)'>Z7J5] 6@:5+F/\ -3_@F?\
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MSNVT;5O#GPE\"^']*COM?@NELM/U*_\ '5A]H86[2O\ W%_\%)/^"9_[/_\
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M+/Q(FDN+_P 2:Q*8_+NKN]OI?+M733M-2TTI$M1^=7_!4W_@VI_9-_X*#_M
M:A^UU;:E\3? OQ=\4?V"/BIX5^'VL>%-)\/?%,Z+HMIH-IK+OXDTZ2#P]XK?
M1],TW3-3U&SNX[?5Q:07E_ E\UY?70!SG[9__!9+X9Q?LL_$C]F+_@F=X_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP%P,= 3CK3Z* &JH7H.O4]2<>N:0HI.[!!(P2"5)XP"2,'(&0ISD G!YI]%
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MBBB@ HHHH **** "BBB@ HHHH **** "BD9@H+,< #)/H!31(I[D>FX8)]<
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M?!;X1?"K]FSQ+/\ LV?$?PO\'O"UQ\1?VM;/X8>(/C]\8?%WPQL/B%I7P?\
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M/ZY\)M?\*P:7XF;5+"2TDU769]+M)3J.DZY!;?GC^RO_ ,%;/B%^V+?6VC?
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M_NUTK4;J=6TN;3[C4?B[P#_P6#D\2_"']K_Q7XT^"&D?#CXC_LZ?"G4OC_\
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MA3KEAXA^']C\1!XR\&>)=1N?#7AS5[675;?2= O]!$VLOINKW$LM[X?T:6W
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M^A^!='UJ\N/#=KKVK7FGZU!I_:_"']N'PK\9_P#@G]I?[>GAWPS=>#?"VM?
MOQ3\8K;PC\1=7@TT:6?">G:W-=:5K/B'2[;58;C1[K4=#GMM.\2Z/I^I#5M+
MN]/U.RT\^=%:5Y5#_P $N/">F^$OC)\(/"O[1W[1?@?]F_X\_$GXF_%+XC?
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MO_?(_P * /Q$_P"&H?\ @NU_TBP_9,_\6"W'_P!#_1_PU#_P7:_Z18?LF?\
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M_P"A_H_X:A_X+M?](L/V3/\ Q8+<?_0_U^W>Q/[J_P#?(_PHV)_=7_OD?X4
M?B)_PU#_ ,%VO^D6'[)G_BP6X_\ H?Z/^&H?^"[7_2+#]DS_ ,6"W'_T/]?M
MWL3^ZO\ WR/\*-B?W5_[Y'^% 'XB?\-0_P#!=K_I%A^R9_XL%N/_ *'^C_AJ
M'_@NU_TBP_9,_P#%@MQ_]#_7[=[$_NK_ -\C_"C8G]U?^^1_A0!^(G_#4/\
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M?_0_U^W>Q/[J_P#?(_PHV)_=7_OD?X4 ?B)_PU#_ ,%VO^D6'[)G_BP6X_\
MH?Z/^&H?^"[7_2+#]DS_ ,6"W'_T/]?MWL3^ZO\ WR/\*-B?W5_[Y'^% 'XB
M?\-0_P#!=K_I%A^R9_XL%N/_ *'^C_AJ'_@NU_TBP_9,_P#%@MQ_]#_7[=[$
M_NK_ -\C_"C8G]U?^^1_A0!^(G_#4/\ P7:_Z18?LF?^+!;C_P"A_H_X:A_X
M+M?](L/V3/\ Q8+<?_0_U^W>Q/[J_P#?(_PHV)_=7_OD?X4 ?B&?VH/^"[1&
M/^'6'[)G_BP6Y_\ H?Q31^T[_P %UPQ8_P#!*[]DLDDG_E(+<9SGJ2?V?R">
MO0#KQ@9!_;[8G]U?^^1_A1L3^ZO_ 'R/\* /Q$_X:A_X+LCI_P $L/V3!Z_\
M;!;C\.G[/P]Z/^&H?^"[7_2+#]DS_P 6"W'_ -#_ %^W>Q/[J_\ ?(_PHV)_
M=7_OD?X4 ?B)_P -0_\ !=K_ *18?LF?^+!;C_Z'^C_AJ'_@NU_TBP_9,_\
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MO_?(_P * /Q$_P"&H?\ @NU_TBP_9,_\6"W'_P!#_1_PU#_P7:_Z18?LF?\
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MK_I%A^R9_P"+!;C_ .A_K]N]B?W5_P"^1_A1L3^ZO_?(_P * /Q$_P"&H?\
M@NU_TBP_9,_\6"W'_P!#_1_PU#_P7:_Z18?LF?\ BP6X_P#H?Z_;O8G]U?\
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M_P!#_1_PU#_P7:_Z18?LF?\ BP6X_P#H?Z_;O8G]U?\ OD?X4;$_NK_WR/\
M"@#\1/\ AJ'_ (+M?](L/V3/_%@MQ_\ 0_T?\-0_\%VO^D6'[)G_ (L%N/\
MZ'^OV[V)_=7_ +Y'^%&Q/[J_]\C_  H _$3_ (:A_P""[7_2+#]DS_Q8+<?_
M $/]'_#4/_!=K_I%A^R9_P"+!;C_ .A_K]N]B?W5_P"^1_A1L3^ZO_?(_P *
M /Q$_P"&H?\ @NT?^<6/[)G_ (L%N/\ Z'\?S%>J_ WX_P#_  5]\5_%KP/X
M=^/O_!/7]G#X2_!W5=7DM_'WQ%\(?MHW/Q%\2^%=&73[V:/4-(\&#X/>'/[>
MN9-1BLK(VW]M6/E0W4ET798"C?K-L3^ZOY#_  H*J5VD KC&",C&,8_+CZ<4
M 0P[MQW=U)S@#</,<(QP3R8PA)!^;K@=!8IH7!S[>G<XS@]@=HXZ#'%.H **
M*ADE"!N#\N"3Q[';R?XA@9Z#.>U 'R[^V5^T_:_L;_L[?$W]I77/AUXJ^)G@
M[X0:!J?C/QWHO@S7/ &@Z_IW@S0M/N-2UO6K&3XC>*_!VAZI=6<,"PV>A6^L
M+JVL7ES;V>FP37$B1O\ GQ>?\%B?$6E_LD^#/VZ]3_X)P_MMO^RUXP^'ND_%
MY_&WAR]_9>\5^,O#'PAUS3X]=TSXG^)_A7I'[04GC2'PM/X4DA\7RS:-8:S>
MZ=X;N8M2U:PL4$ZVWSY_P<.^+-<^*GPH_9,_X)F^ -3GM?'G_!2G]J+P1\*_
M$(L9H5U33_@+\.]3TOQS\9]?@1X;ATM])LHM!BNKM86VJ\L<VV*9I(_U1_;
M^(GP9_8U_8&^/OCCQ1:^'_#GP5^!7[-GBS1[3P[<M#9Z)<:%HW@A_!_@GX?6
M$3*;=I_$M_+H7@;P[I4$3RWVH:G8Z;96L\][%$0#TW]E3]J_X)_MK? ?X?\
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M2>%9#"T-Y]D\"^,[K3M#OVFEE26*[N9DGL(8TDA2,, O\6W@G_@I-XR^#O\
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M/CKPI%I=M#;QSZCKGB&XM/AOX9L-"TC2;:[UK6=4U+1="TK3]1O)[6RGI_\
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M!/[-GP-T/3-7^._CZTUVUE;7-)U_QR;+3=7\0WUK.UEK%CI?B_3[B*198S$
M?T5_M?\ Q1_:-^%OP#\3>+?V3_@3I_[1OQVN-0\.^'_ /P]UKQGI/@3P@EWX
MEUNUTBY\9^-O%&JW-@8/!/@>PN9O$WB"TTG&MZOI]B=/T:5;N[%Q;8WB7]L#
MX:?!WQ5^S?\  ?XY>/O!<7[57[0,>CZ!H7P?^&D6K^(M4USQ5:Z"-1\>^)]
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M^-[,3PM)#<QZ=K^L76E"XM7>VG6Q22!VC*,P!^C5%%% !1110 4444 %%%%
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M+-:N]7\:^+/#WB_Q1!)<:I);6WAS4- @M/- DGF_697?&,;F[EB!@YY!V+T
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MX;N+W4K[_A$;K0;31O"_A71H['2=, /Z+_VNO^"EWA[]C_\ :4_9/_9H\3_
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M0TO4?.=[>2W<9FB7]E^VM_P<)?$GXFZONU#X(?\ !&C]F>Y\(Z+<;9)-/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!)>Z1JB#QC#X6OM,?78]%N]"L[K2%O[@6^GM)?LKJ+JZ(7X&:A^R[^SY\/=
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M+*DEM^H-% 'X\?LD_P#!+OXD?L8_ C6?V2O@_P#MI_$.U_9D%_XU?X?Z-?\
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M+J>I:3X!\+:KXIU&PL(PL@-Y=6FF20P%XVC661'DQ&KL/PQ_X)W_ !>\&?\
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M,_\ @D_^WOH/[3'[-W[??[53>*OVO_V%-3U#0?CEX$\(_#KXDI::W^T-X_\
MB5;Z3<^)O!>A:3;>%6?PP_BGQ#I_@3QQJ<]WX.\"G4/%5K9MITW]N=K!#;K%
M%!'Y,$2>5!&(_+C2&/Y$ABC*@0PQ!5\B*)8X5C $:*H  !>HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** &L-RD XZ<_0@_TK^8C_ (.F?B7X9M/V$OAO^RJ+3P[)
M\5OVX?VA?A;\"_ 6L:KI,=YJ'@GPS9>-_"OC7XD^,M,O(X[W5M'L;8:'X7T?
M79M-BG#:=KA@NXKA2JM_3)J>L:?HUCJ&JZM?66EZ3I-G=:EJFJ:C<Q6.G:9I
MUA!)=7U_J=_=/%:V%E:6T4ES<W=U+';P6T4EQ)((QFOY#?&/[4W[-7[7?_!Q
M[\-O%GB[]HGX':?^S-_P3#_99\2>+/!_BGQ'\6O!5C\._&_[07Q>L(]+O)_"
MFI7NM+X=\2:CX6T+Q=9ZB]WHM[?7.E:GX(L2(XI[56( W]H']C/]E_\ ;A\?
M?\$T/V<O^"7=_P##*?Q)^P/\3/AKXS_:-_;*^%$GA[1M;^#GP5\"^'Y]+C^%
M'BW5-"GL?%7B3XI_'+Q3I0\0:?X)DBO$T%O#>IZEXD?1],U6$ZI^XGQ+_P""
MGO@;P['^U%KGP3^#'Q4_:B\'?L8)X@M_VF?'WPLO/ ND>#/ _B/P=H+>+_&W
MP\\+ZSX]\5>';;XE?$;X>>$VBUCQYX9\$2ZA_P (W+>V>CZE=0>([N+1(OP<
MUWP%^T1^T7_P4?\ ^"B'_!63]A/X8>-/"GPA^&'_  3W^)?P)^"OCJU\+>)/
MA_>_MR?M)#PCJ=O:>-_ 'A^\CTS5?B#X1\"7\<"^'?B/-HUWHOB?7/!_@R#P
MK/KCB>ZTB/\ X(=ZW_P29\=_L ? SX&?$'1IOV@/VKM(M/&&K?'G]D+XGVOQ
MD^-WB"+XZ77C?Q'>>*M?D_9B^(U]K_P@\.:GK-R=/NV\=IX3\.Z)%9K97WBG
MQ'8W&GZA)9 'Z<?\% _^"M'P;N/^"(WQ<_;]_98\8S^*;7XV?#.Y^%7P!NX8
M9[#Q78_&/XLZG/\ "BST>?1HITO=-\;?#;6K[6]9U;24>2:&X\)73VTUW9&*
MXF_.?]M'X8Z__P $U_\ @WU_9<_X)L?"Z&;3_P!I3]M+5_A'^R9;Z=;-C6V^
M)/Q\NY?'/[0.ORPQ7UM.^G:-8?V[X0GO;5A%8W>KZ%:R.J7T;CKO^"A_QC_9
MB_:G_P""JO\ P2<_X)V>$_B;\"M'_9M_9R\>^(?VOOC?IGA[QUX TCX;VOCC
MX/VVHZ3\%O@Q-::7J]EX6/B2/Q;I]YHD_@2TG&KV]AXCO&N-!:Q1F2]\1_C[
M\"_VZ/\ @X:^"ENWQ2\!^,_@+_P2Z_93^(/QP\)IX9\:>&_$^G?%7]IGXG1:
M.6TGX9Z;IVKB7QWXC\*^#[:RUYV\+KK[:7JOP[.EWPL+N\42 '[+?"OXH_!3
M]C;PY\-/^"<G[/WAF^^+_P 7?V:?V6?!NNZE\)O!6KZ'I!\%?#GPQI]IX;T7
M7?B1X\\8:SIWA3PAJWQ#U>*]O?#.E>(=8&OZ^JZKXA:W_L5)M6&;^SC_ ,%4
MOAI^U7_P3S\4_P#!0WX1?"?XCR^"_!>G?$G4?$7PW\8:AX)\(^*[6+X07-P/
MB+-;>([[Q'-X$O\ 3]$TVQU/4[;5K;Q"^GZFNGSV,$R7P:%/YK_C/_P5'\0?
MM,_\$S?^"CW[:/[+OAB_^&OQ8^*FJ^*?!^M_"+]ECX*Z5;_%'X?^"- U6T^#
MWAWXT?MY_':\\%->Z[XZU'X?V^IWV@>$["\AU'PYX)U'0+/P]/<VVF:[JNB>
MH?MZ?M&_LM_ G_@A#^Q9_P $ZOV,OV@?ARU_^V5X7_9H_9<T7Q<VL6OA'4-(
M^%/Q8U&QO_CM\??B-X7UN?2=7\!^&OB/=GQ>/%>H^+].\/Z5*WCCQ!*MP8;,
M@ 'W)^S!^V%^R?\ L>?\$U/CG_P65^'O[*O[0^F>#_VH/BKK7QS^-5Q\7/B_
MX-\2?'KQAH6J^-;[P-X%\21:GXQ\;+X?;PJ-;U.S\*_"GX8^'-66ZL]*UBU-
MI;WEU<W<TWZ$_#/_ (*IV'C/Q/\ ":/Q_P#L??M5_L__  A^*'[./B7]I&__
M &C/C+X=\#:!\&OAIX;\'>'M*\2^)-%^)&O:=XWU:^\+:E9:=KFCK9W6J:=:
M6>MW-^B:*U_%;7T]I^+/_!7OQM^S)XRU_P#X)"_\$8/A9\;?A)H/P3O/C/\
M#?QA^T+J\?Q%\%V'A/PA^SO^RKX BUGPUX0\?ZRWB"'PUIEQ\2D8>(O#VBZ[
M/;:AXG\3^'O";Z<T\NIVJ7WU)_P<^:UX^T__ ()M^ M*\%:!XMUG]G3Q#^TO
M\#-._:OG^'-IJ6H7.G_LN6%Y<ZYK<CCPH1?Q^$-0U+3/#NE7E[;3Q6TH>PLG
MG>SOQ.X!]A_$O_@M=\$O@U\*/@W^U)\5?@C\=O G[%'QV\:Z!X-\ _M3:_IG
MA*RT(6_C#[?)X(\>^)?A?-XGC^+?AOX;^-+'3I]=\.^([_PE]LNO#,EIKUQH
MMK:7EJ)?V5MKJ&[BCGMI(Y[>>-)K>XAD26"X@D1)(IX98RR2PRQNKQ2(S(Z$
M,C,I!/XP?LG#_@D!\>6\">-/V7?"W@7]JM? FF0GPW\:/%NE_$/]HRX^!6A:
M!H@NK&QN/C3^TK>>+-6^$L6D66EV&D:;X(T[Q5I'B+3?L]I8VWABTT_2;M].
M^V_V+OV]_P!D?_@H#\/_ !-\4/V/?C#I?QA\"^#?&-YX!\3:O9>&_&OA*;2/
M%-G9V.HOIUUHWCWPWX6UXPW.F7]A?:=JXTY],U6VG,]I>3JLFP ^@/BU\+=#
M^,WP]\8_"[Q9?:]:>$O'NC77AOQ0/"^N7OAC7;WPYJ<:VVLZ+:>(-*,.J:3;
M:SIYN--U*ZTVYM]4EL;V[@M+^P9HY(_Y(O\ @L;^P+^Q=XM^./\ P2\_X)+?
MLT?LQ_!/X/WO[1WQX/Q7^-.L_"CX<^'_  OXQ\-?LS_"&TEF\=SCQ-HMG'K=
MG/XO@NM<L[34]3O[F6[U?2Q*\EU)'=FOZ^_%GC7PKX#T+4_%?CCQ3X=\%^%-
M%C\_6O%'B[7-,\->&])@+QQK-J&M:S<V>G64!FFBMQ/<7 B%RXMR3(0#_*S_
M ,$O_BQ\,?V\_P#@N]_P4P_;3OOB9X-UNT^!>@^&?V+/V0O"S>*=#N-7UKX>
M^%Y+]_B?X[^'NESW;ZEKOA+6?$OA[7/$HU_0K>33WM_B%<F&[FAN,J ?JY^T
M)^Q1_P $DOV4Y/#G_!0+XJ?L^?L_? %_V.]=G^+5C\6O!WP_\/\ @B[M-6E\
M/:KX T/2M6M_"6E6MWXWFFU+Q=8CP!X+:VN[N;XA1^"[KP[9_P!M6MA%)<U_
M_@K1\./A-\7OV5OAM^TG\"/C5^S=H7[;.HWWA[]F_P"(_P 1SX$NM%U[Q9$G
MAVYL?!?Q%\/>&?%>L>,/A+XHUN+Q5H:Z58^,=&BB:[NY-.OKVTO['48;/\RO
M^#CCQ9::!\6?^"3UK^T59^.++_@F];_M7WWC+]KWQAX2E^(%MHFAZYH%CHEI
M\(I_'&L_#">T\9>'M(TK4M:\0:[I%]IEW;WSWMO=WFE,^M:)IZI^C'P=\??\
M$CM.M+S]JWX=_P#"FO$6@^%-'N;O6/VZ_B=;ZAXTCTE&:,P:#)^UU^T)=ZIX
MP\6Z]K$TC/:^&/"7COQ1JRW,"MK-G8M>:9]O -S]IS_@JO%^R_\ MN_L_P#[
M$7BK]E7XNZUXA_:GU&YTSX"_%RR\9_"#2/A1XUO]'TVTO?$VD7.HZ]XTL==\
M/>(M$N+J/3X_#VJZ(FHZY/=:3)HB7L.JPM'[-X'_ &[-9^(7[2OQC^"'AK]G
M#Q[<_"OX#:O+H_Q)_:VE\>_":#X!Z1?6>FW-_K>DVNHR^+D\0:GXH\'R6KV7
MC[PS9:1+>>!;K=;^*)M-NXI[:/\ GG_X+3>/C_P4A_X);^(OV[O@S\3/ 'PE
M^&G[,WCQ?C%^QEXH3QK9:/\ '7XM^*O"&HC2O$6N6WB+3O$>GZI\);KQ-X2D
MUO5? WPCTYU^,>KI9Z+>^,+;P?JTT/AC3OK+XX?\%C?V7/A]_P $7?V>/VAO
M@_\ "/X(:YX._:7LOA7^S%-\#KWP]:7_ .S3^SSXP^*&@7%I\6/"7[0WAOPS
MHMS8Z'\+_A?:6_BJWUWP9=Z-8W?Q#TX:=::=82:3XAGU*V /M?XU?\%K/@'\
M(_A-\%/VDM'^&'Q4^*_[+/QV_:&T']FOP/\ ';P,_@RWT[7?&?B/5_$.B:7X
MB\*>!_%'B;0_'7CCP%>WOA773I_B/PKHNHOJUG82ZGI=A>:4/MP^R?B[^VGX
M/\ ?'?PM^RMX"\$^+?C=^TKXJ^&&I?&S_A5?@NX\/:-_PB?P@T[75\+)\0OB
M!XM\8ZMH?AOPEH>L^*3)X;\.0W=W<:KKFKVM[;V>G,EI-*/YA_BYXV\%?%3_
M (*S?\$6_P!GKXJ?$'Q]<?L6^!_#WBCXU?!W6[CX)V/PA_94^/W[3'A?3+_P
MW\&O"_P'^&WAWP;:VOA_PI\-K4VD>@:KXN:XTJ[T;5I8_#&I+IOBRS\1^(>A
M_;J^'W[.O[<4L_\ P4T^%'[<7Q1_X)J?\%(_@GH'QE^"%E\+?"/B34;WXT^-
M](^#OQA^)GA_X9^ /$W[-FFW.G_&'Q#K7Q,M;2PU>P\.^$_#NM6?B_1O%VEP
M2^'_ !/86EO,0#^GG]F7]J*P_:2M_C%I=S\-/B!\(?'WP$^*][\%_BGX&\=1
MZ+=/I7B^W\)^%O'EI<^'?%?A74]<\+^+="U3P7XU\,>(-/U?1M2<PIJ<=EJ%
MK8ZC#-:KXW_P4:_X)W_LT_\ !2#X)Z9\(/VJ]7^(VD_"_P %>*E^)S#P%\2;
MKX:V,6K:%IE]:C5_%$ZVUWHVI:=HND7NK- NOV=U;Z8EY>:E;/;74,5[:])_
MP3DN/VK[W]B+]FC5?VYXM-C_ &M]8^'&FZS\<5T_1M,T*Z3Q/>W%W)I'_"3:
M1H<<.CV7CBU\&CPWIOCJWT>"VTJ#Q?:ZY:Z/9V.FQ6>F1_G7^V5\2-2_X*,?
MMOVW_!(7X::_JND_ 3X4^#]#^.O_  4]\=^%M1GL[W7O 5_>VC?##]B_2]7L
M71M+G^.5Y.NM?%Z2UNK2]NOAEHVM^&(9S#J/B#3+H _+C]A3_@@!_P $QOV@
M?C'H'Q[^$WP%\=7'[%OP:\;W5Y\-OB!\9_B7XU\4^+OVYO&7AMXH(/%.D>%G
MNM%\'>'_ -DCPOK:77]A:A-X;?Q-\>?$.EKJ'FZ)\,-)CM_B#J_MV_\ !"/_
M ()4>$_CMH.A^$/A?\?/VE_VX_VL?%_B/Q=X(^!OB/\ :2\6Z=X!M[.76$E\
M=?'?X_:_HFF_\)OX(_9^^'TMZ+K7K^PUC_A(_%%U%:_#SP%%/XBO(?[-_I0_
M;+_:L^"7_!-C]CGQ]^T%XTTFWTCX:_!+P7I^D>"/AWX8MK+23X@UL0VWAWX:
M?"OP7IZB.RL[K7-3;2O#VF16L!M=,LO-N6A:WL"*\!_X)@?LP?$GP'X"U_\
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M]LSX:_\ !-O]H#]K77/VH/BOX_\ C/\ M[?LX_'3XZZ/^SC-HGA[0-&;X_\
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MTOQ5\-/"&E^?HOB'QSX]\>6OASPOX8^'%H^LGQ"+%M,>[X3X_#PA_P $*?\
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M (7^.'_!.W]ICQ=\)OBQ^W_\*OVR_P#@DO\ LV_ 9OB/\-OCG\2KGPU-X7^
MGQGOUU'PY\,/A+\)/BMXGU/5M&M/B))\*[[QK'-X2^'/CK5=%TCP+KPT6TTS
MPU+K1TG4.1_9?_;B^'O[,'_!(S_@I7_P57\1_$GX<S_M:_\ !0?XP?&[XB^
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MZ-\9M%T;3OAC\)? 4MU?:RL":Y\#O#]CIWC75[.8PW?@V#3K@ZI<::T]Q;S
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M/@KI.J>)/A;X#U72K/QI\1?%/B"7PQ$NF^V?\%._V5/VN/#7B#XV?\%$YO\
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M%G;VG_""?\([X3^)FM^%=$\7Z5JMX\W]ORV>N2WUC90W,EK:O<6]I;:M]Q$
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MUABM[6WAMK> 8@@MXHX(81@C$442I'&,$K\JCY69>A(K\:OB%_P4Q^/.C_\
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M:-;:;KOQ#G\$VFH6'A.Z\6W=NB?VU?:%8ZKJ-I8W]XDEZMO=/$\[H%5?5Z*
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MC\L;:D4E?F2/).,_)(#D%O[YQP2>G(SZ4XRR\'RV'O@[<?[7+#'OCCUQF@#
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M2UOW$][H'PBT[7]2\'_"#PA;7$Q>Y&@>'= TVZ7PQ;OB)=!?2)H6EBE29_U
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MWA_Q_P"#?%P\/^,]#L8VTZQ\6>%KG2+V.*>Z=DEEN))Y0#\"+WXG^ OV%O\
M@HW_ ,%L/%GPHEO=._8&_9O_ & _".N_'3]G]=8\0:A^SNW[8GQ,T*UF\,^!
M_!_A:.^O/#'A+Q%XT\._8]'\1Z/X4BT2[C.I^(+6>Q18$AB^Q_\ @C7_ ,$8
M_P!CO]D?]DO]D']J3XK_  PO- _:PT3X;0?M#?$OXA:_\8/C3H7ACPCXN^(.
MB:GXRU)M>^%<OQ%T[X.6UW\./!&OV?@F34M8\#2W>G6WA>/4=1O+C5;-]2E_
M0OXV_P#!(C]DWXW?L6_%K]AVYL_&W@GX=?&[QJOQ1^)GC_PIXE$_QA\:?%J3
MQ%IGBG4/BAXR\=^([/6IO&/C#5M8TBR35;GQ%8W]E+I%K8:-:6-CIEA:6<%[
MQ?\ \$UM1\:_LR?$7]FGQ%^VW^V-XAM?C%X%U7X8?%;XH>+?&'P[\7?$3Q-\
M.M>T'4/#FN^$M%75_AQ_PA/@6+5]+U2\@U'6O"'@_2O$%Z9I)+C579EV@'\R
MW@OP3\+/BA_P2W_X*[?\%IOVJ-3^-"?\-J^(_B9XN^$'P_\ #'QD^*WP>TJ[
M\%_#[5;_ .#_ .QII6O6WPT\6>%-7\93CQKK5E_9GA_QI>^)? UHUX-3/@VX
MFC\]O>/^"D_P*^*?P]_X-;O@H?C;XI\<ZU^T+\ ? 7[.?Q"U+QK?>*M8NOB)
MX<U/Q)XCTBS\0Z#_ ,)<-9&NE+3P1XVNO!MXCZD3)I-M%8R1PB!'M_V,^*__
M  1E^''Q5_8Q_9L_84US]I/XZZ+\"?V8]6\$:[X;TKPWHGP2TZ]\:W'PKNYK
MWX;6WQ&:;X7WNFZYHOAB=X[FYTJ#3]/M/$^HVMKJOBA-3U"%;BL/]L?Q#\+O
M^"D%EXU_X)-?#G78OC:+O1/ 4_[<?QS\-SZ-_P (5^SO\.K;6[;5K#0-2\1>
M'XY?#K_M-?%?4/#=Y#\/_A3H%H\GA31$\0?$#Q;#X8T33O#EEXE ,>Q_8_\
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MD\,>#;K6/B)XSU_PRMS\0AJDY^D/^"*GP<\3_##]D;7O'GQ%^#7B7X$?%_\
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M>_\ E'_(B/F=F/XLQ_EMY_$_3N >9W8^V&8?GDM_2I?*'M_WR/\ &CRA[?\
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MDC#,&*X.>,CY<<H  A4  6:* *@M%);>S.&7:0S,P_B'1]RGY792""",$@L
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex23-2_001.jpg
<TEXT>
begin 644 ex23-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #8 -@# 2(  A$! Q$!_\0
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MA<#)_K6W<P'Q=X;MKJ( W]NWEN!W]?TP?S%<SX@F676[@1_ZJ(^2@[ (-O\
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M<L/?_:/X_@>E>83RS3SO).[O*Q)8N<DGWKTOP]XFAUE?)D417:C)3^%O=?\
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MFN6\3_$;5M2TP:%&R16MK.=DT9*R.HR #Z?UH3;5AM6=SKE2WM(SM2.%!UP
MHIFH1K/IEU&Q&UX7!/89%>8Z-I=UKNI(K&1H5(,LI.0!]?7_ #TKN_%.I1:?
MHDR,^)9T:.-1U.>OZ?TJ'&S*3T/+:4$@@@X(Y!%)16YD?06OGS+V"<\F>TAD
M)]28UK*K0O\ ?]AT3S?];_9<&[Z[?\,5GUSRW-H[!1114C/2;*3S/A_%*?\
MEFF[_OA__K45%IO_ "363/\ SPF_]":BM6]C-+<EO8_,^'\L0_Y9IM_[X?\
M^M7FU>KQ0&?1]7L1]X2SH/\ @?SC_P!#%>4TI]!P$HHHK,LU-!'F7L\ Y,]K
M-&!ZDQM7S^002",$<$&O>=)N?L>KVEP3A4E4M],\_IFO(?&6FG2/&6KV/\,5
MT^W Q\I.X?H16T'I8SEN7_#'BE=.1;&]!^S9)20<[,^H[C/XCW[=;?:38ZS)
M:W8=2T+JZR(<AP#G;]/Y?G7D]207$UM('@E>-@<@JV#3<=1*70]@U"S6_P!/
MGM&8H)4*[@,X_#O6<NLZ5X-2TA3<[0.K"&,Y<\YR?Y_R&*M:+JL6KZ;'<I@/
MC$B _=;_ #S]*Y7Q#X0N&NWN]-3S$D)9XMP!4^V>WMU%9Q71EO8^H=-U"WU7
M3K>^M7#P3H'1@<]:Q?%?A^36($FML?:800JDX#@]LU\\^'O$WB_P1$TMM'*M
MB#AX;A"8^3V].?U/O7J7ACXLZAK.GO<7.F6R,DAC_=NP!X!SS]:U;5C-)W./
M\<^#=?NH;00:1=2R)(5Q&FX8/TXZ@=Z]!^',^J^&/"D%EXM>"P3S1#9+-*!(
M0?X2.W/3GI6#XR^*^LZ781?8(+6&65\!V4M@ <X!//;M7B^KZYJ>O7AN]4O9
M;J8]#(V0![#H/R%$;6T"5^I]F\$=B#7 >*_A-H/B-GNK93IVH$[A- ,*S?[2
M_7TP:\C\'_%S7/#:QVMX3J.GK@".5OWB#_9;\^#G\*]U\+>.]"\70C^SKL"Y
M R]K+\LB_AW^HS5"//9?#FM:#:I'JS1SL"0+B(?*P[9]"1S65<:1IUU)YD]C
M [YR6*#)/N:]ZFACGB:.5%=&&"I&0:\,^)5EJO@S4DU&RQ/H]RV/+D3(A;TR
M,'GDC.?3Z9.'5%J7<@N(YK2Q9=+M8/, RL9.Q?T'^'UKR_6Y]2GU!CJ@=9U&
M A7  ]AZ?GGUKT#0O$]KK),13R+D#/EELAOH>_Y9J7Q!H46M6>T82YC&8I/Z
M'V_EU^JB[.S*:NCRFE )( &2> !0058@C!!P0>U;?@W33J_C+2+'^&2Z0MD9
MX!W'] :V,SV;7QY=[;P=#!:0QD>A$:UEU<U>Y^V:O=W&<AY6*_[N>/TQ5.N9
MO4U2T$HHHI#/2;*/R_A_%$?^6B;?^^W_ /KT5>E@,&D:18G[QE@0_P# /G/_
M * :*WY;F7-8LP?N->O(OX;B))Q[L/D;] E>6:M:?8-6NK7;M6.4A1_L]OTQ
M7J>I'[/=V-[_  I)Y,G^[)@?^A!*XSQ[8>1JL5XH^6X3#?[R\?RQ^5*:T"+U
M.2HHHK$U"N=^*^G_ &E=*\21KG[5%]FN3_TU3H3[E<?E715;6PA\0Z+>^')V
M"FZ'F6KMT2=?N_GT_*K@]29+0\'HJ6YMY;2ZEMIT*31.4D1NH8<'/XU%6YD6
MK#4+K3;@3VLK1N.#CD$>]=%%X]OU3$MM;NW8C*_F,G^E<G12:3*O8U]5\1ZA
MJZ[)W5(0<^7&,*3[]_UKN?"%HUKX=A+<-,3*1Z ]/T KSS2M.EU748K2+@L<
MLV,A5[D_A^O%>J7MU!HVDO,P B@0!5SU[ ?R%1.UK%1[F--:6WB3XD:/H-VS
M_9"V)0C8;)!;KVX _.N?^('AA?"7BZZTV'<;4@2VY8Y)0^_?!R/PJ/PEJ[6_
MQ TK4[EMS&]0N<XX8X/Z'\J]Z^*7@/\ X2_15N;)<ZK9@F$9QYB]T_P]_K5I
M61#>I\PU-:W4]E=1W-K-)#/&=R21L58'VHN[.YT^ZDM;R"2"XC)#QR+M8'W%
M1 $G Y)IB/JGX9>+I/%_A47%T +RV?R)R/XR "&]L@_GFF_%FUANOASJ9F(
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M'Q]WW]N?I5_P;%'+XE@W@'8K,H/KBGW-Y?OXQDC\]VQ<M'L9ODV9Z$=,;?\
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MFUC4<1N$)C#_ /+-,<L??'Z?6J7O.Q/PHT["S_X1O0H[:%5DOYS@ ?QRD?\
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M\*M0[D.78I6=AI7AL+#;1-<7[C@##2O_ $5??@5>BL)KF9+G4F5V0[H[=/\
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=#UV*!GZ^M3T44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex23-2_002.jpg
<TEXT>
begin 644 ex23-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "F M@# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYN9?PEZG(4445]$>"%%%% 'H_P %O^1QN_\ L'O_ .C(Z]UKPKX+?\CC=_\
M8/?_ -&1U[K7S69?[P_1'T.7_P #YL*\B\3?\C)?_P#74UZ[7D7B;_D9+_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSS2IOH5-=2W1116AF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ5YGX%W?\)&-N<>2V['IQU_'%=+?:;XHU-#!/?6-O PPXM]^2/3D9_6M/1=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17,CQ=G
M1;G4?L/^HG$/E^;][WSMJ^FO0S>'7U>&/>$0LT1;!##J,XJ>96N/E=[&O17,
M3>*KQ+:WN(=#GGBEA$K.C$JG)XR%]J;IWBR\U":';H<X@D;!G#EE7U.=N/UH
MYD%G:YU-%<A!XSOKI"]MX>N)D!QNC=F&?J$J])XEN(-"EU&YTJ6!TE$8@D<J
M2#CG)7W].U',K7'RO8Z&BN2/C&^CC\Z;P[=1P8R9"S8 ]>4Q5K4O%T%A!87"
M6[3078+;M^TH!C/&#D\_I3YD+E9T=%8^L:\FEZ?;WD<(N$G=57#[>",YZ&I]
M:U9-&TTW;1^8VX*D>[&XGW_.AM($KFC165H^M+J^EO=I 4D0LK0[LD$=LX[_
M $K$E\:7T$D<<OAZXC>0X17=@6/H!LYH<D@2;.PHKF)?%=S;Z<+JYT>6!FG$
M0CD<J2",[N5J[K/B2#2I8[9()+J[D&5ACZ_C_P#JHYD%F;5%<Y8^+5FO4L]0
ML)]/FD.(_-S@_F 1^52Q>)X6\1R:1+!Y95MJ2[\AFQG&,<?G1=!9F]164=9Q
MXD&D?9^L7F>;O_3&/ZU5\0>)DT.:&%;8W$CJ78!]NT>O0^_Y4N96N%G>QOT5
M1GU)(]%?4HE\Q!#YJKG&1C.,T_3+W^T=-@O/+\OS5W;-V<?C5=;"\RW116+X
M@\0IH20XM_M$LI.$#[< =3T-)M+<:3>QM453M-2@NM)CU'(2)H_,;G.W'4?A
MS7/'QL[!IXM&NI+)3@W&3C'Y8_6AM)V8)-['6T5C7OB6RM-(@U!0\JS\11K]
MYCZ>V*I6?BTO>PVVH:7<6!F.(VDS@G\0*+J]@L[7.FHK#UCQ+#IERMG#;R7=
MXPSY,?;Z\'^50Z=XK2YOELKZQFL+A_N++G#?F 1^5"DF[!9VN=%16%JWB6+3
MKL65M:RWMYC)BB_A'OP?Y4FD^)X]1N7M)[26SO%4MY4G<#WP.?PI<R"S-ZBL
MO0M8_MJP>Z\CR-LA3;OW= .<X'K5#3?%L.HZR; 6WEH2PBF\S(<CVQZ>].^M
M@L]3HZ*P-9\07FEW31Q:-/<PJ@<SJ2%'K_"1Q]:@TSQ3>:C/"!H<Z6\F?W^X
ME!C/?;CMZTN9!RLZ:BL*P\36]SHDVJ7,7V>.)RA7=O)/'3@<G-9__":S;1.V
MAW8LO^>^3C'KTQ^M/F0<K.MHKG]3\56]CIEK?V\/VF&X;:/GV%?7L>:LZCK\
M5GH2ZK!'Y\;[=J[MO7WP:.9:^069KT5'!)YUO'+C&]0V,],BLG6?$<&DS);)
M!)=7<@RL,?7\:&[;B2OL;5%<Y8^+5FO4L]0L)]/FD.(_-S@_F 1^51W?BRYA
MU2YL;;1IKMH#@M$Y)^N IQ2YD/E9T]%96C:I=:FLQN=,FL=A&T2Y^?.>F5%:
M%U<):6LMQ*<)&I9OH*;=E<+:V):*P?#_ (F37)9HFMC;R1J&"E]VX'OT'M^=
M2ZSXBATJ6.V2"2ZO)!E8(^OX_P#ZJ&TE<+.]C9HKGM+\5+>:@+"\L9K&Y;[B
M29.[\P"/RI=2\4I:7S65E8S7]RGWUBSA?;@'^5',@LSH**Q=%\1PZO)+;O!)
M:W40R\4GI]>/Y51G\8E[F2+3-+N+]8SAI(\@?A@'BAR069U%%85IXHMKW3;N
MYCB=9[5"\ENYP>/>K^EZC_:>DQ7WE>7Y@)V;LXP2.N/:BZ"Q>HKFE\6[O#TN
MJ_8<;)O*\KS>O3G./?TJ\FO0S>'7U>&/>$0LT1;!##J,XHYEJ%F:]%<Q-XJO
M$MK>XAT.>>*6$2LZ,2J<GC(7VI-,\5WFI7$"KH<ZP2OM,X<LJ^ISMQ^M%U>P
M6=KG445S^O>*4T2[CMQ:FX9DWOA]NP9P.QK3O-12VTB348U\U%B\Q1NQN'UH
MYE9L+/8NT5D:/KT.KZ7)=QQ['BSOB+9P0,CG'>LQ/%MY/90W-MH<\XD+!A&Y
M;9@]R%H<D@2;.JHKD['QA>7\B>3H,[1,X1I$<LJ^N<)VJ:\\7,E]-;:?I=Q?
M>2=LCQY !_ &ES(?*SIJ*S=&UFWUJT::%61D;:\;]5-7YI4@@DFD.U$4LQ]
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M8[HSWN=+UK0+ 2R)I<_FD0>5&=BN#SC' !R#UI+ZXU719+5]8-CJ5KY@",R
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MW))#=6&3_G\:T=*\+:;I$_GPK)),.%>5@2OTP *-5\+Z;J\WGS+)',?O21,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-1_001.jpg
<TEXT>
begin 644 forms-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 4T# 2(  A$! Q$!_\0
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M^SNY_P"$AUQ,_*;2,X]]YKZ#8X4GT%?/7[/'_(RZW_UYQ_\ H9KZ$?[C?0T
M?$%[*\^H74TC%GDF=V)/))8DU!4D_P#Q\S?]=&_F:CH ]1^ C%?B%, >&L)
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M !7V77Q%JO\ R&M0_P"OJ7_T,T 5**** /8_V>+J1/$>LV8;]U):)*5_VE?
M/Y,:^A:^<_V>_P#D<M4_Z\/_ &HM?1E 'RUX&V)XLU^,8'SOM'L)3_\ 6KT$
M=17CVF:NNB>.;FZD)$!NIHYL?W2YY_#@UZ^KK(BNC!D895@<@CUKY/-Z4HU^
M?HU^1]3E-12H<G5/\SPS7(I8->U".8$2"X<G/?)R#^1JA7M.N>%M-UXB2Y1H
M[A1@31'#8]#V-<T_PPCW?N]6<+_M0@G^=>I0S6@X)3=GZ'FU\KKJ;<%=>IYW
M7KO@&&6+PE 9 0))'= ?[I/'\C5.P^'.EVTJR7<\UWCG80$0_7')_.NOB,6T
MQPE-L1V%4Z*0!Q[<8K@S+'TZ\%3IZZWN=N7X&I1FZE332UC&\9?\BCJ/_7,?
M^A"LOX;HB^&Y64#<URVX_0#%:GC+_D4=1_ZYC_T(5R_PTU)4DN]+=@"^)HO<
MCAA^6#6%*#EE\[=))FU6:CCX7ZQ:.L\5I+)X4U)802_DDX'4@$$_IFO%*^@^
MHYY%<;JGPZT^\G::RN'LV8Y,87<F?8=16N68ZG0BX5-+ZW,\RP52NU.GK;2Q
MY=0>G-=Y_P *QN=W_(4AV_\ 7(Y_G6OI7P\TZQG6>\G>\=#E4*[4S[CO7KSS
M3#15U*_H>5#+,3)V<;&WX9CEB\,::DP(D%NN0>H]/TQ6!\2ID30[6 GYY+C<
M![ '/\Q77W%S#:6[W%S*D4,8RSL< "O'/%&O-X@U8SJ&2VC&R%&ZX[D^YKQ<
MNI2KXGVMM$V_ST_$]C,*L:.&]E?5JWY:_@8E%%%?6'RP4444 >I_"'Q]H?@J
MUU:/6&N%:ZDC:/R8B_"@@Y].M=]JOQM\'7FCWUK%)?>9-;R1IFV(&2I [^]?
M-U% #4!5%!Z@8IU%% 'H?PD\9:1X+UC4KK5VG6.XMTCC\J/><AB3FO66^.O@
MHJ1YM_R/^?4_XU\QT4 /E8/-(PZ,Y(^A-,HHH [;X6>*--\(>+GU+56E%N;5
MX@8H]YW$J1Q^!KV?_A>W@K_GK?\ _@*?\:^8J* +^N7<6H:_J5[!N,-Q=2RQ
M[A@[68D9'T-=WX ^+^H^$K>/3-1A;4-*3B,!L2P#T4G@K['\#7FM% 'U=IWQ
MA\$:C&K'6!:.?^6=U&T9'XXQ^M79_BAX)MTW/XDLB/1&+D_@ :^1** /H+Q-
M\?M-MX)(?#=I+=W!!"W%PI2)??;]YOIQ69\-/BII&D:5J3^*-3N'U*\OFG9_
M)9]RE% Z# '&,=@*\0HH ^C?%?Q>\':KX2U;3[2^G:XN;22*)3;. 6*D#DCB
MO,/A+XNTKP9XAO;W5VF6&:T\E/*CWG=N!Z?05P-% 'T[_P +V\%?\];_ /\
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M;S0>%X9+C<9+B1YR6.2=QX)^N,U3T_X>:3:2K+<R37C*<A9,*GX@=:ZX
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1_002.jpg
<TEXT>
begin 644 forms-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $0 D # 2(  A$! Q$!_\0
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MR*)(8Q'&H55Z 4^BEQ7HI65D>??J)12TE, HQ112&(: *6BD A'%'2E---#
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M25(!1110 4F*6B@!**6C ]: N)BEHHH&(:2G&DI,!**7'%&/>IL,2C%+BBF
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M.YB5ZFK5% %"+1--@C9(K*%5;[P"]>0?Z#\JK6WA?2K7S,6WF>8P8^8=V,=
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M$RP:IJ213L,^4H+/CU('2DDWL,ZK(JI=V-O=X,B8D7[LB':Z_0UPA^,_@O\
MZ"<G_?AJ0_&?P9_T$Y/^_#4^1]A71V*7<^G2+%?OYD#'"70&,>SCM]:U-X)]
M_3->9W/QA\&SVLL2ZFP+H5!>V9@/J.]<7X(^(&FZ!X@U>;6O$;ZA!<QH()A$
M_P NTGY=I^[P:?(V%SZ!W>] 8>M><?\ "YO!G_02D_[\-1_PN;P9_P!!*3_O
MPU3R2[!='HY8>M)D5YS_ ,+F\&?]!.3_ +\-1_PN;P9_T$I/^_#4<DNP71Z,
M&'K2[AZUYQ_PN;P9_P!!.3_OPU'_  N;P9_T$I/^_#4<DNP71Z*Q%)FO._\
MA<O@L]=3D_[\-76:+XATS7[$7FEWD=S#G!*'[I]".U92@UT*31KDTF:S-6UO
M3]$L7O=2NX[:W7J[G]!ZUQQ^,G@S.!J<G_?AJ7))[(JZ/1-PHW5YU_PN3P;_
M -!*3_OPU'_"Y/!O_02D_P"_+4>SGV%='HNZC=7G7_"Y/!O_ $$I/^_+4?\
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M#_P)_P#K4G_"A?!GIJ/_ ($__6KU"BCG?<+(\O\ ^%"^#/34?_ G_P"M2_\
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M/9*1ONFEI&^Z:_1#X(SKS_5O]#7SG\&_^2N-_N7'\Z^C+S_5/_NFOG/X-_\
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M<@^QJXJ[8NQ]G45XC;_M%6/V=/M.@7/G8^?RYEVY]LU)_P -%:5_T ;S_O\
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MG2GC6X*EI!N&SD;>Q_'J*:: 9I'_ "'=/_Z^8_\ T(5]$_%[_DG-[_UUB_\
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M1116H@HHHH%8**** "BBB@ HHHH *#10>E 'TE\'/^2=6G_7>7_T*OGW7?\
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MZ:0,E^U7(C,?GR[&^\N\X-1444"'P?\ 'Q%_OK_.O?X/]6OT%>!VD;2WD$:
ML[2* !WYKWV%2$4'KBOE\_:]SYGOY.G[Q.*7O2#BG#J*^6ZGO]".Y'^E3?[[
M?SJ(BIKG_CZE_P!]OYU%UIS^)FT/A1"XS6#JGA72]4G\^> B4]70[2?K71$4
MTK6E*M.D[P=B*E*-16DKG'_\('HW_/.;_OY2?\()H^?N3?\ ?RNP*<4FP5U?
MVAB/YV<WU&A_*CD?^$$T?_GG-_W\H_X031_[DW_?RNOV4FRG_:&(_G8_J-#^
M5'(_\()HW]R;_OY2?\()H_\ <F_[^5UWE@4;*/[0Q'\[#ZE0_E1R/_"":/\
MW)O^^Z/^$%T<?P3_ /?RNNV4;*/[1Q'\[']1H?RHY#_A!='_ +DW_?RE_P"$
M$T?^Y-_W\KK=E&SBC^T,1_.P^HX?^5&;X8^%VA:MJ#I<17!AC7)Q+CFO8-"\
M.:;X>T];+2[1+>$<D#DL?4GO4'@[3#9Z3YSKB2X._P#X#VKI @ KZK!NI[%>
MT=VSY3&.G[9JFK)&!K_AC2_$EC]CU6T6XBSE<\%3ZJ>U<4_P2\(Y_P!3>?\
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MC_X1[5O^?*3\Q6\\-6YG[K)AB:/*O>7WF92$5J?\(]JW_/E)^E'_  CVK?\
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M1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ HHHH ,48HHH ,48HHH ,48HHH
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&J:7L?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1_003.jpg
<TEXT>
begin 644 forms-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  S )X# 2(  A$! Q$!_\0
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MX<\9&2P\3:QK(/AW6/A@3XF\)/+X>\4>'F:16N'N"L[.Z3.0K#ZW_P""<_\
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M,_S-?M9_MS_\'//[6GP;^(T&N_L/_$7X<_LU?$WPCJFC>)/!7@K]F)-2>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-1_004.jpg
<TEXT>
begin 644 forms-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #C 1$# 2(  A$! Q$!_\0
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MO?0Z+\>;.ZU25;6SFT5H;2:8X3S/,RZ@]CC'UKU+:.N.:CN;&"\VB>))@IW
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M^\\L94QL6ZCKCZ5$9*;]Y;%RBX+W6?%GP5^.WB#4+JWTKQ#IUYJ$$A"1ZE#
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M\277C+Q3K&O7IS>:E=R7<OU=B<?AG'X5]<_L\Z;'X.^$$%[=L(%G,E_*TAP
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M6MG<7]PL%K!)<3,<".)2Q/X"O<_AA^SC/*T>M^-#'IFDP_O/L<SA7DQ_?/\
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M=M/OW1MC8PZ!T(Y //K7VG>>%+C3+N2_\.RI932'?-929^SSGUP/N-[BO/\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-1_005.jpg
<TEXT>
begin 644 forms-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  \ 2D# 2(  A$! Q$!_\0
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MI]M=-9M=":;RMHDV;?E)ST/I7%_\+NC_ .@ _P#X$C_XFKOQJ_Y%W3O^OO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \P^-?_(NZ=_U^?\
MLC5XIWKVOXU_\B[IW_7Y_P"R-7BG>OI<M_@(^>Q_\8ZSX9?\E"TOZR?^BVKW
M#Q><>%[SG^[_ .A"O#_AE_R4+2_K)_Z+:O<M9>R\ZVMI;)+R[F)$43=,#JQ]
M *\S-/XOR/0RW^'\R?0V4>&[)LC:+=>?PJ/PX$E\-68X9&C((Z@\FJQLOLAA
MMI-+M6MKB4*YA8X3KC*GK4EX\>A/:I8V,(%W*(<!BF">_2O+/2.9U73+C0+[
MR[7)TR]EC!7LC!@<?X5V.MWYT_3)'0CSY"(H0>[MP/\ '\*@%Z+G4CI&HV:!
MVC\]"K[T8 _0$'--UC[')>VMM)9)=WDN?*5^B*.K$]A2 +7P\MM:1PKJ-\H5
M<$)+@9[\8]:QM!?^PO%%WHSN?)G^>$D]\<?I_*MW[<^G7-K:7<*)%,?+BEB)
MVAO[I!Z?6J>KV]E97=H?[+M9GN9Q%O<X*L><]#18"?6BNH7EMHRR%?./FS[3
MR(U_Q;%)?^'%O+&6!K^]DW+\JR2Y7=VSQZT^_M+>VN;>XCL+=YYI50R,Q5E)
M[YQ[4_6[][*WA!MXYTGE6 JSE<%N_3I3 SO!.HFYTM[&4_OK1MF/]GM^7(KJ
M:YVR2RM-<6S?3(+>Z:,R12PG(91U[ @UT/:F@8M%%%,04444 %%%% !1110
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B>_-=!118+F5H^FRZ=%*DLXD#,"J*#M0 =LDFM6BBF(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-1_006.jpg
<TEXT>
begin 644 forms-1_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !8 9@# 2(  A$! Q$!_\0
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M[27BZ\U2R@=[+RYID3_5?[=>Y3RG$U*/MEL?&5>*<#1Q,L-/X[\I]>,/44O
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M?;_QG_:.L?!,+Z+H#Q7NN[-KM_RQM_K_ +?^Q7RC>Z]?:]J3W%U++?:A</\
M._WW=Z<OPS\83>"Y?%QT:=]*7YV:X5_/D3KYVS^Y7):?XFN-'OK6^L+EH+FW
M=)H9D_OUS9?A<-AJ3=#WYG7F^,QF.JPJXSW(?RGU/\)?V:;W6/)U3Q6C6EI]
M]-+5_F;_ *Z5]/:7I5OI%G%;6END$"+A(HTVHM>*_ /]I#3OB=;KI6I&.Q\1
M1)GR_P""X7^^G_Q%>[QR#:M?!YE6Q<ZS6)/U[(<)EV'PT)X,EIU-IU>,?6%:
MZF6&W>5_NI\V:^$OC-\9K[XCZ]=VT,S1^'[=]D5K_!-_MO7VKXZCEF\':TEO
MN$[6<VS;_>V'%?E['J/EPHG]SY*^SX<P]*I.=6I]D_+^-<76I4X4:/VCO/#N
MEWWBS7+/2--3SKR[?8J2?^AO7U[X%_9K\->';6&74XFUS4/XI+KE$_W$[5\P
M_LM^(K2Q^,VFI>2JAN89H86?N]?H S_* #@U?$&.K0K>QI^Y Y^$<GPU2C+$
MUH\\S+M?#>E6*[;?3K6#_KG"B4^?PWIMPNV73[:3_KI"AK4HKXWVT^Y^G?5J
M/\ACZ)X5TGPZTC:=I]O8R2\OY*;-U<5^T@_E_!WQ$W^PG_H:5Z6W +#K7E?[
M4#[/@?XE?_8A_P#1R5MAY.6(A?N>?F-.$,!6A#^4^'_[2\ROJ/\ 8\CAOO#_
M (@>5%D*7:X#_P"Y7QI'JO\ MUVG@7XG>,?"%I<KX8N+I(97WR^39^<F^OU/
M-,//%87DA[I^#Y%5A@<=&K6ASGZ*W>CV%[$8KFTMY$_NR(#7Q?\ M%:+H'A/
MQY';:)M@\Z'SKFVA^Y$^_K7*WWQB^+'B)?L[76M;7_AM-/=/_9*SM%^$?Q$\
M676^#PSJ3R3/\]U?'9_X^]?.Y?@_J4_:5ZVA];G6-CG%'V.&PQD_VQ-!LFB?
MR+I/GA_V'K]&_"UU<W7AO39KKY+EK='E_P!_9S7SM\)_V1I])OK75_&-Y%=2
M0OYR:9!_JP_^V_\ '7NGQ'\<:?\ #3P7?ZW>'Y+>/*I_??\ @3\Z\_.L71S"
MM"% ]SAG+<1E%&=;%^[$\)_:P^)R?:(/!]E-E<?:-1*/SC^!*\#\,Z?<^+/$
M&GZ19G?<W<VS_<WUR&K^++OQ%J][JE_+OO+R;SIG_P!NO3OV?OB?X1^&^M7N
MM>(7NGU#9Y-HD%MO1$_C?_?KZJGAYY=@.6BO?/S_ !&(AG6;^UQ,^6!W/[2W
MPW7P)<:1JEC%LL+F'['-_L3(G[MZ\CT'Q9=^%]:L]4LVS<VDR3+_ /$5[S\1
MOVG/AO\ $;PC?Z)=?VE&+E/W3FS/R/\ P/7RE_:/^W3RGZQB,.Z>)@7GE+"8
M?'0KX"9^F_@?QA9>-_"]CK%FV^"X0.%S]UO[M=&N"O'2OB?]D;XP+H?B1O"&
MI2[++5#YEFTC_<F_N?\  Z^UED55VCI7YWF&"E@\1.D?M&29A',L)"K]H^8/
MVR/[4CD\/W \S^Q07W[/N>=_!OKYJCU+YZ_2+7M L/$.ERV-_:QW-K,-KPN.
M#7SWXR_8STZ_=YO#6M3:3O\ G^RS)YT%?1Y/FV'P]+V-<^#XCX8Q>-Q?UO#%
M7X%_$[X<Z7H5C8WGV?2=710LTUU#@S/_ ']^.:]_T^Z\.Z_'OM9M/OD;_GFZ
M/7Q=XA_9:^(VBQO)'96>LQIWLIO+?_OBO+]0LM=\"ZAY5_::AX?O?X-^^%_^
M^ZZ)Y;A\;/FPV).?#YIB\I@J6,PA^C;?#_PW_:%M??V+9BZMVWPSI"$*-^%=
M-;J I %?GMX+_:@\:>#Y$9]3;6;/_GVU'K_P!Z^U/A3\4M-^*WA.+5]/W)\W
ME3PO]^)_0U\]F.6XG!?QGS(^UR?.,#CY<E"'),[ZBF;Z*\,^M&LN5KYV_;BU
MHZ3\#KE$?8UW>VT'_C^__P!DKZ*[UY?\=/@?IGQT\-VFB:I?W>G6UM<_:MUD
M<.SX_P#LC75@ZL*.(A.9YF849XG"3HPW9^6_]L>]?I?^R/:_9_V?_"DA7YYX
M6F_[[<FO+)/^"<O@MU./$>O$^GF1_P#Q%?2GP]\'VOP]\'Z1X<LGEDLM-ME@
MBDF/SMBOI<XS6ECZ4(4>A\9PYD6(RW$SJ8C^4^0_VZOAN^B:I9>.+)/+MKO_
M $+4MGW-_P# _P#[)7RC'XCFC29(IGC@F39-'&_WT_N5^MGC[P-I7Q)\*7_A
M[6K?S].ODV.J_>7_ &J\)C_X)^_#+C<^MY'?[?\ _85OEF?4L/AO8XF%SESC
MA>KB<7]9PT_B/ OV/?AK)\2_B!_;%]#YFC:$_G.7_P"6MS_ OX5^B.T&$X[5
MR/PO^%.@_"'PK#H'AV"2.R1G?=.^]W=NI=Z[((?+([5\]F>8/'XCVR^$^NR?
M*H9;A/8_:/R"\87SZ7XPUZS3_EC?W*)_WV]>Q_L2^(O+^/-K;/\ \OEA<P_^
M@/7N_B?]@?PCXH\3:OK-SKNLV\U_<O<O'#(FQ2_H-E:OPM_8K\.?"GQ[IGBK
M3M=UB[N+ /LAN9%*/O39Z5]7B,YP-;!RH_;Y3X?"\.XVAF$<3]GF.F_:V\5:
MUX3^"NJ7VAM+#,SI%+<0??AA?[[UXS^P['X5UQM9O+K[//XK2X/EI.^]_)[.
MG]_O\]?85W86^H6TMM=P)/:RKY;PR+N1EKYW\7?L+>#-4U?^UO#M_JGA#4-^
M\'39\1K_ , KYG"XFC'#3P\_=D_M'U^.R^M/&PQT?>Y?LGH/Q7^ /AGXK6SR
M7D?V'543;%J%LOSC_>_OU\XR>.OB'^R/JEM8Z\\7B?P=,_EV\DDN)/\ @']Q
M_P#8KT^']E?QE%#Y$GQP\6M!_<38A_[ZJ[X6_8M\$V&J+JWB"XU;QEJ8_P"6
M^MW)D3_OCO\ \"S6U#%4J4?9UI\\#DQ&!Q%:K[7#4O93_F/![[Q%JW[87Q9M
MK&Q9=*\.V,>2MP^72$GYWV?QL]?<^@Z/9^%]'M-*L8_*L[2-(8EKP3Q-^P_X
M2O\ Q3%KOAW4]2\%W:OOVZ/($16]4_N5[CX1T+4_#^@P6.I:O+KMS#\GVZ:-
M$=U_VZQS+$4:T81H_ OLG7D^ K8:K5JXF/OR^T?GU^V5J7D_M!:Y%_TZVO\
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M)]*GO-8U6RTVR3S[V\F2&&/^^[U]WZ/^PWX2.EVOV_4-5DU#R4\V1+KY-_\
M'LXJ_P#"W]B7PI\+O&5AXFMM2U+5;NQ#_9X;V12B._5_K7T6BG\!7IYMGDJT
MX_5):'BY)PU##0E]<AJ?.7_#"_@?_G]U<?\ ;U_]:OFS]J+X'?\ "C]7TR;2
M7N+OP]J*>6D]T^]X;K^YO_VTK])&QW%<-\6OA1I/QB\&7GAS6%=;:8JZ2QGY
MX9%.4=/>N#!YQB*-:,JL_=/3S#A_"5L/.%&'OGY3V_B.YL;R"YMYG@GAF\Z&
M3^X]?I_^SS\6;;XP_#C3]:1D%^G^C7T/]R9.HKQE?^"=/@M>OB/7L^GF)_\
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M^N:52F^*&FC_ %4-Q)^%'(!VE-W"N G^*G_/*P_[^/6=/\2-5N/DBABC_P"
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0_'Y/R?G110!OT445)1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>mgrx-20230930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauCybP9z5Z8KekhvWB5bckq7yYluBqnJCFzw8uGoW0D -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:MGRX="http://mangorx.com/20230930" elementFormDefault="qualified" targetNamespace="http://mangorx.com/20230930">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://mangorx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/StatementsOfOperationsParenthetical" id="StatementsOfOperationsParenthetical">
          <link:definition>00000005 - Statement - Statements of Operations (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" id="StatementOfChangesInStockholdersEquity">
          <link:definition>00000006 - Statement - Statement of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000007 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
          <link:definition>00000008 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/PrepaidExpensesAndDeposits" id="PrepaidExpensesAndDeposits">
          <link:definition>00000010 - Disclosure - PREPAID EXPENSES AND DEPOSITS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/Inventory" id="Inventory">
          <link:definition>00000011 - Disclosure - INVENTORY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000012 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000013 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/NotesPayable" id="NotesPayable">
          <link:definition>00000014 - Disclosure - NOTES PAYABLE</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/CapitalStock" id="CapitalStock">
          <link:definition>00000015 - Disclosure - CAPITAL STOCK</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000017 - Disclosure - SUBSEQUENT EVENTS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/GoingConcern" id="GoingConcern">
          <link:definition>00000018 - Disclosure - GOING CONCERN</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000019 - Disclosure - INCOME TAXES</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/CapitalStockTables" id="CapitalStockTables">
          <link:definition>00000023 - Disclosure - CAPITAL STOCK (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
          <link:definition>00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000025 - Disclosure - INCOME TAXES (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" id="OrganizationAndDescriptionOfBusinessDetailsNarrative">
          <link:definition>00000026 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" id="ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails">
          <link:definition>00000027 - Disclosure - SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" id="PrepaidExpensesAndDepositsDetailsNarrative">
          <link:definition>00000029 - Disclosure - PREPAID EXPENSES AND DEPOSITS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/InventoryDetailsNarrative" id="InventoryDetailsNarrative">
          <link:definition>00000030 - Disclosure - INVENTORY (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
          <link:definition>00000031 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000032 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
          <link:definition>00000034 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" id="ScheduleOfFairValueAssumptionsDetails">
          <link:definition>00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
          <link:definition>00000037 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/CapitalStockDetailsNarrative" id="CapitalStockDetailsNarrative">
          <link:definition>00000038 - Disclosure - CAPITAL STOCK (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" id="ScheduleOfMaturityOfLeaseLiabilitiesDetails">
          <link:definition>00000039 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/GoingConcernDetailsNarrative" id="GoingConcernDetailsNarrative">
          <link:definition>00000042 - Disclosure - GOING CONCERN (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" id="ScheduleOfDeferredTaxAssetDetails">
          <link:definition>00000043 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://mangorx.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000044 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mgrx-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mgrx-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mgrx-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mgrx-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="MGRX_ResaleProspectusMember" name="ResaleProspectusMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_OptionsMember" name="OptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_MasterServicesAgreementMember" name="MasterServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ComputersMember" name="ComputersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_CohenEnterprisesIncMember" name="CohenEnterprisesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ZipDoctorIncMember" name="ZipDoctorIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_JacobDCohenMember" name="JacobDCohenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PHXGlobalLLCMember" name="PHXGlobalLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_EzekielElliottMember" name="EzekielElliottMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_DavidSandlerMember" name="DavidSandlerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_HsiaochingChouMember" name="HsiaochingChouMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_GreentreeFinancialGroupMember" name="GreentreeFinancialGroupMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ServiceAgreementMember" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_TwentyTwentyTwoEquityIncentivePlanMember" name="TwentyTwentyTwoEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_JoanArangoMember" name="JoanArangoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_TwentyTwentyTwoPlanMember" name="TwentyTwentyTwoPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_WhiteUnicornLLCMember" name="WhiteUnicornLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_GlobalCareerNetworksIncMember" name="GlobalCareerNetworksIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_CharteredServicesLLCMember" name="CharteredServicesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_DojoLabsMember" name="DojoLabsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_BethorLtdMember" name="BethorLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_RudmanMember" name="RudmanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_AdvisorAgreementMember" name="AdvisorAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_BoonMember" name="BoonMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ConsultingAgreementsMember" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantOneMember" name="PrivatePlacementWarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantTwoMember" name="PrivatePlacementWarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantThreeMember" name="PrivatePlacementWarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantFourMember" name="PrivatePlacementWarrantFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantFiveMember" name="PrivatePlacementWarrantFiveMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantSixMember" name="PrivatePlacementWarrantSixMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantSevenMember" name="PrivatePlacementWarrantSevenMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_HammerMember" name="HammerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrivatePlacementWarrantMember" name="PrivatePlacementWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_MrAndrewMember" name="MrAndrewMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_MajorDodgeMember" name="MajorDodgeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_StreetGroupLLCMember" name="StreetGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_LeovLawFirmMember" name="LeovLawFirmMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_LucaConsultingLlcMember" name="LucaConsultingLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_FixedAssets" name="FixedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_CostOfRevenues" name="CostOfRevenues" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ImputedInterestRelatedParty" name="ImputedInterestRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_StockIssuedDuringWarrantsExercisedForCashValue" name="StockIssuedDuringWarrantsExercisedForCashValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_StockIssuedDuringWarrantsExercisedForCashShares" name="StockIssuedDuringWarrantsExercisedForCashShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_IssuanceOfCommonStockForServices" name="IssuanceOfCommonStockForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_WarrantsForServiceCancelled" name="WarrantsForServiceCancelled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_DisclosurePrepaidExpensesAndDepositsAbstract" name="DisclosurePrepaidExpensesAndDepositsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrepaidExpensesAndDepositsTextBlock" name="PrepaidExpensesAndDepositsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_RelatedPartiesPolicyTextBlock" name="RelatedPartiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PrepaidExpensesRelatedParty" name="PrepaidExpensesRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_InterestExpenseRelatedPartyPercentage" name="InterestExpenseRelatedPartyPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PercentageOfProportionateRent" name="PercentageOfProportionateRent" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="MGRX_PercentageOfIncrementalBorrowingRate" name="PercentageOfIncrementalBorrowingRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>mgrx-20230930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mangorx.com/role/Cover" xlink:href="mgrx-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/BalanceSheets" xlink:href="mgrx-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/BalanceSheetsParenthetical" xlink:href="mgrx-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfOperations" xlink:href="mgrx-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfOperationsParenthetical" xlink:href="mgrx-20230930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" xlink:href="mgrx-20230930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfCashFlows" xlink:href="mgrx-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="mgrx-20230930.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PrepaidExpensesAndDeposits" xlink:href="mgrx-20230930.xsd#PrepaidExpensesAndDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/Inventory" xlink:href="mgrx-20230930.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipment" xlink:href="mgrx-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/RelatedPartyTransactions" xlink:href="mgrx-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/NotesPayable" xlink:href="mgrx-20230930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStock" xlink:href="mgrx-20230930.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingencies" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SubsequentEvents" xlink:href="mgrx-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/GoingConcern" xlink:href="mgrx-20230930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxes" xlink:href="mgrx-20230930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipmentTables" xlink:href="mgrx-20230930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStockTables" xlink:href="mgrx-20230930.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingenciesTables" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxesTables" xlink:href="mgrx-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:href="mgrx-20230930.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:href="mgrx-20230930.xsd#ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" xlink:href="mgrx-20230930.xsd#PrepaidExpensesAndDepositsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/InventoryDetailsNarrative" xlink:href="mgrx-20230930.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="mgrx-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="mgrx-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/NotesPayableDetailsNarrative" xlink:href="mgrx-20230930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStockDetailsNarrative" xlink:href="mgrx-20230930.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SubsequentEventsDetailsNarrative" xlink:href="mgrx-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/GoingConcernDetailsNarrative" xlink:href="mgrx-20230930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxesDetailsNarrative" xlink:href="mgrx-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_FixedAssets" xlink:label="loc_MGRXFixedAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_MGRXFixedAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_MGRXFixedAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CostOfRevenues" xlink:label="loc_MGRXCostOfRevenues" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_MGRXCostOfRevenues" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ImputedInterestRelatedParty" xlink:label="loc_MGRXImputedInterestRelatedParty" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_MGRXImputedInterestRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Statements of Operations (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Statement of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_IssuanceOfCommonStockForServices" xlink:label="loc_MGRXIssuanceOfCommonStockForServices" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MGRXIssuanceOfCommonStockForServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_WarrantsForServiceCancelled" xlink:label="loc_MGRXWarrantsForServiceCancelled" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MGRXWarrantsForServiceCancelled" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_MGRXIncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_MGRXIncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000008 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PrepaidExpensesAndDeposits" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND DEPOSITS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/Inventory" xlink:title="00000011 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/NotesPayable" xlink:title="00000014 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStock" xlink:title="00000015 - Disclosure - CAPITAL STOCK" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/GoingConcern" xlink:title="00000018 - Disclosure - GOING CONCERN" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStockTables" xlink:title="00000023 - Disclosure - CAPITAL STOCK (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="00000026 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:title="00000027 - Disclosure - SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsFairValueDisclosure" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFairValueNetAssetLiability" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFairValueNetAssetLiability" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND DEPOSITS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/InventoryDetailsNarrative" xlink:title="00000030 - Disclosure - INVENTORY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000032 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStockDetailsNarrative" xlink:title="00000038 - Disclosure - CAPITAL STOCK (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/GoingConcernDetailsNarrative" xlink:title="00000042 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000044 - Disclosure - INCOME TAXES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>mgrx-20230930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mangorx.com/role/Cover" xlink:href="mgrx-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/BalanceSheets" xlink:href="mgrx-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/BalanceSheetsParenthetical" xlink:href="mgrx-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfOperations" xlink:href="mgrx-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfOperationsParenthetical" xlink:href="mgrx-20230930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" xlink:href="mgrx-20230930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfCashFlows" xlink:href="mgrx-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="mgrx-20230930.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PrepaidExpensesAndDeposits" xlink:href="mgrx-20230930.xsd#PrepaidExpensesAndDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/Inventory" xlink:href="mgrx-20230930.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipment" xlink:href="mgrx-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/RelatedPartyTransactions" xlink:href="mgrx-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/NotesPayable" xlink:href="mgrx-20230930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStock" xlink:href="mgrx-20230930.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingencies" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SubsequentEvents" xlink:href="mgrx-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/GoingConcern" xlink:href="mgrx-20230930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxes" xlink:href="mgrx-20230930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipmentTables" xlink:href="mgrx-20230930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStockTables" xlink:href="mgrx-20230930.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingenciesTables" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxesTables" xlink:href="mgrx-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:href="mgrx-20230930.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:href="mgrx-20230930.xsd#ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" xlink:href="mgrx-20230930.xsd#PrepaidExpensesAndDepositsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/InventoryDetailsNarrative" xlink:href="mgrx-20230930.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="mgrx-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="mgrx-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/NotesPayableDetailsNarrative" xlink:href="mgrx-20230930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStockDetailsNarrative" xlink:href="mgrx-20230930.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SubsequentEventsDetailsNarrative" xlink:href="mgrx-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/GoingConcernDetailsNarrative" xlink:href="mgrx-20230930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxesDetailsNarrative" xlink:href="mgrx-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_30" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_30" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_30" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_30" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_30" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_30" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_30" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_30" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_30" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_30" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_30" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_30" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_30" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_30" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_30" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_30" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_30" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_30" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_30" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_30" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_30" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_30" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_30" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_30" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_30" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_30" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_30" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_30" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_30" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_30" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_30" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_30" xlink:type="arc" order="58" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapInventoryNet_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapPrepaidExpenseCurrent_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_100" xlink:to="loc_us-gaapAssetsCurrent_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_FixedAssets" xlink:label="loc_MGRXFixedAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:to="loc_MGRXFixedAssets_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:to="loc_us-gaapOtherAssetsAbstract_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:to="loc_us-gaapDepositsAssets_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract_100" xlink:to="loc_us-gaapOtherAssets_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssets_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapNotesPayableCurrent_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_100" xlink:to="loc_us-gaapLiabilitiesCurrent_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_100" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_100" xlink:to="loc_us-gaapLiabilitiesNoncurrent_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilities_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommitmentsAndContingencies_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapStockholdersEquityAbstract_100" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapCommonStockValue_100" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapAdditionalPaidInCapital_100" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_100" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_100" xlink:to="loc_us-gaapStockholdersEquity_100" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_100" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_100" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCostOfRevenue_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Statement of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockIssuedDuringWarrantsExercisedForCashValue" xlink:label="loc_MGRXStockIssuedDuringWarrantsExercisedForCashValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MGRXStockIssuedDuringWarrantsExercisedForCashValue_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockIssuedDuringWarrantsExercisedForCashShares" xlink:label="loc_MGRXStockIssuedDuringWarrantsExercisedForCashShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MGRXStockIssuedDuringWarrantsExercisedForCashShares_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000008 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/PrepaidExpensesAndDeposits" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND DEPOSITS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/Inventory" xlink:title="00000011 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/NotesPayable" xlink:title="00000014 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStock" xlink:title="00000015 - Disclosure - CAPITAL STOCK" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/GoingConcern" xlink:title="00000018 - Disclosure - GOING CONCERN" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStockTables" xlink:title="00000023 - Disclosure - CAPITAL STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="00000026 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ResaleProspectusMember" xlink:label="loc_MGRXResaleProspectusMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXResaleProspectusMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:title="00000027 - Disclosure - SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_OptionsMember" xlink:label="loc_MGRXOptionsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MGRXOptionsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense_140" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND DEPOSITS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MasterServicesAgreementMember" xlink:label="loc_MGRXMasterServicesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXMasterServicesAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrepaidExpensesRelatedParty" xlink:label="loc_MGRXPrepaidExpensesRelatedParty_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MGRXPrepaidExpensesRelatedParty_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSecurityDeposit_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/InventoryDetailsNarrative" xlink:title="00000030 - Disclosure - INVENTORY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ComputersMember" xlink:label="loc_MGRXComputersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MGRXComputersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000032 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockPurchaseAgreementMember" xlink:label="loc_MGRXStockPurchaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXStockPurchaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CohenEnterprisesIncMember" xlink:label="loc_MGRXCohenEnterprisesIncMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MGRXCohenEnterprisesIncMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ZipDoctorIncMember" xlink:label="loc_MGRXZipDoctorIncMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MGRXZipDoctorIncMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CohenEnterprisesIncMember" xlink:label="loc_MGRXCohenEnterprisesIncMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MGRXCohenEnterprisesIncMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_JacobDCohenMember" xlink:label="loc_MGRXJacobDCohenMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXJacobDCohenMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_InterestExpenseRelatedPartyPercentage" xlink:label="loc_MGRXInterestExpenseRelatedPartyPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_MGRXInterestExpenseRelatedPartyPercentage_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaapPaymentsForAdvanceToAffiliate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForAdvanceToAffiliate_170" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_170" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:label="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStockDetailsNarrative" xlink:title="00000038 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantOneMember" xlink:label="loc_MGRXPrivatePlacementWarrantOneMember_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantOneMember_510" xlink:type="arc" order="511" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantTwoMember" xlink:label="loc_MGRXPrivatePlacementWarrantTwoMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantTwoMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantThreeMember" xlink:label="loc_MGRXPrivatePlacementWarrantThreeMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantThreeMember_550" xlink:type="arc" order="551" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantFourMember" xlink:label="loc_MGRXPrivatePlacementWarrantFourMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantFourMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantFiveMember" xlink:label="loc_MGRXPrivatePlacementWarrantFiveMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantFiveMember_590" xlink:type="arc" order="591" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantSixMember" xlink:label="loc_MGRXPrivatePlacementWarrantSixMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantSixMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantSevenMember" xlink:label="loc_MGRXPrivatePlacementWarrantSevenMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantSevenMember_630" xlink:type="arc" order="631" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantMember" xlink:label="loc_MGRXPrivatePlacementWarrantMember_670" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantMember_670" xlink:type="arc" order="671" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_1030" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_1030" xlink:type="arc" order="1032" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PHXGlobalLLCMember" xlink:label="loc_MGRXPHXGlobalLLCMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXPHXGlobalLLCMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_EzekielElliottMember" xlink:label="loc_MGRXEzekielElliottMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXEzekielElliottMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_GreentreeFinancialGroupMember" xlink:label="loc_MGRXGreentreeFinancialGroupMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXGreentreeFinancialGroupMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_WhiteUnicornLLCMember" xlink:label="loc_MGRXWhiteUnicornLLCMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXWhiteUnicornLLCMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_GlobalCareerNetworksIncMember" xlink:label="loc_MGRXGlobalCareerNetworksIncMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXGlobalCareerNetworksIncMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CharteredServicesLLCMember" xlink:label="loc_MGRXCharteredServicesLLCMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXCharteredServicesLLCMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DojoLabsMember" xlink:label="loc_MGRXDojoLabsMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXDojoLabsMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BethorLtdMember" xlink:label="loc_MGRXBethorLtdMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXBethorLtdMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StreetGroupLLCMember" xlink:label="loc_MGRXStreetGroupLLCMember_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXStreetGroupLLCMember_750" xlink:type="arc" order="751" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LeovLawFirmMember" xlink:label="loc_MGRXLeovLawFirmMember_1140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXLeovLawFirmMember_1140" xlink:type="arc" order="1142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DavidSandlerMember" xlink:label="loc_MGRXDavidSandlerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXDavidSandlerMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_HsiaochingChouMember" xlink:label="loc_MGRXHsiaochingChouMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXHsiaochingChouMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_JoanArangoMember" xlink:label="loc_MGRXJoanArangoMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXJoanArangoMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RudmanMember" xlink:label="loc_MGRXRudmanMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXRudmanMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BoonMember" xlink:label="loc_MGRXBoonMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXBoonMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_HammerMember" xlink:label="loc_MGRXHammerMember_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXHammerMember_650" xlink:type="arc" order="651" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MrAndrewMember" xlink:label="loc_MGRXMrAndrewMember_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXMrAndrewMember_690" xlink:type="arc" order="691" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MajorDodgeMember" xlink:label="loc_MGRXMajorDodgeMember_720" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXMajorDodgeMember_720" xlink:type="arc" order="721" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember_950" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember_950" xlink:type="arc" order="952" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember_960" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember_960" xlink:type="arc" order="962" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_1070" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_1070" xlink:type="arc" order="1071" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ServiceAgreementMember" xlink:label="loc_MGRXServiceAgreementMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXServiceAgreementMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementMember" xlink:label="loc_MGRXConsultingAgreementMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementMember_380" xlink:type="arc" order="383" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_AdvisorAgreementMember" xlink:label="loc_MGRXAdvisorAgreementMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXAdvisorAgreementMember_420" xlink:type="arc" order="423" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementsMember" xlink:label="loc_MGRXConsultingAgreementsMember_470" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementsMember_470" xlink:type="arc" order="471" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_TwentyTwentyTwoEquityIncentivePlanMember" xlink:label="loc_MGRXTwentyTwentyTwoEquityIncentivePlanMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MGRXTwentyTwentyTwoEquityIncentivePlanMember_240" xlink:type="arc" order="243" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_TwentyTwentyTwoPlanMember" xlink:label="loc_MGRXTwentyTwentyTwoPlanMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MGRXTwentyTwentyTwoPlanMember_260" xlink:type="arc" order="263" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_1050" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember_1050" xlink:type="arc" order="1051" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_1230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_1230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_1230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_1230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_1230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_1230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_1230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_1230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_1230" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1230" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_1230" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_1230" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1230" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_1230" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_1230" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_1230" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_1230" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_us-gaapCommonStockConversionFeatures_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockConversionFeatures_1230" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_1230" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1230" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1230" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCash_1230" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_1230" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_1230" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_1230" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_1230" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_1230" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaapPaymentsToEmployees_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsToEmployees_1230" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1230" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1230" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_1230" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1230" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1230" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1230" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1230" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_1230" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1230" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1230" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_1230" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_1230" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1230" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:label="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_1230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_1230" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LeaseAgreementMember" xlink:label="loc_MGRXLeaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXLeaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PercentageOfProportionateRent" xlink:label="loc_MGRXPercentageOfProportionateRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MGRXPercentageOfProportionateRent_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PercentageOfIncrementalBorrowingRate" xlink:label="loc_MGRXPercentageOfIncrementalBorrowingRate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MGRXPercentageOfIncrementalBorrowingRate_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseCost_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_90" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementMember" xlink:label="loc_MGRXConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementsMember" xlink:label="loc_MGRXConsultingAgreementsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LucaConsultingLlcMember" xlink:label="loc_MGRXLucaConsultingLlcMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXLucaConsultingLlcMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DojoLabsMember" xlink:label="loc_MGRXDojoLabsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXDojoLabsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BethorLtdMember" xlink:label="loc_MGRXBethorLtdMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXBethorLtdMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RudmanMember" xlink:label="loc_MGRXRudmanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXRudmanMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BoonMember" xlink:label="loc_MGRXBoonMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXBoonMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssued1_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCash_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_us-gaapCommonStockConversionFeatures_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockConversionFeatures_140" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/GoingConcernDetailsNarrative" xlink:title="00000042 - Disclosure - GOING CONCERN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000044 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_60" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>mgrx-20230930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ResaleProspectusMember" xlink:label="MGRX_ResaleProspectusMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ResaleProspectusMember" xlink:to="MGRX_ResaleProspectusMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ResaleProspectusMember_lbl" xml:lang="en-US">Resale Prospectus [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_OptionsMember" xlink:label="MGRX_OptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_OptionsMember" xlink:to="MGRX_OptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_OptionsMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MasterServicesAgreementMember" xlink:label="MGRX_MasterServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_MasterServicesAgreementMember" xlink:to="MGRX_MasterServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_MasterServicesAgreementMember_lbl" xml:lang="en-US">Master Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ComputersMember" xlink:label="MGRX_ComputersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ComputersMember" xlink:to="MGRX_ComputersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ComputersMember_lbl" xml:lang="en-US">Computers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockPurchaseAgreementMember" xlink:label="MGRX_StockPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_StockPurchaseAgreementMember" xlink:to="MGRX_StockPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CohenEnterprisesIncMember" xlink:label="MGRX_CohenEnterprisesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_CohenEnterprisesIncMember" xlink:to="MGRX_CohenEnterprisesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_CohenEnterprisesIncMember_lbl" xml:lang="en-US">Cohen Enterprises Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ZipDoctorIncMember" xlink:label="MGRX_ZipDoctorIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ZipDoctorIncMember" xlink:to="MGRX_ZipDoctorIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ZipDoctorIncMember_lbl" xml:lang="en-US">Zip Doctor Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_JacobDCohenMember" xlink:label="MGRX_JacobDCohenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_JacobDCohenMember" xlink:to="MGRX_JacobDCohenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_JacobDCohenMember_lbl" xml:lang="en-US">Jacob D Cohen [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PHXGlobalLLCMember" xlink:label="MGRX_PHXGlobalLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PHXGlobalLLCMember" xlink:to="MGRX_PHXGlobalLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PHXGlobalLLCMember_lbl" xml:lang="en-US">P H X Global L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_EzekielElliottMember" xlink:label="MGRX_EzekielElliottMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_EzekielElliottMember" xlink:to="MGRX_EzekielElliottMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_EzekielElliottMember_lbl" xml:lang="en-US">Ezekiel Elliott [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DavidSandlerMember" xlink:label="MGRX_DavidSandlerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_DavidSandlerMember" xlink:to="MGRX_DavidSandlerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_DavidSandlerMember_lbl" xml:lang="en-US">David Sandler [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_HsiaochingChouMember" xlink:label="MGRX_HsiaochingChouMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_HsiaochingChouMember" xlink:to="MGRX_HsiaochingChouMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_HsiaochingChouMember_lbl" xml:lang="en-US">Hsiaoching Chou [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_GreentreeFinancialGroupMember" xlink:label="MGRX_GreentreeFinancialGroupMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_GreentreeFinancialGroupMember" xlink:to="MGRX_GreentreeFinancialGroupMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_GreentreeFinancialGroupMember_lbl" xml:lang="en-US">Greentree Financial Group [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ServiceAgreementMember" xlink:label="MGRX_ServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ServiceAgreementMember" xlink:to="MGRX_ServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ServiceAgreementMember_lbl" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="srt_ChiefFinancialOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">Chief Financial Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_TwentyTwentyTwoEquityIncentivePlanMember" xlink:label="MGRX_TwentyTwentyTwoEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_TwentyTwentyTwoEquityIncentivePlanMember" xlink:to="MGRX_TwentyTwentyTwoEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_TwentyTwentyTwoEquityIncentivePlanMember_lbl" xml:lang="en-US">Twenty Twenty Two Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_JoanArangoMember" xlink:label="MGRX_JoanArangoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_JoanArangoMember" xlink:to="MGRX_JoanArangoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_JoanArangoMember_lbl" xml:lang="en-US">Joan Arango [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_TwentyTwentyTwoPlanMember" xlink:label="MGRX_TwentyTwentyTwoPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_TwentyTwentyTwoPlanMember" xlink:to="MGRX_TwentyTwentyTwoPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_TwentyTwentyTwoPlanMember_lbl" xml:lang="en-US">Twenty Twenty Two Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_WhiteUnicornLLCMember" xlink:label="MGRX_WhiteUnicornLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_WhiteUnicornLLCMember" xlink:to="MGRX_WhiteUnicornLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_WhiteUnicornLLCMember_lbl" xml:lang="en-US">White Unicorn L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_GlobalCareerNetworksIncMember" xlink:label="MGRX_GlobalCareerNetworksIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_GlobalCareerNetworksIncMember" xlink:to="MGRX_GlobalCareerNetworksIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_GlobalCareerNetworksIncMember_lbl" xml:lang="en-US">Global Career Networks Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CharteredServicesLLCMember" xlink:label="MGRX_CharteredServicesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_CharteredServicesLLCMember" xlink:to="MGRX_CharteredServicesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_CharteredServicesLLCMember_lbl" xml:lang="en-US">Chartered Services L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DojoLabsMember" xlink:label="MGRX_DojoLabsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_DojoLabsMember" xlink:to="MGRX_DojoLabsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_DojoLabsMember_lbl" xml:lang="en-US">Dojo Labs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementMember" xlink:label="MGRX_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ConsultingAgreementMember" xlink:to="MGRX_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BethorLtdMember" xlink:label="MGRX_BethorLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_BethorLtdMember" xlink:to="MGRX_BethorLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_BethorLtdMember_lbl" xml:lang="en-US">Bethor Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RudmanMember" xlink:label="MGRX_RudmanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_RudmanMember" xlink:to="MGRX_RudmanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_RudmanMember_lbl" xml:lang="en-US">Rudman [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_AdvisorAgreementMember" xlink:label="MGRX_AdvisorAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_AdvisorAgreementMember" xlink:to="MGRX_AdvisorAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_AdvisorAgreementMember_lbl" xml:lang="en-US">Advisor Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BoonMember" xlink:label="MGRX_BoonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_BoonMember" xlink:to="MGRX_BoonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_BoonMember_lbl" xml:lang="en-US">Boon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementsMember" xlink:label="MGRX_ConsultingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ConsultingAgreementsMember" xlink:to="MGRX_ConsultingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ConsultingAgreementsMember_lbl" xml:lang="en-US">Consulting Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantOneMember" xlink:label="MGRX_PrivatePlacementWarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantOneMember" xlink:to="MGRX_PrivatePlacementWarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantOneMember_lbl" xml:lang="en-US">Private Placement Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantTwoMember" xlink:label="MGRX_PrivatePlacementWarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantTwoMember" xlink:to="MGRX_PrivatePlacementWarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantTwoMember_lbl" xml:lang="en-US">Private Placement Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantThreeMember" xlink:label="MGRX_PrivatePlacementWarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantThreeMember" xlink:to="MGRX_PrivatePlacementWarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantThreeMember_lbl" xml:lang="en-US">Private Placement Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantFourMember" xlink:label="MGRX_PrivatePlacementWarrantFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantFourMember" xlink:to="MGRX_PrivatePlacementWarrantFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantFourMember_lbl" xml:lang="en-US">Private Placement Warrant Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantFiveMember" xlink:label="MGRX_PrivatePlacementWarrantFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantFiveMember" xlink:to="MGRX_PrivatePlacementWarrantFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantFiveMember_lbl" xml:lang="en-US">Private Placement Warrant Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantSixMember" xlink:label="MGRX_PrivatePlacementWarrantSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantSixMember" xlink:to="MGRX_PrivatePlacementWarrantSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantSixMember_lbl" xml:lang="en-US">Private Placement Warrant Six [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantSevenMember" xlink:label="MGRX_PrivatePlacementWarrantSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantSevenMember" xlink:to="MGRX_PrivatePlacementWarrantSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantSevenMember_lbl" xml:lang="en-US">Private Placement Warrant Seven [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_HammerMember" xlink:label="MGRX_HammerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_HammerMember" xlink:to="MGRX_HammerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_HammerMember_lbl" xml:lang="en-US">Hammer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantMember" xlink:label="MGRX_PrivatePlacementWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrivatePlacementWarrantMember" xlink:to="MGRX_PrivatePlacementWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrivatePlacementWarrantMember_lbl" xml:lang="en-US">Private Placement Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MrAndrewMember" xlink:label="MGRX_MrAndrewMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_MrAndrewMember" xlink:to="MGRX_MrAndrewMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_MrAndrewMember_lbl" xml:lang="en-US">Mr Andrew [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MajorDodgeMember" xlink:label="MGRX_MajorDodgeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_MajorDodgeMember" xlink:to="MGRX_MajorDodgeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_MajorDodgeMember_lbl" xml:lang="en-US">Major Dodge [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StreetGroupLLCMember" xlink:label="MGRX_StreetGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_StreetGroupLLCMember" xlink:to="MGRX_StreetGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_StreetGroupLLCMember_lbl" xml:lang="en-US">Street Group L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LeovLawFirmMember" xlink:label="MGRX_LeovLawFirmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_LeovLawFirmMember" xlink:to="MGRX_LeovLawFirmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_LeovLawFirmMember_lbl" xml:lang="en-US">Leov Law Firm [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LeaseAgreementMember" xlink:label="MGRX_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_LeaseAgreementMember" xlink:to="MGRX_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LucaConsultingLlcMember" xlink:label="MGRX_LucaConsultingLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_LucaConsultingLlcMember" xlink:to="MGRX_LucaConsultingLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_LucaConsultingLlcMember_lbl" xml:lang="en-US">Luca Consulting Llc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">TOTAL CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $3,863</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_FixedAssets" xlink:label="MGRX_FixedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_FixedAssets" xlink:to="MGRX_FixedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="MGRX_FixedAssets_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use - asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">TOTAL OTHER ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Payroll tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Right-of-use liability - operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">TOTAL CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG-TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Right-of-use liability - operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">TOTAL LONG-TERM LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (SEE NOTE 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock (par value $.0001, 200,000,000 shares authorized, of which 13,365,000 and 8,000,000 shares issued and outstanding as of December 31, 2022 and 2021, respectively)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CostOfRevenues" xlink:label="MGRX_CostOfRevenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_CostOfRevenues" xlink:to="MGRX_CostOfRevenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MGRX_CostOfRevenues_lbl" xml:lang="en-US">Cost of revenues ($3,255 of related party cost of revenues for the year ended December 31, 2022)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Cost of revenues - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ImputedInterestRelatedParty" xlink:label="MGRX_ImputedInterestRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ImputedInterestRelatedParty" xlink:to="MGRX_ImputedInterestRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MGRX_ImputedInterestRelatedParty_lbl" xml:lang="en-US">Imputed interest &#8211; related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Basic and diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings per share, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings per share, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_lbl" xml:lang="en-US">Basic and diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Cost of revenues - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Imputed Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of Common Stock for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Options and Warrants Vested for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Units for Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockIssuedDuringWarrantsExercisedForCashValue" xlink:label="MGRX_StockIssuedDuringWarrantsExercisedForCashValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_StockIssuedDuringWarrantsExercisedForCashValue" xlink:to="MGRX_StockIssuedDuringWarrantsExercisedForCashValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_StockIssuedDuringWarrantsExercisedForCashValue_lbl" xml:lang="en-US">Warrants exercised for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockIssuedDuringWarrantsExercisedForCashShares" xlink:label="MGRX_StockIssuedDuringWarrantsExercisedForCashShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_StockIssuedDuringWarrantsExercisedForCashShares" xlink:to="MGRX_StockIssuedDuringWarrantsExercisedForCashShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_StockIssuedDuringWarrantsExercisedForCashShares_lbl" xml:lang="en-US">Warrants exercised for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants for Services Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_IssuanceOfCommonStockForServices" xlink:label="MGRX_IssuanceOfCommonStockForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_IssuanceOfCommonStockForServices" xlink:to="MGRX_IssuanceOfCommonStockForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_IssuanceOfCommonStockForServices_lbl" xml:lang="en-US">Issuance of common stock for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Imputed interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Options vested for stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_WarrantsForServiceCancelled" xlink:label="MGRX_WarrantsForServiceCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_WarrantsForServiceCancelled" xlink:to="MGRX_WarrantsForServiceCancelled_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_WarrantsForServiceCancelled_lbl" xml:lang="en-US">Warrants for service cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase) decrease in operating assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Rent deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">(Decrease) increase in operating liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Payroll tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from borrowings on notes payable to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Repayment of borrowings - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sales of units for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContributionOfProperty" xlink:label="us-gaap_ContributionOfProperty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContributionOfProperty" xlink:to="us-gaap_ContributionOfProperty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContributionOfProperty_lbl" xml:lang="en-US">Accounts payable for purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DisclosurePrepaidExpensesAndDepositsAbstract" xlink:label="MGRX_DisclosurePrepaidExpensesAndDepositsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_DisclosurePrepaidExpensesAndDepositsAbstract" xlink:to="MGRX_DisclosurePrepaidExpensesAndDepositsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_DisclosurePrepaidExpensesAndDepositsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrepaidExpensesAndDepositsTextBlock" xlink:label="MGRX_PrepaidExpensesAndDepositsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrepaidExpensesAndDepositsTextBlock" xlink:to="MGRX_PrepaidExpensesAndDepositsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrepaidExpensesAndDepositsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND DEPOSITS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">CAPITAL STOCK</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">GOING CONCERN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Preparation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration and Risks</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Black Scholes Option Pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RelatedPartiesPolicyTextBlock" xlink:label="MGRX_RelatedPartiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_RelatedPartiesPolicyTextBlock" xlink:to="MGRX_RelatedPartiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_RelatedPartiesPolicyTextBlock_lbl" xml:lang="en-US">Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Marketing and advertising</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE ASSUMPTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITY OF LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF DEFERRED TAX ASSET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Fair value, net asset (liability)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property plant and equipment estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Marketing and advertising expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrepaidExpensesRelatedParty" xlink:label="MGRX_PrepaidExpensesRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PrepaidExpensesRelatedParty" xlink:to="MGRX_PrepaidExpensesRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PrepaidExpensesRelatedParty_lbl" xml:lang="en-US">Prepaid expenses related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Securtiy deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Prepaid the related party expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Less accumulated depreciation:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Property acquired value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_3_lbl" xml:lang="en-US">Property plant and equipment net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Property acquired value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Related party advances received</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity ownership interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_2_lbl" xml:lang="en-US">Repayments of related party debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_2_lbl" xml:lang="en-US">Proceeds from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_InterestExpenseRelatedPartyPercentage" xlink:label="MGRX_InterestExpenseRelatedPartyPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_InterestExpenseRelatedPartyPercentage" xlink:to="MGRX_InterestExpenseRelatedPartyPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_InterestExpenseRelatedPartyPercentage_lbl" xml:lang="en-US">Imputed interest percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Related party transaction purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt instrument periodic payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Outstanding Price Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercisable Price Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Option Exercise Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Fair value of common stock on measurement date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Warrants Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Warrants Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Warrants Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xml:lang="en-US">Warrants Exercisable Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable price</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_lbl" xml:lang="en-US">Outstanding and Vested Warrants Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:label="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:to="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Outstanding and Vested Warrants Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Warrants Exercise Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Shares issued value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Proceeds from investors</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2_lbl" xml:lang="en-US">Shares issued in consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Paid in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="us-gaap_CommonStockConversionFeatures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConversionFeatures" xlink:to="us-gaap_CommonStockConversionFeatures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConversionFeatures_lbl" xml:lang="en-US">Settlement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Shares vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Restricted stock issued net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Consideration paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToEmployees_lbl" xml:lang="en-US">Annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Share based compensation arrangement by share-based payment award, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Fair value of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Fair value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Fair value of warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:to="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_2_lbl" xml:lang="en-US">Outstanding and vested warrants expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Remainder of Fiscal Year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Year One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Year Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">Year Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Base rent</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PercentageOfProportionateRent" xlink:label="MGRX_PercentageOfProportionateRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PercentageOfProportionateRent" xlink:to="MGRX_PercentageOfProportionateRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PercentageOfProportionateRent_lbl" xml:lang="en-US">Percentage of proportionate rent</link:label>
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PercentageOfIncrementalBorrowingRate" xlink:label="MGRX_PercentageOfIncrementalBorrowingRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_PercentageOfIncrementalBorrowingRate" xlink:to="MGRX_PercentageOfIncrementalBorrowingRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_PercentageOfIncrementalBorrowingRate_lbl" xml:lang="en-US">Percentage of incremental borrowing rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Right of use of asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock value paid in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable_lbl" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems_lbl" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory federal income tax rate, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">US federal income corporate tax rates, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_FixedAssets" xlink:to="MGRX_FixedAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_FixedAssets_2_lbl" xml:lang="en-US">FixedAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_2_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_CostOfRevenues" xlink:to="MGRX_CostOfRevenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_CostOfRevenues_2_lbl" xml:lang="en-US">CostOfRevenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ImputedInterestRelatedParty" xlink:to="MGRX_ImputedInterestRelatedParty_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ImputedInterestRelatedParty_2_lbl" xml:lang="en-US">ImputedInterestRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposit Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">IncreaseDecreaseInOperatingLeaseRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_2_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_2_lbl" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Machinery and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_2_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:to="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>mgrx-20230930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://mangorx.com/role/Cover" xlink:href="mgrx-20230930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/BalanceSheets" xlink:href="mgrx-20230930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/BalanceSheetsParenthetical" xlink:href="mgrx-20230930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfOperations" xlink:href="mgrx-20230930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfOperationsParenthetical" xlink:href="mgrx-20230930.xsd#StatementsOfOperationsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" xlink:href="mgrx-20230930.xsd#StatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/StatementsOfCashFlows" xlink:href="mgrx-20230930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" xlink:href="mgrx-20230930.xsd#OrganizationAndDescriptionOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PrepaidExpensesAndDeposits" xlink:href="mgrx-20230930.xsd#PrepaidExpensesAndDeposits" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/Inventory" xlink:href="mgrx-20230930.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipment" xlink:href="mgrx-20230930.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/RelatedPartyTransactions" xlink:href="mgrx-20230930.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/NotesPayable" xlink:href="mgrx-20230930.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStock" xlink:href="mgrx-20230930.xsd#CapitalStock" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingencies" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SubsequentEvents" xlink:href="mgrx-20230930.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/GoingConcern" xlink:href="mgrx-20230930.xsd#GoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxes" xlink:href="mgrx-20230930.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipmentTables" xlink:href="mgrx-20230930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStockTables" xlink:href="mgrx-20230930.xsd#CapitalStockTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingenciesTables" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxesTables" xlink:href="mgrx-20230930.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:href="mgrx-20230930.xsd#OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:href="mgrx-20230930.xsd#ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="mgrx-20230930.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" xlink:href="mgrx-20230930.xsd#PrepaidExpensesAndDepositsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/InventoryDetailsNarrative" xlink:href="mgrx-20230930.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="mgrx-20230930.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="mgrx-20230930.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/NotesPayableDetailsNarrative" xlink:href="mgrx-20230930.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfFairValueAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CapitalStockDetailsNarrative" xlink:href="mgrx-20230930.xsd#CapitalStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="mgrx-20230930.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/SubsequentEventsDetailsNarrative" xlink:href="mgrx-20230930.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/GoingConcernDetailsNarrative" xlink:href="mgrx-20230930.xsd#GoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:href="mgrx-20230930.xsd#ScheduleOfDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://mangorx.com/role/IncomeTaxesDetailsNarrative" xlink:href="mgrx-20230930.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_FixedAssets" xlink:label="loc_MGRXFixedAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:to="loc_MGRXFixedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositsAssets" xlink:label="loc_us-gaapDepositsAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:to="loc_us-gaapDepositsAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNetAbstract" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CostOfRevenues" xlink:label="loc_MGRXCostOfRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_MGRXCostOfRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaapCostsAndExpensesRelatedParty" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapCostsAndExpensesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ImputedInterestRelatedParty" xlink:label="loc_MGRXImputedInterestRelatedParty" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_MGRXImputedInterestRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicOtherDisclosuresAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfOperationsParenthetical" xlink:title="00000005 - Statement - Statements of Operations (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - Statement of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockIssuedDuringWarrantsExercisedForCashValue" xlink:label="loc_MGRXStockIssuedDuringWarrantsExercisedForCashValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MGRXStockIssuedDuringWarrantsExercisedForCashValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockIssuedDuringWarrantsExercisedForCashShares" xlink:label="loc_MGRXStockIssuedDuringWarrantsExercisedForCashShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_MGRXStockIssuedDuringWarrantsExercisedForCashShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_IssuanceOfCommonStockForServices" xlink:label="loc_MGRXIssuanceOfCommonStockForServices" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MGRXIssuanceOfCommonStockForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_WarrantsForServiceCancelled" xlink:label="loc_MGRXWarrantsForServiceCancelled" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_MGRXWarrantsForServiceCancelled" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDepositOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="loc_MGRXIncreaseDecreaseInOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_MGRXIncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContributionOfProperty" xlink:label="loc_us-gaapContributionOfProperty" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapContributionOfProperty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/OrganizationAndDescriptionOfBusiness" xlink:title="00000008 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PrepaidExpensesAndDeposits" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND DEPOSITS">
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DisclosurePrepaidExpensesAndDepositsAbstract" xlink:label="loc_MGRXDisclosurePrepaidExpensesAndDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrepaidExpensesAndDepositsTextBlock" xlink:label="loc_MGRXPrepaidExpensesAndDepositsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MGRXDisclosurePrepaidExpensesAndDepositsAbstract" xlink:to="loc_MGRXPrepaidExpensesAndDepositsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/Inventory" xlink:title="00000011 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - PROPERTY AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/NotesPayable" xlink:title="00000014 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStock" xlink:title="00000015 - Disclosure - CAPITAL STOCK">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/GoingConcern" xlink:title="00000018 - Disclosure - GOING CONCERN">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RelatedPartiesPolicyTextBlock" xlink:label="loc_MGRXRelatedPartiesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_MGRXRelatedPartiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipmentTables" xlink:title="00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStockTables" xlink:title="00000023 - Disclosure - CAPITAL STOCK (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingenciesTables" xlink:title="00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxesTables" xlink:title="00000025 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" xlink:title="00000026 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ResaleProspectusMember" xlink:label="loc_MGRXResaleProspectusMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXResaleProspectusMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails" xlink:title="00000027 - Disclosure - SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_OptionsMember" xlink:label="loc_MGRXOptionsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_MGRXOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative" xlink:title="00000029 - Disclosure - PREPAID EXPENSES AND DEPOSITS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DisclosurePrepaidExpensesAndDepositsAbstract" xlink:label="loc_MGRXDisclosurePrepaidExpensesAndDepositsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_MGRXDisclosurePrepaidExpensesAndDepositsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MasterServicesAgreementMember" xlink:label="loc_MGRXMasterServicesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXMasterServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrepaidExpensesRelatedParty" xlink:label="loc_MGRXPrepaidExpensesRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MGRXPrepaidExpensesRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/InventoryDetailsNarrative" xlink:title="00000030 - Disclosure - INVENTORY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000031 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ComputersMember" xlink:label="loc_MGRXComputersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_MGRXComputersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000032 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPaymentsToAcquireMachineryAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StockPurchaseAgreementMember" xlink:label="loc_MGRXStockPurchaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXStockPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CohenEnterprisesIncMember" xlink:label="loc_MGRXCohenEnterprisesIncMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MGRXCohenEnterprisesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ZipDoctorIncMember" xlink:label="loc_MGRXZipDoctorIncMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_MGRXZipDoctorIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srtEquityMethodInvesteeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="loc_srtEquityMethodInvesteeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CohenEnterprisesIncMember" xlink:label="loc_MGRXCohenEnterprisesIncMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtEquityMethodInvesteeNameDomain" xlink:to="loc_MGRXCohenEnterprisesIncMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_JacobDCohenMember" xlink:label="loc_MGRXJacobDCohenMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXJacobDCohenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaapRepaymentsOfRelatedPartyDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRepaymentsOfRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_InterestExpenseRelatedPartyPercentage" xlink:label="loc_MGRXInterestExpenseRelatedPartyPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_MGRXInterestExpenseRelatedPartyPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="loc_us-gaapPaymentsForAdvanceToAffiliate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForAdvanceToAffiliate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/NotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:label="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" xlink:label="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_MGRXShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CapitalStockDetailsNarrative" xlink:title="00000038 - Disclosure - CAPITAL STOCK (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantOneMember" xlink:label="loc_MGRXPrivatePlacementWarrantOneMember" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantTwoMember" xlink:label="loc_MGRXPrivatePlacementWarrantTwoMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantThreeMember" xlink:label="loc_MGRXPrivatePlacementWarrantThreeMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantFourMember" xlink:label="loc_MGRXPrivatePlacementWarrantFourMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantFiveMember" xlink:label="loc_MGRXPrivatePlacementWarrantFiveMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantSixMember" xlink:label="loc_MGRXPrivatePlacementWarrantSixMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantSixMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantSevenMember" xlink:label="loc_MGRXPrivatePlacementWarrantSevenMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantSevenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PrivatePlacementWarrantMember" xlink:label="loc_MGRXPrivatePlacementWarrantMember" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_MGRXPrivatePlacementWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="1040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PHXGlobalLLCMember" xlink:label="loc_MGRXPHXGlobalLLCMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXPHXGlobalLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_EzekielElliottMember" xlink:label="loc_MGRXEzekielElliottMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXEzekielElliottMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_GreentreeFinancialGroupMember" xlink:label="loc_MGRXGreentreeFinancialGroupMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXGreentreeFinancialGroupMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_WhiteUnicornLLCMember" xlink:label="loc_MGRXWhiteUnicornLLCMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXWhiteUnicornLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_GlobalCareerNetworksIncMember" xlink:label="loc_MGRXGlobalCareerNetworksIncMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXGlobalCareerNetworksIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_CharteredServicesLLCMember" xlink:label="loc_MGRXCharteredServicesLLCMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXCharteredServicesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DojoLabsMember" xlink:label="loc_MGRXDojoLabsMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXDojoLabsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BethorLtdMember" xlink:label="loc_MGRXBethorLtdMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXBethorLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_StreetGroupLLCMember" xlink:label="loc_MGRXStreetGroupLLCMember" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXStreetGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LeovLawFirmMember" xlink:label="loc_MGRXLeovLawFirmMember" />
      <link:presentationArc order="1150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXLeovLawFirmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DavidSandlerMember" xlink:label="loc_MGRXDavidSandlerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXDavidSandlerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_HsiaochingChouMember" xlink:label="loc_MGRXHsiaochingChouMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXHsiaochingChouMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srtChiefFinancialOfficerMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefFinancialOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="loc_srtDirectorMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_JoanArangoMember" xlink:label="loc_MGRXJoanArangoMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXJoanArangoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RudmanMember" xlink:label="loc_MGRXRudmanMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXRudmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BoonMember" xlink:label="loc_MGRXBoonMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXBoonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_HammerMember" xlink:label="loc_MGRXHammerMember" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXHammerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MrAndrewMember" xlink:label="loc_MGRXMrAndrewMember" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXMrAndrewMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_MajorDodgeMember" xlink:label="loc_MGRXMajorDodgeMember" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXMajorDodgeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srtChiefExecutiveOfficerMember" />
      <link:presentationArc order="960" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefOperatingOfficerMember" xlink:label="loc_srtChiefOperatingOfficerMember" />
      <link:presentationArc order="970" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_srtChiefOperatingOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="1080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ServiceAgreementMember" xlink:label="loc_MGRXServiceAgreementMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementMember" xlink:label="loc_MGRXConsultingAgreementMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_AdvisorAgreementMember" xlink:label="loc_MGRXAdvisorAgreementMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXAdvisorAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementsMember" xlink:label="loc_MGRXConsultingAgreementsMember" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapPlanNameAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_TwentyTwentyTwoEquityIncentivePlanMember" xlink:label="loc_MGRXTwentyTwentyTwoEquityIncentivePlanMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MGRXTwentyTwentyTwoEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_TwentyTwentyTwoPlanMember" xlink:label="loc_MGRXTwentyTwentyTwoPlanMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_MGRXTwentyTwentyTwoPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="1060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_us-gaapCommonStockConversionFeatures" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockConversionFeatures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaapPaymentsToEmployees" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsToEmployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:label="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_MGRXSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LeaseAgreementMember" xlink:label="loc_MGRXLeaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PercentageOfProportionateRent" xlink:label="loc_MGRXPercentageOfProportionateRent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MGRXPercentageOfProportionateRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_PercentageOfIncrementalBorrowingRate" xlink:label="loc_MGRXPercentageOfIncrementalBorrowingRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_MGRXPercentageOfIncrementalBorrowingRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementMember" xlink:label="loc_MGRXConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_ConsultingAgreementsMember" xlink:label="loc_MGRXConsultingAgreementsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_MGRXConsultingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_LucaConsultingLlcMember" xlink:label="loc_MGRXLucaConsultingLlcMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXLucaConsultingLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_DojoLabsMember" xlink:label="loc_MGRXDojoLabsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXDojoLabsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BethorLtdMember" xlink:label="loc_MGRXBethorLtdMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_MGRXBethorLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_RudmanMember" xlink:label="loc_MGRXRudmanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXRudmanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="mgrx-20230930.xsd#MGRX_BoonMember" xlink:label="loc_MGRXBoonMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_MGRXBoonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_us-gaapCommonStockConversionFeatures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapCommonStockConversionFeatures" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/GoingConcernDetailsNarrative" xlink:title="00000042 - Disclosure - GOING CONCERN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:title="00000043 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://mangorx.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000044 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:label="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739500416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Post-Effective Amendment No. 2 (this &#8220;Amendment&#8221;)
to the Registration Statement on Form S-1 of Mangoceuticals, Inc. (File No. 333- 275993), initially filed on December 11, 2023 and declared
effective by the Securities and Exchange Commission on December 14, 2023 (the &#8220;Registration Statement&#8221;), is being filed to
update the prospectus which forms part of the Registration Statement to (a) fill in blanks on the cover page of the prospectus and throughout
regarding pricing terms and the offering price of $0.30 per share; (b) reflect that a Plan of Compliance is being filed with Nasdaq on
December 18, 2023, and (c) make corresponding updates to the prospectus in connection therewith.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Mangoceuticals,
Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001938046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-3841292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15110
N. Dallas Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">242-9619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">15110
N. Dallas Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Jacob
D. Cohen<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329738833408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,236,747<span></span>
</td>
<td class="nump">$ 682,860<span></span>
</td>
<td class="nump">$ 22,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">21,581<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">84,382<span></span>
</td>
<td class="nump">11,745<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">1,342,710<span></span>
</td>
<td class="nump">694,605<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>FIXED ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $3,863</a></td>
<td class="nump">102,420<span></span>
</td>
<td class="nump">117,499<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_FixedAssets', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">102,420<span></span>
</td>
<td class="nump">117,499<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">16,942<span></span>
</td>
<td class="nump">16,942<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use - asset</a></td>
<td class="nump">133,433<span></span>
</td>
<td class="nump">174,241<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">TOTAL OTHER ASSETS</a></td>
<td class="nump">150,375<span></span>
</td>
<td class="nump">191,183<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,595,505<span></span>
</td>
<td class="nump">1,003,287<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">89,059<span></span>
</td>
<td class="nump">33,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll tax liabilities</a></td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">2,717<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Right-of-use liability - operating lease</a></td>
<td class="nump">61,917<span></span>
</td>
<td class="nump">56,725<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">159,176<span></span>
</td>
<td class="nump">260,577<span></span>
</td>
<td class="nump">39,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Right-of-use liability - operating lease</a></td>
<td class="nump">81,508<span></span>
</td>
<td class="nump">128,680<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">81,508<span></span>
</td>
<td class="nump">128,680<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">240,684<span></span>
</td>
<td class="nump">389,257<span></span>
</td>
<td class="nump">39,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (SEE NOTE 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY (DEFICIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock (par value $.0001, 200,000,000 shares authorized, of which 13,365,000 and 8,000,000 shares issued and outstanding as of December 31, 2022 and 2021, respectively)</a></td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">10,013,268<span></span>
</td>
<td class="nump">2,628,449<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,660,126)<span></span>
</td>
<td class="num">(2,015,756)<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">1,354,821<span></span>
</td>
<td class="nump">614,030<span></span>
</td>
<td class="num">(16,720)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></td>
<td class="nump">1,595,505<span></span>
</td>
<td class="nump">1,003,287<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">89,200<span></span>
</td>
<td class="nump">39,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 78,260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_FixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_FixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739010208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 22,461<span></span>
</td>
<td class="nump">$ 3,863<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,789,500<span></span>
</td>
<td class="nump">13,365,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,789,500<span></span>
</td>
<td class="nump">13,365,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739580896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 245,160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 487,119<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">52,193<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,538<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_CostOfRevenues', window );">Cost of revenues ($3,255 of related party cost of revenues for the year ended December 31, 2022)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Cost of revenues - related party</a></td>
<td class="nump">48,378<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,663<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">144,589<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,918<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,944,049<span></span>
</td>
<td class="nump">991,825<span></span>
</td>
<td class="nump">17,520<span></span>
</td>
<td class="nump">6,939,761<span></span>
</td>
<td class="nump">1,319,727<span></span>
</td>
<td class="nump">1,996,432<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,944,049<span></span>
</td>
<td class="nump">991,825<span></span>
</td>
<td class="nump">17,520<span></span>
</td>
<td class="nump">6,939,761<span></span>
</td>
<td class="nump">1,319,727<span></span>
</td>
<td class="nump">1,996,432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,799,460)<span></span>
</td>
<td class="num">(991,825)<span></span>
</td>
<td class="num">(17,520)<span></span>
</td>
<td class="num">(6,650,843)<span></span>
</td>
<td class="num">(1,319,727)<span></span>
</td>
<td class="num">(1,991,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ImputedInterestRelatedParty', window );">Imputed interest &#8211; related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
<td class="nump">6,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,090<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
<td class="nump">6,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(1,799,460)<span></span>
</td>
<td class="num">(994,915)<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(6,644,370)<span></span>
</td>
<td class="num">(1,324,400)<span></span>
</td>
<td class="num">(1,998,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,799,460)<span></span>
</td>
<td class="num">$ (994,915)<span></span>
</td>
<td class="num">$ (17,701)<span></span>
</td>
<td class="num">$ (6,644,370)<span></span>
</td>
<td class="num">$ (1,324,400)<span></span>
</td>
<td class="num">$ (1,998,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding, Basic</a></td>
<td class="nump">15,923,588<span></span>
</td>
<td class="nump">10,049,100<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">14,923,461<span></span>
</td>
<td class="nump">9,913,388<span></span>
</td>
<td class="nump">10,798,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding, Diluted</a></td>
<td class="nump">15,923,588<span></span>
</td>
<td class="nump">10,049,100<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">14,923,461<span></span>
</td>
<td class="nump">9,913,388<span></span>
</td>
<td class="nump">10,798,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_CostOfRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_CostOfRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ImputedInterestRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ImputedInterestRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739497056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues - related party</a></td>
<td class="nump">$ 3,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329736005728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statement of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Oct. 06, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Oct. 06, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(16,720)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,599)<span></span>
</td>
<td class="num">(19,599)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="num">(37,300)<span></span>
</td>
<td class="num">(35,430)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(16,720)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,324,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">2,164,770<span></span>
</td>
<td class="num">(1,342,400)<span></span>
</td>
<td class="nump">823,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="nump">12,015,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
<td class="num">(16,720)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,998,055)<span></span>
</td>
<td class="num">(1,998,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">539,728<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">540,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">3,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options and Warrants Vested for Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234,088<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Units for Cash</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,999,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants for Services Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(151,821)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(151,821)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,337<span></span>
</td>
<td class="nump">2,628,449<span></span>
</td>
<td class="num">(2,015,756)<span></span>
</td>
<td class="nump">614,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">13,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
<td class="num">(37,300)<span></span>
</td>
<td class="num">(35,430)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,583<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(310,185)<span></span>
</td>
<td class="num">(310,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">224,775<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">227,428<span></span>
</td>
<td class="num">(347,485)<span></span>
</td>
<td class="num">(119,032)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2022</a></td>
<td class="nump">10,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,202<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(994,915)<span></span>
</td>
<td class="num">(994,915)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">264,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">265,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options and Warrants Vested for Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">169,817<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">169,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Units for Cash</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">1,500,350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,500,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, shares</a></td>
<td class="nump">1,500,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">2,164,770<span></span>
</td>
<td class="num">(1,342,400)<span></span>
</td>
<td class="nump">823,572<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2022</a></td>
<td class="nump">12,015,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,337<span></span>
</td>
<td class="nump">2,628,449<span></span>
</td>
<td class="num">(2,015,756)<span></span>
</td>
<td class="nump">614,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">13,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,760<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,560,885)<span></span>
</td>
<td class="num">(2,560,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">699,930<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options and Warrants Vested for Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,271<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Units for Cash</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">4,999,875<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, shares</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1,532<span></span>
</td>
<td class="nump">8,394,285<span></span>
</td>
<td class="num">(4,576,641)<span></span>
</td>
<td class="nump">3,819,176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">15,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,337<span></span>
</td>
<td class="nump">2,628,449<span></span>
</td>
<td class="num">(2,015,756)<span></span>
</td>
<td class="nump">614,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">13,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,644,370)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="nump">10,013,268<span></span>
</td>
<td class="num">(8,660,126)<span></span>
</td>
<td class="nump">1,354,821<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">16,789,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 1,532<span></span>
</td>
<td class="nump">8,394,285<span></span>
</td>
<td class="num">(4,576,641)<span></span>
</td>
<td class="nump">3,819,176<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2023</a></td>
<td class="nump">15,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Imputed Interest</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(8,233)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,284,025)<span></span>
</td>
<td class="num">(2,284,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">386,963<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">387,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options and Warrants Vested for Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,271<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_StockIssuedDuringWarrantsExercisedForCashValue', window );">Warrants exercised for cash</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">1,024,398<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,024,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_StockIssuedDuringWarrantsExercisedForCashShares', window );">Warrants exercised for cash, shares</a></td>
<td class="nump">1,024,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 1,671<span></span>
</td>
<td class="nump">9,861,684<span></span>
</td>
<td class="num">(6,860,666)<span></span>
</td>
<td class="nump">3,002,689<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2023</a></td>
<td class="nump">16,714,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,799,460)<span></span>
</td>
<td class="num">(1,799,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Common Stock for Services</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">84,742<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Options and Warrants Vested for Services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">66,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">66,842<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="nump">$ 10,013,268<span></span>
</td>
<td class="num">$ (8,660,126)<span></span>
</td>
<td class="nump">$ 1,354,821<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Sep. 30, 2023</a></td>
<td class="nump">16,789,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_StockIssuedDuringWarrantsExercisedForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_StockIssuedDuringWarrantsExercisedForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_StockIssuedDuringWarrantsExercisedForCashValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_StockIssuedDuringWarrantsExercisedForCashValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329732812464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,701)<span></span>
</td>
<td class="num">$ (6,644,370)<span></span>
</td>
<td class="num">$ (1,324,400)<span></span>
</td>
<td class="num">$ (1,998,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_IssuanceOfCommonStockForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,171,750<span></span>
</td>
<td class="nump">490,000<span></span>
</td>
<td class="nump">540,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Imputed interest expense</a></td>
<td class="nump">181<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
<td class="nump">6,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Options vested for stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,384<span></span>
</td>
<td class="nump">169,817<span></span>
</td>
<td class="nump">234,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_WarrantsForServiceCancelled', window );">Warrants for service cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(151,821)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in operating assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Rent deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,942)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,581)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(72,637)<span></span>
</td>
<td class="num">(37,719)<span></span>
</td>
<td class="num">(11,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,808<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(174,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>(Decrease) increase in operating liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,384<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease right of use liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(41,980)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">185,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Payroll tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">671<span></span>
</td>
<td class="nump">2,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(17,520)<span></span>
</td>
<td class="num">(5,299,634)<span></span>
</td>
<td class="num">(696,958)<span></span>
</td>
<td class="num">(1,346,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,519)<span></span>
</td>
<td class="num">(2,531)<span></span>
</td>
<td class="num">(43,102)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,519)<span></span>
</td>
<td class="num">(2,531)<span></span>
</td>
<td class="num">(43,102)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from borrowings on notes payable to related parties</a></td>
<td class="nump">39,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,260)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of borrowings - related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(89,200)<span></span>
</td>
<td class="num">(25,070)<span></span>
</td>
<td class="num">(25,070)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sales of units for cash</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">1,500,500<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">40,070<span></span>
</td>
<td class="nump">5,857,040<span></span>
</td>
<td class="nump">1,550,430<span></span>
</td>
<td class="nump">2,049,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">22,550<span></span>
</td>
<td class="nump">553,887<span></span>
</td>
<td class="nump">850,941<span></span>
</td>
<td class="nump">660,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>CASH AND CASH EQUIVALENTS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">682,860<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="nump">22,550<span></span>
</td>
<td class="nump">1,236,747<span></span>
</td>
<td class="nump">873,491<span></span>
</td>
<td class="nump">682,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContributionOfProperty', window );">Accounts payable for purchase of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_IssuanceOfCommonStockForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_IssuanceOfCommonStockForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_WarrantsForServiceCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_WarrantsForServiceCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContributionOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of property contributed in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContributionOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329744480176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF THE BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zusKlb0PZE3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_82C_z7mOY4GaihEh">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals,
Inc. (&#8220;Mangoceuticals&#8221; or the &#8220;Company&#8221;), was incorporated in the State of a Texas on <span id="xdx_90D_edei--EntityIncorporationDateOfIncorporation_c20230101__20230930_zEyjqjOgeTk5" title="Date of incorporation">October 7, 2021</span>, with the
intent of focusing on developing, marketing, and selling a variety of men&#8217;s wellness products and services via a telemedicine platform.
To date, the Company has identified men&#8217;s wellness telemedicine services and products as a growing sector in the most recent years
and especially related to the areas of erectile dysfunction (&#8220;ED&#8221;). In this regard, Mangoceuticals has developed and is commercially
marketing and selling a new brand of ED product under the brand name &#8220;Mango.&#8221; This product is produced at a compounding pharmacy
using a proprietary combination of U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved ingredients and is available to patients
on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently
marketing and selling this new brand of ED product exclusively online via its website at <span style="text-decoration: underline">www.MangoRx.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Initial
Public Offering. </i>In March 2023, the Company completed an initial public offering (the &#8220;IPO&#8221;), in which the Company issued
and sold <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQVOBmR5n01b" title="Issuance of shares">1,250,000</span> shares of authorized common stock for $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQA3db6z22je" title="Share issued price per share">4.00</span> per share for net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zePQZfNAYq1h" title="Net proceeds from issuance of common stock">4.35</span> million, after deducting underwriting
discounts and commissions, and offering costs. At the same time, and as part of the same registration statement, but pursuant to a separate
prospectus (the &#8220;Resale Prospectus&#8221;) the Company registered the sale of <span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zHxlzn0wd4Ad" title="Sale of stock, shares">4,765,000</span> shares of common stock, including <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zGJPlcYPm1Lb" title="Issuance of shares">2,000,000</span>
shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with an exercise price of
$<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zEenTGcvHOu4" title="Share issued price per share">1.00</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zprwrOCul4H8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
1 &#8211; <span id="xdx_825_zhilY9hCUpJ4">ORGANIZATION AND DESCRIPTION OF THE BUSINESS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals, Inc. (&#8220;Mangoceuticals&#8221; or the &#8220;Company&#8221;),
was incorporated in the State of a Texas on <span id="xdx_904_edei--EntityIncorporationDateOfIncorporation_c20220101__20221231_zGBUehANNMM2" title="Date of incorporation">October 7, 2021</span>, with the intent of focusing on developing, marketing, and selling a variety
of men&#8217;s wellness products and services via a telemedicine platform. To date, the Company has identified men&#8217;s wellness telemedicine
services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (ED). In
this regard, Mangoceuticals has developed and is currently in the process of preparing to commercially market a new brand of ED product
under the brand name &#8220;Mango.&#8221; This product is produced at a compounding pharmacy using a proprietary combination of U.S. Food
and Drug Administration (&#8220;FDA&#8221;) approved ingredients and is available to patients on the determination of a prescribing physician
that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling this new brand of
ED product exclusively online via its website at <span style="text-decoration: underline">www.MangoRx.com</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor&#8217;s
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impact
of COVID-19 Pandemic on Consolidated Financial Statements.</i> The outbreak of the 2019 novel coronavirus disease (&#8220;COVID-19&#8221;),
which was declared a global pandemic by the World Health Organization on March 11, 2020, and the related responses by public health and
governmental authorities to contain and combat its outbreak and spread has severely impacted the U.S. and world economies during the
end of the first quarter of 2020, and continuing through the end of 2022. COVID-19 and the U.S. response to the pandemic are significantly
affecting the economy. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as
a result, the ultimate effect of the pandemic is highly uncertain and subject to change. The Company does not yet know the full extent
of the effects on the economy, the markets we serve, our business, or our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moving
forward, economic recessions, increased inflation and/or interest rates, including those brought on by the continued COVID-19 outbreak
may have a negative effect on the demand for our services and our operating results. Any prolonged disruption to our operations or workforce
availability is likely to have a significant adverse effect on our results of operations, cash flows and ability to meet continuing debt
service requirements. All of the above may be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto
continue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739028672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8uc8ZVVcA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
2 &#8211; <span id="xdx_82F_zvOF5ANRGewa">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoM89gSRtiC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z4InLRg3CQJ3">Basis
of Preparation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) under the accrual basis of accounting. These financial statements are presented in
U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The
accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto
for the years ended December 31, 2022 and 2021 included in the Company&#8217;s Registration Statement on Form S-1 (Amendment No. 4),
filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2023 (the &#8220;Form S-1&#8221;). In the opinion
of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position
and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim
periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the Form S-1 have been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zt74Z5NYOB02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z5f5eUmEVx45">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority
of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insures a total cash balance
of up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zCJdFQyH08v8" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits and the excess would be
at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_z8gGFZgDUiMg" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8YyU761TWmg" title="Cash equivalents">no</span></span> cash equivalents at September 30, 2023 and December 31, 2022
and the Company has not experienced any losses related to uninsured deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zeL0KlYdTD41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zJCvRNouYZcd">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
740, <i>Income Taxes</i>. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the
temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income
in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount
that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPyf1Znyl1L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zUdGq2W2Elxi">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted
earnings per share (&#8220;EPS&#8221;) on the face of the statement of operations. Basic EPS is computed by dividing net loss available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. For diluted net loss per share purposes, the Company
excludes stock options and other stock-based awards, including shares issued as a result of option and warrant exercises, whose effect
would be anti-dilutive, from the calculation. There were <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zj4qWpLuazEl" title="Anti-dilutive securities">1,400,000</span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zswAe54AWVKl" title="Anti-dilutive securities">1,250,000</span> options, <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5mOXkQDoyXd" title="Anti-dilutive securities">1,063,000</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPsAaRYHEyLe" title="Anti-dilutive securities">2,000,000</span> warrants and no derivative
securities outstanding as of September 30, 2023 and December 31, 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zVFAYw6EG7ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGVKYnO6DQV2">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will,
differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvGsztSKuih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zEocmiercZQj">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, <i>Fair Value Measurement</i>, which provides guidance with respect to valuation techniques to be utilized in the determination
of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach
(present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement
cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three
broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&#160;&#160;</span></p>

<p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGc2F4ugj03e">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">22,550</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zQlxyzjNg5Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSQun2tac6T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zL77S0uwFqaj">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zv5AdiU3SWYi" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zOzywZjQtBke" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zc4QLMcybnDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zXyxnK0PyS9b">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had
no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmn4mCXQx4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zXaQfJUDULfh">Black
Scholes Option Pricing Model</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVvKL7gtheDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zQSvLXfN6N13">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211;
40)</span>&#8221;</i>. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--RelatedPartiesPolicyTextBlock_ztEzXVMCZP7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zNTKqI17OSA1">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of FASB ASC 850, <i>Related Party Disclosures</i> for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825&#8211;10&#8211;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zGcnex4hEIPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLP4fB0Ithn9">Stock-Based
Compensation</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB ASC 718 <i>Compensation - Stock Compensation</i> (&#8220;ASC 718&#8221;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zq6kwL7zRzYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zVuB9u7zNZ3g">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our
websites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated
through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The
transaction price in the Company&#8217;s contracts with customers is the total amount of consideration to which the Company expects to
be entitled in exchange for transferring products or services to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#8217;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#8217;s completion of its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (&#8220;Doctegrity&#8221;) to provide online
telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii)
the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs
for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its
sole discretion, sets all listed prices charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (&#8220;Contracted Pharmacy&#8221;),
which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts
that include sale of prescription products and to fill prescriptions that are ordered by the Company&#8217;s customers for fulfillment
through the Company&#8217;s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer&#8217;s
prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using
the Company&#8217;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites
for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_z2OaZ4CAzi51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zHrWce5thqYb">Inventories</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or market with cost being determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. The Company writes down its
inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated
market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those
projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zN9k9dblTWd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z6n4niJJiHS4">Marketing
and advertising</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations
$<span id="xdx_904_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230930_zH0FTQGqUCal" title="Marketing and advertising expense">1,633,528</span> and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220930_zlmyhEi4oUcc" title="Marketing and advertising expense">0</span> for the nine months ended September 30, 2023 and 2022. We did not begin advertising until November 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zkZnNZ0OtbVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuSVPpc9WSU7">Subsequent
events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events.
The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 10).</span></p>

<p id="xdx_858_zX8ptlnZnK7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zccpqDWH7U7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="abc_002"></span>NOTE
2 &#8211; <span id="xdx_82B_zKT3SZ5fToSh">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zl0LWu022Ftb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Basis
of Presentation</span> &#8211; </b>The financial statements present the financial position, results of operations and cash flows of the Company
in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_865_zMLgBDKVUJv9" style="display: none">Basis
of Preparation</span></span></p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqGvzgcRejG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zDDDltW6eFD7">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the
majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insures
the total cash balance up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zSUbtzyJPKW2" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, and
the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8qdOIxSTQ1b" title="Cash equivalents"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zXGLVpdMLuI5" title="Cash equivalents">no</span></span> cash equivalents at December 31, 2022
 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zmEN3HlOgpE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z2IJvFQC74Vg">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (&#8220;ASC&#8221;)
740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are measured using enacted tax rates
expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in
tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce
deferred tax assets to the amount that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zigppskZO7Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zrGxXkGjTFR5">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net loss per share in accordance with ASC 260, <i>Earnings</i><i> per Share</i> (&#8220;ASC 260&#8221;). ASC 260
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the statement of operations.
Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares
outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the
period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average
stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or
warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zgaEi1peE4Oa" title="Anti-dilutive securities">1,250,000</span> options, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5Nko9cSctB2" title="Anti-dilutive securities">2,000,000</span>
warrants and no derivative securities outstanding as of December 31, 2022. These were excluded because their effect would be anti-dilutive.
There were no options, warrants nor derivative securities outstanding as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--UseOfEstimates_zy6JJ1GbZep8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zMrRStIaDkw9">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases
will, differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zsPUu87JF5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zbSpYL66boT6">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, <i>Fair Value Measurement</i>, which provides guidance with respect to valuation techniques to be utilized
in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices),
(ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity
of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value into three broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zv48K9wbXr23">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1734">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1735">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1739">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">22,550</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1750">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1758">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zMubUzvLqyDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3zdvDvfpKUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zMy6APj0VJa4">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember_zuZALQuxDMSb" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember_zfeWc2DTshNi" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zExz47PoCRSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zNH1coZdeGv2">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing
operations which were derived from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQJ9Su7Xbslf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Binomial
Calculation Model</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_86E_zp5CMlYlnvY2" style="display: none">Black
Scholes Option Pricing Model</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBASBHZEgpnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zjdxtEXNx2nl">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211;
40)</span></i>. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zp2aZa5mM4Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zTwHksa6PKd4">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section
825&#8211;10&#8211;15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such
as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company;
e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the
management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing
its own separate interests; and g. other parties that can significantly influence the management or operating policies of the
transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to
an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zI8Z0VOgvfCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zv0yc8j1B8m1">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (&#8220;ASC 718&#8221;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zxwhSaUY1Uak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z4IJ12cfj9Kh">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue
is generated by selling directly to consumers through our websites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through
websites. The transaction price in the Company&#8217;s contracts with customers is the total amount of consideration to which the Company
expects to be entitled in exchange for transferring products or services to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#8217;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#8217;s completion of its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a Physician Services Agreement with BrighterMD, LLC &#160;&#160;dba Doctegrity (&#8220;Doctegrity&#8221;) to
provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer;
(ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs
costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company,
at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq &#160;&#160;Scripts, LLC (&#8220;Contracted
Pharmacy&#8221;), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers
for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company&#8217;s customers
for fulfillment through the Company&#8217;s websites. The Company accounts for prescription product revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills
a customer&#8217;s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company,
including using the Company&#8217;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer
for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices
charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zG5ilX5YTyog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNwo7LFpL7P1">Subsequent
events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent
events. The Company will evaluate subsequent events through the date when the financial statements were issued.</span></p>

<p id="xdx_85C_zuYJB86uzqY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329735728336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND DEPOSITS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_DisclosurePrepaidExpensesAndDepositsAbstract', window );"><strong>Prepaid Expenses And Deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_PrepaidExpensesAndDepositsTextBlock', window );">PREPAID EXPENSES AND DEPOSITS</a></td>
<td class="text"><p id="xdx_802_ecustom--PrepaidExpensesAndDepositsTextBlock_zM0A1yqHFbj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span id="xdx_821_z0AGLu4ZJqz9">PREPAID EXPENSES AND DEPOSITS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2023 and the year ended December 31, 2022, and in association with the Master Services
Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy
as a retainer to be credited towards future product sales. As of September 30, 2023 and December 31, 2022, the balance was $<span id="xdx_90A_ecustom--PrepaidExpensesRelatedParty_iI_c20230930_zRNRpL1WIlVl" title="Prepaid expenses related party">84,382</span> and
$<span id="xdx_901_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_zVa22T2R9x0a" title="Prepaid expenses related party">11,745</span>, respectively</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $<span id="xdx_90F_eus-gaap--SecurityDeposit_iI_c20221001_z5nki9dG1w5j" title="Security deposit">16,942</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80B_ecustom--PrepaidExpensesAndDepositsTextBlock_zJSm2YB5uuNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
3 &#8211; <span>PREPAID EXPENSES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_82A_zrsAd8MODQt2">PREPAID
EXPENSES AND DEPOSITS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, and in association with the Master Services Agreement and Statement of Work with our related party
Contracted Pharmacy, the Company prepaid the related party Contracted Pharmacy $<span id="xdx_90A_eus-gaap--OperatingCostsAndExpenses_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zj5pmXl5rOZd" title="Prepaid the related party expense">15,000</span> as a retainer to be credited towards future product
sales. As of December 31, 2022 and December 31, 2021, the balance was $<span id="xdx_903_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_z8FQpn7RYYnf" title="Prepaid expenses related party">11,745</span> and $<span id="xdx_902_ecustom--PrepaidExpensesRelatedParty_iI_c20211231_zooxdSoewhPh" title="Prepaid expenses related party">0</span>. respectively. Additionally, the Company has signed
a lease agreement for office space, effective October 1, 2022. The initial security deposit was $<span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20221001_zVKmOQksLPz6" title="Securtiy deposit">16,942</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_DisclosurePrepaidExpensesAndDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_DisclosurePrepaidExpensesAndDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_PrepaidExpensesAndDepositsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_PrepaidExpensesAndDepositsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742353520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_ztEqO1cYDDqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_82D_zDL0HzKljptd">INVENTORY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company purchased inventories related to
promotional merchandise intended to be sold online. As of September 30, 2023 and December 31, 2022, the inventory balance was $<span id="xdx_901_eus-gaap--InventoryNet_iI_c20230930_zmkp1nJiz2z1" title="Inventory">21,581</span>
and $<span id="xdx_908_eus-gaap--InventoryNet_iI_dxL_c20221231_zF1dXx8jlO8f" title="Inventory::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0701">0</span></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742065184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlBxZ5Yj2RL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_82C_zh0O9PLWN7td">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2023, the Company acquired custom product packaging equipment totaling $<span id="xdx_900_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20230101__20230930_zCyS9eNzto62" title="Property acquired value">3,519</span>. Depreciation expense
for the nine months ended September 30, 2023 and 2022, was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20230930_zr78gp1RqXUj" title="Depreciation expense">18,598</span> and $<span id="xdx_90A_eus-gaap--Depreciation_dxL_c20220101__20220930_zU4Ll2Fvvdpl" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0709">0</span></span>, respectively. Total net property and equipment was $<span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230930_zXg57NZXRzWk" title="Property plant and equipment net">102,420</span>
and $<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zLkhUOZwiQ" title="Property plant and equipment net">117,499</span>, as of September 30, 2023 and December 31, 2022, respectively.</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zonsr7B2iWOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zusoPAkZbQZ" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230930_zO69tluKu5nh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/>
2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zobx2ETRm9G" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zVsot07MGY0d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zkhBR20if40i" style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,300</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zs0GDdoo2Nsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less accumulated depreciation:</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,461</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,863</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zbu3rt5Ghehe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">102,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117,499</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zVBL8PSLs7Vi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxFxaK6Kzs3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
4 &#8211; <span id="xdx_825_zhczP5OaGscj">PROPERTY AND EQUIPMENT</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company acquired computers, office and custom product packaging equipment totaling $<span id="xdx_90F_eus-gaap--PaymentsToAcquireMachineryAndEquipment_c20220101__20221231_zbn6f20ZEsTj" title="Property acquired value">121,362</span>. Depreciation
for the years ended December 31, 2022 and 2021 was $<span id="xdx_907_eus-gaap--Depreciation_c20220101__20221231_z7PtdvaxZH81" title="Depreciation expense">3,863</span> and $<span id="xdx_902_eus-gaap--Depreciation_dxL_c20211007__20211231_z4TndwNWhex6" title="Depreciation expense::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1801">0</span></span>, respectively. Total net property and equipment was $<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zNnW0nU4Kmmd" title="Property plant and equipment net">117,499</span>
and $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20211231_zH2EAcdPLBrc" title="Property plant and equipment net::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1805">0</span></span>, as of December 31, 2022 and December 31, 2021, respectively.</span></p>

<p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxyIOXSUtr3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zcYYUSYfHjej" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zesVQFOY5otk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zUSb9ScIwbq5" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_z6V6muUREk9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zdDH7zmJQxJi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1813">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNR0W1yiGpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,863</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1816">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z81M7spwxWZh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">117,499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zYzqX7hNRBG2" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739499664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWsqC9YWJni7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_826_zNqFaFcaFp2f">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021 and March 18, 2022, the Company received advances of $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zPfcDRhHOYu8" title="Related party advances received">39,200</span> and $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220318__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zGu30BeKGR7h" title="Related party advances received">50,000</span>, respectively, for a total of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zxWQITIbCeNd" title="Related party advances received">89,200</span> from
its previous majority shareholder, American International Holdings Corp (&#8220;AMIH&#8221;), in order to cover various general and administrative
expenses. The advances bear no interest and are due on demand upon the Company&#8217;s ability to repay the advances from either future
revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), an entity owned and controlled
by Jacob D. Cohen, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors, entered into and closed a Stock
Purchase Agreement (the &#8220;SPA&#8221;) for the purchase of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zAjgC1umwcje" title="Issuance of shares">8,000,000</span> shares of the outstanding common stock of the Company which
were then held by AMIH, which represented <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_z2qgLsAV0V3c" title="Equity ownership interest">80</span>% of the Company&#8217;s then outstanding shares of common stock, in consideration for $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zL0xCLZZtY9i" title="Proceeds from issuance of common stock">90,000</span>.
Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zxJcYaEaPQSl" title="Repayments of related party debt">89,200</span> advanced from AMIH to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2022, the Company received an advance of $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zmV2yXiMmhL4" title="Related party advances received">25,000</span> from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z2aac0KzVyPi" title="Repayments of related party debt">25,000</span> on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z4u8ccAnseSa" title="Repayment of related party debt">89,200</span>
as of December 31, 2022. This amount was paid in full on April 4, 2023 and the amount owed to Cohen Enterprises was $<span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z4LBINMC4F13" title="Proceeds from related party">0</span> and $<span id="xdx_903_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zeCK7UyAaz9b" title="Proceeds from related party">89,200</span> as
of September 30, 2023 and December 31, 2022, respectively. Previously recorded imputed interest equal to eight percent (<span id="xdx_905_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zrixixkFFYk2" title="Imputed interest percentage">8</span>%) per annum,
or a total of $<span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_znUmZuSatg48" title="Related party transaction purchases">8,232</span> against the related party advances, was canceled and reversed for the nine months ended September 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company received an advance of $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zJBH0cNK6C76" title="Related party advances received">70</span> from ZipDoctor, Inc., a then wholly-owned subsidiary of its then majority shareholder,
AMIH, which was used to open and establish the Company&#8217;s bank account. The advance bears no interest and is due on demand upon
the Company&#8217;s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May
24, 2022 and the amount owed to ZipDoctor was $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zwlgEno65Sd3">0</span> and $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zfHN6nTio4X1">0</span> as of September 30, 2023 and December 31, 2022, respectively. Imputed interest
at eight percent (<span id="xdx_906_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zijD1xghzHQ3" title="Imputed interest percentage">8</span>%) per annum on this advance was insignificant and therefore was not calculated, recorded or paid during the time
the advance was outstanding from December 10, 2021 to May 24, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information on related party prepaid expenses see Note 3.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4tvWK5IrHA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
5 &#8211; <span id="xdx_829_zixfBrIEA3x6">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021 and March 18, 2022, the Company received advances of $<span id="xdx_907_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zrrvNHsoLfg1" title="Related party advances received">39,200</span> and $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220318__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zDC1i6YtvbAh" title="Related party advances received">50,000</span>, respectively, for a total of $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zba4MXZDMN4h" title="Related party advances received">89,200</span> from
its previous majority shareholder, American International Holdings Corp (&#8220;AMIH&#8221;), in order to cover various general and administrative
expenses. The advances bear no interest and are due on demand upon the Company&#8217;s ability to repay the advances from either future
revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (&#8220;Cohen Enterprises&#8221;), an entity owned
and controlled by Jacob D. Cohen, the Company&#8217;s Chief Executive Officer and Chairman of the Board of Directors, entered into and
closed a Stock Purchase Agreement (the &#8220;SPA&#8221;) for the purchase of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zSIMoXnJdAs" title="Issuance of shares">8,000,000</span> shares of the outstanding common stock of the
Company which were then held by AMIH, which represented <span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zQHQIi6IBnzf" title="Equity ownership interest">80%</span> of the Company&#8217;s then outstanding shares of common stock, in consideration
for $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zaXuJJwEc6bc" title="Proceeds from issuance of common stock">90,000</span>. Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zDWmlutQmvk2" title="Repayments of related party debt">89,200</span> advanced from AMIH
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 29, 2022, the Company received an advance of $<span id="xdx_903_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z11cQwltOsSl" title="Related party advances received">25,000</span> from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $<span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_ziDGZauM3F3" title="Repayments of related party debt">25,000</span> on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $<span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zQ7QgyfEDX06" title="Repayment of related party debt">89,200</span>
as of December 31, 2022. As of December 31, 2021, the balance was $<span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zjiNbnVGufb9" title="Repayment of related party debt">39,200</span>. The Company recorded imputed interest equal to eight percent
(<span id="xdx_905_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zLF3lWetvm4e" title="Imputed interest percentage">8%</span>) per annum, or $<span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zDPICgRm9hF9" title="Related party transaction purchases">4,674</span> and $<span id="xdx_90B_eus-gaap--PaymentsForAdvanceToAffiliate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zLFF26pGTOB7" title="Related party transaction purchases">181</span>, against the related party advances for the years ended December 31, 2022 and December 31, 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 10, 2021, the Company received an advance of $<span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zNfdbIeaqb26" title="Related party advances received">70</span> from ZipDoctor, Inc., a wholly-owned subsidiary of its then majority shareholder,
AMIH, which was used to open and establish the Company&#8217;s bank account. The advance bears no interest and is due on demand upon
the Company&#8217;s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May
24, 2022 and the amount owed to ZipDoctor was $<span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_z8oigcTNmNx7">0</span> and $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zLAqDiNlhVe6">70</span> as of December 31, 2022 and December 31, 2021, respectively. Imputed interest
equal to eight percent (<span id="xdx_90F_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zeA3XM0Bkfg4" title="Imputed interest percentage">8%</span>) per annum, or $<span id="xdx_900_eus-gaap--PaymentsForAdvanceToAffiliate_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zKAFCbSkMNG8" title="Related party transaction purchases">2 </span>and $<span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_z8JXeMrrzjRl" title="Related party transaction purchases">0</span>, was recorded against the related party advance as of December 31, 2022 and 2021,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Chief Executive Officer, Jacob D. Cohen, has made his personal credit card available for purchases on behalf of the Company
to cover various general and administrative expenses. Mr. Cohen has been repaid a total of $<span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__srt--TitleOfIndividualAxis__custom--JacobDCohenMember_zQIoZT8zqsuh" title="Repayments of related party debt">248,151</span> as of December 31, 2022 for Company
purchases made on his personal credit card. &#160;&#160;There was no balance due as of December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information on related party prepaid expense see Note 3 and for related party stock-based transactions see Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742256016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zBbTSUkJpFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
7 &#8211; <span id="xdx_82B_zy2feB68R9Aj">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_z2AXWunyFFj5" title="Debt instrument face amount">78,260</span>. The
note bears no interest and was due in three payments of $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230101_zvLZ4AL6Q227" title="Debt instrument periodic payment"><span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230201__20230201_z1iYVRWVlIhc" title="Debt instrument periodic payment"><span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20230301__20230301_zdfv0d1DhGQ9" title="Debt instrument periodic payment">5,000</span></span></span> each January 1, 2023 through March 1, 2023, a $<span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_zhko9I7tSOo7" title="Debt instrument periodic payment">31,630</span> payment on April
1, 2023 and a final payment on May 1, 2023 for the outstanding balance. The January 1 and March 1, 2023 payments were timely made and
on March 23, 2023, the Company elected to pay off the remaining balance of $<span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20230323__20230323_zsWpalWZFWU5" title="Repayments of notes payable">63,260</span>. The outstanding balance as of September 30, 2023
and December 31, 2022 was $<span id="xdx_90E_eus-gaap--NotesPayable_iI_dxL_c20230930_zgYHm7K6WXO1" title="Notes payable::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0779">0</span></span> and $<span id="xdx_906_eus-gaap--NotesPayable_iI_c20221231_zq7Jk5Wi8av3" title="Notes payable">78,260</span>, respectively.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zrDLVtWx8oxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
6 &#8211; <span id="xdx_82B_zedDvcTXJl8e">NOTES PAYABLE</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On November 18, 2022, the Company
entered into a note payable with a vendor for the purchase of equipment in the amount of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_zBs9iRYygtT9" title="Debt instrument face amount">78,260</span>. The note bears no interest and is due
in three payments of $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230101_zQVCkq8z9e27" title="Debt instrument periodic payment"><span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20230201__20230201_zyoODReq12uf" title="Debt instrument periodic payment"><span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20230301__20230301_zkoKD3h44iql" title="Debt instrument periodic payment">5,000</span></span></span> each on January 1, 2023, February 1, 2023, and March 1, 2023, a $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_z48zBHVYJiA7" title="Debt instrument periodic payment">31,630</span> payment is due on April 1, 2023 and
a final payment is due on May 1, 2023 for the outstanding balance. The outstanding balance on December 31, 2022 was $<span id="xdx_901_eus-gaap--NotesPayable_iI_c20221231_zg7uLcKyjUA5" title="Notes payable">78,260</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742247168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">CAPITAL STOCK</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxJFk2oXgPz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_822_zCtGAgReVxac">CAPITAL STOCK</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to<span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930_zLpoTlhGhTbh" title="Preferred stock, shares authorized"> <span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zvbUkDwjBDR" title="Preferred stock, shares authorized">10,000,000</span></span> shares of &#8220;blank check&#8221; preferred stock, $<span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20230930_zSQGV2nPOM26" title="Preferred stock par value"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zUJm7dbb3Kw7" title="Preferred stock par value">0.0001</span></span> par value. All preferred
stock was undesignated as of September 30, 2023 and December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20230930_zS2JRQIOeAue" title="Common stock, shares authorized"><span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zTZFOqS9Fmm3" title="Common stock, shares authorized">200,000,000</span></span> shares of common stock, par value $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20230930_zNdX2GBL0o3l" title="Common stock par value"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_z5vuSDeyThtg" title="Common stock par value">0.0001</span></span> per share, of which <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20230930_zuRDuZRSy1X7" title="Common stock shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230930_zd0lPBuR3MNk" title="Common stock shares outstanding">16,789,500</span></span> shares were issued
and outstanding at September 30, 2023 and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20221231_zQoPItDPGfFl" title="Common stock shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zcWGcKmXxaRc" title="Common stock shares outstanding">13,365,000</span></span> were issued and outstanding at December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2022, the Company began a private placement of up to $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220808__20220808__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrlPXNlALsL1" title="Shares issued value">2,000,000</span> of units (the &#8220;Units&#8221;), each consisting of one
share of common stock (the &#8220;Shares&#8221;) and a warrant to purchase one share of common stock (the &#8220;Warrants&#8221;), at
a price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zNVESgylncBi" title="Share price">1.00</span> per Unit. The Warrants have a <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_uUSDPShares_c20220808_zGVDFiodftO7" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl0813">five-year</span></span> term and an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220808_zldAAiy3KWRl" title="Exercise price">1.00</span> per share, for which cash would need to
be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise the Warrants are
exercisable on either a cash basis or a cashless basis. The offering of the Units is referred to as the &#8220;Offering.&#8221; The Units
were offered by the Company only to investors that qualify as &#8220;accredited investors,&#8221; as that term is defined in Rule 501(a)
of Regulation D promulgated by the SEC under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The price of
the Units was determined by the Company and such price did not necessarily bear any relation to the book value or other recognized criteria
of value of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering commenced on August 8, 2022 and the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220808__20220808_zjwMzldA73Kl" title="Sale of stock, shares">2,000,000</span> Units at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zW4DcNpuw8ca" title="Share price">1.00</span> per Unit to 23 investors in exchange for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220808__20220808__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIVsdZIyTU3" title="Proceeds from investors">2,000,000</span>
in gross proceeds from the investors, and subsequently issued the investors <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220816__20221231_zFbyWJ5VNGnj" title="Sale of stock, shares">2,000,000</span> Shares and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z24kmFQbpDp8" title="Warrants issued">2,000,000</span> Warrants between August 16,
2022 and December 31, 2022. As of December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zHrhxkBa1f76" title="Fair value of warrants">1,438,299</span>. Because the
Warrants vested immediately the fair value was assessed on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (&#8220;PHX&#8221;), which is owned by Peter &#8220;Casey&#8221;
Jensen, who is a member of the Board of Directors of AMIH and a related party. Pursuant to the Consulting Agreement, PHX agreed to provide
consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was
for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach
30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX
<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVw3BrO6iXg8" title="Shares issued">50,000</span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares
were valued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPLB7zBNysC6" title="Share price">0.28</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0pzosJVQp79" title="Shares issued value">13,921</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#8220;Elliott&#8221;), currently a professional football
player in the National Football League, to provide consulting and general business advisory services as reasonably requested by the Company
during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement by either
party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services
under the agreement, the Company issued Elliott <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcZUOwmODG1j" title="Shares issued">100,000 </span>shares of restricted common stock. The agreement contains customary confidentiality
and non-solicitation provisions. The shares were valued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrSeUjugV734" title="Share price">0.28</span> per share for a total of <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQKy6ySlzhg9" title="Shares issued value">$27,842</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#8220;Sandler&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrwMYTDmxp4d" title="Shares issued">10,000</span>
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJoEzdGBPqMj" title="Share price">0.28 </span>per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwFsi4ymeFgg" title="Shares issued value">2,784</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#8220;Chou&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zO3SuRX8OqKa" title="Shares issued">5,000</span> shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued
at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVGopmaDZ5El" title="Share price">0.28</span> per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPLTXeXrg1T" title="Shares issued value">1,392</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP;
(c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023 and the
year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing
advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing
such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services
and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys,
CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1,
2022) has served as an Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zvc0FVqV6z01" title="Shares issued in consideration">100,000</span> shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zmuWIHwFBSik" title="Paid in cash">50,000</span> in cash, payable as follows: <span id="xdx_903_eus-gaap--CommonStockConversionFeatures_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zbIng9aiQGwj" title="Settlement description">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023</span>. We also agreed to include the <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAPrBDthzOIl" title="Shares new issued">100,000</span>
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein, and to reimburse
Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s activities under the agreement, including
the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification
obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zTMevqJaXP06" title="Share price">0.28</span> per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zWRLgqMXQxm3" title="Shares issued value">27,842</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company executed a Summary of Terms and Conditions (&#8220;Offer Letter&#8221;) with Gene Johnston (&#8220;Johnston&#8221;)
appointing Johnston to serve as the Company&#8217;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to
the Offer Letter, the Company issued Johnston <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr1zHL1GVOah" title="Restricted stock issued">150,000</span> shares of the Company&#8217;s restricted stock and vest over a 6-month period at
the rate of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxiMd9F1QsNc" title="Shares vested">25,000</span> shares per month with the first <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zotYiUMtgZc8" title="Shares vested">25,000</span> shares vesting on November 1, 2022. Johnston is eligible to participate in
any of the Company&#8217;s future sponsored benefit plans, including but not limited to, health insurance benefits, 401k, stock option
or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of the month following 105 days
of Johnston&#8217;s start date. Johnston is also eligible to receive equity incentive grants or cash bonus awards as determined by the
Company&#8217;s Board (or a committee of the Board) in their sole discretion. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z3HgTvHx8Fb7" title="Share price">0.28</span> per share for a total of
$<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221001__20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_znkdrhTiZosc" title="Shares issued value">41,763</span>. Mr. Johnston is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company entered into Director Offer Letter agreements with each of Alex Hamilton (&#8220;Hamilton&#8221;), Dr.
Kenny Myers (&#8220;Myers&#8221;) and Lorraine D&#8217;Alessio (&#8220;Alessio), compensating each of them with <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrt8jMP62pUl" title="Restricted stock issued">75,000</span> shares of restricted
common stock (for a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTliGhmLeLod" title="Restricted stock issued net">225,000</span> shares) (the &#8220;Director Shares&#8221;). The Director Shares were issued under the Company&#8217;s
2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;), with the following vesting schedule: 1/3 of the Director Shares vested on October
14, 2022, and the remaining Director Shares will vest annually in one-third increments commencing on the first anniversary date thereof.
The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zIgs3klM3J6a" title="Share price">0.28</span> per share for a total of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zwnFkWkVJHIj" title="Shares value">20,881</span>. These individuals are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued its Project Manager, Joan Arango, <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221014__20221014__srt--TitleOfIndividualAxis__custom--JoanArangoMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zobh0oSN3ckd" title="Restricted common stock issued">25,000 </span>shares of restricted common stock under the 2022 Plan.
The shares were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#8217;s President
and Chief Operating Officer, Jonathan Arango. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_znf3MuiGjJEb" title="Share price">0.28</span> per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_z2FaGvk0Lzk6" title="Shares value">7,204</span>. Ms. Arango is a related
party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#8220;White Unicorn&#8221;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztBTF3tqU1o" title="Shares issued">100,000</span> shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAYAz4ZWmICj" title="Share price">0.28</span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember_zL2NT57lZuO5" title="Shares value">28,816</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (&#8220;Global&#8221;) to provide marketing
services as reasonably requested by the Company during the term of the agreement, which was for six months unless otherwise earlier terminated
due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company issued Global <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zngwb1LKBlcl" title="Shares issued">100,000</span> shares of restricted common stock. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcuKaVFvj909" title="Share price">0.28</span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zU3J3htYDVOa" title="Shares issued value">28,816</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#8220;Chartered Services&#8221;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which was for six months unless otherwise earlier terminated due to
breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for
agreeing to provide the services under the agreement, the Company agreed to pay Chartered Services $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zx7CH4gNLmXi" title="Paid in cash">150,000</span> in cash (<span id="xdx_902_eus-gaap--CommonStockConversionFeatures_c20221221__20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zT4rTgtD7Kt6" title="Settlement description">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000</span> shares of restricted common
stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zF6RvCTc1ZR" title="Share price">0.28</span> per share for
a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcBn2lQVoBc5" title="Shares issued value">72,039</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#8220;DojoLabs&#8221;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $<span id="xdx_90F_eus-gaap--Cash_iI_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3K5xhtyoLT3" title="Cash">100,000</span> in cash and issued DojoLabs <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzQxVV2oefRg" title="Shares issued">50,000</span> shares of restricted common
stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains
customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHJFCjUwYnVh" title="Share price">1.00 </span>per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeGvMAZ7BfFl" title="Shares issued value">100,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#8220;Bethor&#8221;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuSqpcK1p1Fb" title="Shares issued">250,000</span> shares of restricted common stock with registration rights. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z3bDENf1MwXd" title="Share price">1.00</span> per share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaXZhJWAS4J8" title="Shares issued value">250,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the
&#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#8217;s development of new business ventures
and strategic planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#8220;Dr. Rudman&#8221;)
and Mr. Jarrett Boon (&#8220;Mr. Boon&#8221;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. Rudman&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Dr. Rudman
Consulting Agreement&#8221;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zhPwIMHLM0ge" title="Shares issued"> 25,000</span>
shares of the Company&#8217;s restricted common stock, pay Dr. Rudman $<span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zQtXtbJBL9da" title="Compensation expense">2,000</span> per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests
of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zws41mpvw9Bf" title="Share price">1.00</span> per share for a total
of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zkHNOVi3zuTa" title="Shares issued value">25,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Boon&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Mr. Boon
Consulting Agreement&#8221;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zTIbRW5h7mDb" title="Shares issued"> 25,000 </span>shares
of the Company&#8217;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties to the Company in service
on the Advisory Board. The shares were valued at $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zYngiV2qwhpb" title="Share price">1.00</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zyi1tD0EkqB8" title="Shares issued value">25,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of each agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, <span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXwL6xjhuHD7" title="Settlement description">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</span> Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zKOMGHOyZ0Zf" title="Share price">1.00</span> per
share for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zJL5xzwYHG6j" title="Shares issued value">350,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 22, 2023, the Company sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6NmiXb1rp39" title="Number of shares sold">1,250,000</span> shares of its common stock at a price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCSVEUzUmg46" title="Share price">4.00</span> per share to investors in connection with its
IPO for gross proceeds of $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW9mIS5mZDSb" title="Gross proceeds">5,000,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zlkoPRj84cA2" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price
of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_ztgw9NX9Epu6" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230424__20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zBJjGiLGI8rk" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zX1a5nQTrfzf" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price
of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zycNosj9zZve" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zLMSbslYysAe" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zlSUiou18w68" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price
of $<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_z7tjBUlDUvkj" title="Sale of stock price">1.00 </span>per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zJh7uyEfi7V8" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zE0ce4Edjok5" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price
of $<span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zYV9Jg85otHa" title="Sale of stock price">1.00 </span>per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zmyOLcs22zxj" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_ztVdf344iDa6" title="Warrants to purchase">75,000</span> shares of common stock with an exercise price
of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zkHZTlmoZVg5" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_z31qIAQm4iJc" title="Consideration paid">75,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zRrNgeFtvh46" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price
of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zyPwh7czQSu9" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230426__20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXvXH59NxE5k" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z5IRNo1G3Fhk" title="Warrants to purchase">25,000</span> shares of common stock with an exercise price of
$<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zue27ivEjLd" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zG0ZfLpziaqk" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the &#8220;Employment Agreement&#8221;).
The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending
through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party
provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for
Mrs. Hammer to receive an annual salary of $<span id="xdx_906_eus-gaap--PaymentsToEmployees_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zTbCJliE0LS6" title="Annual salary">150,000</span> per year. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zHCBBu0WVZ1i" title="Share based compensation arrangement by share-based payment award, description">The Employment Agreement also required the Company to grant Mrs. Hammer
a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase
an additional 150,000 shares of common stock of the Company, under the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;Plan&#8221;),
with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company&#8217;s common stock on
the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and
which exercise price was $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_uUSDPShares_c20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zp0vnnuI3XMl" title="Exercise price">1.00</span> per share, with options to purchase <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zbgtJsgZOqOd" title="Shares vesting">50,000</span> shares vesting every twelve months that the Employment Agreement
is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate
option agreement entered into by the Company and Mrs. Hammer.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (&#8220;Redlime&#8221;) to provide software
development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services
under the agreement, the Company agreed to pay Redlime $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvOO9uhDx6sa" title="Consideration paid">300,000</span> in cash and issue Redlime <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zw9f3qurBVT" title="Shares new issues">180,000</span> shares of restricted common stock.
The shares were valued at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zo6V6zDRToRl" title="Share price">1.00</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9ttdPeUMUCi" title="Shares issued value">180,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (&#8220;Mr. Andrew&#8221;), an independent, non-Board member and non-Company
employee, to the Advisory Board. In connection with Mr. Andrew&#8217;s appointment to the Advisory Board, the Company entered into an
Advisor Agreement (the &#8220;Mr. Andrew Consulting Agreement&#8221;), dated effective May 25, 2023, with Mr. Andrew, whereby the Company
agreed to issue Mr. Andrew <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zKjdwYhcKJ1i" title="Shares issued">50,000</span> shares of the Company&#8217;s restricted common stock under the 2022 Plan and to reimburse Mr. Andrew
for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s
requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrLZJo9pUXea" title="Share price">1.10 </span>per share
for a total of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpR0ypG570oa" title="Shares issued value">55,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Consulting Agreement with Major Dodge (&#8220;Major&#8221;), to provide acting and production related
services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of
the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued Major <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zhQrjX8GIiof" title="Shares issued">20,000 </span>shares of restricted common stock under the 2022 Plan. The
agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXzGz0vF7R0j" title="Share price">1.10</span> per share for a total of
$<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTTl3GIc5uM6" title="Shares issued value">22,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (&#8220;New To The Street&#8221;),
to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which was for
3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company
issued New To The Street <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zarrpgFH0yF5" title="Shares issued">50,000</span> shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHZHYZL1B5dj" title="Debt instrument periodic payment">5,000</span>.
The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEy71t101Wx4" title="Share price">1.10</span> per share for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJpVghc0jHmk" title="Shares issued value">55,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 6, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zy2APh38F328" title="Warrants to purchase">150,000</span> shares of common stock with an exercise price
of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zDuAaoCG03pg" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230606__20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z0R8K0WoNDul" title="Consideration paid">150,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 7, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z0AtNk7ZzSrc" title="Warrants to purchase">75,000</span> shares of common stock with an exercise price
of $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zCihRc46gTQd" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230607__20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z5io9mgrj2ui" title="Consideration paid">75,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 8, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zFprQXIQ7Y12" title="Warrants to purchase">24,500</span> shares of common stock with an exercise price
of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zkG6qLVdDHMf" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230608__20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zmRIaLsAl1Ne" title="Consideration paid">24,500</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zCWGS2hIzEOa" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price
of $<span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zTrmJTqCX2c8" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230621__20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zNxZ28dMcs1k" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zzQYHxEv7zw" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price
of $<span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zbQ8lqWkCpx1" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zjczq1iWDCz1" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXmuH1Y2wbyj" title="Warrants to purchase"> 25,000 </span>shares of common stock with an exercise price
of $<span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zNYJ9eGW8Nv2" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_z7bviaGGTqR4" title="Consideration paid">25,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 27, 2023, a warrant holder exercised private placement Warrants to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z9Yuz2pdC8Ci" title="Warrants to purchase">100,000</span> shares of common stock with an exercise price
of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z53VlWraBBp6" title="Sale of stock price">1.00</span> per share in consideration for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230627__20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z9coXxNmfZvk" title="Consideration paid">100,000</span> in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with
the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with
US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024
and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing,
and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose
of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting
services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its
attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed
October 1, 2022) has served as an Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zwHQfx4NYXCg" title="Shares issued in consideration">75,000</span> shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_ziaLGLPbnMjk" title="Paid in cash">40,000</span> in cash, payable as follows: <span id="xdx_90A_eus-gaap--CommonStockConversionFeatures_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zbw8brAuw34k" title="Settlement description">(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before
March 31, 2024.</span> We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s
activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service
Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard
to certain matters. The shares were valued at $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zVpfOyf3jOz1" title="Share price">1.13</span> per share for a total of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zss08gDbTOq7" title="Shares issued value">84,750</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company granted a total of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zQlIcltAJaB" title="Number of options">1,250,000</span> options to purchase shares of common stock of the Company,
under the 2022 Plan, of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zjugoApWhFJ6" title="Number of options granted">750,000</span> were granted to Jacob Cohen, the Company&#8217;s CEO, and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_znuKT5JEptf2" title="Number of options granted">500,000</span> were granted to Jonathan Arango,
the Company&#8217;s President and then COO, related to their respective employment agreement. The options have an exercise price of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVVB4FuGJwFl" title="Exercise price">1.10</span>
per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2K5atqtrGX8" title="Vesting term">three years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2023, the Company granted <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z3qQ4bz98Jmd" title="Number of options">150,000</span> options to purchase shares of common stock of the Company, under the 2022 Plan to Amanda Hammer,
the Company&#8217;s COO, related to her employment agreement. The options have an exercise price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziGnC6iqtl41" title="Exercise price">1.10</span> per share, an original life
of five years and vest at the annual renewal of their employment over <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230501__20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHe2zDhxQIJ2" title="Vesting term">three years</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_zSwvuuykv341" title="Share based compensation">197,954</span> and $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zyAHgS3J7z0g" title="Share based compensation">82,267</span> has been recorded as stock-based compensation. Mr. Cohen, Mr. Arango
and Ms. Hammer are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyi1rsR2Htf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock options activity: The following table summarizes common stock options activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zlnCXFgqu0eg" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average<br/> Exercise Price</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znhH9QhV8Jz9" style="text-align: right" title="Options, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zeKHtmvQD3p8" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zHSc0soTBJ65" style="width: 16%; text-align: right" title="Options, Granted">1,250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zSj0pmVHzf72" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z4M1W5clqAig" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zWw9zwFbNmu4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zLbeTZscYov8" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zikBFPG16421" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhddE771qBg8" style="text-align: right" title="Options, Outstanding Ending Balance">1,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zzpqysnH1Wqk" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z1MP2jF4AFQ7" style="text-align: right" title="Options, Exercisable Ending Balance">133,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zHFZEa6PWQll" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zf1atKcT80X9" style="text-align: right" title="Options, Outstanding Beginning Balance">1,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20230930_zyW2d14wPidh" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_z3Ptx0XNd0V5" style="text-align: right" title="Options, Granted">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zZFpnFBVW2fg" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zWOR2HFj1J1a" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_z14JGxLafKJ7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230930_zrXwuRePGnI" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zLEIlWnHh8m1" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_z6pDRX1w20Mh" style="text-align: right" title="Options, Outstanding Ending Balance">1,400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_z6aTTMyvay9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zfOYJOY5k1o2" style="text-align: right" title="Options, Exercisable Ending Balance">454,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zNfU28RYePX6" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Outstanding Options</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Exercisable Options</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Exercise<br/> Price Per <br/> Share</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Life <br/> (Years)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average <br/> Exercise Price</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average <br/> Exercise Price</b></span></p></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20230101__20230930_zpfuwp5dq2B8" style="width: 13%; text-align: right" title="Option Exercise Price Per Share">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zhhNJGX7130k" style="width: 13%; text-align: right" title="Outstanding Ending Balance">1,400,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z05q5jUmYmX" title="Options Term">4.53</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zjS2Z9bdup3h" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zymTshplVVMd" style="width: 13%; text-align: right" title="Exercisable Ending Balance">454,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zv4uyDEuL4I3" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z3ZpUXQeFDjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, the fair value of options outstanding was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230930_z4xStvq1s4ge" title="Fair value of options outstanding">640,194</span>. The aggregate initial fair value of the options measured on
the grant date of August 31, 2022 and May 1, 2023 was calculated using the Black-Scholes option pricing model based on the following
assumption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEuwjyXnOBz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zIZVbbHJx3N5" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 68%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930_zvk6SeZs4NWb" style="width: 20%; text-align: right" title="Fair value of common stock on measurement date">1.00</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z5rM1yKNJIo1" title="Risk-free interest rate">3.64</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_z0slP4fXaPnb" title="Risk-free interest rate">3.30</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zZ0HuAO9GC46" title="Volatility">224.70</span>% <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdfCWyRnImbd" title="Volatility">92.54</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zCUiNUvFDl07" title="Dividend yield">0</span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zktdNJwouND1" title="Expected term">6.0</span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zxy0hr7KDDEd" title="Expected term">3.5</span></span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, in accordance with staff accounting bulletin (&#8220;SAB&#8221;)14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term</span></td></tr>
  </table>
<p id="xdx_8AF_zTENkGUvqxZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued a total of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z9gv0kRhW6kj" title="Warrants issued">2,000,000</span> Warrants to investors and <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zBHrSr03DRp7" title="Warrants issued for services">210,070</span> Warrants as compensation
for services rendered in connection with the Offering. The Warrants have an original life of five years and vested immediately. The Warrants
for services were expensed as stock-based compensation at the aggregate fair value in the amount of $<span id="xdx_903_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220101__20221231_zWy5hWNJnyT7" title="Fair value of warrant">151,821</span>. Because the Warrants vested
immediately, the fair value was assessed on the grant date. The aggregate fair value of the Warrants were measured using the Black-Scholes
option pricing model. The Company and the holder of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zOQcb9AmtzMh" title="Warrants issued for services">210,070</span> Warrants for services agreed to cancel the Warrants and reversed the entries
for stock-based compensation to zero at year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative
of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zPj1ryfeFcX1" title="Warrants issued">87,500 </span>shares of common stock with an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwMJcNrlIgR5" title="Exercise price">5.00</span> per share, which are exercisable six months after the effective date of the registration statement filed in connection
with the IPO (March 20, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was
$<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230320__20230320_zhYd2LjGR678" title="Fair value of warrants">31,995</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023 and December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zlQoxU6gX5L1" title="Fair value of Warrants outstanding">581,264</span> and $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zO5c5OEQ0BH2" title="Fair value of Warrants outstanding"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zk6NPSL72gMc" title="Fair value of Warrants outstanding">1,438,299</span></span>, respectively.
Because the Warrants vested immediately, the fair value was assessed on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zBNhKo7fwRy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock warrant activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zEBdMiAKxqZg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average<br/> Exercise Price</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoh8dvznIjJh" style="text-align: right" title="Warrants Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmdzcqHQyni8" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQGTuc1YVqmj" style="width: 14%; text-align: right" title="Warrants Granted">2,210,070</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTncY7ZGcOz8" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDh1G5xiXu03" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFtBIZm2jSx5" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1213">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoJUZp1hIQyg" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDGC8QqIw544" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJL28tJgdRc" style="text-align: right" title="Warrants Cancelled">(210,070</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCJmbrIdijk" style="text-align: right" title="Weighted Average Exercise Price Cancelled">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8iRJOGpHFzl" style="text-align: right" title="Warrants Outstanding, Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSV2VZbyu11" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDzgqgo7B9Y6" style="text-align: right" title="Warrants Exercisable Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRg934nPAxXd" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCDjEPEqNrI3" style="text-align: right" title="Warrants Granted">87,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL93hfP3zhW1" style="text-align: right" title="Weighted Average Exercise Price Granted">5.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp61h1Zmertg" style="text-align: right" title="Warrants Exercised">(1,024,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM16wPuNZt8e" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN6LGRvfip1b" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsW6qE1SHTq2" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWwmwXM0Kpu1" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgfUfOllZdyc" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQwkEgQUqG2b" style="text-align: right" title="Warrants Outstanding, Ending balance">1,063,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZs1OBoLSK21" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQtwYXbBSpd" style="text-align: right" title="Warrants Exercisable Ending balance">975,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2OvWN19gtlc" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Warrant Exercise Price Per Share</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY3FElUSndtl" style="width: 30%; text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zviqeeycKM92" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance">1,063,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTDFcVl5jPIb" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term">3.83</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zIUvQSjzqFjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2023, warrants to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDCRYvrtk2S2" title="Warrants outstanding">1,063,000</span> shares of common stock are outstanding and vested, and the vested stock warrants
have a weighted average remaining life of <span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4XXavrzjzc4" title="Outstanding and vested warrants expected term">3.83</span> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXniw0lhn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BB_zmc19E8WnEi5" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHbH2bsAL481" title="Fair value of common stock on measurement date">0.37</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zqA4XUr2W09l" title="Fair value of common stock on measurement date">0.72</span></span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFJjnXUMlQ4" title="Risk-free interest rate">2.95</span>% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zhOsdSKWfmak" title="Risk-free interest rate">4.00</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaz6PgL5z1Ff" title="Volatility">88.92</span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAIYLYlD3Awd" title="Volatility">92.87</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcbCSHkmB32" title="Dividend rate">0</span></td><td style="width: 1%; text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrGkHub8P62" title="Expected term">5</span> years</span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  </table>
<p id="xdx_8A4_zrdq3VifZuSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z19KKraDpTyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b>NOTE 7</b><b> &#8211; <span id="xdx_82B_ziBPst2JUnq9">CAPITAL
STOCK</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue up to <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zgTTndP4Kv4h" title="Preferred stock, shares authorized"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zKFfpPRQNbb4" title="Preferred stock, shares authorized">10,000,000</span></span> shares of &#8220;blank check&#8221; preferred stock, $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zuwynNIVMxpl" title="Preferred stock par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20211231_zC0AAo3JxgRe" title="Preferred stock par value">0.0001</span></span> par value. All preferred
stock were undesignated as of December 31, 2022 and December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfAtL9czMWf" title="Common stock, shares authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zvHmqg1xxAAh" title="Common stock, shares authorized">200,000,000</span></span> shares of common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zh5Ee8uyRmL" title="Common stock par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20211231_zjRAuAZlXFEe" title="Common stock par value">0.0001</span></span> per share, of which <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221231_zs23tA0cKzYe" title="Common stock shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zTiLnhMBhDVf" title="Common stock shares outstanding">13,365,000</span></span> shares were issued
and outstanding at December 31, 2022 and <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20211231_z1dZCQ4H6rgd" title="Common stock shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z8TozicLBGVe" title="Common stock shares outstanding">8,000,000</span></span> were issued and outstanding at December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjZLJeo0w9ke" title="Shares issued in consideration">1,000,000</span> shares of restricted common stock to the Company&#8217;s co-founder and CEO, Jacob D. Cohen,
in consideration for services rendered. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zgg8XQkfODMf" title="Shares issued in consideration,share price">0.10</span> per share, based on recent third-party sales of shares, for a
total of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z7zVIQdSgB82" title="Shares issued in consideration value">100,000</span>. Mr. Cohen is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 6, 2022, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z2YU8G9rZY4j" title="Shares issued in consideration">1,000,000</span> shares of restricted common stock to the Company&#8217;s co-founder, President and COO, Jonathan
Arango, in consideration for services rendered to the Company. The shares were valued at $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zkZl4LQCM1X9" title="Shares issued in consideration,share price">0.10</span> per share, based on recent third-party
sales of shares, for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zs5v12wmxAlh" title="Shares issued in consideration value">100,000</span>. Mr. Arango is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 23, 2022, the Company issued <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220623__20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_ztBmiK6oWup6" title="Shares issued in consideration">250,000</span> shares of restricted common stock to The Loev Law Firm, PC in consideration for legal services
rendered to the Company. The managing partner of The Loev Law Firm, PC is David M. Loev, who is the brother-in-law of the Company&#8217;s
CEO, Jacob D. Cohen. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_z9s6zafao86k" title="Share price">0.10</span> per share, based on recent third-party sales of shares, for a total of $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220623__20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_z0LckWaVlEGg" title="Shares issued in consideration value">25,000</span>.
Mr. Loev is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 8, 2022, the Company began a private placement of up to $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220808__20220808__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAkLjVCwqbOc" title="Shares issued value">2,000,000</span> of units (the &#8220;Units&#8221;), each consisting of one
share of common stock (the &#8220;Shares&#8221;) and a warrant to purchase one share of common stock (the &#8220;Warrants&#8221;), at
a price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zFfLmoJ5GYD9" title="Share price">1.00</span> per Unit. The Warrants have a <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_uUSDPShares_c20220808_zzbQLlVEKDKc" title="Warrants term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1925">five-year</span></span> term and an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220808_zNbDuqumIJ2l" title="Exercise price">1.00</span> per share, for which cash would need to
be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise the Warrants are
exercisable on either a cash basis or a cashless basis. The offering of the Units is referred to as the &#8220;Offering.&#8221; The Units
were offered by the Company only to investors that qualify as &#8220;accredited investors,&#8221; as that term is defined in Rule 501(a)
of Regulation D promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;) under the Securities Act of 1933, as
amended (the &#8220;Securities Act&#8221;). The price of the Units were determined by the Company and such price did not necessarily
bear any relation to the book value or other recognized criteria of value of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering commenced on August 8, 2022 and the Company sold <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220808__20220808_zUHwwSVSt8Oc" title="Sale of stock, shares">2,000,000</span> Units at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zrDWSi3vOZw" title="Share price">1.00</span> per Unit to 23 investors in exchange for $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220808__20220808__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJTOokKTOqbj" title="Proceeds from investors">2,000,000</span>
in gross proceeds from each investor, and subsequently issued the investors <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220816__20221231_zdBnKGmTZl4f" title="Sale of stock, shares">2,000,000</span> Shares and <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z6eGwT7T4OTb" title="Warrants issued">2,000,000</span> Warrants between August 16,
2022 and December 31, 2022. As of December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zqhKMmf1GB48" title="Fair value of warrants">1,438,299</span>. Because the
Warrants vested immediately, the fair value was assessed on the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC &#160;&#160;(&#8220;PHX&#8221;), which is owned by Peter
&#8220;Casey&#8221; Jensen, who is a member of the Board of Directors of AMIH. Pursuant to the Consulting Agreement, PHX agreed
to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement,
which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure
such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company
issued PHX <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcyBwzL9iCJi" title="Shares issued">50,000</span> shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions.
The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQvN4OSsyY6i" title="Share price">0.28</span> per share for a total of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQc319LyiT3" title="Shares issued value">13,921</span>. PHX is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#8220;Elliott&#8221;), currently a professional football
player and the running back for the Dallas Cowboys, to provide consulting and general business advisory services as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Elliott <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkdHKczVU5Ng" title="Shares issued">100,000</span> shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zahdjkEw1887" title="Share price">0.28 </span>per share for a total of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJZft5JsYe5e" title="Shares issued value">27,842</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#8220;Sandler&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zld2LwNFlUQ3" title="Shares issued">10,000</span>
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKeYisrPFYB1" title="Share price">0.28</span> per share for a total of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRFkqWryOUQl" title="Shares issued value">2,784</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#8220;Chou&#8221;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaO5jJWoOXk1" title="Shares issued">5,000</span> shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued
at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvbnHFSMdBs" title="Share price">0.28</span> per share for a total of $<span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8b52etEvnO9" title="Shares issued value">1,392</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#8220;Greentree&#8221; and the &#8220;Service
Agreement&#8221;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US
GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023
and the year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes;
(d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions,
with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing
necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst
the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer
(who was appointed October 1, 2022) has served as Audit Manager for Greentree.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company agreed to issue Greentree <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z2UErOVVDDE" title="Shares issued in consideration">100,000</span> shares of the Company&#8217;s restricted common stock upon the parties&#8217; entry into the
agreement, and to pay Greentree $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z9OWJbKvLao6" title="Paid in cash">50,000</span> in cash, payable as follows: <span id="xdx_906_eus-gaap--CommonStockConversionFeatures_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zyJnm43mMYVa" title="Settlement description">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023</span>. We also agreed to include the <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZq7tgRMzOg5" title="Shares new issued">100,000</span>
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein, and to reimburse
Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#8217;s activities under the agreement, including
the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification
obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at
$<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zwZk8aGIgOc4" title="Share price">0.28</span> per share for a total of $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_ztakrZ6pyCid" title="Shares issued value">27,842</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2022, the Company executed a Summary of Terms and Conditions (&#8220;Offer Letter&#8221;) with Gene Johnston (&#8220;Johnston&#8221;)
appointing Johnston to serve as the Company&#8217;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to
the Offer Letter, the Company issued Johnston <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgb7WDH2nSIe" title="Restricted stock issued">150,000</span> shares of the Company&#8217;s restricted stock and vest over a 6-month period at
the rate of <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoPsUBIlqeaf" title="Shares vested">25,000</span> shares per month with the first <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjtS2cR6FTi9" title="Shares vested">25,000</span> shares vesting on November 1<sup>st</sup>, 2022. Johnston is eligible to participate
in any of the Company&#8217;s future sponsored benefit plans, including but not limited to, health insurance benefits, 401k, stock option
or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of the month following 105 days
of Johnston&#8217;s start date. Johnston is also eligible to receive equity incentive grants or cash bonus awards as determined by the
Company&#8217;s Board (or a committee of the Board) in their sole discretion. The shares were valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zy3rM3OqxRR" title="Share price">0.28 </span>per share for a total of
$<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221001__20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_znHlssWNeWI" title="Shares issued value">41,763</span>. Mr. Johnston is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 13, 2022, the Company approved the appointments of each of Alex Hamilton (&#8220;Hamilton&#8221;), Dr. Kenny Myers (&#8220;Myers&#8221;)
and Lorraine D&#8217;Alessio (&#8220;Alessio) to serve as independent members of the Board of Directors and</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
entered into Director Offer Letter agreements with Hamilton, Myers and D&#8217;Alessio compensating each of them with <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr77GlLClka1" title="Restricted stock issued">75,000</span> shares of
restricted common stock (for a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwwlzsQE5DWb" title="Restricted stock issued net">225,000</span> shares) (the &#8220;Director Shares&#8221;). The Director Shares were issued under the
Company&#8217;s 2022 Equity Incentive Plan (the &#8220;Plan&#8221;), with the following vesting schedule: 1/3 of the Director Shares
vested on October 14, 2022, and the remaining Director Shares will vest annually in one-third increments commencing on the first anniversary
date thereof. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_ztri0cDqr373" title="Share price">0.28</span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zaR0gnNGNcia" title="Shares value">20,881</span>. These individuals are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 14, 2022, the Company issued its Project Manager, Joan Arango, <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221014__20221014__srt--TitleOfIndividualAxis__custom--JoanArangoMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zpuiQkRWCmu9" title="Restricted common stock issued">25,000</span> shares of restricted common stock under the Plan. The shares
were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#8217;s President and Chief
Operating Officer, Jonathan Arango. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_zhHMZQ1vuusk" title="Share price">0.28</span> per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_zVqYUfvgXeqj" title="Shares value">7,204</span>. Ms. Arango is a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#8220;White Unicorn&#8221;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHmzQQ7ITdP9" title="Shares issued">100,000</span> shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeBLn7flpVG8" title="Share price">0.28</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember_z78BNfxG0a42" title="Shares value">28,816</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (&#8220;Global&#8221;) to provide marketing
services as reasonably requested by the Company during the term of the agreement, which is for six months unless otherwise earlier terminated
due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company issued Global <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEKcedeDg98f" title="Shares issued">100,000</span> shares of restricted common stock. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z71FZUg4qjh6" title="Share price">0.28</span> per share for a total of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLLaR31a5p16" title="Shares issued value">28,816</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#8220;Chartered Services&#8221;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company agreed to pay Chartered Services $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zlZlaSxmoxd1" title="Paid in cash">150,000</span> in cash (<span id="xdx_900_eus-gaap--CommonStockConversionFeatures_c20221221__20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zse18P8rkRha" title="Settlement description">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000</span> shares of restricted common stock.
The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_z69c1bCZUoVg" title="Share price">0.28</span> per share for a total
of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQoZNuLCZkh" title="Shares issued value">72,039</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company granted options to purchase a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zIvBl2kuCoZa" title="Number of options">1,250,000</span> shares of common stock,
of which <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zBdm04VV3Pf4" title="Number of options granted">750,000</span> were granted to Jacob Cohen, the Company&#8217;s CEO, and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zWPHaiZbhmZb" title="Number of options granted">500,000</span> were granted to Jonathan Arango, the Company&#8217;s
President and COO, as Bonus Equity Shares related to their respective employment agreement. The options have an exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zElCtDJhEgae" title="Exercise price">1.10</span>
per share, an original life of five years and vest at the annual renewal of their employment over <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2fp8oOGua78" title="Vesting term">three years</span>. As of December 31, 2022,
$<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zip64gV5bRi" title="Share based compensation">82,267</span> has been recorded as stock-based compensation. Both Mr. Cohen and Arango are related parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFQ9mTYd1mUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock options activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmxzQdBkkpvk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfv0MGxuIbe1" style="text-align: right" title="Options, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2035">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zN8BW6OCny14" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2037">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zSrPSGHbvuW6" style="width: 16%; text-align: right" title="Options, Granted">1,250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zuBdwVacSAI" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zbQF8cnMfUL5" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2043">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zOakZRnLunH3" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zBJnFiZ6IWM6" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl2047">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_z6HBjICtft8i" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl2049">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zAtz53k6Gd2b" style="text-align: right" title="Options, Outstanding Ending Balance">1,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zwebE1QXQ4dl" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zJB1Cha6VH4i" style="text-align: right" title="Options, Exercisable Ending Balance">133,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zMZVhPWnSnfd" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20220101__20221231_zQn5skYMKtj4" style="width: 13%; text-align: right" title="Option Exercise Price Per Share">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zUvzjHEQCMk1" style="width: 13%; text-align: right" title="Outstanding Ending Balance">1,250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zu3Ihh8EzdLb" title="Options Term">4.67</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zdfZrNcJrmyk" style="width: 13%; text-align: right" title="Weighted Average Outstanding Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zyn2TAT3PEOa" style="width: 13%; text-align: right" title="Exercisable Ending Balance">133,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zIvM10tSOKHc" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zHD1ZkAoGTa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the fair value of options outstanding was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_zJ1N5gUJA3bf" title="Fair value of options outstanding">688,984</span>. The aggregate initial fair value of the options measured on
the grant date of August 31, 2022 was calculated using the Black-Scholes option &#160;&#160;pricing model based on the following assumption:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQ6JxRHlI772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_znVgFVy2pF38" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231_zzL2TOKhG9N6" style="width: 14%; text-align: right" title="Fair value of common stock on measurement date">1.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zvOrrmtjR2d2" title="Risk-free interest rate">3.30</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zQ460uEm9Xr8" title="Volatility">92.54</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zVlmAjG216zl" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zqyrWwP8FWi8" title="Expected term">3.5</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term.</span></td></tr>
  </table>
<p id="xdx_8AD_zdH82mflRGFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company issued a total of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zhpvu2YSvzp5" title="Warrants issued">2,000,000</span> Warrants to investors and <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zgEJg43hZIZk" title="Warrants issued for services">210,070</span> Warrants as compensation
for services rendered in connection with the Offering. The Warrants have an original life of five years and vest immediately. The Warrants
for services were expensed as stock-based compensation at the aggregate fair value in the amount of $<span id="xdx_902_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220101__20221231_zt0buDyfL3Be" title="Fair value of warrant">151,821</span>. Because the Warrants vest
immediately the fair value was assessed on the grant date. The aggregate fair value of the Warrants were measured using the Black-Scholes
option pricing model. The Company and the holder of <span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_ziZf21L6gey4" title="Warrants issued for services">210,070</span> Warrants for services agreed to cancel the Warrants and reversed the entries
for stock based compensation to zero at year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, the fair value of Warrants outstanding to investors was $<span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zZsoOlnoC6hc" title="Fair value of warrants outstanding">1,438,299</span>. Because the Warrants vested immediately
their fair value was assessed on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpi7F1Mp7Dh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock warrants activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zJk73NNH3RBb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WARRANT ACTIVITY</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRbHK54XpMg3" style="text-align: right" title="Warrants Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNejRM6N0fXb" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2099">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRNn5P0enlGa" style="width: 16%; text-align: right" title="Warrants Granted">2,210,070</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3T9LPDWwQ7" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeTliNAnLnFe" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2105">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z67sIyNRrFuh" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2107">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjJpCUAI8I" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl2109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9T2GOhGthRe" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2111">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdbvENdkeMie" style="text-align: right" title="Warrants Cancelled">(210,070</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znNCowjp1Ai9" style="text-align: right" title="Weighted Average Exercise Price Cancelled">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6iIASFSpjb" style="text-align: right" title="Warrants Outstanding, Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMtyggziK6hd" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3NLjhjGSxYi" style="text-align: right" title="Warrants Exercisable Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoH9R2qqvG4b" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercise</b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Exercisable Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                                                                 (Years)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeQNSF8rmD2" style="width: 30%; text-align: right" title="Warrants Exercise Price Per Share">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8g7Mdt9ysue" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance">2,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthrO8mkf6n2" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term">4.74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zJgo7LfpoZgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2022, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z62apZB4xIM7" title="Warrants outstanding">2,000,000</span> Warrants are outstanding and vested, and the vested stock Warrants have a weighted average remining life
of <span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7jpXEWPVYm7" title="Outstanding and vested warrants expected term">4.74</span> years.</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPEGDsUf92i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_z9wemA891r8" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWISYOmTNbL4" title="Fair value of common stock on measurement date">0.62</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztJTTO9yhpG2" title="Fair value of common stock on measurement date">0.72</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS1lvbebtna7" title="Risk-free interest rate">2.95%</span> to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjd88JF9Jki5" title="Risk-free interest rate">4.00</span></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS2mSedIdXn4" title="Volatility">88.92%</span> to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSqQ4I40eb71" title="Volatility">92.87%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDOCefVqkoc" title="Dividend rate">0%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA55nUZLTbL6" title="Expected term">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  </table>
<p id="xdx_8A3_zd3sFhMDuzC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329831887920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4wQJNloSbsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_829_zfoVTCEQbUvb">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company is not currently subject to any such litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a lease for an office in Dallas, Texas, classified as an operating lease under ASC 842, <i>Leases.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#8220;Landlord&#8221;) to lease and occupy approximately <span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20220928_zKgJj1o9MGa7">2,201</span> square feet of office space located at 15110 Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#8217;s main headquarters (the &#8220;<span style="text-decoration: underline">Lease Agreement</span>&#8221;). <span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZYS0DoDTiAd" title="Operating lease, description">The Lease
Agreement has a term of thirty-eight (<span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zy8nQ2Bjoxvl" title="Lease term">38</span>) months and has a monthly base rent of $<span id="xdx_908_eus-gaap--PaymentsForRent_c20220928__20220928_zhsjLx3nwRbh" title="Base rent">5,778</span>, or $31.50 per square foot, for the from months
3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term</span> (the &#8220;<span style="text-decoration: underline">Base Rent</span>&#8221;).
In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments,
hazard and liability insurance and common area maintenance costs for the building at the rate of <span id="xdx_90F_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zgPXQ0GcHlI3" title="Percentage of proportionate rent">2.45</span>% (the &#8220;<span style="text-decoration: underline">Proportionate Rent</span>&#8221;).
Upon the execution of the Lease Agreement, the Company agreed to prepay the first full month&#8217;s Base Rent along with a security
deposit equal to $<span id="xdx_909_eus-gaap--PaymentsForRent_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z9xGeoroPGq5" title="Base rent">16,942</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily
determinable. The Company used an estimated incremental borrowing rate of <span id="xdx_90A_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zMlOWvijXZJg" title="Percentage of incremental borrowing rate">8</span>% to estimate the present value of the right-of-use liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has right-of-use assets of $<span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230930_zZcUpSuvKlBb" title="Right of use of asset">133,433</span> and $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zJieVvJPtFt2" title="Right of use of asset">174,241</span> and operating lease liabilities of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_c20230930_zLJ5zrwP4I13" title="Operating lease liability">143,424</span> and $<span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20221231_zkGPL5F4H6He" title="Operating lease liability">185,405</span> as of September 30,
2023 and December 31, 2022, respectively. Operating lease expense for the nine months ended September 30, 2023 and 2022 was $<span id="xdx_906_eus-gaap--OperatingLeaseCost_c20230101__20230930_zlP6umDqxl5j" title="Operating lease expense">50,826</span> and
$<span id="xdx_908_eus-gaap--OperatingLeaseCost_c20220101__20220930_zPa41U6jFuH1" title="Operating lease expense">0</span>, respectively. The Company has recorded $<span id="xdx_903_eus-gaap--AssetImpairmentCharges_c20230101__20230930_ze3QG1AuZSf2" title="Asset impairment charges"><span id="xdx_90F_eus-gaap--AssetImpairmentCharges_c20220101__20220930_z9aVKEklHrD4" title="Asset impairment charges">0</span></span> in impairment charges related to right-of-use assets during the nine months ended September
30, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zfxAqQM2PIij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zswRigTIq3uh" style="display: none">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Maturity of Lease Liabilities at September 30, 2023</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zDWWLFhDsfTk" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 82%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_ma1_c20230930_zTpIGPR0wXn6" style="width: 14%; text-align: right" title="Remainder of Fiscal Year">17,516</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_ma1_c20230930_zmD2YYkVOW4h" style="text-align: right" title="Year One">71,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">2025</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_ma1_c20230930_zC43oirSPia" style="padding-bottom: 1.5pt; text-align: right" title="Year Two">67,589</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pp0p0_ma1_c20230930_z0JCCsLn33E7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Year Three"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mt1_c20230930_ztEXhojbu4k3" style="text-align: right" title="Total lease payments">156,821</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zGqopNm9d9W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Less: Imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,397</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zJjgVhWwhBbg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Present value of lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,424</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A7_zhAQOiM0QUN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcayYwRMijae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
9 &#8211; <span id="xdx_82F_zOYkjV8m9q0d">COMMITMENTS AND CONTINGENCIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company is not currently subject to any such litigation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company has a lease for an office in Dallas, TX classified as operating leases </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="background-color: white">under
ASC 842, <i>Leases</i>.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#8220;Landlord&#8221;) to lease and occupy approximately <span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20220928_zE3gPM3ElVsb" title="Area of land">2,201</span> square feet of office space located at 15110 Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#8217;s main headquarters (the &#8220;<span style="text-decoration: underline">Lease Agreement</span>&#8221;). <span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928_zxXiqTuwEBn1" title="Operating lease, description">The Lease
Agreement has a term of thirty-eight (<span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zBCZJtiLvAdl" title="Lease term">38</span>) months and has a monthly base rent of $<span id="xdx_90A_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928_zG08NoHFOMwd" title="Base rent">5,777.63</span>, or $31.50 per square foot, from months 3-18,
which increases at the rate of $1 per square foot per annum thereafter until the end of the lease term</span> (the &#8220;<span style="text-decoration: underline">Base
Rent</span>&#8221;). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real
estate taxes and assessments, hazard and liability insurance and common area maintenance costs for the building at the rate of <span id="xdx_905_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zGRfPgOA6Ttl" title="Percentage of proportionate rent">2.45%</span>
(the &#8220;<span style="text-decoration: underline">Proportionate Rent</span>&#8221;). Upon the execution of the Lease Agreement, the Company agreed to prepay the first full
month&#8217;s Base Rent along with a security deposit equal to $<span id="xdx_907_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGt4WGPE423k" title="Base rent">16,941.79</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company utilizes the incremental borrowing rate </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<span style="background-color: white">in
determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental
borrowing rate of <span id="xdx_900_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zWB9sM41lobh" title="Percentage of incremental borrowing rate">8%</span> to estimate the present value of the right of use liability.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has right-of-use assets of $<span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zcXPKYDcblRf" title="Right of use of asset">174,241</span> and operating lease liabilities of $<span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_c20221231_zpyOi0i6Eqcl" title="Operating lease liability">185,405</span> as of December 31, 2022. Operating lease expense
for the year ended December 31, 2022 was $<span id="xdx_90E_eus-gaap--OperatingLeaseCost_c20220101__20221231_zumUp55RaZoi" title="Operating lease expense">16,942</span>. The Company has recorded $<span id="xdx_90E_eus-gaap--AssetImpairmentCharges_c20220101__20221231_zWBDXPzoF5ob" title="Asset impairment charges">0</span> in impairment charges related to right-of-use assets during
the year ended December 31, 2022.</span></p>

<p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv51npV57e2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zSOjxkum5cj" style="display: none">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity of Lease Liabilities at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z8jP4j647OH3" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20221231_pp0p0" style="width: 16%; text-align: right" title="Year One">69,515</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20221231_pp0p0" style="text-align: right" title="Year Two">71,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_c20221231_pp0p0" style="text-align: right" title="Year Three">67,589</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zqfX6Beqgvbe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,820</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNPS6ta9cobh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,415</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zwnEehXgygM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_ziFmjzeXaIE8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739499664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zbDY2sXtahjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10 &#8211; <span id="xdx_82C_ziWvXwKUMICl">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based on the
evaluation, the Company identified the following subsequent events:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 1, 2023, the Company executed a Summary of Terms and Conditions (&#8220;Consulting Agreement&#8221;) with Gene Johnston (&#8220;Johnston&#8221;)
continuing his appointment as the Company&#8217;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the
Consulting Agreement, the Company issued Johnston <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8RPkUwiI0A1" title="Stock issued during period, shares">50,000</span> shares of the Company&#8217;s common stock and $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmnIvU1NqbD2" title="Stock issued during period, value">2,000</span> per month. The Consulting
Shares were issued under, and subject to the terms of, the Company&#8217;s 2022 Equity Incentive Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (&#8220;Luca Consulting&#8221;), to provide management
consulting and business advisory services to the Company during the term of the agreement, which is for three months. In consideration
for agreeing to provide the services under the agreement, the Company agreed to pay Luca Consulting $<span id="xdx_902_eus-gaap--StockIssued1_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zktTsPvJJ1Oe" title="Stock value paid in cash">15,000</span> in cash and issued Luca Consulting
<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231010__20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zDwg78mazDLd" title="Stock issued during period, shares">200,000</span> shares of restricted common stock. The agreement contains customary confidentiality and non-circumvention provisions. The shares
were valued at $<span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zpnWL06zEUE4" title="Stock issued price per share">0.60</span> per share for a total of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231010__20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zjAe5Judgemg" title="Stock issued during period, value">120,000</span>.</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zjfDU99Gm5ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
11 &#8211; <span id="xdx_827_zKugN4RrnDm3">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#8220;DojoLabs&#8221;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $<span id="xdx_906_eus-gaap--Cash_iI_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfkarDNSR3e" title="Cash">100,000</span> in cash and issued DojoLabs <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zehfNDlvchA7" title="Shares issued">50,000</span> shares of restricted common
stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains
customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zc7P9lX814W2" title="Share price">0.28 </span>per share for a total of $<span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi0TAUs4eep9" title="Shares issued">28,000</span>.&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#8220;Bethor&#8221;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFCl17ukFpog" title="Shares issued">250,000</span> shares of restricted common stock with registration rights. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zppYM6bmdGej" title="Share price">0.28</span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVahsqXlL6td" title="Shares issued value">70,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 6, 2023, the Company established an advisory board (the &#8220;Advisory Board&#8221;) and approved and adopted a charter (the
&#8220;Advisory Board Charter&#8221;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#8217;s development of new business ventures
and strategic planning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#8220;Dr. Rudman&#8221;)
and Mr. Jarrett Boon (&#8220;Mr. Boon&#8221;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Dr. Rudman&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Dr. Rudman
Consulting Agreement&#8221;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuSIeLR0uNRg" title="Shares issued">25,000</span>
shares of the Company&#8217;s restricted common stock, pay Dr. Rudman $<span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4eaOkxvWtbh" title="Compensation expense">2,000</span> per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#8217;s requests
of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztmjmkuCsAY5" title="Share price">0.28 </span>per share for a total
of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE8gqTjmI6cd" title="Shares issued value">7,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Boon&#8217;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#8220;Mr. Boon
Consulting Agreement&#8221;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqb8t2R1Qfz" title="Shares issued">25,000</span> shares
of the Company&#8217;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#8217;s requests of the performance of his duties to the Company in service
on the Advisory Board. The shares were valued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztgMovpx7VGg" title="Share price">0.28</span> per share for a total of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBZpqGn9qTo8" title="Shares issued value">7,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, <span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zG9lE3BeRUqb" title="Settlement description">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</span> Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_z8k6d1Z6Atrc" title="Share price">0.28</span> per
share for a total of $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zJ1UXs6jWio8" title="Shares issued value">98,000</span>.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742242800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">GOING CONCERN</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zXZE06xa5Ecd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8 &#8211; <span id="xdx_822_z3uxcKQ3TfUl">GOING CONCERN</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization
of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying
financials, the Company had a net loss of $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zcoxvJv3YXU9" title="Net loss">1,998,055</span> for the year ended December 31, 2022 and an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zndTQMDnMS11" title="Accumulated deficit">2,015,756</span>
as of December 31, 2022. The Company will need to raise additional capital to successfully execute its business plan of which there can
be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable
terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital
moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to
abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless
management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during
the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742052080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z5WgiUatoOM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
10- <span id="xdx_82F_zwo6ZtOoQlA2">INCOME TAXES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the &#8220;Act&#8221;), which significantly changed U.S. tax law. The
Act lowered the Company&#8217;s U.S. statutory federal income tax rate from <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MaximumMember_zDLuHO10x811" title="Statutory federal income tax rate, percentage">35%</span> to <span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MinimumMember_zdxVJWDYZ5ae" title="Statutory federal income tax rate, percentage">21%</span> effective January 1, 2018, while also imposing
a deemed repatriation tax on previously deferred foreign income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Act also created a new minimum tax on certain future foreign earnings. The impact of the Act increases the Company&#8217;s deferred
tax asset related to the Company&#8217;s net operating loss by approximately $<span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_iI_c20221231_z1pBgVX4Hb4h" title="Deferred tax asset">2,015,756</span> and increase the Company&#8217;s valuation allowance
by approximately $<span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20221231_zxrFYRyzYCGb" title="Deferred tax assets, valuation allowance">2,015,756</span> resulting in no impact to the Company&#8217;s financials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
record tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgement changes as a result of
the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution
may result in a payment that is materially different from our current estimate of the recognized tax benefit liabilities. These differences
will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December
31, 2022, and 2021 we have not recorded any uncertain tax positions in our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The effective US federal income corporate
tax rates for 2022 and 2021 are <span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_z2qxRl9fPgQ2" title="US federal income corporate tax rates, percentage">21%</span> and <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zc85FSnSL1ze" title="US federal income corporate tax rates, percentage">21%</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has net operating loss carry forwards of approximately $<span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zh2hw1HavwYe" title="Net operating loss carry forwards">2,015,756</span> at December 31, 2022 that do not expire. However, utilization
of these losses may be limited pursuant to Section 382 of the Internal Revenue Code due to a recapitalization in 2007 and subsequent
stock issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSa12UH9nVQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a deferred tax asset as shown in the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z3T4mU5qsMo6" style="display: none">SCHEDULE
OF DEFERRED TAX ASSET</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zFmT8XeCbYih" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zEZCNnucIaIl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_zdU2QVNyj0Wl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Deferred Tax Asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,015,756</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">17,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_zHsUZFtj0wx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,015,756</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,701</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_z0L3lNNFcJSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2222">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zhlhlBzKEiJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329732763408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Preparation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoM89gSRtiC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_z4InLRg3CQJ3">Basis
of Preparation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#8220;U.S. GAAP&#8221;) under the accrual basis of accounting. These financial statements are presented in
U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The
accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto
for the years ended December 31, 2022 and 2021 included in the Company&#8217;s Registration Statement on Form S-1 (Amendment No. 4),
filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2023 (the &#8220;Form S-1&#8221;). In the opinion
of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position
and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim
periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the Form S-1 have been omitted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zl0LWu022Ftb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Basis
of Presentation</span> &#8211; </b>The financial statements present the financial position, results of operations and cash flows of the Company
in accordance with accounting principles generally accepted in the United States of America (&#8220;US GAAP&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_865_zMLgBDKVUJv9" style="display: none">Basis
of Preparation</span></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zt74Z5NYOB02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z5f5eUmEVx45">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority
of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insures a total cash balance
of up to $<span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zCJdFQyH08v8" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits and the excess would be
at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_z8gGFZgDUiMg" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8YyU761TWmg" title="Cash equivalents">no</span></span> cash equivalents at September 30, 2023 and December 31, 2022
and the Company has not experienced any losses related to uninsured deposits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqGvzgcRejG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zDDDltW6eFD7">Cash
Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the
majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insures
the total cash balance up to $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zSUbtzyJPKW2" title="Cash, FDIC insured amount">250,000</span> per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, and
the excess would be at risk of loss for purposes of the statement of cash flows. There are <span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8qdOIxSTQ1b" title="Cash equivalents"><span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zXGLVpdMLuI5" title="Cash equivalents">no</span></span> cash equivalents at December 31, 2022
 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zeL0KlYdTD41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zJCvRNouYZcd">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;)
740, <i>Income Taxes</i>. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the
temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income
in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount
that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zmEN3HlOgpE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z2IJvFQC74Vg">Income
Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (&#8220;ASC&#8221;)
740, <i>Income Taxes</i> (&#8220;ASC 740&#8221;). Deferred tax assets and liabilities are measured using enacted tax rates
expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in
tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce
deferred tax assets to the amount that is more likely than not to be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPyf1Znyl1L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zUdGq2W2Elxi">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net loss per share in accordance with ASC 260, <i>Earning per Share</i>. ASC 260 requires presentation of both basic and diluted
earnings per share (&#8220;EPS&#8221;) on the face of the statement of operations. Basic EPS is computed by dividing net loss available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. For diluted net loss per share purposes, the Company
excludes stock options and other stock-based awards, including shares issued as a result of option and warrant exercises, whose effect
would be anti-dilutive, from the calculation. There were <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zj4qWpLuazEl" title="Anti-dilutive securities">1,400,000</span> and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zswAe54AWVKl" title="Anti-dilutive securities">1,250,000</span> options, <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5mOXkQDoyXd" title="Anti-dilutive securities">1,063,000</span> and <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPsAaRYHEyLe" title="Anti-dilutive securities">2,000,000</span> warrants and no derivative
securities outstanding as of September 30, 2023 and December 31, 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zigppskZO7Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zrGxXkGjTFR5">Net
Loss Per Common Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
compute net loss per share in accordance with ASC 260, <i>Earnings</i><i> per Share</i> (&#8220;ASC 260&#8221;). ASC 260
requires presentation of both basic and diluted earnings per share (&#8220;EPS&#8221;) on the face of the statement of operations.
Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares
outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the
period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average
stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or
warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zgaEi1peE4Oa" title="Anti-dilutive securities">1,250,000</span> options, <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5Nko9cSctB2" title="Anti-dilutive securities">2,000,000</span>
warrants and no derivative securities outstanding as of December 31, 2022. These were excluded because their effect would be anti-dilutive.
There were no options, warrants nor derivative securities outstanding as of December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zVFAYw6EG7ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zGVKYnO6DQV2">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will,
differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84C_eus-gaap--UseOfEstimates_zy6JJ1GbZep8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zMrRStIaDkw9">Use
of Estimates and Assumptions</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in accordance with US GAAP requires the Company&#8217;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases
will, differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvGsztSKuih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zEocmiercZQj">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, <i>Fair Value Measurement</i>, which provides guidance with respect to valuation techniques to be utilized in the determination
of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach
(present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement
cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three
broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&#160;&#160;</span></p>

<p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGc2F4ugj03e">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">22,550</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zQlxyzjNg5Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zsPUu87JF5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zbSpYL66boT6">Fair
Value of Financial Instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, <i>Fair Value Measurement</i>, which provides guidance with respect to valuation techniques to be utilized
in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices),
(ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity
of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value into three broad levels. The following is a brief description of those three levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zv48K9wbXr23">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1734">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1735">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1739">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">22,550</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1750">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1758">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zMubUzvLqyDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSQun2tac6T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zL77S0uwFqaj">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zv5AdiU3SWYi" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zOzywZjQtBke" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3zdvDvfpKUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zMy6APj0VJa4">Property
and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember_zuZALQuxDMSb" title="Property plant and equipment estimated useful lives">3</span>) to five (<span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember_zfeWc2DTshNi" title="Property plant and equipment estimated useful lives">5</span>) years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration and Risks</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zc4QLMcybnDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zXyxnK0PyS9b">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had
no significant revenue from continuing operations which were derived from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zExz47PoCRSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zNH1coZdeGv2">Concentration
and Risks</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing
operations which were derived from a single or a few major customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Black Scholes Option Pricing Model</a></td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmn4mCXQx4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zXaQfJUDULfh">Black
Scholes Option Pricing Model</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQJ9Su7Xbslf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>Binomial
Calculation Model</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_86E_zp5CMlYlnvY2" style="display: none">Black
Scholes Option Pricing Model</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVvKL7gtheDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zQSvLXfN6N13">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211;
40)</span>&#8221;</i>. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBASBHZEgpnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zjdxtEXNx2nl">Recently
Issued Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2020-06, <i>&#8220;<span style="text-decoration: underline">Debt &#8211; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8211;
40)</span></i>. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#8217;s own equity. The ASU is part of the FASB&#8217;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#8217;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_RelatedPartiesPolicyTextBlock', window );">Related Parties</a></td>
<td class="text"><p id="xdx_84B_ecustom--RelatedPartiesPolicyTextBlock_ztEzXVMCZP7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zNTKqI17OSA1">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of FASB ASC 850, <i>Related Party Disclosures</i> for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825&#8211;10&#8211;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
<td class="text"><p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zp2aZa5mM4Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zTwHksa6PKd4">Related
Parties</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure
of related party transactions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section
825&#8211;10&#8211;15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such
as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company;
e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the
management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing
its own separate interests; and g. other parties that can significantly influence the management or operating policies of the
transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to
an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zGcnex4hEIPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLP4fB0Ithn9">Stock-Based
Compensation</span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB ASC 718 <i>Compensation - Stock Compensation</i> (&#8220;ASC 718&#8221;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zI8Z0VOgvfCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zv0yc8j1B8m1">Stock-Based
Compensation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (&#8220;ASC 718&#8221;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zq6kwL7zRzYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zVuB9u7zNZ3g">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our
websites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated
through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The
transaction price in the Company&#8217;s contracts with customers is the total amount of consideration to which the Company expects to
be entitled in exchange for transferring products or services to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#8217;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#8217;s completion of its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (&#8220;Doctegrity&#8221;) to provide online
telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii)
the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs
for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its
sole discretion, sets all listed prices charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (&#8220;Contracted Pharmacy&#8221;),
which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts
that include sale of prescription products and to fill prescriptions that are ordered by the Company&#8217;s customers for fulfillment
through the Company&#8217;s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer&#8217;s
prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using
the Company&#8217;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites
for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zxwhSaUY1Uak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_z4IJ12cfj9Kh">Revenue
Recognition</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue
is generated by selling directly to consumers through our websites.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through
websites. The transaction price in the Company&#8217;s contracts with customers is the total amount of consideration to which the Company
expects to be entitled in exchange for transferring products or services to the customer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#8217;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#8217;s completion of its performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has entered into a Physician Services Agreement with BrighterMD, LLC &#160;&#160;dba Doctegrity (&#8220;Doctegrity&#8221;) to
provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer;
(ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs
costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company,
at its sole discretion, sets all listed prices charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq &#160;&#160;Scripts, LLC (&#8220;Contracted
Pharmacy&#8221;), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers
for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company&#8217;s customers
for fulfillment through the Company&#8217;s websites. The Company accounts for prescription product revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills
a customer&#8217;s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company,
including using the Company&#8217;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer
for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices
charged on its websites for products and services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_z2OaZ4CAzi51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zHrWce5thqYb">Inventories</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are stated at the lower of cost or market with cost being determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. The Company writes down its
inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated
market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those
projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Marketing and advertising</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zN9k9dblTWd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z6n4niJJiHS4">Marketing
and advertising</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations
$<span id="xdx_904_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230930_zH0FTQGqUCal" title="Marketing and advertising expense">1,633,528</span> and $<span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220930_zlmyhEi4oUcc" title="Marketing and advertising expense">0</span> for the nine months ended September 30, 2023 and 2022. We did not begin advertising until November 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent events</a></td>
<td class="text"><p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zkZnNZ0OtbVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zuSVPpc9WSU7">Subsequent
events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent events.
The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 10).</span></p>

<span></span>
</td>
<td class="text"><p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zG5ilX5YTyog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zNwo7LFpL7P1">Subsequent
events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, <i>Subsequent Events</i>, for the disclosure of subsequent
events. The Company will evaluate subsequent events through the date when the financial statements were issued.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_RelatedPartiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_RelatedPartiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742057648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zGc2F4ugj03e">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0631">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0634">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0635">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0637">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0638">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0639">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0643">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">22,550</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0647">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0651">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0653">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0658">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0659">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BB_zv48K9wbXr23">SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">682,860</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1734">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1735">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">682,860</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1738">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1739">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1741">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1742">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1743">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">682,860</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1746">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1747">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">Fair Value Measurements at December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 1</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 2</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Level 3</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; padding-bottom: 1.5pt">Cash</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right">22,550</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1750">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1751">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1755">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1757">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1758">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1759">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value, net asset
    (liability)</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,550</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1762">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1763">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742256016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zonsr7B2iWOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BA_zusoPAkZbQZ" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20230930_zO69tluKu5nh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, <br/>
2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20221231_zobx2ETRm9G" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, <br/>
2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zVsot07MGY0d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zkhBR20if40i" style="vertical-align: bottom; background-color: White">
    <td>Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">119,819</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,300</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zs0GDdoo2Nsb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less accumulated depreciation:</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22,461</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,863</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zbu3rt5Ghehe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">102,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">117,499</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxyIOXSUtr3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zcYYUSYfHjej" style="display: none">SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20221231_zesVQFOY5otk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center">December 31, 2022</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20211231_zUSb9ScIwbq5" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center">December 31, 2021</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_z6V6muUREk9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Computers</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">5,062</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1810">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zdDH7zmJQxJi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">116,300</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1813">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNR0W1yiGpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation:</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,863</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1816">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z81M7spwxWZh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">117,499</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1819">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329732731888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyi1rsR2Htf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock options activity: The following table summarizes common stock options activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B7_zlnCXFgqu0eg" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average<br/> Exercise Price</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znhH9QhV8Jz9" style="text-align: right" title="Options, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1101">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zeKHtmvQD3p8" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1103">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zHSc0soTBJ65" style="width: 16%; text-align: right" title="Options, Granted">1,250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zSj0pmVHzf72" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z4M1W5clqAig" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zWw9zwFbNmu4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1111">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zLbeTZscYov8" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1113">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zikBFPG16421" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1115">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhddE771qBg8" style="text-align: right" title="Options, Outstanding Ending Balance">1,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zzpqysnH1Wqk" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z1MP2jF4AFQ7" style="text-align: right" title="Options, Exercisable Ending Balance">133,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zHFZEa6PWQll" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zf1atKcT80X9" style="text-align: right" title="Options, Outstanding Beginning Balance">1,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20230930_zyW2d14wPidh" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_z3Ptx0XNd0V5" style="text-align: right" title="Options, Granted">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zZFpnFBVW2fg" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zWOR2HFj1J1a" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1133">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_z14JGxLafKJ7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1135">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230930_zrXwuRePGnI" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1137">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zLEIlWnHh8m1" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1139">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_z6pDRX1w20Mh" style="text-align: right" title="Options, Outstanding Ending Balance">1,400,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_z6aTTMyvay9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zfOYJOY5k1o2" style="text-align: right" title="Options, Exercisable Ending Balance">454,167</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zNfU28RYePX6" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Outstanding Options</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Exercisable Options</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options Exercise<br/> Price Per <br/> Share</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Life <br/> (Years)</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average <br/> Exercise Price</b></span></p></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Shares</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average <br/> Exercise Price</b></span></p></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20230101__20230930_zpfuwp5dq2B8" style="width: 13%; text-align: right" title="Option Exercise Price Per Share">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zhhNJGX7130k" style="width: 13%; text-align: right" title="Outstanding Ending Balance">1,400,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z05q5jUmYmX" title="Options Term">4.53</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zjS2Z9bdup3h" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zymTshplVVMd" style="width: 13%; text-align: right" title="Exercisable Ending Balance">454,167</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zv4uyDEuL4I3" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFQ9mTYd1mUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock options activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zmxzQdBkkpvk" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfv0MGxuIbe1" style="text-align: right" title="Options, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2035">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zN8BW6OCny14" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2037">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zSrPSGHbvuW6" style="width: 16%; text-align: right" title="Options, Granted">1,250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zuBdwVacSAI" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zbQF8cnMfUL5" style="text-align: right" title="Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2043">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zOakZRnLunH3" style="text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2045">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zBJnFiZ6IWM6" style="text-align: right" title="Options, Expired"><span style="-sec-ix-hidden: xdx2ixbrl2047">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_z6HBjICtft8i" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl2049">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zAtz53k6Gd2b" style="text-align: right" title="Options, Outstanding Ending Balance">1,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zwebE1QXQ4dl" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zJB1Cha6VH4i" style="text-align: right" title="Options, Exercisable Ending Balance">133,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zMZVhPWnSnfd" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance">1.10</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercisable Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Years)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20220101__20221231_zQn5skYMKtj4" style="width: 13%; text-align: right" title="Option Exercise Price Per Share">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zUvzjHEQCMk1" style="width: 13%; text-align: right" title="Outstanding Ending Balance">1,250,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zu3Ihh8EzdLb" title="Options Term">4.67</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zdfZrNcJrmyk" style="width: 13%; text-align: right" title="Weighted Average Outstanding Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zyn2TAT3PEOa" style="width: 13%; text-align: right" title="Exercisable Ending Balance">133,333</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zIvM10tSOKHc" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance">1.10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEuwjyXnOBz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B6_zIZVbbHJx3N5" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 68%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930_zvk6SeZs4NWb" style="width: 20%; text-align: right" title="Fair value of common stock on measurement date">1.00</td><td style="width: 1%; text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z5rM1yKNJIo1" title="Risk-free interest rate">3.64</span>% - <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_z0slP4fXaPnb" title="Risk-free interest rate">3.30</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zZ0HuAO9GC46" title="Volatility">224.70</span>% <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdfCWyRnImbd" title="Volatility">92.54</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zCUiNUvFDl07" title="Dividend yield">0</span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zktdNJwouND1" title="Expected term">6.0</span> - <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zxy0hr7KDDEd" title="Expected term">3.5</span></span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, in accordance with staff accounting bulletin (&#8220;SAB&#8221;)14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term</span></td></tr>
  </table>
<span></span>
</td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQ6JxRHlI772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B1_znVgFVy2pF38" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></span></span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">Fair Value of Common Stock on measurement date</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231_zzL2TOKhG9N6" style="width: 14%; text-align: right" title="Fair value of common stock on measurement date">1.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zvOrrmtjR2d2" title="Risk-free interest rate">3.30</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zQ460uEm9Xr8" title="Volatility">92.54</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zVlmAjG216zl" title="Dividend yield">0</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zqyrWwP8FWi8" title="Expected term">3.5</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zBNhKo7fwRy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock warrant activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zEBdMiAKxqZg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average<br/> Exercise Price</b></span></p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoh8dvznIjJh" style="text-align: right" title="Warrants Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1203">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmdzcqHQyni8" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl1205">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQGTuc1YVqmj" style="width: 14%; text-align: right" title="Warrants Granted">2,210,070</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTncY7ZGcOz8" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDh1G5xiXu03" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFtBIZm2jSx5" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1213">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoJUZp1hIQyg" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1215">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDGC8QqIw544" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJL28tJgdRc" style="text-align: right" title="Warrants Cancelled">(210,070</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCJmbrIdijk" style="text-align: right" title="Weighted Average Exercise Price Cancelled">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8iRJOGpHFzl" style="text-align: right" title="Warrants Outstanding, Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSV2VZbyu11" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDzgqgo7B9Y6" style="text-align: right" title="Warrants Exercisable Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRg934nPAxXd" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCDjEPEqNrI3" style="text-align: right" title="Warrants Granted">87,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL93hfP3zhW1" style="text-align: right" title="Weighted Average Exercise Price Granted">5.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp61h1Zmertg" style="text-align: right" title="Warrants Exercised">(1,024,500</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM16wPuNZt8e" style="text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN6LGRvfip1b" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1239">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsW6qE1SHTq2" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1241">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWwmwXM0Kpu1" style="text-align: right" title="Warrants Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgfUfOllZdyc" style="text-align: right" title="Weighted Average Exercise Price Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1245">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQwkEgQUqG2b" style="text-align: right" title="Warrants Outstanding, Ending balance">1,063,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZs1OBoLSK21" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.30</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercisable, September 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQtwYXbBSpd" style="text-align: right" title="Warrants Exercisable Ending balance">975,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2OvWN19gtlc" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Vested Warrants</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Warrant Exercise Price Per Share</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life (Years)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY3FElUSndtl" style="width: 30%; text-align: right" title="Weighted Average Exercise Price Exercised">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zviqeeycKM92" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance">1,063,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTDFcVl5jPIb" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term">3.83</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpi7F1Mp7Dh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes common stock warrants activity:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zJk73NNH3RBb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
OF WARRANT ACTIVITY</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise Price</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Outstanding, December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRbHK54XpMg3" style="text-align: right" title="Warrants Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2097">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNejRM6N0fXb" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"><span style="-sec-ix-hidden: xdx2ixbrl2099">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%">Granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRNn5P0enlGa" style="width: 16%; text-align: right" title="Warrants Granted">2,210,070</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3T9LPDWwQ7" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Granted">1.00</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeTliNAnLnFe" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2105">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z67sIyNRrFuh" style="text-align: right" title="Weighted Average Exercise Price Exercised"><span style="-sec-ix-hidden: xdx2ixbrl2107">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjJpCUAI8I" style="text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl2109">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9T2GOhGthRe" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl2111">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdbvENdkeMie" style="text-align: right" title="Warrants Cancelled">(210,070</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znNCowjp1Ai9" style="text-align: right" title="Weighted Average Exercise Price Cancelled">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6iIASFSpjb" style="text-align: right" title="Warrants Outstanding, Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMtyggziK6hd" style="text-align: right" title="Weighted Average Exercise Price Ending Balance">1.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercisable, December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3NLjhjGSxYi" style="text-align: right" title="Warrants Exercisable Ending balance">2,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoH9R2qqvG4b" style="text-align: right" title="Weighted Average Exercise Price Exercisable price">1.00</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants Exercise</b></span></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding and Exercisable Warrants</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price Per Share</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Life
                                                                                 (Years)</b></span></p></td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeQNSF8rmD2" style="width: 30%; text-align: right" title="Warrants Exercise Price Per Share">1.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8g7Mdt9ysue" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance">2,000,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthrO8mkf6n2" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term">4.74</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF FAIR VALUE ASSUMPTIONS</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXniw0lhn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BB_zmc19E8WnEi5" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHbH2bsAL481" title="Fair value of common stock on measurement date">0.37</span> - $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zqA4XUr2W09l" title="Fair value of common stock on measurement date">0.72</span></span></td><td style="text-align: left">&#160;</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFJjnXUMlQ4" title="Risk-free interest rate">2.95</span>% to <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zhOsdSKWfmak" title="Risk-free interest rate">4.00</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaz6PgL5z1Ff" title="Volatility">88.92</span>% to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAIYLYlD3Awd" title="Volatility">92.87</span></span></td><td style="text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcbCSHkmB32" title="Dividend rate">0</span></td><td style="width: 1%; text-align: left">%</td>
    </tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrGkHub8P62" title="Expected term">5</span> years</span></td><td style="text-align: left">&#160;</td>
    </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  </table>
<span></span>
</td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPEGDsUf92i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BC_z9wemA891r8" style="display: none">SCHEDULE
OF FAIR VALUE ASSUMPTIONS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fair Value of Common Stock on measurement date</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWISYOmTNbL4" title="Fair value of common stock on measurement date">0.62</span> - $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztJTTO9yhpG2" title="Fair value of common stock on measurement date">0.72</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS1lvbebtna7" title="Risk-free interest rate">2.95%</span> to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjd88JF9Jki5" title="Risk-free interest rate">4.00</span></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS2mSedIdXn4" title="Volatility">88.92%</span> to <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSqQ4I40eb71" title="Volatility">92.87%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 76%; text-align: left">Dividend Yield</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDOCefVqkoc" title="Dividend rate">0%</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected Term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA55nUZLTbL6" title="Expected term">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not expect to pay a dividend in the foreseeable future.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329831888048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITY OF LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zfxAqQM2PIij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zswRigTIq3uh" style="display: none">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Maturity of Lease Liabilities at September 30, 2023</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zDWWLFhDsfTk" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 82%; text-align: justify">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_ma1_c20230930_zTpIGPR0wXn6" style="width: 14%; text-align: right" title="Remainder of Fiscal Year">17,516</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_ma1_c20230930_zmD2YYkVOW4h" style="text-align: right" title="Year One">71,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">2025</td><td>&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_ma1_c20230930_zC43oirSPia" style="padding-bottom: 1.5pt; text-align: right" title="Year Two">67,589</td><td style="text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pp0p0_ma1_c20230930_z0JCCsLn33E7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Year Three"><span style="-sec-ix-hidden: xdx2ixbrl1322">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mt1_c20230930_ztEXhojbu4k3" style="text-align: right" title="Total lease payments">156,821</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zGqopNm9d9W5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: justify">Less: Imputed interest</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,397</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zJjgVhWwhBbg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: justify">Present value of lease liabilities</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">143,424</td><td style="text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
<td class="text"><p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv51npV57e2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zSOjxkum5cj" style="display: none">SCHEDULE
OF MATURITY OF LEASE LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Maturity of Lease Liabilities at December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20221231_z8jP4j647OH3" style="border-bottom: Black 1.5pt solid; text-align: center">Amount</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 80%; text-align: left">2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20221231_pp0p0" style="width: 16%; text-align: right" title="Year One">69,515</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20221231_pp0p0" style="text-align: right" title="Year Two">71,716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_c20221231_pp0p0" style="text-align: right" title="Year Three">67,589</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zqfX6Beqgvbe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">208,820</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNPS6ta9cobh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23,415</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zwnEehXgygM4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Present value of lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">185,405</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329742349824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF DEFERRED TAX ASSET</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSa12UH9nVQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has a deferred tax asset as shown in the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_z3T4mU5qsMo6" style="display: none">SCHEDULE
OF DEFERRED TAX ASSET</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20221231_zFmT8XeCbYih" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2022</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49D_20211231_zEZCNnucIaIl" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Year Ending December 31,</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">2021</p></td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_zdU2QVNyj0Wl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Deferred Tax Asset</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">2,015,756</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">17,701</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_zHsUZFtj0wx6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Valuation Allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,015,756</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,701</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_z0L3lNNFcJSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net Deferred Tax Asset</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2221">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2222">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329735443232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 08, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  07,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  07,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,500,500<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_ResaleProspectusMember', window );">Resale Prospectus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_ResaleProspectusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_ResaleProspectusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739431824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash</a></td>
<td class="nump">$ 682,860<span></span>
</td>
<td class="nump">$ 22,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">682,860<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="nump">682,860<span></span>
</td>
<td class="nump">22,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, net asset (liability)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739524848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Marketing and advertising expense</a></td>
<td class="nump">$ 1,633,528<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property plant and equipment estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MGRX_OptionsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MGRX_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=MGRX_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329735615600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND DEPOSITS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_PrepaidExpensesRelatedParty', window );">Prepaid expenses related party</a></td>
<td class="nump">$ 11,745<span></span>
</td>
<td class="nump">$ 84,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Securtiy deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_MasterServicesAgreementMember', window );">Master Services Agreement [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Prepaid the related party expense</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_PrepaidExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_PrepaidExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_MasterServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_MasterServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739297088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 21,581<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329738974912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation:</a></td>
<td class="num">$ (22,461)<span></span>
</td>
<td class="num">$ (3,863)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">102,420<span></span>
</td>
<td class="nump">117,499<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MGRX_ComputersMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">5,062<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Equipment</a></td>
<td class="nump">$ 119,819<span></span>
</td>
<td class="nump">$ 116,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=MGRX_ComputersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=MGRX_ComputersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329735428832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Property acquired value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,519<span></span>
</td>
<td class="nump">$ 2,531<span></span>
</td>
<td class="nump">$ 43,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property plant and equipment net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 102,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Property acquired value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329735802432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 18, 2022</div></th>
<th class="th"><div>Jun. 29, 2022</div></th>
<th class="th"><div>Jun. 16, 2022</div></th>
<th class="th"><div>Mar. 18, 2022</div></th>
<th class="th"><div>Dec. 10, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,500,500<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">89,200<span></span>
</td>
<td class="nump">25,070<span></span>
</td>
<td class="nump">25,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=MGRX_JacobDCohenMember', window );">Jacob D Cohen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MGRX_CohenEnterprisesIncMember', window );">Cohen Enterprises Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MGRX_CohenEnterprisesIncMember', window );">Cohen Enterprises Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party advances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,200<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_InterestExpenseRelatedPartyPercentage', window );">Imputed interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Related party transaction purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,674<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MGRX_ZipDoctorIncMember', window );">Zip Doctor Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party advances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_InterestExpenseRelatedPartyPercentage', window );">Imputed interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Related party transaction purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Related party advances received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_InterestExpenseRelatedPartyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_InterestExpenseRelatedPartyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_JacobDCohenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_JacobDCohenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MGRX_CohenEnterprisesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=MGRX_CohenEnterprisesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MGRX_CohenEnterprisesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MGRX_CohenEnterprisesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MGRX_ZipDoctorIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=MGRX_ZipDoctorIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739530736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 18, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument periodic payment</a></td>
<td class="nump">$ 31,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,260<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739537664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding Beginning Balance</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding Ending Balance</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Outstanding Price Ending Balance</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable Ending Balance</a></td>
<td class="nump">454,167<span></span>
</td>
<td class="nump">133,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercisable Price Ending Balance</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Option Exercise Price Per Share</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Term</a></td>
<td class="text">4 years 6 months 10 days<span></span>
</td>
<td class="text">4 years 8 months 1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329738703904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock on measurement date</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">224.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock on measurement date</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">92.87%<span></span>
</td>
<td class="nump">92.87%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">92.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock on measurement date</a></td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 0.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">88.92%<span></span>
</td>
<td class="nump">88.92%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329739411296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Beginning Balance</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Beginning Balance</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrants Granted</a></td>
<td class="nump">87,500<span></span>
</td>
<td class="nump">2,210,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Warrants Exercised</a></td>
<td class="num">(1,024,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Warrants Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(210,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants Outstanding, Ending balance</a></td>
<td class="nump">1,063,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Ending Balance</a></td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber', window );">Warrants Exercisable Ending balance</a></td>
<td class="nump">975,500<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber', window );">Outstanding and Vested Warrants Ending balance</a></td>
<td class="nump">$ 1,063,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm', window );">Outstanding and Vested Warrants Expected Term</a></td>
<td class="text">3 years 9 months 29 days<span></span>
</td>
<td class="text">4 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue', window );">Warrants Exercise Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329617660768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 27, 2023</div></th>
<th class="th"><div>Jun. 22, 2023</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Jun. 08, 2023</div></th>
<th class="th"><div>Jun. 07, 2023</div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
<th class="th"><div>Jun. 01, 2023</div></th>
<th class="th"><div>May 25, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Apr. 26, 2023</div></th>
<th class="th"><div>Apr. 25, 2023</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
<th class="th"><div>Apr. 01, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Feb. 01, 2023</div></th>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Jan. 06, 2023</div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 21, 2022</div></th>
<th class="th"><div>Dec. 09, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Oct. 14, 2022</div></th>
<th class="th"><div>Oct. 13, 2022</div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Sep. 06, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
<th class="th"><div>Jun. 23, 2022</div></th>
<th class="th"><div>Apr. 06, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,789,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">13,365,000<span></span>
</td>
<td class="nump">16,789,500<span></span>
</td>
<td class="nump">13,365,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,789,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">13,365,000<span></span>
</td>
<td class="nump">16,789,500<span></span>
</td>
<td class="nump">13,365,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,500,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,438,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,750<span></span>
</td>
<td class="nump">$ 387,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,954<span></span>
</td>
<td class="nump">$ 82,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Fair value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,984<span></span>
</td>
<td class="nump">640,194<span></span>
</td>
<td class="nump">$ 688,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Fair value of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 581,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,438,299<span></span>
</td>
<td class="nump">581,264<span></span>
</td>
<td class="nump">1,438,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ServiceAgreementMember', window );">Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,842<span></span>
</td>
<td class="nump">$ 27,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,500,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,365,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Twenty Twenty Two Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,063,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm', window );">Outstanding and vested warrants expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 29 days<span></span>
</td>
<td class="text">4 years 8 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=MGRX_HammerMember', window );">Hammer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share based compensation arrangement by share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Employment Agreement also required the Company to grant Mrs. Hammer
a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase
an additional 150,000 shares of common stock of the Company, under the Company&#8217;s 2022 Equity Incentive Plan (the &#8220;Plan&#8221;),
with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company&#8217;s common stock on
the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and
which exercise price was $1.00 per share, with options to purchase 50,000 shares vesting every twelve months that the Employment Agreement
is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate
option agreement entered into by the Company and Mrs. Hammer.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Common Stock [Member] | Twenty Twenty Two Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer [Member] | Common Stock [Member] | Twenty Twenty Two Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MGRX_GreentreeFinancialGroupMember', window );">Greentree Financial Group [Member] | Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MGRX_CharteredServicesLLCMember', window );">Chartered Services L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Proceeds from investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Chief Operating Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Leov Law Firm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | David Sandler [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Hsiaoching Chou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Chief Financial Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock issued net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Director [Member] | Twenty Twenty Two Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Joan Arango [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Joan Arango [Member] | Twenty Twenty Two Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Rudman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Rudman [Member] | Advisor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Boon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Boon [Member] | Advisor Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Mr Andrew [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Mr Andrew [Member] | Twenty Twenty Two Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Major Dodge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Major Dodge [Member] | Twenty Twenty Two Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | P H X Global L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Ezekiel Elliott [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Greentree Financial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023<span></span>
</td>
<td class="text">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Greentree Financial Group [Member] | Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before
March 31, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Greentree Financial Group [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | White Unicorn L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Global Career Networks Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Chartered Services L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Dojo Labs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Dojo Labs [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Bethor Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Bethor Ltd [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Street Group L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantOneMember', window );">Private Placement Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantTwoMember', window );">Private Placement Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantThreeMember', window );">Private Placement Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantFourMember', window );">Private Placement Warrant Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantFiveMember', window );">Private Placement Warrant Five [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantSixMember', window );">Private Placement Warrant Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantSevenMember', window );">Private Placement Warrant Seven [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantMember', window );">Private Placement Warrant [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MGRX_TwentyTwentyTwoPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MGRX_TwentyTwentyTwoPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_HammerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_HammerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_GreentreeFinancialGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_GreentreeFinancialGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_CharteredServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_CharteredServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_LeovLawFirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_LeovLawFirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_DavidSandlerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_DavidSandlerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_HsiaochingChouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_HsiaochingChouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=MGRX_TwentyTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=MGRX_TwentyTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_JoanArangoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_JoanArangoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_RudmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_RudmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_AdvisorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_AdvisorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_BoonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_BoonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_MrAndrewMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_MrAndrewMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_MajorDodgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_MajorDodgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_PHXGlobalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_PHXGlobalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_EzekielElliottMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_EzekielElliottMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_WhiteUnicornLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_WhiteUnicornLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_GlobalCareerNetworksIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_GlobalCareerNetworksIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_DojoLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_DojoLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_BethorLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_BethorLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_StreetGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_StreetGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=MGRX_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329743401696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of Fiscal Year</a></td>
<td class="nump">$ 17,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year One</a></td>
<td class="nump">71,716<span></span>
</td>
<td class="nump">$ 69,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year Two</a></td>
<td class="nump">67,589<span></span>
</td>
<td class="nump">71,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">Year Three</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">67,589<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">156,821<span></span>
</td>
<td class="nump">208,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(13,397)<span></span>
</td>
<td class="num">(23,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 143,424<span></span>
</td>
<td class="nump">$ 185,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329740670272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land | ft&#178;</a></td>
<td class="nump">2,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">The Lease
Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,777.63, or $31.50 per square foot, from months 3-18,
which increases at the rate of $1 per square foot per annum thereafter until the end of the lease term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term</a></td>
<td class="text">38 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Base rent</a></td>
<td class="nump">$ 5,777.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_PercentageOfProportionateRent', window );">Percentage of proportionate rent</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_MGRX_PercentageOfIncrementalBorrowingRate', window );">Percentage of incremental borrowing rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use of asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 133,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,241<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,826<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease, description</a></td>
<td class="text">The Lease
Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,778, or $31.50 per square foot, for the from months
3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Base rent</a></td>
<td class="nump">$ 16,941.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_PercentageOfIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_PercentageOfIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_MGRX_PercentageOfProportionateRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">MGRX_PercentageOfProportionateRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>MGRX_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329740035504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 10, 2023</div></th>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Jan. 06, 2023</div></th>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,500,500<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Rudman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Boon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MGRX_DojoLabsMember', window );">Dojo Labs [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=MGRX_BethorLtdMember', window );">Bethor Ltd [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Dojo Labs [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Bethor Ltd [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Subsequent Event [Member] | Luca Consulting Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Stock value paid in cash</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember', window );">Consulting Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember', window );">Consulting Agreements [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Settlement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#8217;s successful launch of a new product category, and 50,000 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#8217;s successful launch of a new product category, and 7,500 shares upon the Company&#8217;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_RudmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_RudmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=MGRX_BoonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=MGRX_BoonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_DojoLabsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_DojoLabsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_BethorLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_BethorLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=MGRX_LucaConsultingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=MGRX_LucaConsultingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=MGRX_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329740647072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOING CONCERN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 1,799,460<span></span>
</td>
<td class="nump">$ 2,284,025<span></span>
</td>
<td class="nump">$ 2,560,885<span></span>
</td>
<td class="nump">$ 994,915<span></span>
</td>
<td class="nump">$ 310,185<span></span>
</td>
<td class="nump">$ 19,599<span></span>
</td>
<td class="nump">$ 17,701<span></span>
</td>
<td class="nump">$ 6,644,370<span></span>
</td>
<td class="nump">$ 1,324,400<span></span>
</td>
<td class="nump">$ 1,998,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 8,660,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,701<span></span>
</td>
<td class="nump">$ 8,660,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,015,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329743682448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF DEFERRED TAX ASSET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred Tax Asset</a></td>
<td class="nump">$ 2,015,756<span></span>
</td>
<td class="nump">$ 17,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(2,015,756)<span></span>
</td>
<td class="num">(17,701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net Deferred Tax Asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140329743363152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,015,756<span></span>
</td>
<td class="nump">$ 17,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,015,756<span></span>
</td>
<td class="nump">$ 17,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">US federal income corporate tax rates, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,015,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate, percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems', window );"><strong>Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>formposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:MGRX="http://mangorx.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="mgrx-20230930.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-072021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2021-10-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-10-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="AsOf2021-10-06_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="AsOf2021-10-06_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="AsOf2021-10-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-10-072021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-02-282023-03-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-02-282023-03-31_custom_ResaleProspectusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:ResaleProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ResaleProspectusMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:ResaleProspectusMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MGRX:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">MGRX:OptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MasterServicesAgreementMember_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:MasterServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ComputersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MGRX:ComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ComputersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MGRX:ComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_ComputersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">MGRX:ComputersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-12-102021-12-10_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-10</startDate>
            <endDate>2021-12-10</endDate>
        </period>
    </context>
    <context id="From2022-03-182022-03-18_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-18</startDate>
            <endDate>2022-03-18</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-16_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-16</instant>
        </period>
    </context>
    <context id="From2022-06-152022-06-16_custom_StockPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-15</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="From2022-06-282022-06-29_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-28</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="From2022-08-172022-08-18_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2021-12-102021-12-10_custom_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-10</startDate>
            <endDate>2021-12-10</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_CohenEnterprisesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:CohenEnterprisesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_custom_ZipDoctorIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">MGRX:ZipDoctorIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_JacobDCohenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JacobDCohenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-11-18</instant>
        </period>
    </context>
    <context id="From2023-01-012023-01-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="From2023-02-012023-02-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-01</endDate>
        </period>
    </context>
    <context id="From2023-03-012023-03-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-01</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="From2023-03-232023-03-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-03-23</startDate>
            <endDate>2023-03-23</endDate>
        </period>
    </context>
    <context id="From2022-08-082022-08-08_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="From2022-08-082022-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <context id="From2022-08-082022-08-08_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-08</endDate>
        </period>
    </context>
    <context id="From2022-08-162022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:PHXGlobalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-06</startDate>
            <endDate>2022-09-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:PHXGlobalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-06</instant>
        </period>
    </context>
    <context id="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:EzekielElliottMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-06</startDate>
            <endDate>2022-09-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:EzekielElliottMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-06</instant>
        </period>
    </context>
    <context id="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:DavidSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:DavidSandlerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HsiaochingChouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HsiaochingChouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-01_us-gaap_RestrictedStockMember_srt_ChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-01</instant>
        </period>
    </context>
    <context id="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-13</startDate>
            <endDate>2022-10-13</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="From2022-10-142022-10-14_custom_JoanArangoMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JoanArangoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JoanArangoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-14</instant>
        </period>
    </context>
    <context id="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:JoanArangoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-14</startDate>
            <endDate>2022-10-14</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:WhiteUnicornLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:WhiteUnicornLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GlobalCareerNetworksIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="From2022-12-212022-12-21_custom_CharteredServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:CharteredServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2022-12-21</endDate>
        </period>
    </context>
    <context id="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:CharteredServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-21</startDate>
            <endDate>2022-12-21</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:CharteredServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-21</instant>
        </period>
    </context>
    <context id="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-03</instant>
        </period>
    </context>
    <context id="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-03</instant>
        </period>
    </context>
    <context id="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:DojoLabsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:AdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="From2023-01-242023-01-24_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-24_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="From2023-01-242023-01-24_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="From2023-03-222023-03-22_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-22_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="AsOf2023-04-24_custom_PrivatePlacementWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="From2023-04-242023-04-24_custom_PrivatePlacementWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-25_custom_PrivatePlacementWarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-25</startDate>
            <endDate>2023-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-25_custom_PrivatePlacementWarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-25</startDate>
            <endDate>2023-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-25_custom_PrivatePlacementWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-25</startDate>
            <endDate>2023-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-25_custom_PrivatePlacementWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-25</instant>
        </period>
    </context>
    <context id="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-25</startDate>
            <endDate>2023-04-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-26_custom_PrivatePlacementWarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-26</instant>
        </period>
    </context>
    <context id="From2023-04-262023-04-26_custom_PrivatePlacementWarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-26</startDate>
            <endDate>2023-04-26</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-01_custom_PrivatePlacementWarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-01_custom_PrivatePlacementWarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="From2023-05-012023-05-01_custom_HammerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HammerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-01_custom_HammerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:HammerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MrAndrewMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MrAndrewMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-25</instant>
        </period>
    </context>
    <context id="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MrAndrewMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-25</startDate>
            <endDate>2023-05-25</endDate>
        </period>
    </context>
    <context id="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MajorDodgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MajorDodgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:MajorDodgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:StreetGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:StreetGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-01</instant>
        </period>
    </context>
    <context id="AsOf2023-06-06_custom_PrivatePlacementWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-06</instant>
        </period>
    </context>
    <context id="From2023-06-062023-06-06_custom_PrivatePlacementWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-07_custom_PrivatePlacementWarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-07</instant>
        </period>
    </context>
    <context id="From2023-06-072023-06-07_custom_PrivatePlacementWarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-07</startDate>
            <endDate>2023-06-07</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-08_custom_PrivatePlacementWarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-08</instant>
        </period>
    </context>
    <context id="From2023-06-082023-06-08_custom_PrivatePlacementWarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-08</startDate>
            <endDate>2023-06-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-21_custom_PrivatePlacementWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="From2023-06-212023-06-21_custom_PrivatePlacementWarrantFourMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-22_custom_PrivatePlacementWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="From2023-06-222023-06-22_custom_PrivatePlacementWarrantFiveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-22_custom_PrivatePlacementWarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-22</instant>
        </period>
    </context>
    <context id="From2023-06-222023-06-22_custom_PrivatePlacementWarrantSixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-22</startDate>
            <endDate>2023-06-22</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-27_custom_PrivatePlacementWarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-27</instant>
        </period>
    </context>
    <context id="From2023-06-272023-06-27_custom_PrivatePlacementWarrantSevenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">MGRX:PrivatePlacementWarrantSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-27</startDate>
            <endDate>2023-06-27</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefOperatingOfficerMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-01_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">MGRX:TwentyTwentyTwoPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="AsOf2023-05-01_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-01_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-20_us-gaap_CommonStockMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="From2023-03-202023-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember40800812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="From2022-06-232022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LeovLawFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LeovLawFirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:GreentreeFinancialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember40801234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember40801390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember40801406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-09-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <instant>2022-09-28</instant>
        </period>
    </context>
    <context id="From2022-09-282022-09-28_custom_LeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:LeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="From2022-09-282022-09-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2022-09-28</startDate>
            <endDate>2022-09-28</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LucaConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-10</startDate>
            <endDate>2023-10-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-10_us-gaap_SubsequentEventMember_custom_ConsultingAgreementMember_custom_LucaConsultingLlcMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:LucaConsultingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-10</instant>
        </period>
    </context>
    <context id="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">MGRX:BethorLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:RudmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-06</startDate>
            <endDate>2023-01-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">MGRX:BoonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="From2023-01-242023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">MGRX:ConsultingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="From2017-12-222017-12-22_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-22</startDate>
            <endDate>2017-12-22</endDate>
        </period>
    </context>
    <context id="From2017-12-222017-12-22_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-22</startDate>
            <endDate>2017-12-22</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001938046</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-09-30">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-09-30">0001938046</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2023-01-01to2023-09-30" id="xdx2ixbrl0012">POS AM</dei:DocumentType>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0044"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-09-30_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-09-30_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0116"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0166"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:CostOfRevenues
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0168"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:CostOfRevenues
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0170"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0176"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0178"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0183"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:ImputedInterestRelatedParty
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0215"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0226"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0227"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0228"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:StockIssuedDuringWarrantsExercisedForCashValue
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0524"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0631"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-09-30"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl0779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-08-08" id="xdx2ixbrl0813">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1101"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1103"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1109"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1111"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1113"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1115"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl1133"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl1135"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl1137"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      id="xdx2ixbrl1139"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1203"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1205"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl1211"
      unitRef="Shares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl1213"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl1215"
      unitRef="Shares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl1217"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      id="xdx2ixbrl1239"
      unitRef="Shares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      id="xdx2ixbrl1241"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      id="xdx2ixbrl1243"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      id="xdx2ixbrl1245"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="AsOf2023-09-30"
      id="xdx2ixbrl1322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1360"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:FixedAssets
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepositsAssets
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherAssets
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedPayrollTaxesCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2021-12-31_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl1398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1456"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:CostOfRevenues
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1490"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-10-06_us-gaap_CommonStockMember"
      id="xdx2ixbrl1518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-10-06_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-10-06_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-10-06"
      id="xdx2ixbrl1521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-10-06_us-gaap_CommonStockMember"
      id="xdx2ixbrl1523"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1527"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1537"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1577"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1580"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl1582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl1586"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1614"
      unitRef="USD"
      xsi:nil="true"/>
    <MGRX:IssuanceOfCommonStockForServices
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1647"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1659"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-10-06"
      id="xdx2ixbrl1686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1695"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContributionOfProperty
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1734"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1735"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1738"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1739"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1741"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1742"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1743"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1746"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1757"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1759"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1763"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Depreciation
      contextRef="From2021-10-072021-12-31"
      id="xdx2ixbrl1801"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_ComputersMember"
      id="xdx2ixbrl1810"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_EquipmentMember"
      id="xdx2ixbrl1813"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1819"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2022-08-08" id="xdx2ixbrl1925">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl2035"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl2037"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2043"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2045"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2047"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl2049"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl2097"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl2099"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl2105"
      unitRef="Shares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl2107"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl2109"
      unitRef="Shares"
      xsi:nil="true"/>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      id="xdx2ixbrl2111"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl2221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl2222"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-09-30">Mangoceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-09-30">TX</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-09-30">87-3841292</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-09-30">15110 N. Dallas Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-09-30">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-09-30">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-09-30">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-09-30">75248</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-09-30">(214)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-09-30">242-9619</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="From2023-01-012023-09-30_dei_BusinessContactMember">Jacob D. Cohen</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-012023-09-30_dei_BusinessContactMember">15110 N. Dallas Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-012023-09-30_dei_BusinessContactMember">Suite 600</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-012023-09-30_dei_BusinessContactMember">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-012023-09-30_dei_BusinessContactMember">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-012023-09-30_dei_BusinessContactMember">75248</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-09-30">(214)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-09-30">242-9619</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-09-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-09-30">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="From2023-01-01to2023-09-30">This Post-Effective Amendment No. 2 (this &#x201c;Amendment&#x201d;)
to the Registration Statement on Form S-1 of Mangoceuticals, Inc. (File No. 333- 275993), initially filed on December 11, 2023 and declared
effective by the Securities and Exchange Commission on December 14, 2023 (the &#x201c;Registration Statement&#x201d;), is being filed to
update the prospectus which forms part of the Registration Statement to (a) fill in blanks on the cover page of the prospectus and throughout
regarding pricing terms and the offering price of $0.30 per share; (b) reflect that a Plan of Compliance is being filed with Nasdaq on
December 18, 2023, and (c) make corresponding updates to the prospectus in connection therewith.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1236747</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">682860</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InventoryNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">21581</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">84382</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">11745</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1342710</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">694605</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">22461</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3863</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">102420</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</us-gaap:PropertyPlantAndEquipmentNet>
    <MGRX:FixedAssets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">102420</MGRX:FixedAssets>
    <MGRX:FixedAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</MGRX:FixedAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">16942</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16942</us-gaap:DepositsAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">133433</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">174241</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">150375</us-gaap:OtherAssets>
    <us-gaap:OtherAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">191183</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1595505</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1003287</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">89059</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">33675</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">8200</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2717</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      unitRef="USD">78260</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">61917</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">56725</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">159176</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">260577</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">81508</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">128680</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">81508</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">128680</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">240684</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">389257</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">16789500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">16789500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1679</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1337</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">10013268</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2628449</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">-8660126</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-2015756</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1354821</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">614030</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1595505</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1003287</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">245160</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">487119</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">52193</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">101538</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">3255</us-gaap:CostOfRevenue>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">48378</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">96663</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">144589</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">288918</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">1944049</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">991825</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6939761</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1319727</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">1944049</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">991825</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6939761</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1319727</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1799460</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-991825</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-6650843</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-1319727</us-gaap:OperatingIncomeLoss>
    <MGRX:ImputedInterestRelatedParty
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-3090</MGRX:ImputedInterestRelatedParty>
    <MGRX:ImputedInterestRelatedParty
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6473</MGRX:ImputedInterestRelatedParty>
    <MGRX:ImputedInterestRelatedParty
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-4673</MGRX:ImputedInterestRelatedParty>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-3090</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">6473</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-4673</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1799460</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-994915</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-6644370</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-1324400</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1799460</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-994915</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-6644370</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-1324400</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">15923588</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-012023-09-30"
      decimals="INF"
      unitRef="Shares">15923588</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">10049100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">10049100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">14923461</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">14923461</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">9913388</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-09-30"
      decimals="INF"
      unitRef="Shares">9913388</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-17701</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-16720</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">889</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">889</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-19599</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-19599</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1070</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-37300</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-35430</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1583</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1583</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">225</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">224775</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">225000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-310185</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-310185</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10250000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1025</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">227428</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-347485</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">-119032</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2202</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">2202</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">265000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">264973</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">265000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">169817</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">169817</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1500500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">150</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1500350</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">1500500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-994915</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-994915</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12015500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1202</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2164770</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1342400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">823572</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13365000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1337</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2628449</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2015756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">614030</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">700000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">70</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">699930</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">700000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">125</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4999875</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1760</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">1760</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">64271</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">64271</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2560885</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-03-31"
      decimals="0"
      unitRef="USD">-2560885</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1532</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8394285</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-4576641</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-03-31" decimals="0" unitRef="USD">3819176</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">375000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">37</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">386963</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">387000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-8233</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-8233</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">64271</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">64271</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <MGRX:StockIssuedDuringWarrantsExercisedForCashShares
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1024500</MGRX:StockIssuedDuringWarrantsExercisedForCashShares>
    <MGRX:StockIssuedDuringWarrantsExercisedForCashValue
      contextRef="From2023-04-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">102</MGRX:StockIssuedDuringWarrantsExercisedForCashValue>
    <MGRX:StockIssuedDuringWarrantsExercisedForCashValue
      contextRef="From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1024398</MGRX:StockIssuedDuringWarrantsExercisedForCashValue>
    <MGRX:StockIssuedDuringWarrantsExercisedForCashValue
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">1024500</MGRX:StockIssuedDuringWarrantsExercisedForCashValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2284025</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012023-06-30"
      decimals="0"
      unitRef="USD">-2284025</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16714500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9861684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6860666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">3002689</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16714500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9861684</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6860666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-06-30" decimals="0" unitRef="USD">3002689</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84742</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">84750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">66842</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">66842</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1799460</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      unitRef="USD">-1799460</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16789500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10013268</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8660126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1354821</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16789500</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1679</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10013268</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-8660126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1354821</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-6644370</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-1324400</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">18598</us-gaap:Depreciation>
    <MGRX:IssuanceOfCommonStockForServices
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1171750</MGRX:IssuanceOfCommonStockForServices>
    <MGRX:IssuanceOfCommonStockForServices
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">490000</MGRX:IssuanceOfCommonStockForServices>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-6473</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">4673</us-gaap:InterestExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">195384</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">169817</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">21581</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">72637</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">37719</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-40808</MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">55384</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-41980</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">5483</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">671</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-5299634</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-696958</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">3519</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">2531</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">-3519</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">-2531</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">75000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">78260</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">89200</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">25070</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1024500</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1500500</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">5857040</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">1550430</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">553887</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">850941</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">682860</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">1236747</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">873491</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zusKlb0PZE3c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_82C_z7mOY4GaihEh"&gt;ORGANIZATION AND DESCRIPTION OF THE BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mangoceuticals,
Inc. (&#x201c;Mangoceuticals&#x201d; or the &#x201c;Company&#x201d;), was incorporated in the State of a Texas on &lt;span id="xdx_90D_edei--EntityIncorporationDateOfIncorporation_c20230101__20230930_zEyjqjOgeTk5" title="Date of incorporation"&gt;October 7, 2021&lt;/span&gt;, with the
intent of focusing on developing, marketing, and selling a variety of men&#x2019;s wellness products and services via a telemedicine platform.
To date, the Company has identified men&#x2019;s wellness telemedicine services and products as a growing sector in the most recent years
and especially related to the areas of erectile dysfunction (&#x201c;ED&#x201d;). In this regard, Mangoceuticals has developed and is commercially
marketing and selling a new brand of ED product under the brand name &#x201c;Mango.&#x201d; This product is produced at a compounding pharmacy
using a proprietary combination of U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) approved ingredients and is available to patients
on the determination of a prescribing physician that the compounded drug is necessary for the individual patient. Mangoceuticals is currently
marketing and selling this new brand of ED product exclusively online via its website at &lt;span style="text-decoration: underline"&gt;www.MangoRx.com&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Initial
Public Offering. &lt;/i&gt;In March 2023, the Company completed an initial public offering (the &#x201c;IPO&#x201d;), in which the Company issued
and sold &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQVOBmR5n01b" title="Issuance of shares"&gt;1,250,000&lt;/span&gt; shares of authorized common stock for $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQA3db6z22je" title="Share issued price per share"&gt;4.00&lt;/span&gt; per share for net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn4n6_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zePQZfNAYq1h" title="Net proceeds from issuance of common stock"&gt;4.35&lt;/span&gt; million, after deducting underwriting
discounts and commissions, and offering costs. At the same time, and as part of the same registration statement, but pursuant to a separate
prospectus (the &#x201c;Resale Prospectus&#x201d;) the Company registered the sale of &lt;span id="xdx_90A_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zHxlzn0wd4Ad" title="Sale of stock, shares"&gt;4,765,000&lt;/span&gt; shares of common stock, including &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230228__20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zGJPlcYPm1Lb" title="Issuance of shares"&gt;2,000,000&lt;/span&gt;
shares of common stock issuable upon the exercise of outstanding warrants to purchase shares of common stock with an exercise price of
$&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230331__us-gaap--SubsidiarySaleOfStockAxis__custom--ResaleProspectusMember_zEenTGcvHOu4" title="Share issued price per share"&gt;1.00&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2023-01-01to2023-09-30">2021-10-07</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-282023-03-31_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-31_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-02-282023-03-31_us-gaap_IPOMember"
      decimals="-4"
      unitRef="USD">4350000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-02-282023-03-31_custom_ResaleProspectusMember"
      decimals="INF"
      unitRef="Shares">4765000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-02-282023-03-31_custom_ResaleProspectusMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-31_custom_ResaleProspectusMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zL8uc8ZVVcA4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 &#x2013; &lt;span id="xdx_82F_zvOF5ANRGewa"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoM89gSRtiC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z4InLRg3CQJ3"&gt;Basis
of Preparation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) under the accrual basis of accounting. These financial statements are presented in
U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The
accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto
for the years ended December 31, 2022 and 2021 included in the Company&#x2019;s Registration Statement on Form S-1 (Amendment No. 4),
filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 28, 2023 (the &#x201c;Form S-1&#x201d;). In the opinion
of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position
and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim
periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the Form S-1 have been omitted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zt74Z5NYOB02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z5f5eUmEVx45"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority
of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insures a total cash balance
of up to $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zCJdFQyH08v8" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt; per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits and the excess would be
at risk of loss for purposes of the statement of cash flows. There are &lt;span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_z8gGFZgDUiMg" title="Cash equivalents"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8YyU761TWmg" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents at September 30, 2023 and December 31, 2022
and the Company has not experienced any losses related to uninsured deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zeL0KlYdTD41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zJCvRNouYZcd"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
740, &lt;i&gt;Income Taxes&lt;/i&gt;. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the
temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income
in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount
that is more likely than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPyf1Znyl1L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zUdGq2W2Elxi"&gt;Net
Loss Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
compute net loss per share in accordance with ASC 260, &lt;i&gt;Earning per Share&lt;/i&gt;. ASC 260 requires presentation of both basic and diluted
earnings per share (&#x201c;EPS&#x201d;) on the face of the statement of operations. Basic EPS is computed by dividing net loss available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. For diluted net loss per share purposes, the Company
excludes stock options and other stock-based awards, including shares issued as a result of option and warrant exercises, whose effect
would be anti-dilutive, from the calculation. There were &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zj4qWpLuazEl" title="Anti-dilutive securities"&gt;1,400,000&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zswAe54AWVKl" title="Anti-dilutive securities"&gt;1,250,000&lt;/span&gt; options, &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5mOXkQDoyXd" title="Anti-dilutive securities"&gt;1,063,000&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPsAaRYHEyLe" title="Anti-dilutive securities"&gt;2,000,000&lt;/span&gt; warrants and no derivative
securities outstanding as of September 30, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zVFAYw6EG7ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zGVKYnO6DQV2"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with US GAAP requires the Company&#x2019;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will,
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvGsztSKuih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zEocmiercZQj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, which provides guidance with respect to valuation techniques to be utilized in the determination
of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach
(present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement
cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three
broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zGc2F4ugj03e"&gt;SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0637"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0639"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zQlxyzjNg5Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSQun2tac6T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zL77S0uwFqaj"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zv5AdiU3SWYi" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt;) to five (&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zOzywZjQtBke" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt;) years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zc4QLMcybnDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zXyxnK0PyS9b"&gt;Concentration
and Risks&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had
no significant revenue from continuing operations which were derived from a single or a few major customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmn4mCXQx4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zXaQfJUDULfh"&gt;Black
Scholes Option Pricing Model&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVvKL7gtheDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zQSvLXfN6N13"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;i&gt;&#x201c;&lt;span style="text-decoration: underline"&gt;Debt &#x2013; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013;
40)&lt;/span&gt;&#x201d;&lt;/i&gt;. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#x2019;s own equity. The ASU is part of the FASB&#x2019;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#x2019;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--RelatedPartiesPolicyTextBlock_ztEzXVMCZP7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zNTKqI17OSA1"&gt;Related
Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows subtopic 850-10 of FASB ASC 850, &lt;i&gt;Related Party Disclosures&lt;/i&gt; for the identification of related parties and disclosure
of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825&#x2013;10&#x2013;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zGcnex4hEIPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zLP4fB0Ithn9"&gt;Stock-Based
Compensation&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs to employees under FASB ASC 718 &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zq6kwL7zRzYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zVuB9u7zNZ3g"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our
websites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated
through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The
transaction price in the Company&#x2019;s contracts with customers is the total amount of consideration to which the Company expects to
be entitled in exchange for transferring products or services to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#x2019;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#x2019;s completion of its performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (&#x201c;Doctegrity&#x201d;) to provide online
telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii)
the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs
for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its
sole discretion, sets all listed prices charged on its websites for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (&#x201c;Contracted Pharmacy&#x201d;),
which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts
that include sale of prescription products and to fill prescriptions that are ordered by the Company&#x2019;s customers for fulfillment
through the Company&#x2019;s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer&#x2019;s
prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using
the Company&#x2019;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites
for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_z2OaZ4CAzi51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zHrWce5thqYb"&gt;Inventories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or market with cost being determined on a first-in, first-out (&#x201c;FIFO&#x201d;) basis. The Company writes down its
inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated
market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those
projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zN9k9dblTWd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_z6n4niJJiHS4"&gt;Marketing
and advertising&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations
$&lt;span id="xdx_904_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230930_zH0FTQGqUCal" title="Marketing and advertising expense"&gt;1,633,528&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220930_zlmyhEi4oUcc" title="Marketing and advertising expense"&gt;0&lt;/span&gt; for the nine months ended September 30, 2023 and 2022. We did not begin advertising until November 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zkZnNZ0OtbVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zuSVPpc9WSU7"&gt;Subsequent
events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, &lt;i&gt;Subsequent Events&lt;/i&gt;, for the disclosure of subsequent events.
The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_858_zX8ptlnZnK7i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zoM89gSRtiC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_z4InLRg3CQJ3"&gt;Basis
of Preparation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America (&#x201c;U.S. GAAP&#x201d;) under the accrual basis of accounting. These financial statements are presented in
U.S. dollars and are prepared on a historical cost basis, except for certain financial instruments which are carried at fair value. The
accompanying unaudited interim financial statements should be read in conjunction with the audited financial statements and notes thereto
for the years ended December 31, 2022 and 2021 included in the Company&#x2019;s Registration Statement on Form S-1 (Amendment No. 4),
filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 28, 2023 (the &#x201c;Form S-1&#x201d;). In the opinion
of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the financial position
and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim
periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would
substantially duplicate the disclosures contained in the Form S-1 have been omitted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zt74Z5NYOB02" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_z5f5eUmEVx45"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the majority
of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insures a total cash balance
of up to $&lt;span id="xdx_90D_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zCJdFQyH08v8" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt; per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits and the excess would be
at risk of loss for purposes of the statement of cash flows. There are &lt;span id="xdx_906_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20230930_z8gGFZgDUiMg" title="Cash equivalents"&gt;&lt;span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8YyU761TWmg" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents at September 30, 2023 and December 31, 2022
and the Company has not experienced any losses related to uninsured deposits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zeL0KlYdTD41" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zJCvRNouYZcd"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;)
740, &lt;i&gt;Income Taxes&lt;/i&gt;. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when the
temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in income
in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce deferred tax assets to the amount
that is more likely than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zPyf1Znyl1L7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zUdGq2W2Elxi"&gt;Net
Loss Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
compute net loss per share in accordance with ASC 260, &lt;i&gt;Earning per Share&lt;/i&gt;. ASC 260 requires presentation of both basic and diluted
earnings per share (&#x201c;EPS&#x201d;) on the face of the statement of operations. Basic EPS is computed by dividing net loss available
to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS
gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred
stock using the if-converted method. In computing Diluted EPS, the average stock price for the period is used in determining the number
of shares assumed to be purchased from the exercise of stock options or warrants. For diluted net loss per share purposes, the Company
excludes stock options and other stock-based awards, including shares issued as a result of option and warrant exercises, whose effect
would be anti-dilutive, from the calculation. There were &lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zj4qWpLuazEl" title="Anti-dilutive securities"&gt;1,400,000&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zswAe54AWVKl" title="Anti-dilutive securities"&gt;1,250,000&lt;/span&gt; options, &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5mOXkQDoyXd" title="Anti-dilutive securities"&gt;1,063,000&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zPsAaRYHEyLe" title="Anti-dilutive securities"&gt;2,000,000&lt;/span&gt; warrants and no derivative
securities outstanding as of September 30, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zVFAYw6EG7ld" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zGVKYnO6DQV2"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with US GAAP requires the Company&#x2019;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases will,
differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zvGsztSKuih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zEocmiercZQj"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, which provides guidance with respect to valuation techniques to be utilized in the determination
of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach
(present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement
cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three
broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zGc2F4ugj03e"&gt;SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0637"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0639"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zQlxyzjNg5Qe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89C_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zYFkpkjSDHeb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zGc2F4ugj03e"&gt;SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zgRFQe7Vx9nk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z1giTSmNd4pc" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0dsOlKWua55" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zgqkLGwYexSd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0630"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0631"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zpfIRtqBLxuh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0634"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0635"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zAHVBqkYLvN7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0637"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0638"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0639"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_zEJ6VioiTSQk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0642"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0643"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; display: none"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; display: none; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zqRAMhrM9Sy" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z0Vo5iEsq6wb" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zF6iLUcyUm17" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_z6cBXTzhx6K1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0647"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zBhQ8MRiWbNh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_zkK6fjCp1O22" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0653"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zkeMXnzubtZ2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0658"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0659"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">682860</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">682860</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">682860</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">22550</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">22550</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">22550</us-gaap:FairValueNetAssetLiability>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSQun2tac6T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zL77S0uwFqaj"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from the disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zv5AdiU3SWYi" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt;) to five (&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zOzywZjQtBke" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt;) years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-09-30_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2023-09-30_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zc4QLMcybnDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zXyxnK0PyS9b"&gt;Concentration
and Risks&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company had
no significant revenue from continuing operations which were derived from a single or a few major customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zmn4mCXQx4Nj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zXaQfJUDULfh"&gt;Black
Scholes Option Pricing Model&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zVvKL7gtheDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_869_zQSvLXfN6N13"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;i&gt;&#x201c;&lt;span style="text-decoration: underline"&gt;Debt &#x2013; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013;
40)&lt;/span&gt;&#x201d;&lt;/i&gt;. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#x2019;s own equity. The ASU is part of the FASB&#x2019;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#x2019;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <MGRX:RelatedPartiesPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84B_ecustom--RelatedPartiesPolicyTextBlock_ztEzXVMCZP7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zNTKqI17OSA1"&gt;Related
Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows subtopic 850-10 of FASB ASC 850, &lt;i&gt;Related Party Disclosures&lt;/i&gt; for the identification of related parties and disclosure
of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section 825&#x2013;10&#x2013;15,
to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing
trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company;
f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and
g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 6 and 8 in the notes to financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</MGRX:RelatedPartiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zGcnex4hEIPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zLP4fB0Ithn9"&gt;Stock-Based
Compensation&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs to employees under FASB ASC 718 &lt;i&gt;Compensation - Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zq6kwL7zRzYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_863_zVuB9u7zNZ3g"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP. Online revenue is generated by selling directly to consumers through our
websites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services and has met its performance obligation. For revenue generated
through its online platform, the Company defines its customer as an individual who purchases products or services through websites. The
transaction price in the Company&#x2019;s contracts with customers is the total amount of consideration to which the Company expects to
be entitled in exchange for transferring products or services to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#x2019;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#x2019;s completion of its performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a Physician Services Agreement with BrighterMD, LLC dba Doctegrity (&#x201c;Doctegrity&#x201d;) to provide online
telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer; (ii)
the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs costs
for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company, at its
sole discretion, sets all listed prices charged on its websites for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC (&#x201c;Contracted Pharmacy&#x201d;),
which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers for contracts
that include sale of prescription products and to fill prescriptions that are ordered by the Company&#x2019;s customers for fulfillment
through the Company&#x2019;s websites. The Company accounts for prescription product revenue as a principal in the arrangement with its
customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills a customer&#x2019;s
prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company, including using
the Company&#x2019;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer for the satisfactory
fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices charged on its websites
for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84C_eus-gaap--InventoryPolicyTextBlock_z2OaZ4CAzi51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zHrWce5thqYb"&gt;Inventories&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or market with cost being determined on a first-in, first-out (&#x201c;FIFO&#x201d;) basis. The Company writes down its
inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated
market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those
projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zN9k9dblTWd3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_z6n4niJJiHS4"&gt;Marketing
and advertising&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the policy of charging the costs of marketing and advertising to expense as incurred. The Company charged to operations
$&lt;span id="xdx_904_eus-gaap--MarketingAndAdvertisingExpense_c20230101__20230930_zH0FTQGqUCal" title="Marketing and advertising expense"&gt;1,633,528&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--MarketingAndAdvertisingExpense_c20220101__20220930_zlmyhEi4oUcc" title="Marketing and advertising expense"&gt;0&lt;/span&gt; for the nine months ended September 30, 2023 and 2022. We did not begin advertising until November 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">1633528</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zkZnNZ0OtbVa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zuSVPpc9WSU7"&gt;Subsequent
events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, &lt;i&gt;Subsequent Events&lt;/i&gt;, for the disclosure of subsequent events.
The Company will evaluate subsequent events through the date when the financial statements were issued (see Note 10).&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <MGRX:PrepaidExpensesAndDepositsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_802_ecustom--PrepaidExpensesAndDepositsTextBlock_zM0A1yqHFbj6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span id="xdx_821_z0AGLu4ZJqz9"&gt;PREPAID EXPENSES AND DEPOSITS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and nine months ended September 30, 2023 and the year ended December 31, 2022, and in association with the Master Services
Agreement and Statement of Work with our related party Contracted Pharmacy, the Company prepays the related party Contracted Pharmacy
as a retainer to be credited towards future product sales. As of September 30, 2023 and December 31, 2022, the balance was $&lt;span id="xdx_90A_ecustom--PrepaidExpensesRelatedParty_iI_c20230930_zRNRpL1WIlVl" title="Prepaid expenses related party"&gt;84,382&lt;/span&gt; and
$&lt;span id="xdx_901_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_zVa22T2R9x0a" title="Prepaid expenses related party"&gt;11,745&lt;/span&gt;, respectively&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company signed a lease agreement for office space, effective October 1, 2022, which included an initial security deposit of $&lt;span id="xdx_90F_eus-gaap--SecurityDeposit_iI_c20221001_z5nki9dG1w5j" title="Security deposit"&gt;16,942&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MGRX:PrepaidExpensesAndDepositsTextBlock>
    <MGRX:PrepaidExpensesRelatedParty contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">84382</MGRX:PrepaidExpensesRelatedParty>
    <MGRX:PrepaidExpensesRelatedParty contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">11745</MGRX:PrepaidExpensesRelatedParty>
    <us-gaap:SecurityDeposit contextRef="AsOf2022-10-01" decimals="0" unitRef="USD">16942</us-gaap:SecurityDeposit>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_ztEqO1cYDDqe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_82D_zDL0HzKljptd"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and nine months ended September 30, 2023 and the year ended December 31, 2022, the Company purchased inventories related to
promotional merchandise intended to be sold online. As of September 30, 2023 and December 31, 2022, the inventory balance was $&lt;span id="xdx_901_eus-gaap--InventoryNet_iI_c20230930_zmkp1nJiz2z1" title="Inventory"&gt;21,581&lt;/span&gt;
and $&lt;span id="xdx_908_eus-gaap--InventoryNet_iI_dxL_c20221231_zF1dXx8jlO8f" title="Inventory::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">21581</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zlBxZ5Yj2RL6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_82C_zh0O9PLWN7td"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2023, the Company acquired custom product packaging equipment totaling $&lt;span id="xdx_900_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_c20230101__20230930_zCyS9eNzto62" title="Property acquired value"&gt;3,519&lt;/span&gt;. Depreciation expense
for the nine months ended September 30, 2023 and 2022, was $&lt;span id="xdx_907_eus-gaap--Depreciation_c20230101__20230930_zr78gp1RqXUj" title="Depreciation expense"&gt;18,598&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--Depreciation_dxL_c20220101__20220930_zU4Ll2Fvvdpl" title="Depreciation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0709"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively. Total net property and equipment was $&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20230930_zXg57NZXRzWk" title="Property plant and equipment net"&gt;102,420&lt;/span&gt;
and $&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zLkhUOZwiQ" title="Property plant and equipment net"&gt;117,499&lt;/span&gt;, as of September 30, 2023 and December 31, 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zonsr7B2iWOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zusoPAkZbQZ" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230930_zO69tluKu5nh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zobx2ETRm9G" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zVsot07MGY0d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Computers&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zkhBR20if40i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;119,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zs0GDdoo2Nsb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22,461&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zbu3rt5Ghehe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;102,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;117,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zVBL8PSLs7Vi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">3519</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">18598</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">102420</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zonsr7B2iWOl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BA_zusoPAkZbQZ" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230930_zO69tluKu5nh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;September 30, &lt;br/&gt;
2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20221231_zobx2ETRm9G" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_zVsot07MGY0d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%"&gt;Computers&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zkhBR20if40i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;119,819&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zs0GDdoo2Nsb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(22,461&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,863&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_zbu3rt5Ghehe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;102,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;117,499&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30_custom_ComputersMember"
      decimals="0"
      unitRef="USD">5062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputersMember"
      decimals="0"
      unitRef="USD">5062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">119819</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">116300</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">22461</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3863</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">102420</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWsqC9YWJni7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_826_zNqFaFcaFp2f"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2021 and March 18, 2022, the Company received advances of $&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zPfcDRhHOYu8" title="Related party advances received"&gt;39,200&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220318__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zGu30BeKGR7h" title="Related party advances received"&gt;50,000&lt;/span&gt;, respectively, for a total of $&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zxWQITIbCeNd" title="Related party advances received"&gt;89,200&lt;/span&gt; from
its previous majority shareholder, American International Holdings Corp (&#x201c;AMIH&#x201d;), in order to cover various general and administrative
expenses. The advances bear no interest and are due on demand upon the Company&#x2019;s ability to repay the advances from either future
revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (&#x201c;Cohen Enterprises&#x201d;), an entity owned and controlled
by Jacob D. Cohen, the Company&#x2019;s Chief Executive Officer and Chairman of the Board of Directors, entered into and closed a Stock
Purchase Agreement (the &#x201c;SPA&#x201d;) for the purchase of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zAjgC1umwcje" title="Issuance of shares"&gt;8,000,000&lt;/span&gt; shares of the outstanding common stock of the Company which
were then held by AMIH, which represented &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_z2qgLsAV0V3c" title="Equity ownership interest"&gt;80&lt;/span&gt;% of the Company&#x2019;s then outstanding shares of common stock, in consideration for $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zL0xCLZZtY9i" title="Proceeds from issuance of common stock"&gt;90,000&lt;/span&gt;.
Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $&lt;span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zxJcYaEaPQSl" title="Repayments of related party debt"&gt;89,200&lt;/span&gt; advanced from AMIH to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 29, 2022, the Company received an advance of $&lt;span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zmV2yXiMmhL4" title="Related party advances received"&gt;25,000&lt;/span&gt; from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z2aac0KzVyPi" title="Repayments of related party debt"&gt;25,000&lt;/span&gt; on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z4u8ccAnseSa" title="Repayment of related party debt"&gt;89,200&lt;/span&gt;
as of December 31, 2022. This amount was paid in full on April 4, 2023 and the amount owed to Cohen Enterprises was $&lt;span id="xdx_90C_eus-gaap--ProceedsFromRelatedPartyDebt_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z4LBINMC4F13" title="Proceeds from related party"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ProceedsFromRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zeCK7UyAaz9b" title="Proceeds from related party"&gt;89,200&lt;/span&gt; as
of September 30, 2023 and December 31, 2022, respectively. Previously recorded imputed interest equal to eight percent (&lt;span id="xdx_905_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zrixixkFFYk2" title="Imputed interest percentage"&gt;8&lt;/span&gt;%) per annum,
or a total of $&lt;span id="xdx_909_eus-gaap--PaymentsForAdvanceToAffiliate_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_znUmZuSatg48" title="Related party transaction purchases"&gt;8,232&lt;/span&gt; against the related party advances, was canceled and reversed for the nine months ended September 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2021, the Company received an advance of $&lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zJBH0cNK6C76" title="Related party advances received"&gt;70&lt;/span&gt; from ZipDoctor, Inc., a then wholly-owned subsidiary of its then majority shareholder,
AMIH, which was used to open and establish the Company&#x2019;s bank account. The advance bears no interest and is due on demand upon
the Company&#x2019;s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May
24, 2022 and the amount owed to ZipDoctor was $&lt;span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zwlgEno65Sd3"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zfHN6nTio4X1"&gt;0&lt;/span&gt; as of September 30, 2023 and December 31, 2022, respectively. Imputed interest
at eight percent (&lt;span id="xdx_906_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20230101__20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zijD1xghzHQ3" title="Imputed interest percentage"&gt;8&lt;/span&gt;%) per annum on this advance was insignificant and therefore was not calculated, recorded or paid during the time
the advance was outstanding from December 10, 2021 to May 24, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
additional information on related party prepaid expenses see Note 3.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-12-102021-12-10_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">39200</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-03-182022-03-18_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2023-01-012023-09-30_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-06-16_custom_CohenEnterprisesIncMember"
      decimals="INF"
      unitRef="Pure">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">90000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-06-152022-06-16_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-06-282022-06-29_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-08-172022-08-18_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:ProceedsFromRelatedPartyDebt>
    <MGRX:InterestExpenseRelatedPartyPercentage
      contextRef="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember"
      decimals="INF"
      unitRef="Pure">0.08</MGRX:InterestExpenseRelatedPartyPercentage>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2023-01-012023-09-30_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">8232</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-12-102021-12-10_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">70</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2023-01-012023-09-30_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <MGRX:InterestExpenseRelatedPartyPercentage
      contextRef="From2023-01-012023-09-30_custom_ZipDoctorIncMember"
      decimals="INF"
      unitRef="Pure">0.08</MGRX:InterestExpenseRelatedPartyPercentage>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zBbTSUkJpFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_82B_zy2feB68R9Aj"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 18, 2022, the Company entered into a note payable with a vendor for the purchase of equipment in the amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_z2AXWunyFFj5" title="Debt instrument face amount"&gt;78,260&lt;/span&gt;. The
note bears no interest and was due in three payments of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230101_zvLZ4AL6Q227" title="Debt instrument periodic payment"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230201__20230201_z1iYVRWVlIhc" title="Debt instrument periodic payment"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20230301__20230301_zdfv0d1DhGQ9" title="Debt instrument periodic payment"&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; each January 1, 2023 through March 1, 2023, a $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_zhko9I7tSOo7" title="Debt instrument periodic payment"&gt;31,630&lt;/span&gt; payment on April
1, 2023 and a final payment on May 1, 2023 for the outstanding balance. The January 1 and March 1, 2023 payments were timely made and
on March 23, 2023, the Company elected to pay off the remaining balance of $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfNotesPayable_c20230323__20230323_zsWpalWZFWU5" title="Repayments of notes payable"&gt;63,260&lt;/span&gt;. The outstanding balance as of September 30, 2023
and December 31, 2022 was $&lt;span id="xdx_90E_eus-gaap--NotesPayable_iI_dxL_c20230930_zgYHm7K6WXO1" title="Notes payable::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0779"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--NotesPayable_iI_c20221231_zq7Jk5Wi8av3" title="Notes payable"&gt;78,260&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-11-18" decimals="0" unitRef="USD">78260</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-01-012023-01-01"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-02-012023-02-01"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-03-012023-03-01"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-04-012023-04-01"
      decimals="0"
      unitRef="USD">31630</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-03-232023-03-23"
      decimals="0"
      unitRef="USD">63260</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NotesPayable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">78260</us-gaap:NotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_80F_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zxJFk2oXgPz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_822_zCtGAgReVxac"&gt;CAPITAL STOCK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue up to&lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20230930_zLpoTlhGhTbh" title="Preferred stock, shares authorized"&gt; &lt;span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zvbUkDwjBDR" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt; shares of &#x201c;blank check&#x201d; preferred stock, $&lt;span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20230930_zSQGV2nPOM26" title="Preferred stock par value"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zUJm7dbb3Kw7" title="Preferred stock par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; par value. All preferred
stock was undesignated as of September 30, 2023 and December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20230930_zS2JRQIOeAue" title="Common stock, shares authorized"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zTZFOqS9Fmm3" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20230930_zNdX2GBL0o3l" title="Common stock par value"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_z5vuSDeyThtg" title="Common stock par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share, of which &lt;span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20230930_zuRDuZRSy1X7" title="Common stock shares issued"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230930_zd0lPBuR3MNk" title="Common stock shares outstanding"&gt;16,789,500&lt;/span&gt;&lt;/span&gt; shares were issued
and outstanding at September 30, 2023 and &lt;span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20221231_zQoPItDPGfFl" title="Common stock shares issued"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zcWGcKmXxaRc" title="Common stock shares outstanding"&gt;13,365,000&lt;/span&gt;&lt;/span&gt; were issued and outstanding at December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 8, 2022, the Company began a private placement of up to $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220808__20220808__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zrlPXNlALsL1" title="Shares issued value"&gt;2,000,000&lt;/span&gt; of units (the &#x201c;Units&#x201d;), each consisting of one
share of common stock (the &#x201c;Shares&#x201d;) and a warrant to purchase one share of common stock (the &#x201c;Warrants&#x201d;), at
a price of $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zNVESgylncBi" title="Share price"&gt;1.00&lt;/span&gt; per Unit. The Warrants have a &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_uUSDPShares_c20220808_zGVDFiodftO7" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0813"&gt;five-year&lt;/span&gt;&lt;/span&gt; term and an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220808_zldAAiy3KWRl" title="Exercise price"&gt;1.00&lt;/span&gt; per share, for which cash would need to
be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise the Warrants are
exercisable on either a cash basis or a cashless basis. The offering of the Units is referred to as the &#x201c;Offering.&#x201d; The Units
were offered by the Company only to investors that qualify as &#x201c;accredited investors,&#x201d; as that term is defined in Rule 501(a)
of Regulation D promulgated by the SEC under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The price of
the Units was determined by the Company and such price did not necessarily bear any relation to the book value or other recognized criteria
of value of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Offering commenced on August 8, 2022 and the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220808__20220808_zjwMzldA73Kl" title="Sale of stock, shares"&gt;2,000,000&lt;/span&gt; Units at $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zW4DcNpuw8ca" title="Share price"&gt;1.00&lt;/span&gt; per Unit to 23 investors in exchange for $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220808__20220808__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zBIVsdZIyTU3" title="Proceeds from investors"&gt;2,000,000&lt;/span&gt;
in gross proceeds from the investors, and subsequently issued the investors &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220816__20221231_zFbyWJ5VNGnj" title="Sale of stock, shares"&gt;2,000,000&lt;/span&gt; Shares and &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z24kmFQbpDp8" title="Warrants issued"&gt;2,000,000&lt;/span&gt; Warrants between August 16,
2022 and December 31, 2022. As of December 31, 2022, the fair value of Warrants outstanding to investors was $&lt;span id="xdx_907_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zHrhxkBa1f76" title="Fair value of warrants"&gt;1,438,299&lt;/span&gt;. Because the
Warrants vested immediately the fair value was assessed on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC (&#x201c;PHX&#x201d;), which is owned by Peter &#x201c;Casey&#x201d;
Jensen, who is a member of the Board of Directors of AMIH and a related party. Pursuant to the Consulting Agreement, PHX agreed to provide
consulting and general business advisory services as reasonably requested by the Company during the term of the agreement, which was
for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach
30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued PHX
&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVw3BrO6iXg8" title="Shares issued"&gt;50,000&lt;/span&gt; shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares
were valued at $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPLB7zBNysC6" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0pzosJVQp79" title="Shares issued value"&gt;13,921&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#x201c;Elliott&#x201d;), currently a professional football
player in the National Football League, to provide consulting and general business advisory services as reasonably requested by the Company
during the term of the agreement, which was for 12 months unless otherwise earlier terminated due to breach of the agreement by either
party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the services
under the agreement, the Company issued Elliott &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcZUOwmODG1j" title="Shares issued"&gt;100,000 &lt;/span&gt;shares of restricted common stock. The agreement contains customary confidentiality
and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrSeUjugV734" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQKy6ySlzhg9" title="Shares issued value"&gt;$27,842&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#x201c;Sandler&#x201d;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrwMYTDmxp4d" title="Shares issued"&gt;10,000&lt;/span&gt;
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJoEzdGBPqMj" title="Share price"&gt;0.28 &lt;/span&gt;per share for a total of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwFsi4ymeFgg" title="Shares issued value"&gt;2,784&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#x201c;Chou&#x201d;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zO3SuRX8OqKa" title="Shares issued"&gt;5,000&lt;/span&gt; shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued
at $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVGopmaDZ5El" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPLTXeXrg1T" title="Shares issued value"&gt;1,392&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#x201c;Greentree&#x201d; and the &#x201c;Service
Agreement&#x201d;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US GAAP;
(c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023 and the
year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing, and providing
advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose of bringing
such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting services
and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its attorneys,
CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed October 1,
2022) has served as an Audit Manager for Greentree.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company agreed to issue Greentree &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zvc0FVqV6z01" title="Shares issued in consideration"&gt;100,000&lt;/span&gt; shares of the Company&#x2019;s restricted common stock upon the parties&#x2019; entry into the
agreement, and to pay Greentree $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zmuWIHwFBSik" title="Paid in cash"&gt;50,000&lt;/span&gt; in cash, payable as follows: &lt;span id="xdx_903_eus-gaap--CommonStockConversionFeatures_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zbIng9aiQGwj" title="Settlement description"&gt;(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023&lt;/span&gt;. We also agreed to include the &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAPrBDthzOIl" title="Shares new issued"&gt;100,000&lt;/span&gt;
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein, and to reimburse
Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#x2019;s activities under the agreement, including
the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification
obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at
$&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zTMevqJaXP06" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zWRLgqMXQxm3" title="Shares issued value"&gt;27,842&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2022, the Company executed a Summary of Terms and Conditions (&#x201c;Offer Letter&#x201d;) with Gene Johnston (&#x201c;Johnston&#x201d;)
appointing Johnston to serve as the Company&#x2019;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to
the Offer Letter, the Company issued Johnston &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr1zHL1GVOah" title="Restricted stock issued"&gt;150,000&lt;/span&gt; shares of the Company&#x2019;s restricted stock and vest over a 6-month period at
the rate of &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zxiMd9F1QsNc" title="Shares vested"&gt;25,000&lt;/span&gt; shares per month with the first &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zotYiUMtgZc8" title="Shares vested"&gt;25,000&lt;/span&gt; shares vesting on November 1, 2022. Johnston is eligible to participate in
any of the Company&#x2019;s future sponsored benefit plans, including but not limited to, health insurance benefits, 401k, stock option
or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of the month following 105 days
of Johnston&#x2019;s start date. Johnston is also eligible to receive equity incentive grants or cash bonus awards as determined by the
Company&#x2019;s Board (or a committee of the Board) in their sole discretion. The shares were valued at $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z3HgTvHx8Fb7" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of
$&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221001__20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_znkdrhTiZosc" title="Shares issued value"&gt;41,763&lt;/span&gt;. Mr. Johnston is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company entered into Director Offer Letter agreements with each of Alex Hamilton (&#x201c;Hamilton&#x201d;), Dr.
Kenny Myers (&#x201c;Myers&#x201d;) and Lorraine D&#x2019;Alessio (&#x201c;Alessio), compensating each of them with &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrt8jMP62pUl" title="Restricted stock issued"&gt;75,000&lt;/span&gt; shares of restricted
common stock (for a total of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTliGhmLeLod" title="Restricted stock issued net"&gt;225,000&lt;/span&gt; shares) (the &#x201c;Director Shares&#x201d;). The Director Shares were issued under the Company&#x2019;s
2022 Equity Incentive Plan (the &#x201c;2022 Plan&#x201d;), with the following vesting schedule: 1/3 of the Director Shares vested on October
14, 2022, and the remaining Director Shares will vest annually in one-third increments commencing on the first anniversary date thereof.
The shares were valued at $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zIgs3klM3J6a" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zwnFkWkVJHIj" title="Shares value"&gt;20,881&lt;/span&gt;. These individuals are related parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 14, 2022, the Company issued its Project Manager, Joan Arango, &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221014__20221014__srt--TitleOfIndividualAxis__custom--JoanArangoMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zobh0oSN3ckd" title="Restricted common stock issued"&gt;25,000 &lt;/span&gt;shares of restricted common stock under the 2022 Plan.
The shares were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#x2019;s President
and Chief Operating Officer, Jonathan Arango. The shares were valued at $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_znf3MuiGjJEb" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_z2FaGvk0Lzk6" title="Shares value"&gt;7,204&lt;/span&gt;. Ms. Arango is a related
party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#x201c;White Unicorn&#x201d;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztBTF3tqU1o" title="Shares issued"&gt;100,000&lt;/span&gt; shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAYAz4ZWmICj" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember_zL2NT57lZuO5" title="Shares value"&gt;28,816&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (&#x201c;Global&#x201d;) to provide marketing
services as reasonably requested by the Company during the term of the agreement, which was for six months unless otherwise earlier terminated
due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company issued Global &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zngwb1LKBlcl" title="Shares issued"&gt;100,000&lt;/span&gt; shares of restricted common stock. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcuKaVFvj909" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zU3J3htYDVOa" title="Shares issued value"&gt;28,816&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#x201c;Chartered Services&#x201d;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which was for six months unless otherwise earlier terminated due to
breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for
agreeing to provide the services under the agreement, the Company agreed to pay Chartered Services $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zx7CH4gNLmXi" title="Paid in cash"&gt;150,000&lt;/span&gt; in cash (&lt;span id="xdx_902_eus-gaap--CommonStockConversionFeatures_c20221221__20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zT4rTgtD7Kt6" title="Settlement description"&gt;with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000&lt;/span&gt; shares of restricted common
stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zF6RvCTc1ZR" title="Share price"&gt;0.28&lt;/span&gt; per share for
a total of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcBn2lQVoBc5" title="Shares issued value"&gt;72,039&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#x201c;DojoLabs&#x201d;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3K5xhtyoLT3" title="Cash"&gt;100,000&lt;/span&gt; in cash and issued DojoLabs &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zzQxVV2oefRg" title="Shares issued"&gt;50,000&lt;/span&gt; shares of restricted common
stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains
customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zHJFCjUwYnVh" title="Share price"&gt;1.00 &lt;/span&gt;per share for a total of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zeGvMAZ7BfFl" title="Shares issued value"&gt;100,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#x201c;Bethor&#x201d;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zuSqpcK1p1Fb" title="Shares issued"&gt;250,000&lt;/span&gt; shares of restricted common stock with registration rights. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_z3bDENf1MwXd" title="Share price"&gt;1.00&lt;/span&gt; per share for a total of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zaXZhJWAS4J8" title="Shares issued value"&gt;250,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 6, 2023, the Company established an advisory board (the &#x201c;Advisory Board&#x201d;) and approved and adopted a charter (the
&#x201c;Advisory Board Charter&#x201d;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#x2019;s development of new business ventures
and strategic planning.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#x201c;Dr. Rudman&#x201d;)
and Mr. Jarrett Boon (&#x201c;Mr. Boon&#x201d;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with Dr. Rudman&#x2019;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#x201c;Dr. Rudman
Consulting Agreement&#x201d;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zhPwIMHLM0ge" title="Shares issued"&gt; 25,000&lt;/span&gt;
shares of the Company&#x2019;s restricted common stock, pay Dr. Rudman $&lt;span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zQtXtbJBL9da" title="Compensation expense"&gt;2,000&lt;/span&gt; per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#x2019;s requests
of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zws41mpvw9Bf" title="Share price"&gt;1.00&lt;/span&gt; per share for a total
of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zkHNOVi3zuTa" title="Shares issued value"&gt;25,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with Mr. Boon&#x2019;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#x201c;Mr. Boon
Consulting Agreement&#x201d;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zTIbRW5h7mDb" title="Shares issued"&gt; 25,000 &lt;/span&gt;shares
of the Company&#x2019;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#x2019;s requests of the performance of his duties to the Company in service
on the Advisory Board. The shares were valued at $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zYngiV2qwhpb" title="Share price"&gt;1.00&lt;/span&gt; per share for a total of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--AdvisorAgreementMember_zyi1tD0EkqB8" title="Shares issued value"&gt;25,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of each agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, &lt;span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXwL6xjhuHD7" title="Settlement description"&gt;the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#x2019;s successful launch of a new product category, and 50,000 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#x2019;s successful launch of a new product category, and 7,500 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.&lt;/span&gt; Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zKOMGHOyZ0Zf" title="Share price"&gt;1.00&lt;/span&gt; per
share for a total of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zJL5xzwYHG6j" title="Shares issued value"&gt;350,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 22, 2023, the Company sold &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6NmiXb1rp39" title="Number of shares sold"&gt;1,250,000&lt;/span&gt; shares of its common stock at a price of $&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCSVEUzUmg46" title="Share price"&gt;4.00&lt;/span&gt; per share to investors in connection with its
IPO for gross proceeds of $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230322__20230322__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zW9mIS5mZDSb" title="Gross proceeds"&gt;5,000,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 24, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zlkoPRj84cA2" title="Warrants to purchase"&gt;100,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_ztgw9NX9Epu6" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230424__20230424__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zBJjGiLGI8rk" title="Consideration paid"&gt;100,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zX1a5nQTrfzf" title="Warrants to purchase"&gt;100,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zycNosj9zZve" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zLMSbslYysAe" title="Consideration paid"&gt;100,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zlSUiou18w68" title="Warrants to purchase"&gt;25,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_z7tjBUlDUvkj" title="Sale of stock price"&gt;1.00 &lt;/span&gt;per share in consideration for $&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zJh7uyEfi7V8" title="Consideration paid"&gt;25,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zE0ce4Edjok5" title="Warrants to purchase"&gt;25,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_903_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zYV9Jg85otHa" title="Sale of stock price"&gt;1.00 &lt;/span&gt;per share in consideration for $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zmyOLcs22zxj" title="Consideration paid"&gt;25,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 25, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_ztVdf344iDa6" title="Warrants to purchase"&gt;75,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zkHZTlmoZVg5" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230425__20230425__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_z31qIAQm4iJc" title="Consideration paid"&gt;75,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 26, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zRrNgeFtvh46" title="Warrants to purchase"&gt;100,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zyPwh7czQSu9" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230426__20230426__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXvXH59NxE5k" title="Consideration paid"&gt;100,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z5IRNo1G3Fhk" title="Warrants to purchase"&gt;25,000&lt;/span&gt; shares of common stock with an exercise price of
$&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zue27ivEjLd" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_zG0ZfLpziaqk" title="Consideration paid"&gt;25,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
and effective on May 1, 2023, the Company entered into an Employment Agreement with Mrs. Amanda Hammer (the &#x201c;Employment Agreement&#x201d;).
The Employment Agreement provides for Mrs. Hammer to serve as Chief Operating Officer of the Company for an initial three-year term extending
through May 1, 2026, provided that the agreement automatically renews for additional one-year terms thereafter in the event neither party
provides the other at least 60 days prior notice of their intention not to renew the terms of the agreement. The agreement provides for
Mrs. Hammer to receive an annual salary of $&lt;span id="xdx_906_eus-gaap--PaymentsToEmployees_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zTbCJliE0LS6" title="Annual salary"&gt;150,000&lt;/span&gt; per year. &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zHCBBu0WVZ1i" title="Share based compensation arrangement by share-based payment award, description"&gt;The Employment Agreement also required the Company to grant Mrs. Hammer
a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase
an additional 150,000 shares of common stock of the Company, under the Company&#x2019;s 2022 Equity Incentive Plan (the &#x201c;Plan&#x201d;),
with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company&#x2019;s common stock on
the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and
which exercise price was $&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iI_uUSDPShares_c20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zp0vnnuI3XMl" title="Exercise price"&gt;1.00&lt;/span&gt; per share, with options to purchase &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230501__20230501__srt--TitleOfIndividualAxis__custom--HammerMember_zbgtJsgZOqOd" title="Shares vesting"&gt;50,000&lt;/span&gt; shares vesting every twelve months that the Employment Agreement
is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate
option agreement entered into by the Company and Mrs. Hammer.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2023, we entered into a Software Development Agreement with Redlime Solutions, Inc. (&#x201c;Redlime&#x201d;) to provide software
development services during the term of the agreement, which is for twelve months. In consideration for agreeing to provide the services
under the agreement, the Company agreed to pay Redlime $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvOO9uhDx6sa" title="Consideration paid"&gt;300,000&lt;/span&gt; in cash and issue Redlime &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zw9f3qurBVT" title="Shares new issues"&gt;180,000&lt;/span&gt; shares of restricted common stock.
The shares were valued at $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_c20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zo6V6zDRToRl" title="Share price"&gt;1.00&lt;/span&gt; per share for a total of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230501__20230501__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9ttdPeUMUCi" title="Shares issued value"&gt;180,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 25, 2023, the Board of Directors appointed Mr. Aaron Andrew (&#x201c;Mr. Andrew&#x201d;), an independent, non-Board member and non-Company
employee, to the Advisory Board. In connection with Mr. Andrew&#x2019;s appointment to the Advisory Board, the Company entered into an
Advisor Agreement (the &#x201c;Mr. Andrew Consulting Agreement&#x201d;), dated effective May 25, 2023, with Mr. Andrew, whereby the Company
agreed to issue Mr. Andrew &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zKjdwYhcKJ1i" title="Shares issued"&gt;50,000&lt;/span&gt; shares of the Company&#x2019;s restricted common stock under the 2022 Plan and to reimburse Mr. Andrew
for reasonable out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#x2019;s
requests of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrLZJo9pUXea" title="Share price"&gt;1.10 &lt;/span&gt;per share
for a total of $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230525__20230525__srt--TitleOfIndividualAxis__custom--MrAndrewMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpR0ypG570oa" title="Shares issued value"&gt;55,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 1, 2023, we entered into a Consulting Agreement with Major Dodge (&#x201c;Major&#x201d;), to provide acting and production related
services to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of
the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company issued Major &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zhQrjX8GIiof" title="Shares issued"&gt;20,000 &lt;/span&gt;shares of restricted common stock under the 2022 Plan. The
agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXzGz0vF7R0j" title="Share price"&gt;1.10&lt;/span&gt; per share for a total of
$&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__srt--TitleOfIndividualAxis__custom--MajorDodgeMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTTl3GIc5uM6" title="Shares issued value"&gt;22,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 1, 2023, we entered into a Production and Broadcasting Agreement with New To The Street Group, LLC (&#x201c;New To The Street&#x201d;),
to provide production, broadcasting and other marketing related services to the Company during the term of the agreement, which was for
3 months unless otherwise earlier terminated. In consideration for agreeing to provide the services under the agreement, the Company
issued New To The Street &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zarrpgFH0yF5" title="Shares issued"&gt;50,000&lt;/span&gt; shares of restricted common stock and agreed to pay New To The Street a monthly cash payment of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHZHYZL1B5dj" title="Debt instrument periodic payment"&gt;5,000&lt;/span&gt;.
The shares were valued at $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEy71t101Wx4" title="Share price"&gt;1.10&lt;/span&gt; per share for a total of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230601__20230601__dei--LegalEntityAxis__custom--StreetGroupLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJpVghc0jHmk" title="Shares issued value"&gt;55,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 6, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zy2APh38F328" title="Warrants to purchase"&gt;150,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_zDuAaoCG03pg" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_901_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230606__20230606__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantOneMember_z0R8K0WoNDul" title="Consideration paid"&gt;150,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 7, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z0AtNk7ZzSrc" title="Warrants to purchase"&gt;75,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_zCihRc46gTQd" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230607__20230607__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantTwoMember_z5io9mgrj2ui" title="Consideration paid"&gt;75,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 8, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zFprQXIQ7Y12" title="Warrants to purchase"&gt;24,500&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zkG6qLVdDHMf" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230608__20230608__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantThreeMember_zmRIaLsAl1Ne" title="Consideration paid"&gt;24,500&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 21, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zCWGS2hIzEOa" title="Warrants to purchase"&gt;100,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_909_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zTrmJTqCX2c8" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230621__20230621__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFourMember_zNxZ28dMcs1k" title="Consideration paid"&gt;100,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zzQYHxEv7zw" title="Warrants to purchase"&gt;100,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zbQ8lqWkCpx1" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantFiveMember_zjczq1iWDCz1" title="Consideration paid"&gt;100,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 22, 2023, a warrant holder exercised private placement Warrants to purchase&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zXmuH1Y2wbyj" title="Warrants to purchase"&gt; 25,000 &lt;/span&gt;shares of common stock with an exercise price
of $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_zNYJ9eGW8Nv2" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230622__20230622__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSixMember_z7bviaGGTqR4" title="Consideration paid"&gt;25,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 27, 2023, a warrant holder exercised private placement Warrants to purchase &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z9Yuz2pdC8Ci" title="Warrants to purchase"&gt;100,000&lt;/span&gt; shares of common stock with an exercise price
of $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_pid_uUSDPShares_c20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z53VlWraBBp6" title="Sale of stock price"&gt;1.00&lt;/span&gt; per share in consideration for $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20230627__20230627__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivatePlacementWarrantSevenMember_z9coXxNmfZvk" title="Consideration paid"&gt;100,000&lt;/span&gt; in cash. The shares of common stock issuable upon exercise of the warrants were registered
under the Securities Act.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2023, we entered into a service agreement with Greentree Financial Group, Inc. (&#x201c;Greentree&#x201d; and the &#x201c;Service
Agreement&#x201d;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2023 through September 30, 2024; (b) advice and assistance to the Company in connection with
the conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with
US GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2023, March 31, 2024, June 30, 2024
and the year ended December 31, 2023, including the structure and entries as well as assistance with US GAAP footnotes; (d) reviewing,
and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions, with the purpose
of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing necessary consulting
services and support as a liaison for the Company to third party service providers, including coordination amongst the Company and its
attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer (who was appointed
October 1, 2022) has served as an Audit Manager for Greentree.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company agreed to issue Greentree &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zwHQfx4NYXCg" title="Shares issued in consideration"&gt;75,000&lt;/span&gt; shares of the Company&#x2019;s restricted common stock upon the parties&#x2019; entry into the
agreement, and to pay Greentree $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_ziaLGLPbnMjk" title="Paid in cash"&gt;40,000&lt;/span&gt; in cash, payable as follows: &lt;span id="xdx_90A_eus-gaap--CommonStockConversionFeatures_c20230101__20230930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zbw8brAuw34k" title="Settlement description"&gt;(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before
March 31, 2024.&lt;/span&gt; We also agreed to reimburse Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#x2019;s
activities under the agreement, including the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service
Agreement includes customary indemnification obligations requiring the Company to indemnify Greentree and its affiliates with regard
to certain matters. The shares were valued at $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zVpfOyf3jOz1" title="Share price"&gt;1.13&lt;/span&gt; per share for a total of $&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zss08gDbTOq7" title="Shares issued value"&gt;84,750&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company granted a total of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zQlIcltAJaB" title="Number of options"&gt;1,250,000&lt;/span&gt; options to purchase shares of common stock of the Company,
under the 2022 Plan, of which &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zjugoApWhFJ6" title="Number of options granted"&gt;750,000&lt;/span&gt; were granted to Jacob Cohen, the Company&#x2019;s CEO, and &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_znuKT5JEptf2" title="Number of options granted"&gt;500,000&lt;/span&gt; were granted to Jonathan Arango,
the Company&#x2019;s President and then COO, related to their respective employment agreement. The options have an exercise price of $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zVVB4FuGJwFl" title="Exercise price"&gt;1.10&lt;/span&gt;
per share, an original life of five years and vest at the annual renewal of their employment over &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2K5atqtrGX8" title="Vesting term"&gt;three years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 1, 2023, the Company granted &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_z3qQ4bz98Jmd" title="Number of options"&gt;150,000&lt;/span&gt; options to purchase shares of common stock of the Company, under the 2022 Plan to Amanda Hammer,
the Company&#x2019;s COO, related to her employment agreement. The options have an exercise price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziGnC6iqtl41" title="Exercise price"&gt;1.10&lt;/span&gt; per share, an original life
of five years and vest at the annual renewal of their employment over &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230501__20230501__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHe2zDhxQIJ2" title="Vesting term"&gt;three years&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023 and December 31, 2022, $&lt;span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20230930_zSwvuuykv341" title="Share based compensation"&gt;197,954&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zyAHgS3J7z0g" title="Share based compensation"&gt;82,267&lt;/span&gt; has been recorded as stock-based compensation. Mr. Cohen, Mr. Arango
and Ms. Hammer are related parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyi1rsR2Htf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock options activity: The following table summarizes common stock options activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zlnCXFgqu0eg" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znhH9QhV8Jz9" style="text-align: right" title="Options, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zeKHtmvQD3p8" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zHSc0soTBJ65" style="width: 16%; text-align: right" title="Options, Granted"&gt;1,250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zSj0pmVHzf72" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z4M1W5clqAig" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zWw9zwFbNmu4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zLbeTZscYov8" style="text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zikBFPG16421" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhddE771qBg8" style="text-align: right" title="Options, Outstanding Ending Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zzpqysnH1Wqk" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z1MP2jF4AFQ7" style="text-align: right" title="Options, Exercisable Ending Balance"&gt;133,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zHFZEa6PWQll" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zf1atKcT80X9" style="text-align: right" title="Options, Outstanding Beginning Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20230930_zyW2d14wPidh" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_z3Ptx0XNd0V5" style="text-align: right" title="Options, Granted"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zZFpnFBVW2fg" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zWOR2HFj1J1a" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_z14JGxLafKJ7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1135"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230930_zrXwuRePGnI" style="text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zLEIlWnHh8m1" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1139"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_z6pDRX1w20Mh" style="text-align: right" title="Options, Outstanding Ending Balance"&gt;1,400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_z6aTTMyvay9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zfOYJOY5k1o2" style="text-align: right" title="Options, Exercisable Ending Balance"&gt;454,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zNfU28RYePX6" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Outstanding Options&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Exercisable Options&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Options Exercise&lt;br/&gt; Price Per &lt;br/&gt; Share&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Life &lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average &lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average &lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20230101__20230930_zpfuwp5dq2B8" style="width: 13%; text-align: right" title="Option Exercise Price Per Share"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zhhNJGX7130k" style="width: 13%; text-align: right" title="Outstanding Ending Balance"&gt;1,400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z05q5jUmYmX" title="Options Term"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zjS2Z9bdup3h" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zymTshplVVMd" style="width: 13%; text-align: right" title="Exercisable Ending Balance"&gt;454,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zv4uyDEuL4I3" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z3ZpUXQeFDjg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023, the fair value of options outstanding was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20230930_z4xStvq1s4ge" title="Fair value of options outstanding"&gt;640,194&lt;/span&gt;. The aggregate initial fair value of the options measured on
the grant date of August 31, 2022 and May 1, 2023 was calculated using the Black-Scholes option pricing model based on the following
assumption:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEuwjyXnOBz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zIZVbbHJx3N5" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 68%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930_zvk6SeZs4NWb" style="width: 20%; text-align: right" title="Fair value of common stock on measurement date"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z5rM1yKNJIo1" title="Risk-free interest rate"&gt;3.64&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_z0slP4fXaPnb" title="Risk-free interest rate"&gt;3.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zZ0HuAO9GC46" title="Volatility"&gt;224.70&lt;/span&gt;% &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdfCWyRnImbd" title="Volatility"&gt;92.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zCUiNUvFDl07" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zktdNJwouND1" title="Expected term"&gt;6.0&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zxy0hr7KDDEd" title="Expected term"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company does not expect to pay a dividend in the foreseeable future&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company, in accordance with staff accounting bulletin (&#x201c;SAB&#x201d;)14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AF_zTENkGUvqxZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued a total of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z9gv0kRhW6kj" title="Warrants issued"&gt;2,000,000&lt;/span&gt; Warrants to investors and &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zBHrSr03DRp7" title="Warrants issued for services"&gt;210,070&lt;/span&gt; Warrants as compensation
for services rendered in connection with the Offering. The Warrants have an original life of five years and vested immediately. The Warrants
for services were expensed as stock-based compensation at the aggregate fair value in the amount of $&lt;span id="xdx_903_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220101__20221231_zWy5hWNJnyT7" title="Fair value of warrant"&gt;151,821&lt;/span&gt;. Because the Warrants vested
immediately, the fair value was assessed on the grant date. The aggregate fair value of the Warrants were measured using the Black-Scholes
option pricing model. The Company and the holder of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zOQcb9AmtzMh" title="Warrants issued for services"&gt;210,070&lt;/span&gt; Warrants for services agreed to cancel the Warrants and reversed the entries
for stock-based compensation to zero at year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
additional consideration in connection with the IPO, upon the closing of the IPO, we granted Boustead Securities, LLC, the representative
of the underwriters named in the Underwriting Agreement for the IPO, warrants to purchase &lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zPj1ryfeFcX1" title="Warrants issued"&gt;87,500 &lt;/span&gt;shares of common stock with an exercise
price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230320__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwMJcNrlIgR5" title="Exercise price"&gt;5.00&lt;/span&gt; per share, which are exercisable six months after the effective date of the registration statement filed in connection
with the IPO (March 20, 2023) and expire five years after such effectiveness date. The fair value of the warrants on the grant date was
$&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20230320__20230320_zhYd2LjGR678" title="Fair value of warrants"&gt;31,995&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023 and December 31, 2022, the fair value of Warrants outstanding to investors was $&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zlQoxU6gX5L1" title="Fair value of Warrants outstanding"&gt;581,264&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zO5c5OEQ0BH2" title="Fair value of Warrants outstanding"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zk6NPSL72gMc" title="Fair value of Warrants outstanding"&gt;1,438,299&lt;/span&gt;&lt;/span&gt;, respectively.
Because the Warrants vested immediately, the fair value was assessed on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zBNhKo7fwRy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock warrant activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zEBdMiAKxqZg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoh8dvznIjJh" style="text-align: right" title="Warrants Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmdzcqHQyni8" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQGTuc1YVqmj" style="width: 14%; text-align: right" title="Warrants Granted"&gt;2,210,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTncY7ZGcOz8" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Granted"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDh1G5xiXu03" style="text-align: right" title="Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFtBIZm2jSx5" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoJUZp1hIQyg" style="text-align: right" title="Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDGC8QqIw544" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJL28tJgdRc" style="text-align: right" title="Warrants Cancelled"&gt;(210,070&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCJmbrIdijk" style="text-align: right" title="Weighted Average Exercise Price Cancelled"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8iRJOGpHFzl" style="text-align: right" title="Warrants Outstanding, Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSV2VZbyu11" style="text-align: right" title="Weighted Average Exercise Price Ending Balance"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDzgqgo7B9Y6" style="text-align: right" title="Warrants Exercisable Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRg934nPAxXd" style="text-align: right" title="Weighted Average Exercise Price Exercisable price"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCDjEPEqNrI3" style="text-align: right" title="Warrants Granted"&gt;87,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL93hfP3zhW1" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp61h1Zmertg" style="text-align: right" title="Warrants Exercised"&gt;(1,024,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM16wPuNZt8e" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN6LGRvfip1b" style="text-align: right" title="Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsW6qE1SHTq2" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWwmwXM0Kpu1" style="text-align: right" title="Warrants Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgfUfOllZdyc" style="text-align: right" title="Weighted Average Exercise Price Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQwkEgQUqG2b" style="text-align: right" title="Warrants Outstanding, Ending balance"&gt;1,063,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZs1OBoLSK21" style="text-align: right" title="Weighted Average Exercise Price Ending Balance"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQtwYXbBSpd" style="text-align: right" title="Warrants Exercisable Ending balance"&gt;975,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2OvWN19gtlc" style="text-align: right" title="Weighted Average Exercise Price Exercisable price"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding and Vested Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Warrant Exercise Price Per Share&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY3FElUSndtl" style="width: 30%; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zviqeeycKM92" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance"&gt;1,063,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTDFcVl5jPIb" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term"&gt;3.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zIUvQSjzqFjd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2023, warrants to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDCRYvrtk2S2" title="Warrants outstanding"&gt;1,063,000&lt;/span&gt; shares of common stock are outstanding and vested, and the vested stock warrants
have a weighted average remaining life of &lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4XXavrzjzc4" title="Outstanding and vested warrants expected term"&gt;3.83&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXniw0lhn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BB_zmc19E8WnEi5" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHbH2bsAL481" title="Fair value of common stock on measurement date"&gt;0.37&lt;/span&gt; - $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zqA4XUr2W09l" title="Fair value of common stock on measurement date"&gt;0.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFJjnXUMlQ4" title="Risk-free interest rate"&gt;2.95&lt;/span&gt;% to &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zhOsdSKWfmak" title="Risk-free interest rate"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaz6PgL5z1Ff" title="Volatility"&gt;88.92&lt;/span&gt;% to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAIYLYlD3Awd" title="Volatility"&gt;92.87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcbCSHkmB32" title="Dividend rate"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrGkHub8P62" title="Expected term"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company does not expect to pay a dividend in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zrdq3VifZuSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">16789500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">16789500</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-08-082022-08-08_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-08"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-08"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-08-082022-08-08"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-08"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2022-08-082022-08-08_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-08-162022-12-31"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1438299</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">13921</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">27842</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">2784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">1392</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommonStockConversionFeatures contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023</us-gaap:CommonStockConversionFeatures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-30_custom_ServiceAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">27842</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-11-012022-11-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-01_us-gaap_RestrictedStockMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">41763</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">225000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember"
      decimals="0"
      unitRef="USD">20881</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-10-142022-10-14_custom_JoanArangoMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember"
      decimals="0"
      unitRef="USD">7204</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">28816</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">28816</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-12-212022-12-21_custom_CharteredServicesLLCMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommonStockConversionFeatures contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000</us-gaap:CommonStockConversionFeatures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember"
      decimals="0"
      unitRef="USD">72039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:Cash
      contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember_custom_ConsultingAgreementMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember_custom_AdvisorAgreementMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockConversionFeatures contextRef="From2023-01-242023-01-24_us-gaap_RestrictedStockMember">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#x2019;s successful launch of a new product category, and 50,000 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#x2019;s successful launch of a new product category, and 7,500 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</us-gaap:CommonStockConversionFeatures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-24_custom_ConsultingAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-242023-01-24_custom_ConsultingAgreementsMember"
      decimals="0"
      unitRef="USD">350000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-03-222023-03-22_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="AsOf2023-03-22_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">4.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-03-222023-03-22_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-24_custom_PrivatePlacementWarrantOneMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-24_custom_PrivatePlacementWarrantOneMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-04-242023-04-24_custom_PrivatePlacementWarrantOneMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantTwoMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantTwoMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantOneMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantThreeMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantThreeMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantThreeMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFourMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFourMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFourMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFiveMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-25_custom_PrivatePlacementWarrantFiveMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-04-252023-04-25_custom_PrivatePlacementWarrantFiveMember"
      decimals="0"
      unitRef="USD">75000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-26_custom_PrivatePlacementWarrantSixMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-04-26_custom_PrivatePlacementWarrantSixMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-04-262023-04-26_custom_PrivatePlacementWarrantSixMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-05-01_custom_PrivatePlacementWarrantSevenMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-05-01_custom_PrivatePlacementWarrantSevenMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantSevenMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsToEmployees
      contextRef="From2023-05-012023-05-01_custom_HammerMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:PaymentsToEmployees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2023-05-012023-05-01_custom_HammerMember">The Employment Agreement also required the Company to grant Mrs. Hammer
a sign-on bonus of (a) 75,000 restricted shares of common stock of the Company, vested in full upon issuance, and (b) options to purchase
an additional 150,000 shares of common stock of the Company, under the Company&#x2019;s 2022 Equity Incentive Plan (the &#x201c;Plan&#x201d;),
with an exercise price of the greater of (i) $1.10 per share; and (ii) the closing sales price of the Company&#x2019;s common stock on
the Nasdaq Capital Market on the date the Employment Agreement and the grant is approved by the Board (which date was May 1, 2023), and
which exercise price was $1.00 per share, with options to purchase 50,000 shares vesting every twelve months that the Employment Agreement
is in effect, subject to the terms of the Plan. The options are exercisable for a period of ten years and are documented by a separate
option agreement entered into by the Company and Mrs. Hammer.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-05-01_custom_HammerMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-05-012023-05-01_custom_HammerMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">180000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-012023-05-01_custom_PrivatePlacementWarrantMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-05-252023-05-25_custom_MrAndrewMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">20000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-06-012023-06-01_custom_MajorDodgeMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">22000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-06-012023-06-01_custom_StreetGroupLLCMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">55000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-06_custom_PrivatePlacementWarrantOneMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-06_custom_PrivatePlacementWarrantOneMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-062023-06-06_custom_PrivatePlacementWarrantOneMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-07_custom_PrivatePlacementWarrantTwoMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-07_custom_PrivatePlacementWarrantTwoMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-072023-06-07_custom_PrivatePlacementWarrantTwoMember"
      decimals="0"
      unitRef="USD">75000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-08_custom_PrivatePlacementWarrantThreeMember"
      decimals="INF"
      unitRef="Shares">24500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-08_custom_PrivatePlacementWarrantThreeMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-082023-06-08_custom_PrivatePlacementWarrantThreeMember"
      decimals="0"
      unitRef="USD">24500</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-21_custom_PrivatePlacementWarrantFourMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-21_custom_PrivatePlacementWarrantFourMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-212023-06-21_custom_PrivatePlacementWarrantFourMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantFiveMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantFiveMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-222023-06-22_custom_PrivatePlacementWarrantFiveMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantSixMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-22_custom_PrivatePlacementWarrantSixMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-222023-06-22_custom_PrivatePlacementWarrantSixMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-27_custom_PrivatePlacementWarrantSevenMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-06-27_custom_PrivatePlacementWarrantSevenMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2023-06-272023-06-27_custom_PrivatePlacementWarrantSevenMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">40000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommonStockConversionFeatures contextRef="From2023-01-012023-09-30_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_custom_ServiceAgreementMember">(a) $20,000 on or before September 30, 2023; (b) $20,000 on or before
March 31, 2024.</us-gaap:CommonStockConversionFeatures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember"
      decimals="INF"
      unitRef="USDPShares">1.13</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-09-30_custom_ServiceAgreementMember_custom_GreentreeFinancialGroupMember"
      decimals="0"
      unitRef="USD">84750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefOperatingOfficerMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-05-01_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-05-01_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2023-05-012023-05-01_us-gaap_CommonStockMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">197954</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">82267</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zyi1rsR2Htf8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock options activity: The following table summarizes common stock options activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B7_zlnCXFgqu0eg" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_znhH9QhV8Jz9" style="text-align: right" title="Options, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zeKHtmvQD3p8" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zHSc0soTBJ65" style="width: 16%; text-align: right" title="Options, Granted"&gt;1,250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zSj0pmVHzf72" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_z4M1W5clqAig" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zWw9zwFbNmu4" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zLbeTZscYov8" style="text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zikBFPG16421" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zhddE771qBg8" style="text-align: right" title="Options, Outstanding Ending Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zzpqysnH1Wqk" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_z1MP2jF4AFQ7" style="text-align: right" title="Options, Exercisable Ending Balance"&gt;133,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zHFZEa6PWQll" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zf1atKcT80X9" style="text-align: right" title="Options, Outstanding Beginning Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20230101__20230930_zyW2d14wPidh" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_z3Ptx0XNd0V5" style="text-align: right" title="Options, Granted"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zZFpnFBVW2fg" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zWOR2HFj1J1a" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_z14JGxLafKJ7" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1135"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230930_zrXwuRePGnI" style="text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20230101__20230930_zLEIlWnHh8m1" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1139"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_z6pDRX1w20Mh" style="text-align: right" title="Options, Outstanding Ending Balance"&gt;1,400,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_z6aTTMyvay9b" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zfOYJOY5k1o2" style="text-align: right" title="Options, Exercisable Ending Balance"&gt;454,167&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zNfU28RYePX6" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for options granted, and exercisable as of September 30, 2023 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Outstanding Options&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Exercisable Options&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Options Exercise&lt;br/&gt; Price Per &lt;br/&gt; Share&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Life &lt;br/&gt; (Years)&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average &lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average &lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20230101__20230930_zpfuwp5dq2B8" style="width: 13%; text-align: right" title="Option Exercise Price Per Share"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zhhNJGX7130k" style="width: 13%; text-align: right" title="Outstanding Ending Balance"&gt;1,400,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_z05q5jUmYmX" title="Options Term"&gt;4.53&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zjS2Z9bdup3h" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20230101__20230930_zymTshplVVMd" style="width: 13%; text-align: right" title="Exercisable Ending Balance"&gt;454,167&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930_zv4uyDEuL4I3" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">133333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">454167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-09-30">P4Y6M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2023-09-30" decimals="INF" unitRef="Shares">454167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">640194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zEuwjyXnOBz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zIZVbbHJx3N5" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 68%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930_zvk6SeZs4NWb" style="width: 20%; text-align: right" title="Fair value of common stock on measurement date"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_z5rM1yKNJIo1" title="Risk-free interest rate"&gt;3.64&lt;/span&gt;% - &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_z0slP4fXaPnb" title="Risk-free interest rate"&gt;3.30&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zZ0HuAO9GC46" title="Volatility"&gt;224.70&lt;/span&gt;% &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdfCWyRnImbd" title="Volatility"&gt;92.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zCUiNUvFDl07" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MaximumMember_zktdNJwouND1" title="Expected term"&gt;6.0&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zxy0hr7KDDEd" title="Expected term"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company does not expect to pay a dividend in the foreseeable future&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company, in accordance with staff accounting bulletin (&#x201c;SAB&#x201d;)14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-09-30"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">2.2470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.9254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-01to2023-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-09-30_srt_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-09-30_srt_MinimumMember">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">210070</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">151821</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">210070</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-20_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="Shares">87500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-20_us-gaap_CommonStockMember_us-gaap_IPOMember"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-03-202023-03-20"
      decimals="0"
      unitRef="USD">31995</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-09-30_us-gaap_InvestorMember"
      decimals="0"
      unitRef="USD">581264</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_InvestorMember"
      decimals="0"
      unitRef="USD">1438299</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_InvestorMember"
      decimals="0"
      unitRef="USD">1438299</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zBNhKo7fwRy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock warrant activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zEBdMiAKxqZg" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;br/&gt; Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoh8dvznIjJh" style="text-align: right" title="Warrants Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1203"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmdzcqHQyni8" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1205"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 64%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQGTuc1YVqmj" style="width: 14%; text-align: right" title="Warrants Granted"&gt;2,210,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTncY7ZGcOz8" style="width: 14%; text-align: right" title="Weighted Average Exercise Price Granted"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDh1G5xiXu03" style="text-align: right" title="Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFtBIZm2jSx5" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1213"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoJUZp1hIQyg" style="text-align: right" title="Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1215"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDGC8QqIw544" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1217"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkJL28tJgdRc" style="text-align: right" title="Warrants Cancelled"&gt;(210,070&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKCJmbrIdijk" style="text-align: right" title="Weighted Average Exercise Price Cancelled"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8iRJOGpHFzl" style="text-align: right" title="Warrants Outstanding, Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSV2VZbyu11" style="text-align: right" title="Weighted Average Exercise Price Ending Balance"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDzgqgo7B9Y6" style="text-align: right" title="Warrants Exercisable Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRg934nPAxXd" style="text-align: right" title="Weighted Average Exercise Price Exercisable price"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCDjEPEqNrI3" style="text-align: right" title="Warrants Granted"&gt;87,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL93hfP3zhW1" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zp61h1Zmertg" style="text-align: right" title="Warrants Exercised"&gt;(1,024,500&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM16wPuNZt8e" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN6LGRvfip1b" style="text-align: right" title="Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1239"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsW6qE1SHTq2" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWwmwXM0Kpu1" style="text-align: right" title="Warrants Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1243"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgfUfOllZdyc" style="text-align: right" title="Weighted Average Exercise Price Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQwkEgQUqG2b" style="text-align: right" title="Warrants Outstanding, Ending balance"&gt;1,063,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZs1OBoLSK21" style="text-align: right" title="Weighted Average Exercise Price Ending Balance"&gt;1.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable, September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrQtwYXbBSpd" style="text-align: right" title="Warrants Exercisable Ending balance"&gt;975,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2OvWN19gtlc" style="text-align: right" title="Weighted Average Exercise Price Exercisable price"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of September 30, 2023, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding and Vested Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Warrant Exercise Price Per Share&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY3FElUSndtl" style="width: 30%; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zviqeeycKM92" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance"&gt;1,063,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTDFcVl5jPIb" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term"&gt;3.83&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="Shares">2210070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="Shares">-210070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.00</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      decimals="INF"
      unitRef="Shares">87500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      decimals="INF"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      decimals="INF"
      unitRef="Shares">-1024500</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      decimals="INF"
      unitRef="USDPShares">1.00</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1063000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">975500</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.00</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      decimals="INF"
      unitRef="USDPShares">1.00</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">1063000</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812">P3Y9M29D</MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1063000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812">P3Y9M29D</MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40801390">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXniw0lhn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BB_zmc19E8WnEi5" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zHbH2bsAL481" title="Fair value of common stock on measurement date"&gt;0.37&lt;/span&gt; - $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zqA4XUr2W09l" title="Fair value of common stock on measurement date"&gt;0.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zYFJjnXUMlQ4" title="Risk-free interest rate"&gt;2.95&lt;/span&gt;% to &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zhOsdSKWfmak" title="Risk-free interest rate"&gt;4.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zaz6PgL5z1Ff" title="Volatility"&gt;88.92&lt;/span&gt;% to &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAIYLYlD3Awd" title="Volatility"&gt;92.87&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcbCSHkmB32" title="Dividend rate"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrGkHub8P62" title="Expected term"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company does not expect to pay a dividend in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-09-30_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.8892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.9287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-09-30_us-gaap_WarrantMember40800812">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4wQJNloSbsi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_829_zfoVTCEQbUvb"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company is not currently subject to any such litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Operating
Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a lease for an office in Dallas, Texas, classified as an operating lease under ASC 842, &lt;i&gt;Leases.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#x201c;Landlord&#x201d;) to lease and occupy approximately &lt;span id="xdx_908_eus-gaap--AreaOfLand_iI_usqft_c20220928_zKgJj1o9MGa7"&gt;2,201&lt;/span&gt; square feet of office space located at 15110 Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#x2019;s main headquarters (the &#x201c;&lt;span style="text-decoration: underline"&gt;Lease Agreement&lt;/span&gt;&#x201d;). &lt;span id="xdx_901_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zZYS0DoDTiAd" title="Operating lease, description"&gt;The Lease
Agreement has a term of thirty-eight (&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zy8nQ2Bjoxvl" title="Lease term"&gt;38&lt;/span&gt;) months and has a monthly base rent of $&lt;span id="xdx_908_eus-gaap--PaymentsForRent_c20220928__20220928_zhsjLx3nwRbh" title="Base rent"&gt;5,778&lt;/span&gt;, or $31.50 per square foot, for the from months
3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term&lt;/span&gt; (the &#x201c;&lt;span style="text-decoration: underline"&gt;Base Rent&lt;/span&gt;&#x201d;).
In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real estate taxes and assessments,
hazard and liability insurance and common area maintenance costs for the building at the rate of &lt;span id="xdx_90F_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zgPXQ0GcHlI3" title="Percentage of proportionate rent"&gt;2.45&lt;/span&gt;% (the &#x201c;&lt;span style="text-decoration: underline"&gt;Proportionate Rent&lt;/span&gt;&#x201d;).
Upon the execution of the Lease Agreement, the Company agreed to prepay the first full month&#x2019;s Base Rent along with a security
deposit equal to $&lt;span id="xdx_909_eus-gaap--PaymentsForRent_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_z9xGeoroPGq5" title="Base rent"&gt;16,942&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes the incremental borrowing rate in determining the present value of lease payments unless the implicit rate is readily
determinable. The Company used an estimated incremental borrowing rate of &lt;span id="xdx_90A_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zMlOWvijXZJg" title="Percentage of incremental borrowing rate"&gt;8&lt;/span&gt;% to estimate the present value of the right-of-use liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has right-of-use assets of $&lt;span id="xdx_900_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20230930_zZcUpSuvKlBb" title="Right of use of asset"&gt;133,433&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zJieVvJPtFt2" title="Right of use of asset"&gt;174,241&lt;/span&gt; and operating lease liabilities of $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_c20230930_zLJ5zrwP4I13" title="Operating lease liability"&gt;143,424&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseLiability_iI_c20221231_zkGPL5F4H6He" title="Operating lease liability"&gt;185,405&lt;/span&gt; as of September 30,
2023 and December 31, 2022, respectively. Operating lease expense for the nine months ended September 30, 2023 and 2022 was $&lt;span id="xdx_906_eus-gaap--OperatingLeaseCost_c20230101__20230930_zlP6umDqxl5j" title="Operating lease expense"&gt;50,826&lt;/span&gt; and
$&lt;span id="xdx_908_eus-gaap--OperatingLeaseCost_c20220101__20220930_zPa41U6jFuH1" title="Operating lease expense"&gt;0&lt;/span&gt;, respectively. The Company has recorded $&lt;span id="xdx_903_eus-gaap--AssetImpairmentCharges_c20230101__20230930_ze3QG1AuZSf2" title="Asset impairment charges"&gt;&lt;span id="xdx_90F_eus-gaap--AssetImpairmentCharges_c20220101__20220930_z9aVKEklHrD4" title="Asset impairment charges"&gt;0&lt;/span&gt;&lt;/span&gt; in impairment charges related to right-of-use assets during the nine months ended September
30, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zfxAqQM2PIij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zswRigTIq3uh" style="display: none"&gt;SCHEDULE
OF MATURITY OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Maturity of Lease Liabilities at September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230930_zDWWLFhDsfTk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 82%; text-align: justify"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_ma1_c20230930_zTpIGPR0wXn6" style="width: 14%; text-align: right" title="Remainder of Fiscal Year"&gt;17,516&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_ma1_c20230930_zmD2YYkVOW4h" style="text-align: right" title="Year One"&gt;71,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_ma1_c20230930_zC43oirSPia" style="padding-bottom: 1.5pt; text-align: right" title="Year Two"&gt;67,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pp0p0_ma1_c20230930_z0JCCsLn33E7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Year Three"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mt1_c20230930_ztEXhojbu4k3" style="text-align: right" title="Total lease payments"&gt;156,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zGqopNm9d9W5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,397&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zJjgVhWwhBbg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;143,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A7_zhAQOiM0QUN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand contextRef="AsOf2022-09-28" decimals="INF" unitRef="sqft">2201</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2022-09-282022-09-28_custom_LeaseAgreementMember">The Lease
Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,778, or $31.50 per square foot, for the from months
3-18 and increases at the rate of $1 per square foot per annum until the end of the lease term</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-09-28">P38M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PaymentsForRent
      contextRef="From2022-09-282022-09-28"
      decimals="0"
      unitRef="USD">5778</us-gaap:PaymentsForRent>
    <MGRX:PercentageOfProportionateRent
      contextRef="From2022-09-282022-09-28"
      decimals="INF"
      unitRef="Pure">0.0245</MGRX:PercentageOfProportionateRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-09-282022-09-28_custom_LeaseAgreementMember"
      decimals="0"
      unitRef="USD">16942</us-gaap:PaymentsForRent>
    <MGRX:PercentageOfIncrementalBorrowingRate
      contextRef="From2022-09-282022-09-28"
      decimals="INF"
      unitRef="Pure">0.08</MGRX:PercentageOfIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">133433</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">174241</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">143424</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">185405</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">50826</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OperatingLeaseCost>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-01-01to2023-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-09-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zfxAqQM2PIij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zswRigTIq3uh" style="display: none"&gt;SCHEDULE
OF MATURITY OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Maturity of Lease Liabilities at September 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230930_zDWWLFhDsfTk" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Amount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 82%; text-align: justify"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_ma1_c20230930_zTpIGPR0wXn6" style="width: 14%; text-align: right" title="Remainder of Fiscal Year"&gt;17,516&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_ma1_c20230930_zmD2YYkVOW4h" style="text-align: right" title="Year One"&gt;71,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_ma1_c20230930_zC43oirSPia" style="padding-bottom: 1.5pt; text-align: right" title="Year Two"&gt;67,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_iI_pp0p0_ma1_c20230930_z0JCCsLn33E7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Year Three"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mt1_c20230930_ztEXhojbu4k3" style="text-align: right" title="Total lease payments"&gt;156,821&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zGqopNm9d9W5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Less: Imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,397&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zJjgVhWwhBbg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: justify"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;143,424&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">17516</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">71716</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">67589</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">156821</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">13397</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2023-09-30" decimals="0" unitRef="USD">143424</us-gaap:OperatingLeaseLiability>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-09-30">&lt;p id="xdx_807_eus-gaap--SubsequentEventsTextBlock_zbDY2sXtahjf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 &#x2013; &lt;span id="xdx_82C_ziWvXwKUMICl"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based on the
evaluation, the Company identified the following subsequent events:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2023, the Company executed a Summary of Terms and Conditions (&#x201c;Consulting Agreement&#x201d;) with Gene Johnston (&#x201c;Johnston&#x201d;)
continuing his appointment as the Company&#x2019;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to the
Consulting Agreement, the Company issued Johnston &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8RPkUwiI0A1" title="Stock issued during period, shares"&gt;50,000&lt;/span&gt; shares of the Company&#x2019;s common stock and $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231001__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmnIvU1NqbD2" title="Stock issued during period, value"&gt;2,000&lt;/span&gt; per month. The Consulting
Shares were issued under, and subject to the terms of, the Company&#x2019;s 2022 Equity Incentive Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 10, 2023, we entered into a Consulting Agreement with Luca Consulting, LLC (&#x201c;Luca Consulting&#x201d;), to provide management
consulting and business advisory services to the Company during the term of the agreement, which is for three months. In consideration
for agreeing to provide the services under the agreement, the Company agreed to pay Luca Consulting $&lt;span id="xdx_902_eus-gaap--StockIssued1_c20231010__20231010__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zktTsPvJJ1Oe" title="Stock value paid in cash"&gt;15,000&lt;/span&gt; in cash and issued Luca Consulting
&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20231010__20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zDwg78mazDLd" title="Stock issued during period, shares"&gt;200,000&lt;/span&gt; shares of restricted common stock. The agreement contains customary confidentiality and non-circumvention provisions. The shares
were valued at $&lt;span id="xdx_90D_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zpnWL06zEUE4" title="Stock issued price per share"&gt;0.60&lt;/span&gt; per share for a total of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pid_c20231010__20231010__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__dei--LegalEntityAxis__custom--LucaConsultingLlcMember_zjAe5Judgemg" title="Stock issued during period, value"&gt;120,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssued1
      contextRef="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember"
      decimals="0"
      unitRef="USD">15000</us-gaap:StockIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-10-10_us-gaap_SubsequentEventMember_custom_ConsultingAgreementMember_custom_LucaConsultingLlcMember"
      decimals="INF"
      unitRef="USDPShares">0.60</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-10-102023-10-10_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember_custom_LucaConsultingLlcMember"
      decimals="0"
      unitRef="USD">120000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">682860</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">11745</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">694605</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3863</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</us-gaap:PropertyPlantAndEquipmentNet>
    <MGRX:FixedAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</MGRX:FixedAssets>
    <us-gaap:DepositsAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">16942</us-gaap:DepositsAssets>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">174241</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">191183</us-gaap:OtherAssets>
    <us-gaap:Assets contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1003287</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">33675</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2717</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2021-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">39270</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      unitRef="USD">78260</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">56725</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">260577</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">39270</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">128680</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">128680</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">389257</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">39270</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">8000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">8000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1337</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">800</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2628449</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">181</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-2015756</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-17701</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">614030</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-16720</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">1003287</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">8939</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2022-01-012022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">3255</us-gaap:CostOfRevenue>
    <MGRX:CostOfRevenues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">4089</MGRX:CostOfRevenues>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">4850</us-gaap:GrossProfit>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1996432</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">17520</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1996432</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">17520</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1991582</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-17520</us-gaap:OperatingIncomeLoss>
    <MGRX:ImputedInterestRelatedParty
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-6473</MGRX:ImputedInterestRelatedParty>
    <MGRX:ImputedInterestRelatedParty
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-181</MGRX:ImputedInterestRelatedParty>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-6473</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-181</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1998055</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-17701</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1998055</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-17701</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-10-072021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-10-072021-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Shares">10798083</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Shares">10798083</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-10-072021-12-31"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-10-072021-12-31"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-072021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">800</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">181</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">181</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-072021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-17701</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-17701</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-17701</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-16720</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">800</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">181</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-17701</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-16720</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3365000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">337</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">539728</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">540065</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">200</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1999800</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">2000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">234088</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">234088</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">151821</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">151821</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6473</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">6473</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1998055</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1998055</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13365000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1337</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2628449</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2015756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">614030</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13365000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1337</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2628449</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2015756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">614030</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1998055</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-17701</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">3863</us-gaap:Depreciation>
    <MGRX:IssuanceOfCommonStockForServices
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">540065</MGRX:IssuanceOfCommonStockForServices>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">6473</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">181</us-gaap:InterestExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">234088</us-gaap:ShareBasedCompensation>
    <MGRX:WarrantsForServiceCancelled
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-151821</MGRX:WarrantsForServiceCancelled>
    <us-gaap:IncreaseDecreaseInDepositOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">16942</us-gaap:IncreaseDecreaseInDepositOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">11745</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">174241</MGRX:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">33675</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">185405</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">2717</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1346518</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">-17520</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">43102</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-43102</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">75000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">39270</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">25070</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">800</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">2049930</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">40070</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">660310</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-10-072021-12-31"
      decimals="0"
      unitRef="USD">22550</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">682860</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22550</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:ContributionOfProperty
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">78260</us-gaap:ContributionOfProperty>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_805_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zprwrOCul4H8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 &#x2013; &lt;span id="xdx_825_zhilY9hCUpJ4"&gt;ORGANIZATION AND DESCRIPTION OF THE BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mangoceuticals, Inc. (&#x201c;Mangoceuticals&#x201d; or the &#x201c;Company&#x201d;),
was incorporated in the State of a Texas on &lt;span id="xdx_904_edei--EntityIncorporationDateOfIncorporation_c20220101__20221231_zGBUehANNMM2" title="Date of incorporation"&gt;October 7, 2021&lt;/span&gt;, with the intent of focusing on developing, marketing, and selling a variety
of men&#x2019;s wellness products and services via a telemedicine platform. To date, the Company has identified men&#x2019;s wellness telemedicine
services and products as a growing sector in the most recent years and especially related to the areas of erectile dysfunction (ED). In
this regard, Mangoceuticals has developed and is currently in the process of preparing to commercially market a new brand of ED product
under the brand name &#x201c;Mango.&#x201d; This product is produced at a compounding pharmacy using a proprietary combination of U.S. Food
and Drug Administration (&#x201c;FDA&#x201d;) approved ingredients and is available to patients on the determination of a prescribing physician
that the compounded drug is necessary for the individual patient. Mangoceuticals is currently marketing and selling this new brand of
ED product exclusively online via its website at &lt;span style="text-decoration: underline"&gt;www.MangoRx.com&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mangoceuticals
plans to market and sell this new brand of ED products exclusively online and will require the use of a telemedicine visit, a doctor&#x2019;s
prescription and the fulfillment of the prescription by pharmacy licensed in the state in which the customer resides.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 25.95pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impact
of COVID-19 Pandemic on Consolidated Financial Statements.&lt;/i&gt; The outbreak of the 2019 novel coronavirus disease (&#x201c;COVID-19&#x201d;),
which was declared a global pandemic by the World Health Organization on March 11, 2020, and the related responses by public health and
governmental authorities to contain and combat its outbreak and spread has severely impacted the U.S. and world economies during the
end of the first quarter of 2020, and continuing through the end of 2022. COVID-19 and the U.S. response to the pandemic are significantly
affecting the economy. There are no comparable events that provide guidance as to the effect the COVID-19 pandemic may have, and, as
a result, the ultimate effect of the pandemic is highly uncertain and subject to change. The Company does not yet know the full extent
of the effects on the economy, the markets we serve, our business, or our operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Moving
forward, economic recessions, increased inflation and/or interest rates, including those brought on by the continued COVID-19 outbreak
may have a negative effect on the demand for our services and our operating results. Any prolonged disruption to our operations or workforce
availability is likely to have a significant adverse effect on our results of operations, cash flows and ability to meet continuing debt
service requirements. All of the above may be exacerbated in the future as the COVID-19 outbreak and the governmental responses thereto
continue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2022-01-012022-12-31">2021-10-07</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zccpqDWH7U7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="abc_002"&gt;&lt;/span&gt;NOTE
2 &#x2013; &lt;span id="xdx_82B_zKT3SZ5fToSh"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zl0LWu022Ftb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Basis
of Presentation&lt;/span&gt; &#x2013; &lt;/b&gt;The financial statements present the financial position, results of operations and cash flows of the Company
in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_865_zMLgBDKVUJv9" style="display: none"&gt;Basis
of Preparation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqGvzgcRejG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zDDDltW6eFD7"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the
majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insures
the total cash balance up to $&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zSUbtzyJPKW2" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt; per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, and
the excess would be at risk of loss for purposes of the statement of cash flows. There are &lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8qdOIxSTQ1b" title="Cash equivalents"&gt;&lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zXGLVpdMLuI5" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents at December 31, 2022
 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zmEN3HlOgpE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z2IJvFQC74Vg"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (&#x201c;ASC&#x201d;)
740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured using enacted tax rates
expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in
tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce
deferred tax assets to the amount that is more likely than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zigppskZO7Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zrGxXkGjTFR5"&gt;Net
Loss Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
compute net loss per share in accordance with ASC 260, &lt;i&gt;Earnings&lt;/i&gt;&lt;i&gt; per Share&lt;/i&gt; (&#x201c;ASC 260&#x201d;). ASC 260
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) on the face of the statement of operations.
Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares
outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the
period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average
stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or
warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zgaEi1peE4Oa" title="Anti-dilutive securities"&gt;1,250,000&lt;/span&gt; options, &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5Nko9cSctB2" title="Anti-dilutive securities"&gt;2,000,000&lt;/span&gt;
warrants and no derivative securities outstanding as of December 31, 2022. These were excluded because their effect would be anti-dilutive.
There were no options, warrants nor derivative securities outstanding as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zy6JJ1GbZep8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zMrRStIaDkw9"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with US GAAP requires the Company&#x2019;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases
will, differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zsPUu87JF5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zbSpYL66boT6"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, which provides guidance with respect to valuation techniques to be utilized
in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices),
(ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity
of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zv48K9wbXr23"&gt;SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1741"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1743"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1758"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1763"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zMubUzvLqyDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3zdvDvfpKUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zMy6APj0VJa4"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember_zuZALQuxDMSb" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt;) to five (&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember_zfeWc2DTshNi" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt;) years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zExz47PoCRSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zNH1coZdeGv2"&gt;Concentration
and Risks&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing
operations which were derived from a single or a few major customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQJ9Su7Xbslf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Binomial
Calculation Model&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_86E_zp5CMlYlnvY2" style="display: none"&gt;Black
Scholes Option Pricing Model&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBASBHZEgpnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zjdxtEXNx2nl"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;i&gt;&#x201c;&lt;span style="text-decoration: underline"&gt;Debt &#x2013; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013;
40)&lt;/span&gt;&lt;/i&gt;. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#x2019;s own equity. The ASU is part of the FASB&#x2019;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#x2019;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zp2aZa5mM4Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zTwHksa6PKd4"&gt;Related
Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure
of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section
825&#x2013;10&#x2013;15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such
as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company;
e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the
management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing
its own separate interests; and g. other parties that can significantly influence the management or operating policies of the
transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to
an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zI8Z0VOgvfCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zv0yc8j1B8m1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (&#x201c;ASC 718&#x201d;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zxwhSaUY1Uak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z4IJ12cfj9Kh"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue
is generated by selling directly to consumers through our websites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through
websites. The transaction price in the Company&#x2019;s contracts with customers is the total amount of consideration to which the Company
expects to be entitled in exchange for transferring products or services to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#x2019;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#x2019;s completion of its performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a Physician Services Agreement with BrighterMD, LLC &#160;&#160;dba Doctegrity (&#x201c;Doctegrity&#x201d;) to
provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer;
(ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs
costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company,
at its sole discretion, sets all listed prices charged on its websites for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq &#160;&#160;Scripts, LLC (&#x201c;Contracted
Pharmacy&#x201d;), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers
for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company&#x2019;s customers
for fulfillment through the Company&#x2019;s websites. The Company accounts for prescription product revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills
a customer&#x2019;s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company,
including using the Company&#x2019;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer
for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices
charged on its websites for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zG5ilX5YTyog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zNwo7LFpL7P1"&gt;Subsequent
events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, &lt;i&gt;Subsequent Events&lt;/i&gt;, for the disclosure of subsequent
events. The Company will evaluate subsequent events through the date when the financial statements were issued.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_85C_zuYJB86uzqY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zl0LWu022Ftb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Basis
of Presentation&lt;/span&gt; &#x2013; &lt;/b&gt;The financial statements present the financial position, results of operations and cash flows of the Company
in accordance with accounting principles generally accepted in the United States of America (&#x201c;US GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_865_zMLgBDKVUJv9" style="display: none"&gt;Basis
of Preparation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zqGvzgcRejG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zDDDltW6eFD7"&gt;Cash
Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Highly
liquid investments with original maturities of three months or less are considered cash equivalents. The Company maintains the
majority of its cash accounts at a commercial bank. The Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) insures
the total cash balance up to $&lt;span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zSUbtzyJPKW2" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt; per commercial bank. From time to time, cash in deposit accounts may exceed the FDIC limits, and
the excess would be at risk of loss for purposes of the statement of cash flows. There are &lt;span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20221231_z8qdOIxSTQ1b" title="Cash equivalents"&gt;&lt;span id="xdx_90F_eus-gaap--CashEquivalentsAtCarryingValue_iI_do_c20211231_zXGLVpdMLuI5" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents at December 31, 2022
 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zmEN3HlOgpE7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_z2IJvFQC74Vg"&gt;Income
Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is a taxable entity and recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Income taxes are
provided in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (&#x201c;ASC&#x201d;)
740, &lt;i&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC 740&#x201d;). Deferred tax assets and liabilities are measured using enacted tax rates
expected to be in effect when the temporary differences reverse. The effect on the deferred tax assets and liabilities of a change in
tax rates is recognized in income in the year that includes the enactment date of the rate change. A valuation allowance is used to reduce
deferred tax assets to the amount that is more likely than not to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zigppskZO7Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86A_zrGxXkGjTFR5"&gt;Net
Loss Per Common Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
compute net loss per share in accordance with ASC 260, &lt;i&gt;Earnings&lt;/i&gt;&lt;i&gt; per Share&lt;/i&gt; (&#x201c;ASC 260&#x201d;). ASC 260
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) on the face of the statement of operations.
Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares
outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the
period using the treasury stock method and convertible preferred stock using the if-converted method. In computing Diluted EPS, the average
stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or
warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. There were &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--OptionsMember_zgaEi1peE4Oa" title="Anti-dilutive securities"&gt;1,250,000&lt;/span&gt; options, &lt;span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z5Nko9cSctB2" title="Anti-dilutive securities"&gt;2,000,000&lt;/span&gt;
warrants and no derivative securities outstanding as of December 31, 2022. These were excluded because their effect would be anti-dilutive.
There were no options, warrants nor derivative securities outstanding as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84C_eus-gaap--UseOfEstimates_zy6JJ1GbZep8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zMrRStIaDkw9"&gt;Use
of Estimates and Assumptions&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in accordance with US GAAP requires the Company&#x2019;s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results can, and in many cases
will, differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2022-01-012022-12-31">&lt;p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zsPUu87JF5K8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86E_zbSpYL66boT6"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB
ASC 820, &lt;i&gt;Fair Value Measurement&lt;/i&gt;, which provides guidance with respect to valuation techniques to be utilized
in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices),
(ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity
of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to
measure fair value into three broad levels. The following is a brief description of those three levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets
or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as
valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zv48K9wbXr23"&gt;SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1741"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1743"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1758"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1763"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zMubUzvLqyDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_z2WdIJ0vhOni" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables summarize our financial instruments measured at fair value as of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BB_zv48K9wbXr23"&gt;SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zygje1pzoxM7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYlh1GtG9a0f" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYvZ1kTI1Eg1" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDz5BF_zzn9u3hYmBCd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1735"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDz5BF_maFVNALzgaY_zcNGzvCyySyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Total assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1739"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzgaY_zqwGSfg3hdBj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1741"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1742"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1743"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzgaY_znxqF4gsjnT9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;682,860&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1747"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zavCcTV9YyPa" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zBDY7Panmep4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwsarL0dItzg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Fair Value Measurements at December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashAndCashEquivalentsFairValueDisclosure_iI_maAFVDze8p_zDirkhizm0Me" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; padding-bottom: 1.5pt"&gt;Cash&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1750"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1751"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsFairValueDisclosure_iTI_mtAFVDze8p_maFVNALzBwY_zNhd9HgVfMzh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LiabilitiesFairValueDisclosure_iTI_msFVNALzBwY_z2VqCPmUWsYk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1757"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1758"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1759"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FairValueNetAssetLiability_iTI_mtFVNALzBwY_zJmWHYzaQbz3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value, net asset
    (liability)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;22,550&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1763"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">682860</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">682860</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">682860</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">22550</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">22550</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">22550</us-gaap:FairValueNetAssetLiability>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84D_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_z3zdvDvfpKUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zMy6APj0VJa4"&gt;Property
and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;Property
and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed
from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial
statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful
lives of three (&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MinimumMember_zuZALQuxDMSb" title="Property plant and equipment estimated useful lives"&gt;3&lt;/span&gt;) to five (&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__srt--RangeAxis__srt--MaximumMember_zfeWc2DTshNi" title="Property plant and equipment estimated useful lives"&gt;5&lt;/span&gt;) years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2022-12-31_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="AsOf2022-12-31_srt_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-012022-12-31">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zExz47PoCRSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_zNH1coZdeGv2"&gt;Concentration
and Risks&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s operations are subject to risks including financial, operational, regulatory and other risks including the potential
risk of business failure. For the years ended December 31, 2022 and December 31, 2021, the Company had no significant revenue from continuing
operations which were derived from a single or a few major customers.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zQJ9Su7Xbslf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;Binomial
Calculation Model&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_86E_zp5CMlYlnvY2" style="display: none"&gt;Black
Scholes Option Pricing Model&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses a Black-Scholes option pricing model to determine the fair value of warrants and options issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zBASBHZEgpnb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zjdxtEXNx2nl"&gt;Recently
Issued Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as
of the specified effective date. Unless otherwise discussed, the Company believes that the effect of recently issued standards that are
not yet effective will not have a material effect on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2020-06, &lt;i&gt;&#x201c;&lt;span style="text-decoration: underline"&gt;Debt &#x2013; Debt with Conversion
and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2013;
40)&lt;/span&gt;&lt;/i&gt;. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity,
including convertible instruments and contracts on an entity&#x2019;s own equity. The ASU is part of the FASB&#x2019;s simplification initiative,
which aims to reduce unnecessary complexity in US GAAP. The ASU&#x2019;s amendments are effective for fiscal years beginning after December
15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact of ASU 2020-06 on its financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <MGRX:RelatedPartiesPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_840_ecustom--RelatedPartiesPolicyTextBlock_zp2aZa5mM4Tg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zTwHksa6PKd4"&gt;Related
Parties&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows subtopic 850-10 of FASB ASC 850, Related Party Disclosures for the identification of related parties and disclosure
of related party transactions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to Section 850-10-20, the related parties include a. affiliates of the Company; b. Entities for which investments in their equity securities
would be required, absent the election of the fair value option under the guidance of Fair Value Option Subsection of Section
825&#x2013;10&#x2013;15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such
as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company;
e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the
management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing
its own separate interests; and g. other parties that can significantly influence the management or operating policies of the
transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to
an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense
allowances, and other similar items in the ordinary course of business. The disclosures shall include: a. the nature of the relationship(s)
involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each
of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects
of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements
are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of
settlement. Material related party transactions have been identified in Notes 3, 5 and 7 in the notes to financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MGRX:RelatedPartiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2022-01-012022-12-31">&lt;p id="xdx_845_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zI8Z0VOgvfCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86D_zv0yc8j1B8m1"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes compensation costs to employees under FASB ASC 718 Compensation - Stock Compensation (&#x201c;ASC 718&#x201d;).
Under ASC 718, companies are required to measure the compensation costs of share-based compensation arrangements based on the grant-date
fair value and recognize the costs in the financial statements over the period during which employees are required to provide services.
Share-based compensation arrangements include stock options and warrants. As such, compensation cost is measured on the date of grant
at their fair value. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_84E_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zxwhSaUY1Uak" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_z4IJ12cfj9Kh"&gt;Revenue
Recognition&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
Company generates our online revenue through the sale of products and services purchased by customers directly through our online platform.
Online revenue represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes
revenue recognition adjustments recorded pursuant to US GAAP primarily relating to deferred revenue and returns reserve. Online revenue
is generated by selling directly to consumers through our websites.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which it expects to be entitled in exchange for those goods or services.&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
revenue generated through its online platform, the Company defines its customer as an individual who purchases products or services through
websites. The transaction price in the Company&#x2019;s contracts with customers is the total amount of consideration to which the Company
expects to be entitled in exchange for transferring products or services to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts that contain prescription products issued as the result of a consultation include two performance obligations:
access to (i) products and (ii) consultation services. The Company&#x2019;s contracts for prescription refills have a single performance
obligation. Revenue is recognized at the time the related performance obligation is satisfied by transferring the promised product to
the customer and, in contracts that contain services, by the provision of consultation services to the customer. The Company satisfies
its performance obligation for products at a point in time, which is upon delivery of the products to a third-party carrier. The Company
satisfies its performance obligation for services over the period of the consultation service, which is typically a few days. The customer
obtains control of the products and services upon the Company&#x2019;s completion of its performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has entered into a Physician Services Agreement with BrighterMD, LLC &#160;&#160;dba Doctegrity (&#x201c;Doctegrity&#x201d;) to
provide online telemedicine technology services to the Company. The Company accounts for service revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company determines which providers provide the consultation to the customer;
(ii) the Company is primarily responsible for the satisfactory fulfillment and acceptability of the services; (iii) the Company incurs
costs for consultation services even for visits that do not result in a prescription and the sale of products; and (iv) the Company,
at its sole discretion, sets all listed prices charged on its websites for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Additionally,
the Company has entered into a Master Services Agreement and Statement of Work with Epiq &#160;&#160;Scripts, LLC (&#x201c;Contracted
Pharmacy&#x201d;), which is a related party, to provide pharmacy and compounding services to the Company to fulfill its promise to customers
for contracts that include sale of prescription products and to fill prescriptions that are ordered by the Company&#x2019;s customers
for fulfillment through the Company&#x2019;s websites. The Company accounts for prescription product revenue as a principal in the arrangement
with its customers. This conclusion is reached because (i) the Company has sole discretion in determining which Contracted Pharmacy fills
a customer&#x2019;s prescription; (ii) Contracted Pharmacy fills the prescription based on fulfillment instructions provided by the Company,
including using the Company&#x2019;s branded packaging for generic products; (iii) the Company is primarily responsible to the customer
for the satisfactory fulfillment and acceptability of the order, and; (iv) the Company, at its sole discretion, sets all listed prices
charged on its websites for products and services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for shipping activities, consisting of direct costs to ship products performed after the control of a product has been
transferred to the customer, in cost of revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_845_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_zG5ilX5YTyog" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_861_zNwo7LFpL7P1"&gt;Subsequent
events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company follows the guidance in subtopic 855-10-50 of FASB ASC 855, &lt;i&gt;Subsequent Events&lt;/i&gt;, for the disclosure of subsequent
events. The Company will evaluate subsequent events through the date when the financial statements were issued.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <MGRX:PrepaidExpensesAndDepositsTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80B_ecustom--PrepaidExpensesAndDepositsTextBlock_zJSm2YB5uuNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 &#x2013; &lt;span&gt;PREPAID EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_82A_zrsAd8MODQt2"&gt;PREPAID
EXPENSES AND DEPOSITS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, and in association with the Master Services Agreement and Statement of Work with our related party
Contracted Pharmacy, the Company prepaid the related party Contracted Pharmacy $&lt;span id="xdx_90A_eus-gaap--OperatingCostsAndExpenses_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--MasterServicesAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zj5pmXl5rOZd" title="Prepaid the related party expense"&gt;15,000&lt;/span&gt; as a retainer to be credited towards future product
sales. As of December 31, 2022 and December 31, 2021, the balance was $&lt;span id="xdx_903_ecustom--PrepaidExpensesRelatedParty_iI_c20221231_z8FQpn7RYYnf" title="Prepaid expenses related party"&gt;11,745&lt;/span&gt; and $&lt;span id="xdx_902_ecustom--PrepaidExpensesRelatedParty_iI_c20211231_zooxdSoewhPh" title="Prepaid expenses related party"&gt;0&lt;/span&gt;. respectively. Additionally, the Company has signed
a lease agreement for office space, effective October 1, 2022. The initial security deposit was $&lt;span id="xdx_90D_eus-gaap--SecurityDeposit_iI_c20221001_zVKmOQksLPz6" title="Securtiy deposit"&gt;16,942&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</MGRX:PrepaidExpensesAndDepositsTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="From2022-01-012022-12-31_custom_MasterServicesAgreementMember_us-gaap_RelatedPartyMember"
      decimals="0"
      unitRef="USD">15000</us-gaap:OperatingCostsAndExpenses>
    <MGRX:PrepaidExpensesRelatedParty contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">11745</MGRX:PrepaidExpensesRelatedParty>
    <MGRX:PrepaidExpensesRelatedParty contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">0</MGRX:PrepaidExpensesRelatedParty>
    <us-gaap:SecurityDeposit contextRef="AsOf2022-10-01" decimals="0" unitRef="USD">16942</us-gaap:SecurityDeposit>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zxFxaK6Kzs3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_825_zhczP5OaGscj"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company acquired computers, office and custom product packaging equipment totaling $&lt;span id="xdx_90F_eus-gaap--PaymentsToAcquireMachineryAndEquipment_c20220101__20221231_zbn6f20ZEsTj" title="Property acquired value"&gt;121,362&lt;/span&gt;. Depreciation
for the years ended December 31, 2022 and 2021 was $&lt;span id="xdx_907_eus-gaap--Depreciation_c20220101__20221231_z7PtdvaxZH81" title="Depreciation expense"&gt;3,863&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Depreciation_dxL_c20211007__20211231_z4TndwNWhex6" title="Depreciation expense::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1801"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively. Total net property and equipment was $&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20221231_zNnW0nU4Kmmd" title="Property plant and equipment net"&gt;117,499&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentNet_iI_dxL_c20211231_zH2EAcdPLBrc" title="Property plant and equipment net::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1805"&gt;0&lt;/span&gt;&lt;/span&gt;, as of December 31, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxyIOXSUtr3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zcYYUSYfHjej" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zesVQFOY5otk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zUSb9ScIwbq5" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_z6V6muUREk9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Computers&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1810"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zdDH7zmJQxJi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;116,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNR0W1yiGpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,863&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z81M7spwxWZh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;117,499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zYzqX7hNRBG2" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">121362</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">3863</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_899_eus-gaap--PropertyPlantAndEquipmentTextBlock_zxyIOXSUtr3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zcYYUSYfHjej" style="display: none"&gt;SCHEDULE
OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20221231_zesVQFOY5otk" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20211231_zUSb9ScIwbq5" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersMember_z6V6muUREk9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Computers&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;5,062&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1810"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zdDH7zmJQxJi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;116,300&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1813"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_zNR0W1yiGpe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less accumulated depreciation:&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,863&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentNet_iTI_z81M7spwxWZh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;117,499&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1819"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_custom_ComputersMember"
      decimals="0"
      unitRef="USD">5062</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">116300</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">3863</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">117499</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4tvWK5IrHA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_829_zixfBrIEA3x6"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2021 and March 18, 2022, the Company received advances of $&lt;span id="xdx_907_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zrrvNHsoLfg1" title="Related party advances received"&gt;39,200&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220318__20220318__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zDC1i6YtvbAh" title="Related party advances received"&gt;50,000&lt;/span&gt;, respectively, for a total of $&lt;span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zba4MXZDMN4h" title="Related party advances received"&gt;89,200&lt;/span&gt; from
its previous majority shareholder, American International Holdings Corp (&#x201c;AMIH&#x201d;), in order to cover various general and administrative
expenses. The advances bear no interest and are due on demand upon the Company&#x2019;s ability to repay the advances from either future
revenues or investment proceeds. On June 16, 2022, Cohen Enterprises, Inc. (&#x201c;Cohen Enterprises&#x201d;), an entity owned
and controlled by Jacob D. Cohen, the Company&#x2019;s Chief Executive Officer and Chairman of the Board of Directors, entered into and
closed a Stock Purchase Agreement (the &#x201c;SPA&#x201d;) for the purchase of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zSIMoXnJdAs" title="Issuance of shares"&gt;8,000,000&lt;/span&gt; shares of the outstanding common stock of the
Company which were then held by AMIH, which represented &lt;span id="xdx_900_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20220616__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--CohenEnterprisesIncMember_zQHQIi6IBnzf" title="Equity ownership interest"&gt;80%&lt;/span&gt; of the Company&#x2019;s then outstanding shares of common stock, in consideration
for $&lt;span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220615__20220616__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zaXuJJwEc6bc" title="Proceeds from issuance of common stock"&gt;90,000&lt;/span&gt;. Pursuant to the terms of the SPA, Cohen Enterprises also acquired the right to be repaid the $&lt;span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220615__20220616__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember_zDWmlutQmvk2" title="Repayments of related party debt"&gt;89,200&lt;/span&gt; advanced from AMIH
to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 29, 2022, the Company received an advance of $&lt;span id="xdx_903_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20220628__20220629__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_z11cQwltOsSl" title="Related party advances received"&gt;25,000&lt;/span&gt; from Cohen Enterprises in order to cover various general and administrative
expenses. The Company repaid Cohen Enterprises $&lt;span id="xdx_90E_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220817__20220818__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_ziDGZauM3F3" title="Repayments of related party debt"&gt;25,000&lt;/span&gt; on August 18, 2022 bringing the total amount owed to Cohen Enterprises to $&lt;span id="xdx_90A_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zQ7QgyfEDX06" title="Repayment of related party debt"&gt;89,200&lt;/span&gt;
as of December 31, 2022. As of December 31, 2021, the balance was $&lt;span id="xdx_901_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zjiNbnVGufb9" title="Repayment of related party debt"&gt;39,200&lt;/span&gt;. The Company recorded imputed interest equal to eight percent
(&lt;span id="xdx_905_ecustom--InterestExpenseRelatedPartyPercentage_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zLF3lWetvm4e" title="Imputed interest percentage"&gt;8%&lt;/span&gt;) per annum, or $&lt;span id="xdx_90D_eus-gaap--PaymentsForAdvanceToAffiliate_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zDPICgRm9hF9" title="Related party transaction purchases"&gt;4,674&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--PaymentsForAdvanceToAffiliate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CohenEnterprisesIncMember_zLFF26pGTOB7" title="Related party transaction purchases"&gt;181&lt;/span&gt;, against the related party advances for the years ended December 31, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 10, 2021, the Company received an advance of $&lt;span id="xdx_902_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20211210__20211210__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zNfdbIeaqb26" title="Related party advances received"&gt;70&lt;/span&gt; from ZipDoctor, Inc., a wholly-owned subsidiary of its then majority shareholder,
AMIH, which was used to open and establish the Company&#x2019;s bank account. The advance bears no interest and is due on demand upon
the Company&#x2019;s ability to repay the advance from either future revenues or investment proceeds. The amount was paid in full on May
24, 2022 and the amount owed to ZipDoctor was $&lt;span id="xdx_907_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_z8oigcTNmNx7"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zLAqDiNlhVe6"&gt;70&lt;/span&gt; as of December 31, 2022 and December 31, 2021, respectively. Imputed interest
equal to eight percent (&lt;span id="xdx_90F_ecustom--InterestExpenseRelatedPartyPercentage_pid_dp_uPure_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zeA3XM0Bkfg4" title="Imputed interest percentage"&gt;8%&lt;/span&gt;) per annum, or $&lt;span id="xdx_900_eus-gaap--PaymentsForAdvanceToAffiliate_c20220101__20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_zKAFCbSkMNG8" title="Related party transaction purchases"&gt;2 &lt;/span&gt;and $&lt;span id="xdx_90F_eus-gaap--PaymentsForAdvanceToAffiliate_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ZipDoctorIncMember_z8JXeMrrzjRl" title="Related party transaction purchases"&gt;0&lt;/span&gt;, was recorded against the related party advance as of December 31, 2022 and 2021,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Chief Executive Officer, Jacob D. Cohen, has made his personal credit card available for purchases on behalf of the Company
to cover various general and administrative expenses. Mr. Cohen has been repaid a total of $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfRelatedPartyDebt_c20220101__20221231__srt--TitleOfIndividualAxis__custom--JacobDCohenMember_zQIoZT8zqsuh" title="Repayments of related party debt"&gt;248,151&lt;/span&gt; as of December 31, 2022 for Company
purchases made on his personal credit card. &#160;&#160;There was no balance due as of December 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
additional information on related party prepaid expense see Note 3 and for related party stock-based transactions see Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-12-102021-12-10_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">39200</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-03-182022-03-18_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2023-01-012023-09-30_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember"
      decimals="INF"
      unitRef="Shares">8000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2022-06-16_custom_CohenEnterprisesIncMember"
      decimals="INF"
      unitRef="Pure">0.80</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-06-152022-06-16_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">90000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-06-152022-06-16_custom_StockPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2022-06-282022-06-29_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-08-172022-08-18_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">89200</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-01-012021-12-31_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">39200</us-gaap:RepaymentsOfRelatedPartyDebt>
    <MGRX:InterestExpenseRelatedPartyPercentage
      contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember"
      decimals="INF"
      unitRef="Pure">0.08</MGRX:InterestExpenseRelatedPartyPercentage>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2022-01-012022-12-31_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">4674</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2021-01-012021-12-31_custom_CohenEnterprisesIncMember"
      decimals="0"
      unitRef="USD">181</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2021-12-102021-12-10_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">70</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2021-01-012021-12-31_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">70</us-gaap:RepaymentsOfRelatedPartyDebt>
    <MGRX:InterestExpenseRelatedPartyPercentage
      contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember"
      decimals="INF"
      unitRef="Pure">0.08</MGRX:InterestExpenseRelatedPartyPercentage>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2022-01-012022-12-31_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">2</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="From2021-01-012021-12-31_custom_ZipDoctorIncMember"
      decimals="0"
      unitRef="USD">0</us-gaap:PaymentsForAdvanceToAffiliate>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2022-01-012022-12-31_custom_JacobDCohenMember"
      decimals="0"
      unitRef="USD">248151</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zrDLVtWx8oxc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 &#x2013; &lt;span id="xdx_82B_zedDvcTXJl8e"&gt;NOTES PAYABLE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;On November 18, 2022, the Company
entered into a note payable with a vendor for the purchase of equipment in the amount of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20221118_zBs9iRYygtT9" title="Debt instrument face amount"&gt;78,260&lt;/span&gt;. The note bears no interest and is due
in three payments of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPayment_c20230101__20230101_zQVCkq8z9e27" title="Debt instrument periodic payment"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20230201__20230201_zyoODReq12uf" title="Debt instrument periodic payment"&gt;&lt;span id="xdx_902_eus-gaap--DebtInstrumentPeriodicPayment_c20230301__20230301_zkoKD3h44iql" title="Debt instrument periodic payment"&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; each on January 1, 2023, February 1, 2023, and March 1, 2023, a $&lt;span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_c20230401__20230401_z48zBHVYJiA7" title="Debt instrument periodic payment"&gt;31,630&lt;/span&gt; payment is due on April 1, 2023 and
a final payment is due on May 1, 2023 for the outstanding balance. The outstanding balance on December 31, 2022 was $&lt;span id="xdx_901_eus-gaap--NotesPayable_iI_c20221231_zg7uLcKyjUA5" title="Notes payable"&gt;78,260&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="AsOf2022-11-18" decimals="0" unitRef="USD">78260</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-01-012023-01-01"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-02-012023-02-01"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-03-012023-03-01"
      decimals="0"
      unitRef="USD">5000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-04-012023-04-01"
      decimals="0"
      unitRef="USD">31630</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:NotesPayable contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">78260</us-gaap:NotesPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z19KKraDpTyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7&lt;/b&gt;&lt;b&gt; &#x2013; &lt;span id="xdx_82B_ziBPst2JUnq9"&gt;CAPITAL
STOCK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue up to &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231_zgTTndP4Kv4h" title="Preferred stock, shares authorized"&gt;&lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zKFfpPRQNbb4" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt;&lt;/span&gt; shares of &#x201c;blank check&#x201d; preferred stock, $&lt;span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zuwynNIVMxpl" title="Preferred stock par value"&gt;&lt;span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_uUSDPShares_c20211231_zC0AAo3JxgRe" title="Preferred stock par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; par value. All preferred
stock were undesignated as of December 31, 2022 and December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Common
Stock&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zfAtL9czMWf" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zvHmqg1xxAAh" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt;&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20221231_zh5Ee8uyRmL" title="Common stock par value"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_uUSDPShares_c20211231_zjRAuAZlXFEe" title="Common stock par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt; per share, of which &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20221231_zs23tA0cKzYe" title="Common stock shares issued"&gt;&lt;span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zTiLnhMBhDVf" title="Common stock shares outstanding"&gt;13,365,000&lt;/span&gt;&lt;/span&gt; shares were issued
and outstanding at December 31, 2022 and &lt;span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20211231_z1dZCQ4H6rgd" title="Common stock shares issued"&gt;&lt;span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z8TozicLBGVe" title="Common stock shares outstanding"&gt;8,000,000&lt;/span&gt;&lt;/span&gt; were issued and outstanding at December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 6, 2022, the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zjZLJeo0w9ke" title="Shares issued in consideration"&gt;1,000,000&lt;/span&gt; shares of restricted common stock to the Company&#x2019;s co-founder and CEO, Jacob D. Cohen,
in consideration for services rendered. The shares were valued at $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zgg8XQkfODMf" title="Shares issued in consideration,share price"&gt;0.10&lt;/span&gt; per share, based on recent third-party sales of shares, for a
total of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z7zVIQdSgB82" title="Shares issued in consideration value"&gt;100,000&lt;/span&gt;. Mr. Cohen is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 6, 2022, the Company issued &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_z2YU8G9rZY4j" title="Shares issued in consideration"&gt;1,000,000&lt;/span&gt; shares of restricted common stock to the Company&#x2019;s co-founder, President and COO, Jonathan
Arango, in consideration for services rendered to the Company. The shares were valued at $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zkZl4LQCM1X9" title="Shares issued in consideration,share price"&gt;0.10&lt;/span&gt; per share, based on recent third-party
sales of shares, for a total of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220406__20220406__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zs5v12wmxAlh" title="Shares issued in consideration value"&gt;100,000&lt;/span&gt;. Mr. Arango is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
June 23, 2022, the Company issued &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220623__20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_ztBmiK6oWup6" title="Shares issued in consideration"&gt;250,000&lt;/span&gt; shares of restricted common stock to The Loev Law Firm, PC in consideration for legal services
rendered to the Company. The managing partner of The Loev Law Firm, PC is David M. Loev, who is the brother-in-law of the Company&#x2019;s
CEO, Jacob D. Cohen. The shares were valued at $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_z9s6zafao86k" title="Share price"&gt;0.10&lt;/span&gt; per share, based on recent third-party sales of shares, for a total of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220623__20220623__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--LeovLawFirmMember_z0LckWaVlEGg" title="Shares issued in consideration value"&gt;25,000&lt;/span&gt;.
Mr. Loev is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 8, 2022, the Company began a private placement of up to $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220808__20220808__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zAkLjVCwqbOc" title="Shares issued value"&gt;2,000,000&lt;/span&gt; of units (the &#x201c;Units&#x201d;), each consisting of one
share of common stock (the &#x201c;Shares&#x201d;) and a warrant to purchase one share of common stock (the &#x201c;Warrants&#x201d;), at
a price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zFfLmoJ5GYD9" title="Share price"&gt;1.00&lt;/span&gt; per Unit. The Warrants have a &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_uUSDPShares_c20220808_zzbQLlVEKDKc" title="Warrants term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1925"&gt;five-year&lt;/span&gt;&lt;/span&gt; term and an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220808_zNbDuqumIJ2l" title="Exercise price"&gt;1.00&lt;/span&gt; per share, for which cash would need to
be remitted to us for exercise in the event that the shares underlying the warrants have been registered, otherwise the Warrants are
exercisable on either a cash basis or a cashless basis. The offering of the Units is referred to as the &#x201c;Offering.&#x201d; The Units
were offered by the Company only to investors that qualify as &#x201c;accredited investors,&#x201d; as that term is defined in Rule 501(a)
of Regulation D promulgated by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) under the Securities Act of 1933, as
amended (the &#x201c;Securities Act&#x201d;). The price of the Units were determined by the Company and such price did not necessarily
bear any relation to the book value or other recognized criteria of value of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Offering commenced on August 8, 2022 and the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220808__20220808_zUHwwSVSt8Oc" title="Sale of stock, shares"&gt;2,000,000&lt;/span&gt; Units at $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220808_zrDWSi3vOZw" title="Share price"&gt;1.00&lt;/span&gt; per Unit to 23 investors in exchange for $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_c20220808__20220808__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJTOokKTOqbj" title="Proceeds from investors"&gt;2,000,000&lt;/span&gt;
in gross proceeds from each investor, and subsequently issued the investors &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220816__20221231_zdBnKGmTZl4f" title="Sale of stock, shares"&gt;2,000,000&lt;/span&gt; Shares and &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_z6eGwT7T4OTb" title="Warrants issued"&gt;2,000,000&lt;/span&gt; Warrants between August 16,
2022 and December 31, 2022. As of December 31, 2022, the fair value of Warrants outstanding to investors was $&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231_zqhKMmf1GB48" title="Fair value of warrants"&gt;1,438,299&lt;/span&gt;. Because the
Warrants vested immediately, the fair value was assessed on the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 6, 2022, we entered into a Consulting Agreement with PHX Global, LLC &#160;&#160;(&#x201c;PHX&#x201d;), which is owned by Peter
&#x201c;Casey&#x201d; Jensen, who is a member of the Board of Directors of AMIH. Pursuant to the Consulting Agreement, PHX agreed
to provide consulting and general business advisory services as reasonably requested by the Company during the term of the agreement,
which was for 12 months, unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure
such breach 30 days after written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company
issued PHX &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcyBwzL9iCJi" title="Shares issued"&gt;50,000&lt;/span&gt; shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions.
The shares were valued at $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQvN4OSsyY6i" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--PHXGlobalLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQc319LyiT3" title="Shares issued value"&gt;13,921&lt;/span&gt;. PHX is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 6, 2022, we entered into a Consulting Agreement with Ezekiel Elliott (&#x201c;Elliott&#x201d;), currently a professional football
player and the running back for the Dallas Cowboys, to provide consulting and general business advisory services as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Elliott &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkdHKczVU5Ng" title="Shares issued"&gt;100,000&lt;/span&gt; shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zahdjkEw1887" title="Share price"&gt;0.28 &lt;/span&gt;per share for a total of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220906__20220906__dei--LegalEntityAxis__custom--EzekielElliottMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zJZft5JsYe5e" title="Shares issued value"&gt;27,842&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 15, 2022, we entered into a Consulting Agreement with David Sandler, an individual (&#x201c;Sandler&#x201d;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Sandler &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zld2LwNFlUQ3" title="Shares issued"&gt;10,000&lt;/span&gt;
shares of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were
valued at $&lt;span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKeYisrPFYB1" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--DavidSandlerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRFkqWryOUQl" title="Shares issued value"&gt;2,784&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 15, 2022, we entered into a Consulting Agreement with Hsiaoching Chou, an individual (&#x201c;Chou&#x201d;), to provide consulting
and general business advisory services as reasonably requested by the Company during the term of the agreement, which was for six months,
unless otherwise earlier terminated due to breach of the agreement by either party, and the failure to cure such breach 30 days after
written notice thereof. In consideration for agreeing to provide the services under the agreement, the Company issued Chou &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zaO5jJWoOXk1" title="Shares issued"&gt;5,000&lt;/span&gt; shares
of restricted common stock. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued
at $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvbnHFSMdBs" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220915__20220915__srt--TitleOfIndividualAxis__custom--HsiaochingChouMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8b52etEvnO9" title="Shares issued value"&gt;1,392&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 22, 2022, we entered into a service agreement with Greentree Financial Group, Inc. (&#x201c;Greentree&#x201d; and the &#x201c;Service
Agreement&#x201d;). Pursuant to the Service Agreement, Greentree agreed to perform the following services: (a) bookkeeping services for
the Company for the period from October 1, 2022 through June 30, 2023; (b) advice and assistance to the Company in connection with the
conversion of its financial reporting systems, including its projected financial statements, to a format that is consistent with US
GAAP; (c) assistance to the Company with compliance filings for the quarters ended September 30, 2022, March 31, 2023, June 30, 2023
and the year ended December 31, 2022, including the structure and entries as well as assistance with US GAAP footnotes;
(d) reviewing, and providing advice to the Company on, all documents and accounting systems relating to its finances and transactions,
with the purpose of bringing such documents and systems into compliance with US GAAP or disclosures required by the SEC; and (e) providing
necessary consulting services and support as a liaison for the Company to third party service providers, including coordination amongst
the Company and its attorneys, CPAs and transfer agent. Since February 2015, Mr. Eugene (Gene) M. Johnston, our Chief Financial Officer
(who was appointed October 1, 2022) has served as Audit Manager for Greentree.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company agreed to issue Greentree &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z2UErOVVDDE" title="Shares issued in consideration"&gt;100,000&lt;/span&gt; shares of the Company&#x2019;s restricted common stock upon the parties&#x2019; entry into the
agreement, and to pay Greentree $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_z9OWJbKvLao6" title="Paid in cash"&gt;50,000&lt;/span&gt; in cash, payable as follows: &lt;span id="xdx_906_eus-gaap--CommonStockConversionFeatures_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember_zyJnm43mMYVa" title="Settlement description"&gt;(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023&lt;/span&gt;. We also agreed to include the &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--GreentreeFinancialGroupMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZq7tgRMzOg5" title="Shares new issued"&gt;100,000&lt;/span&gt;
shares of common stock issued to Greentree in the Resale Prospectus, which shares of common stock are included therein, and to reimburse
Greentree for its reasonable out-of-pocket expenses incurred in connection with Greentree&#x2019;s activities under the agreement, including
the reasonable fees and travel expenses for the meetings on behalf of the Company. The Service Agreement includes customary indemnification
obligations requiring the Company to indemnify Greentree and its affiliates with regard to certain matters. The shares were valued at
$&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_zwZk8aGIgOc4" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember_ztakrZ6pyCid" title="Shares issued value"&gt;27,842&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 1, 2022, the Company executed a Summary of Terms and Conditions (&#x201c;Offer Letter&#x201d;) with Gene Johnston (&#x201c;Johnston&#x201d;)
appointing Johnston to serve as the Company&#x2019;s Chief Financial Officer on a full-time basis for a term of 12 months. Pursuant to
the Offer Letter, the Company issued Johnston &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zgb7WDH2nSIe" title="Restricted stock issued"&gt;150,000&lt;/span&gt; shares of the Company&#x2019;s restricted stock and vest over a 6-month period at
the rate of &lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221001__20221001__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoPsUBIlqeaf" title="Shares vested"&gt;25,000&lt;/span&gt; shares per month with the first &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20221101__20221101__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjtS2cR6FTi9" title="Shares vested"&gt;25,000&lt;/span&gt; shares vesting on November 1&lt;sup&gt;st&lt;/sup&gt;, 2022. Johnston is eligible to participate
in any of the Company&#x2019;s future sponsored benefit plans, including but not limited to, health insurance benefits, 401k, stock option
or restricted stock grants, and other fringe benefits, once established, and no earlier than the first of the month following 105 days
of Johnston&#x2019;s start date. Johnston is also eligible to receive equity incentive grants or cash bonus awards as determined by the
Company&#x2019;s Board (or a committee of the Board) in their sole discretion. The shares were valued at $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zy3rM3OqxRR" title="Share price"&gt;0.28 &lt;/span&gt;per share for a total of
$&lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221001__20221001__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_znHlssWNeWI" title="Shares issued value"&gt;41,763&lt;/span&gt;. Mr. Johnston is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 13, 2022, the Company approved the appointments of each of Alex Hamilton (&#x201c;Hamilton&#x201d;), Dr. Kenny Myers (&#x201c;Myers&#x201d;)
and Lorraine D&#x2019;Alessio (&#x201c;Alessio) to serve as independent members of the Board of Directors and&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
entered into Director Offer Letter agreements with Hamilton, Myers and D&#x2019;Alessio compensating each of them with &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zr77GlLClka1" title="Restricted stock issued"&gt;75,000&lt;/span&gt; shares of
restricted common stock (for a total of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c20221013__20221013__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwwlzsQE5DWb" title="Restricted stock issued net"&gt;225,000&lt;/span&gt; shares) (the &#x201c;Director Shares&#x201d;). The Director Shares were issued under the
Company&#x2019;s 2022 Equity Incentive Plan (the &#x201c;Plan&#x201d;), with the following vesting schedule: 1/3 of the Director Shares
vested on October 14, 2022, and the remaining Director Shares will vest annually in one-third increments commencing on the first anniversary
date thereof. The shares were valued at $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_ztri0cDqr373" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zaR0gnNGNcia" title="Shares value"&gt;20,881&lt;/span&gt;. These individuals are related parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 14, 2022, the Company issued its Project Manager, Joan Arango, &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20221014__20221014__srt--TitleOfIndividualAxis__custom--JoanArangoMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zpuiQkRWCmu9" title="Restricted common stock issued"&gt;25,000&lt;/span&gt; shares of restricted common stock under the Plan. The shares
were issued to Ms. Arango as a bonus for services rendered to date. Ms. Arango is the sister of the Company&#x2019;s President and Chief
Operating Officer, Jonathan Arango. The shares were valued at $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_zhHMZQ1vuusk" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221014__20221014__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__custom--JoanArangoMember_zVqYUfvgXeqj" title="Shares value"&gt;7,204&lt;/span&gt;. Ms. Arango is a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 1, 2022, we entered into a Consulting Agreement with White Unicorn, LLC (&#x201c;White Unicorn&#x201d;), to provide business advisory
services related to product packaging, strategic marketing, branding, advertising and future product development as reasonably requested
by the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued White Unicorn &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHmzQQ7ITdP9" title="Shares issued"&gt;100,000&lt;/span&gt; shares of restricted common stock. The agreement contains customary
confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221101__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zeBLn7flpVG8" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221101__20221101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--WhiteUnicornLLCMember_z78BNfxG0a42" title="Shares value"&gt;28,816&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 9, 2022, we entered into a Consulting Agreement with Global Career Networks, Inc. (&#x201c;Global&#x201d;) to provide marketing
services as reasonably requested by the Company during the term of the agreement, which is for six months unless otherwise earlier terminated
due to breach of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration
for agreeing to provide the services under the agreement, the Company issued Global &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEKcedeDg98f" title="Shares issued"&gt;100,000&lt;/span&gt; shares of restricted common stock. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z71FZUg4qjh6" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221209__20221209__dei--LegalEntityAxis__custom--GlobalCareerNetworksIncMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLLaR31a5p16" title="Shares issued value"&gt;28,816&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 21, 2022, we entered into a Consulting Agreement with Chartered Services, LLC (&#x201c;Chartered Services&#x201d;), to provide
strategic marketing services for advertising and consulting, product distribution, digital marketing and identifying creative and constructive
brand awareness to the Company during the term of the agreement, which is for six months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, the Company agreed to pay Chartered Services $&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zlZlaSxmoxd1" title="Paid in cash"&gt;150,000&lt;/span&gt; in cash (&lt;span id="xdx_900_eus-gaap--CommonStockConversionFeatures_c20221221__20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_zse18P8rkRha" title="Settlement description"&gt;with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000&lt;/span&gt; shares of restricted common stock.
The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20221221__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__dei--LegalEntityAxis__custom--CharteredServicesLLCMember_z69c1bCZUoVg" title="Share price"&gt;0.28&lt;/span&gt; per share for a total
of $&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20221221__20221221__dei--LegalEntityAxis__custom--CharteredServicesLLCMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOQoZNuLCZkh" title="Shares issued value"&gt;72,039&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company granted options to purchase a total of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zIvBl2kuCoZa" title="Number of options"&gt;1,250,000&lt;/span&gt; shares of common stock,
of which &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zBdm04VV3Pf4" title="Number of options granted"&gt;750,000&lt;/span&gt; were granted to Jacob Cohen, the Company&#x2019;s CEO, and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoPlanMember_zWPHaiZbhmZb" title="Number of options granted"&gt;500,000&lt;/span&gt; were granted to Jonathan Arango, the Company&#x2019;s
President and COO, as Bonus Equity Shares related to their respective employment agreement. The options have an exercise price of $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zElCtDJhEgae" title="Exercise price"&gt;1.10&lt;/span&gt;
per share, an original life of five years and vest at the annual renewal of their employment over &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2fp8oOGua78" title="Vesting term"&gt;three years&lt;/span&gt;. As of December 31, 2022,
$&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231_zip64gV5bRi" title="Share based compensation"&gt;82,267&lt;/span&gt; has been recorded as stock-based compensation. Both Mr. Cohen and Arango are related parties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFQ9mTYd1mUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock options activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zmxzQdBkkpvk" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfv0MGxuIbe1" style="text-align: right" title="Options, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2035"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zN8BW6OCny14" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2037"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zSrPSGHbvuW6" style="width: 16%; text-align: right" title="Options, Granted"&gt;1,250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zuBdwVacSAI" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zbQF8cnMfUL5" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2043"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zOakZRnLunH3" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zBJnFiZ6IWM6" style="text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2047"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_z6HBjICtft8i" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2049"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zAtz53k6Gd2b" style="text-align: right" title="Options, Outstanding Ending Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zwebE1QXQ4dl" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zJB1Cha6VH4i" style="text-align: right" title="Options, Exercisable Ending Balance"&gt;133,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zMZVhPWnSnfd" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20220101__20221231_zQn5skYMKtj4" style="width: 13%; text-align: right" title="Option Exercise Price Per Share"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zUvzjHEQCMk1" style="width: 13%; text-align: right" title="Outstanding Ending Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zu3Ihh8EzdLb" title="Options Term"&gt;4.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zdfZrNcJrmyk" style="width: 13%; text-align: right" title="Weighted Average Outstanding Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zyn2TAT3PEOa" style="width: 13%; text-align: right" title="Exercisable Ending Balance"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zIvM10tSOKHc" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zHD1ZkAoGTa8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the fair value of options outstanding was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20221231_zJ1N5gUJA3bf" title="Fair value of options outstanding"&gt;688,984&lt;/span&gt;. The aggregate initial fair value of the options measured on
the grant date of August 31, 2022 was calculated using the Black-Scholes option &#160;&#160;pricing model based on the following assumption:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQ6JxRHlI772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_znVgFVy2pF38" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231_zzL2TOKhG9N6" style="width: 14%; text-align: right" title="Fair value of common stock on measurement date"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zvOrrmtjR2d2" title="Risk-free interest rate"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zQ460uEm9Xr8" title="Volatility"&gt;92.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zVlmAjG216zl" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zqyrWwP8FWi8" title="Expected term"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company does not expect to pay a dividend in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zdH82mflRGFd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ended December 31, 2022, the Company issued a total of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zhpvu2YSvzp5" title="Warrants issued"&gt;2,000,000&lt;/span&gt; Warrants to investors and &lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_zgEJg43hZIZk" title="Warrants issued for services"&gt;210,070&lt;/span&gt; Warrants as compensation
for services rendered in connection with the Offering. The Warrants have an original life of five years and vest immediately. The Warrants
for services were expensed as stock-based compensation at the aggregate fair value in the amount of $&lt;span id="xdx_902_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_c20220101__20221231_zt0buDyfL3Be" title="Fair value of warrant"&gt;151,821&lt;/span&gt;. Because the Warrants vest
immediately the fair value was assessed on the grant date. The aggregate fair value of the Warrants were measured using the Black-Scholes
option pricing model. The Company and the holder of &lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20221231_ziZf21L6gey4" title="Warrants issued for services"&gt;210,070&lt;/span&gt; Warrants for services agreed to cancel the Warrants and reversed the entries
for stock based compensation to zero at year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, the fair value of Warrants outstanding to investors was $&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zZsoOlnoC6hc" title="Fair value of warrants outstanding"&gt;1,438,299&lt;/span&gt;. Because the Warrants vested immediately
their fair value was assessed on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpi7F1Mp7Dh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock warrants activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zJk73NNH3RBb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRbHK54XpMg3" style="text-align: right" title="Warrants Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2097"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNejRM6N0fXb" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2099"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRNn5P0enlGa" style="width: 16%; text-align: right" title="Warrants Granted"&gt;2,210,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3T9LPDWwQ7" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Granted"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeTliNAnLnFe" style="text-align: right" title="Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2105"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z67sIyNRrFuh" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2107"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjJpCUAI8I" style="text-align: right" title="Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9T2GOhGthRe" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2111"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdbvENdkeMie" style="text-align: right" title="Warrants Cancelled"&gt;(210,070&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znNCowjp1Ai9" style="text-align: right" title="Weighted Average Exercise Price Cancelled"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6iIASFSpjb" style="text-align: right" title="Warrants Outstanding, Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMtyggziK6hd" style="text-align: right" title="Weighted Average Exercise Price Ending Balance"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3NLjhjGSxYi" style="text-align: right" title="Warrants Exercisable Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoH9R2qqvG4b" style="text-align: right" title="Weighted Average Exercise Price Exercisable price"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding and Exercisable Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                                                                 (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeQNSF8rmD2" style="width: 30%; text-align: right" title="Warrants Exercise Price Per Share"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8g7Mdt9ysue" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthrO8mkf6n2" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term"&gt;4.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zJgo7LfpoZgb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2022, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z62apZB4xIM7" title="Warrants outstanding"&gt;2,000,000&lt;/span&gt; Warrants are outstanding and vested, and the vested stock Warrants have a weighted average remining life
of &lt;span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7jpXEWPVYm7" title="Outstanding and vested warrants expected term"&gt;4.74&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPEGDsUf92i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BC_z9wemA891r8" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWISYOmTNbL4" title="Fair value of common stock on measurement date"&gt;0.62&lt;/span&gt; - $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztJTTO9yhpG2" title="Fair value of common stock on measurement date"&gt;0.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS1lvbebtna7" title="Risk-free interest rate"&gt;2.95%&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjd88JF9Jki5" title="Risk-free interest rate"&gt;4.00&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS2mSedIdXn4" title="Volatility"&gt;88.92%&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSqQ4I40eb71" title="Volatility"&gt;92.87%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDOCefVqkoc" title="Dividend rate"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA55nUZLTbL6" title="Expected term"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not expect to pay a dividend in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A3_zd3sFhMDuzC9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">13365000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">8000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">8000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefExecutiveOfficerMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-04-062022-04-06_us-gaap_RestrictedStockUnitsRSUMember_srt_ChiefOperatingOfficerMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-06-232022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember"
      decimals="INF"
      unitRef="USDPShares">0.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-06-232022-06-23_us-gaap_RestrictedStockUnitsRSUMember_custom_LeovLawFirmMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-08-082022-08-08_us-gaap_PrivatePlacementMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-08"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-08-08"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-08-082022-08-08"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-08-08"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2022-08-082022-08-08_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="0"
      unitRef="USD">2000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-08-162022-12-31"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">1438299</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-062022-09-06_custom_PHXGlobalLLCMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">13921</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-062022-09-06_custom_EzekielElliottMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">27842</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-152022-09-15_custom_DavidSandlerMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">2784</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-09-152022-09-15_custom_HsiaochingChouMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">1392</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommonStockConversionFeatures contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember">(a) $12,500 on or before September 30, 2022; (b) $12,500 on or before
December 31, 2022; (c) $12,500 or before March 31, 2023; and (d) $12,500 on or before June 30, 2023</us-gaap:CommonStockConversionFeatures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-01-012022-12-31_us-gaap_RestrictedStockMember_custom_GreentreeFinancialGroupMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-31_custom_ServiceAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-01-012022-12-31_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">27842</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-11-012022-11-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-01_us-gaap_RestrictedStockMember_srt_ChiefFinancialOfficerMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-012022-10-01_srt_ChiefFinancialOfficerMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">41763</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2022-10-132022-10-13_srt_DirectorMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">225000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_srt_DirectorMember_custom_TwentyTwentyTwoEquityIncentivePlanMember"
      decimals="0"
      unitRef="USD">20881</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-10-142022-10-14_custom_JoanArangoMember_us-gaap_RestrictedStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-10-142022-10-14_us-gaap_RestrictedStockMember_custom_JoanArangoMember"
      decimals="0"
      unitRef="USD">7204</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-11-012022-11-01_custom_WhiteUnicornLLCMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">28816</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-12-092022-12-09_custom_GlobalCareerNetworksIncMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">28816</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2022-12-212022-12-21_custom_CharteredServicesLLCMember"
      decimals="0"
      unitRef="USD">150000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommonStockConversionFeatures contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember">with $75,000 payable upon entry into the agreement and $75,000 payable on January 31, 2023) and issued Chartered Services 250,000</us-gaap:CommonStockConversionFeatures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2022-12-212022-12-21_us-gaap_RestrictedStockMember_custom_CharteredServicesLLCMember"
      decimals="0"
      unitRef="USD">72039</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember_srt_ChiefOperatingOfficerMember_custom_TwentyTwentyTwoPlanMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember_srt_ChiefExecutiveOfficerMember"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">82267</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zFQ9mTYd1mUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock options activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zmxzQdBkkpvk" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zfv0MGxuIbe1" style="text-align: right" title="Options, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2035"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220101__20221231_zN8BW6OCny14" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2037"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zSrPSGHbvuW6" style="width: 16%; text-align: right" title="Options, Granted"&gt;1,250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zuBdwVacSAI" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zbQF8cnMfUL5" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2043"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_zOakZRnLunH3" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220101__20221231_zBJnFiZ6IWM6" style="text-align: right" title="Options, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2047"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_uUSDPShares_c20220101__20221231_z6HBjICtft8i" style="text-align: right" title="Weighted Average Exercise Price, Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2049"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zAtz53k6Gd2b" style="text-align: right" title="Options, Outstanding Ending Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zwebE1QXQ4dl" style="text-align: right" title="Weighted Average Exercise Price, Outstanding Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zJB1Cha6VH4i" style="text-align: right" title="Options, Exercisable Ending Balance"&gt;133,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zMZVhPWnSnfd" style="text-align: right" title="Weighted Average Exercise Price, Exercisable Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for options granted, and exercisable as of December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Exercisable Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_uUSDPShares_c20220101__20221231_zQn5skYMKtj4" style="width: 13%; text-align: right" title="Option Exercise Price Per Share"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220101__20221231_zUvzjHEQCMk1" style="width: 13%; text-align: right" title="Outstanding Ending Balance"&gt;1,250,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zu3Ihh8EzdLb" title="Options Term"&gt;4.67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zdfZrNcJrmyk" style="width: 13%; text-align: right" title="Weighted Average Outstanding Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20221231_zyn2TAT3PEOa" style="width: 13%; text-align: right" title="Exercisable Ending Balance"&gt;133,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231_zIvM10tSOKHc" style="width: 13%; text-align: right" title="Weighted Average Exercisable Price Ending Balance"&gt;1.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">133333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31">P4Y8M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">133333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">688984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zQ6JxRHlI772" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B1_znVgFVy2pF38" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231_zzL2TOKhG9N6" style="width: 14%; text-align: right" title="Fair value of common stock on measurement date"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231_zvOrrmtjR2d2" title="Risk-free interest rate"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231_zQ460uEm9Xr8" title="Volatility"&gt;92.54&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20221231_zVlmAjG216zl" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231_zqyrWwP8FWi8" title="Expected term"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company does not expect to pay a dividend in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    Company, in accordance with Staff Accounting Bulletin (SAB) 14-D.2, used the simplified method (plain vanilla) to determine
    the overall expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0.0330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0.9254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">2000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">210070</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">151821</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2022-12-31" decimals="INF" unitRef="Shares">210070</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_InvestorMember"
      decimals="0"
      unitRef="USD">1438299</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_89A_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zpi7F1Mp7Dh3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes common stock warrants activity:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zJk73NNH3RBb" style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Outstanding, December 31, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRbHK54XpMg3" style="text-align: right" title="Warrants Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2097"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNejRM6N0fXb" style="text-align: right" title="Weighted Average Exercise Price Beginning Balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2099"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%"&gt;Granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRNn5P0enlGa" style="width: 16%; text-align: right" title="Warrants Granted"&gt;2,210,070&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zF3T9LPDWwQ7" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Granted"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeTliNAnLnFe" style="text-align: right" title="Warrants Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2105"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z67sIyNRrFuh" style="text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2107"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxjJpCUAI8I" style="text-align: right" title="Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2109"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9T2GOhGthRe" style="text-align: right" title="Weighted Average Exercise Price Expired"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2111"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdbvENdkeMie" style="text-align: right" title="Warrants Cancelled"&gt;(210,070&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znNCowjp1Ai9" style="text-align: right" title="Weighted Average Exercise Price Cancelled"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zl6iIASFSpjb" style="text-align: right" title="Warrants Outstanding, Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMtyggziK6hd" style="text-align: right" title="Weighted Average Exercise Price Ending Balance"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercisable, December 31, 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3NLjhjGSxYi" style="text-align: right" title="Warrants Exercisable Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_iE_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoH9R2qqvG4b" style="text-align: right" title="Weighted Average Exercise Price Exercisable price"&gt;1.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average exercise prices, remaining lives for warrants granted, and exercisable as of December 31, 2022, were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Warrants Exercise&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding and Exercisable Warrants&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Price Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life
                                                                                 (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYeQNSF8rmD2" style="width: 30%; text-align: right" title="Warrants Exercise Price Per Share"&gt;1.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber_iE_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8g7Mdt9ysue" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Ending balance"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zthrO8mkf6n2" style="width: 30%; text-align: right" title="Outstanding and Vested Warrants Expected Term"&gt;4.74&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="Shares">2210070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="Shares">-210070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.00</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="USDPShares">1.00</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue>
    <MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">2000000</MGRX:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber>
    <MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234">P4Y8M26D</MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234">P4Y8M26D</MGRX:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801406">&lt;p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--WarrantMember_zrPEGDsUf92i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BC_z9wemA891r8" style="display: none"&gt;SCHEDULE
OF FAIR VALUE ASSUMPTIONS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fair Value of Common Stock on measurement date&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zWISYOmTNbL4" title="Fair value of common stock on measurement date"&gt;0.62&lt;/span&gt; - $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_ztJTTO9yhpG2" title="Fair value of common stock on measurement date"&gt;0.72&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS1lvbebtna7" title="Risk-free interest rate"&gt;2.95%&lt;/span&gt; to &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjd88JF9Jki5" title="Risk-free interest rate"&gt;4.00&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zS2mSedIdXn4" title="Volatility"&gt;88.92%&lt;/span&gt; to &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSqQ4I40eb71" title="Volatility"&gt;92.87%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Dividend Yield&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGDOCefVqkoc" title="Dividend rate"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected Term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA55nUZLTbL6" title="Expected term"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as
    of the measurement date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
trading volatility was determined by calculating the volatility of the Company&#x2019;s peer group.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company does not expect to pay a dividend in the foreseeable future.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.8892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.9287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-12-31_us-gaap_WarrantMember40801234">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zXZE06xa5Ecd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_822_z3uxcKQ3TfUl"&gt;GOING CONCERN&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization
of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying
financials, the Company had a net loss of $&lt;span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_di_c20220101__20221231_zcoxvJv3YXU9" title="Net loss"&gt;1,998,055&lt;/span&gt; for the year ended December 31, 2022 and an accumulated deficit of $&lt;span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20221231_zndTQMDnMS11" title="Accumulated deficit"&gt;2,015,756&lt;/span&gt;
as of December 31, 2022. The Company will need to raise additional capital to successfully execute its business plan of which there can
be no assurance. The sources of this capital are expected to be the sale of equity and debt, which may not be available on favorable
terms, if at all, and may, if sold, cause significant dilution to existing shareholders. If we are unable to access additional capital
moving forward, it may hurt our ability to grow and to generate future revenues, our financial position, and liquidity, or force us to
abandon our business plan. These factors raise substantial doubt about the ability of the Company to continue as a going concern. Unless
management is able to obtain additional financing, it is unlikely that the Company will be able to meet its funding requirements during
the next 12 months. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">-1998055</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">-2015756</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zcayYwRMijae" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_82F_zOYkjV8m9q0d"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
the ordinary course of business, the Company may become a party to lawsuits involving various matters. The impact and outcome of litigation,
if any, is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm
its business. The Company is not currently subject to any such litigation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Operating
Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company has a lease for an office in Dallas, TX classified as operating leases &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="background-color: white"&gt;under
ASC 842, &lt;i&gt;Leases&lt;/i&gt;.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 28, 2022, and with an effective date of October 1, 2022, the Company entered into a Lease Agreement with Rox Trep Tollway,
L.P. (the &#x201c;Landlord&#x201d;) to lease and occupy approximately &lt;span id="xdx_907_eus-gaap--AreaOfLand_iI_usqft_c20220928_zE3gPM3ElVsb" title="Area of land"&gt;2,201&lt;/span&gt; square feet of office space located at 15110 Dallas Parkway,
Suite 600, Dallas, Texas 75248 to serve as the Company&#x2019;s main headquarters (the &#x201c;&lt;span style="text-decoration: underline"&gt;Lease Agreement&lt;/span&gt;&#x201d;). &lt;span id="xdx_903_eus-gaap--LesseeOperatingLeaseDescription_c20220928__20220928_zxXiqTuwEBn1" title="Operating lease, description"&gt;The Lease
Agreement has a term of thirty-eight (&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20220928_zBCZJtiLvAdl" title="Lease term"&gt;38&lt;/span&gt;) months and has a monthly base rent of $&lt;span id="xdx_90A_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928_zG08NoHFOMwd" title="Base rent"&gt;5,777.63&lt;/span&gt;, or $31.50 per square foot, from months 3-18,
which increases at the rate of $1 per square foot per annum thereafter until the end of the lease term&lt;/span&gt; (the &#x201c;&lt;span style="text-decoration: underline"&gt;Base
Rent&lt;/span&gt;&#x201d;). In addition to the Base Rent, the Company is required to reimburse the landlord for its pro-rata share of all real
estate taxes and assessments, hazard and liability insurance and common area maintenance costs for the building at the rate of &lt;span id="xdx_905_ecustom--PercentageOfProportionateRent_pid_dp_uPure_c20220928__20220928_zGRfPgOA6Ttl" title="Percentage of proportionate rent"&gt;2.45%&lt;/span&gt;
(the &#x201c;&lt;span style="text-decoration: underline"&gt;Proportionate Rent&lt;/span&gt;&#x201d;). Upon the execution of the Lease Agreement, the Company agreed to prepay the first full
month&#x2019;s Base Rent along with a security deposit equal to $&lt;span id="xdx_907_eus-gaap--PaymentsForRent_pp2d_c20220928__20220928__us-gaap--TypeOfArrangementAxis__custom--LeaseAgreementMember_zGt4WGPE423k" title="Base rent"&gt;16,941.79&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;The
Company utilizes the incremental borrowing rate &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;span style="background-color: white"&gt;in
determining the present value of lease payments unless the implicit rate is readily determinable. The Company used an estimated incremental
borrowing rate of &lt;span id="xdx_900_ecustom--PercentageOfIncrementalBorrowingRate_pid_dp_uPure_c20220928__20220928_zWB9sM41lobh" title="Percentage of incremental borrowing rate"&gt;8%&lt;/span&gt; to estimate the present value of the right of use liability.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has right-of-use assets of $&lt;span id="xdx_908_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zcXPKYDcblRf" title="Right of use of asset"&gt;174,241&lt;/span&gt; and operating lease liabilities of $&lt;span id="xdx_900_eus-gaap--OperatingLeaseLiability_iI_c20221231_zpyOi0i6Eqcl" title="Operating lease liability"&gt;185,405&lt;/span&gt; as of December 31, 2022. Operating lease expense
for the year ended December 31, 2022 was $&lt;span id="xdx_90E_eus-gaap--OperatingLeaseCost_c20220101__20221231_zumUp55RaZoi" title="Operating lease expense"&gt;16,942&lt;/span&gt;. The Company has recorded $&lt;span id="xdx_90E_eus-gaap--AssetImpairmentCharges_c20220101__20221231_zWBDXPzoF5ob" title="Asset impairment charges"&gt;0&lt;/span&gt; in impairment charges related to right-of-use assets during
the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv51npV57e2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zSOjxkum5cj" style="display: none"&gt;SCHEDULE
OF MATURITY OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity of Lease Liabilities at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_z8jP4j647OH3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20221231_pp0p0" style="width: 16%; text-align: right" title="Year One"&gt;69,515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20221231_pp0p0" style="text-align: right" title="Year Two"&gt;71,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_c20221231_pp0p0" style="text-align: right" title="Year Three"&gt;67,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zqfX6Beqgvbe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNPS6ta9cobh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23,415&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zwnEehXgygM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_ziFmjzeXaIE8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfLand contextRef="AsOf2022-09-28" decimals="INF" unitRef="sqft">2201</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2022-09-282022-09-28">The Lease
Agreement has a term of thirty-eight (38) months and has a monthly base rent of $5,777.63, or $31.50 per square foot, from months 3-18,
which increases at the rate of $1 per square foot per annum thereafter until the end of the lease term</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-09-28">P38M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:PaymentsForRent
      contextRef="From2022-09-282022-09-28"
      decimals="2"
      unitRef="USD">5777.63</us-gaap:PaymentsForRent>
    <MGRX:PercentageOfProportionateRent
      contextRef="From2022-09-282022-09-28"
      decimals="INF"
      unitRef="Pure">0.0245</MGRX:PercentageOfProportionateRent>
    <us-gaap:PaymentsForRent
      contextRef="From2022-09-282022-09-28_custom_LeaseAgreementMember"
      decimals="2"
      unitRef="USD">16941.79</us-gaap:PaymentsForRent>
    <MGRX:PercentageOfIncrementalBorrowingRate
      contextRef="From2022-09-282022-09-28"
      decimals="INF"
      unitRef="Pure">0.08</MGRX:PercentageOfIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">174241</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">185405</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">16942</us-gaap:OperatingLeaseCost>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_897_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zv51npV57e2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zSOjxkum5cj" style="display: none"&gt;SCHEDULE
OF MATURITY OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Maturity of Lease Liabilities at December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_z8jP4j647OH3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20221231_pp0p0" style="width: 16%; text-align: right" title="Year One"&gt;69,515&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c20221231_pp0p0" style="text-align: right" title="Year Two"&gt;71,716&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_c20221231_pp0p0" style="text-align: right" title="Year Three"&gt;67,589&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzowI_zqfX6Beqgvbe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;208,820&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zNPS6ta9cobh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(23,415&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiability_iI_zwnEehXgygM4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,405&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">69515</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">71716</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">67589</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">208820</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">23415</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">185405</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z5WgiUatoOM7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10- &lt;span id="xdx_82F_zwo6ZtOoQlA2"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the &#x201c;Act&#x201d;), which significantly changed U.S. tax law. The
Act lowered the Company&#x2019;s U.S. statutory federal income tax rate from &lt;span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MaximumMember_zDLuHO10x811" title="Statutory federal income tax rate, percentage"&gt;35%&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20171222__20171222__srt--RangeAxis__srt--MinimumMember_zdxVJWDYZ5ae" title="Statutory federal income tax rate, percentage"&gt;21%&lt;/span&gt; effective January 1, 2018, while also imposing
a deemed repatriation tax on previously deferred foreign income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Act also created a new minimum tax on certain future foreign earnings. The impact of the Act increases the Company&#x2019;s deferred
tax asset related to the Company&#x2019;s net operating loss by approximately $&lt;span id="xdx_909_eus-gaap--DeferredTaxAssetsGross_iI_c20221231_z1pBgVX4Hb4h" title="Deferred tax asset"&gt;2,015,756&lt;/span&gt; and increase the Company&#x2019;s valuation allowance
by approximately $&lt;span id="xdx_90A_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20221231_zxrFYRyzYCGb" title="Deferred tax assets, valuation allowance"&gt;2,015,756&lt;/span&gt; resulting in no impact to the Company&#x2019;s financials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
record tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgement changes as a result of
the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution
may result in a payment that is materially different from our current estimate of the recognized tax benefit liabilities. These differences
will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December
31, 2022, and 2021 we have not recorded any uncertain tax positions in our financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The effective US federal income corporate
tax rates for 2022 and 2021 are &lt;span id="xdx_901_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20220101__20221231_z2qxRl9fPgQ2" title="US federal income corporate tax rates, percentage"&gt;21%&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_c20210101__20211231_zc85FSnSL1ze" title="US federal income corporate tax rates, percentage"&gt;21%&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has net operating loss carry forwards of approximately $&lt;span id="xdx_90D_eus-gaap--OperatingLossCarryforwards_iI_c20221231_zh2hw1HavwYe" title="Net operating loss carry forwards"&gt;2,015,756&lt;/span&gt; at December 31, 2022 that do not expire. However, utilization
of these losses may be limited pursuant to Section 382 of the Internal Revenue Code due to a recapitalization in 2007 and subsequent
stock issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSa12UH9nVQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a deferred tax asset as shown in the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z3T4mU5qsMo6" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSET&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zFmT8XeCbYih" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year Ending December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zEZCNnucIaIl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year Ending December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_zdU2QVNyj0Wl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Deferred Tax Asset&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,015,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_zHsUZFtj0wx6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation Allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,015,756&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,701&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_z0L3lNNFcJSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2222"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zhlhlBzKEiJb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2017-12-222017-12-22_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2017-12-222017-12-22_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2015756</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2015756</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2021-01-012021-12-31"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2015756</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zSa12UH9nVQ4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has a deferred tax asset as shown in the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_z3T4mU5qsMo6" style="display: none"&gt;SCHEDULE
OF DEFERRED TAX ASSET&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20221231_zFmT8XeCbYih" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year Ending December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20211231_zEZCNnucIaIl" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Year Ending December 31,&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_maDTANzQFS_zdU2QVNyj0Wl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Deferred Tax Asset&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,015,756&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;17,701&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzQFS_zHsUZFtj0wx6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Valuation Allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,015,756&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(17,701&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzQFS_z0L3lNNFcJSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net Deferred Tax Asset&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2222"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2015756</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17701</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2022-12-31" decimals="0" unitRef="USD">2015756</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17701</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-012022-12-31">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zjfDU99Gm5ih" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_827_zKugN4RrnDm3"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 3, 2023, we entered into a Consulting Agreement with DojoLabs Group, Inc. (&#x201c;DojoLabs&#x201d;), to provide various strategic
marketing related services to the Company pursuant to a defined scope of work during the term of the agreement, which is the earlier
of a) all deliverables being received by the Company pursuant to the scope of work, or b) if terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company agreed to pay DojoLabs $&lt;span id="xdx_906_eus-gaap--Cash_iI_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUfkarDNSR3e" title="Cash"&gt;100,000&lt;/span&gt; in cash and issued DojoLabs &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zehfNDlvchA7" title="Shares issued"&gt;50,000&lt;/span&gt; shares of restricted common
stock with registration rights and fully vest upon the completion of all work performed under the scope of work. The agreement contains
customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zc7P9lX814W2" title="Share price"&gt;0.28 &lt;/span&gt;per share for a total of $&lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230103__20230103__dei--LegalEntityAxis__custom--DojoLabsMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi0TAUs4eep9" title="Shares issued"&gt;28,000&lt;/span&gt;.&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 6, 2023, we entered into a Consulting Agreement with Bethor, Ltd. (&#x201c;Bethor&#x201d;), to provide strategic advisory services
to the Company during the term of the agreement, which is for 12 months unless otherwise earlier terminated due to breach of the agreement
by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing to provide the
services under the agreement, the Company issued Bethor &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFCl17ukFpog" title="Shares issued"&gt;250,000&lt;/span&gt; shares of restricted common stock with registration rights. The agreement
contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90E_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zppYM6bmdGej" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__dei--LegalEntityAxis__custom--BethorLtdMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVahsqXlL6td" title="Shares issued value"&gt;70,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 6, 2023, the Company established an advisory board (the &#x201c;Advisory Board&#x201d;) and approved and adopted a charter (the
&#x201c;Advisory Board Charter&#x201d;) to govern the Advisory Board. Pursuant to the Advisory Board Charter, the Advisory Board shall
be comprised of a minimum of two (2) members, all of whom shall be appointed and subject to removal by the Board of Directors at any
time. In addition to the enumerated responsibilities of the Advisory Board in the Advisory Board Charter, the primary function of the
Advisory Board is to assist the Board of Directors in its general oversight of the Company&#x2019;s development of new business ventures
and strategic planning.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the establishment of the Advisory Board, the Board of Directors appointed Dr. Brian Rudman (&#x201c;Dr. Rudman&#x201d;)
and Mr. Jarrett Boon (&#x201c;Mr. Boon&#x201d;), both of whom are independent, non-Board members and non-Company employees, to the Advisory
Board. Dr. Rudman will serve as Chairman of the Advisory Board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with Dr. Rudman&#x2019;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#x201c;Dr. Rudman
Consulting Agreement&#x201d;), dated effective January 6, 2023, with Dr. Rudman, whereby the Company agreed to issue Dr. Rudman &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuSIeLR0uNRg" title="Shares issued"&gt;25,000&lt;/span&gt;
shares of the Company&#x2019;s restricted common stock, pay Dr. Rudman $&lt;span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4eaOkxvWtbh" title="Compensation expense"&gt;2,000&lt;/span&gt; per month in cash, and reimburse Dr. Rudman for reasonable
out-of-pocket expenses, including, without limitation, travel expenses incurred by him in connection with the Company&#x2019;s requests
of the performance of his duties to the Company in service on the Advisory Board. The shares were valued at $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztmjmkuCsAY5" title="Share price"&gt;0.28 &lt;/span&gt;per share for a total
of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--RudmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zE8gqTjmI6cd" title="Shares issued value"&gt;7,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with Mr. Boon&#x2019;s appointment to the Advisory Board, the Company entered into an Advisor Agreement (the &#x201c;Mr. Boon
Consulting Agreement&#x201d;), dated effective January 6, 2023, with Mr. Boon, whereby the Company agreed to issue Mr. Boon &lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqb8t2R1Qfz" title="Shares issued"&gt;25,000&lt;/span&gt; shares
of the Company&#x2019;s restricted common stock and to reimburse Mr. Boon for reasonable out-of-pocket expenses, including, without limitation,
travel expenses incurred by him in connection with the Company&#x2019;s requests of the performance of his duties to the Company in service
on the Advisory Board. The shares were valued at $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ztgMovpx7VGg" title="Share price"&gt;0.28&lt;/span&gt; per share for a total of $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230106__20230106__srt--TitleOfIndividualAxis__custom--BoonMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBZpqGn9qTo8" title="Shares issued value"&gt;7,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 24, 2023, we entered into Consulting Agreements with four consultants to the Company: (1) Sultan Haroon; (2) John Helfrich; (3)
Justin Baker; and (4) Maja Matthews, each of whom is also an employee of Epiq Scripts. Pursuant to the Consulting Agreements, the Consultants
agreed to provide us services related to the research, development, packaging and marketing for additional pharmaceutical and other over-the-counter
related products during the term of the agreement, which each have a term of 18 months unless otherwise earlier terminated due to breach
of the agreement by either party and the failure to cure such breach 30 days after written notice thereof. In consideration for agreeing
to provide the services under the agreement, &lt;span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zG9lE3BeRUqb" title="Settlement description"&gt;the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#x2019;s successful launch of a new product category, and 50,000 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#x2019;s successful launch of a new product category, and 7,500 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.&lt;/span&gt; Any shares not vested by the eighteen-month anniversary of the applicable agreement
are forfeited. The agreement contains customary confidentiality and non-solicitation provisions. The shares were valued at $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_uUSDPShares_c20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_z8k6d1Z6Atrc" title="Share price"&gt;0.28&lt;/span&gt; per
share for a total of $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20230124__20230124__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementsMember_zJ1UXs6jWio8" title="Shares issued value"&gt;98,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">100000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">50000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-032023-01-03_custom_DojoLabsMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">28000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-062023-01-06_custom_BethorLtdMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">70000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-062023-01-06_custom_RudmanMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-062023-01-06_custom_BoonMember_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockConversionFeatures contextRef="From2023-01-242023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember">the Company issued an aggregate of 350,000 shares of common stock to the consultants as follows: (1) Sultan Haroon 150,000 shares of restricted common stock; (2) John Helfrich 25,000 shares of restricted common stock; (3) Justin Baker 25,000 shares of restricted common stock; and (4) Maja Matthews 150,000 shares of restricted common stock. The shares issued to Haroon and Matthews vest at the rate of 50,000 shares upon entry into the agreement, 50,000 shares upon the Company&#x2019;s successful launch of a new product category, and 50,000 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement. The shares issued to Helfrich and Baker vest at the rate of 10,000 shares upon entry into the agreement, 7,500 shares upon the Company&#x2019;s successful launch of a new product category, and 7,500 shares upon the Company&#x2019;s successful launch of a second and additional new product category, in each case prior to the 18-month anniversary of the applicable agreement.</us-gaap:CommonStockConversionFeatures>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember"
      decimals="INF"
      unitRef="USDPShares">0.28</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-242023-01-24_us-gaap_RestrictedStockMember_custom_ConsultingAgreementsMember"
      decimals="0"
      unitRef="USD">98000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M'\2R5B<;X(H0NIA5A8SO+D5>,RL7XD2*)XZ)M):>&].]"*O:QG<7)Z^IF<H
M,\U?/-N^.]R(QP/2'[JX506/[RY5[ 2>XZEJ.Q4WP![Q^_LN*I5,^.[\_E%@
M7H=))'"M;\]Q#2"D3PY'1_[(Q:A2!G\G:3"%%"8T7$\+(6MUH0'G7J2'- CP
M0(AI$C7< KH85B+A[Z02TP0W$ESD"C\K5<O0C=-0/Y-*%<A.JG"=,+DP%<?/
MB( %BZEG:%H;NP; )F:5%) &*3!U%@;_7N!I1\ 75922U\^:F9,D/&!IHKA5
MV E6;B*L)>L>8XZ%B9-MI03$G;;7<XF12S7% O'KG:WS:D^0;JP?/$*22A3(
M?WSB)?_'D9=44D'>)A6[% 4-D&\O"D@E'^1M\K%+4=  N4M10"H-(6X)>&M1
MT #76!202E+(3D>/MQ4%#9C.HH!4VD)VTI:W% 4-B$U% :E4A;C58)US, \J
M<RB,MY[8&H!^I8&8M:XZZ%+$TCINW8T+1*,9]II4X5D43P_%76+YMKR*/2\N
M(*ONQ3WN'362HR!F<S3U.L>X!V1Q-5HTM,CL=>1,:"T2^Q@Q&C)I.N#WN1!Z
MW3 #E!?4XW\ 4$L#!!0    ( #"*DE?Y(,\11@<  #4H   8    >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&ULM9IK<]HX%(;_BH9V.MF9)%B2;[0),P33EMD$
MLH'L97;V@V)$\-38U!:Y[*]?R2886T*XU/NA#9=S7O0>2\>/95\\Q\FW=$$I
M R_+,$HO6PO&5A_;[=1?T"5)S^,5C?@W\SA9$L;?)H_M=)50,LN2EF$;&8;=
M7I(@:G4OLL]ND^Y%O&9A$-';!*3KY9(DKU<TC)\O6[#U]L%=\+A@XH-V]V)%
M'NF$LOO5;<+?M;<JLV!)HS2((Y#0^66K!S]ZV!8)6<3O 7U.=UX#8>4ACK^)
M-\/99<L0(Z(A]9F0(/S/$^W3,!1*?!S?-Z*M[6^*Q-W7;^J?,_/<S -):3\.
M_PAF;''9<EM@1N=D';*[^/DKW1BRA)X?AVGV/WC>Q!HMX*]3%B\WR7P$RR#*
M_Y*732%V$J"Y)P%M$E#=!+Q)P'43S$V"F54FMY+5P2.,="^2^!DD(IJKB1=9
M,;-L;C^(Q'&?L(1_&_ \UKTB(8E\"B9"(05GX'[B@9/WOURT&5<7,6U_HW25
M*Z$]2A.Z.@?8. 7(0%B1WM>G>]3GZ3!+1XITKWXZ+*>W>4FV=4';NJ!,#^_1
MZTTF@^E$584\SU3GB67Z,5T1GUZV^#I,:?)$6]T/[Z!M?%+5I$DQKR&Q4KWP
MMEY8I][MDW0!2#0#OGA!OZ^#)Q+2B*6J$N925B8E&M-3%R)L.Z9ST7[:K8X<
M9[O(M8URF">'(619153)D+DU9&H-#:,G/OPX>549R%/MW5^$E@LKP]?^@/IX
M -5Q/4+GX'&UMF6PM&6X3>B*!#- 7_B9)J7*PVE)U7!-[*)*->0H"!W3JAQ+
M[6AJU:QDT][:M+4VI^-I[QKT[^_N!J,IV+_X;=D$-I$#*U.R+\?9'=,VJF[E
M,,W,=;9>'&WK^CS\<^!I/#A--K FQ;R&Q$I5<[=5<P],=,Y2"7O-FICH7RM.
M-^P41)R]XCGG$W^]7(>$T1G'"O[[?D R<.'?O<>GKJTZY5VY\G0QD(FJLT41
MQI=&IU.9+5H#/[XV.MO*=&JLC4.SJE//JB),954[HA^W"HT"APSMXAE/OP[N
M-#8WZ0VMGD;5O*;4RJ7;(4FHG2<>7<5IH#[C;U)+QYUWQ.HYHEZ8IQ_($=.C
MH$*HA:AN=ETDUOPZI1R629I2IO2+%"<*;&)<-:R(<TQDPJKC(]A.Z[C@.J@'
MNWSU'UP66/9A&=BQJGX5<1T(75SUJQW4$7X+[(-Z[LO]:IS*[ >M#C]I2U85
M@8:!D>M4O2IH<C\%P(+<H*5M96\T<SWL70VOA]/A0&WH".32=+0FU;RFU,H5
M+* 0ZJFPY_OQFE_#@!5Y)0\AS=B DT"RYA00!N0A" ,6J*$8RFSG=@RK4YTE
M<ACFET)54-0/]-A"%$0)M>C5O26O21R&@)&7@[X=V3<RJAB@B.(4+:V,(X!0
MVP4*&(1Z&LSZ_%D\/Q-]_LWQ*^_X A(Y^$6/(*0DI<H*R#AG\R97O;A5A%FV
M@Z0CWS#UP0+[8!WNJ]M%%&!G<=-VU;4<A_AUD2,=>CD.=Y"SIRFB@N^0GN^N
MQZ,O9]/!W<TA0ZA1T&M4S6M*K5S# O20'O1^9G$@F?!<3@IN99HHPB!R;;>Z
M]:,?Z8^O#K2S/Z@GP7QUU)].,N@I?2MX4.F[81Y$!0^B.CQXR*V,><@T;->L
MVI7CL-M!5K4;J.(TW:" /:2'O?[XYF8XO>'];0)Z(P_TQZ/I</1E,.IS8^!D
M,AB T7@Z !WE?KA>O/X&7_\8(4UW^#_V"U&!G4B/G9/IN/_KU_&U-[B;?'CG
M(NA\ H/?[H?3O\")-_@\[ ^GZFHVRJ&-JGE-J95+6G HTG-H/UXNXPBD+/:_
M@9,52< 3"=<4O#\W#".[YV&<&OD_D"X('P(@:[:(D^!?.CL5EZO/B\!? (A/
ML6UE88)DW6I2D*:";,5W\9JEC+\0S9RD0L*C/ET^T&1[DR:+$[=;3@%/7M'L
M#E[XJCZXBHU3VZG"L"H*8ZD9*,C:V-<*"L1%>L3MS6:!V- C(<@VO(,(^&05
M,!(J_<C\RB_N($:VU-$5I&LCUS2K6UXJR9U;"F5;!<@B/<CV2ON6\\ /E/L5
M2(;1,]>V#8BJ *>*1 :T',NN&E)$0L<Q]GDJP!35 =.C^XR"5+%ENJAZ^T81
M:$/3P-*Y6(X[XY,;[9F2N&!5K.4X^52;G:..];WYL<,;%ZI Y<:%(E"S<8$+
MOL0'^)+F\_66B/WXOV^RMO./TM,1^+?_G-&HFM>46KF(!9]B_0WLFM=MN-';
MV8VJ>4VIE2NX<T=;3[JCF-'MUH^R=C^_2;DIFXRWG(*KFR:>(DQ#P;B@8*RG
MX%$<)?677).LVF]4S6M*K5S'@GQQ(QNNN%'0;53-:TJM7,$"=+$>= \ON2/V
M0=5++A?:?6C$<9'\:,G/_UY>BO;.(UKB@;H;DCP&40I".N?*QKG#1Y+DSZCE
M;UB\RI[:>H@9BY?9RP4E,YJ( /[]/.:UVKP1#X)MGQ3L_@=02P,$%     @
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M'_!S6Z_7]1XV^>_;:OVQVOX/@+G%87Y<+)9=@)6KY%VY7%S:FMZ6#\O6?D9
M9SCH^ZJU/:I:)$6YW2PWGQL,J\"Q_E/;NOC%KFR3'-J%']J%[W#D ,[K<E5N
MYE52MLE/\_9%DNH?$IYR!C&/(G4CS<OFH9Q7KR[L4-)4VZ_5Q4T"44^$,R/"
M*<['\:@7!^K%%.I_2)K[T@)/:@(4,:()3L#YTQ^83O\&M0,E6$$$YK6(/+2(
M1%ODS?KAL;7]\\VFK2QZ"[4 BA#1 L\X>H?3S;)?;UAFF_SK,;%$O@K<ET>5
M.E"E4*K^;=<6_ZJ;!J((+1E!$1'.3 6/?\F,27ML%Z-F'E'Z0)3&8ZII'G<C
M;#?O'4].=O&5W-E:+^<5R.(SK#JJ3I:F?I5O4=<1#!'A%#J@\+C.'G_FP)^9
MS-_\F;_FP%^SY^_[& KQ:* Z=?_UN$2K$3LD4H(51& >_=F!_FSJ^F!6S5\D
M@@U/3MF$B,TF#'NA#=A?(3-M^$"\Y8<'SF-GY=$'SR>&&.HY-L0HP0HB,(]Q
MECIMD)X][^(0$;/*'LAKK2SOA2"5MV+$FT_8D9AB)\^^>-$8HHB 9GL@OZ?F
M*N^17HS;^70YC<,FBYRWY?;0ESE('Y\PBNV-O&$L-6D_B$*K2V%$'ZT [904
M R,9<P*#12N,\><7$P<SW'?L:$:*5E"A^;P[&<%P'1$S:>ZA1N)MBEH C,!Y
M$[0;GCB9DP0,UP2G3)TL7'4/A-L):@ )-TJT@@K-Y]TI#(9+#'0V.&%I/_B@
MMZ1H,U*T@H7BXY()+N60 F%.@C!<@QSUY[OJP09TBHR?)NC/S-KVHSE4)9QI
M:<(Y)#2T3R6Y#&<10.APH0P?>'JG -@D"7#<K<=9 -;Y/&5*A?T:=1X=4I1H
M!16:3[Q3(FR2%)DVCN93II%0J #32&@$3R.0W? TPIT:X+@:.&4:X< R&YQ&
M<-^QX4:*5E"A^;P[4<%Q43%%A>$0,3F <*UOAS_1BT4J=\68.Y^RH^0)+BRP
MF1<O&D,56;X$T!DLS[-4J5[?GF+I4^8T"<<UR<G[H7O<XQ%."-/OWJ%Z42(W
M/.L'%E$BI8 <VKE9#_'D- 0?R46<N^_)PV6^$%H!0^():09D2*1$*ZC0_$9P
MBH;CBN:GARX);*>@S2+YI=QNRTW;)#_;L=$.DZ/Q2I4&X:%$XD*F61#31 Z+
M<8<^G4ZH\.FYD ^;I>6R(_&V;.Y! L,," ^#-USUVX$J#]8^,[QJ,>R$'GEO
MJ>'3XV0&/R/5,;<LH=T=4!3P"H@TT4&*5E"A^0W@E ['E<ZABQ_W;1N?MDU6
MJVH!TGZ"1(![.93.4"SC_?4YE<=B@D>?1R=<^$G"!52*/!0N#)C70['!-<^D
M[&_< X:7G? T2O?7.*&E9C(=VG453K^(L_0+R(((]0N#9VO<>?31#5(!0X7F
M$^\$C, %3,PV_QX*U\LB5 W -C]@!6[S@W;#V_S"J1 Q*;T1M<TOPA4^+)AQ
MW]'Q1HE64*'YO!^=WQJ1,A,$,PX1<V(K%!I,97W!3.6N&'/G4^94C<!5#2:8
M\:(Q5!$!S020*1$L95E?+T\P] ES"D3@"N1DN;S']5;/7/4[-[#2Y](8U0\K
M*FD!.E2#:V?AI(68+BU.DLL"6-;O:A8,B*0Y$%*T@@K-;P0G8,3D/,D_'S=X
MAD  >9(T#%! U7 C@_T<P.Y22"/#G@KE4UB>BH$TB7#B042G2<9) -(D*1QU
MI&D24K2""LTGWJD-@:N-2=/P"0><X+D%$")!>F]&Y:X8<^<?<W821>(2!9N&
M\:(Q)YR)@&8R%$>7>2YSUN_<$PQ]PIRTD".YD5.G81GJ#-X7MS(4!ES+/,B&
MX'6,.0\..1R>A:53(A)7(F?/PC*4)1Q2P7@]8H=#4K2""LUO Z=*)*Y*SMFS
MQJ%C^CX@'W2>,=,/:2J],N[0I_/H2LCT/,SXGK4,3W,Q%00O<)K+QKCH&\[P
MJL6P WM4@SW>Z1,Y79]$[UG+4 WTJ[5GC/3P%RE:087F-X 3/A(7/C%GDV28
M40'.)DE "8%GDP##@;-)@"5V-DDZQ2$G*8ZHLTDRE  #9Y-PY]%A1YHJH4+S
MB7=J1YYT+P0F/+P8 FSQRU +P5O\@.' %C]@B6WQ2R<YY%F71& 6@,-7\!8_
M[CPZ[$@OBE"A^9<.G7!1Y]\4P2%B[A\"21FC^Z,@E;MBS)U/F9,NZO2[(GC1
M&*JH[HHH($G"E4ZS8"=GBJ5/F9,Q:KJ,B5)[*KP\TI\U;U4H<72>YR*(*ZKK
M[8!#@YQ74$YIJ.E'N4Y2>RI<M!LH!X77(W9 )$4KJ-#\-G#R1.'RY!RUAT/'
M]/Y07FC)3?_D I6_8M2?3^;1G?;I8F9<ZZDPP\*"#6P52AS9G4\*4BQXU6+(
M"3TJ['R2<E)#G9%C&=-Z"CBH!>YTXY6([NRD^14J-+\!G-I1D_,KQPE^ ?(-
MY%>4Z&L]!5P:$;GD_=EV!AA>2F6TEL%K%$)+D;'<+F4&XL]I#A6=81FG <BP
M*,& 53?N/#KN2#,L5&@^\4[N*+KS7&K2>2XU]3P78#@@]@!+3.QIISDT_7DN
M/?D\%^X\-NQ(T0HJ-)]XIUSTZ<H%+QI[KY$4;4:*5FA Y]AA5PHS%-E.Y^C)
M]^*/=\W @52'TH9ID_>C&;H8GS+!=3]C#UA>9EJGC/<[-H0IE!P\IZJ=@-'1
M]^/'>8 2#2;+P]U#W'ET4)&J%BHTGWBG6C2N6F(6,AI*J00+&1U* G@A Q@.
M+&0 2W0AHYW.T-$7Y<=I@'(EX$(&=QX==Z3)$BHTG_BC=W&-*)@)VX<X1(0J
MUD!Z)..BG]6G\E>,^O-)<ZI#XZH#G89/R$+ 9!$!S30@5+A=609GRXHIECYE
M3JEH7*F<_M*W,%42K)UU*&E$IG,=!!;511'0H1G<4-!.5^B1DUOG;B#J<,TO
M##0DDF942-$**C3_[7I.W1A<W9RS@8A#1_1^$\HE: .1RE\QZL\GTRD6@RN6
M X'5MVH[7S9[#N<#.X@F/!S&@G2\@2ZA<"GR_HH:KUL,.[#'P=,BQ@D.@PL.
MA!_T%8Z0JO KM.>*]%@8*5I!A>93[[2.F:1U^L>2P;6F":_:6XW#^F2'2BC/
M--.9[ =F:'BI,YUJW9=Z@*5(4RL>!UX!9YSB,),4Q]#I;)@&X-24I0&*NQ,R
M&TC<4:(55&@^\4[KF--?%(P7C9D_J%X5;,"7 .>Y[*?]BRF6/F5.I9CI>9:H
MU:,)SW=E_4@%3F))(_L'V/$:QLPEH#\UQ-'16X%_[]<"AZM_:.6(5R.Z9].^
M%_CW. )FG,@QN,@Y:^5(=6W> $>\[ P4Q#.5%AKUYY/II)"9G&(9W8(T0(HE
MW(J%K."M6,!R8"L6PL2V8C,G0[+H),LH#QF09(&W8G'GL;V8%*V@0GLF_NKH
M*UJZ;^!Y6VX_+VTG756?+'SZHINVML]?:O/\H:T?=M_:\K%NVWJ]^_&^*A?5
MMC.P?_]4U^WW#]T7P1R^6NCF_U!+ P04    "  PBI)7^^B<A= (  "(-
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U;:W.C.A+]*RK?K:V9JLT8
M))[9Q%6.(7M==<?QQIE,[4>"Y80[&!C >?S[E8 8(QHE=NE+@NWN(W34+?61
MX.(ES7\53Y26Z'4;)\7EZ*DLL_/QN B?Z#8HOJ493=@OFS3?!B7[F#^.BRRG
MP;IRVL9CK&G6>!M$R6AR47VWS"<7Z:Z,HX0N<U3LMML@?[NB<?IR.=)'[U_<
M1H]/)?]B/+G(@D>ZHN6/;)FS3^,]RCK:TJ2(T@3E=',YFNKG/G&X0V5Q']&7
MXN :\:X\I.DO_F&^OAQI_(YH3,.20P3LWS.=T3CF2.P^?C>@HWV;W/'P^AW]
MNNH\Z\Q#4-!9&O^,UN73Y<@9H37=!+NXO$U?_J1-ATR.%Z9Q4?U%+[6MS8S#
M75&FV\:9W<$V2NK_P6M#Q($#PX$=<.. /^M &@<B.A@##D;C8(@.UH"#V3A4
M71_7?:^(\X(RF%SDZ0O*N35#XQ<5^Y4WXRM*>*"LRIS]&C&_<K(J@Y*R@2\+
ME&[0+"B>T#4+G@*=H1\K#WWYQ]>+<<G:X=;CL,&\JC'Q "9!W].D?"J0GZSI
M&O"?R?W=C_Q]N;^.)0!C1M">)?S.TA66(GHT_(:(_B^$-:Q#'9*[KVC&W+7*
MG0#NWN?=,43'YV\>2\@@^Y A%1X9P)M-5W^BZ[]N?J[0]>W-=W2S]&^G=_/%
M?]!T=C>_G]_-_=4Y%#4UK '#\AGQO,B"D%Z.V)17T/R9CB;__$.WM']#C*L$
M\U2"^8K .F-C[,?&D*%/%FQIB=.B@.BO/<W*DZ\?SY,SW;8U%L_/A\0"9I9E
M&,36NH8>A$>P86B"H0\9NJZCF>;>L--9<]]94QJ(T_7?;(*L)Z\R9<M6F"9A
M%%.4-"SP;_EUR*>U+[N"KE&4?$5LE<V#,DH>ZV4J*B-:@ %KJ@Q8E6">2C!?
M$5AG#*W]&%K2@/4H PVC@%<-T!!(O>%[0Q#[-8YU$(.Z8[J.$-**6O/[K1''
M(G"TVWNF;"E3\Z+8!4E(^3H=IMLMJ[)8=1#^0JQ:1/QFHI"">2^%/8)"NT^A
M;NNV*<X+?3O#U;3>K- W,]G480W,"<Z>)4?.TC;;E56>EY1UIT3TE=74!86(
M<8"8$&?#OLV99=A$Z'+?RK!$([]OU$'J=-?==]>5=O<FXXE3H&?65=;K*A2J
MH.#%\YK'">_]8'9)P8^=X-P^G:Y)'$/@"C"S7$>W!;;Z9I@8FN/ ?.E:6^]J
M4L9^!GD>\!7C(&W8 L$2*X[!8O-*#G@L2TK1/*5H?H/6B7;=U!VL#[!^H#)T
MZ5+]99Z$3,<6]"M3<?452]'#E;@H: FOP@VT*OY5HGE*T7Q5:-U!PNT@86EJ
MW+)*B@U/EA91"0Z$U/WH@5")YBE%\QNT;B)8KH$'\J"53KJT^I_,DV=&<IJ_
M@?PJ%4@-6J</6#?%%<X[I56PZ%%U^UUJ6^6CRZ7/,J=9$*W?%WRP%))#'%$+
M-4 =<FUL$5LD%[ CMJV[PFH'V;'JRABHAO16(NG2ZIT5".\S;%Q-NCG?..,E
M)%-#]:0+\J14^31HG?)(<S2Q^#ZE43@0^^TQI6M@8V@9:\6*;LF7,8^^+V-1
M BUC<10\1/&PHM1/4!@28E6B>4K1?%5HW9%JQ9(N5TO3,$QWO,S+@K?@(0;K
M?SG$T8,!"!J@_#VE43C*^^T18ME#,T8KH'2Y@I+.& ?Q#3(JA3YF?@5TEZ&[
MCJ@U537H PWJ#A.D0W2V DV7*[1E\):G<8S*X/5#]DZ08S![??%D&HXH6@$K
MR];%A0G08?:!6.MNI[<J#,M5V,*_0]4^\H^5[Z'Y MQ$ACC"D$2Q32P$Q@RR
M,['K6D1,2,C2<BW7%-8G'VR:&!832 -TM/((R^61N*4^7]S[J\]LJ6.EVD@I
MFJ<4S5>%UAVA5AMAN39:[O+PB4V'U3%9EO,5OWQ#0<+JS=^[*..;T.#XG"!+
MP)3&@"(AIEA'>I 9-HF8U9"9071M0-_@5M]@N;[IY344R2!1BE3(# .R!R(*
M4D< 48"9C*A6K6#CJ(R_GB^FB]EG,OX$"2/)>)5HGE(T7Q5:=X1:Y83ERFF9
MIR&EZP)M\G2+'M*<(;"JB$T "4K2DNY+R_KL*0[X!FP6Y$.K.^ZK$N)B\51M
M)K^KSR>"![1GF_UM^ _-NO2U4@G+#W9NF1I_X]-BCR^0'*6Z"/?/7\YL!UMB
M]7A*JV#UJ.KVNURW8@?+Q<X!UYO#2#W[5%RJ.A_"?4%RYKA8C#@/LL.F)F:"
M_[%=EZY6X6"YPNEF-GVE>1@5U;G:2W,X /)T@M20A"B@-S1LF'VV5"D<5???
M);W50?@#'=0AO0CBNI3:)5%S%L,/Z4'>^PK$$5F: 49\$NM-=QY@J#/+'N\^
M8(@%Q.[3,ZWV(9_4/LO;F_NYQ^JDJ_^!ZS_X#$U?A!A:+W=F@)GIF+9FB'P
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M$$4#16&NF<Z,O@N+XC<\$\??S)I A&MRM[!#@0'.&@"G71YC:XI[J':AL.P
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MCC].KF&9DE<J&2N*XWATGI+F!T'A,"B0VC>POG)TI5$,&=43G##&@%F&[IJ
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MXP'N?*$U;3;^@FYN3_X"4$L#!!0    ( #"*DE=BX-6Z8 ,  !0)   9
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MA&04QU_QX8W_;*>)"Y*A'*<X@H!_+N6)#$,<");QS8RYDT^)'=W?=O27!#O
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M#_%^E AB!R"590B^R-0B!KT%W#!"-8C+($53GLU.0;+KT*4$)M#&#Y)Q&">
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M2ZQOHR-TOJ+9 *K/C2$8#D6PH34=@Y*F^LO<,Q-4F6ZV+41BRUNJZ&@PK-'
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M _B.FU3V 2>@W @N[_E_ %!+ P04    "  PBI)7*(W'6Y4%  #Q$   &0
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M">#^7"F[F9"![;\<Y_\!4$L#!!0    ( #"*DE<:@V$9J0@  + ;   9
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;-U96V_;.!9^UZ\@/(M! CBQ+"=M
MFAN0VTRG:*?=IIU]6.P#+5$6&TE422IN_OU\AQ)EV5&"-)W! /L0QR9Y#L_Y
MSH4?I>.ETC<F$\*R;T5>FI-19FUU.)F8.!,%-[NJ$B5F4J4+;O%3+R:FTH(G
M3JC()U$8OI@47):CTV,W]D&?'JO:YK(4'S0S=5%P?7<N<K4\&4U'?N"C7&26
M!B:GQQ5?B&MA/U<?-'Y-.BV)+$1II"J9%NG)Z&QZ>+%'Z]V"/Z18FMYW1I[,
ME;JA'[\E)Z.0#!*YB"UIX/AW*RY$GI,BF/&UU3GJMB3!_G>O_1?G.WR9<R,N
M5/X?F=CL9'0P8HE(>9W;CVKY6K3^[).^6.7&?;)ELS9Z-6)Q;:PJ6F%84,BR
M^<^_M3CT! ["!P2B5B!ZJL"L%9@Y1QO+G%N7W/+38ZV63--J:*,O#ALG#6]D
M25&\MAJS$G+V]/KS^?75OS]?_?Z)7?V!S^OCB85:FIS$K8KS1D7T@(I7[)TJ
M;6;859F(9$#^XG'Y:?2(@@G\Z9R*O%/GT:,:KT6URV;AF$5A-!LRZ''Q2Q%#
M?.K$HT?,F748SYR^V4/FU',COM:BM.SJ%I^&_?=L;JQ&"O]O".Y&V]ZP-BKK
M0U/Q6)R,4+=&Z%LQ.OWYI^F+\&C(U;](V9KC>YWC>X]I?UIR/:[B]_>?KH)I
MR'[^Z2":3H_8/97L4R:""U54O+QCXI;G-;?"X)L#VF;<LHS?"J;BN-9:)(RG
M5FA,")1_SLM8L*9=)I!C\]JRN4!S%&Y%*DNLD#QGQF*Z<#HY)J4QM4AVV3DZ
M2,+0CK Z:'='=QH[:6^53" G4XF53JG*T3MEN4#K[!*CL?>0O2^#][%5<YC8
M).!L79?X)N+:DAOLNFF\3*7LD] %#"L3K"L32288MD681>$1A@R:&FUXMM#"
M>>&FID?;Z#8V8[^*4K W*BO1;LI.S@_XM4&,*I5E38HRB>VJ2LG2DCK&3=]*
M%ZR71X9=9%*D[)<.Q?=I*F.X1OV;I76>[U@<"=2'H0^H8Q3!*<@E=(7"=85=
M]J'6IN;8Q2J'\Y!#&XB[\*Q<V@_'81BRR'WV(0X]QDO!H$50@L G!4.&=FG@
M>EO'_>DQ>_OVHD-M8]*#-R;C*ZUND0SHWR5.2%)(F/I=*'SSVJ  #,!-;J51
MB"[5)# SK?.=BTFM28B&/&3TG:\ 668RSE@+K,TPWB'Z6\EH8]BB7;X&#GL2
M=3I7EI+*SH(:[5EO[M*WR0TG3I[?;<+$_L6F^TT8PB8<X>Z+$'%V/X9:UU,Z
MP_21SH! O^%E334R>TZ<+]47]9;/#?M5J[H: S6<"S[.?G(PP+=<2U4;1DW>
MBH6, U3JC7";:)%S*N"' EOULIT3(X'?6!V#N%&0B15]3_!I7'"=2Z$#+./;
MC.<YU.9@3YK/<Q@P%XU=L< 8<O#N07M<.O0M&3,DSGR;R=09@D(GUY):T.HY
M:"6,V#0NP 8"^"*7*J[MG4M\UQBYS&OM1&/Z;VI(MTIF(1KTG6F[]U)+:T7)
M2F4!(0EKH=+[><T>R>O@N7G=I042NLWD?9_0T0&+#GR7\<GWXCG)=RYLIC1Z
MBTU62=<,#J9<EVKW6T?P8ZVCZ\0 *J?>I COI31=8OT_Q[X]2AKD6=2/],OP
MP4BO'=G@#O-<@F7@U"Y7X9DKKA.V14O;\)[YJ7.:ZLYHP@B'+<QW&O"7J*KA
M '$&%.$ :0D&M> ,=DLZ;4!B 4W:<1:VOOC>6<N&E8V'YDR&SA+,!<)05%HZ
M8H2&0[<66=1-FBT5VXJV62$*'+]F['H1M9),%8T\FI$G%JVS($E?<.<C@[0H
M%#B6[U#-MA"_E&A>5FFD"*A(>1<0JW 9P9.&#7EW1%D7E!_0#;I;4;[,98XE
M2(4V5S>\DD,XK>, 9QT12^NRN9LVFH)-3:[5<P.N8Q^R'[M)4,P%")F&HQ0G
M0Q=1;]PFP4K &W-5N;:!)26NS1V%($:)4C*!0[%K#Q5(;XF2('R(?I3MA=IU
M'8>1SU>O];[_XP?Q[T)WJ<&.M43"?ZP3$)[5P8F)9J@CEF3@.PR_X6#HUD)Q
MCX;2! VLNMX<#:C+&L?&4<25*!-7O*4J=QK+VBQS642C74$65:[NA##CS2P/
MVBI8V0A8D)3N8D0D%W&7FH8'81F$=-U?%[4^<QZLLXT&LG9FE'YM[\3H-Y'5
M?H-$>05CXLI I*EPCU+8_>-JW7PZ%F#'!CU8G8VN4_:AB_9[K+OIF.[K $C]
M(/_]$/G=_A* O+*GP>-7>W!ZL/3.D6CO(<HP9+%I#$E5K5E[G^#N\KMV[!^R
MK>DV+HTTR5YS#2..7#.F6Q)[+?)4X]#'T&P[>%,;;(';[8W01ZY^MO:VV3O^
MA>/#0ND2M>,/>%>&=!_,C</>EQ?-757R*[N.M:SL_8O<L#/C_A3Y$?3H5WN$
M$[7V)[CGTZU.>HK!=9R-^[UQ#+81W_"%OV:MV+@C">TA@89;H:\7/!8UN 5^
MTEK'=EPGWL&WG5C5%(_ ;PN3DCH&VD]E50XV]TBB=]D]>#;%"C;W8?\0Q0J>
M?6UL*19QHP56+.A!#+R:M5P+O$ WQS.(!6#"6:;B&Q_O?L)STSY<,0/)CMOG
MIC[\LTAZPK2O>J L?+D^178&V5[]?(?H8*$]W>Y=>A;FE[6@ J76?7?(>IVW
MT$!DR55,B_?Z-C7($;4>="/7>#;B-[!XB)\@QY ")JUSEG/0HZRAA,13VL)A
M,?$2M/6QL_#']!J!=/ <N2OJX=T0'Y?Z,3>.PM%#DL;-Z<&.JT9&1(D86/N4
MS4%053E: ^[-*S0>PMWG#IG3I,(0[-/O@?WE>/_O0/V'U/Y3H+NC\]7!_:='
MS;/J2>^E"#C_PKTK,LSU[^;]2#?:O8XZ<V]A)JOES;NL=USCZ# L%RE$P]V7
M^R.FF_=#S0^K*O>*!<S4JL)]S01'VZ,%F$^5LOX';="]I#O]$U!+ P04
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M/#P^&H!M'TKMQ)LJ/$Y6QM-3)PP+>ENB90/ZGAOCMQ/>H'^M3O\#4$L#!!0
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M&DMA4A8:!5)8HJ''*2<JP=&XC"I'\?Q!C@X'O<%@ -+?*3)_&QX(SP/YE_-
MH BL<^'3+&AIUK-:LYYMU:R+%-#0\KWZJ#NU:NOH;HXR2$$@R;=["AN2+_51
M31*PAV#!@+QHV,%?9'>I^1>\#DF8+I!7\)I4UFKGHA.C)B9A;C<&% 1 TYO(
M9&"L!CHA<\K"3*J2I@&2Q68*0.D[,='E @W?!D-+$0J%(&K.G ;VZX_.PVU8
MC_--X,R !&CDT0?@JBA00I=*)"Z)'B"2(B^R>Q-W1Y'G]:*"K #"AC16!7B>
MUQG\TXC/R?AU+3Z=[Y]F@#WYI4#J3L:UT(GG3R$-"H6@4Z\?I>![E )D_]?B
M>\N8/*^-R?.MQN2=+N7;# SO-83*&)MBR#L#9+LLRU90W3(%\$4G?/F;%I@_
M5! 'I;"(!%^": U2!/RV@\) "SEZ!C0X4T5*.1N\S;"&O:<#-K'#GC>VP][@
MV0']-<+_TU]=BO)](65;6'E<-F'08OE1S?*CK2R_M13OGH%NS"F113TXL;::
MYQ1#=W%^*\1N(L$T8MLT9&'R(-&'ESL#Z0ZJW8XIRP:]A="@X$QP+8UKLB T
M)G/U 6Q7:S&J68R@:%V!O8E*EPF Y\?8/[ G6\Q($\7CBQC' R]QYDUC>)88
MLX#5%$JLY+J;EE/H>YU6;@&8JX I!4-<41K7#'*: EE0'PQ/65&VQVE.I-(>
MC082S]'00_2B,6A+DIY@ZRNG138':)D-J->=?#S*R'^/C B2$?DG9*1EJGZL
M3=6/6TW5.=8;?L62$R+3N-B+IE;59:VV NV61)Q);)^I%1+-M>+T"S.-1B2Y
M-I7N!4\ZF0LD!3W36)NQ)'86")XHY%Y0$.AU!AH00@AT&T<C<!L!A2YY223,
M;X'OB1B^D%<31) B*I."7[+25EC:L_*/*L/I\L)@[+5;I5SYT?$3GI6BH;DJ
M/N#R,72#R =$-FIPPIRM0:GO)AV] *+13!G6Y[ .DJY,QHJ$>E"OKB>UH==C
MT-6H3)8('0LT_,E72%WI;@4>KLZ:N4E4X=8FVFOKP @9L@ZEP7$-I%P'Z6'5
M^&"%B>?QU#AX(6_3;(T),)AKK "LA,< .\T</-1XQ<$K2 #5.&%IVADRBF=3
M'X5CE(SS9#D)8K9(0XO5\\P66+9U%3)(=F%],2MM_5R6.IJED,#K8'%9BODY
M3&T-A/D8G()H.0R(/LU3J@O+&$$7G,57 =I<,)YF29(MR/+@0^LV(R%_D%E5
M;"A%.T5;J4"C (.>=A=Y5Y\.Y?CTE[,WMV_/KL[E^<6[DW>G%R=OY<6[\?N;
MV\NS=^_'\O+L9'Q[<_9&GKP'!;NXD;^>O+T]$\1#.61>RI'[]T!T:QV9[+4E
M;01RPI)*A;(?Y+.C4>_HV0#^VL/_Q'LJ)SC1\U_NP1=O&QET+X52N4?OG->$
MZE$<2F#$KG]Q^:1CPB^ Z_"!N(Y&O</##:BZ[[XDINWI.F.71X_QZ#$>/<:C
MQWCT&(\>XU,>HY7)# =-Y\Y@:RYS7> VI:N<XNY)CE3I[,W9"JC;&WGHH@5=
MMA[K^C%J&V60I"38(M"7O\UHJ[4TU$50L"U>&$M;E#GD=G'/98SL=>J*JU,O
M3):CJ)I7SBEI6!SH)G=_D3&:9V!%A$L6=5AT;79I7"Z+C&G*OVYK")PHI[;8
M/)" $8AE#8S72#O/6*YNMHS!-&E76NOC?FI7#BWSJD ,P?SE(9?:!,-J=Q$W
M)..DWJ,)SROKLVKL'L"&M#WD'1@DR(V!IO?<"0+BY[-D'*.G52(2H$*P*;8K
M#^1A9Z#R*!M_3C;^_G+1-D=!(^%P^_Y\!L1+?9<++OG&V ^=Y93MD#;L$8?@
M10T^C(CK(ES0OD'"5TU^IQ);)@L:PR%<J_6KUPS"#X6^0]'*"N8/AY&K@Y$!
M.81OU(<A\%LD[ 2Y@R($H4("KHJ%@39TB>04GQ.W>*.:NXO&V!?&CLSU)-;B
MB?TAFWJ0>BM-:K& &"X,BER]CF672X05=>HT).) :P'2WP[,E$0QX\A0R:E>
M<%."ZTJ%&*N[:OM?RMQ/MXJMA2IKS),/8Y[X&LQK:_VHT?K1]A:@1$4?Y#B:
M91A-7U'0#X[ 1$C#RRS62:<!V IT0R\GSB2VS=3*CBM+K2PT:L^/RGA4[D;-
M:10E,*4NYJB45!1O8GQ@^0)<C_+N(G/;" 8RG$T]4Y^%G$FS.0K:J4HB%$Y<
M)B/U'X!W6W::EN?AUK;B5S<:E1[R[ N"&NYB0RB1PM^1WEB2WPZ[F\I^0O&I
M">4YZ)  UTEM _@OAO:+=G]O:P#MQC+4R9);[4[&K^O0!@,@VI;?@]R QD^R
MV(1U"!5GU!GL1GMV*NJD(U</\0L8!GA%TXX1AC*XE=.'[)Y"EE8,!7I>!U$>
MUD0G1M_[2?$;AL3[.HX7#@E;MQ'X%0JL+"PA5&JFQST;*CA0-Z'"=BRP09 D
M>;CI2FVJCIRR8D.[995C\!"SO&''A#BI[L!FH<$<]!K"FC4.-HT/MSEM<34M
M#[=U@PQ"V1L\Z_GF5S#*DY(^#(?N U6XP"%A%<%[HROBX953@MUQ-2FSW$3R
MZ?/!WFCPQ)EW,+_4_,DJ\XN.[W!='CB I&9^*FZ<4>VD]FE7BY3B: @'&^!'
MPT,_6#R%23IMS7^F%LA'+7C4@B^A!6W/TYPX&6YO7+YQ:>6U*K"0T^E?/N.X
MB0,K'-B67^;*(Q8</6*'@[WA@$K]R$HJIQ\"<\.U+>6;H)O[NBIL!2Y9@#:.
MW3$XAK+GI<+GR[E;@2]6JS[V&9C$^(,F@48<RTF?6>%[ZCBH#-MNN7T<$TKF
MCZT/(XA%<P"#^B) W=3$4@,$ZI8_K^<;#H(8@X.2YD#+765XDP%ITI3\7,@#
M$F$;6#7^HT,G'<.!_^.P)[C?WADJUW#O;(K#P.7*[B'CBH+*5>UC&?5E68#*
M-5V&$YWJJ2$[H>=YDBVU;LK;,G='&U'HP2K"BWO8HX7ANH-3&SGN$:&Y 72#
M/[T'0&<FEZU#%\<20BYWH CW!18I5KA7N0@V,.@^6?E63/O.!GO1( UG3H?F
M<:Z6$!9B!7Q*Q?><Q!"3CR)+J.8.J4F8I="YAVE"+9>N=;U91.&M&OH*=Z[-
MFW*W-Y/17L+'DB5&E32K>P5,16IQ-P.'NW7/L=Z!W,TI/2I]QH-G*9988+&4
MX/J]",N]/NX !S#9'B./Q-TJ/6CN?Q>W;0LG,5+>3:2.C<!LX9>&:O8)[%&\
M/K7(K80M>#ME?0KQQ0CLMEJZCVOA\2%OE<*C*B3PSG&&5FS9K)&VDX(=/6R,
M!*WS5;\"CT.Y<T:N,TDH-+IH4VPOR/7]KIJ!97G;!I2!O!]/)H'-*+BCT6?[
MW-8?KK:%QPLTKU1(5&55!&=_.(]#%N_:)\#E^RR!!)WLK0(ELU%A\M XMC$-
M:A'!<^0K:VV:-8U9N'<WIR,1_A&5!!1.,4&3C$9,JVCFE<\?8PK-/34";SHH
MR/0C:\=$!)FC<]2X_EC#D#@XW<7"1Z:-8BAW.*R)MFHKT,(MV]B/;=DB(QOH
MH&+8D]8"X1&5#T=4M$]$^KJ;6R@UX6&;&A^W<]+B2ZU3++&J26* RZYJA"FU
M]1L)H':0D=?GK["&J^.F.^Z8:[M]CXZ(?;DG(PU>]>>JMC"^BX]P]>=#^.1_
M"Y4>&G*,3IO 6.5XLA//\C7+Q66 <0.+!$ %AN<)$:<O+S^ME<%I,MZ]I@ =
M4.9#;0<]^8PF./)D2/UAMRY.;ZBJ?'_Q6'TTT.$<U2VE:VQK=6N*E3?:Q.P_
MQGGK<9[HCO/D7QOGB:UQGOQKXCRQ-<Z3?UF<)QX:"WW5.$]\(LZ37S7.$W\J
MSI-?*<X3?RK.^W*!]&.<]QCG/<9YCW%>$.<=T@3/-\=Y8G.<UZ[E-=<"#+??
M"S NL^C#WFN%U#\-+$5G4>\S#J<'\$4(OQ5-!@=76]8*VS>( '4DX>* .L9\
M/CQJ+5ON29JQ_; S(OY/128XBXHCZHM'Q"U!<X][DF^#,7Q6M@X[Z5P5=P&2
MC'4L$=2%SD?N34@J-OH/R=\[:W2'VYU[J&\B[/(,CR6["6T=*6^X.\@UX#CE
M]\>CV"PUQ%O%RIT&EL@K; ?NB_&#L/!NUA*I_58M+MSOX?;E"7==]];)A5U,
M=8>K(X4W.D02P=LD0)'PPIXQ>HCVFMBTD2$",>KQALX<3X-A]U1-E* 5RP?C
MWGC[B)&])<V^W4HT5QP,M]]Q<.-:*6Z8E1L-Q&><<G>@10!:7E5%K4Y\_1/E
M8Q5870):MW:4LR*K[C@TMRHAJH,<Q%7D=MZ],&! !J[)<CY1MW$TS>H>4C!)
M#H8<G7=?7+5G+;3S';:>V&Z>&0,7 .JA<9<KY;!3T'^\ 0A$QY0N]()%%G=Z
MHJ(/UI_S(_&THIF](51P.U#3]Y:[!!B5PIVZ[,L5%(RM"4L4L3I)4)0:>F1T
M&4!%5 J((Q9Z8@T=*-Q@]/P4"VQ2A$207. 4P0!]Y@99<)>1N!8-D7"ZFBG8
MZ^\5@H,#UR=HG07A^TA<VWLF7,!2NAN"ZON",$=-7&^AO^^)TU0\&KF^""3W
M#(]S (,P;@>]HN"-DFT(7NX4;RB>T\XC8UE347@B4<3?EJ#V%FH,^7'J#IYX
MI#%D 9SQO 08,3SPN9AEM=#:1K1:1',SMED2A!Q\,&+3O5I1O9E(26Y ?Z8S
MWZ#BV,!'9%MT[TB+&P:(K0QP(E&X3? .U/@F)[^F?F<O6X, 9Z5\71,%=G7.
M4$-WF[W*>BM:)8258CE/W/5+WAN4BVP#_^T+O&H--\MAD;OF25OM=PT\:4&L
M_5%X5TX'#DB8UM)!Z$V26+\Q[CK2@D6)4"AO&LVNE3'VAY:Y"R&L?'6BAH/1
M'5F*3"?+-J,X,G<J[)!&3H>,<K%TNHDWGA@]7U(BKVU==M=)MTY9J"7.+]>*
MS1KK2.NYA#</Y9FADS"N+\-9$-<Z$&OL\RV6=7+DAV*^!D],$>^Y@@]=Q]=>
MDJB7M,6(\(FGVD6L1#QNWBYR!&LMESD>=,*+$:E%,59+)V2>5" @?!^3*TRM
M(=1R5(1[MZ& H$O[%'PS4BL^ 4VIIFH'W4*(M+N>+:V!>"^58S_KR5VAN51$
M5NAU@74575R^Z<FW;T]E/%'R31:5^H[NDO+!;_.H;LL(0D VOZ+4F)W%V+6G
M^7A4EF1WRS7)<@MN"U;=YQYPJK;Z:*V#4J,SL$%8R<@ J430,OI^9H@58&%L
MW0 /B2GJFHX49,!D3]J^PK48^EY5AR)[4T)V35)6].68;)((H1H<;>9\[1X&
ME&C9\7";+^*R"(/Z8I?OM$K0$'&#/1\=T'GICN=XD?(TI=E6D  R04C"D3]=
M#MFMYTA;6@$:!&\XXHS2<F>O,3)H&TE?AEB-_HZ=-;YO+:6'VH]<L5G"I:J"
MY+HG^8QG@B>4;'"DD,.QV'<A>4^[8E$"+8)<(8X-]THGRUZ+[!T*<:E@MJ)+
M&Q!H<-GE5/Z6%1]8K,YR\X<<$PDL:XE7"]\?A!LNL/*YBFK]Z(G:<*AVD:(7
MJD[NAG$P"@L'):!*S :EH?($"PA;!G80[8#.\9P= M_;46==-=^ZG#9Q%^L?
M #U\(SR!6O#5=.V>M\9VM181B+((<X?54:V(JMLD="WXK[</*%(KLHRS>;/1
MY,T=DB$YO% UC3SZ(L2-S<>6\:Y@UQ"C+@N$AH-/A+I"6'UQ5YMI83&7#NF(
M+MY,@(B4YD".I*@[#ME!<;B) OWOL$.;S-Z*Q>PT@^)!9I"DD1*WXXW&9Y5A
M?];XB"W&)_2_;0\V,WE.1X^Q=N".L+?OGN7<KZE3T:9+/8]S^1A33DL7K@1A
MA:IU $42BYRB#AZY/A-2V(6(M@PNQ=FP<?U84O@^2PHM54IX?X_.1#B.UZ:0
M*H!E5:0(CSBT6HT0GUV-D'_?:@25&<1:F4%^LS)#N_(COV&903R4LH]EAL<R
MPV.9X;',\&7+#*)=9I#?L,P@?!HAOWV90>P^.-[^FF4&P?'KMRTSB"\3Z7__
M90:Q5F:0WZS,(%IE!OEMR@QBI<P@OVF9X4O9AW^_S"#6RPSR6Y49Q$J9H9,W
M7[_,(#[?#'[),H/X#./S-RHSM#LBFGO:A]LO:K](L>DS*S:=?_R,:\P#D#+X
M6[1O $+\DFQ!'6@.M\+?.\<)%OW"E*;\V;MU]SM44U/8<L^ */!?654VOX1P
M<7Y5!SGNQOW0*BT*$HH8FUFQ;FG<"OFWB)J;<K()RIV-J,^6&K=Y<>[R/#](
M_X'9I^-7<'U0^,,"GG/-J+KIT$\G'.;<;<0F@8__!K=6JPDBZG[F(-9S4BOJ
MY*.Q(%[L2O$W!O!WP.C"Y;4OR0TD?'O)?5;PKR)@@RTE\!@4_LY7&4V6[5]\
MJAUU@ A1<P^)::F7/#@8T)=OFON@UWZ'R=TGR(VK:=8-<D,I[3-D\I,_4S=L
MKKD?;K_G_I((RK<? OUC2$; [,'G3OWYC-O+ZPG$R@2=)U>(NMB/3D:5;* G
M>MT&-]^T9&KCX^9I=,(4>1+K0HWQ=A7>;0ZGBQ_DL/?LX*!W.#J2W;^ \#FX
M?YI/S1W?P^V7?-,)$OP-D))"Y0WWASP4AF 8&UE0GV;!K+TY3'2(QW4.5\\3
M'?9DL+JS3:L[_5Y7QQS9#WYO%)S4'?T,*T9DX$7YIT?KI_5/O9[0#YSN-Z_S
M[\1>DM1:,$M3&#KH/S_<D07_]"I_@!73KY=.LA(\(OTYTPJ"!WP!OI]F6>D_
MX 3U#^"^^G]02P,$%     @ ,(J25]!^ DI% P  1@L  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL[5;?C]HX$'[GKQBEU:F5MIL0%KJW!TC9++21
M@$4$]E2=[L&$@5AU8FH[2]N_OK83TJT:4'7:IU,?P+_F^V:^R3B9_H&+CS)%
M5/ Y8[D<.*E2^QO7E4F*&9&7?(^Y/MERD1&EEV+GRKU LK&@C+F^Y_7<C-#<
M&?;MWEP,^[Q0C.8X%R"++"/BRRTR?A@X;>>XL:"[5)D-=]C?DQW&J%;[N= K
MMV;9T QS27D. K<#)VC?A%?&WAH\4#S()W,P2M:<?S2+:#-P/!,0,DR482!Z
M>,00&3-$.HQ/%:=3NS3 I_,C^]AJUUK61&+(V=]TH]*!<^W !K>D8&K!#^^Q
MTM,U? EGTO[#H;3M]AQ("JEX5H%U!!G-RY%\KO+P!'#MG0#X%<#_54"G G2L
MT#(R*^N.*#+L"WX 8:PUFYG8W%BT5D-S\Q1C)?0IU3@UC%?3:;#X /=CB*-W
MLV@<A<%L"4$8WJ]FRVCV#N;WDRB,1C&\6I(U0_FZ[RKMV,#=I')R6SKQ3SCY
M$Z8\5ZF$4;[!30,^/(]O^V<(7*VXENT?9=_Z9QECW%]"Q[L W_,[30&=A]]A
MHN%M"_?/A-.IGT+'\G5.\ 5)PHM<T7P'<\YH0E'"/\%:*J'+_-^FA)=\5\U\
MYNK?R#U)<.#HNRU1/*(S_.-%N^?]U23VF<A^D'Y52[\ZQSZ,P_>CN]5DI MP
M',V"61@%$XAF\7*QFHYFRQBFHR!>+49W$"QA'$0+> @FJU%33LXZ:I:Q3+&U
MY4R_RTSNE2WPZHU&OR+P0L"6YB1/*&% <_U "OT*4Q(R)+(0N &B8$NH@$?"
M"@0B@6]!EP=F:Q1UB0#)-S_MMN$_:F]-\!$9M*$<_6KLM,8FD <;R+2,KPQ6
MQ_A32"=) BE1R59(9 HOH7?M7USW/#U[8WZM)5<Z$\3:U(=O],&$DC5E5.G2
MK8S8]QUCH6W&=:(N(-=?*$O3>G4T_/*ZP>$S:&W_HE;?O^AV3TBMSIY3Z8_N
MH.EB_J[HWQ7]?ZGH\NO@/FE5,A0[V\%)L)^_LFNI=^LF,;"]D?O=O.PPIT3L
M= $#PZV&>I=ONPZ(LFLK%XKO;>.SYDJW47::ZD87A3'0YUO.U7%A'-2M\_ ;
M4$L#!!0    ( #"*DE?B4H4Q[@(  +8'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;+55;6_3,!#^WE]Q"@AM4EC>NK*.ME+7%3%I+Z7=0 CQP4VN
M;4029[:S;O^>L_-"A[+"!_@2^YQ['M\]/I\'6RY^R VB@L<TR>30VBB5GSJ.
M##>8,GG$<\SHSXJ+E"DRQ=J1N4 6&5":.+[K]IR4Q9DU&IBUF1@->*&2.,.9
M %FD*1-/9YCP[=#RK'IA'J\W2B\XHT'.UKA =9?/!%E.PQ+%*68RYAD(7 VM
ML7<ZZ6I_X_ YQJW<F8/.9,GY#VU<1$/+U0%A@J'2#(R&!YQ@DF@B"N.^XK2:
M+35P=UZS?S"Y4RY+)G'"DR]QI#9#Z\2""%>L2-2<;S]BE<^QY@MY(LT7MJ5O
MEW8,"ZEX6H')3N.L'-ECI<,.X,1] >!7 /]O 4$%"$RB960FK7.FV&@@^!:$
M]B8V/3':&#1E$V?Z%!=*T-^8<&HTF]_,IO/;KS"^/H?II[N+V=7T^A8.;MDR
M07DX<!1MHEV=L"(\*PG]%PC[<,4SM9$PS2*,6O"3_7C/WT/@4'9-BGZ=XIF_
MEW&!^1$$K@V^ZP=M >V'GV-(<,_ _3WA!(WB@>$+7E)<T!44ZLF&6<(R!2R+
M8'I?Q#G=#07?QDNI!!7W]S;I2^9N.[.^\*<R9R$.+;K1$L4#6J,WK[R>^[XM
M[7]$]DR$;B-"=Q_[:#'Y.#V_NYS"S0=H2G!V.:;2>U:(;2+L96Z/&^K].G_8
MKT/%HC!=HC 50V=?&9[=F? T+Q0*":_AV'9[?CUV?AV?Y_7M$Z]/8\\.7+=S
MB5)2JPJ+M$B8PH@Z#$45QDSWL%,X\'V[V_/@$ X"^Z07P&&G+@]3%U@3VY!1
M1W\-GDL W]4S[YW=[?>A[63_JT*[FI@[ ;^O>#M2E4*]?2:1D8;6_B1.)0EY
M[A.E%N(MM-6EL],:4Q1K\V)("'F1J;)+-JO-HS0VO=CYY5Z^:%=,K.-,0H(K
M@KI'[XXM$.4K41J*YZ;1+KFBMFVF&WI846@'^K_B7-6&WJ!YJD<_ 5!+ P04
M    "  PBI)7TIR(S-X&  "-'P  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6SM66U3VS@0_NY?L9.V-V$F.(Z=5]YF0H K<U 8$F ZG?L@8B7Q8%L^
M22'D?OVMY)>$X)BTA7(?^B6QI=U'NZMGI96U-V/\7DPHE? 8^*'8+TVDC':J
M53&<T( (DT4TQ)X1XP&1^,K'51%Q2ERM%/A5V[*:U8!X8>E@3[==\H,]-I6^
M%])+#F(:!(3/#ZG/9ONE6BEMN/+&$ZD:J@=[$1G3/I77T27'MVJ&XGH!#87'
M0N!TM%_JUG9Z'26O!6X\.A-+SZ \N6/L7KV<NOLE2QE$?3J4"H'@WP/M4=]7
M0&C&/PEF*1M2*2X_I^@GVG?TY8X(VF/^K>?*R7ZI70*7CLC4EU=L]IDF_C04
MWI#Y0O_"+)9M=4HPG K)@D09+0B\,/XGCTD<EA3:UAH%.U&P-U5P$@5'.QI;
MIMTZ(I(<['$V ZZD$4T]Z-AH;?3&"]4L]B7'7@_UY$&O>WDZZ)Y!?W#1^PO*
M W+G4[&U5Y6(K22JPP3G,,:QU^!TX)R%<B+@.'2IFZ/?*]:OV04 570J\\Q.
M/3NT"Q'[-#+!L2I@6[:39U"Q^A$=HGI-J]L%YCA9H!V-YZPS9T(XW3Y$QKG0
M8P%FH2":R%W.23BFF!D2[N:P+'=)YKJY.R/<A6]G" FGD@;B[[P)BL>OYX^O
M5H,=$9$AW2]AN@O*'VCIX(\/M::UFQ><5P)[$JIZ%JIZ$?I!O_?Y^.CZ[!@N
M3A)>7EP.3B^^0+<W.+TY'7S-\[X0,M_@P80:(^;C0N:%8Y"*^LEJYOU+!0Q9
M$.#\8 H.[X%%:K)$O.QX<KX#J T_KIWZ:*SST;A(=&[U2H1LZ#Y0C@NK@<RD
MP1WE*3MKL T?8=OX$WFDY&H5NV%5+,N"FEFSC.-'RH>>HM,V"AT_1AY/GB^F
M4D@2NFA_!591[26<CT^0E*>Y\HY3<1PGE7Z"CLDH$_$D(Y_#9_;GCOJ2_;DC
MU*WU#N0HU!OU2JW92L35#!NS-/HDCC[0Q!R(N#>DHH);F=HL%0=\W) $<H)G
M\SV.7:H 6IEJ:J(0 6R49\*,<MT;,TOL+#L)*266_$C;C)4^&B\D LZ\$7W&
MH;3S&;<2SQ>1JYN-=$97PY.W;/SR+/SQ/%I$ZE+-Y(^GU1\?VG;-WDW_,XJN
MMK]INKT]69];\'I<U3, EPBNB?F$N^6OE'"Q]=+\K:/TZC1G#$^C73<7E%Z)
M:<%>ULCVLL;&>]E)]_0*;KIGU\?0[?>OSS51^WF;V6:8QEI,XX1X'&Z(/Z5J
MZGIQ#O7C' HAH$1,>5QRN$12[:]E&5>>N(<1IQ0\9 )&4P)7W8[9K../8\$G
MXX;Y6+?XF'Q@VW6S94''-AMU[#G"E'0I<N>K1WT7E#"F I;K.!D#R@-HFA:B
M-(QR;4O3E>-PVSG#S9!3+L46K'=1%XNB@(0D*9&F0B\3N/GB"G&/QYRY'@V]
MNC;[)@RX]FT.@@ZGW),>4F+FR8E:1R+"-0T5,JXAPL#0:*"5<)A&V8XME)QH
M,C\LG'YNW)#XPZGJ3^Q:$DX&4/4>">=Z(6CM"H@H,GW,V33"H9QXJ$0&7(86
MATQB!JK8@600D3D0<-/P>J$&Q=3%)91JCT93B0X8Y?H3K(H2)<,AXRX),4-T
M'#!!1R/=.@VUR7=3WZ?X!&5EGVWM]KN'^JFVNU6K;Q^9=@6#CJZJ08471+XW
M\O UH'+"7"A'/JXH\$!"S_?)EK(W"X^A5)C*0]]/_%$XV)FW=_SO2+_*]XV)
M_IOD;T=R<R.6]S7+NPN6'V8L1WIOP9L1VRS8,YK9GM'<>,^X[5Y==;\,"H\^
MA6@_7W3AX5-5!FN*KE4#C=M8/*>X+"R 5LLMNV+7<(-N67&6KC\%]-2LX^3B
MC*4:6['."P67K;;_I*"S7BRW%M+)NI$:VFY5&MC:>&IEN5:Q[+KNV4KQ\VS>
M[!QC-9W$4.?E4TRGU=#CQG;^1&$X2V?RNX\QE>+:4,'<X$J(!J5L,9[5;4G/
M=Q6)1N+S(F*.V79R3RJ_)FG6'54VSYK5^O5UDFC=F>4=$^H7$/69$3D\S28B
MB_LJ<Y=/-!E]"\AIK)!SX3B6S_6B0T8KVS!:A1M&FBK?SK5[N5\'"Q&^]^O@
M*X$]<;:=.=M^YP^I[=<,U2N!/0E5)PM5YPT.GYMAOF8=;IE."W]:MB[&\ZKE
M$\X"L,U. W/&6BG+=5^[;79L5:&W6YM4Z+_K\S>KS_.2X#THU;07E,H[WV64
M^J0YE<^H3S&EGC/J-Z'>B5#Q0EA=NO$,*!_KBV!5@N%Q+[[\S%JSN^:NOF*M
M+L3CB^ISPL=>*,"G(U1%RC1*P./+W_A%LDC?G]XQ*5F@'R>4N)0K >P?,2;3
M%S5 =@-_\!]02P,$%     @ ,(J25S-&E[(C P  %0@  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&ULQ59=C]HX%'WG5UREU:J5V,D7 686D)A VTC
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M!=S)G,0XMO09ERA>T)K\]L;M.W^T.? ?D?WD1Z_QHW>-?;(./\UGSXLY/'R
MY73S_!1M/IMX,9^NY["(IO?1(MKH3=GFPE7J]L)/^3K_EJ^S)*H05+T"W\$"
M]94!"TJVE%%E5HHHT#M+8;I%T6POF*:\R%2GC-^".^@&;M^T>C!PNX,J#J"O
M^X>WG=\[&ZX( U:2Y^2UVA5NT.\./;>S0"GO($KS0F$"-%.H12AXY_I=_W8
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M)5>Z^^TVT^,6A0'H\Q7G:F^8"^H!'OX#4$L#!!0    ( #"*DE<4SM??*P4
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MB[2VJ*S;I*H/#MP$5,#,=I)6VH^?#82%AJ!60MI+8F.?<Z_/,1=[LB7T@44
M'#VF2<:F2L1Y?J:J+(@@Q>R4Y)")D26A*>:B2U<JRRG@L "EB6IHVE!-<9PI
M]J1XYE%[0M8\B3/P*&+K-,7TZ1P2LITJNK)[<!.O(BX?J/8DQROP@=_F'A4]
MM68)XQ0R%I,,45A.E9E^YH[E_&+"CQBV;*^-Y$H6A#S(SCR<*II,"!((N&3
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M+H[G13,25S2@<H(87Q+"=QT9H+[TV7\!4$L#!!0    ( #"*DE?K6N9A' (
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M9B'KS]#Z&3F]7'+M?U'=Y X#C/*=-K)L85M!R43SI4_M.1P!X? $$+5 ]*]
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M7R[0*,$91SB+4/"TC'-QH7#T:SAEG(H;X7?=QBF8G7IF>4MV68Y#Z&OB&F1
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MVOA>.K6JI 2/CY_MD_S:Q;6L,(-;$O\3A7P[U/H:"F&-=S%_)(<9E-?C2%]
M8I:_HD,QM]O54+!CG"0E+#I(HK1XQT_E]W $F.< JP2LMH!= G9;H%L"W;:
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MNF&8GDBV2/;<'IF4C":'<R ^\'B ^GW&F'P[B2?(MVV'_P%02P,$%     @
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M$#1,;E= /&!*0+Y?4"IV#\I ?NPU^!=02P,$%     @ ,(J25X8[;HN<F
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M[>-DBN^]\R(@M3+5*E2K4JU&M3K5&E1K4JU%M3;5.E3K4JWW67OX1\W1X\^
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M[GIJ*KHFS99'V?VO:217MES%<E7+U2Q7MUS#<DW+M2S7MES'<EW+]2S7M]S
M<D/+C2PWMMS$<E/+S2PWM]S"<DO+9=MT\!W[%_7P(! \"02/ L&S0/ P$#P-
M!(\#P?- \$ 0/!$$CP3!,T'P4! \%<2-!8_VKZ,'^]?1[2/XZ]?<R6SGDES9
M<A7+52U7LUS=<@W+-2W7LES;<AW+=2W7LUS?<@/+#2TWLMS8<A/+32TWL]S<
M<@O++2V78 _/ <&#0/ D$#P*!,\"P<- \#00/ X$SP/! T'P1! \$@3/!,%#
M0?!4$#<6/-JYGCW8N9X5?L_KR5>Z*61V7[ D5[9<Q7)5R]4L5[=<PW)-R[4L
MU[9<QW)=R_4LU[?<P')#RXTL-[;<Q')3R\TL-[?<PG)+RV5;_K]CP:+>ET'@
MX26@#EZ\/%K_0'-PX8,3']SXX,@'5SXX\\&=#PY]<.F#4Q_<^N#8!]<^+O>/
M%J?G#Q:GY]L7IZ(+W13>??>%27)ERU4L5[5<S7)URS4LU[1<RW)MRW4LU[5<
MSW)]RPTL-[3<R')CRTTL-[7<S')SRRTLM[1<MF7_.Q8FZGT9!(JO !5<^.#$
M!S<^./+!E0_.?'#G@T,?7/K@U >W/CCVP;6/R_VCA>G%@X6I\&3Q]>\T;5Z9
MY$GGQY8K6ZYBN:KE:I:K6ZYAN:;E6I9K6ZYCN:[E>I;K6VY@N:'E1I8;6VYB
MN:GE9I:;6VYAN:7ELBW\W[$R4>_+(/#\P<JTO_?5,2/!B0]N?'#D@RL?G/G@
MS@>'/KCTP:D/;GUP[(-K'YS[N-X_VIE>/MB9"D\,+[PB1?WR].3\S:^G9[^4
MCG\]_[CEFA3RH/-CRY4M5[%<U7(UR]4MU[!<TW(MR[4MU[%<UW(]R_4M-[#<
MT'(CRXTM-['<U'(SR\TMM[#<TG+9-A]\QVI%/3P(!$\"P:- \"P0/ P$3P/!
MXT#P/! \$ 1/!,$C0?!,$#P4!$\%<6/!HPWLU8,-[--9XW_&-2GDH>C'EBM;
MKF*YJN5JEJM;KF&YIN5:EFM;KF.YKN5ZENM;;F"YH>5&EAM;;F*YJ>5FEIM;
M;F&YI>42[.$Y('@0")X$@D>!X%D@>!@(G@:"QX'@>2!X( B>"()'@N"9('@H
M")X*XL:"]9UK?^]^Y]HO/*7\R=>D*&9V7K H5[9<Q7)5R]4L5[=<PW)-R[4L
MU[9<QW)=R_4LU[?<P')#RXTL-[;<Q')3R\TL-[?<PG)+RV5;_G=?L*SW91!X
M>$V*_<-7!U^]7= ^+DY\<..#(Q]<^>#,!W<^./3!I0].?7#K@V,?7/NXW#]:
MG/8?+$Z%IY5OO29%\=UW7Y@D5[9<Q7)5R]4L5[=<PW)-R[4LU[9<QW)=R_4L
MU[?<P')#RXTL-[;<Q')3R\TL-[?<PG)+RV5;]K]C8:+>ET%@ZS4I[./BQ <W
M/CCRP94/SGQPYX-#'USZX-0'MSXX]L&UC\O]HX7IX,'"5'BF\!.N25$,[+XR
M2:YLN8KEJI:K6:YNN8;EFI9K6:YMN8[ENI;K6:YON8'EAI8;66YLN8GEII:;
M66YNN87EEI;+MO!_Q\I$O2^#P,-K4CS;=$D*^[@X\<&-#XY\<.6#,Q_<^>#0
M!Y<^./7!K0^.?7#MXW+_:&4Z?+ R%1X#7'A)BN-?3U<_EZJG9R=G;TY/WI5Z
M/_]\^F9U47QIBN+'VWW#DES9<A7+52U7LUS=<@W+-2W7LES;<AW+=2W7LUS?
M<@/+#2TWLMS8<A/+32TWL]S<<@O++2V7;7/"=VQ8U,.#0/ D$#P*!,\"P<-
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MZ<7JS=7YMHOUR;.&CRU7MES%<E7+U2Q7MUS#<DW+M2S7MES'<EW+]2S7M]S
M<D/+C2PWMMS$<E/+S2PWM]S"<DO+9=M@\!T[%?7P(! \"02/ L&S0/ P$#P-
M!(\#P?- \$ 0/!$$CP3!,T'P4! \%<2-!>NKU\'>_>IU\.GPWS_A8GT'\ICB
M8\N5+5>Q7-5R-<O5+=>P7--R+<NU+=>Q7-=R/<OU+3>PW-!R(\N-+3>QW-1R
M,\O-+;>PW-)R"?;P'! \" 1/ L&C0/ L$#P,!$\#P>- \#P0/! $3P3!(T'P
M3! \% 1/!7%CP:.=:__!SE5X?O#W?(*J6-Q]UY)<V7(5RU4M5[-<W7(-RS4M
MU[)<VW(=RW4MU[-<WW(#RPTM-[+<V'(3RTTM-[/<W'(+RRTMER^3P,/W^+W8
M\!X_'/C@P@<G/KCQP9$/KGQPYH,['QSZX-('ISZX]<&Q#ZY]<.[C>O]HB3IX
ML$05GBC\<(EZN#V5SE97FS<H>>#QL>7*EJM8KFJYFN7JEFM8KFFYEN7:ENM8
MKFNYGN7ZEAM8;FBYD>7&EIM8;FJYF>7FEEM8;FFY?!D#UCXEM>EC4KCPP8D/
M;GQPY(,K'YSYX,X'ASZX],&I#VY]<.R#:Q^<^^#>QP7_T0IU^&"%*CP*>+>/
M75W_V/CWU=G5'_?_=5ZJ_,?'T^M_;)R]N?ZAT]]6I?Z[D[/B3VH5?TV[[V&2
M*UNN8KFJY6J6JUNN8;FFY5J6:UNN8[FNY7J6ZUMN8+FAY4:6&UMN8KFIY6:6
MFUMN8;FEY;)MEOB.=PU2#P\"P9- \"@0/ L$#P/!TT#P.! \#P0/!,$30?!(
M$#P3! \%P5-!W%CP:%L[>K"M'=T^PI_Q2:TCNW-)KFRYBN6JEJM9KFZYAN6:
MEFM9KFVYCN6ZENM9KF^Y@>6&EAM9;FRYB>6FEIM9;FZYA>66EDNPA^> X$$@
M>!(('@6"9X'@82!X&@@>!X+G@>"!('@B"!X)@F>"X*$@>"J(&PL>[5S/'NQ<
MA<</WUVE_?-;"W\[>?=Q\R'!Q<SN"Y;DRI:K6*YJN9KEZI9K6*YIN9;EVI;K
M6*YKN9[E^I8;6&YHN9'EQI:;6&YJN9GEYI9;6&YYQSU[^&; O9<O]Q^]%W!;
MU[]C<Z(>+GQPXH,;'QSYX,H'9SZX\\&A#RY]<.J#6Q\<^^#:!^<^KO>/-J?G
M#S:GPG.(/VU.I0\7IV^^L3')8Y&/+5>V7,5R5<O5+%>W7,-R3<NU+->V7,=R
M7<OU+->WW,!R0\N-+#>VW,1R4\O-+#>WW,)RRSONY8.-:>_'@Y=?+TSR88/[
M'ASXX,(')SZX\<&1#ZY\<.:#.Q\<^N#2!Z<^N/7!L0^N?5SN'RU,+QXL3(5'
M#A=^&*MY?G)6RL7)V2_G6SY<)8])/K9<V7(5RU4M5[-<W7(-RS4MU[)<VW(=
MRW4MU[-<WW(#RPTM-[+<V'(3RTTM-[/<W'(+RRTMEVVSP7=L7]3#@T#P)! \
M"@3/ L'#0/ T$#P.!,\#P0-!\$00/!($SP3!0T'P5! W%CS:OEX^V+X^G7'\
M9WRX2I[&?&RYLN4JEJM:KF:YNN4:EFM:KF6YMN4ZENM:KF>YON4&EAM:;F2Y
ML>4FEIM:;F:YN>46EEM:+L$>G@."!X'@22!X% B>!8*'@>!I('@<")X'@@>"
MX(D@>"0(G@F"AX+@J2!N+'BT<[UZL',5'F[\] ]7R3.7CRU7MES%<E7+U2Q7
MMUS#<DW+M2S7MES'<EW+]2S7M]S <D/+C2PWMMS$<E/+S2PWM]S"<LL[[N&'
MJUX<[!U]_59!^;#!?0\.?'#A@Q,?W/C@R =7/CCSP9T/#GUPZ8-3']SZX-@'
MUSXN]^N+T^'>_>)T6'A"\=;/5A7??>>%B7)ERU4L5[5<S7)URS4LU[1<RW)M
MRW4LU[5<SW)]RPTL-[3<R')CRTTL-[7<S')SRRTLM[SCMGZVBCYL<-^# Q]<
M^.#$!S<^./+!E0_.?'#G@T,?7/K@U >W/CCVP;6/R_VCA6G_P<)4>!KQSI^M
MVGC6U?:CK8J_BMWW+LF5+5>Q7-5R-<O5+=>P7--R+<NU+=>Q7-=R/<OU+3>P
MW-!R(\N-+3>QW-1R,\O-+;>PW-)RV38]?,=^1CT\" 1/ L&C0/ L$#P,!$\#
MP>- \#P0/! $3P3!(T'P3! \% 1/!7%CP:/][.#!?O;IJ.,_X=-7A_)0YF/+
ME2U7L5S5<C7+U2W7L%S3<BW+M2W7L5S7<CW+]2TWL-S0<B/+C2TWL=S4<C/+
MS2VWL-S2<@GV\!P0/ @$3P+!HT#P+! \# 1/ \'C0/ \$#P0!$\$P2-!\$P0
M/!0$3P5Q8\&CG>OPP<Y5>&#QP^^)O3E___[\K'1YNW%]^CC6YEU+'JE\;+FR
MY2J6JUJN9KFZY1J6:UJN9;FVY3J6ZUJN9[F^Y0:6&UIN9+FQY2:6FUIN9KFY
MY1:66]YQSV^YSZ=</=O;V_OZC87R<8,#'USXX,0'-SXX\L&5#\Y\<.>#0Q]<
M^N#4![<^./;!M0_.?5SO'RU11P^6J*.G+E%?O;%P^/'M^ZWO&"SD=]^H)%>V
M7,5R5<O5+%>W7,-R3<NU+->V7,=R7<OU+->WW,!R0\N-+#>VW,1R4\O-+#>W
MW,)R2\MEVUCP'8L7]? @$#P)!(\"P;- \# 0/ T$CP/!\T#P0! \$02/!,$S
M0?!0$#P5Q(T%CQ:O9P\6KT\'&/\9[QB41RT?6ZYLN8KEJI:K6:YNN8;EFI9K
M6:YMN8[ENI;K6:YON8'EAI8;66YLN8GEII:;66YNN87EEI9+L(?G@.!!('@2
M"!X%@F>!X&$@>!H('@>"YX'@@2!X(@@>"8)G@N"A('@JB!L+'NU<SQ_L7(5G
M(#_Y>NW%S.X+EN3*EJM8KFJYFN7JEFM8KFFYEN7:ENM8KFNYGN7ZEAM8;FBY
MD>7&=]S:5;V_>B_9Q#[JU'(SR\TMM[#<TG+9EO7O6)RHAP,?7/C@Q <W/CCR
MP94/SGQPYX-#'USZX-0'MSXX]L&UC\O]H\7IQ8/%J?#XXNW7:Y>G*1];KFRY
MBN6JEJM9KFZYAN6:EFM9KFVYCN6ZENM9KF^Y@>6&EAM9;GS'%5_5>V(?=6JY
MF>7FEEM8;FFY;,OY=RQ,U,.!#RY\<.*#&Q\<^>#*!V<^N//!H0\N?7#J@UL?
M'/O@VL?E_M'"]/+!PE1X]O#Z=YHVKTSR,.1CRY4M5[%<U7(UR]4MU[!<TW(M
MR[4MU[%<UW(]R_4M-[#<T'(CRXWON"T7+)C8AYU:;F:YN>46EEM:+MN*_AT[
M$_5PX8,3']SXX,@'5SXX\\&=#PY]<.F#4Q_<^N#8!]<^./=QO7^T,[UZL#,5
M'CO\^OC\_8?5V>7)U>GY66GUGS?__(WO-LGCD(\M5[9<Q7)5R]4L5[=<PW)-
MR[4LU[9<QW)=R_4LU[?<P')#RXTL-[[C'KX][V#3YB0?=6JYF>7FEEM8;FFY
M;.OZ=VQ.U,.!#RY\<.*#&Q\<^>#*!V<^N//!H0\N?7#J@UL?'/O@VL?E?GUS
M.MJ[WYR."L\?WN4B?M<_DK>_G5Z>7Y3RR\5J]7YU=E5\A;_BQ]YYVZ)<V7(5
MRU4M5[-<W7(-RS4MU[)<VW(=RW4MU[-<WW(#RPTM-[+<V'(3RTTM-[/<W'(+
MRRTMEVTSP^Y;F?7P(! \"02/ L&S0/ P$#P-!(\#P?- \$ 0/!$$CP3!,T'P
M4! \%<2-!8^VLOT'6]FG4X?_A"O\'<GSD8\M5[9<Q7)5R]4L5[=<PW)-R[4L
MU[9<QW)=R_4LU[?<P')#RXTL-[;<Q')3R\TL-[?<PG)+RR78PW- \" 0/ D$
MCP+!LT#P,! \#02/ \'S0/! $#P1!(\$P3-!\% 0/!7$C06/=JZ#!SM7X:G#
M3[["7S&S^X(EN;+E*I:K6JYFN;KE&I9K6JYEN;;E.I;K6JYGN;[E!I8;6FYD
MN?$=M_86PDV?OJ(/.[7<S')SRRTLM[1<MG7].S8GZN'"!R<^N/'!D0^N?'#F
M@SL?'/K@T@>G/KCUP;$/KGUP[N-Z_VAS.GRP.14>-;SU$G_%=]]]8Y)<V7(5
MRU4M5[-<W7(-RS4MU[)<VW(=RW4MU[-<WW(#RPTM-[+<^(Y[N#'M?[4MR8><
M6FYFN;GE%I9;6B[;6OX=VQ+U<-V#\Q[<]^# !Q<^./'!C0^.?'#E@S,?W/G@
MT >7/CCU<:U_M"T=/=B6CI[^?:;-^U(AL/N^)+FRY2J6JUJN9KFZY1J6:UJN
M9;FVY3J6ZUJN9[F^Y0:6&UIN9+GQ';?U^G[T8:>6FUEN;KF%Y9:6R[:B?\?.
M1#U<^.#$!S<^./+!E0_.?'#G@T,?7/K@U >W/CCVP;4/SGU<[Q_M3,\>[$R%
MY_L^_?I^Q<[NJY/DRI:K6*YJN9KEZI9K6*YIN9;EVI;K6*YKN9[E^I8;6&YH
MN9'EQG?<MNO[T4>=6FYFN;GE%I9;6B[;NOX=FQ/U<."#"Q^<^.#&!T<^N/+!
MF0_N?'#H@TL?G/K@U@?'/KCV<;E_M#D]?[ Y%1[P6WA]OW\[/S_;<@$_>1KQ
ML>7*EJM8KFJYFN7JEFM8KFFYEN7:ENM8KFNYGN7ZEAM8;FBYD>7&EIM8;FJY
MF>7FEEM8;FFY;!L*OF/MHAX>!((G@>!1('@6"!X&@J>!X'$@>!X('@B")X+@
MD2!X)@@>"H*G@KBQX-':]>+!VO7IF. _XP)^\D#C8\N5+5>Q7-5R-<O5+=>P
M7--R+<NU+=>Q7-=R/<OU+3>PW-!R(\N-+3>QW-1R,\O-+;>PW-)R"?;P'! \
M" 1/ L&C0/ L$#P,!$\#P>- \#P0/! $3P3!(T'P3! \% 1/!7%CP:.=Z^6#
MG:OPF.&G7\!/GGY\;+FRY2J6JUJN9KFZY1J6:UJN9;FVY3J6ZUJN9[F^Y0:6
M&UIN9+GQ'??P/8(O-KU'4#[JU'(SR\TMM[#<TG+9EO7O6)RHAP,?7/C@Q <W
M/CCRP94/SGQPYX-#'USZX-0'MSXX]L&UC\O]H\7IU8/%J?"4X>W7[Y.''A];
MKFRYBN6JEJM9KFZYAN6:EFM9KFVYCN6ZENM9KF^Y@>6&EAM9;GS'O7RP,.W]
M>/#RJX5)/NK4<C/+S2VWL-S2<MF6\^]8F*B' Q]<^.#$!S<^./+!E0_.?'#G
M@T,?7/K@U >W/CCVP;6/R_WZPO1L[WYA>E9X / 3+N%7#.R\,E&N;+F*Y:J6
MJUFN;KF&Y9J6:UFN;;F.Y;J6ZUFN;[F!Y8:6&UEN?,=MO80??=BIY6:6FUMN
M8;FEY;*MZ+OO3-;#A0].?'#C@R,?7/G@S =W/CCTP:4/3GUPZX-C'US[X-S'
M]?[1SK3_8&<J/,#WZ1>BN/[?>?O;Z>7Y12F_7*Q6[U=G5\57J2A^Y-V7+<F5
M+5>Q7-5R-<O5+=>P7--R+<NU+=>Q7-=R/<OU+3>PW-!R(\N-+3>QW-1R,\O-
M+;>PW-)RV38Q?,=.1CT\" 1/ L&C0/ L$#P,!$\#P>- \#P0/! $3P3!(T'P
M3! \% 1/!7%CP:.=[.#!3O;I:. _X2H5S^0AQL>6*UNN8KFJY6J6JUNN8;FF
MY5J6:UNN8[FNY7J6ZUMN8+FAY4:6&UMN8KFIY6:6FUMN8;FEY1+LX3D@>! (
MG@2"1X'@62!X& B>!H+'@>!Y('@@")X(@D>"X)D@>"@(G@KBQH)'.]?A@YVK
M\(#A)U^EHIC9?<&27-ER%<M5+5>S7-UR#<LU+=>R7-MR'<MU+=>S7-]R \L-
M+3>RW/B.6SO):N,[".7#3BTWL]S<<@O++2V7;5W_CLV)>KCPP8D/;GQPY(,K
M'YSYX,X'ASZX],&I#VY]<.R#:Q^<^[C>/]J<CAYL3D?;-Z>"RU04WWWWC4ER
M9<M5+%>U7,UR=<LU+->T7,MR;<MU+->U7,]R?<L-+#>TW,ARXSONX<:T_]6V
M)!]R:KF9Y>:66UAN:;EL:_EW;$O4PW4/SGMPWX,#'USXX,0'-SXX\L&5#\Y\
M<.>#0Q]<^N#4Q[7^T;;T[,&V5'BT\%.N42'/.CZV7-ER%<M5+5>S7-UR#<LU
M+=>R7-MR'<MU+=>S7-]R \L-+3>RW/B.VWZ-"OFP4\O-+#>WW,)R2\ME6]&_
M8V>B'BY\<.*#&Q\<^>#*!V<^N//!H0\N?7#J@UL?'/O@V@?G/J[WCW:FYP]V
MIL)S@0NO4=&Y*.7L[<7J]RW7HI G&1];KFRYBN6JEJM9KFZYAN6:EFM9KFVY
MCN7^W^[NK3>. T_S]/U\"J(Q%SU H9JDJ-/.K(%W\QP9F1EY/MRQ;'99TRK1
MH.FJZ<5\^%59IAQ*T1%DSJ.;10%]<$E/VE4"WM\?)".FEIM9KK+<W'(+RRTM
MM[+<VG(;RVTMM[/<WG('RZ6M#$ZXO:B'0R"X!()3(+@%@F,@N :"<R"X!X*#
M(+@(@I,@N F"HR"X"N*RX.CV>EV[O3Z]'_A;/(M"OLFX8[FNY7J6ZUMN8+FA
MY4:6*RPWMEQIN8GEII:;6:ZRW-QR"\LM+;>RW-IR&\MM+;>SW-YR!\LEV,,=
M$!P"P240G +!+1 < \$U$)P#P3T0' 3!11"<!,%-$!P%P540EP5'-]>;VLW5
M^&KAIS^+0K[QN&.YKN5ZENM;;F"YH>5&#US]ASY>?OU-3(7]V+'E2LM-+#>U
MW,QRE>7FEEM8;FFYE>76EMM8;FNYG>7VECM8+FV[?L+E1#V\\,$3'[SQP2,?
MO/+!,Y\1]G /! =!<!$$)T%P$P1'07 5Q&7!T>7TMG8Y-;YCN/U9%/*5QQW+
M=2W7LUS?<@/+#2TW>N#>U"ZFBS]??'4OR0\=6ZZTW,1R4\O-+%=9;FZYA>66
MEEM9;FVYC>6VEMM9;F^Y@^72MN8GW$O4P_L>//#!"Q\\\<$;'SSR&6$/]T!P
M$ 0707 2!#=!<!0$5T%<%GQY+[TZ__U>>M7X?N%G_F35Q[^X^L?-A_O__/U_
MW9Y5[Z\_-/_L5?/?P[./+LIU+=>S7-]R \L-+3>R7&&YL>5*RTTL-[7<S'*5
MY>:66UAN:;F5Y=:6VUAN:[F=Y?:6.U@N;>WP_.O,>C@$@DL@. 6"6R X!H)K
M(#@'@GL@. B"BR X"8*;(#@*@JL@+@N.KK.+VG7VZ4W#W^!GKU[)=R)W+->U
M7,]R?<L-+#>TW,ARA>7&EBLM-['<U'(SRU66FUMN8;FEY5:66UMN8[FMY7:6
MVUON8+D$>[@#@D,@N 2"4R"X!8)C(+@&@G,@N >"@R"X"(*3(+@)@J,@N KB
MLN#HYKJLW5R-;QI^PO/9FX'GGU:2ZUJN9[F^Y0:6&UIN],#5'QW]SQ^Z^NJG
MKNC'CBU76FYBN:GE9I:K+#>WW,)R2\NM++>VW,9R6\OM++>WW,%R:5OT$VXF
MZN&%#Y[XX(T/'OG@E0^>^8RPAWL@. B"BR X"8*;(#@*@JL@+@N.;J87M9NI
M\1W#S=]%>/T_;^_.NK<__/6FY;L$Y7N1.Y;K6JYGN;[E!I8;6FYDN<)R8\N5
MEIM8;FJYF>4JR\TMM[#<TG(KRZTMM['<UG([R^TM=[!<VMK@A.N+>C@$@DL@
M. 6"6R X!H)K(#@'@GL@. B"BR X"8*;(#@*@JL@+@N.KJ^KVO5U]>LG?(OO
M$KRR-Y?DNI;K6:YON8'EAI8;6:ZPW-ARI>4FEIM:;F:YRG)SRRTLM[3<RG)K
MRVTLM[7<SG)[RQTLEV /=T!P" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($
M-T%P% 1705P6'-U<+VLW5^,[CY_\A/9FYOD'EN2ZENM9KF^Y@>6&#US]D>J7
MEU]]<]_(?FQAN;'E2LM-+#>UW,QRE>7FEEM8;FFYE>76EMM8;FNYG>7VECM8
M+FV[?L+E1#V\\,$3'[SQP2,?O/(98@_G0' /! =!<!$$)T%P$P1'07 5Q&7!
MT>7TJG8Y-;ZQN/4)[<V__?D7D^2ZENM9KF^Y@>6&#USC(]5']D,+RXTM5UIN
M8KFIY6:6JRPWM]S"<DO+K2RWMMS&<EO+[2RWM]S!<FE;\Q/N)>KA?0\>^."%
M#Y[XX(W/$'LX!X)[(#@(@HL@. F"FR X"H*K("X+CNZEU[5[J?%MP\_^V:I3
MG]$NWZ'<L5S7<CW+]2TWL-S0<B/+%98;6ZZTW,1R4\O-+%=9;FZYA>66EEM9
M;FVYC>6VEMM9;F^Y@^725@\GW&?4PR$07 +!*1#< L$Q$%P#P3D0W /!01!<
M!,%)$-P$P5$07 5Q67!TG[VIW6>?WFG\+7[Z2KY]N6.YKN5ZENM;;F"YH>5&
MEBLL-[9<:;F)Y::6FUFNLMS<<@O++2VWLMS:<AO+;2VWL]S><@?+)=C#'1 <
M L$E$)P"P2T0' /!-1"< \$]$!P$P440G 3!31 <!<%5$)<%1S?7V]K-U?A>
MY*<\HUV^J+ECN:[E>I;K6VY@N>$#5W^H^N77#U4?V8\M+#>V7&FYB>6FEIM9
MKK+<W'(+RRTMM[+<VG(;RVTMM[/<WG('RZ5MT4^XF:B'%SYXXH,W/GCD@U<^
M0^SA' CN@> @""Z"X"0(;H+@* BN@K@L^/)F>GW^^\WTNO%MQ8W?1UB=#<]V
M9X/WMW^Y?G]6?OQ7I_F;!9L_ZMG7%>6ZENM9KF^Y@>6&EAM9KK#<V'*EY2:6
MFUIN9KG*<G/++2RWM-S*<FO+;2RWM=S.<GO+'2R7MD1X_A%F/1P"P240G +!
M+1 < \$U$)P#P3T0' 3!11"<!,%-$!P%P540EP5'1]A%[0C[]/KB;_#-@J_E
MBY8[ENM:KF>YON4&EAM:;F2YPG)CRY66FUAN:KF9Y2K+S2VWL-S2<BO+K2VW
ML=S6<CO+[2UWL%R"/=P!P2$07 +!*1#< L$Q$%P#P3D0W /!01!<!,%)$-P$
MP5$07 5Q67!T<UW6;J[&UQ\_^5'MS<SS#RS)=2W7LUS?<@/+#2TWLEQAN;'E
M2LM-+#>UW,QRE>7FEEM8;FFYE>76EMM8;FNYG>7VECM8+FWS?\*!13T< OE<
M O47CUR\>'MY]"#=X(T/'OG@E0^>^>"=#Q[ZX*4/GOK@K0\>^^"U#Y[[N+T_
MNIQ>U"ZGQE<7MSZJO?FW/_]BDES7<CW+]2TWL-S0<B/+%98;6ZZTW,1R4\O-
M+%=9;FZYA>66EEM9;FVYC>6VEMM9;F^Y@^72-OLG7$S4PR&0SR50?_'(^9\O
MWWQ],-'/Q1L?//+!*Q\\\\$['SSTP4L?//7!6Q\\]L%K'S?W1P?35>U@NGKZ
MEYH>/YD:@>>?3)+K6JYGN;[E!I8;6FYDN<)R8\N5EIM8;FJYF>4JR\TMM[#<
MTG(KRZTMM['<UG([R^TM=[!<VH;_A).)>C@$\KD$ZD]9>OGU4Y:"-SYXY(-7
M/GCF@W<^>.B#ESYXZH.W/GCL@]<^>.[C]O[H9GI9NYD:WSC<^%R*WO][\Q_O
M;MZ?]=Z_?W=[?]_R4 KYIN2.Y;J6ZUFN;[F!Y8:6&UFNL-S8<J7E)I:;6FYF
MN<IR<\LM++>TW,IR:\MM++>UW,YR>\L=+)>V/CCAM*(>#H'@$@A.@> 6"(Z!
MX!H(SH'@'@@.@N B"$Z"X"8(CH+@*HC+@J,+[%7M OOT#N-O\5 *^;;ECN6Z
MENM9KF^Y@>6&EAM9KK#<V'*EY2:6FUIN9KG*<G/++2RWM-S*<FO+;2RWM=S.
M<GO+'2R78 ]W0' (!)= < H$MT!P# 370' .!/= <! $%T%P$@0W07 4!%=!
M7!8<W5RO:S=7XWN)G_Y0"OFZY([ENI;K6:YON8'EAI8;6:ZPW-ARI>4FEIM:
M;F:YRG)SRRTLM[3<RG)KRVTLM[7<SG)[RQTLE[;Y/^' HAX.@7PN@?I#*2Y?
MO[FZ_/K[!>D'XY$/7OG@F0_>^>"A#U[ZX*D/WOK@L0]>^^"YC]O[H\OI3>UR
M:GR[</M#*>3+CCN6ZUJN9[F^Y0:6&UIN9+G"<F/+E9:;6&YJN9GE*LO-+;>P
MW-)R*\NM+;>QW-9R.\OM+7>P7-IF_X2+B7HX!/*Y!-H?2D$_%V]\\,@'KWSP
MS ?O?/#0!R]]\-0';WWPV >O?=S<'QU,;VL'4^.KA9_R4 KYKN..Y;J6ZUFN
M;[F!Y8:6&UFNL-S8<J7E)I:;6FYFN<IR<\LM++>TW,IR:\MM++>UW,YR>\L=
M+)>VX3_A9*(>#H%\+H'Z0RDNSA]_*@7]9+SRP3,?O//!0Q^\],%3'[SUP6,?
MO/;!<Q^\]W&#_^71].;\]Z/I3>.K@!N?2C&XN[GY</_Q?YSUWWVX_O#]N^OW
M'__:[2\_-3^?HOD3GWUE4:YKN9[E^I8;6&YHN9'E"LN-+5=:;F*YJ>5FEJLL
M-[?<PG)+RZTLM[;<QG);R^TLM[?<P7)I*X7G7UG6PR$07 +!*1#< L$Q$%P#
MP3D0W /!01!<!,%)$-P$P5$07 5Q67!TBUW4;K%/KPC^!L^G>"-?9MRQ7-=R
M/<OU+3>PW-!R(\L5EAM;KK3<Q')3R\TL5UEN;KF%Y9:66UEN;;F-Y;:6VUEN
M;[F#Y1+LX0X(#H'@$@A.@> 6"(Z!X!H(SH'@'@@.@N B"$Z"X"8(CH+@*HC+
M@J.;Z[)V<S6^7/CH^13O/IQ]?_OAXQ%V<W=]_^[VP^.WEGS]<<=R7<OU+->W
MW,!R0\N-+%=8;FRYTG(3RTTM-[-<9;FYY1:66UIN9;FUY3:6VUIN9[F]Y0Z6
M2UL)G'!K40^'0' )!*= < L$QT!P#03G0' /! =!<!$$)T%P$P1'03Y70>MW
M <^?\"N/[J,7M?NH\5W"WU77[SZ=1=<___CX-23?;=RQ7-=R/<OU+3>PW-!R
M(\L5EAM;KK3<Q')3R\TL5UEN;KF%Y9:66UEN;;F-Y;:6VUEN;[F#Y=*V^R=<
M0]3#(1!< L$I$-P"P3$07 /!.1#< \%!$%P$P4D0W 3!49#/55!_\.9C+^J>
MM__"HUOHJG8+735_K>CF_O[]S=]N/MR?_7#S\_=W[W[ZXZ\1-4K/OXHDU[5<
MSW)]RPTL-[3<R'*%Y<:6*RTWL=S4<C/+59:;6VYAN:7E5I9;6VYCN:WE=I;;
M6^Y@N;05P E7$?5P" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($-T%P%*2M
M"K[[U^O_=O9?+R[_]/$ .KO]<'9[=_:7FW^_O;LY6][\=/_K(QS.7IS_Z>SR
M_/+ROY_]ZU\>_\7_I7OS_6^_]N+SK_V^]FL_JY/KN^]_?/A5+_[[V?6''\[^
M]8<_^%LH?OEP\_#I+_[@NP/_?_E/=W1_OJS=GXUO2/X_?%;'QU^T_/@'ZMWW
M-V?YZ\=?^.L=V_P@#_D"Z([ENI;K6:YON8'EAI8;6:ZPW-ARI>4FEIM:;F:Y
MRG)SRRTLM[3<RG)KRVTLM[7<SG)[RQTLE[:,..&(I1X.@> 2"$Z!X!8(CH'@
M&@C.@> >" Z"X"((3H+@)@B.@N JB,N"HT/M5>U0^_1:Y6_Q( _Y NB.Y;J6
MZUFN;[F!Y8:6&UFNL-S8<J7E)I:;6FYFN<IR<\LM++>TW,IR:\MM++>UW,YR
M>\L=+)=@#W= < @$ET!P"@2W0' ,!-= < X$]T!P$ 0707 2!#=!<!0$5T%<
M%AS=7*]K-U?C"YE/>I"'?&5TQW)=R_4LU[?<P')#RXTL5UAN;+G2<A/+32TW
MLUQEN;GE%I9;6FYEN;7E-I;;6FYGN;WE#I9+6PF<<&M1#X= < D$IT!P"P3'
M0' -!.= < \$!T%P$00G07 3!$=!/E=!_?$<KU\^^J-KZ(./CJ@WM2.J\27-
M3WC:AWQI=,=R7<OU+->WW,!R0\N-+%=8;FRYTG(3RTTM-[-<9;FYY1:66UIN
M9;FUY3:6VUIN9[F]Y0Z62]ONGW R40^'0' )!*= < L$QT!P#03G0' /! =!
M<!$$)T%P$P1'03Y70?TA'E>//^T#??#1R?2V=C(UOJ+Y60\%D2^/[EBN:[F>
MY?J6&UAN:+F1Y0K+C2U76FYBN:GE9I:K+#>WW,)R2\NM++>VW,9R6\OM++>W
MW,%R:2N $XXGZN$0""Z!X!0(;H'@& BN@> <".Z!X" (+H+@) AN@N H2%L5
M?'ILQN7YG\Y;'YOQXK?'9CSRB__+%T_#N/KS'WQ7(/HG^_(Z>WO^^W7VMO&E
MS?_GC\SHW/[M;Q__N;_\S8]>=\U_)\^^[BC7M5S/<GW+#2PWM-S(<H7EQI8K
M+3>QW-1R,\M5EIM;;F&YI>56EEM;;F.YK>5VEMM;[F"YM!7$\Z\[Z^$0""Z!
MX!0(;H'@& BN@> <".Z!X" (+H+@) AN@N H"*Z"N"PXNM$N:C?:IY<\?X.G
M9;R5KZ/N6*YKN9[E^I8;6&YHN9'E"LN-+5=:;F*YJ>5FEJLL-[?<PG)+RZTL
MM[;<QG);R^TLM[?<P7()]G '!(= < D$IT!P"P3'0' -!.= < \$!T%P$00G
M07 3!$=!<!7$9<'1S759N[D:7T;]Y=,R'C^MY-NL.Y;K6JYGN;[E!I8;6FYD
MN<)R8\N5EIM8;FJYF>4JR\TMM[#<TG(KRZTMM['<UG([R^TM=[!<VH;_A-.*
M>C@$@DL@. 6"6R X!H)K(#@'@GL@. B"BR X"8*;(#@*\KD*Z@_'N#A_]$>]
MVG_ET3GTHG8.-;Z-NO';!+<_OKN_.5M_>/?][=V'L_+COSHMWP@HWWS=L5S7
M<CW+]2TWL-S0<B/+%98;6ZZTW,1R4\O-+%=9;FZYA>66EEM9;FVYC>6VEMM9
M;F^Y@^72U@@G7$[4PR$07 +!*1#< L$Q$%P#P3D0W /!01!<!,%)$-P$P5$0
M7 5Q67!TA5W5KK"K7S_A6WPCX)6]N237M5S/<GW+#2PWM-S(<H7EQI8K+3>Q
MW-1R,\M5EIM;;F&YI>56EEM;;F.YK>5VEMM;[F"Y!'NX X)#(+@$@E,@N 6"
M8R"X!H)S(+@'@H,@N B"DR"X"8*C(+@*XK+@Z.9Z6;NY&E^&?/3:K+]?O__E
MYO$#2[ZCN6.YKN5ZENM;;F"YH>5&EBLL-[9<:;F)Y::6FUFNLMS<<@O++2VW
MLMS:<AO+;2VWL]S^@:L_J?CRS9N+5U]^^\K!?FS:=OV$RXEZ>.&#)SYXXX-'
M/GCE@V<^>.>#ASYXZ8.G/GCK@\<^>.V#YSYN[X\NIU>URZGQE<:?+J>SG^[>
M??\'%Y-\PW+'<EW+]2S7M]S <D/+C2Q76&YLN=)R$\M-+3>S7&6YN>46EEM:
M;F6YM>4VEMM:;F>Y_0/WIG8QG?_Y\LU7!Y/\U+3-^0D'$_7PP <O?/#$!V]\
M\,@'KWSPS ?O?/#0!R]]\-0';WWPV >O?=S<'QU,KVL'4^/KBY_RS GYXN6.
MY;J6ZUFN;[F!Y8:6&UFNL-S8<J7E)I:;6FYFN<IR<\LM++>TW,IR:\MM++>U
MW,YR^P>N[8>D#_9STS;I)QQ-U,,3'[SQP2,?O/+!,Q^\\\%#'[STP5,?O/7!
M8Q^\]L%S'[SW<8-_=#2]J1U-C2\P;GZ!U?O;OUR_/^M\/*MN[LZF-_?_N+W[
MCY_/1A^^;WE A7Q9<\=R7<OU+->WW,!R0\N-+%=8;FRYTG(3RTTM-[-<9;FY
MY1:66UIN9;FUY3:6VUIN9[F]Y0Z62ULJG'",40^'0' )!*= < L$QT!P#03G
M0' /! =!<!$$)T%P$P1'07 5Q&7!T3'VMG:,?7I?\;=X0(5\QW/'<EW+]2S7
MM]S <D/+C2Q76&YLN=)R$\M-+3>S7&6YN>46EEM:;F6YM>4VEMM:;F>YO>4.
MEDNPASL@. 2"2R X!8);(#@&@FL@. >">R X"(*+(#@)@IL@. J"JR N"[ZX
MN2[/SS_?7/_\OYN^ /;$!U2T,,\]L"S7M5S/<GW+#2PWM-S(<H7EQI8K+3>Q
MW-1R,\M5EIM;;F&YI>56EEM;;F.YK>5V#US+$R7V]F,/EDO;KC_[<L(>7OC@
MB0_>^."1#U[YX)D/WOG@H0]>^N"I#][ZX+$/7OO@N8_;^Z/+Z:)V.36^1;CM
M 14MO_WY%Y/DNI;K6:YON8'EAI8;6:ZPW-ARI>4FEIM:;F:YRG)SRRTLM[3<
MRG)KRVTLM[7<[H%K?J+$WG[JP7)IF_,3#B;JX8$/7OC@B0_>^."1#U[YX)D/
MWOG@H0]>^N"I#][ZX+$/7ONXN3\ZF"YK!U/CNXO;'U#1 CS_9))<UW(]R_4M
M-[#<T'(CRQ66&UNNM-S$<E/+S2Q766YNN87EEI9;66YMN8WEMI;;/7!M3Y38
MV\\]6"YMDW["T40]//'!&Q\\\L$K'SSSP3L?//3!2Q\\]<%;'SSVP6L?//?!
M>Q\W^$='TXO:T=3X6N#&!U1T/AY4]S=W__RW/G[RN^\_'E?EQW]U&A]/T?*!
MSS^R)->U7,]R?<L-+#>TW,ARA>7&EBLM-['<U'(SRU66FUMN8;FEY5:66UMN
M8[FMY7:6VUON8+FTA<()IQCU< @$ET!P"@2W0' ,!-= < X$]T!P$ 0707 2
M!#=!<!0$5T%<%AR=8E>U4^SJUT_PCZ=XD-G-);FNY7J6ZUMN8+FAY4:6*RPW
MMEQIN8GEII:;6:ZRW-QR"\LM+;>RW-IR&\MM+;>SW-YR!\LEV,,=$!P"P240
MG +!+1 < \$U$)P#P3T0' 3!11"<!,%-$!P%P540EP5'-]?+VLW5^)[AIS^>
M0K[^N&.YKN5ZENM;;F"YH>5&EBLL-[9<:;F)Y::6FUFNLMS<<@O++2VWLMS:
M<AO+;1^X^O,D7E^>OWC[Y7?Z[>S'[BUWL%S:=OV$RXEZ>.&#)SYXXX-'/GCE
M@V<^>.>#ASYXZ8.G/GCK@\<^>.V#YSYN[X\NIU>URZGQA</MCZ>0[S_N6*YK
MN9[E^I8;6&YHN9'E"LN-+5=:;F*YJ>5FEJLL-[?<PG)+RZTLM[;<QG+;!Z[Y
M>1([^ZE[RQTLE[8Y/^%@HAX>^."%#Y[XX(T/'OG@E0^>^>"=#Q[ZX*4/GOK@
MK0\>^^"UCYO[HX/I=>U@:GS9\'?+F_O[]S=_N_EP?_;#S<_?W[W[Z?[=[8?'
M;R?Y&N2.Y;J6ZUFN;[F!Y8:6&UFNL-S8<J7E)I:;6FYFN<IR<\LM++>TW,IR
M:\MM++=M&[%_O+O_\>R_OG[YI_/S\[.?KO_S^B_O;\Y^^>GVP]G'7;O[S[-W
M'^YOS^Y_O#F[_NO=S:>QN_[PPU>_X^.O+ZX__'+]\7>\N/C3V>7YY8O_]NLO
M_.T;,1[YR>/+E^=_^O7Y%H]]TZ#\SV!ON8/ETM89)UQRU,.Y$=P;P<$17!S!
MR1'<','1$5P=P=D1W!W!X1%<'L'I$=P><?%Q=,F]J5URC6\J;GQF1O?V?]Z>
ME==_^;GE(1GRW<H=RW4MU[-<WW(#RPTM-[)<8;FQY4K+32PWM=S,<I7EYI9;
M6&YIN97EUI;;6&YKN9WE]I8[6"YM97#"[44]' +!)1"< L$M$!P#P340G /!
M/1 <!,%%$)P$P4T0' 7!51"7!4>WU]O:[?7IC<7?XB$9\MW*'<MU+=>S7-]R
M \L-+3>R7&&YL>5*RTTL-[7<S'*5Y>:66UAN:;F5Y=:6VUAN:[F=Y?:6.U@N
MP1[N@. 0""Z!X!0(;H'@& BN@> <".Z!X" (+H+@) AN@N H"*Z"N"SX\N:Z
M./_]YKIH?-?QDQ^2T<P\^\"B7-=R/<OU+3>PW-!R(\L5EAM;KK3<Q')3R\TL
M5UEN;KF%Y9:66UEN_<#5'T-Q^>:K%TYM[,=N+;>SW-YR!\NE;=>??SE9#R]\
M\,0';WSPR >O?/#,!^]\\- '+WWPU =O??#8!Z]]\-S'[?W1Y711NYP:7WK<
M^I",YM_^_(M)<EW+]2S7M]S <D/+C2Q76&YLN=)R$\M-+3>S7&6YN>46EEM:
M;F6Y]0/7_!B*C?W4K>5VEMM;[F"YM,WY"0<3]?# !R]\\,0';WSPR >O?/#,
M!^]\\- '+WWPU =O??#8!Z]]W-P?'4R7M8.I\87'7WZIZ?&32;Z!N6.YKN5Z
MENM;;F"YH>5&EBLL-[9<:;F)Y::6FUFNLMS<<@O++2VWLMSZ@7M5.YE>GC_V
M12;YL5O+[2RWM]S!<FE;]!-N)NKAA0^>^."-#Q[YX)4/GOG@G0\>^N"E#Y[Z
MX*T/'OO@M0^>^[B]/[J97M1NIL8W$W_7N?[YQ\=/)?F&Y([ENI;K6:YON8'E
MAI8;6:ZPW-ARI>4FEIM:;F:YRG)SRRTLM[3<RG+K!Z[^_7@7YX_>2O)SMY;;
M66YON8/ETK;D)]Q*U,,3'[SQP2,?O/+!,Q^\\\%#'[STP5,?O/7!8Q^\]L%S
M'[SW<8-_="M=U6ZEJ\9;:?&L1_=]_(N=VP\___+^_MV'OY[E\R-M&Q_MU_QW
M\/RK2W)=R_4LU[?<P')#RXTL5UAN;+G2<A/+32TWLUQEN;GE%I9;6FYEN;7E
M-I;;6FYGN;WE#I9+6SF<<)M1#X= < D$IT!P"P3'0' -!.= < \$!T%P$00G
M07 3!$=!<!7$9<'1;?:R=IM]>F?Q-WBTWX5\NW+'<EW+]2S7M]S <D/+C2Q7
M6&YLN=)R$\M-+3>S7&6YN>46EEM:;F6YM>4VEMM:;F>YO>4.EDNPASL@. 2"
M2R X!8);(#@&@FL@. >">R X"(*+(#@)@IL@. J"JR N"XYNKE>UFZOQM<=/
M?[2??!MSQW)=R_4LU[?<P')#RXTL5UAN;+G2<A/+32TWLUQEN;GE%I9;6FYE
MN?4#]X1O)92?N[7<SG)[RQTLE[9A/^%THAZ>^."-#Q[YX)4/GOG@G0\>^N"E
M#Y[ZX*T/'OO@M0^>^^"]CQO\H]/I=>UT:GS/</NS_>1KCSN6ZUJN9[F^Y0:6
M&UIN9+G"<F/+E9:;6&YJN9GE*LO-+;>PW-)R*\NM'[@O3J:OKB7YD5O+[2RW
MM]S!<FG;\A.N)>KA=0^>]^!]#Q[XX(4/GOC@C0\>^>"5#Y[YX)T/'OK@I0^>
M^KBM/[J6WM2NI<8W S?^X-7_<W/_X^W=67G_0\M/5LF7&7<LU[5<SW)]RPTL
M-[3<R'*%Y<:6*RTWL=S4<C/+59:;6VYAN:7E5I9;6VYCN:WE=I;;6^Y@N;2E
MP0G'%_5P" 270' *!+= < P$UT!P#@3W0' 0!!=!<!($-T%P% 1705P6'!U?
M;VO'UZ=7!'^+GZR2+S/N6*YKN9[E^I8;6&YHN9'E"LN-+5=:;F*YJ>5FEJLL
M-[?<PG)+RZTLM[;<QG);R^TLM[?<P7()]G '!(= < D$IT!P"P3'0' -!.=
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MM=S,<I7EYI9;6&YIN97EUI;;6&YKN9WE]I8[6"YM0WW"*40]/-GI8@_O>_#
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M@R"X"(*3(+@)@J,@N KBLN#H%GM1N\4^O3/W&SPMXK5\NV_'<EW+]2S7M]S
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M,SDN>&ULK99K;]HP%(;_BI5-4R>MS?T"@T@4J(I$U:K IFK:!Q,.8-6),]M
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MLL39L[3DP/,^T(4E4,V':D&M[3OO ZT&0S4*U1A4XRC-S/:F).S8:\+[SOM
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M[=ZO;@(T2R?DP\L-0C:GQF]?(&'?@,X#!5H AFH!5 NA6@35*%1C4(VC-'-
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MSYLQ>/?K^[XII$.%F6$A_I"+VS?$'?")$K'G8$(B'&GX13T?_!>_JN<MNT;
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M?7XOBAO >D),!_T\Y5P=*F: ^I9G]C]02P,$%     @ ,(J25R*);;(K P
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M^>^D.MWN#<_'WY>/DYVW]XZS@W]1BU]02P,$%     @ ,(J25R[2^,"N 0
MRAH  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS9G-;L(P$(1?!>6*B+&=TA\!
ME[;7ED-?P$TV)"*)+=M0>/LZX4=J1:,B*G4NL1+OSHR]TG?)]&UGR VV==6X
M651X;QX8<VE!M7*Q-M2$G5S;6OGP:I?,J'2EEL3$>#QAJ6X\-7[D6XUH/GVB
M7*TK/WC>AL^NU,TLLE2Y:/"X+VR]9I$RIBI3Y<,^VS39-Y?1P2$.G5V-*TKC
MAJ$@8F<=VIV?#0Y]KQNRMLQHL%#6OZ@Z5+%MQ9S?5>3B?HDS&76>EREE.EW7
MH25VQI+*7$'DZRK>BP[[G7VX8=H_^=7^G4R?8:A<6&U<F)BER^V.(VF[1R8(
MD?5E_Q%/CD'ZZO-1.^V,LE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A
M<MR Y)B Y+@%R7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'
M(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$
M(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3%+(F_TG6=ZU7?_UWI5WC6I7-
MT9]UO[#FGU!+ 0(4 Q0    ( #"*DE<'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ ,(J25V'7Q./O
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ ,(J25YE<G",0!@  G"<  !,              ( !S0$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  PBI)7'LMOQP(&  "L%@
M&               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ ,(J25_D@SQ%&!P  -2@  !@              ("!1@X  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #"*DE<-&H,>UP(
M &L)   8              " @<(5  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  PBI)7<WAY8L@&   E*P  &               @('/
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ,(J25W[Q
M88Q6 @  9 4  !@              ("!S1\  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( #"*DE?_ZG<'&0P  &9H   8
M  " @5DB  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  P
MBI)7^^B<A= (  "(-   &               @(&H+@  >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ ,(J25ZD87@C*!   TPL  !@
M         ("!KC<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( #"*DE=]M!<P61<  .MI   8              " @:X\  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  PBI)7( %85H8#  "2"0
M&0              @($]5   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( #"*DE>T<5_4D@(  ,,%   9              " @?I7  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ,(J25V+@U;I@
M P  % D  !D              ("!PUH  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  PBI)7POD&D*T#  !9"@  &0
M@(%:7@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #"*
MDE?U$<#JJ (  $\'   9              " @3YB  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ ,(J25]OZY0\1&   5X,  !D
M         ("!'64  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  PBI)7*(W'6Y4%  #Q$   &0              @(%E?0  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #"*DE<:@V$9J0@  + ;
M   9              " @3&#  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ ,(J25[@OZ6SK @  0 8  !D              ("!$8P
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  PBI)7^;5Y
MB^P$  "Y"@  &0              @($SCP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( #"*DE>+0_V0^A@   QW   9
M  " @5:4  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M,(J25]!^ DI% P  1@L  !D              ("!AZT  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  PBI)7XE*%,>X"  "V!P  &0
M            @($#L0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( #"*DE?2G(C,W@8  (T?   9              " @2BT  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ,(J25S-&E[(C P
M%0@  !D              ("!/;L  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  PBI)7"HA[_Z8"  #,!0  &0              @(&7
MO@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #"*DE<4
MSM??*P4  *LJ   9              " @73!  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ ,(J25TAE%%*D P  H!,  !D
M     ("!UL8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #"*DE=AE@:H+0,  /<+   9              "
M@<+8  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ ,(J2
M5SJP!*F""   RF4  !D              ("!)MP  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  PBI)7[NWDDZ4#   >%0  &0
M        @('?Y   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( #"*DE<A5+__QP,  '<0   9              " @;OH  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ,(J25WROYD;F!   PAT
M !D              ("!N>P  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  PBI)7);_<OT\$   "$P  &0              @('6\0
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #"*DE>&.VZ+
MG)@  #B_#@ 9              " @5SV  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ ,(J25_V,""0@ P  , D  !D
M ("!+X\! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  P
MBI)7=<AVHID%  ")(0  &0              @(&&D@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #"*DE>*OP!_^PT  (NX   9
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M;',O+G)E;'-02P$"% ,4    "  PBI)7&M>6@D0$  !K'0  #P
M    @ %)M0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ,(J25T<<8+FD
M 0  FQH  !H              ( !NKD! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ ,(J25R[2^,"N 0  RAH  !,
M ( !EKL! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #0 -  C#@  =;T!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>272</ContextCount>
  <ElementCount>240</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/StatementsOfOperationsParenthetical</Role>
      <ShortName>Statements of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statement of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/StatementOfChangesInStockholdersEquity</Role>
      <ShortName>Statement of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF THE BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PREPAID EXPENSES AND DEPOSITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/PrepaidExpensesAndDeposits</Role>
      <ShortName>PREPAID EXPENSES AND DEPOSITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://mangorx.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - CAPITAL STOCK</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/CapitalStock</Role>
      <ShortName>CAPITAL STOCK</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - GOING CONCERN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/GoingConcern</Role>
      <ShortName>GOING CONCERN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mangorx.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mangorx.com/role/PropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - CAPITAL STOCK (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/CapitalStockTables</Role>
      <ShortName>CAPITAL STOCK (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mangorx.com/role/CapitalStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mangorx.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mangorx.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails</Role>
      <ShortName>SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - PREPAID EXPENSES AND DEPOSITS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative</Role>
      <ShortName>PREPAID EXPENSES AND DEPOSITS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/PrepaidExpensesAndDeposits</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - INVENTORY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/InventoryDetailsNarrative</Role>
      <ShortName>INVENTORY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/Inventory</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://mangorx.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/NotesPayable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - CAPITAL STOCK (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/CapitalStockDetailsNarrative</Role>
      <ShortName>CAPITAL STOCK (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/CapitalStockTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/SubsequentEvents</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - GOING CONCERN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/GoingConcernDetailsNarrative</Role>
      <ShortName>GOING CONCERN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/GoingConcern</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails</Role>
      <ShortName>SCHEDULE OF DEFERRED TAX ASSET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="formposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mangorx.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mangorx.com/role/IncomeTaxesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="formposam.htm">formposam.htm</File>
    <File>mgrx-20230930.xsd</File>
    <File>mgrx-20230930_cal.xml</File>
    <File>mgrx-20230930_def.xml</File>
    <File>mgrx-20230930_lab.xml</File>
    <File>mgrx-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>forms-1_001.jpg</File>
    <File>forms-1_002.jpg</File>
    <File>forms-1_003.jpg</File>
    <File>forms-1_004.jpg</File>
    <File>forms-1_005.jpg</File>
    <File>forms-1_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1131">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="28">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "formposam.htm": {
   "nsprefix": "MGRX",
   "nsuri": "http://mangorx.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "formposam.htm"
     ]
    },
    "schema": {
     "local": [
      "mgrx-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "mgrx-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgrx-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "mgrx-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgrx-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 217,
   "keyCustom": 23,
   "axisStandard": 15,
   "axisCustom": 0,
   "memberStandard": 23,
   "memberCustom": 42,
   "hidden": {
    "total": 205,
    "http://fasb.org/us-gaap/2023": 184,
    "http://mangorx.com/20230930": 18,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 272,
   "entityCount": 1,
   "segmentCount": 68,
   "elementCount": 435,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1131,
    "http://xbrl.sec.gov/dei/2023": 28
   },
   "report": {
    "R1": {
     "role": "http://mangorx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://mangorx.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://mangorx.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://mangorx.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://mangorx.com/role/StatementsOfOperationsParenthetical",
     "longName": "00000005 - Statement - Statements of Operations (Parenthetical)",
     "shortName": "Statements of Operations (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_RelatedPartyMember",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_us-gaap_RelatedPartyMember",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://mangorx.com/role/StatementOfChangesInStockholdersEquity",
     "longName": "00000006 - Statement - Statement of Changes in Stockholders' Equity",
     "shortName": "Statement of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2021-10-072021-12-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://mangorx.com/role/StatementsOfCashFlows",
     "longName": "00000007 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2021-10-072021-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "MGRX:IssuanceOfCommonStockForServices",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://mangorx.com/role/OrganizationAndDescriptionOfBusiness",
     "longName": "00000008 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF THE BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://mangorx.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://mangorx.com/role/PrepaidExpensesAndDeposits",
     "longName": "00000010 - Disclosure - PREPAID EXPENSES AND DEPOSITS",
     "shortName": "PREPAID EXPENSES AND DEPOSITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "MGRX:PrepaidExpensesAndDepositsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "MGRX:PrepaidExpensesAndDepositsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://mangorx.com/role/Inventory",
     "longName": "00000011 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://mangorx.com/role/PropertyAndEquipment",
     "longName": "00000012 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://mangorx.com/role/RelatedPartyTransactions",
     "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://mangorx.com/role/NotesPayable",
     "longName": "00000014 - Disclosure - NOTES PAYABLE",
     "shortName": "NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://mangorx.com/role/CapitalStock",
     "longName": "00000015 - Disclosure - CAPITAL STOCK",
     "shortName": "CAPITAL STOCK",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://mangorx.com/role/CommitmentsAndContingencies",
     "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://mangorx.com/role/SubsequentEvents",
     "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://mangorx.com/role/GoingConcern",
     "longName": "00000018 - Disclosure - GOING CONCERN",
     "shortName": "GOING CONCERN",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://mangorx.com/role/IncomeTaxes",
     "longName": "00000019 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000021 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://mangorx.com/role/PropertyAndEquipmentTables",
     "longName": "00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://mangorx.com/role/CapitalStockTables",
     "longName": "00000023 - Disclosure - CAPITAL STOCK (Tables)",
     "shortName": "CAPITAL STOCK (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://mangorx.com/role/CommitmentsAndContingenciesTables",
     "longName": "00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://mangorx.com/role/IncomeTaxesTables",
     "longName": "00000025 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
     "longName": "00000026 - Disclosure - ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF THE BUSINESS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails",
     "longName": "00000027 - Disclosure - SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)",
     "shortName": "SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000028 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative",
     "longName": "00000029 - Disclosure - PREPAID EXPENSES AND DEPOSITS (Details Narrative)",
     "shortName": "PREPAID EXPENSES AND DEPOSITS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "MGRX:PrepaidExpensesRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "MGRX:PrepaidExpensesAndDepositsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "MGRX:PrepaidExpensesRelatedParty",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "MGRX:PrepaidExpensesAndDepositsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://mangorx.com/role/InventoryDetailsNarrative",
     "longName": "00000030 - Disclosure - INVENTORY (Details Narrative)",
     "shortName": "INVENTORY (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:InventoryNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "00000031 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30_custom_ComputersMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000032 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)",
     "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:PaymentsToAcquireMachineryAndEquipment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000033 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2021-10-072021-12-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31_custom_JacobDCohenMember",
      "name": "us-gaap:RepaymentsOfRelatedPartyDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://mangorx.com/role/NotesPayableDetailsNarrative",
     "longName": "00000034 - Disclosure - NOTES PAYABLE (Details Narrative)",
     "shortName": "NOTES PAYABLE (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2022-11-18",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-11-18",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000035 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
     "longName": "00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "shortName": "SCHEDULE OF FAIR VALUE ASSUMPTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://mangorx.com/role/ScheduleOfWarrantActivityDetails",
     "longName": "00000037 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-09-30_us-gaap_WarrantMember40800812",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://mangorx.com/role/CapitalStockDetailsNarrative",
     "longName": "00000038 - Disclosure - CAPITAL STOCK (Details Narrative)",
     "shortName": "CAPITAL STOCK (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails",
     "longName": "00000039 - Disclosure - SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)",
     "shortName": "SCHEDULE OF MATURITY OF LEASE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2022-09-28",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-09-28",
      "name": "us-gaap:AreaOfLand",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://mangorx.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000041 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-03-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-10-012023-10-01_custom_ConsultingAgreementMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://mangorx.com/role/GoingConcernDetailsNarrative",
     "longName": "00000042 - Disclosure - GOING CONCERN (Details Narrative)",
     "shortName": "GOING CONCERN (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails",
     "longName": "00000043 - Disclosure - SCHEDULE OF DEFERRED TAX ASSET (Details)",
     "shortName": "SCHEDULE OF DEFERRED TAX ASSET (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DeferredTaxAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000044 - Disclosure - INCOME TAXES (Details Narrative)",
     "shortName": "INCOME TAXES (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DeferredTaxAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "formposam.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "MGRX_PrivatePlacementWarrantSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantSixMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_PrivatePlacementWarrantSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantSevenMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://mangorx.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r57",
      "r223",
      "r354",
      "r509",
      "r510"
     ]
    },
    "MGRX_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right of use asset",
        "label": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration and Risks",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r114"
     ]
    },
    "MGRX_HammerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "HammerMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hammer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_StockIssuedDuringWarrantsExercisedForCashShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "StockIssuedDuringWarrantsExercisedForCashShares",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised for cash, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Deferred Tax Asset",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Increase) decrease in operating assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r176"
     ]
    },
    "MGRX_PercentageOfIncrementalBorrowingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PercentageOfIncrementalBorrowingRate",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of incremental borrowing rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "(Decrease) increase in operating liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "MGRX_MrAndrewMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "MrAndrewMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Andrew [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://mangorx.com/role/CapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://mangorx.com/role/CapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FAIR VALUE ASSUMPTIONS",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r603"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r176"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r365",
      "r366",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r456",
      "r458",
      "r489",
      "r604"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r94"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/CapitalStockTables",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r524",
      "r525",
      "r526",
      "r527"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued liabilities",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property acquired value",
        "label": "Payments to Acquire Machinery and Equipment",
        "documentation": "The cash outflow for acquisition of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r179",
      "r379",
      "r417",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r460",
      "r461",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r523"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_LeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "LeaseAgreementMember",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LONG-TERM LIABILITIES",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r65",
      "r66",
      "r67",
      "r68",
      "r153",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r331",
      "r332",
      "r333",
      "r345",
      "r567",
      "r605",
      "r606"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity ownership interest",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Expired"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_StreetGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "StreetGroupLLCMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Street Group L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument periodic payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r61"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "MGRX_MajorDodgeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "MajorDodgeMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Dodge [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r371"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r425",
      "r560",
      "r561",
      "r562",
      "r597",
      "r619"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit (loss)",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r153",
      "r180",
      "r186",
      "r190",
      "r192",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r345",
      "r507",
      "r567"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r371"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r29"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Exercise Price Per Share",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r273",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r303",
      "r304",
      "r305",
      "r306"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of borrowings - related parties",
        "label": "Repayments of related party debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues - related party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Fair value, net asset (liability)",
        "label": "Fair Value, Net Asset (Liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction purchases",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/BalanceSheetsParenthetical",
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated depreciation",
        "negatedLabel": "Less accumulated depreciation:",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r132",
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of options outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options, Outstanding Beginning Balance",
        "periodEndLabel": "Outstanding Ending Balance",
        "label": "Number of options",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning Balance",
        "periodEndLabel": "Weighted Average Outstanding Price Ending Balance",
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of common stock on measurement date",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercisable Price Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Right-of-use liability - operating lease",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r344",
      "r373",
      "r374",
      "r375",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/CapitalStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAPITAL STOCK",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r152",
      "r235",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r249",
      "r340",
      "r485",
      "r487",
      "r496"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r153",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r331",
      "r332",
      "r333",
      "r345",
      "r436",
      "r506",
      "r530",
      "r567",
      "r605",
      "r606"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/CapitalStockTables",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Present value of lease liabilities",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock value paid in cash",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative",
      "http://mangorx.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r365",
      "r366",
      "r367",
      "r368",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r456",
      "r458",
      "r489"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://mangorx.com/role/CapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://mangorx.com/role/CapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559"
     ]
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/NotesPayableDetailsNarrative",
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment on notes payable",
        "label": "Repayments of notes payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r22",
      "r125",
      "r142",
      "r143",
      "r144",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r179",
      "r200",
      "r201",
      "r249",
      "r300",
      "r301",
      "r302",
      "r321",
      "r322",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r361",
      "r410",
      "r411",
      "r412",
      "r425",
      "r482"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use liability - operating lease",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r200",
      "r201",
      "r300",
      "r301",
      "r302",
      "r321",
      "r322",
      "r334",
      "r336",
      "r337",
      "r339",
      "r341",
      "r410",
      "r412",
      "r425",
      "r619"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/CapitalStockTables",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r104",
      "r401",
      "r518",
      "r557",
      "r564",
      "r599"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r555"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_ContributionOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContributionOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable for purchase of property and equipment",
        "documentation": "Value of property contributed in noncash investing and financing activities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF DEFERRED TAX ASSET",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "MGRX_PrivatePlacementWarrantFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantFourMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Common Stock for Services",
        "verboseLabel": "Paid in cash",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r42",
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r87",
      "r440",
      "r457",
      "r483",
      "r484",
      "r518",
      "r530",
      "r557",
      "r564",
      "r599",
      "r619"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services, shares",
        "verboseLabel": "Shares issued in consideration",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_PrivatePlacementWarrantFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantFiveMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r500"
     ]
    },
    "MGRX_PrivatePlacementWarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantThreeMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r236"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "MGRX_ServiceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ServiceAgreementMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding and Vested Warrants Expected Term",
        "verboseLabel": "Outstanding and vested warrants expected term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property plant and equipment estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_TwentyTwentyTwoEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "TwentyTwentyTwoEquityIncentivePlanMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Two Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ]
    },
    "MGRX_JoanArangoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "JoanArangoMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Joan Arango [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash",
        "label": "Cash [Default Label]",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r398",
      "r426",
      "r446",
      "r518",
      "r530",
      "r552"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r371"
     ]
    },
    "MGRX_TwentyTwentyTwoPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "TwentyTwentyTwoPlanMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Two Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "MGRX_WhiteUnicornLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "WhiteUnicornLLCMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "White Unicorn L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r6"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r373",
      "r374",
      "r375",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_GlobalCareerNetworksIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "GlobalCareerNetworksIncMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Global Career Networks Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "MGRX_CharteredServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "CharteredServicesLLCMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chartered Services L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "MGRX_CostOfRevenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "CostOfRevenues",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of revenues ($3,255 of related party cost of revenues for the year ended December 31, 2022)",
        "label": "CostOfRevenues"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price Exercisable price",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "MGRX_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r259",
      "r264",
      "r344",
      "r374",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514"
     ]
    },
    "MGRX_DojoLabsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "DojoLabsMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dojo Labs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r259",
      "r264",
      "r344",
      "r373",
      "r512",
      "r513",
      "r514"
     ]
    },
    "MGRX_RudmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "RudmanMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rudman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_PrepaidExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrepaidExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed Interest",
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sales of units for cash",
        "verboseLabel": "Net proceeds from issuance of common stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "MGRX_BethorLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "BethorLtdMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bethor Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r344",
      "r375",
      "r509",
      "r510",
      "r512",
      "r513",
      "r514"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r371"
     ]
    },
    "MGRX_PrivatePlacementWarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantTwoMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://mangorx.com/role/CapitalStockTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANT ACTIVITY",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "MGRX_RelatedPartiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "RelatedPartiesPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_AdvisorAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "AdvisorAgreementMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisor Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r371"
     ]
    },
    "MGRX_PrivatePlacementWarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantOneMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails": {
       "parentTag": "us-gaap_FairValueNetAssetLiability",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "MGRX_BoonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "BoonMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Boon [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ConsultingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ConsultingAgreementsMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r258",
      "r266",
      "r295",
      "r296",
      "r297",
      "r376",
      "r377",
      "r409",
      "r428",
      "r429",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r499",
      "r508",
      "r511",
      "r515",
      "r519",
      "r522",
      "r565",
      "r569",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r266",
      "r377",
      "r409",
      "r428",
      "r429",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r499",
      "r508",
      "r511",
      "r515",
      "r519",
      "r569",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r258",
      "r266",
      "r295",
      "r296",
      "r297",
      "r376",
      "r377",
      "r409",
      "r428",
      "r429",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r499",
      "r508",
      "r511",
      "r515",
      "r519",
      "r522",
      "r565",
      "r569",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US federal income corporate tax rates, percentage",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and advertising",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r266",
      "r377",
      "r409",
      "r428",
      "r429",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r498",
      "r499",
      "r508",
      "r511",
      "r515",
      "r519",
      "r569",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_PrepaidExpensesAndDepositsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrepaidExpensesAndDepositsTextBlock",
     "presentation": [
      "http://mangorx.com/role/PrepaidExpensesAndDeposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAID EXPENSES AND DEPOSITS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT ASSETS",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r138",
      "r153",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r330",
      "r332",
      "r345",
      "r518",
      "r567",
      "r568",
      "r605"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Cancelled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH AND CASH EQUIVALENTS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statutory federal income tax rate, percentage",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r312",
      "r325"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/GoingConcernDetailsNarrative",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity",
      "http://mangorx.com/role/StatementsOfCashFlows",
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss)",
        "label": "Net Loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r85",
      "r106",
      "r126",
      "r139",
      "r140",
      "r144",
      "r153",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r173",
      "r180",
      "r186",
      "r190",
      "r192",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r343",
      "r345",
      "r406",
      "r459",
      "r480",
      "r481",
      "r507",
      "r528",
      "r567"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTable",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table]",
        "documentation": "A summary of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return for which the resultant tax benefit has not been recognized in the financial statements because it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleLineItems",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicOtherDisclosuresAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r308",
      "r313",
      "r314",
      "r319",
      "r323",
      "r326",
      "r327",
      "r328",
      "r421"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expenses",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r461"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r307"
     ]
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r309",
      "r310",
      "r314",
      "r315",
      "r318",
      "r320",
      "r418"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r502",
      "r518"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vested for stock based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_LeovLawFirmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "LeovLawFirmMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leov Law Firm [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r205",
      "r206",
      "r503"
     ]
    },
    "MGRX_PrivatePlacementWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PrivatePlacementWarrantMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r125",
      "r142",
      "r143",
      "r144",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r179",
      "r200",
      "r201",
      "r249",
      "r300",
      "r301",
      "r302",
      "r321",
      "r322",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r361",
      "r410",
      "r411",
      "r412",
      "r425",
      "r482"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://mangorx.com/role/GoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GOING CONCERN",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "MGRX_ResaleProspectusMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ResaleProspectusMember",
     "presentation": [
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Resale Prospectus [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation arrangement by share-based payment award, description",
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49"
     ]
    },
    "MGRX_PercentageOfProportionateRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PercentageOfProportionateRent",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of proportionate rent"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "MGRX_HsiaochingChouMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "HsiaochingChouMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hsiaoching Chou [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r150"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset impairment charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r38"
     ]
    },
    "MGRX_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_MasterServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "MasterServicesAgreementMember",
     "presentation": [
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securtiy deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "MGRX_OptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "OptionsMember",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ComputersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ComputersMember",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_GreentreeFinancialGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "GreentreeFinancialGroupMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Greentree Financial Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party advances received",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r179",
      "r379",
      "r417",
      "r427",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r460",
      "r461",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r523"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_IssuanceOfCommonStockForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "IssuanceOfCommonStockForServices",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for services"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_CohenEnterprisesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "CohenEnterprisesIncMember",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cohen Enterprises Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsExercisedInPeriodGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercise Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://mangorx.com/role/ScheduleofFinancialInstrumentsMeasuredAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_WarrantsForServiceCancelled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "WarrantsForServiceCancelled",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants for service cancelled"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ZipDoctorIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ZipDoctorIncMember",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zip Doctor Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Black Scholes Option Pricing Model",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_JacobDCohenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "JacobDCohenMember",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Jacob D Cohen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_StockIssuedDuringWarrantsExercisedForCashValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "StockIssuedDuringWarrantsExercisedForCashValue",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised for cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "MGRX_PHXGlobalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "PHXGlobalLLCMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "P H X Global L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://mangorx.com/role/BalanceSheetsParenthetical",
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_EzekielElliottMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "EzekielElliottMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ezekiel Elliott [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Warrants Exercisable Ending balance",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ImputedInterestRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ImputedInterestRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Imputed interest \u2013 related party",
        "label": "ImputedInterestRelatedParty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_DavidSandlerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "DavidSandlerMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "David Sandler [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r131",
      "r404"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://mangorx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r372"
     ]
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash equivalents",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r614"
     ]
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payroll tax liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r207",
      "r208",
      "r497",
      "r566"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES (SEE NOTE 9)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r60",
      "r397",
      "r437"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r130",
      "r501"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r123",
      "r168",
      "r169",
      "r184",
      "r311",
      "r324",
      "r408"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_OtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OTHER ASSETS",
        "label": "Other Assets",
        "documentation": "Amount of assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r133",
      "r395",
      "r530"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND DESCRIPTION OF THE BUSINESS",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r99",
      "r415",
      "r416"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right of use - asset",
        "verboseLabel": "Right of use of asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://mangorx.com/role/BalanceSheetsParenthetical",
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock (par value $.0001, 200,000,000 shares authorized, of which 13,365,000 and 8,000,000 shares issued and outstanding as of December 31, 2022 and 2021, respectively)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r399",
      "r518"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://mangorx.com/role/BalanceSheetsParenthetical",
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r438"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://mangorx.com/role/BalanceSheetsParenthetical",
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r70",
      "r438",
      "r457",
      "r619",
      "r620"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToEmployees",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salary",
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations",
      "http://mangorx.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "verboseLabel": "Cost of revenues - related party",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r153",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r345",
      "r567"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r524",
      "r525",
      "r526",
      "r527",
      "r560",
      "r561",
      "r597",
      "r615",
      "r619"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/StatementsOfOperationsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r365",
      "r366",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r456",
      "r458",
      "r489"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "verboseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Granted",
        "verboseLabel": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r115",
      "r118",
      "r122"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL CURRENT LIABILITIES",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r128",
      "r153",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r331",
      "r332",
      "r333",
      "r345",
      "r518",
      "r567",
      "r605",
      "r606"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding and Vested Warrants Ending balance",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumber"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "DirectorMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r616"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting term",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_DepositsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositsAssets",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_OtherAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration paid",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r172",
      "r174",
      "r175",
      "r176",
      "r178",
      "r342",
      "r343",
      "r392",
      "r407",
      "r505"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r462",
      "r463",
      "r466"
     ]
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, shares",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r103",
      "r613"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r83"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r366",
      "r369",
      "r422",
      "r423",
      "r424",
      "r464",
      "r465",
      "r466",
      "r486",
      "r488"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r517"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period",
        "periodEndLabel": "End of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r83",
      "r149"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r466"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "srt_ChiefOperatingOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefOperatingOfficerMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r563",
      "r603"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset",
        "verboseLabel": "Deferred tax asset",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock price",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/PrepaidExpensesAndDepositsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid the related party expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FIXED ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r518",
      "r617"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r438"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r107",
      "r145",
      "r183",
      "r353",
      "r467",
      "r528",
      "r618"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from investors",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76",
      "r105",
      "r180",
      "r186",
      "r190",
      "r192",
      "r393",
      "r405",
      "r507"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_LucaConsultingLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "LucaConsultingLlcMember",
     "presentation": [
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Luca Consulting Llc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "MGRX_FixedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net of accumulated depreciation of $3,863",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Property plant and equipment net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r394",
      "r404",
      "r518"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Property acquired value",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://mangorx.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r151",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued for services",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r14"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Warrants for Services Cancelled",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r41",
      "r93"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r115",
      "r118",
      "r402"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets",
      "http://mangorx.com/role/GoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r93",
      "r400",
      "r413",
      "r414",
      "r420",
      "r439",
      "r518"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates and Assumptions",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r112",
      "r113",
      "r116",
      "r117"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketing and advertising expense",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation Allowance",
        "label": "Deferred tax assets, valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r129",
      "r135",
      "r202",
      "r203",
      "r204",
      "r378",
      "r504"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of Units for Cash",
        "verboseLabel": "Shares issued value",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r70",
      "r93",
      "r425",
      "r482",
      "r495",
      "r529"
     ]
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "MGRX_DisclosurePrepaidExpensesAndDepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "DisclosurePrepaidExpensesAndDepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares vested",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDepositOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDepositOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Rent deposit",
        "label": "Increase (Decrease) in Deposit Assets",
        "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Preparation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r170",
      "r172",
      "r174",
      "r175",
      "r176",
      "r178",
      "r342",
      "r343",
      "r392",
      "r407",
      "r505"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_InterestExpenseRelatedPartyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "InterestExpenseRelatedPartyPercentage",
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed interest percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConversionFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockConversionFeatures",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement description",
        "documentation": "Description of common stock conversion feature. Includes, but is not limited to, conversion price; conversion right; timing of right; terms, event or change in circumstance causing contingency to be met or adjustment to conversion price or number of shares; manner of settlement upon conversion; and method of settlement."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r248"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "MGRX_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r517"
     ]
    },
    "MGRX_FixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://mangorx.com/20230930",
     "localname": "FixedAssets",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL FIXED ASSETS",
        "label": "FixedAssets"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash, shares",
        "verboseLabel": "Issuance of shares",
        "terseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r70",
      "r93",
      "r419",
      "r482",
      "r495"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://mangorx.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULEOF FINANCIAL INSTRUMENTS MEASURED AT FAIR VALUE",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r53",
      "r54",
      "r100"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r544",
      "r545"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative",
      "http://mangorx.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issued price per share",
        "verboseLabel": "Share price",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/StatementOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options and Warrants Vested for Services",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://mangorx.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carry forwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Revenues [Default Label]",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r153",
      "r181",
      "r182",
      "r185",
      "r188",
      "r189",
      "r193",
      "r194",
      "r195",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r345",
      "r393",
      "r567"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://mangorx.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r134",
      "r153",
      "r180",
      "r187",
      "r191",
      "r199",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r330",
      "r332",
      "r345",
      "r396",
      "r451",
      "r518",
      "r530",
      "r567",
      "r568",
      "r605"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r186",
      "r190",
      "r192",
      "r507"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestorMember",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r602"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Cancelled",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted common stock issued",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r93"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings on notes payable to related parties",
        "verboseLabel": "Proceeds from related party",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted stock issued net",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r70",
      "r93"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://mangorx.com/role/CapitalStockDetailsNarrative",
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Warrants Beginning Balance",
        "periodEndLabel": "Warrants Outstanding, Ending balance",
        "label": "Warrants outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283"
     ]
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/ScheduleOfMaturityOfLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfWarrantActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Beginning Balance",
        "periodEndLabel": "Weighted Average Exercise Price Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://mangorx.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://mangorx.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r70",
      "r93",
      "r279"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://mangorx.com/role/CommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCHEDULE OF MATURITY OF LEASE LIABILITIES",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://mangorx.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://mangorx.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payroll tax liabilities",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://mangorx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-40/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001493152-23-045293-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-045293-xbrl.zip
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MJ+>"H:,ZM5!WY-65OI6&_WJW/&H!<?QU9(E;5]\VJH\=ZIO(5U!+ P04
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MPJU$XPNM_A9(O;O&MI)C]<4Y>W(<_R]02P,$%     @ ,(J25TX9%]D %
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M%FECVQ%'MW/=,L1A4BL^C4J3MF$92C.>L3(49KP69LV5%XN\16*_VX%UB:
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M[=3,Z%FOZ9!H3*BB:"KLYF!P%VPVT'.;>P\;YS:28AWZULQ5%K3.:6+JU(8
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M=GJ\-5?%MAYM;SX8.;,%\"1'FZNX9$Z8X\$,  <S/^:&;BB\<BX99BVJ<LK
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MN?V4 8SF=O-@#D#%U3LMVN-Y 9A*"&4_KI5H/GS%=U!<!KZ'\7=4^,&D&,/
M=VT>"*FGSJ)Z &U_X?*UUEYQM<E/!'69RC4 NYR:V.7!7JBJL;77+J?YT,+P
M3@-4/(F2+9**N!=$H>U2C,0G5T!/<8%'4G+QC:7+7-NBY%ZQ]E2S%_0P_:VF
MO>)CUK+@YA1?[O%PQ?*3-J!P8GH*O,N=[N*+(PII.#K#)[X@ 16?IOFDOI)/
M6TSQWHT5]PR=@8Z'SUGQ#1*KB8D%">-@)7Q?.8+E62A^BU="[$]9TZ*;53&%
MXRF;5'S=<5EK67!SBF_PN=RPAJ4WH/!3\A1XEU,XBA_D\6#J_X/^D/WB>N++
M9BEQJX;47BYMTTQ#649[A(G.(MEXU2,!+;[F^6DM4!Z&N/B"PFF(580BTY)B
M=KN1AV$NOI!0!U*!!UN@T@1\9J3PL2"7T8L*ZT\!T%O'YO:'\3?*ZSJGA$"@
MCF.XZ79V.Y^'0=XO7#:DN\XLU!SG82"+#SHB4B<*>Z\ HX%C ;BJ\#?[1>I*
M('$W0@_;J2-P<+;[*?"C$=R!=84^CE.%<Z .,.C/R_@%]XN7'\OVB,G?@J.5
M=-5YF#2*'X^[5).8&4"5P&X? &H!3!7N-3@!, *G&^%/%SW-3!\'7@DUDZMJ
MK-,Z*-[#MZK&.K"6XDW69VJL [ 7/_+PF1KK .R%ZQ+/VEBG=3"9=5G9!<RB
MGN);NSQK8QU80.&Y%L_66 > +UP1>K;&.@!\X0K JAKKM Z*M\-6U5@'UK+B
M+G%/VH<5=XE[$MZKT"7N\8UU8 %5Z!+W).JI0I>X)Y'0JKO$/07[Q7M9GJVQ
M#@!?N!KQ=)?V8?'F8E%E X>3%;0E@O8IF(IG3&RX%8G0'V+0!?:9!S-"1(?%
MIPH_ 69-I/$MLX N?N"/947#B'R6:1J%SR['#]A(?>@'H?,W?;^@__@!>BE^
M6D]AI/R$-,^E&S6UCG#<\:8W:FHW.T76 )>PI((:-<%"BZ[=?2!;J>A&3>WF
M:NHC5]^H"5:^[IU@%ECBQO:!66#M=1>8=O-H)02P#EU@ #=%$\@&=(%IMYIK
MU;ZC EU@ &4;V,#CR3AY:0T\GHJPTMI&GO(>#V!Y-^Q>.D.7Z_3;;A=?QK4P
M2#/4[O:CFCS@=P/'MCG^B0 &" ;W+"[H=]?Q?KP5UH /&3S7O*>_!P&^8M@/
M[K<!GD[SJ-/<N1=P9N3/X7@$ZQ+.$(SG5V_BUV2>+%\E_"A0;X*+<!G.6[5B
M6MV<_G;RGO@N(&&@9_UE_+5CXP\]AP<F+0+@&H3AZ.V;-W=W=SN"6SM]__;-
MR?F_7KUO-INMH\YA<W?_W9O)F^.7O<E[FWK7B [*% A@7@5T5-XG*]'/27Z;
MO(M[=NH>7''R;CM]A_XZ_7;]G4+E@NA-7O7=YL[W#Y%P/"X$)GL P2A]825H
M3W#)^\BLDN_5+S9 <C]R'<M1<)JV Q<*H/*?7\%BWIX1G,>V'6##%:$^W "A
M'M\[XM5[O"9WP1*HJ>>G('N3"]J&4<I$?YFU.7R.A]Z-, <Y^I?BD*-%Q3HB
M1\%>'G*FA]).M0!90]:2I+XFJ[D!O49("0LV?_H7R6KR[GE^7K."@U'O??7V
M_MG/_=?<[C\O;/MSD?!23G]- 16C@-)Y0&N-%:/6,R&G%H[5$X[/OO<U:ZP8
M:RR/ A+7RT'&];(^3'+26W%0'6]%XGT^R(Y&6T_DMA^!W/8S(+>U(<A=VL_V
MK,A=,]VI .1F>&[QR)W.,5U/Y*IU+(7<5MG(G=>SY*5K-JM5;"M\,&>HP],-
M8]:88*Y#0!;>+B/O&*[W/0R\9VED:LT;I_G.V.SYW78V?^/GKO^E$,&,OE:;
MO_OY"]_4;0?ITZD9?348O=J+Y]OLFM%7C]$_.Q'4C+X*C/ZYMGU]#.QG1LY^
M.C1>2\&5GH3]DJ/@V<VNI6 EI>#S$D$M!2LB!9]EV]=5"I:-G-KI5QTI6+KA
M7SO]JB\%GYD(:BE8#2E8?B9P[?2K"*/OE&W;3FYVS>BKQ^B?G0AJ1E\%1O]<
MV[Z6YLYS(*=V^E5'"I9KVTYN=BT%*RD%GY<(:BE8$2GX+-N^KE*P7.0\/(QZ
M\X]#5:2@VHOGV^Q:"E9/"CX[$=12L I2\+FV?2VE8'G(R2NAJGVCJY2'192$
M=9ZML*;VK592GJXS$=7R>&7R> W)9GWD^5H@=S=&;NT;KI(6L/L(8MDONS!\
M!K'46D!%M8!U(J):"ZB,%K &9+.^6D ED9OM55-K 571 BK9>V<&L=1:0$6U
M@'4BHEH+J(P64#VRR0P+J)W6E1%4CYP74*YO8S:QU(*JBH)JS8BH%E35$%3K
M039K:JY6%;F[,7)KIW65M("E?1N=LGT;LXFEU@(JJ@6L$Q'56D!EM( U()OU
MU0(JB=QL]_I:"ZB*%E"];ORSB:76 BJJ!:P3$=5:0&6T@.J1S53+_UI054)0
M57*$P6QBJ055%075FA%1+:BJ(:@J23:SQZ?4@FK]TO)71BRUH*JBH%HS(JH%
M534$5;7()NEI6SO\*M+!H5W^"._:85=)\;)*(JC%0Q4Z.#S7MJ]/V.PYD5.'
MO:HC!3O/O=FU%*R>%'QV(JBE8!6D8'G;GL0=V]OMPYP<Y//+BPW8\Z@K'-MA
MP?B:N?RB1]P\N]_Q.E<96<0]6#:R6%(B[(P>US4Y/-N)+ZE1\\P3;T4B](?
M\04@Y3+PQ8A;8;0)''_V=G_Y=/7'V_P5UWP@CP_41+(R(GEF[M#*YB&IC;\8
MH4J\ ?M]#$^U'3<*G5M^S:TH %V?B[-[RXUL;B,:4#.,0%F$VRYZ6@V\Y,'U
M@ 7\PSC_ 2F*R:!JE=SD,>4UI==F3P1E:O):3_*J5O!F)O?2ZNOO+ B 4];T
M-9>^]$LRV*HYV&)AY9K$UH_$JL7%)EQQ(@B_?W$\9Q@-UY>H8!%OKYC7YW+[
M\<_,FC;.L9:WB>Q^\S8QO:9-W43-XNN36-XF/MM8UOHD;L F:F7K(W."WY@;
M\7,/-!'QF=]RM[6^VZJUHGA9'\;QQU_@+2RP!F-:9%:+FH.&ETP)[9H24FAX
MR930J2DAA89-I83)4J1:.E14.K2J0 FU=*B =*@$)=32H0+2H71*:%-!Y!JU
MR<N*SF;*05GNK+9,1.X+$R$/KGEPZUA<'/<#3LESDB92:8(N"[E]R8)PO/Z'
MZ68\XA>]8_1,]VFUJ;#;7'P\>'26@2*-TQL 13"+(GX?QNE?)K,6)_>A]JGG
MN6,5<<L !@\V(.!\&?B EW!\Z0)C./9LS&X=X>,^C)&<4Q0\L>A-=]K66[WJ
MK2[=[IN,\L<(>2%[K2^>6/>FG^QZNZNPW<_FU:D9^:H9^;,;Z_7)WLSM3II(
MH6&;?-)GG)*O+Z/ &C#!)VRL=2:">8;EO#6OS(A3^[*4$3=Q3RFY=YWMUF'R
MJ2:;BI&-VI<E;?_,/<^1%5R33;7(IJJ9OOO;K;WXTWZBB ZX=P;7!Z/ $5R<
M>];ZT\PR3D>EF<[ PBJ9#V[8LLP'M[8\Q^,FTPYFGUT#%':$A7.RK/X+#P>^
M?>[=<A$FQ?;I;SG_RH:\:I24[:Z2IHE28B[YG*462!412-5B)6FR:1_&GXXV
MDJELFD!:LJ!;;6VI5'2XW3J(/QW65%1Y*L(-6Y:*#DNUJ6:F#=145%DJJE!4
M_B'+O*:B:E)1)0WUF=[D_W-&I[X5^L'+))_IY=?NY(6X3TTW5:&;2O*;F;I/
M33=5H9M*:CNMF&ZF,AMJ;:>*VD[K$53T# .89E!1S7VJPGTJ23<SI=:OS/*[
MIW3ZUI=L,!1QXX08ASCW;.?6L2/FIJAC:I&U:)K(K 0"/%S7$IE6RM=5<D_$
MUEI5$A6A3*?O*<4(:\?(;:\U<MN/0&Z[;.1V8N1VUAJYG4<@MU,V<G=CY.ZN
M-7)W'X'<W?(IM]U)/JTO<A'ZY2DWN:>D$&#S,/D4YUU?!LXMO.O29=:&I!XL
MT/(]?]&KC?<UEXX:I^\I)8T)7[ ^IS";SY-&3BGY/-GSM#YHJC#E/<BLKK@(
M \<*N4V'^IOGA.+J^MOZ\ZSC.Q;8T\4A<]=;LZOI))?]Q'1>YQ.9Y)15PX]-
MT^>:^\DG[4FZ_.6/3Z[?9>[GSR=3?2(RM+N^9]3FSMO/O,_<,P(VY6*:7OV#
M9[)XIK!Z9H $L2PS2-]3TDC?FDI?-)5.#L]LEIO>G<\?S_[F/QSNGKFNXX?3
MG70VGO;RUO\BJ&_M>&1-J2^44I^=3^HR&/RDJ>^4W3KV-?-LEP>;2GL/!2RG
M<? BZ&^:4RY?A9.^IR1.6=-J3:M3O#*ANF?DE;\(A_G6P/'Z)P,_>JD4F(>%
M%T&#:\<O:WI]T?3ZG#QS]C3 7#1H"OT4<%@1_.>CXS'/<IC[*?"CT?H28RDT
M\33[:BZ.5\8_*UEM4 85QX\X\8=#WUMS9KMQ]+W,HJ]#(+>DT0;V"_0]^'-B
MW.+41M>';$Y[:-7E^Z5TX,A=[8JT@O*:R#[8#:S>])HK3!C=-'PA^40S!$\&
M#N_%?/VBUP,TOD37#_XT!Q<OPIR9,+\SLSH63=9HEII(2]41FH9;-0W7-/P0
M#3^F.JFD&I'L )\'#)\'Z'H=*7=EEDV)1Z8L9U+I<Y+@!:U.\HGH[=0).-:<
MOE#6F5W^B^262 K+2_Q6&=4=:6[9VEV 6TY0K[*#;NX 'V/]7U_Z%<X]"[%T
MBU42:UPF7%6&6N)!P@V;:+BZZ ZODI>W=LOFY;OU6:G/REJ>E1P9M/L(&;1;
M@@R:><)TLPF?><?HC_(749EF'+/U/E</MJJ80%%UU:IBCU9]EIZBS\TX7^MX
M0*HH>!YW,E^(?E33WF;37H5YY$POMZ+)WP=.R+]YCN4'WHNL]\I%0'55BI?F
MUZYIM:;5*>G>*MN3C:F7R:<X98SJ0D]8P'GPE8=W?O C:<+YDNAP+B)>!#U.
M\DXDDV5Y9_J>4GAG3;LU[2XPHCJAPI)X:;N5?(I;.@_@D/  D"#SK$0LSS:+
MW&:O<[7LJOV(!JOM<M-P)@AE(9-ZL\BH@HG:-?TN(6YKJJVI-KU+$X*V78;1
MDB3H@U74B:NN_3_]SZPK7IY^EUWY2U/H%!F4I]"I%]04]Z(I+J<T8>D6ONE[
M2BE8>BQU)E-G/!&YH>/U-Z#D9?W)=YD7SROLF;FM-<NN#T5]**I5\%85J9(Y
M2OO))WTL/O!PX >?0[L^2U-G:0(W]6%:U6%:KJ7BQ#UEJ6CU$:J/4$6/T)22
M5F*OQYF2Y2JRASKO<[$S<6S?.L(/-N! /)3SE<;-YI^)_'VM9<H<F5(?GOKP
M5.7P5$*:?/#]^CCD'H<$,_5AJ"5)?7#J@U/)@_/L4J2]FWS:O*C>^@7:VLM5
MEDS<4Q*?;._.<<B(]2>/)5T5BX8-2N0+[1++WZ;Y0KWY*]W\"G.)S+CB=O)I
M,SOLKF.S6=R-98DE?4\I(J4FD5622%:8I#>[E,3%W90(F9PU_3M#OAM>>'P#
MMG[VJ&TY>O"!M:^.!';+UB=V8WVB)H;J$<.DR-A]A'ZQ6[85 B_8>X!P;NXV
MH//"(PDG7OM*N4BYTTSP!0L30\U%5L]%EAO%-''/RKC( "R]%TLZJ=77G*0F
MB)41Q*9PDX]^M $-N!]).\GB:UY2D\.*R&%C.(ES^W*E4++XFI/4Y+ B<E@7
M3K+_ .E<._<OEG+BM:^4CY2;U8$OJ(FAJL20PT66SHU+WU,*%]E+]66<A3Q^
MR]>X#?E322=9_>HXR5ZIC1+5"VJ"J#)!3'*3-$DLRDW2]Y22&Y)/1K^PX7"=
MIY,]..0^M;Z:).8(F)H07IZP6"39?AUIX8E2I.J9]B^93=647%-R-?BL=A/N
MI=R$7X)CSP[XW3)53"]JKE060=4ES&5>O!93I12A+L_;2_:4/O;TU(=C=8>C
M1*Y=<G#GZ5R[IKN-H+L*\\:$6O=C6VX_I0%_87_ZP:EO]WFM9<PBZ D459>D
M-U'/V'^$#;E?M@WY^!-4'Y!5'I#2=(W]LBW$(KAW37L;0GL5YI$/4>QU&' >
M?@K\:/0B!P+FK;^FV2K*]9I27RBE/HMDS]#<0PE==>';JDF@W.R^_;CS7TT,
MU2.&',FU=';??MF=[^ %!W4M=95KJ7&'RN8B!S4Q5)48<KC(P2.XR$'97.2P
M+IVM7NGL%"<Y+)N3'-8$466"R.$FAX_@)H<E<Y/V0YE6=?'LRGE)*3-.T[RD
MW:K)H;KD,,U)EAS4/'%/69RD71?/5JUX=HJ3E-%T,,-)VC4Y5)<<<CC)TFU*
M]\MN4[H Z=3ELS4?J8FA*K745>4B#SG8ZM+9E==2XRZ5S4D.:H*H,D'D<)-'
M>%W;97A=,X._E(E\M-UI+I:!^RG@@ ?XST?'8Y[E,)<B]=F+KGEPZUA\ T8:
MK2Q==G9^Q-P=*#118MXXB_PM7N41:STBL0?IOE2!30=K[JE8Z&"M\]$I@8I6
M>8!*TQK2M%C6G,=6394U5:X]7VUOM]K;G=;LJ2\;62Y4^EB898"H:A5/BJ4J
M*BF/I;9CEOHP08H@_'XR<'CO[)Y;4>C< O/I 8\):H(MEV#GU''@3W/VY$6<
MEPRS;S^"V4^<LN+MU$>=L@MX(<-9>_4IJ\PIR]^3^I2M]I0MK%(](,'JHU,]
M ;5N>M5$KZQ:O:_5^]ED6%Y[K$7)L*:R#=CLF3TGZVVO2,%N)9LY=K;;S3D"
M2O]R?GE1$TTA$FE.^%=?$B-[=4P*R:)4)H4O2#ZMAJJ*.-1I1"TQ2OP9@G7Q
MT?5N.6B9&V#>7'$74&5? I;'-P'S!+-"N$!\&*=_F3A+F=5O7%!LAM5;[_G*
M]_PYK,O,.<_T&%[G+5]03"_74WG=#O:#R4V9Y>\V#YO-PU:[WO87&4Y.(@R[
MLA&&^C0K$^Z;YX3BZOK;YGM$%TMWR^+C!7E#)_WYN\MVYIBXIPQ_?DW)-24_
M3,D9S2M#DZ7D2SR-S^9'$&OJK%; MN:S-277E+Q:/KN_W>XDGQ:D3A55_<S]
MV\_L[J,3#&NR+"'1=PJ_J^2H2![+<M3T/:5PU)IF:YJ=R3O3U/><.;V/KXK;
M?%I\%AJL9H%$M;+Y2J3BS4R(V!CZ+L%E7)TLD&H=LHG@X<;6/%>[_'>UE3[U
MIJ]DT]>'*]3AY1?%#V:&EUOMSFZ][2^2(RR?B]#J'*THIZ]4;;H:Q%'5W(.%
M.<EN<[\FCI?-.3" ](7=.\-HC?V<&):Y0O4RB=)DUE1SB 6(P/$VCPC2:ZJ)
M8.&DU<T@B%(5SG6CR.=,@E^ MM9=XE22ME8E\BJ8AUUSL(WC8!66J8^AS9H#
M;A 'K#!M+N)%KKGEQG'+YRR 6X"V:FZW0=RN@H&1FH-M' >KOC=U*=JL.> &
M<< *TZ:2R:TZ:V#E60.M\A4OL!K:A^O3M"6;>(VPEZHYX N23TEJ/Q,O)<$J
M;ZVK9)3I+5^T.B1]3RE"/$LFZW.:JH_<SG:KJ3UB]$F?P1/?$Y&+!7238R*T
MP,+V7/RO"!G][<8?TYGH*$1S2G<\2Z%T.G,B%^<K]*,1R2SI1\O<4Q)%MYK)
MIR=2="R4(HLEC_CL6C7!5Y;@%P%A3N5;_DZO]IBUENV=E[FGC/0$>;@6.CNS
MC][F'JX5DO;JSW>E#U<F&IXY)F5%P_>33YKB/_!PX >?0WM"!N66H:WC.9A-
M A-++Y3D"RWN*S?^N%Q;DXE[2LDWJ^GSQ=)G-D.H56JSDID\\2JRAWK$P.81
MW)RN-41VZ=6_")I;.YY8T^>+HL]*\,0/OO]B*2Y9^XN@M[7CAS5MOAC:?'9>
MV-Y-/BW6RB;'HR'6E_Y6UJWFD<XC405^V=Y=GE\F]Y3$+VOZK>EW(9Z:4&+A
M/+5U@)DN[7;R:3-RWJJ:<J:QO P[FKRG\-#H+")8]Z3<JN;$5I((VJTX)U9E
MOZUI.DWK$4F=K4*3.B//D9C]=GTZB<0A9R(*^'M'^+OMUL%;N$0_2O^4>3X^
M*__AUP,6<#'K^6KQ=,TC7P"@7>:_A,R>:83BG5^C(?;7]J>%\^)KGP0OYYFI
M-YYRSQ\ZW@/O?! ?DR_->:S^.;W\A]%X":^8OTLC^/C(/1)_]<)9#X_"X"W^
MOM"CW[UQ[M\";OPHL+B ;^B+ 6<V'LUW;V#-[PW#>#<R13AVX8SW@/#?FJWF
M*#1O@.4*\RN_,Z_\(?,:\HN&>0WGI?>3.61!W_'>FGAI\R<3C\LV<YT^?&7!
M*4?9\DZ,F)=^\G:/#1UW_/:A9].UPOF;2U!>O?_O_VKM-W]Z]P8?^/[=F]'[
M-8#Y7??]L3!ZCLMM\\X)!V8XX'"Q%05.Z,"3F&>;9_?6 $69B9TX'8$"SH3_
MG7)+BKW68<-$?7'GW9ON^_5:?OE;%CC]05CPCEWQO@.F"L-1>L97?\?L=#K;
M[8.]HZ-.@5NP'?HC6E+\1=</P2A4WSW_QOQ_V]OF1X>[]EOS*G+Y]B4#FMS>
M?O\.&(1^Z9UCAP-\2/.?KS(_=/T V(E<TP>763_,74"$\%W'_LE4/^KUR=];
M.WO)%6D T_ A;U+_38'W)@/?VFY"?99+A/E0'>9O7\]OSDZ-ZYOCF[/KM>*@
M>@779R??KLYOSL^NC>.OI^;9'R>_''_]=&:>7'SY<GY]?7[Q=:V6U5;+^IV)
M@>/U0]]K&*<[)SL@X_9VC]9J*86?XBJ<X</504QT<>F+</NLU^,6CDPSCL$\
MM]%$-U$2M]]U@S>HM#Y$):M>1>A/PE@.:52<ZC0/^^@'0T,^$6V;>_O^^U'S
MY#NWN;.]?>I;T5#ERWZW[S]_MU#=;;::K>_?Z=-1I_G][]-_N\>?0_?N\@=_
M9888IOOYU=NW?YS^\?;MY<7U/]O-XR\30&\+;FT[]]L#Q[8YK S>VG;0-FHV
M<1CL]78KWA_US[KQGC63R;&"??;I_/KFZO@&9)>4S%_.OMZL'_IA*>\<T#!.
MSZ[ IEY#^I$+N/GES$B4#//XY,:\^&BVCCJ=]5S5FIT*S2,S#Z.WV=SRI1GZ
MUHP\,*%<Q^/ZK0D?W55\5&:U:NO5"[^R(<_GI2>GY_][</C#_NM? WB<<__6
M\SURQ3F6J=R>5[PWV4,K]).F2*],CZ$_&%-J\][[ZOT7YO5]BT>A8S%7-(QS
MS]HASU/RKO?KSG]AU[;.[ID5&KAFT^^9"19,)LSK$;?0!6Z;CF>>A\(\&;
M8'B]?DO-.U0AZ[H<WN6Z\*T%ROS/KX P\.\1LVW]]]+K2CD98M^!Y;LN&PD
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M4/VZ,#SJXQBNK)ONFLO><@=;[/56^_76A]?:HL]ZW7:F*JY:V0-V?Q-#?4E
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M+:8&N<L.B0&/B1\(0XTFUC-?6*_'G(#&>]#U:>J*Z9I@<0AG-%/>HEYHM--
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MU% >*F3+A#*;=$\!?X. \2E+I&$.0 N_Q22NM"=<H#+$3 %DZO1@[8B@(=:
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M8#W!)#4?;Y(:V"40]/M$:4J=N@PU4:S>8B,1R2,AB^!E31B8A@-^)W/^8:G
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M9$_Q[CB%%U+D23%2SA+<=+^/R4+83D ]]0=7W0H5A-0!-VZ^:^CGI[W?H%[
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MQ8IF*F6/.K"CER.4*1!Q@WG=DHCT1CMS"R**@T5'K05VC&L^8JA.8J?%3Y1
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M@\4<.*!W(ISK,?[[JS>:YA%).RK;89"[%M!(RRD9 )*]MX")(ZE-9\M<C2&
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M_,2^MQ#D@NH?^=5CHJ0O:_BX/>8;Z4A7+:'CAHZO')JGG.Y+K;-E$T6;[I
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MDTU5+NNXXIV#VK L-!%.@'O#XN]2NJAJ+1GK-3#(&@ Q6PQG=^HYG_+)-S^
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M%2#F,KXY@#?HSP-?;SVO[#2I TMM)ZF[(RJMXA@ !IA/ &^7HORSJKQH9K%
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M;2\4&\) 6K*G**XS6N6T"@A*@OSE>?K1Q%D33S)D4B_SAIL!NE1F[K=2UQQ
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M^%SD+<89_2LP\"#I!D:Y9Y).8#<E[$&2;5)+Y))]GV1E'<<__;$$$O++ M7
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MX<^!(HXZYX@!$$/3K$6,CSAVOYYP3I0LQR9TU[(?LFXD!",CN3B-U)TBB*-
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MC57\BBR,C[HOS\L#J^WS\DA+![M LS2K(FE0K(;#FXIT=V)*V;1_E+.B)@M
MQM)_B>>SO"CD-+TM09TA:?:$M$MFG*/O:=WL-S!7//<J*\I/V23+M9HB_;VL
M8+[8 Q5=[UCR@7)08SW\;A.\.W7Z?7@4M:G.,WM\ BO10TF)I:6NUO[G+21<
M<++TN?"Q &J-+SS>04?- U-#G<GJ&;< 4::.V/4K"+ J,X15^71 4K*5%ZR#
M='I<B&7(R#VZ,%I7" AG=\F&/F(!BQ-QT362I7)+IA=:NJ&CU9O3'#42,<YE
ME>+H%ARWKU4DV-=KZD)Z3>W^=7YW,Z1[I 6'V'%"6!X1'*TZ7BZXPA2!$4'J
M1^>OF2TBY3H-LRJU@D-SX.ZX$F&KF&4GRQ9Z8]Y_S5J&'2Y;N&5: 2@)VOSM
MI7 V-Y4?<^-<N$-L-Y!Z*RE7 TL-HBM(3IWFYE.FN@Y4E_.45&ZQ7L+Z<J_E
M6Q@4V[LCL&$2!YT8:$\-T8$(C<2*"B+0CID5I,OS6(.\W'Z&V6E2!Y;:3E)W
M3U[^L4R=K'2=IWS,'&)2'&Y+#R0;B,B!*[=^IW>:U(&EMI/4W1%TUJ:MS&+9
ML*-?7%H5^SX!IG;6S"[3 @=^W/H]WFE2!Y;:3E)W1\39WD%,H,,)(4DW\-G6
M[]U.DSJPU':2NCNBRYJA^)U-O%Z44FCD>B"K>(M':6T&_MOZ/=UI4@>6VDY2
M=T^DC<OBW!22[Z,]4]J94-P)1,M'!Q[<^GW=:5('EMI.4G='K%D_6B>1+%]Q
MHIB%HD8^M/95JJ7$3!YB1%Y^+D\O:LV6MNT-Z-\+;@EE$7^".K:;Q/89.'D@
M=1".N[-/.RX<Z^9!6$*MK0BX-B1#:<QHV1C;2D\SU+6CKVT.KO*TA9S^-6!O
MMBK]=B<K[%^EQ:I=.($:&BX9R,L"-2+=!IW<0E$*<O)<GY1JDNDRG]+O%'<O
M[/E.;]@"!*Y4DFJ3H,X@B:<IFIU']2Q;<+_(1NC.RPM.-ZX!!2U_TE^N@T#U
MU$6YA-$D!*?1LBBI7VK70,E4(M=R%JX=7P4Q*6WW>IN1[GITIWFN:%?A:C(T
M3Y4%!1A:R6!+.Z;HSVX[GF>5[[YA*8B8@L3U_K:_K]%#1Q9"51J>R@+Y\%S=
M0H^//]+QMK0'$-S<AAP98@"SH;'.>,%="9DNA53-<;].%011T.+)K5 ]*V7'
M1H:8(2LKNT3A.F"93'$&H4'#:?4-*CJQ-!O+TS3)-]%2.M=G)9*UDF8I7!PJ
MD X5=L'9M J58&1E&+P'4RI,CFHO=//R%5))O$0SV09 0TS=-*T>5( .$P!T
MFW8\3N>+E,ZG'($HG91T<OF%](QVN.;Y(%T%#R_*'"U/ZK!7MK )T3?GKA?+
M++<\%W=XKJP\*H-EFJL91=<V$.\]^[_>-ZUGNP+ #9']7%8DC=<9LF(DYRFX
M)IHR:K%GG9%02GGC DX%?W _-V!F+98-[V.-VKBR4, G/>"<%XEZJ41IU:8:
M\N?P)(D@Y47C;N21':>VU9?: (>QFS(N4))1Y -#(],MF\KU$2E.!D2*&T6D
M.#X<$"G^DH@4]U<^W9U=$'9)BZ[$I$"+LY+UD#Q_\+$H+PI-_RI2?);UA:8Q
M\T43ED?R8$M5PM/P(M=R6K[U%.<Q:K6UMQ'+VC5H:Y?>6GTCZ-:FMVQ]69\\
M5KX*XU%6QWTHJU$;9=4"0X4H5+;T5TI^OQ(:U&!4?NE$ MBV+CB:YV"G]0;6
MTEJY>F#*<:UZ$MB//2;<@0(IV#,7K9\Y/E1J2W6M->BI:^4SM>U2:E9=O9@4
M3=7&VT8D8QE+AT,VR'P!O("46(5WS<YR)D#80'>T$NAC-BE86XVY^Z\#)B%"
MYZ6U:QWP)9$]+]$6D9<()=-GP_'9[1D*.-++:11@=;<.F&UYB-ZXY<0GJ/CX
M;HB^,G)8@PQO$U2,N2JT-:! NH\8Z6%N (93,PR*OU7T?%B)#W"3#B:RF7QM
MH,W[SXLW.9'7RRH*ME^1X=MZ!#M7"@L\Z?Z6.&9I/ZZ2RP3LR9XA=OFH<F,;
MI0,(@AU0:=5$ZPI#B_DSH&I+LW.\-,=A,.U$K8WG0*&@+*X]WQI*;",HG.'Y
MB(+S(=_!BPQ7P3A*Q4PQ\O%QYZA9+_$,,_U-85_PJ\4-H%*%_';=2D1%A/O)
M=SY^.77^//ZXZ<.-$406OV;]^"MVTZS7K+O;;?Q]U=(BT?BN//OM-L)*<CW+
MIN+*LOLT,<2;0.)NX!76^TZ:8=7HCX5=+*O6G>JF"8TWE6[VF2(HQ8HBTUT2
M5V2F/:\"SAI55B9>OJ:^>;7UMS('6/4Y7^G*%.8L58><@L/#1ZEK3;^7EL>M
M6N#:ZAUP91;E/!N[)QS@N!P_T68"K/0 +\RJ%]!!F&\\QKW LDM7L@TKQ$OO
MOC8O)R8?7&5;-I46GK:@X_->*E9OH)NB ?"R0O=-QG$:+^&<;>$0A_A4&,YJ
M&0J^SYC&1?\KK+RC_?I(7>@2W;#^XBG]OQB'#?O>,QBN5CWGINC9##H+6I6+
MA/J*BL(]8K@;UPA^-.)AMVAIELT\K+//N&$$0L=_<M\0E33H&,UC<3M*B(>Y
MRO.D,A58Z*Q*YQU\M5;TPG;U@*OQK P:P8#1LT;<!_!:+(O,0Y>)4>1XMPR.
M ?-QSFPI&D13MFU2#\'M/2L'T>NEMP(YRB-=&%TW"U&.>>E44O>?+32NSTWK
M(\%I"\Z47CNMR1U$I\5*^D=B=%;'^/KQK<OG65W3;K771)M08D-T:S8<<K'<
MRPO[=;< 2=A?)P*LX/I%U=<KA]LVV,9M6!NI\AYS1W>2$>BUP_T\H% P;2"^
MZ+%MDP!J4_'M(E(^<E:K;,*^?.?559#LJJ:2?DASMHU'=%,%D3!H!]0G/8F1
MLX5VIH! K,M\TFE@SP%'_@5#'C[^G@E1W$QBP)')?4'HUS+<!PEXV87+8H'C
M+H8M!=*PB)V0QX!WA1=.26QXJ^1=0TQA$24_E-5'.5$_+;(_XG?C*EM OU7<
MT$I[FT NKNSYPFDC#17Q4]?()Z</%;5T0;$> $7V7'FFA(8'"-='3V@1TL9X
M]?)%)IUX)#21+^>C+/W:5OK >'WMK.J(!!*QR8CYS=U($\EN$(D""7)\^+UM
MA<,"Y?C[%A%,)5U,:AY])V^2I#1("-(V#HYQ[1";.7N-AW6MF92C[]E)I&1=
MFP[]Z,]91?K"*7UFPI\B%G_U[E3'3_0##KGU\\XB27Q(\O;A2Z/.N3LY^@_&
MJIV$K99SP1[Y1SHN1_$+N)W)@!=GV7-@XM)N"J[O+#/3^*=/9KQD*_4U#$-3
M)>%1I>O6G597:2;MQR)[>@]:5-)D:[I-<]O#%(?XMX9LUW^+SO'6G&?$5*?C
M,2U&IN "STFCH+L?/^[I9OSV]O2Y+N%^X-U!2I*G*!R$=Q(?9SD6_UBF%6OL
M;^S3>[#4Z768I.=I3DN]'ZMXJNW]UR=N>.).,GT7G^9I_3%-XM,J^S?9JOCA
M8UK4*6W0<[CLTDF91,_+HD":"ZUM$K^@7;M(X57XF?Z>3>B=OYN23BS]\ O]
M)<N2^.4DG97T/U *RJP&SO0D2S'\R_*"_ON?^HE_ JMY_)$V_U\ENHOQ(Z\
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MR]#]H^F_8A#W@H9=]IG;[NIVCT!6S0RUM'1>Y8:/%_EY._92=4<FL6_FR"_
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M8"GX]S9OD$S/KNP!2QI(*=^]CF^N-<EGXP[%^T'_,$,C%IG46L9(OF4W5HF
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M+G!IDA7U2A^DKTIIZ'QP*SL ]K5KU; >XE$GM:06<. J6Z0^.+4-]!.IX5/
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M/!L]WH<FLC)D][M]$>7:#2L3K8R_2BX*0,1F?EG&M]\!Z8J_^6M; 9?M1T]
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MM3:#Z9$O+$IH*Z2[[+N79ARI 7;=HTL3W;!I(-94Q& !DRGZAEI*)_G?CBD
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MV0K1?T$K2K*09=>Q&&VU@(%.Q3F^D>,;M*\;$E9X(PJ_1'^^H/%8&SOKRR%
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MNGA0"Z/P@M)&EEE=BO6JD00V;0Z<U=&9VXKJF6!(6&79]H1FJ#U_:#>O^K?
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M&L_9XK'X](W.+IVUXVPNN A6@O++\P/4*TU#(^;)DD9UL2?YFS'D5B!#'(+
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MR:ZZ5+ BG\^ZGJ=5^02FQ_LS4D^7C-3-9J2^7C)22T9J\:O?YU?#?\A^D_]
M?_POL@>!7O6<R:Y:^?IK@T[$1ZS]J*!KJ'%<+XI6+O)G_.6@^%?_GEE$=!R
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MJ7/@I/-9?'5_=BW#"UM/]3&=DET=H4S6=CK/Y8#=HHF\(DWJ 3@'Z1>9" 8
M/%"CM@5]P 'J#N#WT>E^?--)F/Z2/WCR4-Q;G)$UK$.!8<S4V164>O5WI2_#
M; DX5G*/DZWV]"&;/VYML/9LD@&6'X'-4N=3OG5PX[VU%0$5>,YPA7^P!(%_
M!WWIP1</!<1\[*3K/S8R5#%T<L[$MJ8/#$Z(T?@4^A=?LJW/M^EV)\5!'I]U
M?H;+&;E%$Y&HUVO;^,RX% &H AT;(T\<MD 7WF%U? &I)TD://)Y%&FET.Y6
M7[\&O/JV>639):O9R@Z>$$H>"XTD1?6(W)VD^%B,A5(- 9)Z*0._;1-Y7C.C
MP=EY=B4.W%P5AX\<%8>1)<,WEP?^)%E#DE?_P.>@1>'D]1;A*:DU0B:5K!\(
M>F M57EEA[!V(ME)0;#]W8"/GSS-.=M\WDL01 [$@XF@FW#+8"/*#":28ARD
M\ZS"-754](-[H8KT(>,R"PWJ!+FB]XYUF&5^9)8R7#S@R=-'F$@FU"\Y8T.=
M@.8+H#_UOH@J:GN7O-#CN8"*P;!X!% /GR3YZO8Q&-*9@&G(*E^VW=MX5$.;
M)4GGL?<-F4%!:5 95%6K08MV-_P^G_?F.I3UN)K)$[,-"O*O$;Q=[)@IJ#U;
ML\ ][QPIG Q8V'A&&V#40H[:E5T#K##Z'"?,:;#T- '"6:ZZ6S21Z[=#?K$D
MGV\V^?SG)?F\))_OI&[Z-"#)K^*[Z+7>14OF\W.[1;^X+*H/%= ',6.\*0;R
M;VVY.+0F L\'F;)UJ4QS5;/AT(#60K,9U*.>#W$G)B.,0\>+%W,+)V+8O3$M
M%6\Z6;:@ &S*(5#O'9&-L0]M3WZS.2O 5/=E(_1_7'0X"I*'\#G&IBE@7RP&
M.O<*. '::;4Z+VMN"!3J5[*$.9+$_]A6/7+M-'BH([:BJVXU;B\$1ACDA547
MH%?NP?[=&T%,$JJ"/:I Y8($BOP6=JZ0>@>.MR3ZYZCN I]JKXT6#$'*@B9.
MKZ2R GHB>OCR%11<=O2!R6N-BG%;_AH@JAB[A_G&:$Y"--7Y^/O*RA;0Q? :
M"-+5KD2>GP\&#1.%U!@$>X_XQ?Q @,Y^1GYUWQOQ<^^ZP8AN,>^3_'MVE]'B
MR!X\_3<&=XR<^]J=R<.9/1B.(.J=9#&D:U""HL=5@2VUINP YP,%$NX/>W'C
M>'=9QZ"X><,XQ]QWN3\HJ^A7]'0&= (0I;'B(;>(T^\9P )E3ZS";$Q2=6!,
MJ\(?>? QZ=@TUYQ3,5*:DJ2GK+R-Y66D(4G=2,PBW-.AL>YN:1"7A!7([=YW
MPPHS<RBP1D;60C1UVW!=@\0U>D,AYL;U*$7 3=PDFN<"_CVM<-^T*UIH$G4G
M3 ?,J%9*04S7[B.6+NZYJ#5DPZRFV "DG^3YNK( 7B8%XOCN/R%KD*&5:^48
ML(H/$2,9@,*6ZC$*#XQJ8ZX4+TUIH<A#R=UZ.[5X,B_)([3!;U%*TPC=5@U9
M<QP\ 1 VMV6+X/G"OK_< U4Z=R<$=S)V'Z?NY0=/-G'XR"N+_,GK/V3&\_PW
M=?&"L_G!8WI\\O3CKBNYIC<TR$_@S7SSU=??W-#0/_)8A>R11Z=8R,*#M]N!
M6Y!M '3V29)>^H.2B2%<<"M$\;;*WB)L?JSKBG<<PPOE4*&==%#:;Z,8D=M^
M$;?;M(5W2=P4+07CBTAGK892ZWQ#VR.,I0BM,ZH]D-+FU9B43L'*6<3S-FWY
M71)/]04Q/L6^B&JGC9H69=BD$!<QNT5;=Y?$+-:"(F8KADTCCW2+KF;%;$$+
M=P!?FA4WS0K=(T?M3DXD"CX@D)206&_;1B(LR@]N_0D:!QJZ:E=K5Y&BZ#$^
M.QM?;=>XO>_2VS@TT@,R7F1%HKM\^8$Q6I^?62)"6:SC:->TB$0AXQ52GDMJ
M.'97_0N_4.BTJADU[F68(C."ZN_LL4'DX])E6CKH,1#XA5(SLV,D.1]I8=@1
MCA-Y[#F)M7]02"1>4^/],EZJ#/4E-K=Z/X4QQT0%GV^)B-^>3"K+P,^N=N>.
MY.3<2L&4F? G&(*-C]N]EHS&DFC]W(E61C,;PJX%($11$]&?5)ETH=YL6K*M
MV8KFK.4MENB\3WY!,9SN090I2$;6-\?M"(S\(P"322^D*;!H&#$LDN&("IC*
MPJYR2Z?RB\N %W,H2_V1339$V ! 8] P?OL5L0; .RLWPB '9=/ ?::%Y[H#
M&%3/.=^N_P]?G)AI&4'(P-B;M4!5A\>O?C\PF@?M I[-=2  7[9T7,XZY(4.
M04S#7VTH/1L'#6B1_0I(YZ7D"*0CTQ"'+JHR6DU.;7=<^:MYA[C-M; $NB>R
M!+!I2A;J*4U1?=GO&+')VD/EZWR4I4-CRZR=#/L3 <29A>"G8&V&CZ2]8:&O
MN&53H=LZB[0P,[,P"66$DNOO]@-P.LE^LZ![QF+\S0<I!\X36@+<BXO ^PE2
M<OSQK"XOM7^A&VO-\^W:FMG>^OR,^W!\WC66P]WYOF=0 ^9,VO&)Z2/E8=H!
M,/<AGXRPEG2KU<)!7B208USJKI:M]KDNS"NW;2ITURB)MEX0!B8=L?>@@Y\4
M,YL.40%.? '%0(414^!5]H@%0T-#C]?'"EO0TQURJDW=L0\6BV.,3WWJPK=@
M6NFHUD&ZIPCPA\R[F9]JBJ,L%^#,E5SH69:7P9*C(PBF86[/IIMNS8T<()K2
M)#6WQ ?4@-EURL+98P<QN:YXQ*&?+:#/JT.J:Z!-&QO]>K1X,\#UP,"=KB\,
MURQ HH_(S*NO?)0<%&XUXCVM=;=\BE-_)\_WM0#FOEQJ_&^VQO^;I<;_#UGC
M_QE@)#\:H2N;G'952X$5[FJ+I<Z%*'YK',)#'?@G;=NUJR4^D5T9G] OSD4H
M@!;+B#769+X$*N[<5#@89GL;N&DFYN.,2-Z\/Y0=\X=R\8<^F2^4S?I"^:PO
ME)JB1XSOE/_]*H-Z0ER?559;\'Y&C0F:<F(->J[HL4M!CV,.7A#?@RUD23'<
MGA0#9Q'^TXOYRW8U2JTO;QQ0R/._E9=+3N%SYQ3X+G^18O]];]A_1?[7/?S)
ML&?T3Z\'!'%N[;92Q>'!8N:9J<I!03(8P\\IK\&VDJX@G]0U,%?_O3CY&+S!
M4CLBV*>5YGD\$&UAAP!?$R!&3ZT<L-1\^9UZIYDT6+BUCYL*\N:03#"BK%H:
MT&[C1'ZG<(^*V2LB+A<I@$PY@U"#+%MSJ6Q-,EL"S8:OTQVWF QJVP9V,8Z/
M%F)R")\8T!&%\?JR[ 7BL-0T!1\NKM)#IT;C@TS)9SCN@H^%B(P@&4G/'"KY
M_ .*'#U#C''4:;L(CU L9Z8YJX0LR[?H".DUW^>6%-B4*R4N/$>-0G_NHN&7
M@<"M]01U4Z3'%O20%2W&=3Y>1(^'K<$-57+$.?@&?J\#),GPX,(>6Q@LB916
MG*D%5S;"46>* !H,8Y 55M2K(O^5O),A9U,)%!-#1_);J%&%VW37 1VWX\XQ
M@=?Q5'01M*Y82PF86RXI)QM>9GJ&HUG2+W1,@(6+P>><I/'QW*EHE754*3-5
MJKRJCK5O$Q<$I$*<)4(L!0-\2(RE)_^I.RN;ZE]J2[\@MPSL0#"#-<8'F%EI
MEB1K=B?M/HKJ*' GZ>41\0?Z^T'^S?="F,^GO0QRNPRR#[@,[KSNO#>7@/%N
M"0'H6CPJ/BV%YZ#954T5M-R;[UX4![*)]KA0I$JN485XN_A^&T?_'_E>8U61
M0#R=,RL8VXTDW2NX:"NH*9(J[JT458WWAB\_7PGR=R5)7X&,+NAEOD^Q=G-\
MLJ5V=LZ99I,99->:0>'IJ@POLQ3 I5-NS>854X.NEX+Q3D[[KJSD[CM4Q9XT
MM!5&'KT)C=I*^G))%4GWG$".0[$?O:=P24ASJKOF6_/P5JTZH&=G'C V5(8B
M8X$&\0=:?'<H,^(\CS36NE D1 ;-97Y5$3II=<30DC$P5=(:7%ODS,,4IKL@
M8ZA!N9VB=->OM"G]NEH92J/+<?M5L"&<.O?I?LL.'4A@?BT)S$P"#2%+(A;A
M,N!>9/;F?Z6K+=C^ K#% .&"W!MU_?9]GK;Y5KTM5+4!R+43 JEVM0(</ GK
M6U>#;XW>3V_?6PK+JCF3[)#P3O'3#?1.)XQ+V%58(_2,LCO!EHQ>A/*:/((*
M!X6ZA\,27,M,\H)\?5M62]!B%UU_BR;B 4FDKL?ZL=T!$KUE&05!@NPG&F5I
MP6C:VT.$<=^+'\-C&[/9XOW=PHF8&#QY7#Q^C/]% ,]3>2A'VMV.OJV8XRGR
M^_33:A@J9\5FBH$ P)(&_@"GWCF?7@D(GA!X*_TUISDL0+H&=BCXV[TXJCM"
M;D3M8%KC"Y!7 3&X4EY)60DL 6Q@IO-H5BXSLF:9'FR+=B-3GDXR&A_T>@P/
M39-!!@4V!6@#"O%^II\2,%/V>/%T!)\S7R18,;7XSF J!JF,WRFOA"].-QQ]
M[=#WC_SG2 )E]QV]*_(7<L 1:BX(?.0R4_B':WJ%\* >(Q,P0/WYO^-2U:"X
M5QUB'6'6$?4%YNNK[J<Z2#1*%@#X-^;,1%Y;[*T4A_Y+H YHVI2YZ)(MPDB6
M9L85BW9F@]+G*?:^"@YN]Z.G1_TBVZ!  8AEYWD:(JVL:]Q6N*[JT9H[:$"9
MA]%-(/DGI!C\-OGB1<@EB&C/:WHM/!'R$N_7E60:GF*@9Q53/UB0(X,U'<EM
M>O2QW"KH02C_(S!Z>%20>+6CPI8D%1F](=U8KL2)%NH(.Y6^F2>@?)7V!"^1
MDKW15$^G>Y"22N&9A2? P/S]WS-[I\!_>_=W(HN'##S7%!]>T^OR5')$ZC.2
M02[W[*'1=6W$T&=+-=&-5A-]^7BI)OI#5A,MNNF#',+G=($^,BJ(#'=O;Q4@
M[94A=D5,EU11$?-414^AK_@$4J%WI.>,<,5Q/L?LD/UAY?,D'KE!!QDP1')P
M?$=QP;5#($<0U-]',K/XJC<TD6_S4[J>SKIV;-:L[-KN+VSC#>XSIS!9HDK#
M,NK5^RD'6%GO$4MC40&QB6+3FU6;'9B+\MC$:(4EQSU'B"E;+W#"^Q?3\'G"
M=R9<DX,34IG&)%_R +?5B+!V%M.FS4FWYI:BR0/(4')EW@26N2L=2V]>=#*5
MF-&LB]GTPD$\R030SS)'$B2%O;OV!2_6<QY&]+EPX#Z)P'X>@#B:VC&CX[=B
MQ]U_F#C>^D>\(_3XIKWLRMTL7LH"*/<^N!'.8_$(R_4%#G_36CEG'"SF;$[;
M<^<K9Q!\0;/D-[1OCPLR!D\2.9NP-K#.IMU6%MAA % FS&6PXAY#X4]X*E-M
M=SJ,9-T4G-/]@]2Y_N'XM/6&M_DP' YU$:G;*5)W1\%:7L94[&E=-F_)-7*K
MMX?LTG&$-:1GD-:7X"GG"$AA&SL@>)D,HC<)W:+X7O,G4Q/S6]'U-P92MDCZ
MHCP7Y7EW1.KN*$^/9HP13@N$&!LL+0N%&M2"QMN"B??9G-;[-4-NET-FU36!
M[YJCA])X&85+0#<0!TS)'2E[,$W(S1K:-B3&B"A0H)>V'"$RR09N!^P]<-DK
M,R!XN:^.XNSU?8C=H.1AAGJWGP1.-2YZJB5<UF*'(J_JO&VE]).C2/KTV2A3
MOC]@+Q9JHR@P]KERD/?D0'PJH+NJ9WY3!Y9I%FU!M\/&ON&-_=B1\(\PSSLU
MVIN6I _),V@U(/I849S<</EHTPZ2>-GNZ@KQ&G@(_UWVZ_*?OG=7T3D=Z[M>
MFTRA<D(;(S0-%P,U;7XVEAUI3:?J\$!]H*S&G@G)9(XJAL^4]T99F4^Y1#<&
M2O ![T21",>[/*:KL*EP4D,9V%^]_DDJK]T$9H?WXG!Q_2I:O_"/94>.X-/'
M3[\H9K:":\!0N*G]?;;!X3&HB4==5K_?GK9USF+Q]/&W/_[GW_\__/CDVY/\
MO]N!!8?K<Z2]A\N%]%G%5<)A)>416)$'_N'1QN-Y_N;E\__)K+U:&8<],<]S
MFM69$@'I>O9AO38!9#828S_+0I]N7^BUX2W@+0W,54X+_J>G)\_H7J?KO&VR
M2M=1XY'68L_/X$KK/WWA/\H[(=73H::'1X&.=BOK0=W@GYYI@29]HW%L3:P
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M/'ZDAP3WE'C)/:FE_]IY: [5]&3#\@3EPM/'_VZGFC[4S%R:FG),UCZ%INV
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M=W20Z)=?X/RN;5GP9<[O8+!\!(:S: M6<_4Z. 7)VE_R3J]0]T=VQF[H#.
MD5D;,5"!+J.*7HW.NRF\ S:072!"PPSN;W')T?PIW A!TT?2$)0E62HF>BU^
MSPA@7" =VT7.Y!EZC!#@2+AZP84^"E1W%&(:)5.!_*D/7I'5+<3<XF)R7XOU
M)^D2K1W5SK7?8R)8HZ9O1=D!O8E1#Q2I-]GK@,@",?3">?9\Z-6;U[6P_*C>
M$BD8"-]/XYLV?HQ&#4S'F@LRA]W4]9J>T GH.])W8").#@=,Q,-B(DX&3,17
MC8D8[N>MP<59WN 3L;%B?G'C[N0ZH2',7,4ICD)IC-P-4FLVU,_LUM["]J(=
M9)N"(\GHD!V75]YFYMGZ]0\SI6P"#CU9"[@&VL(>2%#[%!,7F=0^UYD-'I@9
MOS(*+/&G&D=BS7"ZQ)5:N.)0CNTJ>K5IM^E)H\1=/BB16J+:P(T#N&OX,0(Y
MJ$S$:M#*S&NMGVG@[$"\6E1PTK-*Y94TZ.5>]BNU?VPMBQV;0[!F"I5M* .B
M0"IKN\AC65)VDAS FAZ;Q!M-5'HO5I[QS(+J77_;4S>H/ON$O@LG9'8MBIPD
M!Y=X7OP5UFYE'EXYXQB[M"9';S7JUI*"[?))2U8!. 6]P#6(TGMRV/&;5HQ8
MBT:"."T159"^)=L55K_>,J_57^Y_S4[;58KWV=EIVG570 .?112^'J&_+&T_
M] U95X[!7<4H::AR7"D(]T>'IT><-G8BUI)_7&8Q_0Z"@W))K1QTY\7)[[.1
MIE8#1:?AWC#%,BP #D,A"@H9+NL%K5(X.N6HX%EHX0BM',*Y<_SM*=)YN2%.
MK_*<&42:@?A_C\C2#KP3Z]5O^">6F3-0\.R]IH??8.Y>LCX0JU4T3]ED^VVZ
M.FBK%TZ2XR'Q.UH[<D"54F-S'E<0#;8$TB\%7<,(;DR1!ZTQXXDNLA2B7A)E
MD)(4Y>0G5-6V&="NSK)/XV0JTCDFDTG3Z((X7 !RPO#,U2KE=%1L2VA=V*J%
MH]-76D0H/X?68VGQ(I+*E9?_(2\#CI3N?I.5ZTLKR70UP20[WB2DUE$U'H##
M*?2J,LN5R_9TQLE/YJJFN;"F-$EX3OOPT> 1'00JX_*9UKOV,NM(KCZ>E'DQ
ML2,K\]15;.O.AB[C7>FJ;\ZNRT"E3CFP0_S2MLYP'SSL?1 X+:_PFJ[V4M@K
M]/J$]("%%@D[3]:GY-OXF1?*)U-!3:067+O1[&#UQ9#=T>EW:]_2\Q]YBE]#
MGW*.%? $/;L-P,FWZ/Q)HTY!0"3@$J+ET8N@@7:U\,OK:^!_.G.//6B30"5]
M1TXIF,"\ 2S2N+66HH7LQ&>F3#!'_X;KM0%'FP%:<G?W;F/GKF;\NML0QE='
M]UQS744=/N\ 7X?-Z"VI@NPI*Z\3._8HD+V@O9'5I\<]P]2>=U?I??.C%PV2
M7E][H_%R\25/-J[,^O#4<0Z@:!M>!?7Z^>OQNEQ;XBP\B4/VJ>G]FB_%SOY0
M+)D@CQP$@)V(0%]H];I]$,P:SL[B@N8K 7QGF2'3)A%!KH5<*O%*0B>N9#2[
MY4)@KV.B+3+M B7U(@D\7*!(T_K<O-R+DBVU&##:!AIYUHWEQ.MQ:Z,5K',D
M%0M0/6<Z5TB<*A[#;4;SYOB68R&?]]9ZFC?4YW')_Z[],WX%N=\O0MCWV=W0
MI[F!GR/6#1A[B\R'*[3 JD&J]_>#MP=*8G?;(GOS2[HDWB>E_L(PB_X*'!/A
M_N>SFI45N8!COU^#Y0:<J=L0T-7')1%E45M0&;=+0FRQJ,@_%<=L8?*FZ218
MVQ2A*O>&L&8QC9^EUN/.ZPEX['Q2M:B?MB,0V@Y227.R?"R(% H0'DX"3=JP
M*K1)A'8D_C+(_!T3@A &97S3BAXDF7A*+G0N/'_@$63Y8Y%0R*,5 Y%%!.^5
M= /_3/-L0:<B-?&,T1B"[6.39-/O@KAAWF#'V<=<HVR";,N$@Q_J7'=/2>2&
M/U,/NN?8E&6.D#DL6PG]S&L(,KF\:7YK9@&?<_D5C1CA"^82=0=ZG9+U('PK
MXV$V1/7<2?W&F!6FV1 \6I\9MCA-KQ(KT3OG6'9I_AK@+EG<NKDBT,/?7M+R
M@$J^??I!F]7NX<)%>IE 4FCUYBEP\!-3W6 @OZ(8,.81__X.RTH&XJ\&F?76
MX@;>LBO?9Z]>$WZ/L&&7])1"LEP!/.KE4'A 9661LC[?2ELMN010X%38!ET5
M?HJN>C)'^LGIJ#],X#P@$Z>5</:!6I;I0]UEC5.C/+-JI*]OM+U\!9W(\M,^
MV1'\1YH[C10@IUC)=^1^#]#(<&6)@RS7$,VAAA:0)[-0(TH'/^F&PY\<AO4B
M:J"B#[E0V].SXDB7S$(HT>)&CTGL5>B!(\N\RXI)3AUS"_$3K*8$N#,/RYP#
MNTK:5V?6AY5B.?^IH<FD8"Z7-H]9B1@!M+5:-GI6\0XYW$$!;5-CX\C0+#D"
M/Y<^U8LD4UI%^<:=5(,#&N#S#WY[M-EH0)L]+-KL=$";#6BS?=5!G\<#_UE)
MX@/T(F8O@RXT3ME)CH[ON2D#=+C&0H!#BFBVEV;;;V&7PY+[#3BTW=KUOZNK
M8WO->I$*OU_"Q%A*?0E).^D@FVYSFPWX+O62#9AL#M 5\P9:!Z7GG5$P-[%D
MR5WG <<-SNF)LI/,%A\M:IH-<"3::U2@/VBYLL)^4582M;=C1*%RQ=\.UKY-
M#K16)BZ0S<XXMDT;1*Y@S=87>9-+Q(A ?<GCKS-Q:,4A;\Q)S]BMXO=VB-;&
MIAE:#S%0MY#_IMZB1/2ESP<MY"]F4M3P Q%)D(>@_+ )9OE4#!L1&UZK"#ZW
MDF^SGFO@#2G\[W@9BZ?WJBQBDT;=$;TF?UR*TU&8_ELW^*4%_76F5>%\;?!N
M<-*^$2OAIW8,G;H509=KHMM001M%L"O>E'K8+TO=!(I6FM*)U@,B5_T%Z4":
M(JG4?I:$I7-F S6FM?;)HBP]QUEDO-=5CC9B*X<P];YFPIOXM6NM89-5F^(?
M&G22F))9D7XD9<CTX30H_4='/)O8TH^O__WJIY>CBR\3Z!U$YR%!%%E@=S]R
M6\\-$+2=K'9CL20M&H?1"G%[<RSI>N%((!>O ?R50:Z:ZPIFFI3@L7)%5&0V
M8ZPH;CW6<D&+Q<,*J')/L4ZME2VXB2/Z:L\QDX'4'O<2/15*DHM2,RD81GLH
M"0"YL1=F(@D3V) QXM9-0M:+%CM[0;_)?VAE7;314E6P"NZH;'OR7#A45':C
MAET)[!?O<3,<L >=Z>LL$/#G2"K%#\4D_",OZ&+_;SE-KPNR8)+_2()A>A6#
M;L$P;99(=%VQY\\^KJI>B9M+KJ YMQ)[TSX/1KJ.D4'#M ^,U&X:/=DC>Q"^
MMCW71D?^"'_/F+7\;<4-$5V]=1RZ9ELDK\6"NVUI(R>7=] !*Z<(>I)8$9>T
MXK+.N'8C%77 A\6]H:UI[$ML&S+)Q)*KOV#UP93JG,'A"7/-OEVBGH'2Q"_)
M?$^#D2,PNDQ1G$MVJOL=]Y++Q685[,;,/\KM(^Q;5EKZT1I$9S9S&C"LPY=<
M>E*29,*NE(YG6<-J$%?<B420D?(*05T)1A1!76!=/'_ KR'N6H2N"\R4#@-9
MH<KV\I>V9FS\L,;]X8O SP\Z_^'&ZR/3Q)<M07N;4EZ#P9TD#3@X20J4: !V
M:*UM)%R[K_ M+TPX38IIO01JVS8CZ??YS/NK&/AK-MN=F9TF9(O/H**?LQ'4
M1,HUF-!\H:1?TD<O ELF722+A? DX+NI)6[3HJE.#U!;+EY(";E@Y !6?>EC
MSIEF+B>I6%BYL;Q;UFISZQG,\N$Z>%(S[3'5W3%JV>33N(KI1.<KD@U-[VJQ
M3?9RB7@$'342DF79]$M<Y3?,:>O!1DB'Q98IA$2K ".)<_E-49!!5BYW!:\Q
MB-K#6AXD9.5M269ER1?&=9UFQK5UG<5+;I&E'3159&P[#B,%#H51QDR!)W8E
MTO<)35Q45_]7D^F/Q#W\1=+RL+/!XL!*^L;$_+_Z4Y'6-(>U7*&_%5DM, LT
MHX^67>QVEOF\NF$4;X&&D#/^;[KSYW4VE:MH>CLQQ<NXJF(FI8R+R,EV%=J/
M<X"[ILE,66:6R,1>)WF*&7;Y*"PI+?UQ45W=ME:(_8PF",U%%[+(G?*5>"JA
M%W?,O-4*EDA=L%\E_4M-]7+"$3KT^;QF#)?/B.A#1!2);']GZ?\L-HWMPILK
MFIAT%&O&)\2.*&JEI<5Z3(S?%%7,&M-"9$@!"]E1=<'5@&4,YM"F;;IN92?_
MS)A9T5"XTB58;RV/!BB-%R)$ABZN[;9KTT)A+5!??LWO-"[(L?,\/D]RR16C
M44)>NX:%RVK736N=5<[5[&PZ>G=X 'DT:T :]VUI2:K[WH-4:<)I:HOW@55<
M)9(N,I^YEHP%:S*V(KL+MFYW=V1O[6D9G,>G-=/MT_7C(5W_L.GZLR%=_U6G
MZ[]N[?;Y<_LN%6I+O_C6;*C/$=%-*O9WQ%CS?NO5R_)=J7;'KO@U@W1\P$MQ
MAJ+&/RQ)OIGU"8#CT8>XH# Q5O(988)4DXV3X:T<>VF;$SHH>NOA@3Q<"><=
MH+0/G+"& 7<N^/U!!^$ZZ"#X_*"#]6\+Z"#X!-"!"Q7RXRS<@#ML>M4T6\$^
MX"*XK_L*1'+Z&M#@O(V"'615?-#^VAH5EB/(+4A;V)R\<#VBO"E81P]X+(=<
M"*DBTC'3-Q59^$O6[2V]7M/3@B@$ E'P(0B_9_/X.A<?OV]Y.=">&LU^M2'[
M#"<V\:Q!SI1N3K:ZT2T))Q R2VD0.$BV/<G=KM@(J=MN#^1#8@P<?VWH _2O
MGBKG,^5T.<P%W26?'8$I>GUZA;8R<2UG.CYMUBS/++_),$;&7_0)F:0=2D3K
MQ3?GLD^WNK?35&/;TC&5R[H"=SJE+=>T,WB,;5.*L$%U]$SO0U5;'7A'4SDQ
MP*UWY,)[E05KT*DP+I:2KI,Z'5.2?2[U07=4[+!8QIG5.%F6UYE6GJ\G\)H[
M:PIR@((5R +*L_(?_@/);U'[Y/CR1R=_278=VT9B%B1FDV7V[NSFHD DPEH#
M/6 X2T+_6.3Y#,%K4UQ+=0/.LYE>9617+[BF S58"(VX$@Z01MO[E^Y'7/"3
M6/\=ER5*(PIC_@/-RL$LK7W*;%$FLZ_5MO3,54]%X1(ZEC8D"IKCU89)Y5Z*
MEE79^III>O)#JZZ!+BP$: -@Y[1V<<;D.1HSC?5C+[/HA,16DUEA0<<XQY/>
MQ<-%"IIKE?"]*FA.,;G\,1B\R?LE34:+1A]IC4D@V+IU <6/%82',?T]_D],
M4RZ2E:9\ZX*=).46CGEMDK+Y?<.K45TQ^DX"FR5=KC'?##+]?R:S&=W^/W/8
M,6O6,'+-ZE$-M^0I>W';K:1?$'EB)Y"=<6W<A6A'Z>6&E5A\Q?R"2CT@@VAZ
M4TNY3X18I8])$4&)K)1$]M1$;@7U(I/)AIBL94+@Y^;T>Y=>9=LC\"N3<;5H
M=,+R-Y7KI7]E.\9M3ZJ5(2> $5DD$]*5N>$;9B$)]#5#Q"\^1&W4G.E/VNP-
M/0-7E@5GOFT8JV+5'%M1^V9DE>+8Z-B47,;3(K=7<N!;U^O6_Q5-!,NAZ0VF
M? 2ED_'AL%U3K(QL2K>UBH($X-VXNVIQ<S!8&5=4N+YT_':XN3\8R+@3M ZI
M\#&779:Q+>KN-V<3%D5^4UT-48T]F-"E;'S04DPMM[]),'F><IER4E0V&O>"
MBPE$C/?QREQ@)M"[Y]!DK+[X ITG, ;D=LPS4W&=-BGJ*3JG,,=AX_9K?6?7
M+^:J6-^7%Y/!:DO/L=E6X#W9#D"1D7&&K;>0Q^>:6POGM?.K?:$6MCVLHK^C
M]A3Y-9KS"E>G+%O'\];  ]]W-D?J?8OV0NX6>_+5<J"=2<D>JVP3\"79N@L$
MK-TMH@XI?A%8#N!"C5>FANKL9ZTFF^9;A11 2W(;3@9!ETWCPE8^>3^QPF?I
M"I[0*7MR:H-\PT; _3@7AWJDDXF+:23T'06 LJ906VWSQ:0!AU8LJH5EM/PU
MP5QM=X7#*>5&8@E_T80GX]CK&Y<8M[:9LRS=8?&,Q^_H'QY0()^P&R(*J3F'
MILM"TTH)^"KA.XUCE;#?23L-PKW#$[H,;*C-JDLGJB:[3HI<8LPBJ^Q%I.H,
M,LM![,()';B)M S&]0ADY7>.@,^A.K]3:A;1O($->\9)T280;8ML40L<7PO)
M-FO4CS7[@ON:?4/\;J<3MZYCAM<F"9KR5D38(N^C4+H@Z_8R"+L@EU21Q0+
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M8%2#$MJY+1F4D%-"\<S\7TT68'I+GBNWA+!T<B@AJJX&N=K[40T*:.>V9%!
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M=Y3:4UV:'-K@L&88MEZ? */$-,EXT^2&C7IW#O43/V%W!YS/AX#SPP:<CX:
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M MDDKRQ2Z3?4XOK;+K67B'KXT@V(E.!7+!9)BGAKE^<?A&.')]2>RET0^_$
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M!R%"-$'4C1!^_<X^7%P<DT'>K-7X.#H^[.S"8+;M\(2V!SP<#X"'AP4\7 R
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ME>@D4A<]4ZP4!OL,OE[G2^;68<]=,21-9%:%;UM0U$68OC]&M0$!+ZV6),E
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MR*%ZD#5_S&7S*% +7#BI=;%N@; $4,8SB;\269;6,WYX50N2;7-<?9IG%6)
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M'Z.;^S1YI\_O5[YR7BDN?XVJLXQ@53J.3XNZ:4^XSBT:HD3*R(J&+P/D/5F
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MC^](LR7$ +3WZXB>RWL5K83=?Z93U0YG]1FT+)-=1/J4Q\5L3^4Z489[JY\
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MW9=9.JNO00$-EV -^LA<<(L)J/US*XGO;8@7.J:0DX=8%QO[SD6\C)K.9M]
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M2%.#^R%-#35IZAZHAO>#37*G-JA3X3C9#O;4[E:[-2#640?$VBP0ZVD'Q.J
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M.>FZ=T]ATTRSA/X3Y3/VSJ,!B0A$$P2[2AW3JS>R@[E+^:AB)$ .)HMP%A>
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MD/TFVM^!ILSEG8.^.B(MI/V6E'V1JQE?6A7<+]IO07.L[VS _MLO;.Y$+#.
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MU57R-!(:)5-4S%*WZAIS$:M$^BX5)JK 2J##I^#)X.Z@J@:.XI!+Z2T?OYK
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M_KVR6D-W:+9X0&T6N9R-%I/<UZ!7G"]!_]G5KZWN<)75#<D=S,07KJ_L^[7
MNQUSM;6M280< B$?Z=L*^NK,[.U:1RC^=OG:8L.ML+TKU?ZCI2@6M"BY<%>\
MZ@SHJ,"$HF#J_IHKQA<KIP,^0)"N[.$P0YTZ?4DSQ(I#HG$^.PC9C-!QO_[S
MYQR:=$/._2>-+DEW@JL#E!]41O=I<1DM#DBVU3' XC,-&0*0(8-5F=LZ:'DV
MJH9EX4/RQBV=L]'R*]8D"J^3D*LZ*?-A=&?SSM^K1/[XFKGX\]UY$[2Y]C0X
ME@ING)ZK=/>?/W,5_8#^;N\?9J0!EJ1N?61E[<RI6PU+HR2=Y1P]>XD/XT&%
MR;I!QP/;<:\C-.LJYJY8J(V],NEV_#BT%Z7U735Z)G64:"T=D V-X@\NC4 ]
MSA(Z (!.Y$E6EIT>M<T# N7YC FIA(QJ^4)LH5OJ+L1M6D+4U#:KM^P*:]:6
M7>4-DDO1.*V,'\SUG*G'YT8W;F*GCK3#*Q ,34-0%C5^TLEB >Y%XX9?TK.3
MZ+\D;!P$3<1^ENA'CI854P>5Z<([5PPGV+,%58P_S@=O[;_@*YQ%G>N:EP +
M T--J_"PVV+A>WS_&."0 X4YZE.3>+JMV:!^OL;U/)/KC-UB_>?[^KYS59!G
M]L+#'SVW>KIWP\K]H;U=D2F0_#8>H.9D^*XJ*P:KZ]*Q2_[*_A.\Q_G[Z:I7
MO72VPSL>.4<+!'K%MXX_F627#?\5%T4V_&P\C&XJE1N?"'^D#9:H*$^=E5YQ
MYYHI/'S6IB(5'ESW$\BHC,+E]-D.)2H#8(3?:%BN5(9]6WVI: W8Q?#.R:D*
MW<*]/_IY81'&&?.&.?#F+QL@N8.Z,\(Z-/&MX4BA1FX1[,7[IN#M,$N!]M#W
M+1V:7_-H/HV'-+L(N(A&MA?3 _0=3F65QCI1]6.)_6>0MLNW])OL,B)U5\.Z
MV!%I^Q>1U)EDI8R!$7YOD2D@$W8.: 4B/:4^_[]%^05TN;?1)6D-TRQ+I-UX
M6>F3XM=_T6S6$?/7<.A&UJF*G[U399[1;\/_2]]-/$=-$6CD=J=-;,D]NCY^
MZ[3#;VT6O]7O\%O?-7[KUH[QM_=[V\7C71" O*FC,E;QNX7JTCMI*=V7D6M9
M21N,I'J,\<_&[KU==-7#7K,K"J?< K]L8R4Y6*D2Q9'*I70;U_^KQF/ZG%V#
MVN:!V2!^8,_G6%NV)C^$#"/2ZQMO#F[L\104@?LC]B>S*A^7I5)7>TO;,ULV
MK!EOUZH__'W-$8@ N?6MFZP9ZGCU7BQ:P[BA'2>PN9M/PD#37N\/8H0G] EB
M#NSE!3]'0K9N3%I=+SQ'F#,C*SP*="800U 0?:>].3'.:<1*L?E@.;+YCB9K
M(I$WJ81EAQ'TQ'(A5CF&H)L#SKE*"Y7@?/DM,6B!35BR:I$T&IAT)8LYH#$,
MR3"=D47LI-,6P#A2CSDQN)K3GR[A2U%W6M*A:B_23[1,7\KP7392F(+763:J
M$X4_5H,/T; 7?%"H<SR"DZJVJ'OAV?FG/\]ZO,[_EWY/NF R"\^X=_3MAZ02
MS\.')*(_F1&,%BC[.Q,;_N3PD"QVZ6YW?G=ZA'1F6Z\DL'&(>X/A8.)1P<'#
ML1PL^)NW61&>I1,%-YZ-NOR>53G[E9!)(,Y<N@/B>:RC1KK)9W6*'^3 7^AL
M<'9)]X:):B*'<+5,<;%H.H]@8&Z=D7?K(#D>I!5THYY/(^HN1$F:I8_A!J/;
M2U-?B(1@X1&,LV&%HT8?#,GB+(5H8S(E84*"H01]Q RG-E$7,1P]<BH8!,3>
M7XB+OQ6B<"0FZ*C/8T%LQ"1#J@B'U7VI0?&*0ZS4\*,!4%5!!/XAG=8(THV,
M [1#'D=W\G9ZA(;2XD3@;8=/VS>[JZ'-,[+W ?D1M@6.=FB.!FQO'(()&%?D
M1J+-_SXM$;? _9A&HZC;,3L]PC99;>/B8/-8BHR+DSY<XJ+XTV1-K/*W?\IR
M>CN$5ZB9-T!"04V8ID&/]$$RPC[(KJ2?^A^TQ=__=Z4<9[JKD=#C_P*%0 EQ
MJO>M?OVI)C8(?Z_HNB ]!,(=FI4,3[,<D*"<7B(Y/T\=YSY?6?4]Y6J*TGK_
ML#L5.SU",*.V&)P:9UEHH&6+9*6M=./,1&IV&)%NP*E.=.(2-4%DC15DTLX#
MX6(T",[/:7:9J-&$?UYG2(J,MMR-FE*@TZ1WQ2O'53:<"AO;X(U[^(MX)R-L
M+NU&W',/><(>_I9X0W:IR5$Z%7BDW1TFO<M^\#:B#Y#U$EGFV##AS^A=I4[8
M$AX<&)2/P267"&I#0_C9OG,\1O2#VH<&H"B8AX:,'UHB[-9P*-J6:9W_ZB=M
M70$SM8/X*-FUBR;H=&@3TP*XX7HMS#I/#OP)BG4'Y*0\?JU9Z'"E0A$=A9JL
MS>!L7K_YX\\S4FHGH.#+U1+;FX$=\\0T/-B8F+D%J+K(L/YSXU302+%^8QUO
MZ@KOZ41(3;.UPAN^["\_MSK K[X.\$=&NK(X&CQO^MD(@XF^R%+P\P?AWMFG
M__/K3W]$Q2CZSWY/,JIHO=#N*-#>3..QA&4XK K-<#>)\IED71G.5P8()1GF
M&]1T^ND>'I\S#JO!\U"0BJ^B0G!%4';FL7@TYYP.Q9I^4<WGI'P5&K*UG%AH
MP&B-55@+$O^;FLU)HY_$0Q=O[>#F!'_FOO2YI)BVO*=D"!4RV&97O9.^2E6A
MWO!>1'9, ^WMHO8.G1$V]UG@[C&XH.H3+'M,D%X]N[-6Q5EJ5)CYA;.!A,=V
M-B<E5"PO;T>]4_%E%7Q2PVE* I,.^7E&A_OMIY?AWE]__&5VE7^,>VL2#;L\
M#SQOO[P,?XDSN+?U=+&I9@1&T+)81_VE:)9DAIJ3O'+/?%0I0'<VM.!UA"17
MG,35+/PUR09L  MSI;PL\,C!&A!)D[_@J02EI S78/A_J=@R7NH1N&T<-1L]
M;AU'4(_#[?[K3V_<K& A;3:GLI;**_&'*V9L9J;*U6E>@:0\^"7.:]GLH#\/
MEZ"+1_N\[+\K.O4Z:?%M-*-+U().#Y\V#^3AOJ4JC%H2"P!L_$6EPRF20P.C
M8.TY+1R>.J?L\&ECNVI23J2=XU*GN_8I:6)/^)6GQV%"+TP+530>\C(,2M^1
M$KRTCI2:QO/>J3NW2T]Z^)K@^MC!IQUV<+/8P:,.._C0L8/;==8?OC1;SV_:
M,.:^S6$:>XQSAN[)>DF7..:<#'AQK-H_V4Y!(:PZ,Z>F,N=T!,=P=)0E+L_2
M7<,[XFA%U4^GXN=V^%F_QW6]DQ$V5ON.D)'T5OT^W\VV)AZR!0'9X1P?X @%
MYV@WSF'[QN%$^0_8!*T,BIRC)PR$KVG7_,%;P_6O&N_@I:;]J;UX@FH<<2)=
MP6'&>#9/^%(K-.<7,X I+ABD#%<,[U&WM4D>S0I-<BAO$RY&H7[50 "<N(](
M%C2N##-N\6,80SQH3@2@A]=. FD5[U-E:(X,Z=G'15&J6='3CF#7I6F&8G":
M=E)Z4N@DH$Y#5N2JF,// X46 X2'M5#*D%/-$R%\ZKDTD6[QO+J IHO.LF %
MGZG*+;L2 [4500 9ER><5?WGSY^YPJ9_Y$U530,G:88?IHLB'L91ZE5[\=C?
M')=/H\Y+8_B!00/Y?79:<"K<5?F$V\0[Q& K+/-D.$QH<+ID2<858YAPTRX*
M/S4FPRAAX%HGY'9ZA+B!97O6L"+2V=W<7T.T42.+WL7#/!O$XDR6%/O/232E
M%S9\8D(O(D@>P?!HWWJ>S4'5QHG"W"I:"3Y@[^:--EY&9& 7FKY1&GU^VNVZ
MG1[A6H9H+3DW887Z;.<UM5I@[QB/7\VOR\CE-LW-YDM8EX"X2\&ZD[3%3XHL
M>D1@)0@5VG]I!;U+9=P"6_Y-&H!$+!]QP)O],Q)H;$?%Y:@OEXMR2TJ>"J%E
MI%EION CCR /LY.E*0@J9DJ.(8C*DCHB>]QG2Y#LP2PEO0C5,1-F*P_K:NHH
MA9X@ "Y!<NG9 8>A2!N:<:E.N[G\NNF7<<+POUCJ;^++<9PS-MOK%?2M*8T"
MG8:"%135 !D"&$BN'J<Z>JMSE'+50I<LZ0V#!;_$;>R^KK]NI[<,Y'V%RK%&
M_N3*$%\+#^T5C@2YP:3$)&VP DS>CDG2AD&A8S/E$KI1R@8/,T'3JWG7LDR4
MGAR$U*NV]P*=4Y73+&?3D?:9[FQ(5UT!LU!O/6D&1B[;L.Q=Y6WXRR*)+@L!
MW]#E1P8<FH ^1_:0O#?0O]%&F]SF>-;.TBQ:<!";3B!7V5I"/W#/>ZN@2[U5
M<(2>0Z@>^%%F7D#-E4Y+2N>MX/+'X1D7_XRXW*Y\C_"QKFX[U2:0F8Y(^CZ
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M\RXJO]FH_),N*M]%Y;MKZ3KSXCWB:'7-.(!#.QOCO@/PP2JV#$/)ZO-IP/"
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M_W';Q^H6.KT#L[KE'>QFL)O!^^Y@_Y8[>$=7X%_"\OOUTW';=UU&&CV(#\]
M?Y-M8@FW=6/MRD76]:KK5=>KA]RK'32_;OD:>IOE>12G*GRIL<]GB0+]PO:O
MY;;>1_^GF[JO[>F[;NJZJ;OSJ3O?_JGK;":>&,:F?J@+>F[_PFWKGN\NJ8<L
M+K9UZG;%3.CF;R>NJQTRLU#]RRD-N_U+N*U'H+NX.A.AN_-W:.IV8-?9ZTIG
M[>YH1L/M ^$WAW8OL_D&,"F'!T>;3H")[=3&FX6<2%]O/_<N%LC,IGI_^]TU
MR:+<1]3<;BL\Y@]GH_KE-VW%I1US"Y--4Q2R<[Y_J^]P<G;=Y+SX^YSR=W<P
MY>\,>6QSCF_]'NKR]NZE9!72/ ('S-HE4][GHORE N:75P6.6UQ,U4C&MISS
M?!6!W3OZ7R-X*NRHED2!JSBC_+?B^M^%J2BE<SA-G8GE/&M-R6 ;&D)&%VV4
M"@?AORWAQ!]2F-@4!.:T;NJVYMF:SQ,2Q= 4P<B?5PFFZ%(*Y7G5B2.IYIHH
M+E'!&>*6$KN5UH&)Y*0(138+9[2(J"P:USEJ*PEBF8[;5B -A"$5['GTJQM/
M+RH6"Z-K_>::*<3,AB;HN&JN OG)GS1%M&,>GST^WAOLHT!'"U-(E\6^10,!
MUYSL,G]C"=VNNW=ZFK)2$QQ'O*$M_8'#(:>^S$F'T>S'31)[4]Z"#Q/X^X71
M<@KY4C1*P$1EF<>#J@2W@I1R:/! TN:J62FC(<ABF':2J7:9TS:/4Q#7*TL0
M^>^4:RQP&0B7 <82-_]Z=O;!,#<'/CD>E]'@(HHO0BX*P13;-5&O\-SQIZ:&
MC!8AIB"%%)OQ.K54[:#N/7AO4,EAAK[V0"&<5U%2Z*KA+!JE)]05GO18"15,
ME"S^:Q@E'*K+MI'(.L_1'-CZ0E"8C;CHPHC$V85*3/V21'U!B0&P!]4]%")H
M:0-"L5X-+G61L^PT)<V=ENL&F?O2:05</*C0G*7T+)=;QLA,@4'Z,X_ TQWH
MTNBK%N>B?;?$PO*36*Y!KF#00G_X@KNYMZ*9AC /QKHD1W'@2UMLZ6AH[HFI
M B.2W=-,$H1UK!(FZ 0SMTM]Z*PHEEK7JU])911<1'F<55Q@Z ($(AC O*++
M>EC7'>$/A4/H\>M,9#;_SM3*YE9!@30*SZ,Y&-S"MV_/06/R^LT??YZYI%!Q
M2MM/BM:;BCACLHHZZ;Y% UF[R&/_\+#CD]PLG^1)QR?9\4EVPNEZFS(:9:*W
M+9N2Y],H+U&K28@%I3R%:%A:BZ(+RMZ^*VTM6W:DX_7IPAEW$2:\Q4X^/WWZ
M_!:"F;?@_-(%B#)2NKGN'W=TZ%!OH(B?KM."?\Y)HU!2(1 ZJ<=>C[8NL_RS
MK4#C^"L<G53KNZX-12IIJ-))-)%ZH%5Q>^B;;W75;^%6WLY>W0-15[=1[K)7
MNR/DR')^S"4]V$"'4Y<=8]Q?MJSA3RNAWJ19^EB<9FS.<^$G]FCPPR,13]\H
MVT1R6B<]JOZB(W4G41'8E&L0PS\;JA&JRG:[?>=[U8G%K5N2[U4L%JID$<5E
MZ<)I+!7FM.3A7K-S>S9/LH527#B6/I@I[[.O4/7<$I.M=94+&[CC7J!.=QWE
M2Z)+XUTWA8L[N;C[O>KDXM8M22<7(1>7!*+HAZC.F9(HS+-2(H<<)C05X728
ML)-:6[H9.ZG5;90')K6R01E):601,Z@%:&S+2 ?->S4 *DI3KD+:"\=Y-OL*
MFW:DBF$>#_#WGH997-F =,1OQ)8GM#'__U"GXG+QV,3^:]NW)W .%$P"UB('
M%$"#$@1N8$QS+AV=*P0)5[;+G9$YZD&OG2N(<O.WZ+0BYT5AI9] "T6QIA2:
MJ:ZOBN!Z/!'Y3]]/F)@4WE%Z(UK-LS$#O-"#J"JGF2[;A-LA%H"XA$FHMR.9
ME NIY%IP(5%=)3Y+%9J;9;D_Q]S#(AQ&>1ZC=#;ITGH.>(48'D==EHJ.MH3C
M2%%OI!IL-9QR)_0\,IR"D2KPD>1*WU,H'Q8.5'FI5/H5&P6M5D4#>]/>A#A"
M6IMQMHIY<J@ZP;CSO>INT*U;DN_U!K5WI@$6B\-8NXD7(A AYTCU)S&;1VDA
MU;,]G/% <:'NA*MKSZN\J  4HR_>E&H6/CE\@OOE3VL%A!\?_PL7Q:Q*)MRZ
MEN# 7W*Y<3Q:B?7!L!>&]*7T(>,4G5XP'*[;Y[O>JTX@;MV2= *1U<69K0G>
MLZKK#1V_C!FH<K)!)E")1Q=QP44V ;.%O"6)1T*PQ^*6?],S#I-,=&['Q4)6
M +VLD+[4'F4\.LQRJ,^9:(G2>]L..[)K53VD,:4VUH:GC7=;7D9&5<F/\)B0
M5&-KHC(8FHT/:Y*XZC2],<H%CKP"!8UF722\&_5CS=V!&DMN!L/1G4?J! _4
M=0=>W[U,C/L<*_7:OO^L?ORC?9SQRCU[]:":*RK$NM/O6# 'K>+C=M/\&IBM
MQ[>.+MI=^!D21I9JU*+TKLG?*+)$V?5<L%L EB04EURQ6L);L.2="Y![6M"I
M)*4C![J/.F A0O2QSEX0-+ODIN O>C18LE9Q_/AGF36WJ4O4T9%2LX80X(X.
MLSGC2-$1\5EHL[<G'ZTX/39)@(X#U*,ADC/P0+$HH(>UY!GH%IM.7-ML?9P'
M51&GL&3IR5$U+$6L\7'10ND@?$-3.*)^,FZJ!?!H4VF^?A5". APH+6D=.;"
M'E\C8MG\QK]5:[;= ]CS#^;P2FZM6_[**5W:*"&]JAQMV"7E;LEJKD[*75%T
M^(:IN=<EXVK9&;2_[)O3;)>JQS?2;"\SIR.!J7K?6FKYNES;5ZL3:)N3$/F.
MTI[_O7$E!D[Z\8KI>0 ;\,&=))N*L.H ?5U"PJI]V>4E/-"\A)VJ)'S7/=]%
M)P4H#MA7:Z&^K$$;LV$0%;%(@:'5F":9R=7.!G\CVG;!BGY")HTX;:%YGT]C
M-0Y??5'#"C\(WX_))*^OD4:Z1#RV#F-ZW3R*+>S7R?)>I]FYR@&W8W6.E/W$
MI%FPW[>UX_C3L /4CFO'E<VCS]6L0@8X"[J]>(RN[AL3:T6G,'F(,*;R=C.2
M+-U2/^).G>VNJ[O@FN[6Z0'<#XVHWLK[P1?H;<(<'!MBL4!LBK,E$V&YK<"^
M;@<_D*YV6VH[N[J+0M$5@1(N8C$H'F>C!;H"L9&;ED2K@,P;BP9MNS?DGLA@
M^AT9S&;)8$X[,IB'3@;3^=(Z7UKG2UO9UQB,?T"F>-ZC$=Q)A88>0C&(4PC=
M)<4 4:!R\5A<19Z7Z0HM80MV\@YMW:ZKG56T:^NT.^(O*@H=_*ZACJ'.TV%8
MT,)B(2$&YWGV95&C^31JCWU) C\R0/"JCI$+^6FW;;=]*^QT5[LMM9U=W2%)
MZ+$E&9SA7.4DQ(J8F:[1=?/%,"JF9.TN!-1<HR'M]ZZ:B*\'*E7C&'S4.5#-
M\AR2Z]F9KMWHPI-DJ$:Z';[UNV:GN]IMJ>WLZNX(S7ALD9 ]*(>C:MA,P(>[
M?85;75('!6TF91@<R'M#U=SB5+]N\SZ0KG9;:CN[NCORT 89/>B;0>GE"G5I
ME-3KT,EM K;P<H"R9<P:],214TOQSC/1MCT@>6\Y9T-!7DNNF:9,U6F2JR'6
MU/<%8-:<^\2):74"5,^D.L$T8((;R9D:@9N5,3C^)3K,4I1JB9"B*CFF2(DJ
M5-+(B-(E52YCLFXX81^[*5F$DC5:Q(CB8)LUZ;&7+9F5#-B<OPF"%?W"@_"W
M[%)= )<N\4%AA=796F" B<7@DK$Q*\_JT9$6H;/7EH:)%WM#Y?RS%0D@,@5H
M.#9Y("[!"@;"A<L8]FG;J[-MF6PFDOHV-@UDL##))*:4S<=7YUTNQ18-1'+,
M3"(9K7Z W6XSC;JDL9LOSXMP$ T_3W)4;$*T/LM_0@)*J>XHF^Q&68%2N=!/
M$0M3OP47)6];0&;5N^(@N"X!"Y4>6_*T"JZ'AO0TSKTR,O-F?7_("_SPMS#T
M!-+NJ(<+T./,LT+9'7BC?<![45C%XD(4C 'G3-+ '_($=KB3#G?RP"Q%+FM(
M;<)6E, "Z?]JF<P2NBEIR2.NL,F4CN-8THX+D_9L#4/]I&-D:ENRI3+C$&4C
M1UQM%'I0:O6BF@4]T?4_M2FC_7*HS:OK319D^ZAIEHR4,,S0V\;0K2^B823\
M,BLK0W9^EZW?H3O=U6Y+;6=7=T= CU!E.)NS+\^5J<(#ME*N6@>)4BR]#;PP
M,K66A7"GQ<Z85'0G)&#9Z7;RUN^.G>YJMZ6VLZN[(QR'609>L-INK46>Y4G4
M^F*ADO'C.GM^-==/C[WA0V/KXF^K^C9T7 ^K*(7M:SDJ+[ (QBA==+'CG=A4
M.]W5;DMM9U=W1Z;Z":J:A31O)*A"S$4<OFKS5#?-?](^<_I:8Q1%=EY.51JF
M:JB*(LH7=QI+-GF+G5-Y0T[EFSF/:0O)9I%X912:V#5'JX4$5$FE#D$@,+>N
MB5=P=+,+1.ST"-]7^0WW#,?*K4SY&G]BFR\Q6/8E,O.MXT^4<%W+B[A'C+:P
M(7RC'+J=L'VFS=[H$.U]IL5UWA:,*D[UDP(#/*O"5;O@D MIMI^%6#>;<Y$#
M;@W%(.&'!6MDJ\<TI56^SFVZE^4& J39)GM!9%'D*Y[:[\[A3H_0Q+11!I0)
MSY)DX0:X!4F#/3".A[T0R:BS:F;<_\-(6!Q9;!O>T)DJX8(O/M/QT%]AY]J+
MWH>08=_23D9MHH/@31I.%*!FB6"2ZLB$I"/40#:[[=W&>BM%@CZ?1:A&E72:
M.8?,]/:H"882E0LPI7JEHT#]G,? X_3"SVEVF:C1Q))B&S+J'A-:3X1)VGL\
M5_-*7&X]#]S3(_%1C#)-R\]6ZB!&E2RAF)[GJJ#!,VGK@-9#"+/I'S9<ZXFH
M!X"*>6#PGG84SY6<(D<=I\AF.46>=IPB#YU3I!-5WRZJS#U)UV]]/W4HQ/M=
M&K%R@V5"> WTU8H5]?1O+F!AU((6[:?)Y7Z6AD &'AV^<"N$&"6*O^J_@(T^
M4F/2;D:!ULE(,X3G!IFH!=SG#'.F;C")F<X;#9VB]<:8TKYOKMH)E'DU(&4L
MCG*&9;B0:<?+3DHI:WU>(<Q .,6UHQT14<>-K]]B&7S;W/J7696,1)4:DS95
M.QC<P?/3ZHO*ARC8P;5*ZEGZNQI-X,0*4'$ZRO.%T+*4.E%" ]BAR,7BL8AL
MVP?A^_;U03$2PQP,0 TO;&+I+4=U_YTI?T?MG6=3E08,]Z2_SI#-F_58V;YB
M?0NSP)%=8#.C?]RT"($,R7E+,')&=:&,ZY!V3C$D:X*>&1E+LH!M*@N:I<DB
M;.TK#T;KPIV2NT4#>4/[CHTV;!3K]? -G-H8L_87[<Y9AA/CUNN17Z91":H.
MMO.^0*DP>1RVX(]7$]?)@PB<.HRV+!#20-VRN>=:"''[2*JPG9:4^/9?BMB:
M1&G\W]J%9#:M6CJA05PX!YYEH<TW=00DBYW5K4#T\@1=0@!%]%R"?*Q1=P#N
M2:D@->EC;6US0: JM<X/>XGP7N]TIOO;7&>!XQ1!,1OX6*;B&QW:15,UB5#+
M93R+%N$H(WL:SEDYDJ*(7.;P0TNY63ADR-"C>ZD0!"P:^ZB0-Q?EBU[0/^GW
M#\,_#L*7=(_3/?LARC]?(M'N8Q73^T\/#WOZ*QJ3^D*_>'IR].09BJ;0!5[-
MN:KM4,5S*P2'[IYS]0 ($-882&@,$\5W+:W$9U+;M!) -MI8/&E1TC.7/_NN
MTZR4BF1P5!LERGG-953HW#A(TVRN!:3WHQZ][;/B9+DY*Z%Q:;E$2'"I@O43
ME$6<(\>/OKK$G"^_3#OTC13<*_;Q$5<DBGET=L(/PG]?.T.-*0ED2L*KIL1;
M0SM!*X<](*7OQK-X"Y/Q ,[MKEX*'T#&O AHO5XQ^V+X_I(,):@GW2UP?[OI
MD\ZWA5 89?0H3K$4KQ+Z[$5H^3+#S*R81,I0@X!:[P[5O1^J:!+%*5VSOZD1
MTK2[ [4=!PK![ E90TI']J:R/*%9KH1#>7 HF"=8)=-Z55R0C3>0:!>&P+A)
M8WMYP6@Q [7MI-\E1S:(+L4GP64&2XFK@[^GBI/1BW!J\OS)ODK$$=(_?5%,
MP?]31*2/:!<//P^N [KVHXG@4!SKK^>9@E:,#*L\ISZ30N$+%+K2I_$@+NO(
MO6.2'H1_*6;A13<M#'_-AXUO9ES!/.X$T_T))J\H[)]T#FB;+3JYM/9&.CX^
M>'K"<[DY%%$:O"?]>$#&T-%I+SPZ/#I>B0%P*DVR=X=)%I4.O:.JI?8E1Z'<
M0):"Q"PUOGR5YV1P955!VOL9Y! U\,80<@>_1# '/:Z//;2@K0YOW#PU(VI:
M>'5^"BO4@D72S0\_GR?1)< )NB=ZJ;2=LM\3^Y6:4N.Q5)\3TX/Z9V?#3 :S
MMS"Y2*99=*V_(AC'7(#;O$Q =J; IQ:'9!!54G6>1?*K+T(6)+@LQCA(Q_%#
M'G#_\"7_\D]J#7\\[IN9=YJRS9P-RX"^[C\_?L*UR".-D]J[Z935KUN:+8.O
M6')K\QL+Q?9J.6TXP=_J7W/#)Z>'S[YN*5]CC@.[H&BM:/3P'F3Z+1S%!R15
M6-_QCV#-IV2DP@R;B 2+J$1&/BA'/D1:/EC"?DW.[[$*,=.0UBI"C=Z;*<=O
M'-2$K%Z\QCE?-SXLY^@O-:/K2S8W9%-4ZH-!:A7*<KI\4KHTFU.".ICG:AZQ
M'S^,AB!&XE,$Y)*F3V29A*_R$2,\K?N4CTKH'Q7!7KHSS J23P0U%[1PKB8T
MX> Z";B4M1(:IK Q6F%^DDF<0?_C<(&EJ&*?^S"JN.(F\B/3,H\'5:E&-1V:
M)1,7W].*@1X$=7GOQG9:>4E!2\9HJ[GL#)EH?[6NWF3^W%B_$V89\TX*>O:9
M>P)46S8R:UU.<R7/)@IC'=/,T&HL5$0OG*,9RS@E=TVJ QBKMT+8NA4"=X;N
M39LUTNK.M>@U8&#''0QLLS"P9QT,K(.!=8:L8\B.H%:$K^A*&!:=!7M_.\B@
M[XW1!65EQ">*UX8NX%\,^.%<ZRE[-H3E_+"PJIN A[1&!'ZN=AQ1*\G_0?"7
M<:GA45T_17%TC0TSR=XSA=F]#EBTQ&7$2'I1ZP"(HG>N>&221VE9QT_G.2DQ
M\9S,I2701,__00C+->6TE/H'&DCFE@2V(S/EW-G\BVFMHCP<5VGM8:.)USKX
MGX8J/'A-#X3/'O^K\[EMT4#(',CUH1G :9QF=L>9[;3&SL/!T RQ]5EPD(M=
M0L4]7D]_3>.B3-0@R2Y5'GS(LU*[EHPWK+NOMB$25-]9WH*%2PMFKZS&[_C+
MZRXN (9;+JY>8(]JSV%FEC_*/*H).DC'3,NF]U?<"FW]83 N2Q9)@N<,N%'M
M+=9N43;=.R%Q?T*"%R!X:;+V.J%PCTHL JW!I0)LSH%:2#:I@[BP*9:]5=B[
M.DVS3L=$R%3*LDAB-K)*X;3O>>F;3I9E4"[F B-.5#H!T&]<0XCK9$Z;P<G=
M,&3,=/@O%;*Z.<\A@G4-_+I)-[7I =8M*.FOF<Z C;\X(/^@D81!DLV&LNOQ
M 0R6(4T\"B^0$B&9'#0+P ::;(-"<T++]$3.6Y6MYJ7'XZ*7NQ31+1W(^S0X
MJR;(EY:H9;^W;K#-7D1130& P)VXBW7LRCULO/TS1DS0OT9N.%0R9NAMG&4$
M?W=JR#7"#U5>5%%:6J<WWH%38=[O1L.L&&:GO1MY6]CDGU1=)@L;@Z,W?:IC
M;>?1'"ZEX!U FCK$ -0DI,D<][#XNHMJ\+?6Z2/.(L*5'W->DC'JEGSS8@@*
MW0)3@-D95GIV>\T(!N072CS,$U2\N)PN +GT@&0]@,42.J'4E\LLE.&K<,^)
MT-!QSR[WG?G6BD,2@>8D&_]$O][GI\7%;KW].I)K$K]>P"S9&^PO 4QY4AE@
MRSI2LQRJSK6*4Q;#K(W57QJF![<I.T"T*;OKRZ(7Z,H@; OW#Q__:]\&P)KY
M5C2U65V#=17)!):-';!V9S7;L0/7(3=)B H:W9VRA!Z8.V3,S@(RZA54.2/-
M:=U(:(\DOT@6CE,RKEI9X*G-@M:96_]..:ZDOI#:6=:+I4/F!?M**@:#\\([
M&Z2M/:%*8#HZ0W& 1L:*+DRYNJY\/&A_/-*A>$L>@%RK.-79@3E^\O;77S[]
M[_\WW*MX.'35H;8/YH)GLP#[@\IUM32N#&3 4+$)]PRC DSOY31H]DJ"5RL&
MM7_@RPHC)&BIHI2[[N3^ ;COMA/+''.J#,T=JK=H=7Z<)33;U-.? GE/3P]1
M^X.6)\1YC41CZ6 8Z4!J1 2G$AW^<IJ"[@*_)ON!Q \9%F1B5,Q,D=-5/H%,
MPDL2>GN%+3L$S"NP #%1@]!GN^HKQB4]?Z#W\S6QKB==K&NSL:[G7:SKH<>Z
M-G=B]?PQW!1ZPD]A-2?["#)^+65[0)?Z5XNFMK>VD?1MU'' +<6C__EA]C>O
MN'$:O+)P&ZZE8R2V"^6[$_?"[>,2-NR'J2?.@SWR:>F<,O?KJ;7:42C"NE!2
MYYNQCK5=0&K[4.6I@?=X^"&2=WOQ/CMCW>H?A<J%GJ%H!.:6(G<!]#!)H>0P
MFS'4AA%NB;)&V6HX$JO6!L7Z5(SC< \06P;H<AK<2S5D!3\\[O,/CJR'^<.K
M][7UZ>/!O&$E8-1_04.CL6$ L,-F&2G5TW@R31;UC]5H>4B%FWZ)KM-;)=E4
M,4&?G9KE)P-_M/031KLV!]1G&P C$T(^LG?V'.-7P*RSN-2.(+$UF5H:0Z(Q
M57/^'8T*=[.V?9T%#"2-G:9:!WF1>2_D&'5HS=I?<\<7P%.&U$<S$M0?K$&!
MKA:O#7AG0J*T98/0D\OCI\9E8:$H",8YT:@YO=30?. B,<T9=-P]HFKOQ-]U
M([UK_<&NIZ$UZU U=3)1PI<)HZ_7XGGLEPJU/$6O  /.3(SA#U:\?,B*6.YB
MZ%T^<[+W](M0SXY])[^MGE*7?IF&BAG^GQ^.F@KK33K<KKN\%ASE_U51WNQT
M:P];9\+I]'7/;W"$K:K8;= P;YJJ(:(+IAD1"G>AYWN/]AO=OOF:=QMDC=AA
M6C5A;]_C_MA>J;E9>5!FU(TSR1K%%!;5_.>]/DTE_N%-Z&8%]'<RO^\E=:Z;
MX-N:X#.ROMZSR>&G%IJ9/KK]F>ZNDO:E^9254?+=7B7+A6;:#8(V)O-\,M@[
M.GS2.SI^UCLZ.=E?-AJTW7'\]!]M?M[?HV$V"%]J$L1FY_6S1_]HWZ/^K_JM
M+V@_"/J1D\8C.8[0#S_#9EWQQ%>\Y*Y[__2P=WAXN+O]YQ#RT:J'=F  9&+O
M]@H\.3WJ/3VYV0#D#CNQ=]A6#&3GM]+I\<U7XNY$>]LNV-3E=O[JO923F49Q
M3@_(_CJV^\O3CZY:DW47HOT>Z%_UL[;F;JDK*W9RUYNN-P^]-]\BP_Z20CMF
M"'<URNM^>*=3WG6FZ\QWUIF[5GM^S]*(X\A"WG_[:LF2>7I/BW/2:NGLTNUR
M:[U9807>4V^.#Y_U3M;IC>C9IPT[[KM8L2<G:\[1P["P/N2J8 ASS^'+=G%S
MG<FU19NSZTW7FUU0GSJ+J^M,UYGOKC-WK0:]JE#-+GQW$/Z>3=.BK,&$#]_H
MVK8+9IMZ\Z3?>WIZO*Z9\_1[-'.VJS?K+MCM"YM-!J]>OY<-]N1.C:>=OT6Z
MSG2=V>G.&,FDTTAW-5>NSDYQLU&:V2HW'M@5*2CK-]*20+RL,-ZX3X<'1[>;
M]=.R-[^RD[>^(P3SNX%NWW(_W[@$]-Q+YHRT98TET2R:@;*\,/13NDHR:@IF
M235+N8 0?L>\D\+-,H[B/+P H0'GQ^E*18:8TE3R<:G5BVEVF?8XX1 <\]R9
M%?SX!7#L;34$7/IY)B01+KU<:0XK9'$Z);R'R*4$@U#]F$[@3*1RDY05,5W!
MJ_^=QGCB(QAD"N:Y\<IFO+9TK&=UFQ]M]6AFP[+\+JT_.<]&\=@4/_R4S>-A
M^+3_;+_'G4"ZH?JBB_U**0+NH:G\J&B#S#A7DWHT5C$*)16V5H L@C#^\=(4
MS87,U3CAU$HNLY0DS17E3LBJXHWT UT\KK&^HRHW'<3B]NBGY32K)K)\3MDJ
M)Y?S0@DADDD(M:0D8!B+TTH9?EZ?+[]=F;TG6;BMPN]N[[_=ZFJW>^YY221K
M8_O[^=+08QD61I)4)/T*NA *[C0"?Y(03]\4G&FN*0F9'PDL=;1=%KU0DTZQ
M+)Q,D)U?FDNVO; +26@F>V* Q*,^1\4/PC^REB1R=(1$;JJ$A#S-TL=:1M>%
M4;@"G\]N &+']#\5S=XXA@!78[!%-:Y71ZP;*2T,67C9(+M0?I^X+Z;8NYO\
M7A-!F:HLEB"O+@>4Z6>&N,'2565B"A16X>O),)%YK<RC6#2)9LY]DWY NM_)
MA2TZ;SO=U6[WW/>M<KP;M\J[7"=N\?6!OP0 )_J^&H+ZH:9;\<N1U54/2=0U
MJ&)Z+H=F:#EN.A&W38N_TUWM=L]]B[@GNR/B3(B9R9"B^3Q#=1VKFIU/8S5V
MG">F0.$Z\DXS7W6";9N6?*>[VNV>^Q9L)[LAV-ZGH2:O-_Q[($KF[GH5"L0%
M3H:^8O,Y8U/4^C+E&_Z7]7"?&[KI6CVL3>6PH $]IF8'H._A<@=S6PAA7N7#
M:52(\?U4D@N$>-PPW<^8 1U,,+YX=:II?U'Y$-5?YWDL]2$>]0_ZAS"6I2G]
MTY;7AD?>*\5AK#V[BBO7]H]"ZD$Y+6JNO'H"8L?MWB/U=Q*G3,?X$8[Z62WN
MC\6+;3J@"VV4*I]9#G2.*G2WPC:=EYWN:K=[[OM6.-V-6T&FM.5N,''$3=X-
MXBSXJLOAY/#.+X?^Z6GO]/2TNQRZX_VPNMKMGON^')[NQN7PJMV%P?T5 \)U
M>!@\A>=!Z2\I]<XC%EQ"7Y4DH/&TR'.I6@-Q&V:TXT@BGCYF66L(QR,!NG U
M'^TV/CIQWP0)+T_8NV@<Y]2>_S,CT5%#B][D"&8:G?2"13)^)S6/X:46F>U<
M#,PASE@3+@+TZ/#@Z%E]R<BU20^77/HX?"0@Z':1;J"$NXDDW/I.^]V]LLK-
M25?E!E]NK,H-/=F5N5D)+'X@96XZJ;.*;[<J4?D0FS%X)2 7S;U+%X;#-__X
M53KJ2K"L[O06E6")6*%9KFOBE&;)ZE5OP$\-J*>E4$F*(AF!!O%^K&8S,#4L
M%^JYBUH975V,EKH8R[?CJNP1GH-OI[KN/]D\U[7'_]WL]Y90?)]N.<6WRU'O
MLZ?(L,S@-DSPO6X^Y$8JNJP0"U#N;FG5;X'8_8^*)33PJG4I8:XRFBP@FJO4
M> I'UA6W][_VC?]0RJ)MY1'9HLFRGW]?TZ4%Z2O?U<Q,[=_9%*@O\U@'"N E
M^7[&[YP8[>?*Z30PE'ZL/5H<(F!7$E#YVIU$I^;[F21=)MYF9-UPJA[M,X3L
M+N_/;RJ \.1P"PL@G.XZ;_J* 3QM)Z:\\CV<]KKQWC^Z6<<1C=S=:=^<,OW\
MQ_Z/9#L_7:$G[\Z4;-51NN%F_-:^=SQR76>ZSFQ[9QXV6?9VL5V=K$L*S7G%
M7].5)1&_II)Q3Q-R9QK#0R9;6V?-N](;.R&,N\YTG=GV"_S.N5>WZP[?;9&^
MV].R=F_6KK[!$;K;6J&C9S<O 7+;%(*;#WQ>'<?O& 2W <'<,0A>FP/IP)@W
MG.=RDQQ([H7-.;F_'$CN1P,4W:6Y?.>)"CO=U6[WW'>:RXYPY=U19GR7_=A=
M"P_C8.]T5[O=<]_7PHZ0W7W?V8^=Q-VFO;C37>UVSWU+W!WAWCN/DF&5<$F
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M=0!4Y9A(LGFQYVR:/NKKG9,A4O6H)N([\HK]2[^@92?9E0EGWQ,;"Y+_Q%T
M@U.#CX[Q.%U>4>3FPKU!)GX4=%S!PT1WFMG=RX+I]PE'8$909Y_O]/WZK9C
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M^0"8-97L'YP">A2&/2=P3,LYM:ZO&S2#Z$=8X6E9U<IL-D5+>/'$2) -X!5
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M&$D1:;]CJ.X(2"AH)!<[11,F#%K;-82+I]8CQ'KO_M<""Z,6L!"[XFGB@!L
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M3KB7X(WPSWCJT34:CO<CF@AH .(?,RR]<-HZ!UUK@Q9$)OK1AA#._!#"6W2
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M2PQ%S$M,4F))!K6=PHN*_LG.\;>[H646MN/L<M>SU3J!^K;5A95ZYU79+/;
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M;^YV]B?M>.V:L/N&ZQ-R3=JC_[+98]#U9D?G*R8'&PUBEE)EK0G=^4&\@ZT
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MP57&>^N45)=%3G75@K9BL@X:!.@DS,,6[$J\!V\ "]^8\8AXT*_@'H.H0%<
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MU*DG2-'F2OSG-_)\1Z;ZK/9NMP(#\48ZO5"/#29)2'*=<.YR&HNQURRSG,;
M%!R8V$_9W-,02!OB<6E$G'%(W0W1_% 6#DG)D\Q_JV2T8N>Q3E&(GVH7J*8P
M_DFW#J1+3C59H[=T-(CKEH]%<AAFP"2-FM\'I2L#"RC9-R8$@L-HZ!O%EEO1
M46L^#9)'>Q2W6)&8CL4C0QKD^*,7#X,<WR(Y;EA&?Y=4_FL0.&FQ=',)),+/
MBI7F)-7-@XCD%+L!+85 8\S\8(5."&HA$R!Q9ZN,/6F-(ICPJS5W#HD,#S#
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M*ROKQP(0O+SOHF:!Q;8)4LMO(./!5IE^L6P*O=7?4+X6MZI[Z4G9]&_?S/^
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MG!8)&,B+GOI*!+SYDR3B*A,I2/(,:#Z ZX.'TRR2\.F"##=GOHX=HQZIP>[
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M>MBT3@T[%%ZPS/^I[MB>BK,>FZI:;@$/=.(8<8\H9WC/7GRS2BXQ#*3GWGA
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M'W#5/OKPC<>F7(DM%\I?_PDN\%MDI(V9!R(2S0 I@)0#*2'/"WF1WQ12I8K
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M-W;;--[ _KS%F,:V+KL%[8Z<YUU*^)AC3\N0'6]*H5!AQ7(,<:BUY5_BHBP
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MM2?\*.Y/N!?6MMSG5G_S\)OO51O*GP=Y=ZN/TF[?L*IXUY9[?,OD/A?"[B2
M> ?Q#N+=)R+K:]KN?-#Z/3OX62D??J^J9]7]B??2VK;[W.H?1S>\=B]*LM1-
MJ^V^48WZKFWWN!:);7?Q_0GWW:0W5M8%)52?I&6=$1,U%7G*-5:>U/1EQH@.
MO V\G56B V\#;V>5Z,#;P-L)(WKH/8=5T5;JR[:L/C*.5%,>Z.88.W*!>P\W
MW.^Z=C.1;FOQWGM8MWQKS2L041+Z!A&F0XI=B86W)-TA!OO)760P>L\.2IB,
M/K9,2]((%T#UY;Y@F 91D7@R O\!_P'_I9!PP'_ ?\DY6^"_]*0'$G=,@$'
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M'P"LA )K7350 C4 W+IW;MVE&GC/ AYRK" VLB,VTAEC _X#_DL7&8'_@/^
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M6'8F.!>\"<XED9L?!=W7!PHR3'N(<T=M=Z8_QT@_1>+=HZ6FMLQ"B!JG!]*
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M!=;+"NNM';F'RU+ K?OGUJT#]Q&8,$FX=5O"=DTYAL;(B6<P0&9"D;FN'JF
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M>]P8CL864NCR5(=F#+*)!L(ID\+IE;35'')VF 0NE,5T":9ML[Z D&0B9'N
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M4.46,I!IS?3XX?FOUL61=G7/QSNH9->SP?:DTFWR@L0"B16#Q*IPF9-8  X
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MY5Z;[80$BX^ZJ]T/[Q6LYKMF.\P=)E[Q0STGCXT"0+E;" U^?SP4@LLICO:
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M"K?9*9JT:Y&-'+JJ&W-#-U2=RJ*;,NPYZ1W62_BRQY^[-!0OG30<O,$R/3X
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M%SMAC^'Z_RNKV^B  CG?Q7JF/1/+1@[O(EAIP2O#OTK-;6XE"M(@#9#M=-B
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MJC2;NJ'#6JQV:\W;SI-74]Q6/NE2V TZ\7W?$UW$8V?XQ=R\G,KFQL!!MK"
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MX< ,8JVIF_2D?.W!_ OIS$_E%\*A7&LMS!A#4MS'U-^.9[3H$HJ/JW:PQ[:
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MN(DY^*-CFXU3A\<SMX4U >("I2]2T?;8?"\2Y+N@A"954=GM!X_P>1.0WWZ
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MU,[DX:&0O# NKS\N9G-URW-@W*-]M J*6UI-:W1'H)M*(M.H(Q+XE***X#R
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M5/C?V!KX&UB/F#U_PTUOT'!6@MUOSVARU?>PR)AMKGBVU1P.IQO:-]+$E_8
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M^)*JQXSAG(XA\^%P(X3FU@D1L75"4%MW0DQKKLQ"+GL;Q-*EESH@[%77H>Z
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MWC89KIWJJ<B)X#MP).K;D%4IM"!/6)ZJY'*-.JO65#Q.GL<WJ@MJL\^JPL+
MI/=,,5DM*#GM-3,=F&1_=92:OMJ^V("\.K[=JZU!Y4/IA<\E[N(%#V]>/9!W
M_;M7Z_"93JA4+^:U0AU_70OJ"/0F1SB/Q^-.K;)N8Z#P?T6I1;0QSF@C;\D;
M>E]1Q8G +U!*X6+2[-[?=Y2<X((O#3^ 8J=/6*:8]&:O-BGE+EZM20_RJ,"S
M&[S:*[X67^Z#N3>/PHTIR-.)-K-UG$_$Q./1./G_3<EJ&>11U"I/%L<NHCVW
M"NT533,(RH<B;Z<XI6"D>^S5=2;)K4:[B)^P3&W)5:^M&3K:9(M$L<.[2UI:
MO.\):>E97/UN9?:8C3%,;AX6>K,!)+ CT8EH(IW:B-Z(^B0_HS+X55,%/="6
M*5)&W=L73F/^Q&_ZV]%68@O:,M^=*,G:0VDB*J/<06C+#\GA,VWY<:3LKJ*,
MH!KW6M@@CS9C@F!;V@R#/X>.'J7@RT,!GCP2I''0MKAGP >VZH&.)A+AK7/?
M'3P[!A&R.Y<TK_56\CQ:*J_(K%1G1;XB%]DA6G1G.BV-N_%[OE:55/WUD"U,
MTS-2>!.#*%,<.>9!*< %=,'T@Z29;#297#^6,)2\L@FD=F09.KM^ -".A2H-
M06?1KODRJ\I O-K<<-^NR(E6K<+'K2(TWXIY4>F&I%9A?GXQ/NO1AWF_K::]
M]=CRAV$U.-/_G<66.3=.IZ*95-J_4/#W$\K\D1PN**,ST8QC;&0W?*UMR5R.
M(5MU$94+-2\_#21!EHXHP;=)M/EH27DU)2^C-)#M+'0R&D^<RB8V%#,>D>.;
M6$%]"SXB:5FLG)*!A\L Q3<8U&/5;33_/.9I9B@7*XEPBW7&I6[#;=H//LBF
MHOZ8QWVMP_AI+MLQ(^H()K;]B_>'?ZV5Z,>YMK[5%R(LQRD#>"#:X$K)N.N;
M5='D'4J$U_54',A2\3QHO2]H\!>#%Y%/WA5E5N9$^+MF;6_7SK\"5!SP&_GU
M/[$8=2$*$O^#JK,]8.>F\&X(,H>^E69^4CBN"C]3L9@I8GAQY-TB7+AE&E,L
MYA.XH"29_(89%OT;CL99_YY_QYJM]P[776&- 1:<F-K%^K#8T?:ZL]\7,3OH
M+*#]I%KC(9P@KX*(XWY251!\!+!5!4&02=B_]:_U-?2GF2RQ!,FO?P'4#D!7
M!?8MUA% $,*SAQAI=NHZ&AC/P?,72_55)*[_ _P'*J$=C\\*:<E[T<\_*!2T
M%#G@<7Q!X-XB4A9XF3>[!HAVT".<8)H^2>M#RZ59*A90'V< \\FS:4JO\_LV
M7[VL%<OWK4HQ?].,4I5J\9Q,KOP"5^_\;DZ53 2(V>S@4F3-ERN&E$Z]"2?+
ML4O$LVV:3K0GN08_S!K73 )MLS$&<.XQ_@3(7PN(5&SV,\[SS@!ZMCGXO,G%
M,T^^O[=)KNM]88=/3A\,QT-@_K\S9@:]9*[01HY.G([3[?:L(B:7+XS&H_)S
M)3N;C.CTG@M%I<">HIX%5MWP7+[=(-_&U1;Q>*;=GM5==,:MNE!Z*3QW^VMO
M "8>!90@*F#?J<J JG&Z@K+_&9S\I[]50 L/$9DLN<CK[N@U]K-O_*_X:EGF
M!7Z_N%SQ5;VO*D:O?QQP=PVW>P3 9C%4ZW1+Q2K^'/0(;DK[=-,CY-*M7A*V
MXZR=(MD01H)L"-K<X/0_K<9UXJ*N/8A,($%94WFGD_\X!&//?EMG6KRL^37F
MGY6!-\LR^,=[=,_Z2O(?QW#:ZB]M_IYCN\#:J?P6PE!0OSWYT%L/=_S[!WL9
MZ'B*93HY2%V/=8CYJ.D%&#DXO!VGX?]V#W1GH[E$> N?/+9FI]*^#L,MS%84
M%Q5-KW7M9%AM#X?Q8;S-B^V)QE^UNJ)V_SC89KS6=A5\+CH1'12Y1:IY5.K;
M4@-2>:X2VG8O4D^_X$<XS^W=:=COF"M5]&;NIO3 V^JI%\X=FQN^.UY?*6J[
MB#=6"6+&*T*@6_4RN9[M3G#*A4MW34]F#+X8)@(!6?++M<Q?H*2CXU8Y@/=/
MS_.;WZ)/ [X4'-"7C,:S3D*PLS:/Y%I  /?\[OD!H4:85QF<V\>T&WM)UZ6J
M:%I=5;JX)I1NM2<WF>+5GU2QRO0R^QUW>/8;'X8:XM-0WR3XQV$;#&S "=:
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MZ00SQ'.G2(YY ]QB@JY X68\^N=\8N_H=<2*S-P*'.Y)JX,GEDF</+'@4!:
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M&(^5Q.,V;D=0F513U'NEE^/4&(L]M_EUB'3LO9WH3YK:-S(:/<Y..V6MK\]
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MUR6UAZEDF.;EL_8RA.7,.\!P*#K7!'OUBU>&55Z82O+^^:76R]'3)'Z!E5@
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ME#*<(7D,<UO#;T879X:+-7]RIF"GLR<)U8Z$8:KY\O[2 PF]9\D^-QO3-$S
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M"9(RA']%$3&]"3K^$6E.#4Q_O+Z+&K&J*.CC"'P7I!1FZ,Q/C?J #\B"IJ$
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M/'#N*7L39]R;$+5P1"/)L5YI_!CAL)VEP36;LGO4J*<LT@&L$ 58@S4\_C2
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MW.OGX;Z#VF@]#9*,8/0DO69@",,''?" +0*XDB8K5!JTJ63YWM5=*F5ZM"0
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M\FGN9=1MC:YS=>G4;+V"?%J_KM[>/:%<6KVYKUU?5J_NMD)8_^^:7V:6K*V
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MN_IEKUNZWQ1"/[-D-XI.9584"K^/1;47Y8IJU,K+Z.HV^9@:*J=]DED).W7
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MG^^*H[^FW=VH-R^:X(\M>&%ZGRTF4KE8 U(L:0 T<7#!0Q=$,KKM.#P[##3
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MEZ=0QXMS@*1+:O#3;!U]7#@$._HL' 30:18>C\_26J/FI>UXCP;DH$^)DK'
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M: (QBCXM#21%966'-+$M#714( 54(!.BTH86\)*JLLP'^AY^9^JJG!!9?VJ
MMT+/#QM,*ZJ-1T]70CX4$S4"$RQBO._QH5BC&R:X;%MCJJH.J P &0>DT-,'
M, 0]>["BT;DM7'O7-BBRVX;(2-L0!J':Q#NC@/0ST0CJV8QV4;HU()3"T@W!
M2Q[=[NLFSLAVIRH46G0)=(_T'M(Y6W21E-[J@M2DO]-MP=N!\\/#,:'M>@O;
MJ3.,,#WAA8JL5'JAZZ3B"Z.8S2C%"!8]@0\<BO>:2N<4?%8"B@0._/0F7"T_
M_/@6H1:P@H_:FJJ\$8J*T3P($($/UB.4A *BMFV6O6$ $AF<O<FV :0>N0B]
MJ6(J+?;HNKLF0]-(EBCKB&R*A@6I1)A4DH$KLY]Q13V(RZ93F;9JB6T()X I
M*-" 1KM8;P,T8*_6\"OU,5^U1 [1Y@J#=EF3*XAG](JTJ$AP3$4%RB_I)8F3
MRM,^_C'?0)1#2\.G]]M+Y54B.R>9EV(E\Y.74?WI[?6AV"O]3<K??E7JEY>U
MN\OJU5U#+%\=@XQ^1V7UZE6E5FWL)?6-+KZF(:W2#4K*)&,8(?,&957@+DV"
M1$<2J?C.>(LJO9LVT$1%&^@JLJ2!9"@ZY0Y4)K&0L0'Y4^@@+0N9B8]T@?#=
M05D](0!#U8")FL E7KD10]& ^X/IUR5P"NS*$?7D 8%5<_+(9&_8A2'J(#<X
MB\#5TW4!0T(22F$#P[-_D<P"\Y2,GN"71((2CL(L+"W;@!51CN%;)_Q.!9NN
M;TM?B0[OS.(IC?H_Y5>]#T(.L.,+(IE0OTG9TYF-+#XJ!N&=Q?GXS9==E.Q4
M."Q4]5#^;T/1'7JECZF4+=$9[OZ(+?K!I#(UV@Y$W3EF]J8I+CV!+S!2[$[H
M-\00RHV*6,Q"$KWRRT.[PW TU2Z=WDZCWK=?=4UHD+[%M-9TT2ER +P#W8)T
M&M)N4PJN# @Z_H GU:F^ L^[-1'\3!"#5-#( S1?Q&,6RQV#,,T#1[W5/\ 3
MV1?O=%5]IWJA<'%X?2A^AW% <$HG_[V@2Z ()..?J7]_("?%L9!!4OV_3]E5
MOV_H'U1]MT [F11#7#:(5&_#H)BL9?YM6]PN5$H77T;53.?Z,E-5'TROY#B\
M@AR8OC3-/N$-'V.'2)8.TL6%$I5@J=AU.9F*-?V8?VU0BMN@?=$5<[H @0Y$
MI,(T6EHH T_E4JDDIQ7BM62\(>@;5#@A8CZ93'ADA'S0)PJY=+:(Y@AB#%"S
MC/+&09E:L4LD&=: @H3_& .8BKA,]ZD;R/U_BD@55 52CT-XPG?FG/YA5-$#
M]W OJ!Q"B,O1<*ACJM,8"@;+^ [ZQ3ORCS_*WSO[O7JD>9:I>I!:)NBAN*/,
M&#H$Y^P_\2">3%DI4GQV903ORC#*#T85KLM2P?( JT2(WR<9[(+3A*K0WSKU
MA?%'%I=%;X9L7?KOQ5'E^=Q2+@9E676!Q$YJ:C35!-1WHJ10^0^#:-Y5?_N5
M*<9$/_W@Y@4D&0R*^ 6E%1!D):+4'&7V]+=^XI%8T+OKEO[[TN^GY6B,.DT6
MK_2SD_KEN]>2YLB99QH%"4T39U4.H]=,!"4=MF?F$H5"X3"?B2,H:,/Z7R9U
MF$N*]#A<^J+K5H)I!QRPF8-4,2$PNZ"BM0PF8W CD<'9Q?]2X4'P;TFC"V:F
M2ZE-T8FNT5)4?!.<L=S&I;K8%A?BMA"Y@7,1;J,(3<VSA:'Z0P?'0X2'@YQ.
M,1WS%C/H$J771 41U\WY%\IJH#!13G5 %R(QDR9LCQ);],4(!.U=HB5]$(:K
MX)(Q3<2'!$7<D63(W,CH6  5C5MX\7N>WRL!QX(+8A$-?VOIIN7Y99JVHK*2
M*L'S"6-_SJLG<TT,B#JE-Z_>OC;TOFZ@C= B["J,YS6$K\1M^[I3+^?O+(]^
M>&/"Y'W_J!-O"M9<F;B@I5Z:J7F'V?B\0V$AG SL1XQ$SON^SGQGS"D P.'W
M),0_@Y@JP=>(I.A7'#(WG6*8E@@^!@%OL\O1772G&*I3=&&"H!,Q-J0P0M,W
M^ >8NV*,?A86H9]>5"\49JFW?9&Q+.K704K<JKM3-^+>RCZ>7E>SZ<S;FJ@O
M7]!+U'H6I<RI?**431T62G&D^0N93.;HNY+?]UU9<M^5PK[ORK[ORG_(U#&C
ME<V&T-,1#Y1!B19H.F5S%#,-_1U=FL"=5U0'BP-X)I.:H@G_?WOOWMPVCJP/
M_\]/@9/9/65/R8XE^99D3JH<7S+..HXW=F9F]ZVWIB 2LIA0I$)2=IQ/_^MN
M +R)DF6;DDD;<\[.6!()-!J-QH/N1K>.I-6QLR,,O(%].TG\(M'S2.UNZ,A%
MYW,LO0T>A7W0< C*<@<H3Z)S46CSQOUQ),BC '"53"Y.ED%6@4$EN'*C'%<>
MIXV\TVU,NS9;@)=_OGL5?=QL>T%O, 5>3I_"N6'F-/J6B39W9]YOUA-2+@,$
M]<E: !\PZ"(Y11C#Z^-6@<J:]FF&UH+^&LZ0"LDK,TWL3C7P?,86/O6_1'A/
M3,3Y%+$_[;_._O6? [OG?>YG4H!DI$)' MX&E6=V6DT45@$2[VRV.IO3C9]D
M#\X;[G)QBV5<W)C*Q1.]. K\&]U\<C?<[</OMC?-7)@NK+OQ,.ER(=S;W6IM
M;DR/&IP:N%8<' :*^1BX.D^8(5[SF&#ZX52F[P=17!ZF.1Y^&6UM?>;_#=RI
M;%>4W8WIV&75H9LE1[FI><7R6RMI +0*(#MG,HZ6V3&\Y8:X)^U3J&YYY0_8
M'@_^.OL9'&T%&:\&OD^Q!K(!)H-];XUY+>]WL1R<GF[9]4N& !R40:5HC"M1
MIYGPLUG"^^#4NK/CJ<I< (D&^,ACLK',S)"[<XOKXY;6_OYYM=7V1W]L[8B.
MW9S(JGP<U;NMOW^>?_KZX]MXN&5_G2>?[<>]BR^?CR_^P^#OD\.]\T-V<KSW
M[OCD^"(;:+405-_D>H5S&UA*JGAI^<,=1MHG3S+[,H^GEVK7W=ZSNI<6D\U7
MW8PZW/UZMOEU>W/GT^_=!Q8 VQO">2R^.[$+SDNA"9 9CN6I5\W];C$+BS2"
M '.ZRZR>LCFOZM(&V8.Q.(7F+ZZ%=R4^DM,I@\I&HXW11K*U814R]LF?*+?3
M+J;%F5EN9RX]/8.\BBXBR*/@Q):X_:JUU2Y#<X^0*&5*,J(R*2R5O,U*$J6D
MPK5[#^%"F;FX#F;+%#QP]W+R=Y4C1<EBQ6>GW=IIE]UB>?S<A7<6GZV*Q><^
MNNG8_PR[+#Q!LS<(A;A%DO"1Q<O2)%D+UDH[K:W=,I?5/<4JV;]S2<'F'?W?
M[L7QW\/XY-/)"9Q^KH___OF]_]?V._']\JJ7,G])>NXB0--CW@Z[J 11E<K0
M(HP1G8W=UF[G]IIO]Q"45_,*RA<?;[@B?A/.X0^\.R;1G+Z\^//T['P[YJ]L
M,BH_DH*;6AD5A_::P3E\+.WO,B_, V#SO7#P+(&\6TM*9%<>(+/3)G0A MQM
M;<X!OZ84.IYDX>H,B=Z:ST;Y\]H_%(._+F\N/VXN5KD51]614G56[G3*F&!O
M8T_G?N))K]$=24_,+M][OU;F4J>U,.7.P=YJ*Q)N__W3/1I^_2G^XL>'N_>O
MQ3-_.6SEM*_.GJ1#JR0+EG*54B8-N. _;K\XF<UI,.NUOW]N_7GI?N%Q\ EK
M]S7%F*>N2;8WULHN2%X'V_^-/P7_]O8Z+]X>G^Y_^GC(+O;^,O<A'_^R2&*Q
MPVL?G8WVC@PTI-QRPN<RDP!\ =+*]L<JK<B'H!>Q/3O.A>K"9QW7J#,+9+(!
M>#=HU?<OH3EJ.X;V/'Y-7A,+F_*":[IF4G8E@=[ F-IQ'(0WK"] ZP,(=VD=
M45/R?G]8DG@^>PH\U#=?DA7XF2)-\6(]:'F*X-R+CV3SY[J_W,,300SMG7:G
MTT$OC?YKGMS=!R?CWS^U-W[L9M)HG-\VP!:&6:LPAMNVL0J&6N8+:N^@7NQT
MTK\6E:B[>[<J( <UF>9\_G_GQQ\?_CSXSW^WN'@2T[R <B^3<0#)-*<7U3YP
M?XP7MLFKT-XE_>()!AT$Z#<,,$>FQ:%7,005@B'1<2@'3UP-*/_2%5[1IH"H
MO@A1U6"<(V@HQ?\G%(C;'.*U]J>9Q.LF=+.-^=# 4 J;GD!U%5XG<=%S)U0"
MH=R5>Q4DA0VGEUC*-A8M"A9V0E[EK,^Y[ U,7)4)3L$45KWBO<6969<.5)>P
M^L@%'[T/*;-5+CBE/7IW^<=?F[_W-M,X./TB2VB]33F4=[608_1M^90(-NBY
M*&7LE2[WBM=H@FN\[F+=SMF]69Q-*\CJ%@ML_A$>_>?SS<__[+_OS6 SB&\)
M<7=F_B0UCS,3,F\$2B^L)C_0:V:*O*=IW(Q^? 3B_Q26#",B<=09JC"9<S&5
M'R;?"QVZ)4;W>_!J_L[FAKQ^1@F65)Z0['O7 R'S6'T=.RJ3E$3ID<P[I7*,
M!'T*LA'I,@ -BSK:]:64DOCC-<!TETU2B:VS=T(F!U-J&9,$>N*'BB.(DI1.
M2%PAY0D^CL(ZE'?)HD!F%+,P<TF:_X1K0[Q,:^)2'A9@*,=L:XX+*((NAM+Q
M  >KLIFD8;8ZJ!8X#0>6GVKQ]X0O^FZ<99C.\*4;M45DZ919:3I$'F6VG2#$
MY:KWH" +]E2<FTZ?"+N*&U R17EZ*C(8<WRE3-W+Q?E9W7;VJC_\U<;,:I1_
M$B<FB46CN&_-Y()0N7XA(UJ:MFNYBS]GQ%EP7P@;4J#YY;R(RH%O([S<)RR-
MS^4%S"3[(O$:;X 6]Z;VK4<2F3-K#+I861UA%FXO+O6S\_W'9^]5_^SRWVE]
MV!F$)P>+Z.$GBS***XT9?,!Q 2=C5J3E0^:@G<Q!6X5?[VX=G?OG)^V?HK9S
MT$[FH+VD.6BA5AY)FCV\CM"LW;;14*%X :'DI&+S$,T.,G\F[1^WP.N#4I<5
M-+6/+>F&"JAZT!E<MW_G5]?_$;E,O#.)F=\M4^S]D<XS)<&.$GZH!)>PN;N8
M*/GWX%I<B;"E;J)QG:59@;$ ,P.H1'. -(8N HC1.(S&F$(5\,*YD.SH[G8T
M3J'JJIC8\[/,9 J@W0%,,I;I4W&OEPE356^XKW<V-G9(06(V4KH;&ENR>K@;
M85< 9)X2OJ\\B[T]$,[8$Y_Z$\>Z/=_)!,'.C//..H#OV>+?/\]YN_/E]U?^
M'__>;(Q[:#+MF3-QRD;4' V":S^MVH#G9%CQKQ<CF(L,9G_W]\_NQ>;PR];W
MZ&.P/4\T^\'AT>'GSX<'Z!>#L]OYX<5R0MA-9/RT2(D9L1XZ;+P\8.9^#=P2
M][Z5P?]'PXO=O\1^[S_NX(%Q[^EBROGO)[WW+]Y2N..A3 *=W?EHJEG%_]R!
M+GG+8'2?D)U'F,:#S!'B\+_[I_[8/N;'GIE&9$N%TWAK2.%T,_R0'USLG?[\
M]]'YWS^=+YU__W%Z\W7C3V\AH8-*76V77^9(3-'H?"<JEUWK]WXW+>KA=[CG
M!8HGQ-R[G?I+[FFW=DIS5#[\:DIY4.1<#AP9U#N,TD7Z>_3EOT?QUXWK']O5
MQ4M.#B4AAB74+#CN^Y8@VAIZF&Z+^EYM)L>6LY#N%DV\/6OAG&*Z"+HTD2Z3
MC9.N=WIZ9'\X7\Q>-DD^&GVF[V%W$X&)V-\RQ9D]S&!.TC7WQ]K =1P!SP#7
M.NZ/7NAU $:_H!1\[4ZN#N,=1/ 1:>\\C/:[A05W__XY\ ;>NY__.G0_]!IC
M;WA8;KH=DYNNXMQTNR8WG<E-5X5!:1G52J5U_/ *N3LMFK];*$Y:^L[?/[_V
M#[Z\>O5^N)4QU-1==R:A_.VI)8]V_O[YK_'EZ>;GT#\8=E^\/?_R[OSPWU\.
M3R_8X1]8^,B$]3]V6+\.F.V29PK^?2V*A1Q @^A L$(UAX/@:W#">Q%[CS6Y
M6^S8M]?9B@KSUS^FL?Z4A3C DLM)':0H1E_WI6M;LFB]K!PG RNQ^(!KRV"8
M;$[CK-.+' 144#RR@Q$IO.L@_*8R_M!K:?I\(=,ARRS)*G6Y#/<4//1<$5)1
MU%5*S^T(S\7,\Z D(]83DBY;P'=4NWP:/51%,4L))53OK6+Y0Y5=D8I?2A<<
M[E5 1)$X#&<4+I5HDK6D=(76/G<]C&G%LG_X7RJJI!KI;C"'WT1,9E2_#MT8
MU#XZ&+$@!.5:#_J4XQR47^0Z*AY %I3!CHE=Z03!&U8R 92JNLC *6FF^4TJ
M%A-NXNQ99)]' ^T0[FZT057^[0@7[_!><N_0C]WX)I_]63>K8N;3K-%[Z-Y%
M9"&?S]0M!?%R,=+J'#V8.M;^2_\;#P].SS]W4[<S$G.;086>*3OU=6GOZ.JL
MT 4ZU>M_EU)S[Y/BQD9K8V-FFBP;R)71M%$TQG17>E9FI<0CTH[IA0-:0F<4
M:W:.F>OAL'A-/T79.5OV[(E!__3 N[('>SOI30DB3PWTMFF<;XBE<3)JHI<R
MY?E:,)*Z%V^W9D][)!D!"B5,NE8U I07G_1V"!J7-"]RA\Z5\KJ6+#M[!:^R
ML<XW+X,P=2PGJD92L",1XC"@^50YY!2?C+-/] 6QD[M^9$F6R:IZ?A]T#54\
MU?5F851K>#BR <A2IZ20(@Q=4B5MY1#Q#IB\>$P%;F:6AI;,DU-^!DP1,./T
M'54$@O5T)I]8OBJR=\Y>>7_MMC?_[.2%&8;MWAXZ/G5@CZ2F\C*;,O;%VXWU
MSF0F6YU+F6J$#&2)D! +WE#FC++LG8>WJRHZD=="4[D;%WM?HDTA1J\JU53Y
M$3ZZHIJT^^[.TE'KV7S7C4;/C28^ _VW[P/]WXEX$(0M=A([*>277Y8"_@3H
M8UE2-\);C1I>6@5\?P?LCOHBJ26MDYQ3<=-K+&>J8/U31MX*W$G.SRR$=T=H
MMYTHS.W;%*;L'"3AH1KS:-]K[XR_'8V"RT?"=MOI7UIE%D>W.'#7N3^Z8[/1
M70&,61J,L>6 L<.'@+'EB=]H])^/V[VA\UY\718:6Z*4W0K'M)C-#\?>W1N.
M/89V^8,/HN]_>2?;L5.N7:0(+QJ5+4G%3&: G*E<GE)0=V.(+P-AN8JZ$7II
MW&@@=$%WB9QZ =8%S.54T3^]PY^2TKETIQ-O;EP)1UWP#$;RYCRF3D>\@JU8
MI:VP??E(MA#O);042L- _N%U=E8P@Y8WUBK[#;2-YUD]:6S 0O14!)(G-_L1
MIET';*6SRH:T!K#(O4<ZZ7H0#.7[>"\"QAI@:CQ'7V'0)>A#,0RNL!*,--W*
M;O%:I!O"$T%(2:F!Y58,,U9:"E+XZ#PB#(E7EQ#*90M-E(S*+>-3G@\P6-I\
M^V/?SM3TLXHMD0T<JWO+R[EE]&-B_#ABE\*G>V4X3Y&N\E&>T>!*>,%HJ"JA
MXAW2WCAR?430Z)X"E!M9Q,4$N8\\[F,.!:,K'H'X8Q]1FZ\N^1#0(['4*D)/
MY*3(M::*?+):#L)U]BYT@=3/8P>H29TX\(/\2FL!DHF/\/4''H8BCJ'A('T>
M?\ OTC-@#XYCR4)%4.'"D6:$%1CP*(,(4U*F%G:".Q,=.!QYP8V@2]YYQ6(I
MQ9/2R.B*=5*T&I::&^+7I6PQ4EP/*<Z+&.DF)9CRIG[9;C*K\+ROG\V8++);
M9=J?56;>2"77(64_F5LHM9?DR4>[!-!1\ ZFKC$"F5EIG96!["&G=4HP=8$
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M),^U=V_S&ECW3N)6J=? 6F .MV*RC.Z$^R +J+2?)BO^7&>VBJ:)?LF=^"F
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MIB;?F^Z"]I*,<$CNRE%3E78WLKT@HH(0&"WJAFF:JPR:P"8/?P!@\B]IG$.
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MK?5$/PBA[1'-FN(S#*Q!3,XQ- &YO_">_3>@U1<YH:>_7S,WAL;L%V\O:'0
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MT<$PNR:@] E81:LJ!67PZ1WQZ>Y61]E*-Y=\M[4,5[;86>"Y]@T\':I0 #L
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MYE9H@,^!<X/_'<1#[^W_ U!+ P04    "  PBI)7$,\;U*L2  "1$P  #P
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MO\)#Z&6(2SUNNOO]J6 !5/!BK8/[>_3S2@^1J!>*^UDK%,##@HC#LYTAXRB
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M?!?+Q50E MM8]6<PH2%'0B5A%D[@%+*HYR)KY?+GO2J[)P3=L5E=71EIR8W
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M[;+]B(([@57?[+P=5ZT:D]E./1E),8$AK_M\K\Y#WL6:M*@KA\;#M"S679P
M :#D;4GZ>%+[7,33M_>/BZMH7Z]X^V@)8X-F]5Q&,K'K(CK/7'M;3E1>P[EV
M=-F?!;M5IET*S%B$YLQ8P;GNQD"LM.G^0[#%(J)0&VD75V_OH-'/ V1KWQ-?
MEF/Z1W(:R"4!<:>)*UN5LG>^V9'%'_B9L-NEX=;=)^X0__3TW_R67K!?!_?;
M3&SHXH#:G!1TN/Z\SW9<(U?8G&L3$R:T@)3[S-%:TWS,&"[A)5/<[Q,LAJ2S
M#3R=HJ_ <UJUIQ2^B_D=W7R9]1N,9@PA '?6J&<Q^ZI/;D7;*/:-. PM9#$9
MW9?K>R4IGO["3 *"* Q>IHY'H/\!,&7V'U!+ P04    "  PBI)7<(H</-I?
M  !B9P  #P   &9O<FUS+3%?,# R+FIP9YRZ!514;?<W/#2*@$BW$M(@)<T0
MTB""= I(2W<.H(#D"-("(]V@TBTM @X-TMW=.?,=C.>^G_=]_^_ZOF]89RW.
MN7+O_=O[M_=U#G(<.0>ZJRBK( M"04$!O0#^0,A)D#0(&Q,3"Q,#&PL+Z]8M
M[-MWB'#OX.#<(;]'B$]$34%+0TU!176?@9/I/AT[/145LP +^R-N/CX^6B8A
M,4$>44Y>/IZ;25"P;]VZ@W.'#!>7C.<!U0.>_\\_Y%<0 3;*750)-!0Z$"H!
M"AH!"K(=1 L"H6"@_/J!_OQ04-'0,3"QL&_=Q@$Z5-X%H:*@H:&BHV%@H*,#
MK7Y .PB= ./> VY)3$(U$RPZ)R*>P)@,;'JISRW$Z@-[#+RFSD&W;I.0DI%3
M,#YD8F9AY>-_+" H)"S]1$963EY!\;F&II:VCJZ>V4MS"TLK:QL75S=W#T\O
M[]=O@D-"WX:%Q[Z/BT](3$I.R<S*SLG-RR\H_%)>45E575-;U]K6WM'9]:W[
M^^#0\,CHV/C/B?F%Q:7EE=6U]8W]@\.CXY/3L_.+&[E00&@H?W__1[D( +E0
MT='1T+%NY$)!];CI0(".\8 ;\YZD&I:)$R$=3R VD51,QN>66_2\ZGO$ILX#
MMTD8^.89]V]$^R79_SO!@OY_2?8?P?Z1:P)T!PT%,!X: 0@,.HWM$K,6$"AA
MV50P&#,/.:%>FYFIT(9M4, BZ)KJ])4\K+0VYDWMDAF?V&B84?.FTJS$KOC)
M>J-X=+K(GAR7"=8,-\C=$UD?,C:8J"]I4%?%I%*@\UMX#(VG;#2J&!:5=)K7
MW7U(2C!#F6_RY&"O13/^Y0ONV16^K<OPM>U3< G&E$>I..UV$A^UO9.'#_\P
MJ>J)6QRJLI5D:U3##CEQ!%[)PD]U!R'.S"=LO#6O8^X48]_F[J%;4E]^OR&2
M-?BZ=FTVAS(;<>Q5D8A@(1U=N<6EURI$5EQ"0[YP2,0FO'T>C>/4136 5[;@
MDI=<.K%M3Y_FY$#%0)ZQ2JEOW699ZL=RT+10)\:@\-![J!I<0G?O6[$D>H"C
M=[B!^H@;36!CHS4.-X+5G7E2]5F__<EQEH_W8(Q"^(=O?/C<]13/MC<5PK'T
MM/VZ7C*['^?,^%FSY'YX+_6%>H7"<'M3.8>(A;LBU$&\@L1A5UWMZ986;M^F
M[,IQ9CCG5\.^S:?H,:/)2BH*81DX B4/3X[SW+)HAAMW%OM1P#-\]="2ARQ.
MFOD5A$['64['.2U9=A0A@347 PG'6=9Y&!WJ*Z;]]HNRBYNJN?$9>5/H4WZ
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M %R5U X^1=2^.6.Z8\E6.'=Q#HQ]CR :!!#U D@J88A&09,LVHI6G3"EK2P
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M M\(A]1W?4<2Y@7RZJLC?)/T;9YFVR?SU"^1HY9&<Z^;UR5++9T87!UFCF=
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M?,I^XFMXA0@XW\!5_TZ$ZK3ZC(%/KSH_I@:MQ"<H>=N0U'\1U@?ZHWV2H4O
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MX(\0"LXN)XO\"R?7Z#=KWHEVT$P'2'I$A'\7A\2S6RUNQ0AB6[YR"-G<<=]
MM)0:[3FHS;SSU53,L3(L6GQ?YNWNFB[N&1.6KRU61F%3O-P^:RUC:P4TD-C[
M6ON>L#4+.19 &(PW?L,7*P?UDYG.C7\A6,(V[6 ":.99]N$MC=..Y*+Z#,-[
MS^=/O#1\?U)W@]\Z(X<VT1(>Y;]DK2\Y;IJB2E(AQ84;,.+$_P%02P,$%
M  @ ,(J25\G0P'R7#P  $!$   \   !F;W)M<RTQ7S P,RYJ<&>E5GE44]>Z
M/Q P@&(,R#P$! 6+0F4H53$1J4R*P1FA$!4+8AZB(A(UYL@\I! 5+14N1(L(
M"C2E3%8C,21"*5<F%311DI.T,D9.'.+1)"?W^-Y;]_WSWEIWO;O/VGNML_:W
MOV__ON'W;<,S@QQ8$AT>%0X8&1D!^[$/,$B!L,]__];XK.3?U6%D>  0S8
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M%9I[!.R ;0Z>&+&P]0R$EJL_0_M/9/\:L-S_%[)_ OL?7!)@$<X("QZ."%
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MO]$O#X168@35HCXTT].GXL(\"A2)#*'6-<^$(]U8!UHFHO7IVEQ]'\Q>V@R
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M>)%<NKHV99HXX%(F&=D,+-W^KT_0\/P?4$L#!!0    ( #"*DE?C@_XEOS8
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M54>_$(\SJ/8$'%<UDN0YWKZB$O@;I>V"K8^U^\PF:_CAQWW .8T2C'=$G."
MH545?HFO?5@QZ)V1#S7JQPV^'^$T84KAU4VX+VT,-YJJV).#W)A=8&^H:9RX
M&K^=3B6H69CBCKI;%6+S9>J%7'_C?4T'PQ#)T4:&9\?% VX\,3']Y0._:VZF
MG!L9.MV=[0QT]9-;*W!K5W",#>"I"DS3RP@(T/]87=/XXKU:-"!Y0Q09Y95#
M2?C3RQ4_MU\X)G<I]8[6T\';-NMO7N-R(#I5('<%7/))@-DOD_*KYL+T.E_Z
M4<EPSKOQ\B$REP<QXN$4Z"-5Q]4-GCZ&;JBU!;+SY/ZVSX.%I<J=/^Y7M478
MFN +2_>,S4T1Z),G4?>^W_AO(2+SB%;CE7.0_+CL=K)CDDYP(&JG_IY]0N"C
MB_SY2<T)N$&IB.^["B]'M8Y H3-0"SCD;*QQN"CT%TSQ'/45:B,X6IOV!G5U
MA\J^#^OF(/@>OP.POX3&3H#$X"*1Z:YUJF^;@0\M/VNM[,;_SAVZTV0Y?7H-
M4%)K[\BZ!W.-8<!"9*\!76C"XVO DX+X[/*I*(.M25<D9KU+Z7Z9;4#AS<N-
MIXFLI[_E#.JL1VV&3D QA0B>,;C/<JP6< ;"*"5[(DS+.CFUDU/P*V>J1<^\
M58<GZ&UV?A$4%ZA2#)HQ,JW0><#S#C91]T<JGK\:%F]1W3S*\8W:E<6+[!J
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MD8":AO,4%3:3O>[%)M&7J!29HEM':XZERUD..KB13\S;UF,%DVS"P(V=:9J
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M5#=T-XG;-N)A!V=!7O;<&JX@ TPPDJ.2]B2)D-0NAW\QMB-T*)MU_Y:I\<&
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M/ 7110(IH'QOYP7'O,!OZ6?HY6M .$B&$.+'VQ"I(E4&9=;V#H,Z[J2?PEV
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MP4DUB'51SQP-96R][^[[[]='>*[4:/(8(-HN;'7'U^Q\ ._?HP'GF*X>]M*
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M,EA9#G/F&W"_5ZK*(__E4]KX/P!02P,$%     @ ,(J25Y<UF;6$'P  PB
M  \   !F;W)M<RTQ7S P-BYJ<&>=>0E0$UL;9:/R$! C.X*0IZBHJ/A$P 43
MWT-$X$D4E" (D8>"@(CL($G:C5W( P04A"C*OD2$@*R1'50($""L F&3G;!D
M3V?B7[/43$U-S<SMOE6I[MLW]_3WW?.=4RT:$(T#NRPNF5\")"0D@-OB Q -
M R; UBU;?IWBMDU\2FZ7E-RV35)&2NJW[3MD=NR0E9&5E=NIL$MNI_Q.6=E=
M*KOD%964E95WP%355)34%)24E7Y-(K%5_,PV26E)26DE.5DYI?_G)OH"R&\'
M["1>;978!VR1E]@J+R%J N  ("$I\9\&_-<FL46\QM^DMDO+R(H'D'<!6R2V
M;MVR;>NO58OOXL3W@6WRD@I[__CS-\5KSE+[?)1./HE_MUW[KY)Z9>ONU?WZ
M__@^E991457;K7[@H,ZAPT=.&1@:G3YSUN2BZ26SR^86-M=OV*+M;MJ[W+GK
MZG;/W<///R P*#CDT;/G8>$1D5'1"8DODY)37KU.S7S_(2L[)S<O_U-I&;F\
MXG-E54-C4W-+:UO[UQY:;U\_?6!P:((Q.34],_MS;IZYMKZQR6)SN+Q?N"2
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MRY".\(E FT%0].!U=%87#G> OFR]/2</-NO]-+0E-8P-D!J),MC0[. "*WI
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M^WO_N)YG-MA/--[Y]R4I>7L2N=&:90.YU*_4F!;@!S J7H7W;_J3=@ZT)E3
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MQ"(J_!FS?P%=WN-U_*@;K?Q<JU^9_GNQA#'C8SJF\-2ZP^#E3+' 8_;")47
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M&I1PRO#*L"B;W#2_%URI(V<B)XWS52>> 1ME.7 (#! SIC=&Z,$M965R-$6
M#!)-.]CCQ%AI'(H.<3]/6PE^0*FD",M(/9=:?6X9-9/"U%$M>K\Y!?O9H1W<
MHZLL=W,GXJVNT7Y\/A'2LB_VWM="(8WV_30H[0 [?2VB#F\S_&OOK\FFA61(
M3Z1UAJ.6S^.)$!6IXE5W0G":MOGACNH<%(N#L0]:9=;<!<?3$;).==KTTKD9
M';%6=(I?1;+NTO!;/5*S9@A%'BE=\_(MB?9.EU^DT9:1J%JG#)]7MTMES!LG
MHQBK$/K5W=,Q5HBI*.0]TI#*V#@B[4/%0(IM+>55IKW8$_H6I#Q:%VI ,M+C
M,7TB(*KX=?Y<$=3D>1*Z3<_#WA*FU6@P\R$QQ3;9TLVNE4>T/YT?FI[TO\)G
M"G_4]4T^RA$H$AMHI1HP)4^5[>"3ABN"!6J].*6_$H[KI+UAE71W:D?.-&"E
MQ)0LU[=:(':02W(FPK&2VF"]I;U\.S$]YT0DFJRR4AY.=MXD7JTE? L.#+JX
M6=P(:9;FP+@9I%;AYU;(@/P!K#\CV.OAEQ=,L.NE02'O+H-)CY0.)#KG++D<
MUK+:%X>+)904;%\CRF>7S!@_S.&QN0JG(?XO7_2.4D)IQ&&^4& /B@URG7K8
MZ$K^-7+B2D/:EM^+Z1.SBZ-B(S6!C4+$3G#P0\0UON_?-#')>#N]?49[<HM;
M'K Y$*IF-FK4]MGCIA>FL(]88_XI&C.967>%B+4AVI61O4K_WHM<ZF6.FCQ,
MRTP2,TY ;H9DZOFXF'U@A5W%#VG:@^%'VD/F0CYZ\/IOFQIA/J7!EO:?1,"_
M^%I#ZC+JNELO]FZ6S[%/CCGLR2N;%QY):H2%? <55L3J:G+!"D.]ZUC!R7$=
M6_ ZB&+#<:C?-:>5VQJ9.F:)*]QN$5"7Y&,<D-DN O06X/R%"YIRRO'PF%-1
MB"4!,MTJXW?:'7Y%%YRC]E9.YD@*JX,@$(K#@XM&EM\'9Y=A_,6KDD.ZY\E"
M0V0M;KN8#_K<C9W?-[)7&&_E\N_ZV6#_ZA;374HRR)M)LO".5K\G F[(-1'#
M]CP.?#G:\%D:.@)2=6%\SF8ZLBG6=G(J6DW,<H^]W_\+NSIVC1JP0[H*;=?*
M#YB1'PTNM>,3/6*1(P-)OO2)EBSL,%F605P]MG)=ZEHN9\&,AA<RQ*PT8B&V
MH,\7K/L=7&.RC(D;/6"E?6I0X]+!UME@/%V'/5L<?MI:C;7OJ#O4?'E/(5ZA
MEQP^5C1OQ117J2)26U+WW)!I<0HLQ5/F G'QQOPAB9>\__F[V;:LS&C@D+CK
M)M!K/(6Q!0<SRO5\M)>&PS>+RVM*6U2E/2=C;F;QHZ:JNZ30PMJB5K; 6 2P
M.OTS6UL#_9QP<6N[_8=)W-GS"!3<7;HU_2A!V!NV?JNEQ#-HLL@)7CK8(9EY
MD(KP'[R@^:,R+Q9N65DS.!-R.#T)W8CX76M?:4@R7-ME<;"J(+@!6<I!<)'5
M.[]V<L2V]O<0,5$S<G?VY&-N"<-;0M/3!"_=AA=L/<\YBG/EF%AJ^S[Z]U P
MNEF:<6_V;L6)[>6;Q=$U_ D4+]U$N%$,10$)E^.S65XQMZ;IA*._5_(-\BU!
MI&#]B:X.(S#O6"V9G(EH2IO!$9L=?BCT%&W4J@POSE>/&E43&&]E7)K41\9.
M_MP9)0*N'"PX&TC.O^6T7_61[K#8G2;7L[.\NR_ _O--4MRSKYD"?QJ\-/)9
M2MZ?*-PHK"9)_F2;Z+DH((7ZW$.9CT_.<IRSVZ%\ST@$X68/]J@(R+ 7S_LD
M2\FF6CG>'A6NVKC\PZ$=$@1<JU/WB*$MKH%?<C,+7K^(@93K2H1BP[=,%),N
MW0Z:I@C9IDJ/?04&?1H0CB9D=:#@C;(B@%%))@C;?F;FS]@>;UTEBX#IXDQP
M7!K]EN-\F[CPX(%8]C[I-MT[J!Y8)]F]Q.4;O1I;ZB\J3W3WA+*'#D%1ILJ_
MA>6+5PHW5;HJ\7_J3FZ,R/V)K?W%N</R$\)II:M2[_=+"YMS%L4)U,3,-*Y3
MZU5&0%^GC7<S=+VDKB1HE'U>UQ*':_^I:V@%JPA(<4F/GX)ASQ0YSE^=K]M=
M4_DL*'F5,F9Q**_$3'E<\Q_-+1I$LHD//+W4M<VS (2[AX;PT4)N9G2U@FGN
MP% P^_*8"D==U8NPSZMP5,^NWU@'-FAPS-"S^@X_L7Z]V_2R^C>FE!ET)HL@
MC(A1]FAM43F;Q'"X4+&3*L"CVKG=IH!WMZGR ;AH\+\ 4$L#!!0    ( #"*
MDE=)-)&SU@T  -B/   1    ;6=R>"TR,#(S,#DS,"YX<V3M75MWXC@2?M]S
M]C]X>=G9!T(NTY=DDIECP*0] ]B+G4[WO.P1M@!-&XN6; +]ZU?R!? 5F20]
MGEW/0P]():E*GZI*51+*[2^;I2.M(:$(NW>MB[/SE@1="]O(G=^U'HRV;/14
MM27]\O/?_R:Q_V[_T6Y+ P0=^T;J8ZNMNC/\DS0&2W@CW4,7$N!A\I/T$3@^
M+\$#Y$ B]?!RY4 /LHIPI!OIS=GEN26UVP+]?H2NC<G#1-WUN_"\%;WI=)Z>
MGLY<O 9/F'RA9Q9>BG5H>,#SZ:ZW\\UY])]8\Q&BUJ[Q]=O1BK[;3-"G.73?
M^WW@/M%'X/>V4_WZVYO?W_\&ORS6C]TW4^O+UW?;SX[?_>K^VAM\>WKOW^/'
M\WXXY"VU%G )) :&2^]:7+Y(O*>K,TSFG<OS\XO.I]'0".A:(>'-QD'NESSR
MB^OKZTY0&Y-F*#=3XL1=7W5X]110N.N9U:(2>N12#[A6@M[V=@T.B=]TPLH$
M*<HE?1N2HIC4ABDZ"JVS.5YW6 6CO[R*"7W:G@.PVA'/ )T&G485"6)*O"PA
M*TP3M;WM"M)<TK JT<#V2*I!8M98=8=7\S:7[?.K]M5%W')T/_FT:[0$[AR3
M#5_,0??GUU=<)1VXA*XWP&39AS/@.TR"KSYPT Q!NR5Y@,RAQU<G70$+EG<6
MKW#@NI@I M/&J(27K5:(K?1= 2OB*^.&8 >:C'N)?V":F#L"K^OT,#,F+0G9
M=ZWPXT%?<6\VG"$7!2-'BG<AM;F:^5Q(]C%H>=M)$V=[\BFT-??GX/.*0,J:
M!Q(-64'4/B(I;VL!Q_*=DYKN^2MK&97'\_B,">X"ARN>L8#0H^%$)XN$)OR2
MS3(W@S":\:@+*>RCF?KC4Z\#PD1>0 \Q"7)P2-8+@7)5"HKT0Z++?S4@Y8*T
MFT"JS;05WY"PH2-%*:@3 N?'%#C[OB0\D_:]-;!4@"5'B40(A0![(PA8HU?5
M -1FO06KA%1U#0];7Q;8L=FN7OGJ(V^;PK"<5@C&MT4P<A2CWB7D2H?]_U,*
M1VB@/*J+/4 7 P<_Y5C(?9404.]*]8UW)@6]-:#D@J*1.7#1MX!7V;7[D%H$
MK?@W;=;U*7(AC3 2HA2"[#W?=K-HUL'4)Y!]T2;W\EC]7395;2S)X[[45XS>
M1-6#[]I ,C\H4O?!4,>*830XYBN7OUP"LM5F!IJ[+#ZS@.O)EH5]UT/N7,<.
MLA",M4V,5@C+ZS26QL-H)$\^<]@,]7ZL#M2>/#8EN=?3'L:F.KZ7=&VH]E2E
M03(?29W %4"VLEE!ET(:J-H*4Q2'727U(HA=G*<1TR>*+JM]2?FD*V-#,2(-
MU#5#-1N0\D%2W363$I-HY['_*@3!11H"=?Q1&9O:Y',SW04Z@=G&V=NRQ<ZW
M6"ONWV-MR*D1 N$RJP>:KDS,S\'Z5_[]H.HC!DJ#2"XB$\CXA#:+8;RM28!+
M@740\1;6"B%SE49FH@QE4^E+NLSA,2?RV)![?'/0F*=\=,;8@RQXW8*I T-$
M$B5"*/R81F&LF<PYZ/)GN3M4FHG/ST.#%?* $T2%43KZL$1HXM^D)[XGZZHI
M#R7#U'J_-1-?< "P7"(OB/N8*^CA8"L+W?VFMXQ "):W&5BTT4@UN8\(MTP]
M+=C?*N-F<UL2IDPI_.HS216^8]H%)*E2(4#>94./KL'\-@-$4OA^J@$A'X1[
MS)8^TP +$C<$(%$B-/F9&/Y>X[$=TX&>,ADW$U\0-;"/T 2;V"@=%@A->R;<
M5L?,#"F2*7]J;,ZS4B.GI$@JI4HN,X&W>*I$^B$>JCDG> [()M_^5H(X:B$$
M<":LKP)P.% #KW@"X!#,DGHAZ 23 0U,XN'/(3PYY4*P9#(!B5"H0>/DF"@!
MSE$R(:PR^8+2^*C!3GBK>(A5ME@(FTQ*X7#;V$#Q_"/2/O0 <N@8$'Z]8PW%
MCTPS+84 S20CJARA2C]$@TJ[41OL"[:5U@+:O@/Q;(!<P&PB<%27>B2X,DI'
M$/#IMV5O ! )KF9',QMM,4]M+;0&LOF/W@>E_S!4&-P#=2PS.\L\I3HVS,E#
M:(5'BFP\3)2^))O20%8GTD=Y^*#LED.S")X36^2;@!/;"BV 3 ZF2KS1F(!G
MG\?G(UZ!7@CE3,JG]+R^ ;;Z&7X^CL75(K!=9;(]NS/^!J+*[E>;Q0&^[G #
M>A#EYSI< 7HA$+,9G<C%<A.[2Q'HP\#*)A,%C4^MG- ILJ<"E$)H"B=Y&OU\
MYBV0?"2%J870K'!+I$'TI)LC^2B64@@A5WZSI 'K!/<89%:U(+4@,Z5:(V];
MX!A+*(7 RZ22#EUBF);5PJP#5[Z/JOFY\87",.X2 3*E_G)U:!W3.):1"@&9
M22$= GF0'9 -%E;J23O:('D,R4=NNWBH7ZJ,!51"^!6F?SA^C_)D$H;^C0Y6
M/KG*]WNE%$*(9?(UJ=.LQN]55K,1\'S"-$>;#2&@<(C %#F,$UAD-H\W$((R
M^[.7 ^4;R29CWPSR<$-%-A1IJ,I==:B:AYFW!MS*IY8%BEFA@0BX/V92-T=.
M,AN]/?'V9U'*_ B5$(@YEW%2MT,;X$ZZ,9H/6BF%$&"9[$SB1FD#U@G>L0]G
MD!!HFV##H@18E"LM(A."+9.&.?2$?66@3/B!HRE_XH&$TB1&*US\*#J7*"80
M0BR3?DE>!OD_US/^#W^2; )G4O"4V0U_/^NN11%_3*X5E2T(G-VUEG.R:<<O
M7/V'B7VV63HQ"1^AY"FS .ST3$4#QUT 8F5ZR3RUQCH)$N1LN].)F8\[\)#'
MF^L'PTA\'&8".B\HN0.F525G3:#SBB(/>?^O(2M;H%5E3:WI5Y*XMQ_E->1F
MVE55[J1"OI+8_=T@6:EO.\F7Y=CW].MSMTQP3#S)S;QB5_;Z8/ANXA!;05<E
M3?BW=MRNS8O:%Y?MJXNS#;7WG%9A8C\-U9B(VYW 1,$;B'GCTR)R_B%83**#
M%KRE6#IH;IL.=#P:EYS,PN'+B\_@(>BF$A/'GW,L8N=8R^ [/6D1!/>7R+;*
M0CAL$G\Y#8W]FYEB0,3T(0C\&<U3ASUA%60'+UP"T6N;P2://\[YGPFDP($Z
MP70%+<^G([B<\E<N.9/\-+6@%CD./YN[:WG$Y]:2OZEZPZPHPK89&'O;#]\@
M:TFA\=^](7ICXR5 KNK!):=D,K)0G-E9GU/?$^RO[EIA=XB1E+$>'C"E.$X7
MUH'1$: >) 8D:V1!*L\)# B2C!\CJH,@_+%CGW&9FO-L<1V8#9+HND^L!?-(
M!9-^A*8.8O3P KJ*RZ9W11#ES\U9Z=DO)JB# +^C51];'B89SG-KZL#RK\#"
MTWXPL4F.\RKJP+#^X=.]@Z? &0Y[28YS:^K LO(-?D'041P'82^EE@5U=6"[
M#];(-H!K.Y DF<ZMJ0/+'R@"V%KPW.D"^TFF"^KJP/8]L\9L P?A[G<-0?,D
M_\>(ZB!(Y-.+7%!1;1U8-Y_8UVW\+PZ?'F76FGU':\COO2:%J4!?!_%^Q<"5
M"<^.ILQ\MKP.[*9F]^CTUVZ^'Q>,XL%%%B9NQE,55=:!\="%]@#343*&7O!'
M.3+;F6-$=1"DMP"$[12A'0<:&1A**>H@0A__@8=@FHI!,J5U8+7'(E'?X5<%
M"HQ_&4$=!.A";X')T+.3;&>+Z\#LQ+>7:8N8*JL#F[*]1A23@A516%L'UKL8
MI^8W45('%G,T*I.M**&H@P@Z06O@\=V2%=1$%S@U%Z9"N^-T-1:'[4^$Q#FD
MJ[,X"[:6Q 1*4-98I 'VB9!$"<(Z"\1B$#&!#@EK+)"!-D+R'-+561RX3B?<
MA"CK(-('L%RF,T*ILCJP63"?0I->*T%&1'9M I]2ARCITEJP"O[ I(_M><KX
MY)37@5V#I].\H$DF."RHJP/;0XC70_ T0&29Y#FOHAX,%Y]+%=35@FW? OLM
M]-!))4&*J^O _ !MH!W</Z4QP\FBHTR&]VR\N&H:_AT[QBR<(B_F/*Q;8A=Z
M@&Q?)*JAGC:;<*_GPQWKF=(*4_Q=V5>#\V%;Y8>4D'J'O]&.92DG.5TPBT#[
M%24+#I!52GUH]WW"5GSD*ZFR@<1"%-H#3/@?B I^1IDX=J[2ZJ\OO[$ 9+]R
MJS>K;#U""AJT?XDES)CE,ZK-^$^!</@WWQB3<99TMXZ/T]552V,,]MSV^+".
MP_\.;Y2C+R6IJV"JR[2 .=0^#/^ONM&?2&0.BG^?H/F"&=('"@,_L(.R<K/:
MJNG^*G[QRU$RZYL :R=^M38@^A3+?K+">MP<O$BD4\2T"3=>UPG^>$8<[XB0
M/F/_XL7=O$26>^\9X]?!MQF)CA'51);4Q.?M"\I):KI=BW<Q$=>'3.O,O_&?
M2<SAWLR($3\#LU78STOX>^Y/N\SXV?S2'^,W&%'F7F$>D':W>Q(=;'F1_ 2(
M'5\%V+U,J7D+2,P%<*,;FSO/K[IZ(-1NK_!=A_RS]QG?4=I'R!T8"W[6S*O-
MX3WW['VV]G:O?OP)"(CP]#Q%"#BM.5 K1+ZO'J0'_%_6@H2LM="!RAS]Q36@
MP IPD<9^(MWXFB.([QWJM<1+9$NMG=BZZ@19SU_(IX];=:;KM5J/*O!'MGF#
M]@NMW*JCG;:*7S(#Q,68'I=TFI8T[W$QO@>VF'@F),O$5+[2 "?ZN;BTULLR
MDU*+/<R?X>2J,5,/_[:/OL*G?C'A73!6)]#=94F.$=4B:CMD,LAJ\6K@=#$A
M^ FY\PGC-T^@$MKO+-=M)_PI)/OX7U!+ P04    "  PBI)7HDC7M&4/  !8
MMP  %0   &UG<G@M,C R,S Y,S!?8V%L+GAM;.T=67/;N/F],_T/K#O3V7U0
MY"/9;)RD.[1$>SF52%6BLTE?=F@*LCE+$5J2LJW^^@(4)?/ :9$",M,\Q):,
M#_SN"R#PZ9?G960\@B0-8?SYY.S-Z8D!X@#.P_C^\\GMK&?.!K9]8J29'\_]
M",;@\TD,3W[YYU__8J!_G_[6ZQG7(8CFE\80!CT[7L"/AN,OP:5Q V*0^!E,
M/AI?_&B-OX'780028P"7JPAD /UA^^!+X]V;\]/ Z/4$YOT"XCE,;J?V?MZ'
M+%NEE_W^T]/3FQ@^^D\P^2-]$\"EV(2SS,_6Z7ZVT^?3XM\6_%,4QG]<XO_N
M_!08B%]Q>OF<AI]/\'.+QSY=O(')??_\]/2L_W4\F@4/8.GWPACS+0 G.R@\
M"PGN[,.'#_W\K[NAC9'/=TFT>\9%?X?.?F;TUY QOH1)&EZF.7HC&/A9+G;N
M8PSJ"/RIMQO6PU_USLY[%V=OGM/YR8[Y.0<3&($I6!CX)Y+>_JE+/[Z'R3.6
M5Q__K3^ 2!\1HCG40P(6GT^6]\DSFOS\XO3#Q2F>^N^50=EFA?0R#;%:G1C]
MUSWVRH\PAV8/ &0I[_'$P>VC,?$3$&</( L#/Y+"B0C9"H+87, 239ZZ"W>%
M31SI$)=A;*@.$9-BH<04[:+L+@8/Z(\@M>-9!H,_'F T1[[1^G,=9AMAK(5F
M:9W7 S]]N([@DY0.-(!:0<M-[OTX_&\N-C.>#T$:).$*?W(75^LTC$'*Q5)F
MCG9XN5XN_63C+F;A?1PND)+%F1D$<!UG* I/8!0&(> S5VJ65A"?)&#EAW/K
M>07B%*0YLU8P#?GNDP_9"H)V_(BT#29<"VH,;(D_$/F0;(/(PR:XPJK/YPP=
MIA6DIB!"5CA'/BW;>(D?IWX@Y,!Y<*T@Y\ ,('>[\>_P)&R$2&-;06+@K\+,
MCW(/RDU#"&/;00(NEV&6.TND"@.86S'*S 4\@0!H2W[K+@5_KM%S+&P] AZ*
M/+X59&X@(A+1&H DYB%"&MN2OT&_ L]_Y@N),/2(P:3=H-))<!%[M(>MOR4R
MJG-U%@'$4.9#MN[KQ!"C0W3M]P3Q$YV@;8L70X\*<+3\=P@R/XQ2QT]P>?/(
MC;.'S-F.)P@>P'P= ;BX#F-4X89^9,=IEJQS(8^!GZX3,#>S:S],\AY.@0W7
M*QPX[Q'=G*S,#INUX^) EACYF=HM'F3QY0*V:A7N8A<J)A&6<BE>2-J!^$R=
MQ49YU1"?H]/J219QV7E:KZYD$1:!;5FO\Q3#S2.-B;CS&&8;:8WFS]$RTOM@
M8:;I>KDJ"U4<:X%)6D;[-RQ+'"->R6<V?.NIJJSVBL"VS-&QGZT3Q IW,4*9
M!!B%_ET8A=E+V!5GKO!476?@TFR7GZJ3SH1\^B0&WWKG0A91$=B6]7H(%B!!
M>3$J89!W O))!F>"MLLR^>R-"\I",?"C8!WEQ=((?:Y @.<,Q',PW\V#415<
M!LW"#(\M%J;/C!Y>Q<X+%?1K,;(K1,AKG16$SA$6^]4=]'L!8A0P!6([U"(8
M5-")\$(TK"WY[A;U\^7FA9_>Y6O.Z[1W[_NK/A99'T19NOLF%V(NP.*+WW/E
M2@?K)"FUT"/_#D3Y$W\OQM6&]97@BE?#L(=$/W >^^A'N<_,!DCU-LC$\V2
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M:ZWR>.$$P?$393R5'Q#60N59CD&5:ZU&[BP0N:>3X5>"'^/YYF"P2/7<!K6
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MUH^38-(BS\L8-Z,(":_WI4W56I8X>HM+ H5/Q5)8$PY55O;A4%62KB8!SMU
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MC5 ?BH)&-0-/+@GHAEB 6/X1J-"XO@@6''O&=GT9X^M&T2K7N%LWJ"]B'"G
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M,4"DS,6O).FQ0>Y4L;R;^F*J+!L(M+'XU6:3%4UP9[$,\#,2;3LXQ#4##98
MA,9<A(K-$%?RS?+5\6:YC2*7^$O)T"RA]YJ!7Z+(H+74-I;5Q^LCN-ZOB.6T
MD==\H!/:/?K*$J5M)T:[1&IU$2YU'NIH>3H5 ]JGL6A8&]W%W3"*R8H)MX[?
M^.Y&5M&^6M"L9E:@(@L$G+F#M85GS8WMIFICUX';"M8DZ*MJ9B!5R0\:E;%
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M(56 WI+IXS#7F(R$=<E'A"\86)ZDH']3KGLSI)LZ^I74@ :S(<%+3!C'3HP
M;%@C89N7").:T&"LMSK$NJ%+$C&<X H3@A_I^!]1GA2 @YI^#_@)98=@-%:\
M=#CM)SG4P>PV8ID'))@^A<U>(LK*<D,(&ZL8.F1YFXMY5L5VU^"[0?508@A/
M8\4]A\RV<*0\3!GM=X/B3E@(0&-%.\E<T5TL'9\P$5MSA]R+3FWSZ5\PD *!
M(3"_F,EXK^XB])\5Y;'SP%2@E@@^SZ2Y;Z_&G7_==OJ31N=;D@ZV)OE[)&$&
M.4YB$FQA*"E[R(\LK<JEMB8Q*H/C.,DID/TU35G]@]J@[E\3C:^)1BAT]IIH
M+!/AUT1C$M=A-QQ1/5#G6"W;"-)/:YMQ%(I4]ERK#@,\F@"F=^93W^2O3"HX
M!VSN5/K1<DZ_2NR/@ WJX)%(I+4HX</AM'VPJBLALVUBQL^0:5N*S:'$-OD4
M9<)CLY]0$H35^ 1EHRCS_[CDAAP'^6@10B/W$$J9^2+DOKO'#V<>\M=XT!_V
M,-!?ICUT[P2=,/;C9V#=H509(JO7&A[#92>F<VIYS0HX0U&20PK-ZX5 8QC@
ML-HEH6R-6CG%Y]:ZWA+2E>OL_>E>X(JK2/G4V@M)(3O%:JR"&X22"UC:^ _<
M<^[$>[1#HJGNXXD*JN1P")IGR3O>*Q3/,>G%GE"%1U33C_;ID,<BI,2/YD*T
M[/BH?'-Z1&:UF\!G&5*]N;OQ92?'(^']58EDH3<,G+#O+.2;I$J^S<SVEX]L
MSG/Y)VC7JOUR[:W(2A?.L*59NJT_>GA+MJWGDFMW=W1,"%A1;A#2<L.A$8E3
M<-+?]E#27Z835EW"ZDZW[S4!:S^E!4BM7O]AMD'WRZCVV=M9(Q0D]AC-_>4$
M2_; / %EG6A>J:48"+!2TT?EB["%,%JY5%8'M=:PR&CE+9Q0N.E,DTP_:U[&
M3A@I6" "I-[/96_K,18K=T^@O5"U'-4>"0 I]HNY*_A%;ZKVT6/R4=$W:'?M
MI^>\J\CT)VYZI[PP>R0-A*6Y71^?^>0*L.)('C:O.9 \8< HL 4XBNYX3U'5
M$)5SL?+-OAL1K7E4?9T2:E(;6,0"5)I-K>JU['IH?L^K=9%HFQ_)K@>XY<BI
M)SR19_3AQ0*'VQ=/'Q!A.\5KQ"[K%+D7PF9U@51!" BOU,E=C6?+OF+J^U!6
M741"M7-E%\?GRKX.NOVO[%K15F?4YYXIJ^JRU/T=?=NA-'&>DF-]H@M@/UR*
M+H!M=ZX[HU&GW9@T?VLTQ^/.1,.MK]V0_H@H\ZJWO'XX%J';;PUN.HQIFRYU
M'?OWH3_S72<Y7DGGM6YX&Q+D8OKGOQ*TKE!(E1A3YV*$G B'SEWP/,11Y-\%
M*#/8.*Y565]@R)D\B7W9(<,R.K?G3&*YIG3LX98'A)D3CY*X\XC)!"=L4A^;
M2]*4" 'F2:9G'Z\"!!C2W#)LZ$ B5U^8SYH=^90\ZK0U#Z*H<IW9?8G6;YPG
M?[%:B/1^0**[*!^P50QS9\7<<$,5(E-KFD1[.:U<KQGV0,4:BYYV9C/D,I]X
MYW2/DAO0Z)!U_<!?[\+C:T39=()Q3+=NE(?G V+8YRJA\^DG0SO=2AVLLA1C
M75+E>.<925Z9YM._3- %LEJ75,GPRE)!:[,, OS('G'+ 6JV\7>",""X=6D<
M_GRT?F]GY8?WFUN^<"@8RNI]O$SP<\IO79IH?Y,;%;CE$/(\PX25;0HPA]N\
M3(PE\BIDI:!@]N;O[!_V,AG]R_\'4$L#!!0    ( #"*DE<B9-VV@E$  $C+
M!  5    ;6=R>"TR,#(S,#DS,%]L86(N>&ULY;U[<^,XEB?Z_XVXWP&W=F*C
M*L)9C\P[LU,UT[LARW*6=IR6QI*SJJ=BHX(F(9M=-*D&*:?=GWX!\"&2>%*F
M@"/73'26;9X#_ [PP\'[X-__U_-C@IXPR>,L_<M7/WS[_5<(IV$6Q>G]7[ZZ
M7;V;K*;S^5<H+X(T"I(LQ7_Y*LV^^E__\__]?Q#]OW___]Z]0Y<Q3J*?T$46
MOINGF^S?T'7PB']"'W&*25!DY-_0YR#9L;]DEW&""9IFC]L$%YA^*#/^"?WS
MM^^_#]&[=Q;I?L9IE)';FWF3[D-1;/.?OOONRY<OWZ;94_ E(W_DWX;9HUV"
MJR(H=GF3VO?/WU?_5ZK_>Q*G?_S$_KD+<HQH>:7Y3\]Y_)>O6+Y5ME\^?)N1
M^^_>?__]#]_]^NEJ%3[@Q^!=G+)R"_%7M19+1:;WPX\__O@=_UJ+"I+/=R2I
M\_CP70VG29E^C37R+21Y_%/.X5UE85#P:C=F@Y02[+=WM=@[]J=W/[Q_]^&'
M;Y_SZ*NZ\'D)DBS!-WB#N)D_%2];2J4\9DSXJOK; \$;.9B$D.^8_G<IO@\*
M'+&,?F09_? O+*/_5OWY*KC#R5>(25)^*.WZL9-6I?2=:[!+3.(LFJ6'H>YK
M>X)/VPXI7F% 6]^Y">NL")*#P+<UG<.^QH>5^%[/?4E3/X\/*^F6YE%@%R+D
MP<4K+]>$_?&*_M2!B)\+VH'AJ ;)DM!X8)X#[QBJM)O4L["3;L*\>49$VUG/
MR-/,<?CM??;T781CFO;[#^R'=^P';C;]Y?=96L3%RR2*",YSG%<_K&GZD^<X
MKY/F=OWE*QN%[_J@F>J$U,@#$AK,KR2^"S/:>6V+=TE9T*7ZAF2/=CBJ@LIL
MI']/[IH<RJ*E(!2F=,1H(MF.A'A0S;;ML2[8"N)C0E78. VG[VY77_W/4@DU
M6F?UCX@IHM^8ZO_Y]^_V>3F@U/DNCU,*89JE11 6G_#C'282@Q5RK@BDA5GS
M1BH$@BXZ9'V6U+*H$D:_E>+C,F,3Y'<<_"Y_=Q\$VY(>."GR^B][GE1_^/T&
M)WQD0(<$+VL2I#E%1\>G^?E+^XO$%1V2@ MF'6X8H]QP;>]</!ARGZ25&.)R
M9T?S7Z]EJ=2=Z01]L4YT:&HID"S2NK0.6^#XL^LL);9D4<BZY(L6;ILR4D$P
MK-&AZQ-G+PN-.VQ1"C_BM)C]?4<'=6S)+$OIK[FF^S/HN.22%?PVI[0*8+AE
M@U(8E7-1M)>%TI%11(]9NBJR\ ^M:Y+(N:22$F:;/H(0&,JHD/5I4LHA+@C'
M#=$)9,Q&;D&R#.)HGDZ#;5P$B98O!AV7W+&"W^:15@$,IVQ0]OFUUT%,Z5V<
MHDH-#MMN<!'0N6DT"T@:I_>Y87@M%W8[Q-8![@ZS99)@&*6%)PZW2V%42\-A
MT&IWE\=1')"759#@Q8:[4]V022WO=+AD@MT9*JF$P;#)A+!/*":%LDW=^<$8
M'LV7"ZW_:7UW214!5IL:S4<P5.@CZE<]_3Z:]WB\)\^\'K__\</WO"X_?;SY
ME?JVG/)K2;)\B\-B)^]5M)(NZM<"*JMIC9CW.C=C$WL2)HSVTG!ZDDE:4!>6
M[(KX":]PN"-T](3SV7.8["(<7=(Z8S.Z7<&/4"PV=5>XQ&3U$!!\_B)/0-,7
M'35'IZ/NXQ==9\Q^O.R\-REW-@KSA98"VFN,U#LK7/5BR[<)U!ZZ)^#,,4N!
M-?ZX\]4[9Y20^E5<R<#QN;\$A 2I?)-8(>/2KTGAM3U11\ [#W2H^E2H9(Y,
MA9P4+1K0W_84H+_\?D,1R4Z:]+ZYJ'(I'%;5G0_>JUB&1IA<L4XA+^(P2- G
M'.0[PE>PCSK-,E3TISB-'W>/TG8N^>ZJPJ6PZDKO? 11\3)$_<JO9/RVZT_!
ML[ZZN]^=5;<,5E/=[8\PJEN"2*CN4@9.CWX9Q(2?JS]_:7[\.<:$EM_#RQ5^
MHA6KGA#9*KL< PPSJ#TXL-/T3K6#X/9YR#3*^Q2HT4%!&J'KR6<HZWN-5?.4
M3IQR;M(/VJ&G5L,+"=70I<P3Q>'138E1S;$S5"J=(:Z&?@#H_UIFO1],LO=0
M2/9^&,G>GP#)WA](LO>P2?9A,,D^0"'9AV$D^W ")/MP(,D^P"$9.X*[V$S8
M,L$]GT!J!FX*69?$TL)M4THJ"(9,.G3B":*$:F<DX$NV+1T^\FK_OB@>,$'%
M0Y"BKM)1%W<_!7F!R0J3ISC$^>2>8(Y&O=AK4'"V^&L%O%D,UDI[)Y8U1'%J
MR710K80:+3@N:DFR+2;%RY("+R9IQ$Y>;AG$\Q?%';9!FB[=UP!3VL[,0LT[
M X=C[5/Q*DOOWUU1?Q6A-?U[?)=0=Y?G>*PU387_*G?8,-%L3PDBSGR4 ESC
ME7K?O;-  TIR,K:4@N-I&JYJ1]F"E$L/HH#8]A8]$>^<T..2G:O?CMH!*=H]
M/Y6VI 8^!#FV&+;HY9UY!!O8C7O0"7OGA2U"<>>+'2>L=8XP8E%V% \XG:74
M96U)G.-\GH:Z+D,I[+#S, !N=2,*21@D,<$3NQ8JCUH*=/X=^MTL8Z&#HAT[
M-5M>'/J$BX<LFJ=/."_V-X_:?\68Q3%2[)N_+CE76W%C&%WOW+TF+>\L'LD
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M'#M\\@NLC0J,"ZP<U&*+V?-4Z;T5B5323DFDA]PAD5P4#HFT^.0D:E0<D6C
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MF H8_AX,73B&.EG]C"ZO%K^LT.7-XA-:+&<WD_7\^B.:3-?SS_REQY].XV2
MVU&"Q4%@.3S9 8$$P@&!SN"3+<.G89S@CA'K;!S_<IRLO,U71BXLY91FI'S
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MZ0:LG0F='5F]"AAFV>$4-O!Q@:ZR/$=4#95QT1%7]\ZVVQPO-K.\B!^#0AG
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M\D:*-W>.5SI-;!7%P,%]]L[>__%0J,TK0@[S]M[$/1FL'#B,%D[(?V,=.B8
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M=R6F"[J;417#JWJ<?J)PFL=(EFCZH78'A%)<>&\94SJA4 TH^2>G(_,6F,X
MG/X=VKRNA4DXL0-ADG91'9%4>/I?XN)AGD;LD<U=D+2%V(V4-%<=FGU]LBX)
M-58AM,GXVC3!N+N1#)&<5VLD$2Y%O;<&[L-E-_9E L['M<)==_$K&-8(D""?
MJZHW@"]IF;..G5UIG:=Q$0?)<G>7Q.%B0]M ZVQIS]@!^FYO"0PTJWM1P%(9
M#.6&(NXSDJ\14$:6J7@G9>MH@_0$IOHD1$_<TT$4\[%1A2P80AD "AZ-BK.M
MS>K> @C/9CH?LTA??_"IEP:D<T]2\X8<>^HD )&8UJC%\5=+$6V#V/_R2[64
ME*^SV>,VR5ZP<D%%*NFT:U5#[72BHA@8$JFQ]:DR25,ZM$=YD 3DQ3M+#KY\
M?;'?NM(-6E^=]$E$(I84QBC!+%OI@F'ZB,;(9S%\(9QM'NUGM,$^=73W4E[(
M>E?*;<L<4,"R.(.UH_K*E?]Q'DQW!."4]J5&"$WK)'=HRZ_.+3_\)@3$7J(J
MA=8EIB-$[%9EXO@,Y5%Z$*-M?;Z4G]DT,BM53Y0RW8=YU>=0QL\&X-F^(QII
MY ^Z)\;'BP'SJ-5R;"/ .L[:L9MRP+>AAD.__7=H<?!_V&&69H]?=<MUW"Q.
M8@*I*9Q1&J$D_=,?#JB-ZK>A2@C&A?!)PM/%D=QP_5$ 6V67K!]F4)O/=II@
MF#H(KNWBAG<^CMC!S=."Q&D>AT=YX\R<WTGX>MMB.]+HJYL9F+9U; OU%RCK
MX;UEC">(%]9G0?C0E54=HGM]NH OK:N+X177UL5$P;2;L2PQ7%U'FXR@O+HQ
MY[UIU =2JFW;21K5<%OW^A:$EDW\J-KU')B&2\H?9%Z;WH,2 $/E0U!;W8OW
MSE==("M%8>A5H(08DY%/)P^&:Q8@[4(N0 @+>>C0Z;2>%GT#&Q@'VZSLG?VQ
M[\T\D0)FA\.1G:;74DH"[AT<KE]+ ;%Z=H7S'./%EI^U2^^O,"V'JSBXBQ/:
MLNI36#?X,8C3B V!+^,\#)*_XJ#_I-@8";KLAE]O>-MM'YX:&"_\:A/$*X.5
M+.O?2VG$Q$^#\Q<L)O)SL?Z"DR?\*4N+!]7,Y_#DP/%=8_1@MDO2.BVNJPWH
M,YVQ&BU2_[N)MG8QP.LOV2M+ITD%(H][)AY"WRJ)DV-M%[>4K/3SR9!UGMYD
M"<WXGMM%,U?MA+PF08@45AM^")O%U$Z.V$H3Y!QG B?#\E<6#4P&OX:O;F-4
M9D60Z(XM#43=)^2:I8\2IE4?L?>_[*^UZ9;.8/,PV['C>;/GD(I.'MEOAY2/
M.BTPI#69:\U@54)NZ/QC2><4W[-S%0<3VF!$G]TLK9_0_'&[*WC0S@)3T/ZW
M"13&*0I$*>V2HP;(;18J1,%TZGI\DN?P<G;OJ-D0*'UE4JG% '9))P0'B\U5
MD*J> 6T+.#TP)@#K' IKOH*AA@!)N-1)!3@)J(CW>I=Y2O-U3:.6[Z[/<,G2
MH *&2W8XA47Z6K[T,[ N.G:-Z9UR+U=5ZX]L)T)U[GMX,OYZ.GLCU5V@.0TP
MI#T0N#CN8GTDB'VD>@ITF9$;K)PE"%(^PB+T(,I"(E0B8/@BQ]6G ]L?1P2_
M_H#.XSUYYE7\_8\?ON?5S/=2EYB:E!:4HHO-DF3;C#!W22<:DAJW47!1^?;
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M;PGT/#&1$/]GYL0IB8-G".BUPD#<_V0)[@)AL58H[-3$9U!!L*^7!H+_9TO
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M^])P6'[;<[NM]2;AC+A9'+/$TJ$WCL)X]VM^/IG3H.,*:/%;EW:@:PYO?&O
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ML445H ?F-AH8E6S8)$TVA"7G".^A)(DJ0$FR<5VHDLTD23H!LR_X->=S) 0
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MH(>8&258C996L,KV+^P_=TY"Z+_\?U!+ 0(4 Q0    ( #"*DE?/= >85 ,
M !H1   *              "  0    !E>#(S+3$N:'1M4$L! A0#%     @
M,(J25_2'9\!<!   E1\   H              ( !? ,  &5X,C,M,BYH=&U0
M2P$"% ,4    "  PBI)73AD7V0 4  #%@@  "0              @ $ "
M97@U+3$N:'1M4$L! A0#%     @ ,(J25\_/?)23-@4 "AXS  T
M     ( !)QP  &9O<FUP;W-A;2YH=&U02P$"% ,4    "  PBI)7$,\;U*L2
M  "1$P  #P              @ 'E4@4 9F]R;7,M,5\P,#$N:G!G4$L! A0#
M%     @ ,(J25W"*'#S:7P  8F<   \              ( !O64% &9O<FUS
M+3%?,# R+FIP9U!+ 0(4 Q0    ( #"*DE?)T,!\EP\  ! 1   /
M      "  <3%!0!F;W)M<RTQ7S P,RYJ<&=02P$"% ,4    "  PBI)7XX/^
M);\V  #'.   #P              @ &(U04 9F]R;7,M,5\P,#0N:G!G4$L!
M A0#%     @ ,(J25P,3U%:]#   JPT   \              ( != P& &9O
M<FUS+3%?,# U+FIP9U!+ 0(4 Q0    ( #"*DE>7-9FUA!\  ,(@   /
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M!@!M9W)X+3(P,C,P.3,P7VQA8BYX;6Q02P$"% ,4    "  PBI)7R#C5[X9
M  #K,@0 %0              @ '!VP8 ;6=R>"TR,#(S,#DS,%]P<F4N>&UL
64$L%!@     /  \ FP,  'H<!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
